[{"article": "2017.\nProfessor Coleman said: \"If the test is negative for this gene, then they can be offered this bone strengthening treatment, which can give them a better chance of surviving their cancer.\u201d\n\nA test for the gene, known as MAFTest, has been developed by a Spanish medical company called Inbiomotion following work conducted at the Institute for Research in Biomedicine (IRB) in Barcelona.\n\u201cIt only seems to be effective in some patients, particularly older women, while others show no response and in some younger women it may even be harmful.\u201d\n\nThe new study, which is published in the journal Lancet Oncology, has shown it may be possible to identify women who will benefit from bisphosphonates by using a test that looks for a gene known as MAF.\n\u201cThe discovery made at IRB Barcelona and tested in the current study could be of great use to clinicians and would avoid unnecessary treatment of patients who would not benefit or could be harmed by the treatment,\" added Professor Roger Gomis, leader of the growth control and cancer metastasis group at IRB Barcelona, who was a co-author on the study.\nThe new study, which is published in the journal Lancet Oncology, was part of an international phase 3 clinical trial involving 3,360 women with stage II or III breast cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that \u201cThe results need to be confirmed in a second trial, currently underway in the United States, before the test is likely to receive approval for wider use in patients.\u201d \u00a0A direct statement that the test is not yet available anywhere would have been more helpful to readers but the quote does let readers know that the test is part of another trial and has not yet been approved.", "answer": 1}, {"article": "The research team retrospectively analyzed more than 100 cases of atypical moles.\n\u201cThis test integrates anatomic pathology and analytical chemistry in a very useful and meaningful way.\u201d\n\nThe finding suggests that IMS analysis, based on proteomic signatures, may improve both diagnosis and prediction of outcomes for patients with ambiguous moles, the researchers said.\nThe researchers found that in nearly all cases, the IMS analysis was a more accurate predictor, both of benign lesions and melanomas, than standard microscopic examination.\nThe test, which analyzes proteins in cells, could provide more reliable results for clinicians with patients who might be at risk for this deadly cancer.\n\u200b\u200b\u200b\u200bCalifornia Skin Institute \u2014 A recently developed test for assessing suspicious moles for melanoma is more accurate than standard analyses, according to Dr. Rossitza Lazova, a former Yale investigator.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "While IMS use is growing in different fields of medicine, the news release doesn\u2019t explain how accessible it is. Can a patient request one from their local dermatologist? Would most dermatologists know how to interpret the test results? The news release makes no attempt to inform us.", "answer": 0}, {"article": "The biggest variable is patients themselves.\nEven the most fit patients face a long period of rehabilitation after surgery and may not be able to resume high-impact activities.\nTo accommodate them, implant makers are working to build joints with longer-wearing materials, and surgeons are offering more options like partial knee replacements, hip resurfacing and minimally invasive procedures.\nAnd staying as fit and strong as possible is also critical to joint preservation.\n\"I know that the technology is capable of this level of athletic function.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that knee and hip replacement are widely available across the United States.", "answer": 1}, {"article": "Source: Stewart RAH, Wallentin L, Benatar J, et al.\nThis classic diet does not exclude a dinnertime glass of wine, however, sugary drinks, fried food, and sweets are not on the menu.\nThey answered questions about their diet and reported how many times a week they consumed servings from separate food groups.\nIn fact, every one-point increase in a participant\u2019s Mediterranean diet score was linked with a 7 percent reduction in risk of heart attack, stroke, or death.\nNow here\u2019s the interesting part: eating more foods thought to be less healthy \u2014 those typical of Western diets \u2014did not link to an increase in heart attacks, strokes, or deaths.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both Western and Mediterranean foods are widely available. However, Western foods are known to be\u00a0cheaper and more widely available in low-income areas, and that could have been mentioned.\u00a0", "answer": 2}, {"article": "THURSDAY, Jan. 5, 2012 (HealthDay News) -- Preliminary findings suggest a drug used to treat another disease might also reduce painful flare-ups in gout patients starting new medication regimens.\n\"This is a very expensive drug,\" he said.\nHowever, he cautioned that the high cost of rilonacept will most likely curtail its use.\nDr. Michael A. Becker, a professor emeritus of medicine at the University of Chicago, described the findings as \"very promising.\"\nRilonacept patients were less likely to have flare-ups, with 15 percent experiencing flare-ups three-months into the study compared with 45 percent among the non-rilonacept group, the researchers found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We are not told that the drug was approved by the FDA for use in gout in November 2011.", "answer": 0}, {"article": "\u201cThe results support the recommendation that people get more than five servings of fruits and vegetables a day, which would likely lead to a major reduction in the number of strokes worldwide, according to previous research.\u201d\n\nOther studies have shown that high lycopene levels may be linked to a reduced risk of certain cancers.\nTomatoes are not the only food that is rich in this antioxidant.\nTomatoes are rich in the antioxidant lycopene.\nMen who had the highest lycopene levels were 59% less likely to have this kind of stroke than men with the lowest levels.\nDuring that time, 67 men had a stroke.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of tomatoes isn\u2019t in question.", "answer": 2}, {"article": "\"[2]\n\nWriting in a linked Comment, Louise Cullen and William Parsonage from the Royal Brisbane and Women's Hospital, Queensland, Australia, and Martin Than from Christchurch Hospital, New Zealand, say, \"The ultimate validation for the safety and efficacy of discharging patients with cardiac troponin concentrations less than 5 ng/L will be the report of clinical outcomes after this threshold is implemented in routine clinical practice...Finally, what further assessment, if any, is needed for those patients identified as low risk and suitable for early discharge?\nAt one year, these patients had a three times lower risk of heart attack and cardiac death than those who had troponin levels 5 ng/L or higher.\nThese proteins are released when the heart muscle has been damaged, like during a heart attack.\nThis study shows that low plasma cardiac troponin concentrations at presentation identify up to two-thirds of patients who are at very low risk of heart attack and could be safely discharged from the Emergency Department.\nThe test used in this study is more sensitive than the standard version and can detect far lower levels of troponin in the blood.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release never explicitly states whether this is now being used, either at the study sites involved or elsewhere.", "answer": 0}, {"article": "This was especially true in the left hemisphere regions of the brain responsible for language.\n\"These scientists used sensors to record electrical brain activity across many different regions on the scalp,\" explained Geraldine Dawson, chief science officer at the advocacy group Autism Speaks.\nThe children with autism also had increased connectivity between brain regions that were farther apart, which might be a mechanism developed to compensate for reduced short range connectivity, the researchers said.\n\"They then looked at the extent to which brain activity from one region was synchronized with brain activity from another region,\" a phenomenon known as \"EEG coherence,\" said Dawson, who was not involved in the research.\n\"Synchronization between different brain regions indicates that those regions are functioning in a coordinated, rather than independent, fashion -- in other words, they are functionally connected and communicating with each other,\" she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is not clear from this story that EEGs are widely used in research or whether they currently have other clinical applications. We can\u2019t assume that consumers know this. If my chlid is not speaking by a certain age, can I go to my doctor and ask for an EEG? And, if I do, what would be the next steps?\n\u00a0\n\u00a0", "answer": 0}, {"article": "Their conclusion?\nAt that time, the group, which represents about 60,000 pediatricians nationwide, concluded that there was no clear evidence for or against circumcising newborns.\n\"We've reviewed the data and, you know, we have gone through them with a fine-tooth comb, and the data are pretty convincing,\" she says.\n\"The health benefits of male circumcision include a drop in the risk of urinary tract infection in the first year of life by up to 90 percent,\" she says.\n\"I think that all healthy newborn babies should be circumcised,\" says Edgar Schoen, a professor emeritus at the University of California, San Francisco.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability is clear in the story, as is the decline in use\u2026and the fact that many state Medicaid programs have stopped covering it.", "answer": 1}, {"article": "http://www.\nAmsterdam, July 3, 2017 - Doctors should consider radiosurgery earlier for patients with severe facial pain, according to a new study in the International Journal of Radiation Oncology*Biology*Physics (the \"Red Journal\") - the official journal of the American Society for Radiation Oncology (ASTRO).\nThis journal has a particular interest in prospective clinical trials, outcomes research, and large database interrogation, as well as reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging.\nThe article is \"Stereotactic Radiosurgery for Trigeminal Neuralgia Improves Patient-Reported Quality-of-Life and Reduces Depression,\" by Rupesh Kotecha, Jacob A. Miller, Sujith Modugula, Gene H. Barnett, Erin S. Murphy, Chandana A. Reddy, John H. Suh, Gennady Neyman, Andre Machado, and Sean Nagel.\nIn the research, radiosurgery helped improve the quality of life for patients with trigeminal neuralgia and reduced their depression, which is often exacerbated by the side effects of other treatments.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The authors suggest in the release that the radiation treatments should be used more, which implies it is not in wide use: \u201cit [radiosurgery] is often overlooked or delayed as a treatment because there is a lack of capability and experience with the method.\u201d This statement highlights that this may actually not be possible due to lack of trained clinicians.", "answer": 1}, {"article": "Candace's treatment, Downing said, involved a one-size-fits-all approach to mental health that sees medications as a magic pill.\nThe treatment worked, she said, because \"getting all the stuff out of your head that you don't need there gives you more room for all the stuff you need to have in your head.\"\n\"Screening a child to find out what the root of the problem is can be useful,\" Downing said.\nDowning's family offers a powerful case study into the pros and cons of new guidelines recommending widespread screening of adolescents for mental disorders: Last month, the U.S. Preventive Services Task Force, a federal group that makes public health recommendations, said that all adolescents between ages 12 and 18 should be screened for major depression.\nIn March, the Institute of Medicine, which advises Congress on scientific matters, told policymakers that early screening was key to reducing the financial and medical burden of mental disorders in the United States.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story failed to provide information about the availability of recommended treatments for major depressive disorder in adolescents. \u00a0It provided some information about vendors that provided testing for this target population, but it was unclear from the piece where someone ought to turn for help with this. \u00a0It would have been worth mentioning that therapists specializing in adolescents are in short supply.", "answer": 0}, {"article": "Broccoli has been linked to a growing list of health benefits, such as a reduced risk of cancer and osteoporosis. New research suggests consuming broccoli could also slow or reverse blood-vessel damage and atherosclerosis due to high cholesterol.\n\nThe study, in Experimental Biology and Medicine, found that a high-cholesterol diet combined with supplements containing sulforaphane, a natural compound in cruciferous vegetables such as broccoli and Brussels sprouts, significantly reduced levels of LDL, the so-called bad cholesterol,...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article offers no information on availability of the supplement, nor does it reflect on the type of intervention that might make sense to people (i.e., eat lots of cruciferous veggies, take sulforaphane supplements). The basic nature of the research likely makes all of that premature, but that then raises the question of why a media outlet would publicize research at such an early stage.\nAnd this is an important question to ask, because it\u2019s not hard to envision that based on this story alone, companies that make supplements (which are held to a much lower standard of efficacy compared to medication classified as drugs) could start marketing this supplement, and use this single study and news story to back up its usefulness.", "answer": 0}, {"article": "We're sorry, but Newspapers.com doesn't work properly without JavaScript enabled. You will need to enable Javascript by changing your browser settings. Learn how to enable it.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that cethromycin, the new antibiotic under development, is not yet approved for sale.\u00a0 ", "answer": 1}, {"article": "Aug. 4, 2010 -- The plant extract resveratrol, found in the skin of red grapes, appears to suppress inflammation and may fight aging in humans, according to a new study.\nThe researchers signed up 20 people and put them at random into two groups, one receiving a placebo and the other a supplement containing 40 milligrams of resveratrol.\nStudy author Husam Ghanim, PhD, of the University of Buffalo says the popular plant extract has been shown to prolong life and reduce the rate of aging in roundworms, fruit flies, and yeast, apparently because resveratrol affects a gene associated with longevity.\nPeople taking resveratrol also showed suppression of the inflammatory protein tumor necrosis factor, or TNF, and other compounds that increase blood vessel inflammation and interfere with insulin action, causing insulin resistance and the risk of developing diabetes.\nResults showed that resveratrol suppressed the generation of \u201cfree radicals\u201d -- unstable molecules known to cause oxidative stress and release pro-inflammatory substances into the blood, resulting in damage to the blood vessel lining.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that resveratrol can be found in common food sources.\u00a0 But the study was about resveratrol supplements in pill form and the story never explained to readers whether these were available.\u00a0 Are they at the corner drug store or health food store?\u00a0 Are they experimental?\u00a0 The story should have explained. ", "answer": 0}, {"article": "STOCKHOLM (Reuters) - Giving patients with a history of heart attacks a margarine enriched with omega-3 oils in addition to standard drugs appears to make no difference to their chances of having a repeat attack.\n\u201cThis may also be why the rate of major cardiovascular events during follow-up was no lower in the fatty acid groups than in the placebo group.\u201d\n\nAll the men and women in the Dutch study were aged between 60 and 80 and had suffered a heart attack roughly four years previously.\nThe results of the study, which was supported by the Netherlands Heart Foundation, the National Institutes of Health, and Unilever, were also published in the New England Journal of Medicine.\nThe finding raised questions about the benefits of omega-3, which has been shown in previous studies to make for healthier hearts.\n\u201cWe found the cardiovascular mortality rate in the study population was only half that expected, probably because of their excellent treatment,\u201d he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story indicated that the margarine used in the study was created for the researchers by Unilever, suggesting that they aren\u2019t commercially available. But why not make that point explicitly?", "answer": 1}, {"article": "To the age-old question \u201cIs coffee bad for you?\u201d, researchers are in more agreement than ever that the answer is a resounding \u201cno.\u201d A new study published in the journal found that older people with low levels of inflammation \u2014 which drives many, if not most, major diseases \u2014 had something surprising in common: they were all caffeine drinkers.\n\u201cThere was no boundary, apparently.\u201d\n\nIn the study, Furman and his colleagues analyzed blood samples from 100 young and old people.\nBut with aging, the process isn\u2019t regulated as well as it is in a younger body.\nThe older people tended to have more activity in several inflammation-related genes compared with the younger group \u2014 no surprise, since as people get older, inflammation throughout the body tends to rise.\nIn fact, inflammation is an important function of the immune system, which uses it to fight off infections and remove potentially toxic compounds.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As with cost, it can be assumed that most readers are familiar with how to make or purchase coffee. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "But given the 2013 research suggesting \u201ctoxicity of high coffee doses\u201d in some people, he said, \u201cto me the most reasonable approach would be to keep coffee intake to two to three cups most days.\u201d\n\nSecond Take: STAT knows better than to get between coffee lovers and their cup o\u2019 joe, so if you want to take this study as permission to keep beating a path to your Keurig, we\u2019re not going to slow you down.\nis enough to make STAT cross-eyed.\nOverall, the conclusions have been pro-coffee.\nTakeaway: Observational studies that associate coffee drinking with health benefits are strongly suggestive but not definitive.\nthat causes the observed benefit.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Coffee is widely available, and that\u2019s obvious from the story.", "answer": 1}, {"article": ", and receive monthly highlights by signing up at http://www.\nIt is the world's most cited biology journal according to the Institute for Scientific Information and has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century.\nThe researchers first exposed the tissue to native hormones such as oxytocin and chemical compounds to make it contract, mimicking normal or premature labor.\nBy activating the bitter taste receptors in the uterus, the bitter substances relaxed the contracted uterine muscle tissue more completely than the current drugs used to prevent preterm labor in humans.\nThis could be good news for those trying to prevent preterm labor: New research published online in The FASEB Journal suggests that exposing bitter taste receptors in the uterus to certain substances can stop many unwanted contractions that occur during premature labor.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does not mention the name of the substances tested, so there is no way to know anything about availability. After looking at the research paper we found that the substance was chloroquine which is readily available.", "answer": 0}, {"article": "This article has been updated to include additional comment from Kathryn Cullen.\n\"Adolescence is a very important time for studying depression, first because depression often starts during these years, and second because it is an important time for brain development,\" Kathryn Cullen, from the Department of Psychiatry at UM, told Newsweek.\n\"Although ketamine is potentially a huge breakthrough in the treatment of depression, we still don\u2019t know about the long-term safety, or about how to keep people well from depression without requiring regular ketamine dosing,\" Stone added.\n\"The purpose of our study was to investigate the effects of ketamine for TRD in younger patients for whom this indication for ketamine administration is not well studied,\" Mark Roback, a professor of pediatrics at the University of Minnesota, told Newsweek.\nKetamine is perhaps best known for being a popular recreational drug and a useful medical anesthetic, but a growing body of research is indicating that the compound could be an effective treatment for depression.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story called ketamine \u201ca popular recreational drug and a useful medical anesthetic.\u201d It could have added that while ketamine is an FDA-approved drug for years and is widely available at medical facilities, it hasn\u2019t been approved by regulators for use as an antidepressant.\nIn addition, Johnson & Johnson has said it is close to seeking FDA approval of a ketamine derivative called esketamine, which would be taken as a nasal spray.", "answer": 1}, {"article": "The American Heart Association recommends that adults eat less than 1.5 g of sodium per day.\nBy the end of the trial, sixteen people had dropped out of the study, including 10 out of 48 from the seaweed group, according to findings published in the American Journal of Clinical Nutrition.\nAccording to the researchers, the higher sodium content of the alginate drink \u2014 a little over one gram per dose, or about half a teaspoon of salt \u2014 could have offset any potential blood-pressure reducing effect of the supplement.\nThere are many different types of alginate, said Richard Mattes, who has studied the effect of alginate fiber on appetite at Purdue University in West Lafayette, Indiana \u2014 so the trick is to find the right alginate in the right dose.\nThe new supplement used in this study is less unpleasant \u2014 but there\u2019s still room for improvement, said Astrup.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The fact that alginate is already available in pill form \u2013 and that the FDA does not regulate such supplements \u2013 was mentioned.", "answer": 1}, {"article": "Studies suggest that for more than half of depressed patients, antidepressants alone don\u2019t eliminate symptoms.\nIt\u2019s a medication that works differently than everything else.\u201d\n\nThe study was funded by a grant from the National Institutes of Mental Health, but the SAMe pills and placebo pills were provided by the dietary supplement maker Pharmavite.\nAs a result, doctors are looking for additional treatments to help these patients, referred to as \u201cnonresponders.\u201d\n\nModern antidepressants essentially work by building up concentrations of neurotransmitters, which amplifies their effect on the brain.\n\u201cIt provides clues to new treatments, and it provides clues to understanding what causes depression as well as what goes on biochemically when people get better from depression.\u201d\n\nThe researchers studied the use of SAMe or a placebo in 73 adults with depression who were not responding to prescription antidepressant treatment.\nThat\u2019s probably the best hypothesis.\u201d\n\nOther studies have suggested that SAMe can relieve symptoms of depression.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We learn that this supplement is available and popular, and we get its costs.\u00a0 Because the story meets the lowest standard for this criterion, we rule it satisfactory.\u00a0 However\u2026..\nWe don\u2019t learn why it\u2019s been widely used for depression in Europe but not in the U.S. That claim of widespread European use is dubious and could lead readers to falsely conclude that Europeans have concluded it is an effective treatment. Following lemmings off the cliff may be programmed into our nature, but the outcome is often undesirable. \n And what\u2019s it used for with such great popularity in the U.S.?", "answer": 1}, {"article": "Age-related macular degeneration affects upward of 15 million Americans.\n\u201cThese induced neural progenitor stem cells are a novel source of adult-derived cells which should have powerful effects on slowing down vision loss associated with macular degeneration,\u201d said Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute and contributing author to the study.\n\u201cThis is the first study to show preservation of vision after a single injection of adult-derived human cells into a rat model with age-related macular degeneration,\u201d said Shaomei Wang, MD, PhD, lead author of the study published in the journal STEM CELLS and a research scientist in the Eye Program at the Cedars-Sinai Board of Governors Regenerative Medicine Institute.\nCedars-Sinai researchers in the Induced Pluripotent Stem Cell (iPSC) Core, directed by Dhruv Sareen, PhD, with support from the David and Janet Polak Foundation Stem Cell Core Laboratory, first converted adult human skin cells into powerful induced pluripotent stem cells (iPSC), which can be expanded indefinitely and then made into any cell of the human body.\nWhen animal models with macular degeneration were injected with induced neural progenitor stem cells, which derive from the more commonly known induced pluripotent stem cells, healthy cells began to migrate around the retina and formed a protective layer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release suggests, through researcher quotes and other descriptions that this treatment may be just around the corner.\u00a0 That is clearly an exaggeration.\u00a0 The researchers still need more work in animal models.\u00a0\u00a0 Then they will require FDA approval for an investigational drug.\u00a0 If that comes about, then substantial clinical trials in humans will be needed.\u00a0 All told, that could mean\u00a0years of additional wor, before the procedure might be available for people.\nIs that how you would define \u201csoon\u201d or \u201cclose to a time\u201d?", "answer": 0}, {"article": "What would that look / sound / smell like?\nProfessor Jackie Andrade, Professor in Psychology at the University of Plymouth, is one of the co-creators of FIT, and she explains: \"FIT is based on two decades of research showing that mental imagery is more strongly emotionally charged than other types of thought.\nThe study showed how after six months people who used the FIT intervention lost an average of 4.11kg, compared with an average of 0.74kg among the MI group.\nDr Solbrig, who completed the work as part of a PhD funded by The National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) South West Peninsula, said: \"It's fantastic that people lost significantly more weight on this intervention, as, unlike most studies, it provided no diet/physical activity advice or education.\nThe full study, entitled Functional Imagery Training versus Motivational Interviewing for Weight Loss: A randomised controlled trial of brief individual interventions for overweight and obesity is available to view in the International Journal of Obesity (doi: 10.1038/s41366-018-0122-1).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release describes FIT as a \u201cnew motivational intervention.\u201d Is it in widespread use? How difficult would it be for someone to find a practice that can provide FIT for weight loss? The release doesn\u2019t address this.", "answer": 0}, {"article": "You should go through six to eight weeks of conservative management.\u2019 \u201d\n\nAt the Partners Healthcare System in Boston, spine experts have the same struggle to convince patients that an M.R.I.\nSixty percent had herniated disks, the scans showed.\n\u201cA lot of people are driven by wanting to have imaging,\u201d Dr. Modic said.\nAnd so repairing the tears would not eliminate the pain.\nThey tended to occur along with arthritis and were a part of the disease process itself.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly MRIs, CT scans and other scans are widely available.", "answer": 1}, {"article": "\"The issue is, can you detect these in patients that don't have advanced cancer?\" Venook said. \"The answer is, we don't know.\" The numbers tested by the MD Anderson researchers -- 251 patients with pancreatic cancer (five of whom had very early lesions), 32 with chronic pancreatitis and 120 healthy controls -- aren't nearly large enough to draw such conclusions. And getting a clear answer, Venook said, would probably require lengthy and expensive studies on very large populations.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article gives no indication when the discovery could be translated into a clinical screening tool but reviewers don\u2019t see that as a drawback in this story. The article is cautious about the implications of the finding and\u00a0 highlights experts calling for additional research so we can assume the tool is some years off.", "answer": 1}, {"article": "The key asset Pfizer wanted?\nOne PARP inhibitor has already been approved by the Food and Drug Administration: olaparib, sold by AstraZeneca as Lynparza.\n\u201cAt this time, there\u2019s nothing available that has been approved by regulatory agencies for these women who have recurrence to their ovarian cancer.\u201d\n\nThe company aims to use its PARP inhibitor, rucaparib, to treat only patients with BRCA mutations who have had two or more chemotherapies.\nMore and more clinical trials will spring up to test PARP inhibitors in combination with other cancer treatments, such as immunotherapy, said Dr. Christina Annunziata, an investigator at the National Cancer Institute who studied the efficacy of Lynparza in ovarian cancer patients.\nBut the data it presented at the European conference showed that the drug may not actually be more effective than Lynparza, the PARP inhibitor that\u2019s been marketed by AstraZeneca since 2014.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As said above, Lynparza is approved and already being used. And the information provided on the other three newer drugs makes clear they are in various stages of clinical trials and not yet on the market.", "answer": 1}, {"article": "It also has a very low rate of false positives - it is 98% accurate at ruling out RA.'\nThe Kennedy Institute's Professor Kim Midwood said: 'What is particularly exciting is that when we looked at samples taken from people before their arthritis began, we could see these antibodies to cTNC up to 16 years before the disease occurred - on average the antibodies could be found seven years before the disease appeared.\nWe decided to see if it could be citrullinated and, if so, whether it was a target for the autoantibodies that attack the body in RA.\nThis latest research provides the basis of tests that could improve diagnosis and, importantly, detect disease at a very early stage, with the promise even that people at risk of developing rheumatoid arthritis can be followed before the disease begins.\nWhile tests for individual proteins usually have a relatively low diagnostic sensitivity, a more general test called CCP, that detects synthetic citrullinated peptides, identifies a lot more RA cases.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "As noted above under \u201cCost,\u201d if the test is promising enough to issue a news release about it, readers should be given some idea of when and where it might be available.\nWe aren\u2019t told until the very last paragraph that the research \u201cprovides the basis of tests that could improve diagnosis and, importantly, detect disease at a very early stage, with the promise even that people at risk of developing rheumatoid arthritis can be followed before the disease begins.\u201d In other words, it could be a very long way off. We think there should have been a caveat that more studies are needed or that this test may be years off before it will be ready for routine practice.", "answer": 0}, {"article": "CHICAGO (Reuters) - Measuring certain proteins in spinal fluid can accurately diagnose Alzheimer\u2019s and predict which patients with memory problems will develop the fatal brain-wasting disease, Belgian researchers said on Monday.\nCurrently, only an autopsy can confirm that a person has Alzheimer\u2019s, a fatal and incurable deterioration of the brain that affects more than 26 million people globally.\n\u201cThe unexpected presence of the Alzheimer\u2019s disease signature in more than one-third of cognitively normal subjects suggests that Alzheimer\u2019s disease pathology is active and detectable earlier than has heretofore been envisioned,\u201d Geert De Meyer of Ghent University in Belgium and colleagues wrote.\nLast month, experts at the National Institute on Aging and the Alzheimer\u2019s Association proposed new guidelines for diagnosing Alzheimer\u2019s even before patients have symptoms.\nIn the study, De Meyer and colleagues analyzed spinal fluid from 114 adults with normal brain function, 200 who had mild cognitive impairment \u2014 a precursor to dementia \u2014 and 102 who had Alzheimer\u2019s.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThis story does not point out the hurdles that need to be cleared before this sort of spinal fluid test for Alzheimer\u2019s Disease could be considered for use outside of research trials, so readers may get an unrealistic sense of how soon it might enter routine clinical use.", "answer": 0}, {"article": "In addition to tennis players, Bishop sees the injury in gardeners with their shovels and trowels; painters with brushes; and golfers with clubs.\nNot all physical therapists are sold on the FlexBar.\nAnd the FlexBar makes it simple to do this kind of stretch.\nIt usually happens when people grip things too hard or too long.\n\"This wasn't a traumatic injury,\" explains Holzman.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that the FlexBar is commercially available.", "answer": 1}, {"article": "Gardasil protects against several strains of HPV, which is the leading cause of cervical cancer in women.\nAlthough the U.S. Centers for Disease Control and Prevention recommends that 11- and 12-year-old girls begin receiving the vaccine as part of school vaccination efforts, an advisory panel voted against routine use of the vaccine in boys and men.\nThe researchers also saw some reduction in the number of precancerous penile lesions, although at this point they said it's impossible to know whether this will result in a lower rate of penile cancers.\n\"Studies like this underscore the 'human' in human papillomavirus,\" said Fred Wyand, director of the HPV Resource Center at the American Social Health Association.\nWEDNESDAY, Feb. 2, 2011 (HealthDay News) -- A large international trial finds that the Gardasil vaccine shields young men from human papillomavirus (HPV) as well as it protects young women.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story met this standard by telling us the vaccination is \"approved\" by the FDA, but not \"recommended\" by the CDC advisory board. Some readers will be a bit confused processing that seeming contradiction. \nEven better would be telling us why these two \"expert\" bodies appear to disagree about the widespread benefits to most young men. How about saying: \"While the FDA labeled the vaccine as safe, the CDC\u2019s advisers do not recommend it for routine use.\" Why not? Even better would be a quote from one of those advisors about the why not, and whether this new evidence has the potential to change CDC recommendations.", "answer": 1}, {"article": "That's the tantalizing premise behind Deplin, a prescription form of the B-vitamin folate. Although it has been on the market since 2006, Deplin is generating growing buzz at psychiatric conferences and among clinicians and patients, particularly those who haven't responded to antidepressants or did for a while only to have their depression return.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story accurately describes\u00a0Deplin\u2019s status as a \u201cmedical food\u201d\u00a0and notes that physician supervision is required while taking Deplin.", "answer": 1}, {"article": "According to Professor Andrew Worster, also from McMaster University, \"This lab score may reduce both the number of blood tests and time spent in the emergency department for chest pain patients.\"\nPatients with chest pain symptoms require multiple blood tests over several hours before a diagnosis is reached.\nThis could result in the safest laboratory approach for physicians to use at presentation in the emergency department,\" says Dr. Kavsak.\nThe authors suggest the score can be useful for standardizing diagnoses and improving safety.\nA positive (or high-risk) clinical chemistry score also identified about 75% of patients at high risk of heart attack or death when positive compared with a low of 40% detected when the high-sensitivity cardiac troponin test alone was positive.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the score is based on commonly available tests.", "answer": 1}, {"article": "\u2022 None New guidelines outline how to handle back pain \n\n\n\nIn the study, 320 adults with moderate to severe back pain received one of three approaches over 12 weeks:\n\u2022 Education about how to cope with back pain\n\n\n\nYoga was just as effective as physical therapy -- and both groups were about 20 percent less likely to use pain medication than patients receiving education alone.\n\"Yoga was as effective as physical therapy for reducing pain intensity,\" Saper said.\nOpiate overdoses are now the leading cause of death for adults under age 50 -- an especially compelling reason to find approaches to chronic pain that don't involve narcotics.\n\"I'm much more comfortable with movement,\" she told CBS News.\n\"Yoga makes me think about my back and how I'm standing and if I'm standing properly, then I can function better.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Yoga is widely available, although it may be harder to find for rural and low-income neighborhoods. Ironically, the story does not tell us that the 320 patients in this research study were primarily low-income. The study publication itself does say that.", "answer": 1}, {"article": "Bardwell hasn't worked since November because his condition, inherited, makes breathing so difficult.\nThe study calls for Torre to implant the system, done through small puncture holes in the lower back, in 20 patients with advanced heart failure, then conducting tests on them after one, two and three months to measure heart function.\nThe method, commonly used to treat pain, activates nerves that Methodist Hospital doctors think will improve the heart's ability to pump effectively, lowering blood pressure, reducing the amount of irregular heartbeats and stopping stress hormones from overreacting and causing cardiac damage.\nThe hope is that such stimulation will modulate nervous system responses, such as toning down the release of hormones that typically occur at times of stress and increasing the flow of blood.\nNew pathway to the heart\n\nElectrical stimulation of the spinal column may ease cardiac problems without drugs\n\nIn a possible new way to treat heart failure, Houston surgeons implanted a device and wire in a Pearland man Monday that will electrically stimulate portions of his spinal cord.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story is clear that this treatment is in the early stages of development, It doesn\u2019t give readers a very good sense as to when\u00a0it might be available to the general public. Paraphrasing one of the\u00a0researchers, the story states that it \"likely will take about a month before doctors have a good idea whether the therapy is working,\" which might suggest to some readers that it might soon be available after that. Yet this is a phase I study which is primarily geared to assess\u00a0safety. It is not until Phase II and III studies are completed and successful that companies will go for FDA device approval. This could take many years and the research may never come to fruition.\u00a0The story never explained this.", "answer": 0}, {"article": "Screening patients for heart disease with a heart-imaging test prompted greater follow-up care but had little to no effect on the number of heart attacks and other cardiovascular events in those patients, a new study found.\n\nResearchers at Johns Hopkins Hospital in Baltimore led the study, which was published online Monday in the Archives of Internal Medicine.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that the test is available in the U.S. and is being used with increasing frequency.\u00a0 It is actually not clear how often it is being used \u2013 the article said \u201cSome anecdotal evidence suggests such screening is happening and becoming more common.\u201d", "answer": 1}, {"article": "The California Walnut Commission (CWC) prohibits discrimination in all programs and activities on the basis of race, color, national origin, age, disability, sex, marital status, familial status, parental status, religion, sexual orientation, genetic information, political beliefs, reprisal, or because all or part of an individual's income is derived from any public assistance programs.\nThese factors are major contributors to heart disease risk, and reducing them is a critical step toward a healthier heart.\nThe dose of nuts varied from 5 to 100g/day and most participants followed their typical diet.\nCWC is an equal opportunity employer and provider.\nWalnuts were investigated in 21 of the 61 trials, more than any other nut reviewed in this study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Walnuts are widely available so we won\u2019t ding the story for not saying so.", "answer": 2}, {"article": "March 5, 2012 (Orlando, Fla.) -- A traditional Chinese herbal remedy known as kampo helped to relieve daily asthma symptoms in nearly all of more than 200 people studied, Japanese researchers report.\nThe study did not look at possible side effects of kampo herbs.\nIn kampo medicine, most herbs are taken as a fixed formula.\nThere have been cases in which poisonous plants found their way into the herbal mix, resulting in kidney damage, for example.\nThe number of people in the U.S. with asthma is growing.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t discuss the availability or use of the kampo herbs in the US.", "answer": 0}, {"article": "And on a Tuesday evening earlier this summer, the company partnered with a women\u2019s group to host a conversation about \u201cproactive steps you can take today to reach your future family building goals.\u201d Appetizers, wine, and beer were served \u2014 and, in a gesture to the crowd full of women with pregnancy on their minds, non-alcoholic beverages were on the menu, too.\nSmith has mostly positive feelings about her Fertilome test.\nSo a patient may see a table showing that her genetic variants make her twice as likely to have a condition known as recurrent pregnancy loss, defined as repeated miscarriages.\nAnd she had 24 additional genetic variants that are more weakly associated with various conditions that can play a role in fertility problems.\nThe Celmatix CEO, Piraye Yurttas Beim, said her team has heard of a small wave of \u201cFertilome babies\u201d on the way.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The text is clear that the test has been available since January 2017 and has been utilized by some doctors.", "answer": 1}, {"article": "Learn more about brain health at http://www.\nOn the other hand, the more closely people followed a Western diet--a diet that is high in saturated fats and red meats and low in fruits and vegetables--the more likely they were to develop depression.\nThe study found that people whose diets adhered more closely to the Dietary Approaches to Stop Hypertension (DASH) diet were less likely to develop depression than people who did not closely follow the diet.\n\"Depression is common in older adults and more frequent in people with memory problems, vascular risk factors such as high blood pressure or high cholesterol, or people who have had a stroke,\" said study author Laurel Cherian, MD, of Rush University Medical Center in Chicago and a member of the American Academy of Neurology.\nThe odds of becoming depressed over time was 11 percent lower among the top group of DASH adherers versus the lowest group.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release refers repeatedly to the DASH diet. However, while the DASH diet has been around for years, many readers will likely never have heard of it. The release appears to assume that the DASH diet is common knowledge. While the DASH diet isn\u2019t a secret, it\u2019s not something you can assume readers are familiar with either. This could have been addressed by simply noting that the DASH diet has, well, been around for years. It could even have referred readers to a description of the plan on an NIH website.", "answer": 0}, {"article": "Hair changes about as fast as grass grows, which is to say it\u2019s extraordinarily slow and not visible to anyone checking impatiently in the mirror every day.\n\u201cThere aren\u2019t a lot of options, and I\u2019d love to be able to say to my patients, \u2018This is something you can try that is worth the money.\u2019 But I can\u2019t do that yet.\u201d\n\nHarklinikken\u2019s formula, refined over 20 years, is derived from plants and cow\u2019s milk.\nIn the 1990s, clients mixed it with Rogaine, Mr. Skjoth said, \u201cand then we took the Rogaine part away and started focusing on the actual liquid.\u201d\n\nSmall studies have shown the efficacy of various plant-derived ingredients, mostly in mice.\nOne is how much emphasis the company places on compliance, the major stumbling block in the efficacy of any treatment, said Dr. Senna, an author of studies on the subject.\nBut during regular follow-up appointments, Harklinikken uses high-tech equipment to photograph and magnify the scalp and count new hairs and active follicles, which motivates users to adhere to the regimen.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says the company \u201cis beginning an aggressive expansion into the $3.6 billion hair-loss market in the United States, meaning you\u2019re likely to hear a lot more about it.\u201d It also mentions clinics has a physical presence in New York City, Florida and Beverly Hills, Calif., and plans to \u201chave a presence in every state in the next two years.\u201d The product also appears to be available online.\nThe story also says that the company is \u201coffering a customized hair extract that\u2019s given only to those who pass a fairly rigorous selection process,\u201d and its products \u201care not available to anyone with autoimmune illnesses like alopecia or baldness from scarring, or anyone who is unlikely to see at least a 30 percent increase in growth.\u201d\nThe story also mentions that the treatment requires nightly six-hour applications, which could be prohibitive for some people.", "answer": 1}, {"article": "The research was funded by the National Institute for Health Research Imperial Biomedical Research Centre and the Biotechnology and Biological Sciences Research Council\nThis study is filling in a missing bit of the jigsaw -- and shows that this supplement can decrease activity in brain areas associated with food reward at the same time as reducing the amount of food they eat.\"\nIn a second part of the study, which is published in July edition of the American Journal of Clinical Nutrition, the volunteers were given a bowl of pasta with tomato sauce, and asked to eat as much as they like.\nThe team found that when volunteers drank the milkshake containing inulin-propionate ester, they had less activity in areas of their brain linked to reward -- but only when looking at the high calorie foods.\nAfter drinking the milkshakes, the participants in the current study underwent an MRI scan, where they were shown pictures of various low or high calorie foods such as salad, fish and vegetables or chocolate, cake and pizza.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release implicitly makes the point that the powder used in the experiment is not available to the public, but the release would have been better if this had been explicit.", "answer": 1}, {"article": "Reuters - A nicotine addiction pill can help smokers quit gradually when they can\u2019t go cold turkey, a study finds, suggesting that it may be time to revisit practice guidelines that focus primarily on immediate cessation.\nSmokers who took the pill, sold as Chantix in the U.S. and Champix elsewhere, were much more likely to quit after cutting back on cigarettes than smokers who didn\u2019t use the drug, the study found.\nBy the last ten weeks of treatment, weeks 15 to 24, the group taking the pill had significantly higher abstinence rates than the group on placebo.\n\u201cThis is the first study of its kind to enroll a group of smokers who are not traditionally enrolled in clinical trials because they are not ready to quit,\u201d said Dr. Caryn Lerman, professor of psychiatry and deputy director of the Abramson Cancer Center at the University of Pennsylvania in Philadelphia.\nTen years after quitting, the risk of lung cancer drops by half, according to the CDC.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that Chantix is already available in the U.S. and elsewhere.", "answer": 1}, {"article": "Orlando, Fla - Researchers at Orlando Health have developed a blood test that can detect even the most subtle signs of a concussion in children, correctly identifying the presence of traumatic brain injuries 94 percent of the time in a recent study.\nMoreover, the study showed that the blood test detected symptoms of concussions, even when brain injuries were not visible on the CT scan.\nAs expected, the high definition imagery from the CT scans was able to identify which patients had suffered visible traumatic brain injuries.\nResearchers plan to do more studies with the blood test, but they hope it will be commercially available within the next 5 years.\nWhat makes them unique is that they pass the blood-brain barrier and enter the bloodstream, which makes them easy to detect with this particular test.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that the GFAP test is not available for clinical use, and that the researchers hope to develop a test for clinical applications within the next five years.", "answer": 1}, {"article": "TUESDAY, Aug. 11, 2015 (HealthDay News) -- Colonoscopy can save lives, but experts agree that testing rates remain too low.\nSo, patients scoring at the lower end of risk for colon cancer might be able to have less invasive screening tests (such as the fecal occult blood test), while those at higher risk would require a colonoscopy, Imperiale's team concluded.\nThe system might also make colon cancer screening more efficient and boost the number of people who get checked for the disease, said a team led by Dr. Thomas Imperiale of Indiana University Medical Center, in Indianapolis.\n\"A risk stratification tool is critical in helping physicians make appropriate screening recommendations for patients,\" Garbus said.\nSwaminath noted that one study published in 2012 found that \"colonoscopy reduced the risk of death from colon cancer by 53 percent, by removing polyps.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although availability isn\u2019t explicitly addressed, this risk calculator is now available (implicitly) by virtue of publication of the paper. \u00a0It is a simple scoring system that can be implemented based on the information in the paper, and the story makes this clear. We\u2019ll rate this Satisfactory.", "answer": 1}, {"article": "In addition to trying colored-lens sunglasses, the article suggests other ways to mitigate photophobia including wearing a wide-brimmed hat when outdoors, adjusting digital screen and device settings to an appropriate hue and brightness or purchasing filters for screens.\nThe goal is to help the concussion patient feel better as the brain heals.\n\"We compare the colored glasses to being like a brace or cast but for the brain,\" he says.\nHowever, the researchers noted, they do not recommend wearing colored glasses while driving.\nCertain colors make seeing stop lights or emergency vehicle lights difficult.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "These lenses are presumably available at optical shops, but it\u2019s unclear from the release.", "answer": 0}, {"article": "Is that a big difference?\nStudy author Dr. William Weintraub, chief of cardiology at Christiana Care Health System in Newark, Del., is presenting the data at the annual meeting of the American College of Cardiology in Chicago.\nPut another way, 21 percent of stented patients had died after four years compared with 16 percent of surgery patients.\n\"It's a very big deal to recommend coronary surgery to patients,\" Weintraub says.\nAlthough the pro-surgery outcome is not a game-changer, Weintraub says it might cause some doctors and patients to consider surgery.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Unlike the Wall Street Journal story and the Associated Press story we reviewed, this story at least mentioned the fact that more people have been opting for stents instead of bypass surgery.", "answer": 1}, {"article": "Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.\nCoolSculpting for the double chin is already clinically proven to reduce fat up to 20 percent in the treated area after one treatment.1\n\n\"Allergan is committed to advancing innovation for CoolSculpting\u00ae to meet the needs of patients seeking non-invasive aesthetic treatments,\" said David Nicholson, Chief Research and Development Officer at Allergan.\nFollowing the procedure, typical side effects include temporary redness, swelling, blanching, bruising, firmness, tingling, stinging, tenderness, cramping, aching, itching, or skin sensitivity, and sensation of fullness in the back of the throat after submental area treatment.\nThe CoolSculpting procedure is not for everyone.\nIt is also FDA-cleared to affect the appearance of lax tissue with submental area treatments.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release says the technology is available through a network of CoolSculpting centers worldwide. It also refers readers to its website, where you can search for a list of clinicians and specialists offering the procedure.\nWe rate this one Satisfactory.", "answer": 1}, {"article": "This post has been updated.\nThe results of the comparison showed that slow metabolizers did just as well on a nicotine patch or the drug varenicline (marketed as Chantix), a drug that works on the nicotine receptors in the brain.\nBut the patch costs less and has fewer side-effects than varenicline (including nausea, difficulty sleeping and abnormal dreams), so the researchers concluded that slow metabolizers should be put on the patch.\nThe researchers, led by Caryn Lerman, a professort of psychiatry, divided 1,246 subjects into slow metabolizers of nicotine and normal metabolizers of the addictive chemical, based on the length of time it took for them to rid their bodies of the drug.\nThe ratio of two metabolites, or byproducts, of the body's processing of nicotine allows easy identification of the two groups.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The therapies in the story are widely available, but the patch is available over the counter and varenicline requires a prescription, which certainly impacts access. The story didn\u2019t mention this. In addition, the story doesn\u2019t describe the availability of the screening test that separates smokers into \u201cfast\u201d and \u201cslow\u201d metabolizers. We could not tell if that is easy for any primary care physician to order.", "answer": 0}, {"article": "\u201cJet lag itself is really a nuisance syndrome as it is self-resolving,\u201d said senior author Jamie Zeitzer, assistant professor of psychiatry and behavioral sciences at the Stanford University School of Medicine in California.\nIn experiments, the technique \u2013 which is based on the way non-visual parts of the brain respond to light \u2013 was much more effective than sustained bright light similar to that from devices sometimes used to combat sleep disorders or seasonal depression.\nZeitzer was on the committee that removed jet lag as a \u201cdisease\u201d from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), the guide that psychiatrists use to diagnose mental illnesses.\n\u201cThis is one of the real advantages of this system - you can change circadian timing while you sleep, without interfering with sleep,\u201d he said.\nThe study included 39 people, 31 of whom were exposed to a series of two-millisecond light flashes with changing intervals while sleeping, and eight of whom were exposed to 60 minutes of continuous bright light.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This article made it fairly clear that this technology wasn\u2019t ready for consumers by mentioning that further research needed to happen and that frequent flyers shouldn\u2019t try this on their own.", "answer": 1}, {"article": "There\u2019s ample reason for caution.\n\u201cIt appears to be safe and to not raise blood pressure,\u201d Shah told CNN, \u201cbut it\u2019s not a slam-dunk.\u201d For one thing, despite improved cholesterol levels, patients did not see less inflammation in their blood vessels.\n\u201cIt\u2019s like a rocket that landed on Jupiter, rather than the moon.\u201d Still, Eckel warned it\u2019s too soon to say whether ancetrapib would actually prevent disease over the long run.\nIf the same benefit were seen in all patients at risk of heart disease \u2013 far from a sure thing \u2013 it would translate to hundreds of thousands of fewer deaths and heart attacks over a five-year period, according to Dr. Christopher Cannon, the lead study author and a cardiologist at Brigham and Women\u2019s Hospital in Boston.\nThe first patients will be enrolled in April, according to Dr. Rory Collins of Oxford University, where the research will be overseen.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nWe\u2019ll let this story pass on this criterion because it mentions that the next phase of clinical trials will take at least four years to complete and because it notes that success is not a sure thing. \nHowever, the lead sentence about people having a new cholesterol treatment option \u201csoon\u201d gives us pause. Also, the prediction in the story attributed to a drug company spokesman that application for approval could come in 2015 seems questionable, since the next study is not scheduled to begin recruiting participants until April 2011, and then there will be four years of observation, followed by data analysis. The trial just presented began in April 2008 and the participants were followed for an average of 14 to 16 months, yet it took more than a year after that for these results to be announced. The next trial may include 20 times as many patients.", "answer": 1}, {"article": "This test will most definitely save lives.\"\n\"There is concern about the validity of many genetic tests that are being offered,\" said Joan Scott, deputy director of the Center for Genetics and Public Policy at Johns Hopkins University.\nAn FDA spokeswoman said the agency had just become aware of the new test and could not say whether it would take any action, though she noted that in August the agency sent a letter expressing concern to another company marketing a questionable genetic test for ovarian cancer.\n\"There is at least a significant chance this test will could falsely reassure some women and alarm others,\" said Eric Winer, a breast cancer expert at Harvard Medical School and a spokesman for the American Society of Clinical Oncology.\nPreviously, the only tests for breast cancer risk were for relatively rare genes, leaving most women with no way to assess their individual genetic predisposition.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The focus of the story is a new, widely available genetic test. The story says that any doctor can order this test to assess a woman\u2019s risk of developing of developing one of the more common forms of breast cancer. The story notes that the FDA does not regulate this or similar types of predictive genetic tests, and there are questions about the validity of tests that have not been subjected to external review.\u00a0 ", "answer": 1}, {"article": "Risk reduction [was] probably in the range of 80 to 95 percent,\" said researcher Timothy Rebbeck, an epidemiologist at the University of Pennsylvania.\nA new study in the Journal of the American Medical Association shows the clearest evidence yet that women carrying the BRCA1 and BRCA2 genes should consider preventive surgery because they are at a very high risk for breast and ovarian cancers.\nOnly 3 percent of those who had surgery died, compared with 10 percent of those who did not, during the follow-up period.\n\"A lot of times I see these women having had a very preventable type of breast cancer.\nIt confirms what smaller studies have suggested in the past: Women who have a family history of breast cancer can greatly reduce their chances of getting the disease by having a double mastectomy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not mention that the type and quality of genetic testing, genetic counseling, surgery and surveillance offered to women in this study may not be available to women in other settings.", "answer": 0}, {"article": "Might non-opioid painkillers work just as well as these addictive drugs?\nThe study involved 416 adults (average age, 37) who had gone to an emergency department with an extremity injury causing moderate to severe pain (averaging 8.7 on a scale of 1 to 10).\nEven for people who initially had rated their pain as a 10 (for the worst pain possible) or had broken a bone, there was virtually no difference in pain reduction between those who had and had not taken an opioid.\nResearch has shown that even short-term opioid use, such as that stemming from an initial prescription for pain from an injury or surgery, can make people predisposed to a dependence on the powerful drugs \u2014 partly from their effectiveness at relieving pain and partly from the euphoria they produce.\nAbuse of opioids has become an epidemic in the United States, with opioids now causing 60 percent of drug overdose deaths.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While the story doesn\u2019t explicitly state that the relevant drugs are clinically available, acetaminophen and ibuprofen are both sufficiently well-known over-the-counter painkillers that the writer can assume most readers are familiar with their availability. Opioid drugs, meanwhile, are generally much harder to access and tightly regulated in many states.", "answer": 1}, {"article": "Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.\nThere have been two clinical studies showing positive safety and effectiveness of the device in the increase of tear production completed with 145 aqueous deficient dry eye adult patients.\n\"Interestingly, neurostimulation has been used as an approach for a wide variety of disorders for more than 30 years.\nTrueTear\u2122 is the first of its kind to provide a temporary increase in tear production in this way.\"\nAllergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model \u2013 Growth Pharma.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release says that the device has been granted marketing authorization by the FDA. One can safely assume the product will be on the market by the end of the year.", "answer": 1}, {"article": "The research is so early that the drug hasn't been named.\nBut the study provides the first clinical evidence that targeting the HCV protein NS5A may be an effective strategy for curing patients who are chronically infected with the HCV virus, says Nicholas A. Meanwell, PhD, who is executive director of chemistry with Bristol-Myers Squibb.\nA unique thing about the NS5A-targeting drug, according to Meanwell, is that laboratory studies show it to be effective against all HCV genotypes.\nThe current treatment for chronic HCV -- intravenously administered peg-interferon and ribavirin -- cures about half of people with genotype 1 who take it.\nIn preliminary research published this week in Nature, researchers from Bristol-Myers Squibb -- the maker of the drug -- report that patients who took the drug showed dramatic reductions in viral load while exhibiting few side effects.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story called the research on BMS-790052 \"preliminary\" and made it clear that\u00a0the drug\u00a0was not close to approval. It also was more cautious than the competing HealthDay piece in its description of two other antiviral drugs that are nearing FDA approval.", "answer": 1}, {"article": "WASHINGTON--A new dietary review of 49 observational and controlled studies finds plant-based vegetarian diets, especially vegan diets, are associated with lower levels of total cholesterol, including lower levels of HDL and LDL cholesterol, compared to omnivorous diets.\n\"Our goal with studying plasma lipids throughout the lifespan is to capture the net risk reduction of using a vegetarian diet to control lipid levels.\n\"To make any form of health care work and to truly power economic mobility, we have to get healthy,\" says Levin.\nThe study authors hypothesize that the greater risk reduction for total, HDL, and LDL cholesterol levels observed in the longitudinal studies is likely due to long-term adherence to plant-based eating patterns and changes in body composition.\nWhat I've found is that if you want your patients to make significant health changes, you have to make them yourself.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that registered dietitians can help people transition to a plant-based vegetarian diet. It also recommends the vegetarian diet plans contained in the 2015 Dietary Guidelines for Americans.", "answer": 1}, {"article": "Take this test to see how well you're managing your diabetes\n\nThe researchers looked at over half a million people from 50 previous studies on the Mediterranean diet, which included people in Spain, Greece, the U.S., France, Sweden, Italy and Australia, among other countries.\nPanagiotakos concludes that this pattern of eating can be easily adopted by people of various cultures and populations.\nBy now, you've probably heard all the buzz about the Mediterranean diet, or perhaps you've tried it.\nThe study notes physical activity is also an important part in preventing the risk factors for the metabolic syndrome.\nThat translates into 2.9 million young people.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story opened by indicating that readers had likely heard about or even tried the\u00a0\u2018Mediterranean diet\u2019.", "answer": 1}, {"article": "Knee surgery for a torn meniscus is done about half a million times each year in the U.S.\nAs it is now, \"millions of people are being exposed to potential risks associated with a treatment that may or may not offer specific benefit, and the costs are substantial,\" she wrote.\nWhen that happens, it's tough to tell if the pain is from the tear or the arthritis \u2014 or whether surgery is needed or will help.\nIt would be quite reasonable to try physical therapy first because the chances are quite good that you'll do quite well,\" said one study leader, Dr. Jeffrey Katz, a joint specialist at Brigham and Women's Hospital and Harvard Medical School.\n\"There are patients who would like to get better in a 'fix me' approach\" and surgery may be best for them, said Elena Losina, another study leader from Brigham and Women's Hospital.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of the various treatment approaches is not in question. The story could have cited stats from the study:\n\u201cThis procedure, in which the surgeon trims the torn meniscus back to a stable rim, is performed for a range of indications in more than 465,000 persons annually in the United States.\u201d", "answer": 2}, {"article": "U.S. News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual \"America's Best Hospitals\" survey.\nThe results show that if validated and adopted clinically, IsoPSA could significantly reduce the rate of unnecessary biopsies by almost 50 percent.\nThe study directly compared the clinical performance of a new test based on PSA, called IsoPSA, to PSA itself with patients already scheduled for prostate biopsy.\nThe former indication is potentially useful for using IsoPSA for screening by primary care physicians, while the second is helpful for urologists in identifying patients who would benefit from curative intent therapy and other applications.\nBy identifying molecular changes in the prostate specific antigen (PSA) protein, the findings, published online last month by European Urology, suggest that once validated, use of IsoPSA may substantially reduce the need for biopsy, and may thus lower the likelihood of overdetection and overtreatment of nonlethal prostate cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release makes it clear that IsoPSA is not available at your local doctor\u2019s office, since this blood test needs to undergo further study and then be adopted clinically.", "answer": 1}, {"article": "\u201cThis legitimises current guidelines which recommend treating this population with statins.\u201d\n\nRay said people with lower levels of cholesterol, around 4mmol/L, who otherwise appear healthy, should also be treated with statins.\nThere was also an 18% reduced risk of dying from any cause over the 20-year period.\nResearchers from Imperial College London and the University of Glasgow found impressive results among those on statins, who were given the widely-prescribed type pravastatin.\nStatins cut the risk of dying from heart disease by 28% among men, according to the longest study of its kind.\n\u201cThe role of cholesterol in causing heart disease has been disputed by some, but this paper provides yet more evidence of the link, and the benefits of statins to prevent heart disease.\u201d\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Statins are widely available drugs, and the story tacitly implies they\u2019ve been available for about 20 years.", "answer": 1}, {"article": "Anderson doctor healthy and thriving nearly 15 months after he was diagnosed with the deadly disease he treats: brain cancer.\nThe greatest promise seems to involve blood and microscopic cancers, but targets for immunotherapies in clinical trials range from lymphoma and brain cancer to cancers of the breast, prostate, colon and lung.\nThe idea is simple: Instead of poisoning the cancer and causing grueling side effects, it signals the patient's immune system to attack malignant cells, much as the body does with viruses and bacteria.\nAs a result, the researchers are now giving one-two punches of drugs that energize the immune system and direct it to go after cancer cells it had hardly noticed.\n\"So many claims have been made about immunotherapy that have not borne out,\" says Dr. Steven Rosenberg, an NCI scientist who conducted the melanoma study but also published a review about the lack of randomized trials in support of the therapy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story claims that many immunotherapies are almost ready to go up for FDA approval. This is not sufficient information on availability. The story should have made it clear that these therapies are currently only available through clinical trials. Furthermore, the story should have cautioned the reader that these therapies would only be appropriate after first-line treatments have failed (except in certain rare cases).", "answer": 0}, {"article": "There is only \u201cmoderate\u2019\u2019 evidence that the newly approved prostate cancer drug Provenge helps patients, according to an analysis done for Medicare that was made public on Wednesday.\nThe Medicare review might be more designed to limit off-label use of the expensive drug, such as for patients who already have symptoms.\ndeclined to approve Provenge in 2007, setting off protests by patients and Dendreon investors.\nThe review for Medicare said there was insufficient evidence to judge whether Provenge would work if used off-label.\nMedicare advisers will meet next Wednesday to discuss the drug, which was developed by Dendreon, a Seattle-based biotechnology company.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story reports that treatment with Provenge has been approved for certain patients with advanced prostate cancer but that availability is limited by manufacturing capacity.", "answer": 1}, {"article": "To learn more, visit njhealth.org.\nExperts say there is more research to be done, but that the goal of the trial is to discover the best combination of bacteria to clear eczema from the skin and then make it available to patients as a prescription cream.\n\"What the cream does is help the skin gain back its natural balance and create that barrier needed to keep it healthy.\"\nThe next steps involve testing those different combinations, ensuring they're safe and conducting a longer trial to see if the benefits of bacterial cream can truly provide a permanent solution for eczema patients.\nIt may seem strange to fight bacteria with more bacteria, but it could lead to a long-term solution for eczema patients\n\nEczema is the most common skin disease worldwide.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release suggests the benefit of the cream was already proven and hints that the treatment would be available soon.\nIt would have been helpful to note for readers something like, \u201cbecause this lotion is in clinical trials, it is not currently available on the market; furthermore the preliminary results have not been published or peer-reviewed.\u201d", "answer": 0}, {"article": "THURSDAY, May 27, 2010 (HealthDay News) -- A new approach to treating irregular heartbeats appears to have demonstrated success in halting abnormal electrical pulses in both patients and pigs, new research indicates.\nAll had already undergone at least one failed drug regimen.\nIn fact, with this new approach, the study team found that physicians could destroy such cells with 100 percent accuracy.\nThe traditional means for getting at misfiring cells relies on pre-intervention X-rays for a much less precise snapshot form of visual guidance.\nFor more on irregular heartbeats, visit the U.S. National Library of Medicine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is never made clear whether the device and approach are still experimental or already in clinical use. ", "answer": 0}, {"article": "This study will be presented at a medical conference.\nThe cause of the disease is unknown, and the risk of developing it increases with age.\nThe participants were followed for 20-22 years and filled out questionnaires about the foods they ate.\nNor is it clear why the results differed for men and women.\nThe results showed that men who ate the most foods rich in flavonoids had a 35% lower risk of Parkinson\u2019s disease compared with those who ate the least.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. The availability of the flavonoid-containing foods mentioned in the story is not in question.", "answer": 2}, {"article": "Dr. Len Horovitz, a pulmonary specialist at Lenox Hill Hospital in New York City, agreed.\nMONDAY, Feb. 12, 2018 (HealthDay News) -- As a particularly nasty flu season rages across the United States, scientists have found a powerful new disinfectant that makes \"light\" work of the virus.\nIt appears that low-dose far-UV light is safe and effective, and has the advantage of inactivating a wide range of disease-causing viruses.\"\nHe noted that the technology's cost \"is not prohibitive, and it is safe.\nBut this type of light can cause skin cancer and cataracts, so it's not used in public spaces.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We get the idea that UVC lamps are available and already used to disinfect surgical equipment. What\u2019s not clear is if \u201cfar-UVC only\u201d lamps are commercially available at this time.", "answer": 0}, {"article": "The studies that served as the basis for the FDA approval of the drugs, along with recently released guidelines from the American Society of Clinical Oncology (ASCO), set the threshold at a five-year Gail score of 1.67 percent.\nBut this is where it gets more complicated.\nThe effect was even larger during the first five years of the study.\nThese basic tenets of leading a healthy lifestyle have been shown to be important factors in breast cancer prevention.\nGiven that these drugs seem to offer some protection, why are they not in widespread use?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story discusses the availability of these drug therapies.", "answer": 1}, {"article": "The World Health Organization estimates that more than 300 million people suffer from clinical depression world-wide. But cost, time, stigma, distance to travel, language barriers and other factors prevent many from seeking help.\n\nNow, a growing group of health-care providers are betting that technology\u2014from web-based courses to mobile apps that send prompts via text\u2014can help bridge that gap.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story identifies several therapeutic apps and, in a video, shows one individual using a \u201cmobile therapy platform\u201d to text and videochat with a therapist.\u00a0 Several comments in the story about the continuing evolution of these applications suggest that these strategies remain works in progress.", "answer": 1}, {"article": "(CNN) A new review of the \"little pink pill\" for women with low sexual desire says the drug doesn't work very well -- but some doctors and patients who've been using the treatment disagree.\nThe researchers said the drug had significant known side effects, such as dizziness, sleepiness, and nausea.\nThe drug, Addyi, or flibanserin , has been on the market since October.\n\"I should be able to choose whether the side effects are worth the benefit,\" she wrote.\nOne of those studies used a dosage of the drug that was half as high as what the FDA approved.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the drug has been on the market since October, 2015.", "answer": 1}, {"article": "Overall, the study found, measures of spasticity dropped an average of three points \u2014about 30 percent \u2014 on a 24-point scale when patients smoked marijuana, but didn\u2019t change after they smoked the placebo.\nAnd a new clinical trial suggests they are not just blowing smoke.\nThe new study, reported in the Canadian Medical Association Journal, included 30 MS patients with muscle spasticity that had failed to get better with standard medication.\n\u201cBut smoking marijuana does not appear to be a long-term solution, because of the cognitive effects,\u201d he told Reuters Health.\nBut the evidence that pot smoking actually helps with spasticity has been anecdotal.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained that some people with MS are already using medical marijuana to treat certain symptoms.", "answer": 1}, {"article": "The treatments that were compared and ranked included acetaminophen; ibuprofen; intra-articular (IA) or joint injections of cortisone; platelet-rich plasma (PRP); hyaluronic acid (HA); several NSAIDs, such as naproxen, celecoxib, and diclofenac; and both oral and IA placebo.\nThis new research analyzed data from multiple trials to determine the relative effectiveness of various nonsurgical treatments for knee OA.\n\"Because knee OA has both a high disease burden and high treatment costs, additional prospective studies using similar outcomes, timelines, and measures of clinically important changes are needed,\" explained Dr. Jevsevar.\nAn analysis of 12 articles also found that results with HA are not significantly different from those with IA placebo for treatment of knee OA.\nKnee OA treatments were ranked on a scale of one to five, with one being the most effective.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that all the treatments noted in the release are generally available.", "answer": 1}, {"article": "Two studies published Tuesday lend support to controversial new cholesterol guidelines that could vastly increase the number of Americans advised to take cholesterol-lowering drugs called statins.\nOne study suggests that the new guidelines are better at identifying who is truly at risk of a heart attack and should be given statins than the older guidelines are.\nBut they could help dispel some of the criticism of the new guidelines and strengthen the position of those who contend treatment should be extended to more people.\n\u201cThere is no longer any question as to whether to offer treatment with statins for patients for primary prevention, and there should now be fewer questions about how to treat and in whom,\u201d said an editorial that accompanied the publication of the studies in JAMA, a journal of the American Medical Association.\nThe other suggests that treating people based on the new guidelines would be cost-effective, even with the tremendously increased use of statins.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made it clear that statins are widely prescribed. One in four Americans take them by some estimates.", "answer": 1}, {"article": "Oct. 18, 2010 -- Vitamin B12 may help protect the brain against Alzheimer's disease, according to new evidence that suggests the vitamin and an amino acid called homocysteine may both be involved in the development of Alzheimer\u2019s.\nDuring the study, published in Neurology, 17 people developed Alzheimer\u2019s disease.\n\u201cLow levels of vitamin B12 are surprisingly common in the elderly.\"\nThe seven-year study followed 271 Finnish people ages 65 to 79 who did not have any symptoms of Alzheimer's disease at the start of the study.\n\u201cOur findings show the need for further research on the role of vitamin B12 as a marker for identifying people who are at increased risk of Alzheimer\u2019s disease,\u201d says researcher Babak Hooshmand, MD, MSc, with Karolinska Institutet in Stockholm, Sweden, in a news release.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Israel is director of the respiratory therapy department at Brigham and Women's Hospital in Boston.\n\"There was a small but significant improvement in the airway narrowing in these patients, which we didn't expect because we didn't think the mast cells were necessarily promoting that airway narrowing all the time,\" Israel said.\n\"It has been a while since a new approach and treatment for severe asthma has emerged,\" Horovitz said.\nGleevec (imatinib) reduced the \"twitchiness\" of airways, making them less likely to reflexively constrict when exposed to an allergen or asthma trigger, said senior researcher Dr. Elliot Israel.\n\"We showed we could decrease the amount of airway twitchiness by a third,\" Israel said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story tempers expectations when it quotes a researcher saying it will \u201clikely will be three to four years before Gleevec could be approved for asthma treatment.\u201d Further, it quotes an independent expert: \u201cIt will take years of study to determine the usefulness of this drug in treatment.\u201d", "answer": 1}, {"article": "Doctor are taking the first steps to move this treatment beyond the world of the elite athlete.\n\"I knew something was wrong, and I knew that I was going to have to take some time to heal,\" Bornstein says.\nThe hope is that the same technology that allowed Bornstein to get back on the field so quickly can now be used to treat injuries in weekend warriors as well.\n\"I was pretty bummed to find out I might be missing the first game, maybe a couple more games,\" Bornstein says.\nThe hope is that if PRP can get an elite athlete like Bornstein up and running, it can help the baby boom generation and their creaky joints get back in the game.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story only hinted at the limited availability of the Platelet Rich Plasma Therapy procedure.\u00a0 While it said that \"doctors have now taken first steps tomove this treatment beyond the world for elite athlete,\" and mentioned that clinical trials had begun, it did not answer viewers\u2019 probable questions of \"Where can I get it?\" or \"Is it being tried at my local hospital?\"\u00a0 And when the story lead-in frames the problem as one pertinent to 15-million American medical visits per year, this is an oversight.\u00a0 The very limited availability and preliminary nature of the research should have been emphasized STRONGLY. ", "answer": 0}, {"article": "The other half got a heart health education program.\nThe Chinese developed tai chi thousands of years ago, but it has recently piqued the interest of Western medicine as an alternative mind-body therapy to treat disease.\nThe study authors say there's a usually a strong relationship between depression and heart failure, so the fact that tai chi helped cheer people up was an especially good sign.\nThe movement is tai chi, an ancient martial art turned exercise, and a study out this week in Archives of Internal Medicine says it may help people suffering from heart failure feel better about life.\n\"Historically, patients with chronic systolic heart failure were considered too frail to exercise and, through the late 1980s, avoidance of physical activity was a standard recommendation,\" the study's authors write.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story suggests that tai chi is widely practiced in China,\u00a0but\u00a0it didn\u2019t discuss the\u00a0availability of classes in the United States. While it isn\u2019t hard to find trained instructors in\u00a0a city such as Boston, where the study being\u00a0covered was conducted, readers from rural areas might find it difficult to locate classes led by someone experienced in this form of therapy.\u00a0\u00a0Someone with\u00a0heart failure may also have trouble finding transportation to a class. The story should have mentioned these issues.", "answer": 0}, {"article": "They also put tested at against petroleum jelly and regular moisturizer on 22 people with dry, flaky legs.\nThe cream\u2019s effects are detailed in a scientific report in the journal Nature Materials, but as part of the school\u2019s close association with the companies, it\u2019s being patented and produced at almost the same time.\n\u201cRubber alone would not be that strong.\u201d\n\nIn this case, the catalyst is platinum-based and it turns the gel into a thin, stretchy sheet.\n\u201cMany people have tried to do this, and the materials that have been available up until this have not had the properties of being flexible, comfortable, nonirritating, and able to conform to the movement of the skin and return to its original shape.\u201d\n\nThey screened about 100 compounds before settling on polysiloxane, a silicone-based gel.\n\u201cThe results confirmed the XPL as a \u2018second skin\u2019 barrier that protects the skin from excessive moisture loss to the environment,\u201d they wrote.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Since the story mentions that the material has been licensed to two private companies, readers will assume that it\u2019s not on the market yet but may be in the near future.\u00a0 It\u2019s pretty clear that it is not available for public use yet.", "answer": 1}, {"article": "\u201cWe believe the benefits increase with age.\nBut there are harms, and particularly in their 40s, women have to make a decision for themselves.\u201d\n\nOne potential harm is false positives, in which a suspicious mammogram finding leads to more tests, sometimes even biopsies, but turns out to be harmless.\nThe guidelines state that from ages 40 to 74, screening will reduce the odds of dying from breast cancer, with women 40 to 49 benefiting the least and those 60 to 69 benefiting the most.\nThe guidelines relied in part on a study of records from 405,191 women who had digital mammograms from 2003 to 2011, which found that false positives were common, especially in younger women.\nThe task force said it concluded \u201cwith moderate certainty\u201d that the benefit was moderate in women 50 to 74 and small in women 40 to 49.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the use of mammograms as breast cancer screening tools is longstanding and well established. The story also discusses insurance coverage issues that would affect availability for many women. The story states, \u201cThe recommendations are not immediately expected to affect insurance coverage. In December, Congress passed a bill requiring private insurers to pay for screening mammograms for women 40 and over every one to two years without copays, coinsurance or deductibles, through 2017.\u201d", "answer": 1}, {"article": "She noted that medicine\u2019s veterinary counterparts have been using water therapy for years with injured racehorses.\nIt works like a lock on a canal, he said.\nThe water height can be adjusted to the patient\u2019s abilities.\nAn alternative to a water treadmill: Some pool companies will install a water flow system you can work out against.\n\u201cTaking some of that pressure off the knee helps them tolerate that knee injury longer,\u201d said Johnson.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear from the story how widely available underwater treadmills are for the general public.", "answer": 0}, {"article": "And Maxwell stressed that their preliminary findings need to be replicated in the future.\nAlthough no one can pinpoint a reason for the link with certainty, \"essentially we think that alcohol may be having an effect by reducing the immune response, which leads to joint inflammation, and also that it may have a mild pain-killing effect,\" said Maxwell.\n\"We would wish to point out that, at the moment, that our findings are preliminary, and would not recommend that patients drink alcohol with the specific purpose of treating their arthritis,\" said Dr. James Maxwell, lead author of the study and a consultant rheumatologist at The Rotherham NHS Foundation Trust in England.\nBecause the researchers assessed drinking frequency, rather than the amount of alcohol consumed, it is not clear how much alcohol might be helpful, they said.\nThe benefit of ethanol exposure for these rodents seemed to be due to higher levels of testosterone, the researchers wrote.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. The availability of alcohol is not in question.\u00a0 In fact, we need a drink after reading another story that conflates association with causation. ", "answer": 2}, {"article": "WEDNESDAY, April 20, 2011 (HealthDay News) -- Researchers have developed a blood test that they say could help physicians predict whether pregnant women will deliver their babies prematurely.\nIt would require several years to go through the U.S. Food and Drug Administration approval process.\nOne option is to provide drugs that dampen the immune system so the baby's lungs develop faster, said Dr. Jennifer Wu, an obstetrician-gynecologist at Lenox Hill Hospital in New York City.\nThe test wasn't as effective at 24 weeks of gestation.\nThe closer to the preterm birth, the more likely you are to have significant changes in the physiology of the woman that is observed in the blood.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that \u201cIt would require several years to go through the U.S. Food and Drug Administration approval process.\u201d", "answer": 1}, {"article": "The new drug is no miracle cure and it is not approved for young children, who are one of the most vulnerable groups, so the C.D.C.\nThe new antiviral, generically known as baloxavir marboxil but sold under the brand name Xofluza, is a single dose treatment.\nThe first new flu drug in 20 years won approval Wednesday from the Food and Drug Administration.\nGenentech will offer coupons that lower the price to $30 for patients with health insurance and to about $90 for the uninsured.\nstill strongly recommends that every American over the age of six months get a flu shot as soon as possible.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that Xofluza has received FDA approval.", "answer": 1}, {"article": "Woodrum and his colleagues are scheduled to discuss their findings Sunday in New Orleans at the annual meeting of the Society of Interventional Radiology.\nFor his part, Dr. David Carbone, a professor and director of the James Thoracic Center at the Ohio State University Wexner Medical Center, said that the findings regarding cryoablation are \"not incredibly novel,\" given that the procedure has been around for years.\nFunding for their work was provided by Galil Medical, a medical device manufacturer based in Arden Hills, Minn.\n\nBecause this study was presented at a medical meeting, the conclusions should be considered preliminary until published in a peer-reviewed journal.\n\"It would be overreaching to say that we're curing cancer with this,\" Woodrum said.\n\"But this is one of many therapy options that is looking to turn cancer into a chronic fight, and to give patients for whom the choices are limited a chance at a good quality of life with minimal treatment complications.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story at least noted that cryoablation \u201chas been around for years.\u201d\u00a0 But to what degree?\u00a0 Around for years in how many places?\u00a0 What level of proliferation/penetration?\u00a0 How likely is a lung cancer patient in Arkansas or Alabama or Albuquerque to find the approach in use nearby?", "answer": 0}, {"article": "The surgery worked.\n\"It was the first time in my life that I've ever lost a lot of weight and was able to maintain it.\"\nIf the stomach pouch has stretched, new sutures are put in place to once again reduce the size of the stomach.\nWatson says we don't know for sure, but it's possible the body begins to adapt to those changes, which is why the weight loss is reversed over time.\nAfter the surgery, Watson says, patients report feeling fuller and less hungry and they ultimately gain greater control over what they are eating.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although not explicitly stated, it is apparent that the TORe procedure is available since cost and insurance coverage are noted. It would have been useful to include additional details on how widely the procedure is used, whether it\u2019s used by both gastroenterologists and bariatric surgeons, and whether patients should look for doctors who have special training or credentials for performing this procedure.", "answer": 1}, {"article": "In a statement, she said the trial would help address how the procedure, if approved by federal regulators, \u201cshould be appropriately managed to minimize complications.\u201d\n\nSome experts have speculated that the adverse effects were dose-related.\nThe use of a bioengineered protein should be \u201cdiscontinued either permanently or until further information becomes available regarding how to use it safely,\u201d said Dr. Thomas A. Einhorn, chairman of orthopedic surgery at Boston University.\nWhile use of the products in such operations has since fallen, one expert said the new report should convince doctors to stop using them in anterior cervical fusions, as the procedure is known.\nThe high complication rate was seen in 2006 data..\n\n\u201cI would have hoped that this sort of surveillance would be a routine part of F.D.A practice,\u201d Dr. Deyo said.\nBy 2006, just four years after such products were first sold, the proteins were used in about 25 percent of all spinal fusions, the review found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n \nThe story notes that bone-growth protein infusion received FDA approval in 2002 for use in spinal fusions to treat lower back pain. It reports that by 2006 the proteins were used in about one-quarter of all spinal fusion procedures in the hospitals included in the study, including procedures in other regions of the spine\u00a0\nThe story also states that the use of these proteins in upper spine fusion procedures has dropped following reports of complications.", "answer": 1}, {"article": "Although the technique's potential to identify brain disorders and diseases was noted years ago, fcMRI-based diagnostic tests have yet to make their way into doctors' offices.\nThe consistency of the fcMRI scans makes them a promising diagnostic tool.\nAll of the scanned brains belonged to young, healthy scientists and doctors.\nIt's exciting to think that these individual differences may be related to personality, cognitive ability, or psychiatric or neurological disease.\nWe show here that it's not measuring what you're thinking, but how your brain is organized.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We are not told how available fcMRIs are to the general public.", "answer": 0}, {"article": "\"Mindfulness-based therapeutic interventions promote the use of meditative practices to increase present-moment awareness of conscious thoughts, feelings, and body sensations in an effort to manage negative experiences more effectively.\u201d\n\nChildren who are at a high risk for bipolar disorder or other anxiety disorders, such as the participants, often have poor coping skills when confronted by stress, and only a lucky few get help.\nSome mental health professionals have suggested that mindfulness exercises can help bridge the treatment gap, and there is some encouraging, if early, evidence showing that these techniques can be used to prevent relapses of depression or anxiety.\nBut a team of researchers from the University of Cincinnati set out to explore other treatment options that focus more on the mind and less on pharmaceutical solutions.\nMindfulness-based therapies for mood disorders is one such example with promising evidence,\" said Cotton, adding the university is both studying and implenting these therapies.\nAnxiety disorders plague more than one in four adolescents between the ages of 13 and 18, and many of them are treated with antidepressants and other medications to try and help them live a relatively healthy childhood.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear to readers whether mindfulness-based cognitive therapy for children with anxiety disorders is still in experimental development by a select group of researchers or is widely available. Can local therapists learn this technique?", "answer": 0}, {"article": "Not the smells of their colognes or perfumes, not of the laundry detergents they use \u2014 the smells of them?\nThe breath of diabetics sometimes smells of rotten apples, experts report; the skin of typhoid patients, like baking bread.\nModern medical research, too, confirms that the smell of someone\u2019s skin, breath and bodily fluids can be suggestive of illness.\nEach of us has a unique \u201codorprint\u201d made up of thousands of organic compounds.\nBut not every physician\u2019s nose is a precision instrument, and dogs, while adept at sniffing out cancer, get distracted.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told we\u2019re 3-5 years away from seeing this technology on the street, so that establishes\u00a0its current (lack of) availability.\nBut the certainty with which this estimate is passed along by a researcher who\u2019s developing such products should have received more scrutiny. This assumes that current testing will work out as planned. Moreover, three to five\u00a0years is likely\u00a0only enough time to show that the detection of cancer may be earlier by using the odor technology, and not the needed outcomes that we discussed above.\n5-year predictions in medicine generally have a poor track record.", "answer": 0}, {"article": "That's according to a study just published in the journal CANCER.\nTen years ago, the American College of Surgeons Commission on Cancer decreed that doctors should use these types of clinical staging tests to help decide how to treat cancers.\nThey say what's really needed is a set of tests that classify prostate tumors by what genes are turned on or off in the cells.\nOnce this is sorted out, doctors treating prostate cancer will be less like the blind men who try to guess what kind of creature they're dealing with when they grasp the elephant's trunk or tail.\nIt includes criteria like whether the doctor can feel a nodule through rectal examination, and whether a tumor is detected through a test called trans-rectal ultrasound.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that clinical staging is \u201cwidely used\u201d and that 10 years ago the American College of Surgeons \u201cdecreed that doctors should use these types of clinical staging tests to help decide how to treat cancers.\u201d", "answer": 1}, {"article": "A surgically implanted electrical device that stimulates the sacral nerve can calm an overactive bladder, according to a company that sells it. Physicians say sacral neural stimulation works well for many patients, but a test period with an external device is recommended first.\n\nMillions of Americans suffer from \"urge incontinence,\" accidents caused by a strong, sudden need to get to the bathroom, or overly frequent urination, defined as eight or more times a day. Quality of life is affected, as sufferers must...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly the device is available, but it is not clear how widely and how many practitioners are trained in implanting the device.", "answer": 0}, {"article": "\"Might this be a good application to help that person recover or prevent this decay from advancing?\n\"An alternative could simply be brushing better in a certain location and not drinking Coca-Cola all day long,\" says Mark Wolff, a professor of dentistry at New York University who specializes in cariology, or the study of tooth decay.\n\"We aim to treat these intermediate lesions -- not the very early ones, but the intermediate ones -- where usually, as a dentist, you are not sure whether you should make a filling or not,\" Paris says.\nHowever, some dentists argue that any time before a cavity actually forms, tooth decay can be stopped -- and even reversed -- by the patients themselves, using, for example, fluoride toothpaste.\n\"When you take a sugar cube and you put it into your coffee, you will see that it is soaked up with the coffee,\" Paris says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe story reports that this product has been available in the United States for just over a year. However, it does not say whether dentists need to be trained to use the product.", "answer": 1}, {"article": "For those at high risk, doctors recommend blood pressure medicine, quitting smoking, exercising more and eating a healthier diet \u2014 but so far chocolate isn\u2019t on the list.\nNearly 800,000 Americans suffer a stroke every year, with about a sixth of them dying of it and many more left disabled.\nThe women ranged in age from 49 to 83 years.\nOver the next decade, there were 1,549 strokes, and the more chocolate women ate, the lower their risk.\nWhether that theoretical benefit translates into real-life benefits remains to be proven by rigorous studies, however.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of chocolate is not in question. The story appropriately notes that there is a stronger statistical association with dark chocolate as opposed to milk chocolate.", "answer": 1}, {"article": "Scientists at a growing number of research centers are pinning their hopes that these images will help them unlock some of the secrets of everything from what causes childhood disorders like Attention Deficit Hyperactivity Disorder to how neurons in the brain process vision and memory.\nThe images of the children in the study -- MRIs of the brain -- were taken at 12 to 29 months while their language was assessed one to two years later at 30 to 48 months.\nThe spectrum is wide and some are destined to be on the mild end and be very talkative, sometimes almost indistinguishable from those without the disorder in some settings, while others will suffer from a more severe form and have trouble being able to speak basic words.\nThere\u2019s no such thing as a blood test, cheek swab or other accepted biological marker so specialists must depend on parent and teacher reports, observations and play assessments.\nBrain imaging has become a popular subject of research in recent years as the technology to be able to scan, store and analyze the terabytes of information in the pictures has become more affordable.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t state when or if clinicians will adopt the testing protocol for newly diagnosed autism patients. Because the research was only recently published in a journal, one must assume clinicians will not be implementing the protocol anytime soon. But the story doesn\u2019t make this clear or provide any sort of time frame for readers.", "answer": 0}, {"article": "While some cases of anosmia may be treated by caring for an underlying cause (often nasal obstruction, in which odors can\u2019t reach the nerves of the olfactory system due to swelling, polyps or sinus disease), other cases involving damage to the sensory nerves of the nose (i.e.\nIn the report, the researchers describe endoscopic procedures to position electrodes in the sinus cavities of five patients with an intact ability to smell.\nOur scientists are driven by a mission to discover the basic biology underlying these conditions and to develop new treatments and cures.\nThe findings described in the International Forum of Allergy & Rhinology report demonstrate this feasibility.\n\u201cThere\u2019s currently so little that we can do for these patients, and we hope to eventually be able to reestablish smell in people who don\u2019t have a sense of smell,\u201d Dr. Holbrook said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that a tremendous amount of work needs to be done before any relevant treatment technology might become available.", "answer": 1}, {"article": "\"Why is a higher adherence to the MedDiet related to slowing down the rate of cognitive decline?\nIn total, 18 out of the 135 articles met their strict inclusion criteria.\nAttention, memory, and language improved.\nTwo of the included studies focused on younger adults and they both found improvements in cognition using computerized assessments.\nThe MedDiet offers the opportunity to change some of the modifiable risk factors,\" he explained.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The ingredients of the Mediterranean Diet are available worldwide.", "answer": 2}, {"article": "A reality check on nootropics and other efforts to keep aging at bay\nThat\u2019s because when you up one circuit in the brain, you\u2019re probably impairing another system.\u201d\n\nEarly studies attributed a lot of short-term benefits to nootropics \u2014 so much so that in 1983, Russian scientists turned to phenylpiracetam to boost the physical and mental performance of cosmonauts during space flight.\nNgo has experimented with piracetam himself (\u201cThe first time I tried it, I thought, \u2018Wow, this is pretty strong for a supplement.\u2019 I had a little bit of reflux, heartburn, but in general it was a cognitive enhancer.\nI\u2019m trying to give them a little more wiggle room \u2014 but in a safe way.\u201d\n\nHe says he screens his patients for addiction and cardiovascular problems and creates individual treatment plans based on their health histories and blood tests.\nAs Plato is said to have stated, \u201cI fast for greater physical and mental efficiency.\u201d The philosopher Pythagoras reportedly demanded that his students fast 40 days before attending his lectures.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a good job here, although it injects confusion when it states that in the U.S. piracetam \u201ccan be sold only for research purposes,\u201d but later says that piracetam and similar drugs are available online. In fact, the FDA at least twice warned suppliers, in 2010 and 2012, that piracetam was classified as a drug and could not be sold as a supplement. According to online accounts, that FDA action prompted major retailers to stop carrying it, which could explain why it\u2019s not present in some products marketed as nootropics.\nThe story also states: \u201cA number of companies now market nootropic \u2018stacks,\u2019 or formulas, some of which include piracetam, herbal remedies, amino acids and citicoline, a naturally occurring brain chemical that can be taken orally as a supplement, intravenously or as a shot.\u201d", "answer": 1}, {"article": "\u201cIt\u2019s reasonable to screen for something that\u2019s common, dangerous and has a treatment that\u2019s effective and safe.\u201d\n\nDr. William Cooper, a pediatrics and preventive medicine professor at Vanderbilt University, called it \u201can innovative approach\u201d that finds not just kids at risk but also parents while they\u2019re still young enough to benefit from preventive treatment, such as cholesterol-lowering statin drugs.\nThe study authors in England estimated that if cholesterol testing costs $7 and gene testing costs $300, it would cost $2,900 for every person identified as having the disorder.\nIn the US, cholesterol tests cost around $80 and usually are covered by health insurance though much lower prices often are negotiated.\n\u201cI hadn\u2019t heard of it before.\u201d\n\nThe study did not address whether screening is cost-effective.\nThe study also revealed parents who had the condition but didn\u2019t know it, and had passed it on to their children.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Are these sorts of genetic tests available for parents to buy off the shelf, or ask for a referral from a doctor to get? The story doesn\u2019t clarify.", "answer": 0}, {"article": "\"It's protecting against a severe disease, particularly in elderly adults,\" he said, \"so the benefit, I think, is overwhelming that we should be using this because it's recommended.\"\nThe CDC has more on the shingles vaccine.\nThe findings are published in the Jan. 12 issue of the Journal of the American Medical Association.\nBut the vaccine can cost a couple of hundred dollars, he said, perhaps making it out of reach for those with limited resources.\nFor now, he advises getting it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story reports that the vaccine has been available since 2006. ", "answer": 1}, {"article": "The study appears in the latest issue of the journal Ophthalmology.\nAbout 3 million Americans and 60 million people worldwide have glaucoma, and the numbers are projected to rise over the next few decades as the population ages.\nIn the study, researchers were able to predict who was at increased risk of developing the eye disease with some accuracy by measuring blood vessel thickness in the retinas of study participants using a computer-based imaging tool.\nEarly detection is key, but without regular eye exams, most people don\u2019t know they have a problem, says ophthalmologist Andrew Iwach, MD.\nCompared with the group as a whole, those people who were diagnosed with the eye disease during the following decade were older, had higher blood pressure, and were more likely to be female.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There was no discussion of what the \u201ccomputer-based imaging tool\u201d really was.\u00a0 Is it equipment already readily available and in use?\u00a0 If not, what is it, and what would it take to implement?\nNo details were provided \u2013 a weak spot in the story.\nThe story should have made the connection between retinal photography that is currently done for diabetic eye screening and this new, alternative use of the same images.", "answer": 0}, {"article": "We are excited to announce that FibromyalgiaTreating.com is now part of RedOrbit.com. All of the same great people, writers and editors but now with more firepower. We now have access to an enormous amount of additional research information from doctors and scientists. We can now extend to other conditions that may be part of your everyday lives and help you on a broad level if that is what you need. We are here for you and now, better than ever so sit back and enjoy the new Fibromyalgia Treating by RedOrbit!", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that about 30% of mammography centers use computer-aided detection (CAD) technology. ", "answer": 1}, {"article": "The prostate study sought a better way to use PSA tests, which are troublesome because PSA can be high for many reasons besides cancer, and doctors don't know which cancers need treatment or whether screening saves lives.\nThis thing documents it,\" Brawley said.\nHPV tests cost $80 to $100 compared to $20 to $40 for Paps.\nCervical cancer is easy to prevent.\nFew of the Swedish men were treated for prostate cancer as most men are today, which can affect survival.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "With his colleagues, he looked back at some 40,000 such surgeries done at dozens of academic medical centers in the U.S. \u2014 roughly 14,000 open procedures and 26,000 laparoscopic ones.\nFirst, it looks only at academic medical centers.\n\u201cOverall, this study shows benefit from laparoscopy on every aspect, including cost,\u201d he told Reuters Health.\nBut when you become sicker, laparoscopy is better,\u201d said Oleynikov.\nDoctors say this type of operation hurts patients less afterward than the conventional \u201copen\u201d method, which involves one long incision in the abdomen of up to 12 inches.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The widespread use of laparascopic appendectomy was clear in the story.", "answer": 1}, {"article": "\"Sixty to 80 percent [success] for something that somebody's not going to get guaranteed pain relief -- in my mind, it's not something I would go for,\" Duggal says.\nIt's the same technology used since the 1980s to blast kidney stones, an application called lithotripsy, but for foot problems doctors use less intense shock waves.\nIt's called platelet-rich plasma, and it involves isolating blood cells called platelets from patients' own blood and injecting them into the plantar fascia.\nIt's a kind of paradox: Theodore is damaging her foot in order to heal it.\nIn high-impact activities like running, the forces even exceed the actual weight because it's so concentrated in a narrow spot where the fascia attaches to the heel bone.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story\u00a0says that shockwave therapy is \"beginning to catch on around the U.S.\" While this\u00a0gives readers the accurate impression that the treatment is approved for use and available in some places, it doesn\u2019t really give readers a sense as to how\u00a0likely they are to find it at their local doctor\u2019s\u00a0or orthopedist\u2019s office. Although it earns a satisfactory, the story could have provided a bit more detail on the history of these devices in the U.S. (they were first approved for use in 2000) and how widespread they have become.", "answer": 1}, {"article": "But investors had been anticipating a bigger effect.\nVictoza is only the second diabetes drug to show such heart benefits, after Eli Lilly (LLY.N) and Boehringer Ingelheim\u2019s pill Jardiance.\nThere were fewer cases of pancreatitis, which has been viewed as a potential problem, but more cases of pancreatic cancer, although the difference was not statistically significant.\nThere was also concern that Victoza did not appear to lower heart risks in American patients monitored in the study, despite doing so in other parts of the world and producing a solid result globally.\nLilly is conducting a similar large study to try and prove the heart benefits of its once-weekly GLP-1 drug Trulicity.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is already established on the market, calling it \u201ctop-selling\u201d in the first line and mentioning that it is typically prescribed as a third or fourth option.", "answer": 1}, {"article": "By comparison, the only approved long-term prescription weight loss medication available on the market today, Xenical, is associated with a seven-pound weight loss when combined with diet and exercise.\nThe Food and Drug Administration denied the request, asking for more safety data from the company before moving forward.\nThe drugs, phentermine and Topamax, in combination with lifestyle and weight-loss counseling were associated with a 18-22 pound weight loss in trial participants, compared with a three-pound weight loss in patients who received counseling alone.\n\"But unless it's paired with aggressive lifestyle changes, it may not be great in the long term.\"\nPhentermine is commonly used as a short-term weight loss treatment, and was previously paired with fenfluramine to make the successful but now-discontinued weight loss drug Fen-phen.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that Qnexa was not approved: \u201cThe Food and Drug Administration denied the request, asking for more safety data from the company before moving forward.\u201d", "answer": 1}, {"article": "(That\u2019s a high dose; a 3 oz.\nWhat\u2019s more, the people who showed the highest blood levels of the omega-3 fats (people absorb it at different rates) showed the greatest reduction in scarring \u2014 13% \u2014 compared to those with the lowest levels.\nFor the study, published in the journal , they studied nearly 360 people who recently had a heart attack, who were randomly assigned to take 4g of omega-3 fatty acids or a placebo pill for six months.\nResearchers led by Dr. Raymond Kwong at Brigham and Women\u2019s Hospital wanted to find out, so they took advantage of more sophisticated imaging techniques that can provide detailed pictures of the heart and how it\u2019s changing in the days and weeks after a heart attack.\nIt\u2019s the first encouraging strategy for protecting the heart a heart attack; the more remaining healthy tissue that can be saved, the stronger the heart will be.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Most people understand that fish oil is available over the counter, so we\u2019ll rate this Satisfactory\u2013though just marginally, because the fish oil prescribed to people in the treatment arm of the study was not standard over-the-counter fish oil pills; see our discussion on\u00a0this in the \u201cDiscuss costs\u201d section\u00a0above.", "answer": 1}, {"article": "Despite the fact that there have been no randomized controlled trials on whether metformin really can prevent cancer, researchers expressed excitement both over this animal study and previous epidemiological evidence pointing to this possibility.\nInsulin may have a relationship with cancer.\nAnd when the drug was administered by injection, the improvement seen was 73 percent.\nAnderson Cancer Center in Houston, at a Wednesday news conference.\nOthers believed that the finding might influence the choice of drugs in people with diabetes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The current widespread use and availability of metformin is clear from the story", "answer": 1}, {"article": "The number of deaths caused by the condition dropped only little, however: from 12.3 per 100,000 in 1998 to 11.9 per 100,000 in 2006.\n\u201cI think doctors should think carefully about the pretest probability of a pulmonary embolism before they order this test,\u201d Wiener told Reuters Health.\nIt\u2019s been estimated that more than 600,000 Americans have a pulmonary embolism each year.\nThe condition usually occurs when a blood clot travels from the legs to the lungs, sometimes with fatal results.\n\u201cRight now, it is a difficult place for the patient to be in,\u201d Wiener said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that chest CT scans are \u201cbeing used in millions of patients every year in the US.\u201d", "answer": 1}, {"article": "But there is debate about whether the eye movement makes a difference, said Stephen Holland, founder of the Capital Institute for Cognitive Therapy and co-author of the textbook \u201cTreatment Plans and Interventions for Depression and Anxiety Disorders.\u201d \u201cThe question is whether stimulation adds to it.\u201d He does not use it in his practice because he considers it no more effective than cognitive behavioral therapy.\n\u201cIt\u2019s integrating what\u2019s stuck in time,\u201d explained Kalin, the psychologist.\nShe occupied herself with press inquiries and funeral arrangements.\nWhat are we doing?\u201d\n\nBut Henn was encouraged by the progress she made.\nKalin nodded, and they began processing memories again.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that one can find clinical psychologists who will administer the therapy.", "answer": 1}, {"article": "European regulatory bodies recommend pharmaceutical-grade chondroitin sulfate as well as pharmaceutical-grade glucosamine sulfate as first-line treatments for osteoarthritis, Reginster said by email, because of the side effects associated with celecoxib and other non-steroidal inflammatory drugs (NSAIDs) including stomach ulcers, bleeding, liver and kidney problems.\n\u201cStudies like this highlight that medicine is still an art - we do not have perfect answers, and we have to individualize for each patient.\u201d\n\nThe study was sponsored by IBSA Institut Biochimique SA, a pharmaceutical company based in Lugano, Switzerland, that makes the chondroitin sulfate supplements used in the test.\nSome have found the supplements to be as effective as ibuprofen (also an NSAID), and some have found that chondroitin sulfate is no more effective than placebo, he told Reuters Health.\nThose who took chondroitin sulfate or celecoxib had similar levels of pain relief at the end of the study, and in both groups the improvement was greater than for those taking just a placebo, according to the report in Annals of the Rheumatic Diseases.\nDr. Michael Shepard of Hoag Orthopedic Institute in Orange, California, noted that the study had a relatively low number of participants and that most U.S. studies of this type would run two years rather than six months.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that pharmaceutical-grade chondroitin is not the same as the labeled supplement one might buy over-the-counter, but makes no mention of how else to obtain it. Can doctors prescribe it? And do patients need a prescription to obtain it? Is there a brand name associated with the high-grade\u00a0formulation?", "answer": 0}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\nWashington, DC--For years after it was administered, growth hormone continued to reduce the risk of fractures and helped maintain bone density in postmenopausal women who had osteoporosis, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.\n\"Our study is the largest and longest controlled study of growth hormone treatment for osteoporosis in postmenopausal women to date,\" said one of the study's authors, Emily Krantz, MD, of S\u00f6dra \u00c4lvsborgs Hospital in Bor\u00e5s, Sweden.\nMore than 10 million American adults have osteoporosis, and 80 percent of the people being treated for the condition nationwide are women, according to the Society's Endocrine Facts and Figures Report.\n\"The findings indicate the beneficial effects of growth hormone remained long after the treatment ceased,\" Krantz said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Many readers may know that growth hormones are available and already used for the treatment of short stature in children. But the release doesn\u2019t establish this for those who might not know. Are these hormones prescription-only? Over the counter? Was it a new formulation developed for use in the study? It\u2019s impossible to tell.", "answer": 0}, {"article": "The Claim: Red palm oil, a deep orange fat pressed from the palm tree fruit, is a superfood\u2014packed with healthy antioxidants and good for the heart, say companies who sell it.\n\nThe Verdict: The colorful oil is rich in tocotrienols, nutrients in the vitamin E family, and carotenoids, which the body converts into vitamin A. Several studies suggest possible benefits in stroke and liver disease from vitamin extracts made from the oil, but so far there isn\u2019t proof that consuming the oil can ward off disease, scientists say.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As noted above, the story mentions some specific brands. It also provides some details about the differences between varieties of red palm oil.", "answer": 1}, {"article": "With statins you get toxicity \u2013 with these drugs we don\u2019t see any side effects with the antibody.\u201d\n\nIn an accompanying editorial, authors Dr. Stephen G. Young, and Loren G. Fong, Ph.D. write: \u201cAt this point, the status of PCSK9 therapeutics appears to be full speed ahead.\n\u201cThis is a hot research area and everybody is so close together.\"\nAll of those subjects were also receiving treatment with the statin Lipitor.\nA control group of subjects with nonfamilial high cholesterol was treated only with a special diet.\nThe REGN727 study included three trial arms.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that this is an experimental approach.", "answer": 1}, {"article": "This research builds upon previous studies demonstrating that art, music, and other similar therapies can effectively reduce symptoms of dementia without medication.\nThe apps were freely available on iTunes and varied greatly in their cognitive complexity--from an app that displayed puppy photos to one that featured Sudoku puzzles.\nThe researchers found that tablet use was safe for every patient, regardless of the severity of their dementia, and that with proper supervision and training, the engagement rate with the devices was nearly 100 percent.\n\"Tablet use as a nonpharmacologic intervention for agitation in older adults, including those with severe dementia, appears to be feasible, safe, and of potential utility,\" said Vahia.\nThe tablet, however, gives you the option of switching from one app to another easily, modifying the therapy seamlessly to suit the individual.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that computer tablets are widely available, and at ever-diminishing costs. The release explained that all of the 70 apps used were available for free on iTunes.", "answer": 1}, {"article": "Results of the regenerative medicine study published in the journal Nature Nanotechnology.\nWe have shown that skin is a fertile land where we can grow the elements of any organ that is declining,\" said Dr. Chandan Sen, director of Ohio State's Center for Regenerative Medicine & Cell Based Therapies, who co-led the study with L. James Lee, professor of chemical and biomolecular engineering with Ohio State's College of Engineering in collaboration with Ohio State's Nanoscale Science and Engineering Center.\nOur technology keeps the cells in the body under immune surveillance, so immune suppression is not necessary,\" said Sen, who also is executive director of Ohio State's Comprehensive Wound Center.\nResearchers at The Ohio State University Wexner Medical Center and Ohio State's College of Engineering have developed a new technology, Tissue Nanotransfection (TNT), that can generate any cell type of interest for treatment within the patient's own body.\nThis cargo, when delivered using the chip, converts an adult cell from one type to another, said first author Daniel Gallego-Perez, an assistant professor of biomedical engineering and general surgery who also was a postdoctoral researcher in both Sen's and Lee's laboratories.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "From the final sentence we get a hint that applicability in humans is a long way off: \u201cResearchers\u00a0plan to start clinical trials next year to test this technology in humans.\u201d\nIt\u2019s important to note that\u00a0potential treatments in mice fail to materialize as a treatment in humans about 95 percent of the time. The release should have been a lot more cautious and pointed out that this concept will require many years of study.", "answer": 1}, {"article": "But such evidence often does not pan out in human studies.\nFor heart disease, the benefit of metformin over most other drugs for Type 2 diabetics has been seen repeatedly in clinical trials.\nSo much metformin is taken in the United States \u2014 some 72 million prescriptions were written for it in 2013 \u2014 that a recent study found higher trace levels of it (presumably from the urine of people taking it) in Lake Michigan than of any other drug, including caffeine.\nFor those with Type 1, metformin is being tested only as an add-on to insulin.\nHe theorizes that the risk of developing Type 1 rises when excess demand for insulin is placed on the pancreas in children who are even slightly overweight.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly notes that metformin is an existing prescription drug marketed under a number of unpronounceable names.", "answer": 1}, {"article": "BOSTON (Sept. 14, 2016) -- Although targeted drugs like Gleevec have revolutionized the treatment of chronic myelogenous leukemia (CML), patients generally must take them for the rest of their lives and may cease benefiting from them over time.\nThe findings, reported online today by the journal Cancer Discovery, raise the prospect that Ezh2 blockers, in combination with Gleevec and similar drugs, could eradicate the disease in some patients in relatively rapid fashion or could be an effective therapy for those who become resistant to Gleevec-like agents, the authors state.\nAlthough adding Ezh2-targeting agents to the standard drug regimen for CML has the potential to dramatically shorten the treatment period for many patients, ethical considerations may lead to the agents' first being tested in patients who don't respond to Gleevec and similar drugs, either initially or after drug resistance develops, Orkin remarks.\nIn laboratory experiments, the Dana-Farber/Boston Children's researchers found not only that Ezh2 is overabundant in leukemia stem cells but that it helps them survive and give rise to full-fledged CML cells.\n\"The stem cells' dependence on Ezh2 suggests they will be especially vulnerable to drugs that target the protein,\" Orkin remarks.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes imatinib-like drugs are\u00a0the standard of care for CML patients, implying a\u00a0diagnosis would grant access to the drugs by prescription.\u00a0Though it doesn\u2019t name the potential\u00a0Ezh2 inhibitor drug, the release does note it\u2019s part of a Phase 1 trial, as well as other clinical trials\u00a0\u2014 implying it\u2019s not readily available. A\u00a0lack of absolute clarity here isn\u2019t helpful to readers, but there\u2019s enough to mark\u00a0this satisfactory. A statement that clarified that it would likely be years before testing in humans would be complete would have been appropriate here.", "answer": 1}, {"article": "The surgery she's upset about may be archaic - but it's very common.\nLike all laparoscopic procedures, a camera is inserted through a tiny incision to see into the abdomen; two other small incisions are made so that tools can be inserted to perform the surgery.\nIt's all over in about an hour, and patients are usually home within a day and back to normal within a week or two.\n\"You would think in today's age and the way that we've improved in so many areas of medicine, women would begin questioning this, but we're finding that they're not,\" said Beth Cahill of the National Womens Health Resource Center.\nWhat's happening now is that the vast majority, about 70 percent, are done the old-fashioned way, with a large surgical incision, lots of pain, and a six-to-eight-week recovery.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does comment on the fact that the availability of laparoscopic hysterectomy is somewhat limited. However, the story does not address the reasons why laparoscopic hysterectomy is limited, including the fact that it doesn\u2019t provide many advantages compared to vaginal hysterectomy. In fact, according to a Cochrane review, laparoscopic hysterectomy is associated with increased operating time and blood loss relative to vaginal hysterectomy.", "answer": 0}, {"article": "For more information, visit www.idri.org.\nEarly results from the Phase I study should be available in 2018, and the partners are currently exploring mechanisms to advance the vaccine through later-phase clinical trials should results from the Phase I study (clinical trial NCT03302897) support further evaluation.\n\"We believe this may be the most exciting breakthrough in leprosy treatment since multi-drug therapy, the current treatment for leprosy, was launched in the 1980s.\nScientists at IDRI, along with national and international collaborators including the National Hansen's Disease Program and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, with financial support from American Leprosy Missions, have developed a promising leprosy vaccine candidate designed to help treat leprosy and prevent exposed individuals from developing disease and the resulting disabilities.\nIn addition to IDRI and American Leprosy Missions, a variety of partners are taking part in efforts to eliminate leprosy, including Novartis and the Novartis Foundation.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does a good job here, noting: \u201cEarly results from the Phase I study should be available in 2018, and the partners are currently exploring mechanisms to advance the vaccine through later-phase clinical trials should results from the Phase I study (clinical trial NCT03302897) support further evaluation.\u201d", "answer": 1}, {"article": "TUHS neither provides nor controls the provision of health care.\n\"We show that we can intervene after disease is established and pharmacologically rescue mice that have tau-induced memory deficits,\" explained senior investigator Domenico Pratic\u00f2, MD, Scott Richards North Star Foundation Chair for Alzheimer's Research, Professor in the Departments of Pharmacology and Microbiology, and Director of the Alzheimer's Center at Temple at LKSOM.\nTo recapitulate the clinical situation of dementia in humans, in which patients are already symptomatic by the time they are diagnosed, Dr. Pratic\u00f2 and colleagues used specially engineered tau transgenic mice, which develop tau pathology - characterized by neurofibrillary tangles, disrupted synapses (the junctions between neurons that allow them to communicate with one another), and declines in memory and learning ability - as they age.\n\"At the onset of dementia, leukotrienes attempt to protect nerve cells, but over the long term, they cause damage,\" Dr. Pratic\u00f2 said.\nThey show, for the first time in an animal model, that tau pathology - the second-most important lesion in the brain in patients with Alzheimer's disease - can be reversed by a drug.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes the statement, albeit at the very end, that the research could \u201csoon translate\u201d into clinical use. That is at best misleading and provides a false hope for patients and their families, given that no timetable or process is given for what would be required to take the step to human use. \u00a0A plus is that the drug already is approved for use in asthma, but it is likely that even if further animal studies confirm the current work, clinical use is still months or even years away.", "answer": 0}, {"article": "Allergan Inc. said that two large human tests of its Botox drug, best known for smoothing wrinkles, showed that periodic injections prevent headaches in adults who suffer from chronic migraines.\n\nEven though details of the study weren't released, the announcement, which surprised many physicians and investors, sent Allergan's shares soaring 11%, or $5.95, to $60.53 at 4 p.m. in New York Stock Exchange composite trading. Botox has been used to treat severe headaches for many years, but some researchers have long been skeptical...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that Botox is available and FDA-approved for several other indications.", "answer": 1}, {"article": "\u201cIf it\u2019s happening because of fear or the common reason I hear \u2013 \u2018I just want to be done with it\u2019 \u2013 that\u2019s a different situation.\u201d\n\nTuttle\u2019s study found 60 percent of women with breast cancer chose lumpectomies, which remove only the tumors, not the whole breasts.\nThen the women can have genetic tests and assess their risks for follow-up cancers before deciding whether to have one or both breasts removed.\nIt\u2019s an emotional decision that women often make quickly, considering that surgeries often take place within days of their cancer diagnosis.\nResearch has found this procedure is equally effective, particularly with smaller tumors and often when used in combination with radiation.\nThe safety concerns have been reduced and cosmetic procedures have improved, but some women still probably regret the decision, she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article implies, accurately, that double mastectomy is available at any facility that provides breast cancer treatment. ", "answer": 1}, {"article": "This benefit was independent of other heart risk factors such as advancing age, high blood pressure, family history of heart attack, body mass index, exercise, smoking, and caffeine and alcohol intake.\nOne serving of blueberries or strawberries equals about one cup.\nDuring the study period, 405 participants had heart attacks.\nBesides flavonoids, berries also are loaded with other nutrients, including vitamin C, potassium and folate.\nFind out at the American Heart Association.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of strawberries and blueberries is not in question.", "answer": 2}, {"article": "\"To address inconsistencies in prior studies on vitamin D and to investigate associations in population subgroups, we analyzed participant-level data, collected before colorectal cancer diagnosis, from 17 prospective cohorts and used standardized criteria across the studies,\" said Stephanie Smith-Warner, PhD, an epidemiologist at the Harvard T.H.\nVitamin D can be obtained in the diet, particularly from fortified foods, from supplements, and from sun exposure.\nProtective associations were seen in all subgroups examined.\nChan School of Public Health and co-senior author on the article.\n\"This calibration approach enabled us to systematically explore risk over the broad range of vitamin D levels seen internationally.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Supplements, vitamin D-containing foods, and sunlight are pretty much available everywhere.", "answer": 2}, {"article": "Specifically, seizure frequency dropped in the CBD-treated group by 39 percent from a median of nearly 12 convulsive seizures per month before the study to about six; three patients' seizures stopped entirely.\nThe study included a liquid pharmaceutical formulation of CBD, called Epidiolex, which is manufactured by GW Pharmaceuticals and has not been approved by the U.S. Food and Drug Administration.\nIn addition to Dr. Devinsky, the co-authors in this study were: J. Helen Cross, PhD, FRCPCH, Linda Laux, MD, Eric Marsh, MD, Ian Miller, MD, Rima Nabbout, MD, Ingrid E Scheffer, MD, PhD , Elizabeth Thiele, MD, and Stephen Wright, MD on behalf of The Cannabidiol in Dravet Syndrome Study Group.\nIn that program, both the researchers and patient's families knew they were receiving CBD, which may have introduced a bias into the results.\nThe difference in the degree of seizure reduction between the CBD group and the placebo group was both statistically significant and clinically consistent.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that Epidiolex \u201chas not been approved by the U.S. Food and Drug Administration\u201d yet, so readers can assume that it is not yet available to the public. The FDA does, however, consider cannabidiol an investigational product for treating children with epilepsy and has \u201cexpanded access provisions\u201d that allow its use. This would have been useful information to include in the release.", "answer": 1}, {"article": "MONDAY, March 22, 2010 (HealthDay News) -- The anti-clotting drug Plavix is of modest benefit in cutting the odds of death in patients with heart failure and heart attack who don't undergo angioplasty, a new study finds.\nDanish researchers analyzed data from more than 31,000 patients hospitalized with heart attack between 2000 and 2005 and divided the patients into four groups: two groups with heart failure (one that received Plavix and one that did not) and two groups without heart failure (one that received Plavix and one that did not).\nThe study appears online March 23 and in the March 30 print issue of the Journal of the American College of Cardiology.\nHe said the benefit of the drug found in this study is \"of unquestionable practical importance,\" and added that the positive outcomes seen in a relatively short follow-up suggests potentially even better long-term survival.\nA randomized study comparing conventional heart failure therapy with and without Plavix \"is needed urgently,\" the editorial writer concluded.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0Plavix (clopidogrel) is a medication already on the market. \u00a0While the story did not state this explicitly, it was implied.", "answer": 1}, {"article": "Scientists had previously observed that cinnamaldehyde, an essential oil that gives cinnamon its flavor, appeared to protect mice against obesity and hyperglycemia.\nThe study is titled \"Cinnamaldehyde induces fat cell-autonomous thermogenesis and metabolic reprogramming,\" DOI: 10.1016/j.metabol.2017.08.006.\nTheir findings, which appear in the December issue of the journal Metabolism, indicated that cinnamaldehyde improves metabolic health by acting directly on fat cells, or adipocytes, inducing them to start burning energy through a process called thermogenesis.\n\"It's only been relatively recently that energy surplus has become a problem,\" Wu said.\nAnd because it is already used widely in the food industry, it might be easier to convince patients to stick to a cinnamon-based treatment than to a traditional drug regimen.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release strongly suggests that cinnamon is not yet ready as a weight loss aid without saying the actual words. The news release warns that researchers have not yet determined \u201chow best to harness cinnamaldehyde\u2019s metabolic benefits without causing adverse side effects.\u201d It also cautions against using cinnamon as an obesity protectant or treatment at this time.", "answer": 1}, {"article": "Antioxidants can also provide some protection but there has been controversy over the effectiveness of such food supplements, he said: \u201cPersonally, I think it is much better to eat lots of vegetables and fruit rather than taking any supplements.\u201d\n\nDr Richard Russell, a consultant respiratory physician in the NHS and medical advisor to the British Lung Foundation, who was not involved in the research, said the inhaler was both credible and promising: \u201cEctoine is a beautifully elegant molecule and it clearly works by helping water to stabilise, giving you a film of water in times of stress.\u201d\n\n\u201cThe work that has been published thus far, in credible, internationally recognised journals, show that this stuff has positive properties, protecting against triggered inflammation,\u201d he told the Guardian.\nI was in New York last week, and the air was also not very clean.\u201d\n\nThe protective effect of ectoine was discovered by Prof Jean Krutmann and colleagues at the Leibniz Research Institute for Environmental Medicine, while investigating whether the molecule could protect skin against sun damage.\nThis means large clinical trials are not required for official approval and the inhaler could be on sale soon, at an estimated cost of \u00a317 a month, after Bitop selects a marketing partner.\nA version of the product for use in nebulisers will be available this year in Germany and Poland, while an ectoine-based nasal spray for allergy relief is already available.\nThe best thing is that we have clean air because then we don\u2019t need any prophylactic treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it relatively clear that the inhaler isn\u2019t available but should be soon.\u00a0More specifics would have been helpful, though.", "answer": 1}, {"article": "Researchers used CAR-T to treat a man with brain cancer to some success\n\nGlioblastoma is one of the deadliest cancers \u2014 an illness that responds to few treatment options, and often poorly. But a single case study that uses an experimental immunotherapy to treat these brain tumors might give oncologists a new way to approach the disease.\n\nThe therapy, called CAR-T, is controversial and has faced hurdles in clinical trials. It has shown great promise in treating blood cancers like leukemia and lymphoma \u2014 but has proven challenging in treating other forms of the disease, including solid tumors.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The STAT story\u00a0notes the availability of CAR-T commercially (by naming the companies) for blood cancers, and it quotes an outside source as essentially saying \u201cdon\u2019t hold your breath\u201d awaiting the viability of this treatment for glioblastoma.", "answer": 1}, {"article": "With more than a decade of experience designing and creating rapid, point-of-care diagnostics, Henrick was formerly an integral part of the team that developed and optimized the world's fastest point-of-care HIV test in 2005.\nA stool sample containing high levels of these markers will be strong enough to change the test's liquid display from pink to yellow, indicating high levels of Bifidobacterium.\nIn a landmark clinical trial, Evivo produced rapid, substantial and persistent stabilization of the infant gut microbiome, to help set a foundation for life-long health.\nEvivo's quick and non-invasive test measures the presence of markers that indicate low or high levels of good Bifidobacterium , such as acetate and lactate.\nEvolve BioSystems' Evivo is the only baby probiotic clinically proven to restore Bifidobacterium to a baby's gut and reduce potentially harmful bacteria by 80 percent.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The Evivo stool test is described as a prototype, implying it\u2019s not available on the market.", "answer": 1}, {"article": "CHICAGO\u2014Using whole-brain radiation to treat cancer that has spread to the brain is a treatment that for many patients is worse than the disease, a new study suggests.\n\nResearchers said the technique, when used after a more precise radiotherapy to kill the cancer, resulted in more memory loss and other cognitive deficits than treating with radiotherapy alone. While the more aggressive treatment was better at preventing recurrence of tumors in the brain, it didn\u2019t extend survival.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that whole-brain radiation treatment was prevalent for many years and is now declining in popularity.", "answer": 1}, {"article": "\"With my technique, there is a much more limited scar and it limits the scarring in the fold of the breast, which is usually the most uncomfortable. By the third day, most women are up and around and doing most of their activities.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that 140,000 women per year get breast reduction surgery. This clearly implies wide availability. ", "answer": 1}, {"article": "Dr Francoise Soussaline, PhD, DSc, IMSTAR's president said: \"To bring a universal 'liquid biopsy' blood test for cancer to market, it must achieve a number of criteria, including high sensitivity and specificity and be fully automated with high throughput for a medical routine use.\nThe research team believes that the test could be the first screening tool to 'rule in, or rule out' cancer in patients under suspicion of the disease, alongside other traditional diagnostics methods.\nThe Bradford team had scored 100 cells per slide, but the Pathfinder\u2122 system is able to analyse up to 10,000 cells per slide, and uses Artificial Intelligence concepts in its proprietary software.\nIt measures the damage to the DNA of white blood cells when subjected to different intensities of ultraviolet (UV) light, revealing measurable differences in the cells' susceptibility to further damage in patients with cancer.\n\"We believe that the combination of Bradford's innovation and IMSTAR's unique expertise has shown that TumorScan can achieve these requisites.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The text offers only a general statement at its end indicating that work to develop the test will continue. Ideally the release would have explained that a prospective trial is still needed.", "answer": 0}, {"article": "She lived a healthy lifestyle.\nIt is a good example of how this disease sneaks up on people and gives no warning.\u201d\n\nA test for pancreatic cancer could save lives, perhaps even Flippo-Morton\u2019s, Raghavan said.\n\u201cUsing this test we were 100 percent accurate at identifying all cancer patients.\u201d\n\nIn 2015 48,960 Americans will be diagnosed with pancreatic cancer, according to estimates by the National Cancer Institute.\n\u201cIt kills people and it kills them quickly.\u201d\n\nA screening test could have a huge effect, said Dr. Timothy Donahue, an associate professor of surgery and molecular and medical pharmacology and chief of pancreas and gastrointestinal surgery at the University of California, Los Angeles.\nIt now needs to be taken over by some diagnostic corporation before it can launch into something for widespread use.\u201d\n\nWhat needs to be determined is \u201cwhat the sensitivity and specificity would be in a screening population of 100,000 people,\u201d said Dr. Brian Wolpin, of the Dana Farber Cancer Institute.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We were surprised to see mention in the story that a clinical test could be available within a year. Given that the test will need to be further validated in a much larger group of study subjects, we think that\u2019s very unlikely. The story does frame the comment as \u201cjust speculation\u201d and notes that additional research will be needed. We\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "And certain rigorous laboratory procedures had to be followed.\n\u201cIt\u2019s very important to educate health care providers that pregnant women are buying these tests.\u201d\n\nAnother type of test not studied by the researchers has become popular because it is cheaper and can be done at home.\nThe tests are not regulated by the Food and Drug Administration because they are not used for medical purposes, a spokeswoman said, but the agency is investigating the explosion of home genetic tests like these and genome-sequencing kits.\nDr. Diana Bianchi, executive director of the Mother Infant Research Institute at Tufts Medical Center in Boston and the lead author of the sex-determination report, said, \u201cA very important aspect of the study is how this advances prenatal care.\u201d\n\nBut there are potential concerns too, she said, including that women may spend more than $250 for the tests when they don\u2019t have insurance for prenatal care.\nSex-determination tests are part of a new frontier of fetal DNA testing, which can be used to determine paternity and blood type, and is being used to develop early screening tests for genetic diseases or disorders like Down syndrome.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Yes, the story explains there are a variety of tests that have been widely available to consumers. But the story could have done a better job of connecting the dots for readers. Exactly how does one get a blood test done for a home test kit? Raises questions like: do I go to a lab? Finger stick? Are their costs other than the test? Shipping? Do I do this at home myself? Working with my medical care team? How soon do I get the results?, etc. Process of using several common kits could have been better described.", "answer": 1}, {"article": "\"All our patients considered the [treatment] to be worthwhile and beneficial, though some patients experienced side effects,\" study head Weiqiong Gu, MD, of Ruijin Hospital in Shanghai, tells WebMD.\nThe blood stem cells are then removed from the body and frozen.\nOne patient has gone without insulin injections for 3.5 years.\nThe study was very small, and the procedure is not ready for widespread use.\nThis is the latest of several stem cell studies to show promising results for the treatment of type 1 diabetes, Ratner notes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that the procedure was not ready for widespread use.", "answer": 1}, {"article": "Sept. 28, 2010 -- Intrauterine devices (IUDs) -- used to prevent pregnancy -- may also be an effective treatment for some patients with early-stage uterine cancer who want to preserve their fertility.\n\nIn a small, early study, carefully selected patients with cancer that had not spread beyond the inner lining of the uterus were treated with IUDs that released the hormone progesterone.\n\nThe treatment was found to be as effective as oral hormone therapy, which is the most widely used nonsurgical, fertility-sparing treatment for the cancer.\n\n\u201cOur results show promise for the treatment of younger endometrial cancer patients with early disease who desire pregnancy in the future,\u201d gynecologic oncologist Lucas Minig tells WebMD. \u201cBut patients must be screened very carefully to make sure their disease has not spread.\u201d", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Progestin IUD is clearly available.", "answer": 1}, {"article": "Other studies are further along.\nSo it's possible, Gorodeski explained, that the \"modest\" symptom improvements would have happened anyway.\n\"They've shown that this approach is feasible,\" said Dr. Eiran Gorodeski, a heart failure specialist at the Cleveland Clinic in Ohio.\nThe message for patients, he added, is that heart failure can be treated, and researchers are looking for \"innovative\" ways to improve that treatment.\nThe theory, he said, is that \"hibernating\" cells in the heart muscle can then function better.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is another strong point, with the story making it very clear that this is not a viable treatment option for the foreseeable future. \u201cAll stem-cell therapies remain experimental,\u201d the story says at one point. Shortly thereafter, the story quotes a heart failure specialist as saying: \u201cThere\u2019s no cell therapy we can offer patients right now.\u201d", "answer": 1}, {"article": "Call 911 or your doctor for all medical emergencies.Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.\nResponsibility for the information and views expressed therein lies entirely with the author(s).\nThere was no significant association between healthy dietary patterns and risk of kidney failure.\nThis content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition.\nASN does not offer medical advice.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of healthy dietary options is one of the main points of the release.", "answer": 1}, {"article": "368 infants from the Basel-Bern Infant Lung Development birth cohort in Switzerland were included in the study.\nThis is the first time that we were able to show the effect of the 17q21 variants on respiratory symptoms during the 1st year of life, depending on breastfeeding status.\nIt is already known that environmental factors have a modifying effect on specific genetic risk, so the aim of this new study was to find out whether this could also be true for breastfeeding and this specific gene related to asthma with the respect to respiratory symptoms in early infancy.\nDr Gorlanova said: \"As research in this field progresses, we are understanding more and more about the gene-environment interaction for the development of asthma.\nInfants who have a genetic profile linked with asthma risk could be protected against respiratory symptoms if they are breastfeed, according to a new study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Breastfeeding is indeed routinely available but the availability of genetic testing for the\u00a0chromosome 17q21 variant is not described. Is this test generally available and if so, is it covered by insurance? The release doesn\u2019t say.", "answer": 0}, {"article": "These findings provide strong evidence against current practice and can thus be expected to change paediatric intensive care worldwide.\nThe artificial nutrition is infused directly into the bloodstream.\nCritically ill children in intensive care are unable to eat independently.\nThey conducted a randomized controlled trial that involved 1,440 critically ill children.\nThis common practice is based on the assumption that it will help them recover more quickly.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Parenteral feedings are a part of standard care and that is understood.", "answer": 2}, {"article": "The recommendations also support the position of the American College of Cardiology and the American Heart Association, which in 2013 radically shifted their advice from suggesting that doctors focus on the level of a patient\u2019s low-density lipoproteins (LDL) or \u201cbad cholesterol\u201d to looking at a more comprehensive picture of risk based on things such as weight and blood pressure, as well as lifestyle factors.\nThey are more likely to not only get to the hospital and survive until they are discharged but also survive in greater numbers a year after their hospitalization than those who do not use statins.\nThe task force and AHA groups carry tremendous influence in medical practice and in what insurance companies will cover.\nIt is also slightly more conservative when it comes to determining the benefits of taking the medications, which include Lipitor, Crestor and Zocor.\n\u201cPeople in this group should make an individual decision with their doctor about whether to start taking statins,\u201d the task force advised.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear and obvious that statins are available via\u00a0a doctor\u2019s prescription.", "answer": 2}, {"article": "If media wish to link to the paper once it's published, they can use the following link, which will go live when the embargo lifts: http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(16)30179-5/abstract\nThe research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as \"a game changer for future treatment of asthma.\"\nThe study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.\nThe NIHR Leicester Respiratory Biomedical Research Unit - a partnership between the University of Leicester and Leicester's Hospitals - focuses on promoting the development of new and effective therapies for the treatment of respiratory diseases including severe asthma and chronic obstructive pulmonary disease (COPD).\nThe sputum eosinophil is an inflammation measurement of a white blood cell that increases in asthma and is used to assess the severity of this condition.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is fairly clear in pointing out that this was a clinical trial and that the drug, fevipiprant, isn\u2019t available to the public as of yet.", "answer": 1}, {"article": "It's the first study to specifically examine...\nNow, it may be good for the brain as well.\nNow, it may be good for the brain as well.\nWe've long known that the Mediterranean diet is good for the heart.\nWe've long known that the Mediterranean diet is good for the heart.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of components of the Mediterranean diet is not in question.", "answer": 2}, {"article": "LONDON -- Sanofi-Aventis SA's obesity drug Acomplia can improve blood-sugar levels and weight loss in diabetic patients, according to a study presented at the World Diabetes Congress in South Africa.\n\nThe findings from the clinical trial have shown newly diagnosed patients with type-two diabetes who weren't taking antidiabetic drugs had significantly improved blood-sugar levels and lost more weight with Acomplia, compared with a dummy pill over a period of six months. In addition, Acomplia -- also known as rimonabant -- helped...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The fact that the drug discussed in this story is not currently available in the US is not completely clear in this story.\u00a0 The article does mention that this drug is available in Europe, but doesn't clearly state it isn't available in the US.\u00a0 It ends with the prediction that the new data should result in eventual approval of rimonabant by the FDA, though the time frame for such approval is not predictable.", "answer": 0}, {"article": "Her team reviewed MRI images from 130 patients treated for clot-caused strokes at Sainte-Anne Hospital in Paris between May 2006 and October 2008.\n\"A tool that can estimate the age of stroke would be of great value in cases of unknown stroke onset time,\" said lead researcher Dr. Catherine Oppenheim, professor of radiology at Universite Paris Descartes in France.\n\"This concerns as many as a quarter of all stroke patients who cannot be given tPA because they wake up with stroke symptoms or are unable to say when their stroke began.\"\n\"It's potentially helpful, and I don't know that it would take years to prove that,\" said Dr. Larry B. Goldstein, director of the Duke University Stroke Center in Durham, N.C.\n\nGoldstein noted that about 40 percent of stroke patients who arrive at his facility within two hours of symptom onset receive tPA.\nA study in The Lancet Neurology also found that a slight increase in deaths and bleeding in an extended treatment group over a three-month follow-up period underlined the notion that treatment within 3 hours -- although not required -- is still optimal.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story could have done a better job raising the question of availability of MRI around the US for urgent use at times like those described in the story or in the study \u2013 when there is a question about the 3 hour window. \u00a0The story alluded to this but was not fully discussed in the context of availability of treatment. Do 80% of hospitals or hospital regions have MRIs ready for this use?\u00a0 50%?\u00a0 10%? Availability of the technology in question is a key concern \u2013 with huge cost implications.", "answer": 0}, {"article": "Powerful chemotherapy and radiation treatments for cancer can impair a woman's fertility.\nTUESDAY, Oct. 6, 2015 (HealthDay News) -- Cancer patients who have ovarian tissue removed and stored for later transplantation have a chance at a successful pregnancy, a new study finds.\n\"So some of these women will still be able to have more children and avoid menopausal symptoms,\" she said, noting two more pregnancies have been reported to her laboratory since the study's publication.\n\"The pregnancy rate with frozen embryos is close to 50 percent, and results are getting better,\" he said, referring to another option for women hoping for a future pregnancy.\n\"This procedure is gaining ground worldwide as an optional fertility treatment for fertile female cancer patients who after cancer treatment most likely will be infertile,\" said lead researcher Dr. Annette Jensen, from the Laboratory of Reproductive Biology at Rigshospitalet in Copenhagen.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not say whether this approach, which requires a lot of planning ahead for a cancer patient, is widely available outside of research centers. The research was done in Denmark and it\u2019s not clear if it\u2019s offered here in the United States or how widely.", "answer": 0}, {"article": "This new development represents a big step forward in personalised medicine.\nWe are excited that CURATE.AI could ultimately enhance patient accessibility to important new combination therapies, saving lives in the process,\" said Prof Ho, who is also from the Biomedical Engineering and Pharmacology departments at NUS, as well as a member of the Biomedical Institute for Global Health Research and Technology (BIGHEART) at NUS.\nThis calibration is then used to create an individualised CURATE.AI profile, or map, that identifies the drug doses which enable the best possible treatment outcome at any given point in time.\nInitially, the doses of ZEN-3694 and enzalutamide were adjusted by the clinicians to better manage patient-reported quality of life.\nHowever, CURATE.AI has shown that patients can still respond to the therapies that have seemingly stopped working by continuously identifying the patient's optimal dosing parameters.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does make clear that clinical trials are under way. That\u2019s good. However, the release is written as if the clinical trials have already been completed successfully. For example, the release states that \u201cCURATE.AI is applicable to all diseases and all patients.\u201d There is, as far as can be discerned from everything else in the release, nothing that supports that statement. And despite the sweeping language used in the release, it is not at all clear when CURATE.AI may be available for clinical use.", "answer": 0}, {"article": "In 2012, a federally funded panel of experts on preventive care concluded there are more risks than benefits to screening American men for prostate cancer with the PSA test. And in April 2017, the U.S. Preventive Services Task Force dumped the decision squarely into the laps of patients and their doctors. Some men between 55 and 69 years of age might well decide to get their PSA checked, the task force said. After hearing the ledger of pros and cons, however, others in that age bracket might just as reasonably skip the screening test, the panel concluded.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that PSA screening is widely available.", "answer": 1}, {"article": "We don\u2019t want to hurt their feelings.\nIn decades past, there was a belief that surgery could \u201cget it all\u201d \u2014 eradicate the cancer before it could spread to organs and bones.\nThe modern approach is to cut out obvious tumors \u2014 because lumps big enough to detect may be too dense for drugs and radiation to destroy \u2014 and to use radiation and chemotherapy to wipe out microscopic disease in other places.\nThe results mean that women like those in the study will still have to have at least one removed, to look for cancer and decide whether they will need more treatment.\nThe new results do not apply to all patients, only to women whose disease and treatment meet the criteria in the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that removing all under-arm lymph nodes is the standard of care for women with breast cancer and that feelings about that standard are entrenched.", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nThe new study, supported by NIH\u2019s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), provides strong evidence that even a partial course can have some benefit.\nSteroids improve survival and reduce the chances of certain birth defects for extremely premature infants, even if the treatment course is not finished before delivery, according to a study funded by the National Institutes of Health (NIH).\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nAbout the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): The NICHD sponsors research on development, before and after birth; maternal, child, and family health; reproductive biology and population issues; and medical rehabilitation.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release reveals high up in the article that steroids are a standard treatment for pregnant women expecting preterm delivery, or before 34 weeks. \u201cThese drugs are known to reduce the chance of complications and heath among premature infants,\u201d it states.\nSince the release makes it clear that steroids are nothing new, we give it a Satisfactory rating here.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070902/10healthwatch.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly, oophorectomy, surgical removal of the ovaries, is available.", "answer": 1}, {"article": "Moreover, the higher the mean systolic BP was during the first week, the more it dropped on the second week of melatonin administration.\nMelatonin significantly reduced BP.\nFirst week control data were collected for 7 successive days.\nThe hypotensive effect was dependent on time.\nIncreased blood pressure and reduced robustness of circadian rhythms are frequently reported in elderly subjects.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Melatonin supplements are available almost everywhere.", "answer": 2}, {"article": "The bar was developed over the past 10 years by a team of scientists led by Drs.\n6 McCann, J. C., and Ames, B. N. (2009) Vitamin K, an example of triage theory: is micronutrient inadequacy linked to diseases of aging?\nUCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\nThe full potential of food-based supplements to do the work of some drugs without their negative side effects is just beginning to be seriously investigated.\nBecause of the strong flavors associated with some vitamins and minerals, CHORI partnered with the United States Department of Agriculture to produce a tasty bar.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "One can only assume that something at the clinical trial stage is not yet available to consumers. But the press release does not make that clear. Some enthusiastic commenters out there can\u2019t wait to get their hands on the product!", "answer": 0}, {"article": "But Gee believes reimbursing patients to play games could cut other health costs \u2014 by promoting exercise and preventing disease, for example, or even reducing the amount of expensive drugs people take.\nIt might seem like a strange vision for an industry known best for issuing denial letters.\nDrug companies are keeping an eye on these games, too.\nPatients and families fill out forms on mood and attention.\nAnd I have to do this without crashing the car.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that these video games are experimental and not currently available.", "answer": 1}, {"article": "The Food and Drug Administration has approved DBS therapy for movement disorders such as Parkinson's disease, tremor and dystonia \u2014 usually in people who haven't responded well to medications.\nThe current study used a brain stimulation device already approved for hard-to-treat epilepsy.\nThey rigged some mice to this intermittent stimulator.\nFew are willing to undergo brain surgery for the purpose of research.\nAnother study published Monday in PNAS suggests that DBS could help boost memory and other research is exploring its use for substance abuse and other reward-seeking behaviors.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that this is very early research and that the treatment is not clinically available for behavioral problems.", "answer": 1}, {"article": "Bringing this program into the mainstream presents some challenges, however.\nOverall, the trained group found 51 early melanomas during the study, compared to 18 melanomas found by a comparison group of patients and partners who didn\u2019t receive training.\nFor now, she said people can go to the American Academy of Dermatology's website to learn the steps - known as the ABCDEs - of finding melanoma (bit.ly/2h9zl0Y).\n\u201cFor example, men can\u2019t see the top of their bald heads or the back of their necks or ears,\u201d Robinson said.\n\u201cTheir confidence level goes up and plateaus at eight to 12 months, and it doesn\u2019t go down,\u201d said Robinson.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of having a partner help with mole-spotting would seem to depend on the individual patient. The writer does mention that bringing a partner program into standard practice \u201cpresents some challenges\u201d due to the need for training, and that the\u00a0researchers are looking at ways to help people learn to identify melanomas without reinforcement by physicians. This\u00a0is enough to\u00a0earn a satisfactory rating.", "answer": 1}, {"article": "WASHINGTON (Reuters) - The U.S. Food and Drug Administration took a fresh step on Thursday towards setting a maximum nicotine level for tobacco products in a bid to lower tobacco-related deaths across the country, saying it would collect public comment and scientific research over the next three months.\n\u201cWe\u2019ll also advance key parts of our tobacco plan very soon,\u201d he said.\nMajor tobacco players such as Altria Group and British American Tobacco are grappling with sales declines in the U.S. market and hoping to recoup revenue through novel tobacco and nicotine products such as e-cigarettes.\n\u201cThere is no other single action our country can take that would prevent more young people from smoking or save more lives,\u201d said Matthew L. Myers, president of Campaign for Tobacco-Free Kids.\nThat plan marked a major shift designed to give adult smokers a wider range of alternatives, including potentially less harmful e-cigarettes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that lowering nicotine in cigarettes is in the proposal stage.", "answer": 1}, {"article": "First published on July 1, 2008 at 12:00 am\n\"When a patient transitions from one therapy to another, the dialysis dose is unlikely to be equivalent,\" he said, adding that results could be affected by different methods in the high-intensity and low-intensity groups.\nAnd, he said, the results cannot be simply applied to patients with chronic kidney disease, who then have acute kidney injury, since the study excluded any patients with advanced chronic kidney disease.\nDr. Bonventre wrote that the study had \"a predominance of male patients,\" so there is a question of whether its results can be applied to female patients.\nThroughout the study, patients remained in intensive or less intensive therapy, although as their clinical conditions changed, they could change forms of therapy, Dr. Palevsky said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is not clear from this story whether both intensities of treatment are in general use and if not, which represented usual care. In addition,\u00a0treatment of kidney injury is complicated and it was not clear from this story how an individual would weigh in about treatment preference.\u00a0", "answer": 0}, {"article": "This is the first to correct an inherited genetic mutation.\nThe drug will be available in the United States in early spring, with an estimated 1,000 to 2,000 people in the US standing to benefit from this treatment, according to Spark.\nThe mutation affects both eyes, usually at the same pace, so most patients would need treatment for both eyes, a Spark Therapeutics spokeswoman said.\n\"For a one-time therapy, like Luxturna, a non-traditional payment and distribution model is necessary to ensure needs of all parties -- patients, payers and providers -- are addressed,\" said Jennifer Luddy, a spokeswoman for Express Scripts.\n\"The new payment models announced today are merely a way to disguise a price that is simply too high,\" David Mitchell, president and founder of Patients For Affordable Drugs, said in a statement .\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t discuss where one can have access to this treatment. It likely will be very limited. And will it be available to anyone with this condition, or will some people be ruled out?", "answer": 0}, {"article": "The boy is currently on chemotherapy, the study authors noted.\n\"This is a very good first step, but it's a little scary and we need to move to safer vectors,\" said Dr. Mary Ellen Conley, director of the Program in Genetic Immunodeficiencies at St. Jude Children's Research Hospital in Memphis, Tenn.\n\n\"The study shows proof-of-principle that gene therapy with stem cells in a genetic disorder like this has strong potential,\" added Paul Sanberg, a stem cell specialist who is director of the University of South Florida Center of Excellence for Aging and Brain Repair in Tampa.\n\"This is a first step that says you can correct the disease but I think most people would look at it and say the risk of leukemia is something, and that, let's see if we can avoid that,\" said Conley, whose team at St. Jude is working on a therapy involving a different type of vector.\nIn this study, the researchers inserted a healthy gene capable of producing WAS protein into hematopoietic stem cells (the \"granddaddy\" cells that give rise to different blood cells), then transferred these stem cells back into the patient using a viral vector.\n\"One of the long-lasting complications is the kids couldn't do this, they couldn't do that, they see themselves as different,\" Conley said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story never explicitly addresses the availability of this new technique or how close it may be to approval. However, it does\u00a0note that the research represents just\u00a0a \u201cfirst step\u201d and \u201cproof of concept\u201d for the new approach. Although we would like to have seen\u00a0a more direct comment about the many years of testing that lie ahead for any therapy based on this technique, we think most readers\u00a0will understand that this is preliminary research and not something they\u2019re likely to have access to anytime soon.", "answer": 1}, {"article": ".\n\"It's provocative in the fact that the results are pretty amazing,\" said Dr. Robert Graham, an internist and vitamin D expert at Lenox Hill Hospital in New York City.\nMenstrual cramps, known by the medical name dysmenorrhea, typically begin just before or at the start of a woman's menstrual period and can last several days.\nThe 300,000 IU dose of vitamin D3 given in the study also far exceeds the daily intake of 600 IUs recommended for American women of reproductive age, both Graham and Rabin said.\nIn the study, 40 Italian women were split into two groups: one receiving a single oral dose of 300,000 IUs of vitamin D3 and the other getting a placebo five days before the expected start of their menstrual periods.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story could have done a better job on this point. Although Vitamin D is available over the counter, it is available in the high dose used in the study only by prescription. Just to put this dose issue in context, when people are Vitamin D deficient, a typical replacement dose is 50,000 units weekly for 8 weeks (a total of 400,000 units).\u00a0 So the 300,000 one-time doses are not as outlandish as they seem when compared with a typical maintenance dose of 600-800 IU/day.", "answer": 0}, {"article": "You've seen high-definition televisions. Now some medical centers are marketing their high-definitioncolonoscopes, which they say will detect more pre-cancerous polyps. Several recent studies have found a small benefit to high-definition colonoscopy over the standard variety, but gastroenterologists say physician technique is more important in detecting polyps than equipment.\n\nColonoscopy, a screening test doctors recommend for most people starting at age 50, allows doctors to remove pre-cancerous growths before they become...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Three graphs in, the story says, \"Many hospitals now use high-definition colonoscopes, which are sold by a number of companies.\" That\u2019s a vague sentence in a story that provides a lot more specifics in other areas. How many hospitals?\u00a0 Where?\u00a0 How likely is a reader to be in a situation where she/he is encouraged to have this type? ", "answer": 0}, {"article": "In 2008, Gao struck out on his own, taking a job as director of a brand-new gene therapy center at UMass.\n\u201cWe are probably in the greatest innovative period of understanding human disease and how to make cures ever.\u201d\n\nThe concept of gene therapy is straightforward, beautiful even: Fix an illness caused by a faulty gene by replacing or supplementing a healthy new copy of the gene.\nFor the next 13 years, Gao would work for Wilson, engineering new and better viruses for the therapies, called \u201cviral vectors.\u201d These molecular FedEx trucks can be loaded with healthy versions of genes and deliver them to the correct location in the body.\nAdditionally, the brain is a closed compartment, so the risks of gene therapy are minimized\u2014other parts of the body, the liver or the lungs, say, are undisturbed.\nThe most promising candidate was adeno-associated virus (AAV)\u2014a virus that grows in the presence of adenovirus but is a completely different type.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told early on \u201cthere is no treatment and no cure for Canavan disease,\u201d but then later a researcher is quoted as saying: \u201cWe have the therapy. We are ready.\u201d\nThe word \u201ctherapy\u201d implies effective treatment of people.\u00a0Therapeutic misconception like this is confusing\u00a0to readers, and the story needed to counter this confusion by more strongly indicating this specific intervention\u00a0is and will be experimental for years to come.\nThis was made more confusing by the discussions of available gene therapies for other illnesses, including two that are in use in China and Europe, and one that might be approved in the U.S. How far behind are all the gene therapy approaches discussed in the piece? This is important to counter false hope among patients who may read this story and think that these are signals that availability of these other therapies can\u2019t be far away.", "answer": 0}, {"article": "The results were presented Thursday at the American College of Neuropsychopharmacology annual meeting in Hollywood, Fla.\nThe new drug -- called GLYX-13 -- is so far given in an intravenous form and was recently tested in patients who had not responded to other antidepressants.\n\"We saw a robust, rapid-acting, long-lasting effect,\" said lead researcher Joseph Moskal, a research professor of biomedical engineering at Northwestern's McCormick School of Engineering and Applied Science and director of the school's Falk Center for Molecular Therapeutics.\nAn advantage is that the drug doesn't have the side effects of other drugs that target these same areas, such as hallucinations and schizophrenia-like symptoms, the researchers noted.\nMany unknowns remain about the drug, including its long-term effects, whether some people won't respond to it and the effects of stopping its use.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states that the study is in phase II clinical trials and that results are considered preliminary. The lead researcher says that the new drug is not projected to be available before 2016. The independent expert also cautions that the long-term effects of the drug need to be studied before it can be used regularly in clinical practice.", "answer": 1}, {"article": "March 7, 2011 -- Traditional Chinese acupuncture may be useful in reducing the severity of hot flashes and other symptoms of menopause, a new study suggests.\nLevels of estrogen and other hormones were measured before the study and after the first and last acupuncture sessions in both those receiving real and sham treatments.\nHalf of them received traditional acupuncture treatment.\nThe rest were treated with \u201csham\u201d acupuncture needles that were blunted and did not penetrate the skin.\nThose in the comparison group were treated with shams needles at the same acupuncture points.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "No discussion of the availability of acupuncture.\u00a0 Picture a woman who\u2019s just begun experiencing menopause and has never had any reason to think about acupuncture.\u00a0 She reads this story about Turkish research on Chinese acupuncture.\u00a0 Even if she\u2019s interested, she is not given any clue about the availability of the approach in the U.S.", "answer": 0}, {"article": "He will run Islexa with Michael Bennet from CGT and Anne Lewendon from Aberdeen University.\nIf clinical trials are successful, the technology means tens of thousands more people could live without the need for frequent insulin injections, although it will take a few years until the treatment is available.\nIt is a lifelong condition that occurs when the pancreas does not produce any insulin, while type 2 diabetes \u2013 far more common, especially as obesity rises around the world \u2013 is a condition where the pancreas does not produce enough insulin or the body\u2019s cells do not react to it.\nJohn Casey, consultant transplant surgeon at the Royal Infirmary of Edinburgh and lead clinician for the islet transplantation programme in Scotland, said: \u201cIslet transplantation can transform the lives of patients with type 1 diabetes, and in some cases can result in long-term freedom from insulin injections with excellent glucose control.\u201d\nThe promising early results have given them the confidence to form a wider consortium with the Scottish Islet Transplant Programme, the University of Edinburgh and the Scottish National Blood Transfusion Service.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There are vague mentions of the need for clinical trials and reference to a \u201cfew years\u201d before treatment with the lab grown islets are available, but readers will not come away with a reasonable sense of what needs to happen before a treatment based on this approach would become available.", "answer": 0}, {"article": "But this could take a few years to develop.\n\"This is the earliest phase, and you now have to show that it actually breaks down the gluten peptides that trigger a response in the stomach at a speed that will protect the human,\" said Dr. Joseph Murray, a professor of medicine in the division of gastroenterology and the department of immunology at the Mayo Clinic, in Rochester, Minn. \"Let's see how it goes with a whole slice of bread.\"\n\"For those who are hypersensitive, this probably is not going to solve the problem, but it would allow them to go to dinner, and in case any gluten ended up in their meal, they wouldn't have to worry about it.\"\nIn this case, the researchers re-engineered the natural enzyme to recognize the peptide that triggers celiac disease and modified the protein in the laboratory so it would survive the acidic stomach environment.\n\"It will probably be helpful to someone who gets a low-level exposure [to glutens] by accident,\" he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this is an experimental treatment and not available to the public, although we\u2019re a little uncomfortable with the prediction that a pill could\u00a0be available \u201cin a few years.\u201d That\u2019s true, but it\u2019s also possible that such a pill might\u00a0never be available. Why not mention that possibility as well?", "answer": 1}, {"article": "Trulance, taken orally once daily, works locally in the upper GI tract to stimulate secretion of intestinal fluid and support regular bowel function.\nThe safety and efficacy of Trulance were established in two 12-week, placebo-controlled trials including 1,775 adult participants.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe U.S. Food and Drug Administration today approved Trulance (plecanatide) for the treatment of Chronic Idiopathic Constipation (CIC) in adult patients.\nThe agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The FDA release announces approval and most readers will understand that this is essentially the last big step in market availability. The release would have been stronger had it noted that the drug may not be available widely for a short time.", "answer": 1}, {"article": "Phd Christian Fabiansen \n\nDepartment of Nutrition, Exercise and Sports, University of Copenhagen \n\nTelephone: +45 22440844 \n\nMail: chfa@nexs.ku.dk\n\nProfessor Henrik Friis \n\nDepartment of Nutrition, Exercise and Sports, University of Copenhagen \n\nTelephone: +45 26253968 \n\nMail: hfr@nexs.ku.dk\n\nKristian Levring Madsen \n\nCommunication Manager \n\nDepartment of Nutrition, Exercise and Sports, University of Copenhagen \n\nTelephone: +45 4048 1684 \n\nMail: kma@nexs.ku.dk\nThose with the most severe acute malnutrition have more than ten times increased mortality, and those surviving may have impaired development, compared to children without malnutrition.\nThe results of the study can be used directly both in the treatment and prevention of acute malnutrition.\nEarlier peer-reviewed articles from the study have appeared in the American Journal of Clinical Nutrition, BMC Nutrition, and Appetite.\nSo, I hope we can use the results to provide the best possible treatment for more vulnerable children.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release assumes availability of both types of supplements, though no specific information is provided about how much each is currently used for treatment of moderate acute malnutrition in infants.", "answer": 1}, {"article": "A drug derived from this bushy sea creature showed modest, preliminary promise as an Alzheimer's treatment.\n\nIn small Alzheimer\u2019s study, hints of modest benefit from unusual drug\n\nA little-known drug company announced modestly encouraging results for its experimental Alzheimer\u2019s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.\n\nA mid-stage study by a tiny company wouldn\u2019t usually attract much attention, but the results unveiled by Neurotrope BioScience have been eagerly anticipated because its drug \u2014 derived from a bushy, hermaphroditic sea creature \u2014 takes a novel approach.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains where the drug is in the regulatory process\u2013still far from being on the market.\nAnd it indicates how likely it is for the drug to get approval, saying, \u201cA\u00a02.6-point edge over placebo may\u00a0fall slightly short of what the\u00a0Food and Drug Administration would require for approval of a new Alzheimer\u2019s drug\u2026\u00a0the FDA typically wants to see a net benefit of at least\u00a03 or 4 points.\u201d", "answer": 1}, {"article": "Keenly awaited clinical trial results released on Sunday showed heart-attack survivors on one of three doses of canakinumab were 15 percent less likely to suffer another major cardiac event than those on a placebo.\n\u201cThe modest absolute clinical benefit of canakinumab cannot justify its routine use in patients with previous myocardial infarction until we understand more about the efficacy and safety trade-offs and unless a price restructuring and formal cost-effectiveness evaluation supports it,\u201d wrote Dr. Robert Harrington, chair of the Stanford University School of Medicine, in an editorial in the New England Journal of Medicine.\n\u201cIf the company cuts the price of the product in its current orphan indications, then it instantly sacrifices sales which currently total about $400 million per year with the hope that future sales in a new CV setting will more than offset this,\u201d Anderson said in a note.\nHe downplayed critics who said the benefit was small, saying that one large subgroup in the so-called Cantos trial had shown a 27 percent reduction in cardiovascular risk.\nNovartis had said in June that the drug met its goal in the study but details were only unveiled at European Society of Cardiology meeting in Barcelona.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The lede graph says \u201cNovartis will seek regulatory approval\u201d for the drug\u2019s use against heart disease, \u201cthough some experts fear fatal infection risks and a high price may overshadow the medicine\u2019s limited scientific benefits.\u201d At least for now.", "answer": 1}, {"article": "April 9, 2012 -- Taking soy to relieve hot flashes has received mixed reviews over the years.\n\"I personally think foods [containing soy] are better.\"\nTwo co-authors, not including Melby, have ties to the soy industry.\n\"What this study shows is that ingesting soy isoflavones will help you,\" she says.\nNow, researchers who took another look at 19 published studies find that soy supplements may help, at least over time.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of soy supplements is not in question.", "answer": 2}, {"article": "\"The wealth of clinical experience from treating hundreds of patients with ketamine has supplanted the preliminary data that emerged from the initial open-label and small double-blinded studies,\" said Dr. Henderson, who is a board certified psychiatrist, specializing in diagnosing and treating complex conditions, based in Denver, Colorado.\nIn contrast, this retrospective study of over three years of clinical experience, shows lasting benefits for many patients, with no apparent risk of addiction.\n\"Activation of brain-derived neurotrophic factor (BDNF) appears to have an important role in the antidepressant effects of ketamine.\nEvidence points to the regeneration of brain cells as a critical mechanism for the relief of depression, as published in peer-reviewed journal Neural Regeneration Research, February 2016 issue.\nKetamine is a dissociative anesthetic in use since 1970's.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Other than to note that the author of the study is co-founder of an unspecified number of ketamine infusion centers, the news release does not address where to access the treatment.", "answer": 0}, {"article": "\"The trend is away from traditional soda pop [toward] products claiming to provide magical health benefits,\" Silverglade says.\nA 2007 study found that research on health drinks that was funded entirely by beverage companies was between four and eight times more likely to find a favorable result than research with no industry support.\n\"Once I learned they were really just cleverly marketed sugar waters, I stopped.\"\nThe FTC, along with the Food and Drug Administration (FDA), has been cracking down on food and beverage makers for allegedly overselling the health benefits of their products.\n\"These days it's possible for a food company to pay just about anybody to conduct a study,\" says Silverglade.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We know that one company racked up $91 m in sales in one recent year, giving some indication of how widespread is the use of some of these products.", "answer": 1}, {"article": "These included 1 percent who had blood clots and 1 percent who suffered bleeding.\nThe efficacy of the drug has been proven previously, he noted, but this study provides an in-depth analysis of Avastin's safety profile under \"real life\" conditions, he added.\n\"The practical implication is the possibility to incorporate Avastin with any chemotherapy regimen in the frontline therapy of metastatic non-squamous lung cancer,\" he added.\nTUESDAY, July 20, 2010 (HealthDay News) -- The cancer drug Avastin, when used in combination with standard chemotherapy, is safe and can effectively treat an advanced form of one of the most common lung cancers, researchers report.\n\"Today we have a new option to treat non-squamous lung cancer, incorporating Avastin in chemotherapy regimens and in maintenance therapy,\" said lead researcher Dr. Lucio Crino, director of medical oncology at S. Maria della Misericordia Hospital in Perugia, Italy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This piece correctly indicated that this drug is currently available for use. \u00a0 The story used the trade-name Avastin (as opposed to its generic name bevacizumab)\u00a0nearly exclusively throughout and, at the end, mentioned that this drug has already received FDA approval for use in the treatment of other types of cancer.\nThe story could have clarified that the use of Avastin in the treatment of metastic non-squamous cell lung cancer is still an off-label indication for this drug, which is more common in cancer treatment than in other diseases.", "answer": 1}, {"article": "\"Oh absolutely,\" she said.\nBut this study - the most definitive so far - may encourage more doctors to consider ultrasound, which is easier and less expensive.\nAnd it's an important story, because about half of women under the age of 50 are found to have dense breast tissue when they get their mammograms.\n\"This could have gone on for years before anybody found it, and it could have been a whole different story,\" she said.\n\"It's just very difficult to be able to pick out the boundaries of that mass.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Ultrasound machines are typically available in most medical centers. The broadcast does not mention that physicians and ultrasonographers in the study cited were trained using standardized screening protocols.\u00a0 In a real-world clinical setting, the availability of properly trained physicians and technicians can vary, resulting in greater false-negative or false-positive test results.\u00a0 The editorial accompanying the source article states, \"It is questionable whether the diagnostic accuracy achieved in the study..would have been the same if nonradiologists had performed screening ultrasound.\" ", "answer": 0}, {"article": "If you can tolerate the side effects, I think many women will opt to take the extra years of letrozole, so this study is practice-changing.\u201d\n\nDr. J. Leonard Lichtenfeld, deputy chief medical officer for the American Cancer Society cautioned, however, that \u201cone has to be cautious in interpreting these results,\u201d partly because \u201cbased on what they show, there is no overall change in survival.\u201d\nThe women had taken another breast cancer drug, tamoxifen, for several years and then were started on an aromatase inhibitor, which doctors usually prescribe for five years.\nIn a randomized controlled trial, 959 women were given the drug and 959 a placebo.\nOf those taking an inert pill, or placebo, 91 percent did.\nAbout two-thirds of breast cancers are hormone-receptor positive, and they have a good prognosis.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The drug letrozole is already available, and the story makes this clear.", "answer": 1}, {"article": "What to do?\n\"Health systems should invest in developing electronic health records systems that prompt providers at the point-of-care when screening is needed and when it can be postponed,\" study senior author Joshua Fenton, an associate professor of family and community medicine at UC Davis, said in the news release.\nHowever, the study also found that those risk factors -- a small body frame, a history of fractures, or taking medications that could thin bones -- had only a slight effect on a woman's decision to get her bones tested.\nThe researchers looked at whether or not women were getting a dual-energy X-ray absorptiometry (DXA) test, which measures bone mineral density.\nOver seven years, more than 42 percent of eligible women aged 65 to 74 were not screened, Amarath's team found, nor were nearly 57 percent of those older than 75.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not say how commonly available the screening test is, but provides the impression that it\u2019s widely used. Since the test has been widely available for many years, we\u2019ll give the story a pass here.", "answer": 1}, {"article": "EWING, N.J., March 14, 2016 /PRNewswire/ -- Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced positive results from the Phase 3 trial of VYXEOS\u2122 (cytarabine: daunorubicin) Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML) compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3.\nThe Company is seeking research and development collaborations with other biotechnology/pharmaceutical companies where its proprietary technology may provide benefit.\nThe first trial was conducted in newly diagnosed elderly AML patients and the second trial was conducted in patients with AML in first relapse.\nFurthermore, approximately half of those patients are considered suitable for intensive treatment.\nIn patients over 60 years of age, the 5 year survival rate is less than 10%.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We learn that the company hasn\u2019t yet sought regulatory and marketing approval for the new drug but will be doing so soon.", "answer": 1}, {"article": "But he also emphasized the structured nature of the program tested in his study.\nIn general, \"mindfulness\" practices encourage people to focus their attention on the present moment, instead of the past or future, and to take an objective look at their thoughts and emotions.\n\"It'll be interesting to see whether people can learn mindfulness techniques, then see durable effects,\" he said.\nBy the end of the study, the mindfulness group was showing a significant improvement -- shaving about three points, on average, from their scores on the sleep-problem scale.\nThen there's the fact that sleep issues become common as people age, Spira said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the type of meditation therapy is available in various forms and even includes a link to the specific therapy from UCLA that was included in the study. In addition, there was a very nice general description of the technique to help readers imagine how it works: \u201cIn general, \u2018mindfulness\u2019 practices encourage people to focus their attention on the present moment, instead of the past or future, and to take an objective look at their thoughts and emotions.", "answer": 1}, {"article": "For information on mammography visit Mammography Saves Lives or the Society of Breast Imaging website.\nI encourage women to speak with their providers about mammography benefits and limitations and create a schedule to get their annual mammograms,\" said Debra Monticciolo, MD, FACR, chair of the American College of Radiology Breast Imaging Commission.\nThis approach saves many more lives than screening started at a later age or with less frequent exams.\n\"Mammography screening is not perfect but has been shown to markedly reduce the number of women each year who die from breast cancer,\" said Elizabeth Morris, MD, FACR, president of the Society of Breast Imaging.\n\"The decision whether or not to get a mammogram remains with women.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Availability isn\u2019t mentioned. But because getting a mammogram is relatively routine, we\u2019ll mark this one \u201cnot applicable.\u201d", "answer": 2}, {"article": "Like a patch on faulty software, C.B.T.\nThis further emphasizes the point that many insomniacs aren\u2019t that different from normal sleepers.\nIn this way, unless exacerbated by physical causes \u2014 like sleep apnea or restless leg syndrome \u2014 insomnia is a condition of the mind that then infects the body.\nIt demonstrated progress \u2014 the nights in which I got only four or five hours of sleep became less common, and, on average, my nights of sleep lengthened by 30 minutes.\nMany nights I might have considered \u201cbad\u201d \u2014 and fretted over \u2014 were ones in which I got only one hour less sleep than my target of seven hours.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We are not given a lot of detail, but consider both CBT and medications to be widely available.\u00a0This is particularly true because the writer makes it clear that an online program was helpful (rather than requiring a specialized clinic or provider).", "answer": 1}, {"article": "Kite Pharma is racing to get the first FDA approval of an experimental gene therapy to fight cancer.\n\nAn experimental gene therapy that turns a patient\u2019s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.\n\nIn all, 82 percent of patients had their cancer shrink at least by half at some point in the study.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story\u00a0mentions this is an \u201cexperimental gene therapy\u201d and that, if approved, it could become the first such treatment to be available\u00a0in the United States. The story notes that the company is seeking approval for the drug by the end of March. While this is sufficient for a satisfactory grade, we think the story could have elaborated on this a bit, and noted that the approval would be based on preliminary phase 2 data \u2014 not the typical phase 3 study data that the FDA normally requires for approval. The drug appears to be eligible for expedited approval based on the FDA\u2019s \u201cbreakthrough\u201d therapies program.", "answer": 1}, {"article": "The most common sexually transmitted disease is often silent and invisible: human papillomavirus (also called HPV).\nThe study was not done as a randomized controlled trial, the gold standard for determining whether a drug works better than chance.\nEighteen women with high-grade precancerous cervical lesions participated in the phase 1 study.\nThe vaccine consists of three injections in the arm over three months, Kim said.\nBut there are a lot of people out there who still have HPV, and nothing protects against all 130 strains of the virus.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "They did briefly discuss future clinical trials and did not try to estimate when a vaccine would be available.", "answer": 1}, {"article": "The treatments available don\u2019t always help, and some have severe side effects\n\nWhen birth control pills or over-the-counter painkillers fail to help endometriosis pain, women are often left choosing between a monthly injection called Lupron Depot, which can put women into a profoundly menopausal state, or Danazol, a male hormone that often causes acne and facial hair growth.\nIt\u2019s sometimes mistaken or dismissed for regular period pain.\nThe success of surgery also depends on finding a skilled and experienced surgeon, and there\u2019s always the risk of surgical complications.\nMany women in the trial experienced the symptoms of menopause \u2014 hot flashes, headache, insomnia \u2014 and researchers have also found the drug causes bone loss.\nThe drug\u2019s side effects also concerned her, as did the lack of knowledge about its long-term impact.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The text offers a likely date when this just-approved drug would become available at pharmacies.", "answer": 1}, {"article": "New research by scientists at the University of Maryland School of Medicine has found that esophageal cancer patients treated with proton therapy experienced significantly less toxic side effects than patients treated with older radiation therapies.\nWhile most cancer patients are well served with today's state-of-the-art radiation therapy technology, up to 30 percent are expected to have a greater benefit from the new form of targeted proton beam therapy.\nOthers include:\n\u2022 Selective Internal Radiation Therapy, a precision modality for treating patients with particularly difficult-to-remove tumors involving the liver such as those from colorectal cancers;\n\u2022 Thermal Therapies, the use of \"heat\" in treating a broad spectrum of malignancies.\nThe treatment works well for many kinds of tumors, including those found in the brain, esophagus, lung, head and neck, prostate, liver, spinal cord and gastrointestinal system.\nThe results have particular relevance for the University of Maryland School of Medicine; this fall the school will open the Maryland Proton Treatment Center (MPTC).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There are at least a dozen centers in the United States that currently offer proton therapy for cancer treatment, but that\u2019s not clear from the information in the release. The only treatment center mentioned in the release is the one that UMD plans to open this fall. What\u2019s more, proton therapy is repeatedly characterized as \u201cnew\u201d \u2014 when it has been a subject of widespread discussion (and reporting) for years.\u00a0 Additionally, most insurers still consider proton beam therapy to be \u201cnot medically necessary\u201d under usual circumstances except for a small number of conditions noted earlier.", "answer": 0}, {"article": "WEDNESDAY, June 15, 2016 (HealthDay News) -- Reiterating a recommendation last made in 2008, an influential U.S. panel of health experts is advocating that regular colon cancer screening begin at age 50 and continue until at least age 75.\nThe U.S. Centers for Disease Control and Prevention has more on colon cancer screening.\nThe panel said there were no comparison studies that suggested that any of the screening methods were any more effective than others.\nDr. Arun Swaminath is one of them.\nAll of the recommendations are specific to symptom-free people 50 years of age or older with an average risk colorectal cancer, the panel stressed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that all of the screening tests mentioned in the story are generally available.", "answer": 1}, {"article": "A controller the size of a cellphone enables her to set her Esteem to different environments, such as \"home,\" \"restaurant\" or \"school.\"\n\"This really fills a need for adults with moderate to severe sensorineural hearing loss,\" Marzo said.\nMerlo's doctor, ear surgeon Sam Marzo of Loyola University Medical Center in Maywood, has performed 40 Esteem implants since he was trained by its manufacturer, Envoy Medical Corp. in St. Paul, Minn., in 2010.\n\"When I wore a hearing aid, I turned it off when I got home because all the background noise was so agitating,\" said Merlo, 40.\n\"There are little things that I probably heard when I was younger, before my hearing loss, but I don't remember them,\" she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story mentions that the Esteem implant is FDA approved, it is not clear why Dr. Marzo is the only surgeon in the entire Chicagoland area authorized to implant the device. Is this typical of other cities? Why is the procedure not more widespread?", "answer": 0}, {"article": "Beaumont's center is one of just 28 proton therapy centers in the U.S.\nThe facilities are impressive, clean and welcoming, but the difference is the people \u2013 best hospital staff I've ever encountered.\nSaid Tracy, \"We were told that I should prepare myself for the loss of functionality below the waist \u2013 including bowel, bladder and sexual functions.\nThe results supported the use of high-dose definitive radiation therapy, via proton beam therapy, for selected patients with unresected spine and sacral chordomas.\"\n\"I then determined, definitive radiation therapy was the way to go, but I had to decide which type and where.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that there are 28 proton therapy centers in the U.S. and that the center at issue here is the only one located in Michigan.", "answer": 1}, {"article": "IVs are one of the most common things in health care.\nSince there are about 30 million people hospitalized in the U.S. alone each year, \u201cthere are tens or hundreds of thousands of patients who would be spared death or severe kidney problems by using balanced fluids instead of saline,\u201d said one study leader, Vanderbilt\u2019s Dr. Matthew Semler.\n\u201cWe\u2019ve been sounding the alarm for 20 years\u201d about possible harms from saline, said Dr. John Kellum, a critical care specialist at the University of Pittsburgh.\nThe fluids cost about the same \u2014 a dollar or two per IV \u2014 and many suppliers make both types, so switching should not be hard or expensive, doctors said.\nOther IV solutions called balanced fluids include saline but also contain potassium and other things that make them more like plasma, the clear part of blood.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article does well in including this important context:\nIVs are one of the most common things in health care \u2026 saline \u2014 salt dissolved in water \u2014 has been the most widely used fluid in the U.S. for centuries \u2026 other IV solutions called balanced fluids include saline but also potassium and other things that make them more like plasma, the clear part of blood. They\u2019re widely used in Europe and Australia.", "answer": 1}, {"article": "Ingelfinger, who wrote an editorial published with the study, echoed Montgomery's cautious optimism.\n\"The desensitization protocols now in use are time-consuming, and they don't always work,\" she said, noting that they can leave dangerous antibodies behind.\nIn the study, 10 patients had an episode of antibody-mediated rejection anywhere from two weeks to five months after their transplant.\nNow the new research suggests a simple approach -- an infusion of a particular enzyme hours before the transplant -- could offer a better alternative.\nThe findings were published in the Aug. 2 issue of the New England Journal of Medicine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that the only way for patients to receive the experimental therapy at present is through a clinical trial, although it does not say where such trials are taking place or recruiting patients.", "answer": 1}, {"article": "(Reuters) - Dermira Inc said its experimental topical therapy for excessive underarm sweating was successful in two late-stage studies, bringing it one step closer to providing an easy-to-use therapy for the often embarrassing condition.\nOral medicines can be used to systemically limit sweating.\nThe first line of defense are anti-perspirants.\nWhile the function of sweating is to prevent overheating, those affected sweat even when the body does not need cooling.\nSufferers can also opt for localized surgery, like liposuction, to remove or injure sweat glands.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We learn it is still in its experimental stages.", "answer": 1}, {"article": "These studies have been done with people, but other promising research has only been done with lab animals so far. In one 2009 study in the Journal of Medicinal Food, tart cherries helped fat rats. Not our favorite role models perhaps, but the obese beasties' risk of Type 2 diabetes and heart disease were reduced significantly, and parallel studies are now in the works with members of our own species, says lead author E. Mitchell Seymour: \"There are some interesting and potentially exciting results on the horizon. Stay tuned.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of cherries is not in question.", "answer": 2}, {"article": "Canha, who wasn\u2019t involved with this study, researches indoor air quality and sleep during different ventilation patterns.\n\u201cOpening an internal door can be a reasonably good alternative if you don\u2019t want to open windows, either for noise concerns or security concerns,\u201d Mishra said.\nClosed environments tended to have less background noise \u2013 but they also had significantly higher carbon dioxide levels, which indicated lower ventilation levels.\nNotably, carbon dioxide levels were lower when windows or doors were open.\n\u201cSleep quality is affected by many factors, such as health and emotional states, bedding conditions and different environmental conditions, including noise levels and temperature,\u201d said Dr. Nuno Canha of the University of Lisbon in Portugal.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Windows and doors are widely available, and the story mentions that opening them might not work if there are noise or security concerns.", "answer": 2}, {"article": "Pereira wrote about blood pressure reductions in a patient getting deep brain stimulation in the January 2010 issue of the Journal of Clinical Neuroscience.\nWhile the case study is only an example of the phenomenon occurring in a single person, previous reports have observed the same kinds of reductions in blood pressure in people getting deep brain stimulation for pain, though researchers had believed that the blood pressure benefit was directly tied to the degree of pain relief the person experienced.\n\u201cPain creates stress and that can have an effect on one\u2019s blood pressure,\u201d says Nikunj J. Patel, MD, a neurosurgeon at Frenchay Hospital in Bristol, U.K., and an author of the case study.\n\u201cWhat their case report shows is that blood pressure can be reduced in a sustained fashion in a patient with unsuccessful deep brain stimulation for pain,\u201d says Erlick Pereira, MD, a neurosurgeon at the University of Oxford.\nThough his pain eventually returned after four months, his doctors report that their patient\u2019s previously uncontrolled blood pressure has remained normal for nearly three years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story implies that we are not close to seeing\u00a0DBS used to\u00a0treat hypertension outside of a research setting. Unlike the competing HealthDay coverage, the story notes that DBS is FDA approved for Parkinson\u2019s disease and essential tremor, and that it is used for other conditions. We would have liked to have seen at least an expert view on the number of devices that are implanted every year or a statistic on this\u00a0from one of the manufacturers.", "answer": 1}, {"article": "\u201cThis is a very important claim for us to allow to be incorporated into food labels,\u201d said Dr. Scott Gottlieb, the commissioner of the F.D.A.\nThe product, called Hello, Peanut, can be mixed into pur\u00e9ed baby food to expose infants to peanuts starting around five months old.\nA new powdered peanut product is the first food item allowed to claim it may reduce peanut allergies in infants, though parents of susceptible babies are urged to consult a doctor before trying it.\nWhile many foods like whole grains, nuts and supplements carry qualified health claims stating that they may reduce the risk of diseases like cancer or heart disease, this is the first time a food product label will be allowed to make a qualified claim that it reduces the risk of an allergy, officials said.\n\u201cThe guidelines for how to approach allergens in children are changing, the science is changing, and it\u2019s important for parents to know.\u201d\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the product is available for purchase and goes so far as to hyperlink to its website, where people can place an order. We\u2019d call this establishing availability \u2013 sure. But it also might go a step beyond and risk actually advertising the product under scrutiny in the story.", "answer": 1}, {"article": "\"Without sensory feedback, somebody would have to actually have to look at the prosthetic, look at the cup, start to close the hand, (and) visually see the cup is starting to deform,\" he says.\nBut they have relied entirely on vision to know whether the arm is going in the right direction or grasping an object with the proper amount of force.\nFor several years now, people have been able to control robotic arms using thoughts alone.\nBut he also describes many of the sensations coming from his robotic hand as \"natural.\"\nThen they waited for the brain to heal, as it adjusted to the presence of the electrodes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear this patient is the first to receive this treatment in an experimental setting, so it is clear that this is not available except in a laboratory.", "answer": 1}, {"article": "The main side effects, Vertex said, were headache, upper respiratory tract infections, nasal congestion, rash and dizziness.\n\u201cI\u2019ve been doing clinical trials for 30 years in C.F.\nVertex has not said how much it will charge for VX-770.\nNow, 22 years later, a drug that tries to compensate for the genetic defect might be nearing the market.\nThe company is hoping that by late May it will win approval to sell a new type of drug for hepatitis C, which analysts expect will be a blockbuster.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "\"If [Livia] gets more women to know about TENS, then great,\" she said.\nGunter's main question about Livia is whether it will be significantly different from the already available and effective TENS devices, which usually cost around $35.\n(The company says the device would retail at $149, about the cost of four TENS units.\nWhen the frequency from the device hits the brain faster than the pain, the brain takes that signal first and is distracted from the menstrual aches, the company claims.\nSo far, Nachum said they have tested the device on 163 women in two different trials \u2014 and more than 80 percent experienced relief with the device.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the device is not available at the present time, and it makes it clear that there are available TENS units now that are not as expensive.", "answer": 1}, {"article": "\"The low rate of serious adverse events and significant interventions supports the safety of procedural sedation in the hands of emergency department physicians,\" said Dr. Bhatt.\nThe most common events were a decrease in oxygen saturation (5.6%) and vomiting (5.2%).\nThe results of the study show that choice of sedation medication had the biggest impact on the incidence of adverse events and need for significant interventions in response to those events.\nAccording to the authors, this study represents the largest and most robust prospective emergency department procedural sedation cohort to date.\nWhen children and youth present at an emergency department and require an immediate painful procedure, it is standard to sedate the patient so they can tolerate the treatment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of the different sedation methods isn\u2019t addressed. Readers must assume that the study looked at the common types of sedation used.", "answer": 2}, {"article": "The requested URL /usnews/health/articles/070520/28healthwatch.lede.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. The story didn\u2019t discuss availability of multivitamins but this is common knowledge.\u00a0 ", "answer": 2}, {"article": "Philip Gehrman, a Penn clinical psychologist who was senior author, said the study proves that rapid treatment of depression is possible. But more research is needed to figure out why sleep deprivation works. His team is now conducting its own study. He's not hoping to use sleep deprivation as a treatment but thinks that pinpointing what it does to the brain will help doctors develop other, more sustained treatments.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains it is not widely available as a therapeutic in clinics.\n\u201cExperts theorize that sleep deprivation may reset the circadian clock. But it is rarely used for treatment because it wears off so fast.\n\u201cI know of about three clinics worldwide that routinely use it,\u201d Gehrman said. There are some studies showing that it can be helpful when combined with light or antidepressant medication treatment.\u201d", "answer": 1}, {"article": "The FDA granted the approval of the LeukoStrat CDx FLT3 Mutation Assay to Invivoscribe Technologies Inc.\nIn addition, patients who received Rydapt in combination with chemotherapy in the trial went longer (median 8.2 months) without certain complications (failure to achieve complete remission within 60 days of starting treatment, progression of leukemia or death) than patients who received chemotherapy alone (median three months).\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\n\u201cRydapt is the first targeted therapy to treat patients with AML, in combination with chemotherapy,\u201d said Richard Pazdur, M.D., acting director of the Office of Hematology and Oncology Products in the FDA\u2019s Center for Drug Evaluation and Research and director of the FDA\u2019s Oncology Center of Excellence.\nThe agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "While the release doesn\u2019t specifically state the availability of the drug, the FDA approval for its use suggests that it should start to become available in a matter of months and not years.", "answer": 1}, {"article": "A drug-coated stent made by Abbott Laboratories that is awaiting U.S. regulatory approval is as safe as, and potentially more effective than, the market-leading version of the heart device made by Boston Scientific Corp., according to findings presented Tuesday at the EuroPCR conference in Barcelona.\n\nClinical-trial data analyzed by Abbott two years after its Xience V stents were implanted in patients are likely to reassure investors and regulators about the product's long-term safety and could restore some investor confidence...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that the stent in question is not yet approved by the FDA. ", "answer": 1}, {"article": "Dr Furyk's research was recently published in the Annals of Emergency Medicine: http://www.annemergmed.com/article/S0196-0644(16)30364-X/abstract\n\nAbout the Emergency Medicine Foundation - EMF is an Australasian non-profit organisation funds innovative, evidence-based emergency medicine research that will improve clinical practices to save lives, as well as deliver significant economic benefits to the healthcare system.\nEMF runs two research grant programs - a national Rural and Remote program and a highly successful Queensland program - as well as a Research Support Network.\nPatients with kidney stones were treated with the drug Tamsulosin in an Emergency Medicine Foundation Australasia (EMF) funded clinical trial run across five Australian hospital emergency departments.\nTrial leader and specialist emergency medicine physician at The Townsville Hospital, Dr Jeremy Furyk, said Tamsulosin was normally used to treat an enlarged prostate, but the research team found the treatment could also assist the passage of large kidney stones in the urine.\nWe're very excited because Tamsulosin treatment may also allow patients to be treated closer to home rather than needing referral to a major centre.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Tamsulosin is currently prescribed for patients with benign prostatic hyperplasia (BPH), or enlarged prostate and other conditions and is readily available.", "answer": 2}, {"article": "\u201cThat was the biggest drawback.\u201d\n\nDr. Neil Spielholz, of Nova Southeastern University in Fort Lauderdale, was involved with the initial study submitted to the FDA - the same one that showed the success of laser treatment in UK smokers.\nThere's limited research showing that laser therapy might help some smokers quit.\nThose in the three treatment group, in turn, had better success rates than a control group that was given fake laser treatments.\nIn response, Laser Therapeutics is designing another study to address those comments, he said.\nThe lack of any drugs involved in laser therapy \u201cwould be the beauty of this,\u201d he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains how these laser treatments are part of an emerging trend that grew out of acupuncture.", "answer": 1}, {"article": "Still, little is known about its cause.\nThe many potential preventive health benefits of breastfeeding should also be communicated openly to the general public, not only to mothers, so breastfeeding can be more socially accepted and facilitated.\nThe authors suggest several biological mechanisms of breast milk may explain their results, including that breast milk contains many immunologically active components and anti-inflammatory defense mechanisms that influence the development of an infant\u2019s immune system.\nIn a review of all 18 studies, the authors found breastfeeding for six months or longer was associated with a 19 percent lower risk compared with no breastfeeding or breastfeeding for a shorter period of time.\nIn addition, more high-quality studies are needed to clarify the biological mechanisms underlying this association between breastfeeding and lower childhood leukemia morbidity,\u201d the study concludes.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "While it may be assumed that breastfeeding is available to all, this is an oversimplification. Many women have trouble initiating breastfeeding and may have jobs or other limitations that make it difficult to breastfeed. The public can be hostile to breastfeeding women. Some women do not produce enough milk to exclusively breastfeed their babies. Studies have found that while about 75% of women attempt to breastfeed in the first week, only about 30% are still exclusively breastfeeding by three months. Some acknowledgment of the difficulties involved would have provided an opportunity to mention programs and interventions, including postpartum skin-to-skin contact, partner education, lactation consultants, etc, that may improve breastfeeding success.", "answer": 0}, {"article": "Dr Carol Routledge, from Alzheimer's Research UK, said: \"The diseases that cause dementia begin in the brain up to 20 years before any symptoms start to show, presenting a vital window of opportunity for us to intervene before widespread damage occurs.\n\"It was able to predict every single case that advanced to Alzheimer's disease.\"\nAs a final test, it was given a set of 40 scans from 40 patients it had never studied before.\n\"Although the sample sizes and test sets were relatively small, the results are so promising that a much larger study would be worthwhile.\"\nThe research is published in the latest issue of the journal Radiology.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that this machine-learning technology is not yet available and needs further study.", "answer": 1}, {"article": "\"In 2012, scientists took that particular frog and wanted to know why is it, why do these frogs keep milk fresh?\n'It makes the virus particle fall apart'\n\nThe researchers observed how the peptides interacted with influenza viruses under a microscope and in mice.\nIn the new study, the peptide was delivered to mice through their noses, where flu viruses were also delivered.\n\"I need to come up with a strategy to deliver it systemically as well; maybe an injectable, which goes in the bloodstream and kills influenza viruses,\" Jacob mused.\nHowever, the flu-killing power of such peptides has been demonstrated only under a microscope and in lab mice.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it very clear\u00a0that research has been conducted only in mice and that much more work needs to be done before it can even be assessed in humans.", "answer": 1}, {"article": "For more information about deep brain stimulation, visit the American Association of Neurological Surgeons\n\"It's a really interesting paper,\" said Dr. Nicholas D. Schiff, director of the Laboratory of Cognitive Neuromodulation at New York-Presbyterian Hospital/Weill Cornell Medical Center.\nThe finding introduces the possibility that deep brain stimulation -- a surgical implant that delivers electrical pulses to the brain -- might one day become a treatment for drug-resistant hypertension or lead to clues about the brain's role in regulating blood pressure.\nAbout 10 percent of high blood pressure cases either can't be controlled with medication or patients cannot tolerate them, study author Dr. Nikunj K. Patel, a neurosurgeon at Frenchay Hospital in Bristol, England, said in a journal news release.\nThe study adds to other recent research focused on neuromodulation, which harnesses the power of electrical impulses in the body for therapeutic benefit.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers will come away from this story understanding that DBS is not currently available for the treatment of high blood pressure \u2014 and probably won\u2019t be any time soon. That satisfies the\u00a0main expectation of this criterion, so we\u2019ll award a satisfactory. The story could have provided more\u00a0information about which\u00a0conditions DBS\u00a0currently is used\u00a0to treat.\u00a0(DBS is\u00a0FDA-approved for the treatment of\u00a0several movement disorders, including Parkinson\u2019s disease, and is sometimes used to treat other conditions, including chronic\u00a0pain and depression.) It also could have explained that DBS is\u00a0available primarily at large urban medical centers,\u00a0and that doctors\u2019 experience with the procedure can vary widely.", "answer": 1}, {"article": "The Dana-Farber scientists say current [EGFR] inhibitors Iressa and Tarceva prevent EGFR from sending signals that are essential to keep tumor cells growing, the researchers say.\nThe scientists say in the news release that not only did they find that a compound called WZ4002 can slow tumor growth, but that it is possible to \"selectively target the drug-resistant mutant EGFR in tumors, with relatively less effect on the normal EGFR in health tissues.\"\nThe scientists say non-small cell lung cancers that had become invulnerable to the chemotherapy drugs Iressa and Tarceva were stymied in a study by a compound designed and formulated in the Dana-Farber laboratory.\nThe researchers say the framework of the new compound is different from that of other cancer drugs and acts against a protein that carries a structural defect, according to a news release.\nIt's early to discuss the use of such compounds in patients, the scientists say, but one of the researchers, Michael J. Eck, MD, PhD, also of Dana-Farber, says he's optimistic their approach \"will lead to an effective treatment for the thousands of non-small cell lung cancer patients worldwide who develop resistance to Iressa and Tarceva every year.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not until the very end of the article do we learn that the dramatic results against NSCLC tumors occurred in mice, not human beings. In fact, it never states the setting for any results \u2014 an important point because the article fails to reveal that some results, such as the compound\u2019s apparent ability to spare normal tissues, were achieved in cell lines, not even in mice, according to the\u00a0press release\u00a0and\u00a0article\u00a0published in Nature.\u00a0Therefore, most of the article is misleading .\nRead the pivotal sentence below. Without any mention of animals preceding it, how could we\u00a0not\u00a0assume that the lungs, cancers, and powerful treatment effects were in humans?\nThis sentence, if not the article\u2019s title, should have been qualified with the word \"animal,\" \"mouse,\" or even \"murine.\" \nThe article provides almost no caveats about the preliminary nature of these results, nor the limitations of extrapolating to humans any data obtained from cell lines and animals.\u00a0While the article does contain two statements, essentially quoting the\u00a0press release, about what lies ahead following these early data, both sentences contain a \"but\" followed by the investigators\u2019 optimism.", "answer": 0}, {"article": "Could root canal procedures go by the wayside in the not-too-distant future?\n\"We're trying to provide an alternative material, an alternative therapy,\" he said, because the current method involves the dentist removing all of the infected pulp tissue, \"scraping it out, and it can be very painful.\"\nThough the work is still in its early stages, and has not yet been tested in people, the scientists won an award from the Royal Society of Chemistry for their idea: regenerative dental fillings.\nIt's like this material goes over and just taps it on the shoulder and says, 'Wake up, wake up,' and then it starts to repair itself.\"\nWhen dental pulp disease and injury happen, a root canal is typically performed to remove the infected tissues, explained Dr. Adam Celiz, Marie Curie Research Fellow at the University of Nottingham.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the research is \u201cstill in its early stages, and has not yet been tested in people.\u201d It also quotes a researcher saying, \u201cIt\u2019s hard to put timeline on it, but we\u2019re talking years before we test it in humans.\u201d\nStill, the story could have been more skeptical in its approach, pointing out that the therapy may never pan out.", "answer": 1}, {"article": "Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting up to 12% of women.\nThe potential of irisin as a meaningful drug target in PCOS is very promising,\" said Dr Bacopoulou.\nThe findings suggest that irisin could be a marker for PCOS allowing the condition to be diagnosed more easily.\nThey found that teenagers with PCOS had significantly higher irisin levels compared to the control group, and that this was associated with higher levels of the male sex hormone testosterone, a key marker of PCOS.\nPrevious studies have associated high levels of irisin, a newly discovered hormone which is released from muscles and regulates energy metabolism, with PCOS in adults.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that it is too early to say whether irisin will serve as a good indicator for PCOS diagnosis.", "answer": 1}, {"article": "(CNN) The first large head-to-head comparison of two opioid addiction medications found that, although they were equally effective in getting people off of high levels of opioids, users had a significantly more difficult time starting a regimen of naltrexone, compared with buprenorphine.\nThe body also produces natural opioids, but the more narcotics a person takes, the less opioids the body naturally produces.\nIf a person is using opioids and takes naltrexone, it can induce a feeling of withdrawal.\nWithout the opioids, people can go into withdrawal, all contributing to a cycle of dependency.\n\"To feel normal, they need opiates on those receptors,\" Banta-Green said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All three drugs mentioned in the story are available, though more could have been said about how accessible they are to people who are trying to overcome addiction.", "answer": 1}, {"article": "Breast cancer test kits by genetic testing company 23andMe just received Food and Drug Administration approval.\nStill, the company, which already tests DNA for other health risks as well as ancestry, said this cancer test is \"a step in the right direction.\"\nThose most at risk of developing such cancers are of Eastern European Jewish descent.\nMore: Breast cancer: Study finds tumor risk increased by use of oral contraceptives\n\nBut \u201cit has a lot of caveats,\u201d warned Donald St. Pierre, acting director of the FDA's Office of In Vitro Diagnostics and Radiological Health.\nThese tests might help with prevention, but cannot diagnose cancer and cannot rule out your chances of getting cancer, 23andMe said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t make it clear when this test will be available.\u00a0\u00a0The company\u2019s website notes that said testing results will be available \u201cin the coming weeks.\u201d", "answer": 0}, {"article": "\u201cMentally, people feel calmer, sharper, maybe more content.\nWe thought it\u2019s time to see if we could pull all [the literature] together \u2026 to see if there\u2019s enough evidence that the benefits individual people notice can be used to help people with mental illness.\u201d\n\nTheir findings suggest that yoga does in fact have positive effects on mild depression and sleep problems, and it improves the symptoms of psychiatric disorders like schizophrenia and ADHD among patients using medication.\nIf a large national study were done, it could turn out that yoga is just as good and may be a low cost alternative to people with unmet needs.\u201d In the meantime, he says it doesn\u2019t hurt to add yoga to existing treatments so patients can take advantage of any potential benefits.\nFor instance, yoga may influence brain chemicals known as neurotransmitters (boosting levels of feel-good agents like serotonin), lower inflammation, reduce oxidative stress and produce a healthier balance of lipids and growth factors \u2014 just as other forms of exercise do.\n\u201cYoga has also become such a cultural phenomenon that it has become difficult for physicians and consumers to differentiate legitimate claims from hype,\u201d researchers from Duke University Medical Center write in their study, published in the journal Frontiers in Psychiatry.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Yoga classes are widely available, but there is no standardized curriculum. So it\u2019s not clear if classes at the local community center will provide the same benefits observed in these studies.\u00a0The story should have addressed\u00a0this uncertainty.", "answer": 0}, {"article": "The US is far from that at the moment.\nThis is a big part of the 12 steps, with the final step even invoking \u201ca spiritual awakening.\u201d For people who aren\u2019t religious or spiritual, this can be a big turn-off; that\u2019s one reason SMART and LifeRing exist to begin with \u2014 they\u2019re meant to be secular alternatives to the 12 steps.\nThe study\u2019s survey data suggests this is in fact what was going on: When researchers controlled for people\u2019s recovery goals \u2014 meaning, whether they wanted to commit to lifetime total abstinence or not \u2014 the differences between the 12-step groups, SMART, and LifeRing went away.\nWhile alternatives like SMART or LifeRing do exist, they\u2019re not nearly as available as AA \u2014 and they certainly aren\u2019t built into professional treatment programs in the same way as the 12 steps.\n\u201cThat\u2019s why you\u2019re seeing these associations between SMART and LifeRing affiliation at baseline and worse recovery outcomes when you control for involvement.\u201d She added, \u201cBut I want to emphasize that these go away when you control for recovery goals.\u201d\n\nAgain, the study is not the final word.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story thoroughly addresses the gulf in availability between 12-step programs and alternative approaches.\nMost treatment facilities in America are, according to the\u00a0survey data and research, at least partly based on the 12 steps \u2014 making it the\u00a0only option for many people. While alternatives like SMART or LifeRing do exist, they\u2019re not nearly as available as AA \u2014 and they certainly aren\u2019t built into professional treatment programs in the same way as the 12 steps.", "answer": 1}, {"article": "Outside of heart attacks, doctors are often too quick to use a common $20,000 procedure to treat patients suffering from coronary artery disease, a new study suggests.\n\nAbout 600,000 angioplasty procedures, which almost always involve placement of a tiny metal tube called a stent, are done in the U.S. each year. Roughly 70% of these procedures are performed on patients suffering symptoms of a heart attack and aren't medically controversial. But the remainder are done on stable patients who are suffering mild symptoms or no symptoms...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes the widespread availability \u2013 too widespread \u2013 of stenting quite clear.", "answer": 1}, {"article": "Tensions ran so high at one point that two prostate cancer specialists, who had urged the F.D.A.\nThe only approved treatment for them now is the chemotherapy drug Taxotere, from Sanofi-Aventis, which extended median survival by about three months in trials.\nBased on those results, an advisory panel to the F.D.A., meeting in March 2007, voted 13 to 4 that there was \"substantial evidence\" that the drug worked and 17-0 that the drug was safe.\nCancer vaccines of the type represented by Provenge, known as immunotherapy, are different from conventional vaccines in that they do not aim to prevent disease, but to enlist the body\u2019s defenses in attacking the disease after it occurs.\nThe F.D.A.\u2019s decision two years ago ignited an outcry from some prostate cancer patients and from investors in Dendreon, who said the agency was being unreasonable and denying patients a treatment that might work.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story describes the findings of the clinical trial as \"decisive,\" and speculates the \"widely anticipated results could pave the way\" for the drug\u2019s approval. \nThe result is to imply imminent availability, an outcome that is by no means certain.\u00a0 ", "answer": 0}, {"article": "Another sensor, just approved by the F.D.A.\nand made by DexCom, is said by some researchers to be a bit more accurate, as is a third device, from Abbot, which has not yet been approved.\nIt has to be placed above the hip or the buttocks, which makes reaching it awkward, and then the wire leading from the sensor has to be connected to a transmitter that wirelessly sends the information to the pump.\nI also had three sensor catheters slip out and require early replacement, which would be especially annoying to anyone paying the $35 that each sensor costs; I wasn\u2019t, because MiniMed had supplied everything free for testing, but everybody else will, since the sensors are not yet covered by insurance.\nThe device, made by Medtronic MiniMed, is called the Paradigm Real-Time, a combination insulin pump and continuous glucose sensor.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states the \u201cParadigm Real-Time\u201d combination insulin pump and glucose sensor was approved by the FDA, implying it is available to consumers. It was a little confusing to hear one man\u2019s story about traveling to another city for a \u201ctest-period\u201d in which the manufacturer paid for supplies, which sounded a bit like a study scenario or a special promotional deal. And, it\u2019s still not clear whether this is available everywhere or only at certain locations. But, the article also tells readers that insurance won\u2019t pay for the supplies as yet (even though the anecdotal story-teller felt it was worth it to him to start paying this), adding to the idea that if one wanted to pay the out-of-pocket expense, one could obtain this device. ", "answer": 1}, {"article": "Patients who said their level of pain was at least 4 on a 10-point scale received one of three treatments: acupuncture alone; acupuncture with painkillers; or painkillers alone.\n\"While acupuncture is widely used by practitioners in community settings for treating pain, it is rarely used in hospital emergency departments,\" said study lead investigator Marc Cohen.\n\"Emergency nurses and doctors need a variety of pain-relieving options when treating patients, given the concerns around opioids such as morphine, which carry the risk of addiction when used long-term,\" Cohen said in a university news release.\nOne hour after treatment, less than 40 percent of all patients had significant pain reduction, meaning at least a 2-point decline on the 10-point scale.\nThe study -- billed as the world's largest randomized, controlled trial of acupuncture in the emergency department -- included 528 patients.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While acupuncture is becoming more widely available in most communities, there is no information in the story that suggests how available it might be in large hospital emergency departments. Also, would it be available in a timely manner?", "answer": 0}, {"article": "Patches in the mouse study contained an array of 100 needles, each some 650 microns in length, or about the width of a few strands of human hair.\n\"It's a technological approach that makes a lot of sense,\" said Dr. Jan Drutz, a general pediatrician at Texas Children's Hospital who calls needle-phobia common in both kids and adults.\nHe also said that although initially there will be start-up costs, he thinks the price will be no more than traditional flu vaccines once it is mass-produced.\nIn the study, one group of mice received the influenza vaccine from traditional hypodermic needles; another group received the vaccine through the dissolving microneedles; and a control group received the microneedle patches not containing any vaccine.\nFlu patch may take sting out of your fears\n\nIn what would be a boon for needle-phobes of all ages, researchers have developed a skin patch that vaccinates against the flu and could be available in five years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this technology is not yet available. But why waste the introduction\u00a0predicting that the patch \"could be available in 5 years\"?\u00a0That\u00a0space\u00a0would have been better used to provide an important detail about the research: This was a mouse study!\u00a0Instead, readers have to wait 5 paragraphs to learn this. And what is that five-year prediction based on besides the hopes and prayers of a researcher and whatever company will market it? ", "answer": 0}, {"article": "\"There is a growing sense that VE [vasogenic edema] or ARIA [amyloid-related imaging abnormalities] is a manageable side effect and may actually be a sign that the drug is clearing amyloid from the brain and the blood vessels,\" said Salloway.\n\"I think it is too early to tell from the data from this small Phase 2 safety trial,\" said Ian Murray, an assistant professor of neuroscience and experimental therapeutics at Texas A&M Health Science Center College of Medicine in College Station.\nThe researchers, who said monitoring of bapineuzumab will continue, are now awaiting the results of a larger Phase III trial on the drug.\nWEDNESDAY, July 20 (HealthDay News)-- An experimental drug for treating Alzheimer's disease that previously showed troubling side effects may actually be safe in the long run, researchers report.\nAlthough bapineuzumab has shown promise in certain Alzheimer's patients, other research found that patients taking a higher dose of the drug had an increased risk of brain inflammation from water retention.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The subject of the story is the drug bapineuzumab, which was reported as not yet available to consumers.\nIt would have been useful to include a link to Clinicaltrials.gov so that readers who might be interested could learn about the other trials being conducted.\nhttp://clinicaltrials.gov/ct2/results?term=Bapineuzumab", "answer": 1}, {"article": "But she said it\u2019s more convenient and less time-consuming to administer.\nThe device would be available only for use by medical professionals as part of a more comprehensive assessment of cognitive function.\nThe subjects, ranging in age from 55 to 95, were classified in three groups based on cognitive abilities: normal, mild cognitive impairment and impaired.\nOther parts of the test challenge memory recall or the ability to recognize letters and shapes.\nThat number is expected to reach 13.5 million by 2050, according to the Alzheimer\u2019s Association.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the device/test was approved by the FDA and that it is available for use.", "answer": 1}, {"article": "gov.\nAnyone considering changing or beginning treatment of any kind should consult with a physician.\nTesting and measurements were done once, providing no data for comparison over time or to determine any link to dementia.\nThey had lower brain volume, indicating shrinkage comparable to two additional years of aging.\nThose with the lowest levels of omega-3s showed signs of accelerated aging.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of fish and fish oil is not in question.", "answer": 2}, {"article": "\u201cMen don\u2019t say, \u2018Let me go to the urologist and give a semen sample.\u2019\u201d That reluctance has created a $440 million-a-year market for male fertility tests in the U.S., Lopez says.\nA new at-home sperm-analysis test allows men to assess their babymaking abilities.\nWhen it comes to infertility, the burden seems to often fall on women.\nThey\u2019re poked and prodded and scoped in an effort to figure out what\u2019s complicating conception.\nHard to believe.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The entire story is based on the pending \u201cdebut\u201d of the test.\n\u00a0", "answer": 1}, {"article": "This barrier works to protect the brain from toxins.\nStudy funded by Ivy Foundation shows PPF could help treat glioblastomas by sensitizing tumors to chemotherapy and radiation treatments\n\nPHOENIX, Ariz. -- Nov. 12, 2015 -- In a significant breakthrough, the Translational Genomics Research Institute (TGen) has identified a drug, propentofylline or PPF, that could help treat patients with deadly brain cancer.\nIn a study published today in the Journal of NeuroOncology, TGen researchers report that PPF works to limit the spread of glioblastoma multiforme, or GBM -- the most common primary tumor of the brain and central nervous system -- by targeting a protein called TROY.\n\"We showed that PPF decreased glioblastoma cell expression of TROY, inhibited glioma cell invasion, and made brain cancer cells more vulnerable to TMZ and radiation,\" said Dr. Nhan Tran, Associate Professor and head of TGen's Central Nervous System Tumor Research Lab.\nIn addition, TGen laboratory research also found that PPF increases the effectiveness of a standard-of-care chemotherapy drug called temozolomide (TMZ), and radiation, to treat glioblastoma.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although the release is clear that this approach is experimental, by failing to clearly point out the fact that the drug has yet to be tested in a single glioblastoma multiforme patient, it obscures just how preliminary and tentative these results are.The release gives the reader the false impression that PPF has already been approved for this purpose with this statement:\n\u201cAn advantage of small-molecule PPF \u2014 which has been previously used in clinical trials in an attempt to treat Alzheimer\u2019s disease and dementia \u2014 is that it can penetrate the blood-brain barrier and reach the tumor. And, the FDA has already approved it.\u201d", "answer": 0}, {"article": "\"And with the one oral option we have today, there has been a lot of concern over a possible risk for immune suppression and also an increased risk for cancer,\" added Zamvil, who was not a part of the current study team.\nBut there's a lot of excitement about this new option and these results, because even though the injectables are safe and effective in terms of convenience and patient compliance, oral drugs are much better than shots.\"\nThe findings concern the experimental drug laquinimod, and stem from work with over 1,100 MS patients at 139 medical facilities in 24 countries.\nThe incidence of liver enzyme elevation was higher in patients treated with laquinimod, according to Comi, but he added that the elevations were temporary, reversible and did not lead to any signs of liver problems.\nIf the experimental medication is eventually approved for use, it would be only the second oral MS drug available to patients, alongside a number of long-standing injectable options.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains early that the drug is currently not available and also that it is only one of many options by saying, \u201cIf the experimental medication is eventually approved for use, it would be only the second oral MS drug available to patients, alongside a number of long-standing injectable options.\u201d", "answer": 1}, {"article": "The study entitled \"A Pecan-Rich Diet Improves Cardiometabolic Risk Factors in Overweight and Obese Adults: A Randomized Controlled Trial\" is available online and will be presented at the American Society for Nutrition Annual Conference, Nutrition 2018 held in Boston this June.\nCalorie levels, as well as protein, carbohydrate, and total fat, were kept the same.\nThe study was funded by the National Pecan Shellers Association.\nObesity is a risk factor for T2D, and both obesity and T2D increase CVD risk.\nBoth the control diet and the pecan-rich diet were low in fruits, vegetables and fiber.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Pecans are known to be widely available.", "answer": 2}, {"article": "APA's membership includes more than 122,500 researchers, educators, clinicians, consultants and students.\nThe study was too short to reveal any long-term effects so the researchers plan to follow the participants as they age to provide additional evidence of whether college studies may reduce the risk or delay the onset of dementia.\nPrior research has shown that college study earlier in life may increase cognitive capacity, and it appears the same may be true for older adults, Lenehan said.\nAn Australian study called the Tasmanian Healthy Brain Project recruited 359 participants ages 50 to 79 who took a series of cognitive tests before completing at least a year of full-time or part-time study at the University of Tasmania.\nThe researchers suspect that campus study may provide greater benefits in boosting cognitive capacity because of social interaction with professors and fellow students, but the study didn't analyze any differences between on-campus or online courses.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Not noted explicitly but university courses are widely available especially at community colleges. This is suggested by the release so we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "For example, before adjusting for these kinds of differences between the groups, the researchers found that light drinking was connected with 33% lower rates of overall behavior problems in boys \u2014 after the adjustment, that effect fell to 23%.\nEven More Evidence for the Health Benefits of Drinking\n\nPhotos: What Booze Looks like Under a Microscope\nWhatever the case, American health authorities remain united in their advice that no amount of alcohol is safe for the fetus during pregnancy \u2014 and anyone who is familiar with fetal alcohol syndrome knows why.\nIf women who say they are drinking at \u201clight\u201d levels are actually drinking at moderately or heavily, that might make the data on light drinking look more dangerous than they are.\nThe study did find negative effects in children whose mothers drank moderately: this was defined as not having more than 3 to 6 British units of alcohol per week or more than 3 to 5 units on a single occasion.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This does not seem to apply here.", "answer": 2}, {"article": "[3] Analysis only included cases occurring 10 days after receiving the vaccine to account for the incubation period of the Ebola virus.\nIn case of Ebola flare-ups prior to approval, access to the vaccine is being made available through a procedure called \"compassionate use\" that enables use of the vaccine after informed consent.\nThe vaccine's manufacturer, Merck, Sharpe & Dohme, this year received Breakthrough Therapy Designation from the United States Food and Drug Administration and PRIME status from the European Medicines Agency, enabling faster regulatory review of the vaccine once it is submitted.\nIn addition to showing high efficacy among those vaccinated, the trial also shows that unvaccinated people in the rings were indirectly protected from Ebola virus through the ring vaccination approach (so-called \"herd immunity\").\nAs part of this agreement, Merck committed to ensure that 300,000 doses of the vaccine are available for emergency use in the interim, and to submit the vaccine for licensure by the end of 2017.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release provides fairly detailed information about the next steps in the vaccine approval process, noting that Merck has committed to submitting the vaccine for regulatory approval by the end of 2017 and that the company has committed to making 300,000 doses available should an outbreak occur before approval is gained. It also notes that if an outbreak occurred before the vaccine is approved, it could be used, with informed consent of those vaccinated, through a \u201ccompassionate use\u201d program.", "answer": 1}, {"article": "The trial was registered at http://www.\nResearchers at Baylor Scott & White Health in Temple, Texas, found that dry needling, which uses filament needles to stimulate sensitive loci, or trigger points, in the muscles, is as effective as cortisone injection in reducing pain and improving movement problems caused by greater trochanteric pain syndrome (GPTS).\nAbout the Journal of Orthopaedic & Sports Physical Therapy\n\nThe Journal of Orthopaedic & Sports Physical Therapy\u00ae (JOSPT\u00ae) publishes scientifically rigorous, clinically relevant content for physical therapists and others in the health care community to advance musculoskeletal and sports-related practice globally.\nDry needling may be a viable treatment alternative to cortisone injection for patients with chronic, intermittent pain and tenderness on the outside of the hip, thus avoiding the potentially harmful effects of steroids\n\nDry needling may be a viable treatment alternative to cortisone injection for patients with chronic, intermittent pain and tenderness on the outside of the hip, thus avoiding the potentially harmful effects of steroids, according to a new study published in the April 2017 issue of the Journal of Orthopaedic & Sports Physical Therapy\u00ae (JOSPT\u00ae).\n\"Evidence for dry needling of the hip in lieu of steroid injection is in its infancy,\" acknowledges lead author Kindyle L. Brennan, PT, PhD, with Baylor Scott & White Health.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no discussion of what\u2019s involved with dry needling. While steroid injections take about five minutes and are usually done in a physician\u2019s office once every six weeks or more, dry needling is usually performed by a physical therapist and requires more frequent treatments of about 20 minutes apiece.\nDuring this six-week study, the dry needling group received an average of 5.4 treatments while those who received cortisone injections had one shot.\nDry needling might be more convenient than steroid injections if it\u2019s part of treatment strategy that also involves physical therapy.", "answer": 0}, {"article": "Researchers conducted a systematic review of existing peer-reviewed research evaluating infusion care for several conditions, including cystic fibrosis, antibiotics following orthopedic surgery and several cancers requiring infused chemotherapies.\nThe research showed that patients receiving intravenous therapy at home had as good or better clinical outcomes as those patients who received the same therapy in a traditional health care setting.\nDespite this, clinical outcomes and quality of care have not previously been systematically evaluated.\nThis unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs.\nCare is administered by experienced infusion nurses and pharmacists, and in addition, patients receive additional disease management education and support throughout their treatment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Home infusion services are widely available. Their reimbursement is not widely available.", "answer": 1}, {"article": "Benign prostate hyperplasia, also known as enlarged prostate, is a non-cancerous condition familiar to millions of aging males.\nHowever, the authors did not see as great an improvement in \"urodynamic\" results, such as improved flow rate of the urine, which would indicate how well the bladder and urethra are performing; in this area, the patients did not improve as much as those who underwent TURP surgery, they noted.\nThe treatment -- called prostatic artery embolization, or PAE -- is ready to be used in certain patients, namely those with a prostate larger than 60 cubic centimeters, \"with severe lower urinary tract symptoms and a weakened urinary stream,\" said Dr. Joao Martins Pisco, lead author of a study slated to be presented March 29 at the annual meeting of the Society of Interventional Radiology in Chicago.\nMeanwhile, there is no size limitation for PAE, which requires only local anesthesia and also lowers the risk of other side effects, such as blood loss and retrograde ejaculation, which occurs when semen leaks into the bladder, researchers said.\nAnother drawback is that few doctors are trained in PAE so far, said Pisco, chair of radiology at Hospital Pulido Valente and professor in the Faculty of Medical Sciences at New University of Lisbon in Portugal.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story allowed the lead researcher to boast that prostatic artery emoblization was \u2018ready to be used in certain patients\u2019.\u00a0 But then it quickly countered that with \u201cbut other experts aren\u2019t so sure.\u201d\nThe story could have stated much more emphatically that it is a stretch to think that PAE would be utilized in this new population on the basis of a single, small scale study, presented as an oral presentation at a meeting. \u00a0Given that the procedure is still experimental at this point, it is unlikely to be widely available.\nAnd although the story noted that few physicians are \u2018trained to perform the procedure\u2019 it should have been explicit that this is currently not an option for most men.\nNonetheless, we\u2019ll give the story a BARELY satisfactory on this criterion.", "answer": 1}, {"article": "But there\u2019s one big stumbling block for both of them, a problem that has dogged medical genetics for decades: Data for non-white populations is sorely lacking.\nThere just aren\u2019t.\u201d (Today there is that resource, based on Muenke and the NIH\u2019s work.)\nBut they differ in a key way: Whereas the algorithm the NIH uses can predict if someone has a given genetic disorder, the Face2Gene algorithm spits out not diagnoses, but probabilities.\nFor one thing, it can be the factor that sends someone to get a genetic test in the first place.\n(The program is funded by the NIH\u2019s Fogarty International Center; President Trump eliminated funding for the center in his 2018 \u201cskinny\u201d budget proposal announced in March.)\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear if this technology is available to anyone or if it is entirely in the research phase. This sounds developmental, but it was not clear. On visiting their website, it appears that it is already available for use.", "answer": 0}, {"article": "The Journal of Medical Entomology is published by the Entomological Society of America, the largest organization in the world serving the professional and scientific needs of entomologists and people in related disciplines.\nSkepticism is inherent to the trade.\nThe study was done outdoors in order to replicate real-world conditions.\n\"In vector control, we see more often than not that tools available for consumers don't work for the intended purpose,\" said Bibbs.\nBut it was nice for a change of pace that one of these devices could actually do some good.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s understood that the device is widely available.", "answer": 1}, {"article": "They suggested limiting consumption of grouper, Chilean sea bass, bluefish, halibut, black cod, Spanish mackerel and fresh tuna.\nFish is rich in omega-3 fatty acids, B vitamins, iodine, selenium and vitamin D. And numerous studies show that the nutrients in fish are particularly important for brain development in fetuses and nursing infants.\nThe report also acknowledges the risk of mercury exposure from certain kinds of seafoods, and notes that women who are pregnant, nursing or may become pregnant should avoid certain kinds \u2014 tilefish, shark, swordfish and king mackerel \u2014 because of their high mercury content.\nAs a result, health officials recommend fish like sardines, salmon, tilapia and trout that are lower on the food chain and have accumulated less mercury in their tissue.\n\u201cIt may be that the issue is re-evaluated and there is no change.\u201d\n\nMercury levels in our oceans are on the rise due to an increase in industrial mercury emissions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not address the availability of tuna fish. However, most readers can be expected to be familiar with canned tuna, which is widely available.", "answer": 2}, {"article": "It is the first shingles vaccine to combine a non-live antigen with a specifically designed adjuvant.\nMany vaccines are made from a weakened form of the virus, but Shingrix is made from just a single protein--known as glycoprotein E--that comes from the outer shell of the herpes zoster virus.\n\"The efficacy is approximately 90% for all age groups--even for those over 70 years of age.\n\"The second dose of the vaccine is important to ensure long-term protection,\" Professor Cunningham said.\n\"Our research shows that the vaccine stimulates your immune system to produce more antibodies and it generates a 24-fold increase in T cells.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no mention of whether Shingrix is widely available. It is, including in the US where it received FDA approval in October 2017.", "answer": 0}, {"article": "Lona Sandon, a registered dietitian and assistant professor of clinical nutrition at the University of Texas Southwestern Dallas, reacted with cautious optimism to the findings.\nThe authors concluded that fish oil supplementation appears to be a safe and effective way to prevent malnutrition among cancer patients, and may ultimately prove to be of benefit for other groups of people, such as elderly patients who also face a significant ongoing risk for muscle loss.\n\"Fish oil may prevent loss of weight and muscle by interfering with some of the pathways that are altered in advanced cancer,\" study author Dr. Vera Mazurak, of the University of Alberta in Edmonton, Canada, said in a news release.\n\"But I would caution that the amount of pure concentrated fish oil supplement the people in this study were given is a lot,\" she added.\nTo explore the therapeutic potential of fish oil supplements, the authors offered 16 cancer patients undergoing an initial 10-week chemotherapy regimen a daily dose of 2.2 grams of a particular omega-3 fatty acid called eicosapentaenoic (EPA).\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There isn\u2019t any question about the availability of fish oil supplements.\u00a0 More importantly, the independent perspective from dietitian Lona Sandon pointed out that the amount of concentrated fish oil supplement used in the study was much more than any recommended dietary allowane.", "answer": 1}, {"article": "SOURCE: bit.ly/zZIYa1\nThe analysis, which appeared in the Journal of Urology, compared increasingly common robotic surgery with two other techniques for the same surgery and found that direct costs can be up to several thousand dollars higher for the robotic type.\nWe were going to get patients out of the hospital quicker, have better potency and incontinence outcomes,\u201d he told Reuters Health.\nThe open-surgery group also stayed in the hospital about one day longer than the robotic group.\n\u201cI think the take home message is that robotic (surgery), looking at our study, had certain beneficial outcomes compared to open and laparoscopic procedures,\u201d said study leader Jim Hu at Brigham and Women\u2019s Hospital in Boston.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of all 3 surgical approaches studies \u2013 while not explicitly described \u2013 could be inferred from the study details reported.", "answer": 1}, {"article": "A blood test for 10 different types of cancers could one day help doctors screen for the disease before patients show symptoms, researchers at the world\u2019s largest gathering of oncologists have said.\n\u201cWe hope this test could save many lives.\u201d\n\nThe study, by a research team that also included scientists from Stanford University, was presented at the annual conference of the American Society of Clinical Oncologists in Chicago.\nThe blood test found lymphoma and myeloma with slightly less accuracy, at 77% and 73%, and bowel cancer in two out of three patients.\nThe test had particularly good results for ovarian and pancreatic cancers, though the number of cancers detected was small.\nThe test, called a liquid biopsy, screens for cancer by detecting tiny bits of DNA released by cancer cells into blood.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability of liquid biopsies are not directly addressed, though it is implied they are not yet available. We\u2019ll give this one a just-barely satisfactory.", "answer": 1}, {"article": "It can hinder recovery and cause clouding of the cornea, which is the clear outer layer of the eye.\nAlthough approved by the FDA, the femtosecond laser procedure is not widely used in the U.S., according to the American Academy of Ophthalmology.\nCurrently, most aspects of cataract surgery, including the initial incision and the breakup and removal of the clouded lens from the lens capsule, are performed manually by the surgeon.\n\"There certainly seems to be a benefit to using the laser,\" says American Academy of Ophthalmology (AAO) spokesman James Salz, MD, clinical professor of ophthalmology at the University of Southern California in Los Angeles.\nThe surgery is performed to remove the natural lens of the eye after it has become clouded over time.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the\u00a0femtosecond laser procedure is approved by the FDA, but not widely used in the U.S.", "answer": 1}, {"article": "Svetsky cautioned that weight gain from eating large amounts of dark chocolate would counteract any benefits on blood pressure.\nUniversity of Cologne researcher Dr. Dirk Taubert, the study's lead author, said the blood pressure reductions with dark chocolate were small but still substantial enough to potentially reduce cardiovascular disease risks, although study volunteers weren't followed long enough to measure that effect.\nChocolate-makers have embraced these findings and have developed new ways to satisfy the sweet tooth and curb the guilt by introducing more varieties of dark chocolates, fortifying them with vitamins and anti-oxidants, reports Miller.\nVolunteers for the study ate just over six grams of dark chocolate daily for almost five months \u2014 one square from a German chocolate bar called Ritter Sport, equal to about 1\u00bd Hershey's Kisses.\n\"When you take cocoa bean and break it between your hands, you get the nibs,\" Torres said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The study that this story reported on found\u00a0one particular type of dark chocolate (Ritter Sport Halbbitter) had an effect on blood pressure.\u00a0 While the story was helpful in that it included information about portion size in terms a typical consumer could understand (i.e. about one and a half Hershey\u2019s dark chocolate kisses), it failed to provide information about the availability of the chocolate used in this study. Is it common?\u00a0 Is it found in many other products?\u00a0 ", "answer": 0}, {"article": "NEW YORK (Reuters Health) - A fresh look at the medical evidence shows women who eat more fiber are less likely to get breast cancer.\nAnd those in the top fifth of fiber intake were 11 percent less likely to do so than women in the bottom fifth.\nChinese researchers found those who ate the most of the healthy plant components were 11 percent less likely to develop breast cancer than women who ate the least.\n\u201cIncreasing dietary fiber intake in the general public is of great public health significance,\u201d the Chinese team concludes.\nKnown benefits of a high-fiber diet include lower cholesterol and weight loss.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that fruits, vegetables, beans and whole grains are all high in fiber.", "answer": 1}, {"article": "Along with Hernandez, CTE has been diagnosed in San Diego Charger and Hall of Famer Junior Seau, as well as the Philadelphia Eagles' Kevin Turner and the Oakland Raiders' Ken Stabler, to name a few.\nAn early step in the right direction\n\nMcKee also cautioned that this is still early research.\nIt is believed to result from repeated trauma to the head, which causes a buildup of the abnormal protein tau which clumps in the brain.\n\"The findings of this study are the early steps toward identifying CTE during life.\nOnce we can successfully diagnose CTE in living individuals, we will be much closer to discovering treatments for those who suffer from it,\" said McKee.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Once readers get past the first couple paragraphs, the story makes clear that this research is far removed from clinical applications.", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nIt could also become useful as a non-invasive way to assess breast cancer treatment progress.\u201d\n\nThe team plans to complete safety testing of the imaging agent during the next three years.\n\u201cWe showed with this technique that we can detect very tiny tumors of just a few hundred cells,\u201d Lu said, adding that the study pushed imaging boundaries, revealing smaller cancers than can be detected with current clinical imaging modalities.\nMore importantly, the fibronectin part of the complex is expressed during a cell\u2019s transition to cancer and plays a role in cell growth, migration and differentiation.\n\u201cThe recurrence rates of some forms of breast cancer and the consequence of metastatic cancer make these efforts urgent and important,\u201d said Lu, adding that his research team also hopes to advance the approach for prostate cancer detection.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although it takes time to get there, the release does explain that this is not available for clinical use now and will not be until further work is done.", "answer": 1}, {"article": "How miserable is combing a child's hair, lock by lock, to pick off head lice? So miserable that some parents are buying $30 shampoos and other washes that promise to ward off the tiny, grayish bugs.\n\nThe parents get peace of mind that they are doing something. Conveniently for the product makers, there's no way to tell if they kept lice at bay, or if children wouldn't have gotten lice anyway. Makers say sales are growing fast.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story includes the staggering sales figures of prescription and over the counter lice control products \u2013 totaling more than $151 million last year \u2013 making availability quite clear.", "answer": 1}, {"article": "The Mount Sinai Hospital is in the \"Honor Roll\" of best hospitals in America, ranked No.\nMore specifically, the non-wire electrodes were less traumatic, causing less injury and minimizing fractures inside the inner ear.\n\"This is an exciting time in this field, and the advancement in hearing technology and continued improvements in techniques and outcomes will benefit patients and their families.\"\nThe study found that the actual brand of the electrode did not make a difference; the presence or absence of wire was the only distinguishing factor.\n\"This study is a breakthrough for patients with hearing loss, and improvements in practice and techniques will allow them to enjoy many hearing benefits such as music enjoyment, listening in complex environments, and sound localization.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Are these types of surgeries or cochlear implants available anywhere in the US? \u00a0We have no idea from reading this news release.", "answer": 0}, {"article": "Chest compressions or CPR can help restore circulation, increasing the odds of survival.\n\u201cIn contrast, if CPR is not initiated before the arrival of the emergency medical services, only 1 in 30 people survive a cardiac arrest.\u201d\n\nFor the current study, researchers looked at 30-day survival for patients who had cardiac arrests outside of a hospital between 2005 and 2011.\n\u201cEarly CPR saves lives, and the lack of CPR efforts from bystanders could result in significantly decreased chances of survival,\u201d said lead study author Dr. Shahzleen Rajan of Copenhagen University Hospital in Denmark.\nThe biggest obstacle to bystander CPR remains that too few people know how to do it, said Dr. Peter Pons, an emergency physician in Denver and professor emeritus at the University of Colorado School of Medicine.\nIf the ambulance took more than 13 minutes, the survival rate was 3.7 percent in the CPR group and 1.5 percent for the others - a difference that wasn\u2019t statistically meaningful.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t outright state that pretty much anybody is capable of performing CPR. However, it does imply that CPR is widely available\u00a0by explaining that the biggest barrier to bystander CPR is that too few people know how to do it. More explanation about how easy it is to learn the procedure (training can be done in just a few minutes) would have improved that aspect of the article.", "answer": 1}, {"article": "Biomarkers of inflammation were measured at the beginning and end of the study.\n\"We know from our previous studies that by losing weight, people can reduce their overall levels of inflammation, and there is some evidence suggesting that taking vitamin D supplements can have a similar effect if one has insufficient levels of the nutrient,\" said lead and corresponding author Catherine Duggan, Ph.D., a principal staff scientist in the Public Health Sciences Division at Fred Hutch.\nThere is also some evidence that increased body mass \"dilutes\" vitamin D, possibly by sequestering it in fat tissue.\nAt the end of the study, all of the participants had reduced levels of inflammation, regardless of whether they took vitamin D, \"which highlights the importance of weight loss in reducing inflammation,\" Duggan said.\nResults of the randomized, controlled clinical trial -- which involved more than 200 overweight, postmenopausal women who had insufficient levels of vitamin D at the beginning of the study -- are published online ahead of the July print issue of Cancer Prevention Research, a journal of the American Association for Cancer Research.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Primary care physicians and other health providers are well positioned to monitor blood levels of vitamin D, along with dietary and exercise regimens. The news release makes that clear, albeit indirectly. As noted above, we think the release goes too far in suggesting that people ask their doctors about having their vitamin D levels checked. But we\u2019ve already docked points for that, so we\u2019ll award a Satisfactory rating here.", "answer": 1}, {"article": "For them, a combination of two existing CFTR modulators can ease breathing problems -- but the overall effects are only \"modest,\" Rowe said.\nBoth new trials focused on those two groups of patients.\nIf the experimental drugs are ultimately approved, there will be the real-world issue of price.\nAt one time, children with CF usually died before they reached school age.\nOver time, extensive lung damage leads to respiratory failure.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that these drugs are not on the market.", "answer": 1}, {"article": "If you are interested in enrolling in a clinical trial, you can find one at clinicaltrials.gov.\nThe study shows the results of a six-month follow-up with patients in 2007, and researchers are presently working with data from the two-year follow-up.\n(CNN) -- If you've just had your first heart attack, doctors may one day be able to reverse the damage done with stem cell therapy.\nThe study is a step forward in a field in which a lot of approaches have been tried in animals and preliminary human trials, but none has been approved for widespread clinical use for heart patients.\nThe largest national stem cell study for heart disease, sponsored by Baxter Inc., uses this surgical method, and recently announced success in a 12-month phase II trial for patients with severe angina.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Most of the story makes it clear that the technique is in early trials and not in clinical use. Only the opening line is troubling \u2013 \"If you\u2019ve just had your first heart attack, doctors may one day be able to reverse the damage done with stem cell therapy.\" Due to clumsy wording,\u00a0 this suggests that if you had your first\u00a0 heart attack in late 2009, doctors may someday be able to reverse today\u2019s damage from it \u2013 which is not\u00a0 at all the case. \nBut this misstep is remedied by a later statement that it would take a best-case scenario to have such an approach approved even in five years. \n", "answer": 1}, {"article": "Follow us: facebook.com/mars, twitter.com/marsglobal, youtube.com/mars, linkedin.com/company/mars\n\nDaniela Mastroiacovo, Catherine Kwik-Uribe, Davide Grassi, Stefano Necozione, Angelo Raffaele, Luana Pistacchio, Roberta Righetti, Raffaella Bocale, Maria Carmela Lechiara, Carmine Marini, Claudio Ferri, and Giovambattista Desideri.\nOver the past decade, there has been significant evidence indicating that consuming cocoa flavanols improves vascular function.\nThis second study just published in the AJCN looked to address this question.\nFinding a way to defer the onset of these issues becomes increasingly important as life expectancy gets longer and global populations age.\nIn the high- and intermediate-flavanol groups, both systolic and diastolic blood pressures were reduced and insulin resistance was significantly improved.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states in an editor\u2019s note that this test product is not commercially available.", "answer": 1}, {"article": "The U.S. Preventive Services Task Force (USPSTF) says there is no proof that the benefits of routine mammogram screening outweigh the risks for average-risk women in their 40s.\n\"Let's say 10,000 women in the world were going to die of breast cancer that developed in their 40s,\" Brawley tells WebMD.\n\"What we are seeing is that women with mammogram -detected breast cancer require less treatment,\" Malmgren tells WebMD.\nThe finding comes from a careful study of nearly 2,000 women diagnosed with first-time breast cancer at age 40 to 49.\nAnd a certain proportion of women are going to be so inconvenienced so many times with the mammograms they got in their 40s that they will walk away from it in their 50s and 60s when it is a much better test.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 Mammograms are widely available (if you have access to the proper facility and a way to pay for it). So we don\u2019t expect that the story directly address availability.", "answer": 2}, {"article": "One major trial was carried out at Queen Mary University of London (QMUL) in the United Kingdom and published in the journal Hypertension.\n\"The possibility of using a natural product, rather than another pill, to help lower blood pressure, is very appealing,\" adds Dr. Amoils.\n\"It is hugely beneficial for people to be able to take steps in controlling their blood pressure through non-clinical means, such as eating vegetables,\" Prof. Ahluwalia adds.\nBeetroot contains high levels of dietary nitrate (NO3), which the body converts into biologically active nitrite (NO2) and nitric oxide (NO).\nThe first figure is systolic pressure, generated when the heart is pumping, and the second figure is diastolic pressure, created when the heart is relaxing and filling with blood.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story could have mentioned options for purchasing or preparing beet juice. While it didn\u2019t emphasize this or discuss the availability of beets or other nitrate-containing vegetables, we think most readers will understand that these foods and juices are available.", "answer": 2}, {"article": "Lung cancer is the No.\nPatients who had taken the drugs to control diabetes were much less likely to have lung cancer spread \u2014 which is when it becomes most deadly \u2014 the researchers told a meeting of the American College of Chest Physicians.\n\u201cHowever, unique to this study, we have been able to report less advanced cancer in those who do develop cancer, a decreased frequency of squamous cell and small cell carcinomas, and improved survival, when controlled for stage, in people taking metformin and/or TZDs.\u201d\n\nThe team reviewed the medical records of 157 lung cancer survivors with diabetes.\n\u201cThis new information adds to the growing body of evidence that metformin may help prevent and inhibit the progression of lung cancer,\u201d Gutterman said.\n\u201cOur study, as well as other research, suggests an association between metformin and/or TZD use and the risk of developing lung cancer,\u201d said Dr. Peter Mazzone of the Cleveland Clinic in Ohio, who led the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that these drugs are commonly used for diabetes and some are available generically. Ideally the article could\u2019ve stated explicitly that they\u2019re not approved to prevent or control cancer.", "answer": 1}, {"article": "Half ate 22 grams of freeze-dried blueberry powder (equivalent to a cup of blueberries) daily for eight weeks.\nThe lead author, Sarah A. Johnson, a postdoctoral researcher at Florida State University, said she saw no reason for people to radically change their diet, but that if they are not eating blueberries, they might want to try them.\nThe study, in The Journal of the Academy of Nutrition and Dietetics, found that those who ate the blueberry preparation saw an average 5.1 percent decrease in systolic blood pressure (the top number) and a 6.3 percent decrease in diastolic pressure.\nBut, they say, eating blueberries in larger amounts or for longer periods could increase the effect.\n\u201cThere is something very special about the composition of blueberries that is responsible for their effect on blood pressure,\u201d she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not discuss or mention the availability of blueberries or blueberry products. Since the investigators were studying a freeze-dried blueberry powder that may be harder to find than typical grocery store blueberries, we would expect the story to look for and comment on the availability of this product.", "answer": 0}, {"article": "What's that like for Mason?\nResearchers have followed Mason and five other patients -- all with the most severe spinal cord injuries.\nToday, the company sponsoring the trial reported four of the six patients experienced improvement in both motor strength and function.\n\"My two cents is it worked, that this actually changed his neurological recovery and function,\" Dr. Jenkins said.\n\"I'm just super excited, ready to just get it done and go back to rehab and start proving the doctors wrong even more,\" said Mason.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the treatment is experimental, and correspondent LaPook acknowledges at the end, \u201cMore research will be needed to try to establish whether (stem cells) actually repair damage to the spinal cord.\u201d But that strikes us as too little, too late. The story does not explain that it takes years to gain FDA approval for a new treatment, and many therapies particularly in the stem cell field never reach the finish line due to cost, safety, and efficacy hurdles.", "answer": 0}, {"article": "The device is being developed by Cameron Health, a small company in San Clemente, Calif., that was co-founded by Dr. Bardy.\nBefore the device can be sold here, Cameron Health will have to submit more extensive human trial data to the F.D.A.. Dr. Bardy said a larger study of the device has just begun in this country and overseas and that it will most likely take a year or more to assemble data from it for the agency\u2019s review.\nIn recent years, the safety of defibrillator wires has come in particular focus because a model made by Medtronic has been prone to fracturing.\nThe device will not be suitable for a significant number of heart patients, particularly those who require units that also include a pacemaker, which regulates a heart that is beating too fast or too slowly.\nDr. Douglas P. Zipes, a professor at the Indiana University School of Medicine in Indianapolis, said the new device could someday displace existing models used in many patients Every month, about 10,000 patients in this country get a defibrillator, either for the first time or as replacements for devices whose batteries have worn out.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\nThe story points out that the new type of implantable defibrillator is available in some countries in Europe, but that further trials are needed to produce evidence that could be used to apply for FDA approval in the United States.", "answer": 1}, {"article": "\"As the kids with cystic fibrosis are living longer and longer, a lot of these ancillary problems are become more apparent,\" said C. Michael White, director of the Evidence-based Practice Center and lead author of the study.\nBut with antibiotics and other medical advances, the median age for people with the disease increased to 37 by 2008.\nLungs are clogged with a thick mucus, which can lead to lung infections.\nIn the 1950s, children with cystic fibrosis generally died before age 8.\nCaused by defective genes, cystic fibrosis affects multiple organs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 2}, {"article": "The folks who carried out this egg industry-funded research were from the Pennington Biomedical Research Center in Baton Rouge, La.\nNews flash: Eggs are really good for you.\nThis place conducts some serious research on diet and weight.\nAfter a two-week gap, the groups were switched.\nThey could have just asked people if they liked eating eggs for breakfast.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of eggs and cereal is not in question.", "answer": 2}, {"article": "April 12, 2012 -- The next new acne treatment may be found in the produce section of your food store.\n\"The problem with treatments containing benzoyl peroxide is the side effects they are associated with,\" namely a burning sensation and skin irritation.\n\"Herbal preparations are less harsh on the skin due to their anti-inflammatory properties, while our results suggest they can be just as, if not more, effective than chemical treatments,\" she says.\nIn fact, the thyme tincture was more powerful than standard concentrations of benzoyl peroxide, which is the active ingredient in many acne products.\nBut some U.S. dermatologists are quick to caution that while intriguing, this research is still preliminary, and thyme-tinged acne treatments are not yet ready for prime time.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The bold headline promising that thyme as an \u201cacne remedy may be coming soon\u201d promises an imminent availability that is beyond the evidence.", "answer": 0}, {"article": "We need more studies, funded by someone other than the company that makes the product.\u201d\n\nSmoking is the largest cause of preventable death in the United States, killing more than 480,000 Americans a year.\nAbout 1,500 patients at 61 clinics in the United States and abroad participated in the study.\nThe study was funded by Pfizer, the drug company that makes Chantix, a treatment that costs about $250 a month.\nOne got Chantix, the brand name of the drug varenicline, which is taken twice a day by mouth as a pill; the other group got a placebo.\nIf such studies were funded by the government, which sustains a lot of academic research, taxpayers would bear the burden for what the company would eventually profit from, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that Chantix is already on the market.", "answer": 1}, {"article": "Or she could allow doctors to implant two long, thin electrodes deep into her brain, along with an electrical generator about the size of an iPod in her chest.\nThe results come at time when a growing number of people are reaching their late 50s and early 60s, when they are most likely to be diagnosed with the disease, which affects between 500,000 and 1.5 million Americans.\n\"This (the JAMA study) is the largest, most complete and thorough analysis of deep brain stimulation to date,\" Hiner said.\n\"That's huge,\" said lead author Fran Weaver, a researcher with the Hines VA Hospital in Hines, Ill.\n\nShe said the best drugs provide only one to two hours of added improvement, or \"on time.\"\nThe six-month study, which involved 255 people, found that those who underwent surgery had 4.6 more hours each day of good control of their symptoms than those who got the best drug therapy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the article does not make a clear statement about availability, it does imply that deep brain stimulation is available in at least some hospitals, has been in use since at least 2005, and is applied to a variety of conditions. \nThe story says that only 2 percent of patients get the surgery, while 15 percent are eligible. It would have been useful to know if availability played any role in this discrepancy. ", "answer": 1}, {"article": "Newswise \u2014 Lap band surgery has significant benefits for severely obese teenagers and, despite its controversial nature, should still be considered as a first option to manage obesity during adolescence, a new study has found.\nHowever there is no data available in Australian adolescents beyond 24 months post-surgery.\n\u201cThe median BMI reduction of 10 kg/m2 with the lap band is a good result when compared to BMI reduction using the few medications available or lifestyle measures, which is around 1-3 kg/m2,\u201d says Dr Pe\u00f1a.\n\u201cLap band surgery is reversible and allows time for adolescents to mature to make a more informed decision on a permanent surgical procedure if required later on in life.\nThis is not the case for other surgeries currently offered for obesity management.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that lap bands are now in use. The question posed here is whether they would be appropriate for seriously obese teenagers.", "answer": 1}, {"article": "\"Getting double-blind clinical studies like this one published helps to bring credibility to parental reports.\"\n\"All the data seem to suggest that manipulating the oxytocin system has a powerful effect on the core symptoms of autism,\" said Eric Hollander, director of the compulsive, impulsive and autism spectrum disorders program at the Montefiore Medical Center in New York.\nBecause previous research has indicated that some people with autism might have abnormally low levels of oxytocin, conducting tests to identify those people and administering them the hormone might help as well, said Karen Parker, an assistant professor of psychiatry at Stanford University School of Medicine.\n\"I think it's going to be a very exciting finding for a lot of people,\" said Alex Martin, chief of cognitive neuropsychology at the National Institute of Mental Health.\n\"Many families are using it with success and reporting improvement,\" said Wendy Fournier, president of the National Autism Association.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The treatment, oxytocin nasal spray, is not commercially available as such and is not approved for this indication. These facts are not explicitly noted in the story. However, the story does note the apparent use of the drug for this purpose by some, without noting the lack of FDA approval of the product. Although this could have been much more clear, the story does make it clear that some people are getting the stuff somehow.\u00a0 It would have been relatively easy to explain how. \n", "answer": 1}, {"article": "The U.S. Food and Drug Administration today approved three new indications for Ilaris (canakinumab).\nHealth care professionals should review the prescribing information in the labeling for detailed information about the approved uses.\nThe new indications are for rare and serious auto-inflammatory diseases in adult and pediatric patients:\n\nAll three syndromes are hereditary diseases that are characterized by periodic attacks of fever and inflammation, as well as severe muscle pain.\nPatients should not get live vaccines if receiving Ilaris.\nThe agency is also responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Since the drug has already been approved for two other conditions, it\u2019s safe to assume that the drug is already on the market and generally available.", "answer": 1}, {"article": "Kris-Etherton and colleagues did an intensive study with 45 typical Americans \u2013 all overweight or obese, but with healthy cholesterol and blood pressure levels.\n\u201cI love guacamole and with my recipe, I'll use avocados, cilantro, lime juice and garlic... and then sometimes I'll put salsa in, or red pepper flakes.\u201d\n\nBut like anything, too much of a good thing can be harmful.\nSo that was the only difference between the two diets, which then tells us that it's the avocado that has additional benefits which are beyond the unsaturated fat.\u201d\n\nThe findings are similar to a batch of studies that showed people who were given olive oil and nuts and told to add them to their diets ended up healthier.\nIt\u2019s tough to test diets in real life, because people eat so many different things, but the team controlled what everyone ate, feeding them carefully calibrated diets.\nSaturated fat \u2013 the kind found in meat and butter \u2013 has a different chemical structure from the unsaturated fats found in plant products.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story gives the impression (largely correct) that avocados are widely available. As with the competing stories, we would have liked to have seen some acknowledgment that there are areas where avocados may be more difficult to find.", "answer": 1}, {"article": "AIDS researchers have rejected the approach on any kind of scale for patients with HIV.\n\u201cIt is possibly a cure, that\u2019s for sure, you won\u2019t know for absolute sure until the person dies and undergoes extreme PCR (genetic) analysis of post-mortem tissue.\u201d\n\nThe mutation affects a receptor, a cellular doorway, called CCR5, that the AIDS virus uses to get into the cells it infects.\nNearly four years after the transplant, the patient is free of the virus and it does not appear to be hiding anywhere in his body, Thomas Schneider of Berlin Charite hospital and colleagues said.\n\u201cIt\u2019s not practical and it can kill people,\u201d said Dr. Robert Gallo of the Institute of Human Virology at the University of Maryland, who helped discover the human immunodeficiency virus that causes AIDS.\nThis patient appears to have a fully functioning immune system, they found, which appears genetically identical to cells from the donor \u2014 not the patient\u2019s own immune cells.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that it is based on the findings in one patient and that it couldn\u2019t be applied broadly.\u00a0The story shows that bone marrow transplants are available and points out the unique aspects of the procedure in this single patient; that is, while bone marrow transplants are available, marrow from recipients with the CCR5 mutation is not.", "answer": 1}, {"article": "Yorkshire Cancer Research; Prostate Cancer UK; The British Columbia Cancer Agency Strategic Priorities Fund.\nProfessor Norman Maitland, from the University of York's Department of Biology, said: \"Unnecessary prostate treatment has both physical consequences for patients and their families, but is also a substantial financial burden on the NHS, where each operation will cost around \u00a310,000.\nDr Davide Pellacani, who began these studies in York, before moving to the University of British Columbia, said: \"Using this computer analysis, not only could we see which tissue samples had cancer and which didn't, but also which cancers were dangerous and which ones less so.\nThe research, published in the British Journal of Cancer, was funded by The Freemasons of the Province of Yorkshire (North and East Ridings) and The Masonic Samaritan Fund.\n\"Cancers that are contained in the prostate, however, have the potential to be 'actively monitored' which is not only cheaper, but has far fewer negative side-effects in patients with non-life threatening cancer.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "At the very end of the news release, the authors write that the next step is, \u201cto take this method out of the laboratory,\u201d and that the researchers hope that they will find a commercial partner to develop the test for general use. But this should have come much sooner, ideally in the first paragraph. The entire release (including the headline) made it sound like this test is already available, likely frustrating patients who felt duped at the end of the release.", "answer": 0}, {"article": "But it also sends a signal to the brain that says \u2018you\u2019ve eaten.\u2019 Fructose doesn\u2019t stimulate insulin secretion, and if there\u2019s no insulin, you don\u2019t get the information that you\u2019re full.\u201d\n\nDoes this mean that it is a good idea to avoid fruit, because it contains fructose?\nPage said.\n\u201cDon\u2019t stop eating fruit.\nThere was no difference in leptin or ghrelin levels between fructose and glucose drinkers.\nAs they did so, they rated their hunger using the scale.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not relevant to this story.", "answer": 2}, {"article": "\u201cI wouldn\u2019t say it\u2019s a cure.\nSo, that these results were so positive for something that\u2019s very safe is an impressive accomplishment.\u201d\n\nRecent studies have suggested that tai chi, with its slow exercises, breathing and meditation, could benefit patients with other chronic conditions, including arthritis.\nAnd Dr. Gloria Yeh, a Beth Israel Deaconess internist and co-author of the editorial, said others \u201cwill say, \u2018It\u2019s too slow, I can\u2019t do that.\u2019 \u201d\n\nBut she said it offered a \u201cgentler option\u201d for patients deterred by other physical activities.\n\u201cI was an entire mess from head to foot.\u201d\n\nShe had tried and rejected medication, physical therapy, swimming and other approaches.\n\u201cI was used to being treated in a condescending manner because they couldn\u2019t diagnose me: \u2018She\u2019s menopausal, she\u2019s crazy.\u2019 \u201d\n\nBefore the study, \u201cI didn\u2019t know tai chi from a sneeze,\u201d said Ms. Petersen, who has diabetes and other conditions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story makes it clear that there are multiple versions of tai chi. It could have been more clear about how widely available it might be, especially in sparsely populated areas.", "answer": 0}, {"article": "\"Unfortunately, that is not the case.\n\"These are very delicate operations and a sophisticated image guidance system has been developed to help the surgeons, but they don't trust the system because sometimes it is spot on and other times it is off the mark,\" said Robert Webster, associate professor of mechanical engineering and otolaryngology, who is developing a surgical robot designed specifically for endonasal surgery.\n\"Actually, we do have a solution to this problem but it involves drilling and attaching the markers directly to the skull...which we don't like to do because it is painful and it's a step backwards from the majority of what we are doing,\" said Assistant Professor of Otolaryngology Paul Russell, who is collaborating with the engineers on the project.\nIn fact, previous research has found that when everything goes well, the guidance system produces targeting errors of about 2 millimeters but, in about one operation out of seven, the target error is much larger, forcing the surgeon to redo the registration process.\nIn essence, that is what a team of Vanderbilt University engineers are proposing in an effort to improve the reliability of the sophisticated \"GPS\" system that surgeons use for these delicate operations.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does the minimum, saying \u201cVanderbilt University has applied for a patent on the design and the technology is available for licensing. (Interested parties should contact the Vanderbilt Center for Technology Transfer and Commercialization.)\u201d A companion video states that \u201cthe next step is to work with a commercial partner to make it an FDA-approved product.\u201d\nInformation on how long FDA approval could take, as well as a nod to the fact that this might never make it to market, would have made this better.", "answer": 1}, {"article": "For example, Walmart sells Equate loratadine tablets (the same active ingredient as Claritin) for about $7 for 60 24-hour doses\n\nAntihistamines make perfect sense for someone who suffers a few sneezy days each season and doesn't want to use a spray for weeks or months, Eghrari-Sabet says.\nSo use these medications sparingly, Sublett says.\nLook for one that does not make you sleepy, Sublett says.\nAn allergist can test you to find out what's causing your symptoms and offer additional treatments.\nThey also can be cheaper, because they are available in store-brand versions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All these drugs are available over the counter, which the article mentions early in the story.", "answer": 1}, {"article": "The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives in a future epidemic of the deadly disease.\n\nThe research, by doctors from the U.S. and Liberian governments and elsewhere, was published Wednesday in the New England Journal of Medicine. The study looked at 1,500 patients in Liberia, and took place amid and after the outbreak of Ebola in Liberia from 2014 into 2015.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of an Ebola vaccine would be reasonable to address. For example, it a new epidemic developed today, would one of these vaccines be used? This is an important clinical point that researchers might have been able to provide information about.", "answer": 0}, {"article": "The website for LipoFuze says that the supplement \"increases the metabolic mechanism in your body.\" The site also says the green tea and caffeine will \"rev up your metabolism\" and \"increase energy, focus and physical performance.\" The site features testimonials it says are from users who claim they have lost huge amounts of weight with the help of LipoFuze. One man says he dropped more than 100 pounds, although it's unclear how long that took. A woman says she lost 40 pounds in less than a year, including 20 pounds in her first month.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The column says that one of the products mentioned is available at many drugstores.\u00a0 There isn\u2019t any comment on availability of the other product mentioned.\u00a0 We\u2019ll give the story the benefit of the doubt on this one.", "answer": 1}, {"article": "WEDNESDAY, Nov. 28, 2012 (HealthDay News) -- A new insomnia drug helped people get a bit more shut-eye in a lab study, researchers report.\nIt's promising news, Bazil added, that there were no serious side effects in this study.\nBetween 21 and 37 fewer minutes were spent awake during those sleep periods.\nFor most people, he said, medication should be a temporary treatment; behavior change is the long-term fix.\nBut, Herring said, seniors were part of a larger, 12-month trial, and Merck has submitted those results to the FDA.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained that the drug is \u201cbeing developed\u201d and has been submitted to the FDA for approval.", "answer": 1}, {"article": "The compound WAY-316606 could therefore be used to treat baldness, without patients suffering the same side effects as they would on CsA.\nThe other option is minimally invasive hair transplant surgery.\nThe scientists were then able to identify that WAY-316606, a compound used to treat osteoporosis, has a similar effect on how SFRP1 is expressed.\nFor that reason new treatments are exciting as they give people more treatment options that may be effective.\n\u201cFor individuals with hair loss, treatments can be very hit and miss, there isn\u2019t one which is universally effective.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made it clear that this is early research and human testing hasn\u2019t even begun yet.", "answer": 1}, {"article": "In the new study of 24 patients, scores on a standard test measuring the disturbances of memory, language, attention, and other cognitive skills that are hallmark symptoms of Alzheimer's disease dropped an average of slightly more than five points in those treated with IVIG.\nThe IVIG treatment also appeared to slow the rate of brain shrinkage by about 45%, he tells WebMD.\nIt's a form of intravenous immunoglobulin, or IVIG, drugs that are usually used to treat immune system disorders.\nThat compares with a 15-point decline in patients who initially received placebo and switched to IVIG, says Norman Relkin, MD, of Cornell Weill College of Medicine in New York City.\nThe findings were presented at the American Academy of Neurology meeting.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told that IVIG is a decades-old drug. ", "answer": 1}, {"article": "Learning skills for positive emotions result in less HIV in blood and less anti-depressant use\n\u2022 Positive emotions are possible even with stress of chronic health problems\n\u2022 Men using positive emotion skills learned to cope with their stress, while control group went on anti-depressants\n\nCHICAGO --- When individuals recently diagnosed with HIV were coached to practice skills to help them experience positive emotions, the result was less HIV in their blood and lower antidepressant use, reports a new Northwestern Medicine study.\nIn addition, the intervention group was significantly less likely to have repeating, intrusive thoughts about HIV.\nThe reduced viral load could be because of a stronger immune system, Moskowitz said.\nAt baseline, about 17 percent of the control group and intervention group reported being on antidepressants.\n\"The group that learned coping skills did not increase antidepressant use, whereas overall the control group increased its antidepressant use,\" Moskowitz said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address availability of the training. In claiming this research has not been done before it suggests that the intervention would only be available via clinical trials. \u00a0The release could have been more specific about whether the skills training has been standardized or whether it is in widespread use in any context. Because we can\u2019t give the release a satisfactory score \u2013 because availability wasn\u2019t addressed \u2013 we also didn\u2019t think we could ding it with an unsatisfactory score. \u00a0Thus, the N/A score.", "answer": 2}, {"article": "\u201cOur study essentially shows that what happens in the real world is very different\u201d from what happens in clinical trials, said Hillel R. Alpert of Harvard, a co-author with Dr. Connolly and Lois Biener of the , .\nThe researchers argue that while nicotine replacement appears to help people quit, it is not enough to prevent relapse in the longer run.\nDoctors who treat smokers said that the study findings were not unexpected, given the haphazard way many smokers used the products.\nThe use of replacement products made no difference, whether they were taken for the recommended two-month period (they usually were not), or with the guidance of a cessation counselor.\nAt each stage, about one-third of the people trying to quit had relapsed, the study found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story talks about the sales figures for nicotine products as one indication of widespread availability and use.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Testing women for human papillomavirus (HPV) may catch more pre-cancerous growths than standard cervical cancer screening does \u2014 but more evidence is needed before the newer tests become routine, a study published Monday concludes.\nSeveral other clinical trials in the review looked at HPV testing.\nThey found that both tests had nearly the same \u201csensitivity\u201d \u2014 which refers to their ability to detect cancer or pre-cancer.\nClinical trials are ongoing, Whitlock said.\nIt may not even be the doctor\u2019s \u2014 but may instead depend on whatever health system he or she is part of.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The different testing methods are all widely available and that can be inferred from the story.", "answer": 1}, {"article": "Despite the fact that a link between taking folic acid and reducing autism risk isn't fully proven, Halladay says there's no harm in taking the supplement, and women should be taking it anyway to prevent birth defects.\nThe same dose appears to provide some benefit in preventing autism, according to the research.\n\"Caring for individuals with autism and their families would be a whole lot easier if we had simple answers about cause and risk,\" he says.\n\"It actually supports the idea of actionable things women can do before they become pregnant, and right as conception happens.\"\n\"This is another piece of evidence that supports the beneficial uses of folic acid during pregnancy,\" said Halladay, who was not connected with the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of folic acid supplements is not in question.", "answer": 2}, {"article": "\"Previous patients got sick, but it wasn't clear at the time whether it was due to the T cells or an infection,\" said pediatric oncologist Stephan Grupp, who oversaw Emily's care at Children's Hospital of Philadelphia. \"Now we know the main reason they were sick was the cells. But now we can intervene. She taught us.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that this treatment is not yet available commercially.\nBut it would have been useful to include some information about whether and how someone might get enrolled in a clinical trial. Although it is unlikely that this program is ready to handle an influx of new cases, patients and parents might be desperate for any information on this question.", "answer": 1}, {"article": "This is in line with some of our recent studies which indicate that the GI tract microbiome in Alzheimer's is significantly altered in composition when compared to age-matched controls, and that both the GI tract and blood-brain barriersbecome significantly more leaky with aging, thus allowing GI tract microbial exudates (e.g.\nWalter Lukiw, Professor of Neurology, Neuroscience and Ophthalmology and Bollinger Professor of Alzheimer's disease at Louisiana State University, who reviewed the study but was not involved in the research, said: \"This early study is interesting and important because it provides evidence for gastrointestinal (GI) tract microbiome components playing a role in neurological function, and indicates that probiotics can in principle improve human cognition.\nAt the beginning and the end of the 12-week experimental period, the scientists took blood samples for biochemical analyses and tested the cognitive function of the subjects with the MMSE questionnaire, which includes tasks like giving the current date, counting backwards from 100 by sevens, naming objects, repeating a phrase, and copying a picture.\n\"In a previous study, we showed that probiotic treatment improves the impaired spatial learning and memory in diabetic rats, but this is the first time that probiotic supplementation has been shown to benefit cognition in cognitively impaired humans,\" says Professor Mahmoud Salami from Kashan University, the senior author of the study.\nBut scientists have long hypothesized that probiotics might also boost cognition, as there is continuous two-way communication between the intestinal microflora, the gastrointestinal tract, and the brain through the nervous system, the immune system, and hormones (along the so-called \"microbiota-gut-brain axis\").\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release provided a thorough description of the probiotic milk intervention, but did not mention the fact that it was manufactured (in Iran) specifically for this study and is not available for purchase. A brief discussion of what it would take to get such a product on the market \u2014 in addition to its cost \u2014 would be beneficial.", "answer": 0}, {"article": ".\nThey also calculated the elasticity ratio of the lesions and adjacent normal skin and used laboratory analysis to confirm their diagnoses.\nThey found that elastography correctly identified 98 percent of cancerous lesions and 82 percent of benign lesions, and they also determined that elastography was more accurate than ultrasound in gauging the size of the lesions.\n\"There's a lot of room to improve specificity with ultrasound, and elastography can help us do that,\" Dr. Stamatia V. Destounis, a diagnostic radiologist at Elizabeth Wende Breast Care in Rochester, N.Y., and the study's lead author, said in a news release from the Radiological Society of North America.\n\"The visualized portion of a skin lesion can be just the tip of the iceberg, and most dermatologists operate 'blindly' beyond what they can see on the surface,\" Siegel said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes no mention of the availability of elastography. The test is still under evaluation and is not widely available outside of research settings.", "answer": 0}, {"article": "The pain relief could last for weeks.\n\u201cBut it\u2019s not.\u201d The pain associated with tendinopathies tends to fall somewhere around a 7 or so on a 10-point scale of pain.\nThere will always be a longing for a magical pill, the quick fix, especially when the other widely accepted and studied alternatives for treating sore tendons are to do nothing or, more onerous to some people, to rigorously exercise the sore joint during physical therapy.\nBut this is not the case for those getting cortisone shots, he wrote; they \u201ctend to lag behind significantly at those time frames.\u201d In other words, in some way, the cortisone shots impede full recovery, and compared with those adopting a wait-and-see policy, those getting the shots \u201care worse off.\u201d Those people receiving multiple injections may be at particularly high risk for continuing damage.\nThe reviewers determined that, for most of those who suffered from tennis elbow, cortisone injections did, as promised, bring fast and significant pain relief, compared with doing nothing or following a regimen of physical therapy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\nThe story explained the history of steroid injections, hinting at trends in availability. Steroid injections are widely available in both primary care and specialty settings. .\n", "answer": 1}, {"article": "\"Although there appear to be some benefit of an overall lower death rate in both groups, the [special panel] recommended stopping the trial,\" Nabel said.\nThe patients were further divided into those who also received blood-pressure-lowering medication or drugs to improve their cholesterol levels.\nMany earlier studies had shown that tightly controlling blood sugar significantly reduced the risk of many complications.\nThe researchers stressed that the findings would not alter current guidelines or treatment for most diabetics, many of whom can control their blood sugar without drugs.\nOfficials defended the study, saying previous research had suggested that intensive blood sugar lowering would be beneficial.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that the medications used in this study where those that are commonly used for lowering blood sugar.\u00a0 ", "answer": 1}, {"article": "Johnston says the fight against obesity needs creative solutions that help people manage their weight, appetite and hunger by offering socially acceptable food choices.\nThis is especially true if a student doesn't have access to other meals during the school day.\nThe study acknowledged that snacking is more common during the adolescent years and that the unhealthy eating habit can lead to an unhealthy weight.\n\"We have a lot of kids skipping meals for a whole bunch of reasons,\" he said.\nThe researchers conclude that afterschool programs and schools can replace energy dense, unhealthy snacks with peanuts to provide a healthier alternative for children (researchers in the study ensured students did not suffer from nut allergies).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that peanuts and peanut butter are available in every grocery and convenience store in the United States.", "answer": 2}, {"article": "Some researchers question whether symptoms could be alleviated using probiotic therapy, or \"healthy\" bacteria to restore bacterial balance in the gut.\nResearchers from the University of Turin, Italy, found that a few daily drops of Lactobacillus reuteri, a bacterium that can help improve digestion, significantly reduced crying among infants with colic.\nHowever, recent research suggests colic may linked to an immature immune system struggling with bacterial imbalances in the gastrointestinal tract, and that high levels of E. coli bacteria in particular may contribute to colic symptoms.\nColic affects up to 28% of infants and has no known cause or cure.\nThe infants' mothers were also advised to avoid cow's milk in their own diets during the study period.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not enough information here. The probiotic tested in this study is actually a commercially available product distributed by the study\u2019s sponsor, BioGaia\u2013information which was never provided to readers.\u00a0(More on this later under the \"Sources\" criterion below.) Moreover, the story\u00a0attributed the benefits\u00a0observed in the study to\u00a0the Lactobacillus reuteri\u00a0species of probiotic; it should have pointed\u00a0out\u00a0that the researchers\u00a0tested a specific commercial strain of\u00a0L. reuteri\u00a0known as\u00a0Lactobacillus\u00a0reuteri DSM 17 938. Different strains of the same probiotic are known to produce widely varying effects, so the\u00a0reduction in crying\u00a0observed in the study might not be seen with other strains of L. reuteri. \u00a0\u00a0\u00a0\u00a0", "answer": 0}, {"article": "The study, conducted at the University of Texas M.D.\nThey were followed for six to 11 years.\nA serving was a half-cup.\n\"I went into the study expecting to see a difference between the two groups,\" he said.\nBreast cancer study: Fruits, veggies not the answer\n\nBut researchers at M.D.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This criterion does not apply in this story. ", "answer": 2}, {"article": "The research was paid for by the Danish government and private foundations.\nThe author of that editorial, Dr. Christopher E. Ramsden, from the National Institutes of Health, said the findings would help doctors develop a \u201cprecision medicine\u201d approach in which fish-oil treatment could be tailored to women who are most likely to benefit.\nMore than six million children in the United States have asthma, according to the Centers for Disease Control and Prevention, as do more than 330 million children and adults worldwide, according to the Global Asthma Network.\nBut many other types are considered safe, especially smaller fish like sardines that are not at the top of the food chain and therefore not likely to accumulate mercury and other contaminants from eating other fish.\nDoctors are eager to find ways to prevent asthma, a chronic disease that causes wheezing, coughing and breathing trouble, and that sends many families to the emergency room again and again.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the\u00a0\u201ccapsules were an over-the-counter product called Incromega TG33/22, a fish extract made by the British chemical company Croda Health Care.\u201d\nAnd in regard to whether women should start taking the supplement to lower asthma risk in their babies, the story lets us know researchers \u201care not ready to recommend that pregnant women routinely take fish oil\u201d due to the very high dose used in this study. Further research is needed first\u00a0to establish safety and confirm benefit.", "answer": 1}, {"article": "And you could see that they were sort of asking, 'Why can't they do something for me?'\"\nIt was the worst kind of luck that gave Kanzius the idea to use radio waves to kill cancer cells: six years ago, he was diagnosed with terminal leukemia and since then has undergone 36 rounds of toxic chemotherapy.\nIt's not something that a layman like me should be in, it should be left to doctors and research people,\" he told Stahl.\nHere's how it works: one box sends radio waves over to the other, creating enough energy to activate gas in a fluorescent light.\nHis wife Marianne woke up that night to a lot of banging and clamoring.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The segment makes clear that the technique is not available for human use. It says it is at least four years away from human trials, assuming all goes well.", "answer": 1}, {"article": "Still, the big questions surrounding sauna bathing\u2019s safety have always centered on its occupant\u2019s (and her heart\u2019s) ability to withstand the heat.\nThat may sound freaky or even unsafe, but neonatal beds for newborns have long utilized infrared heating elements to ensure babies are kept warm without being stifled.\nFrom the Jewish to Mesoamerican \u201chouses of heat,\u201d people all over the world have long associated a good sweat with a wide assortment of health benefits.\nPeople who spent 15 minutes a day for two weeks in an infrared sauna enjoyed a significant drop in blood pressure compared to a control group who spend the same amount of time in a \u201croom-temperature\u201d space, one Japanese study reported.\n(For men hoping to father children, spending time in hot saunas or baths has long been a no-no.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Saunas\u00a0can be found in many health gyms\u2013but what about infrared saunas, which is the focus of the piece? We\u2019re not told.", "answer": 0}, {"article": "(R) Anthony L. Asher, MD, FACS, medical director at Carolinas HealthCare System's Neurosciences Institute and the senior author on the report, and (L) Stuart H. Burri, MD, chairman, department of radiation oncology at Levine Cancer Institute, spearheaded an international, multi-institutional, randomized trial that will ultimately improve the standard of care for patients with a specific type of brain tumor, brain metastases, by reducing the toxicity of their treatment without reducing the effectiveness.Video - http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/CarolinasHealthCareSystem.mp4Photo - http://photos.prnewswire.com/prnh/20160726/392955\nThe technique was pioneered at Levine Cancer Institute and they are looking to expand and further validate the approach with the National Cancer Institute.\nAnother way to state that principle for cancer care, is that when two cancer therapies produce similar survival, it's important to understand which therapy offers patients a better quality of life.\"\nTypical therapies for these types of brain tumors include surgery, whole brain radiation therapy and focused radiation, also known as stereotactic radiosurgery.\n\"Whole brain radiation patients also reported worse quality of life compared with patients who only received the focused radiation,\" adds Dr. Burri.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that the treatments are currently in general use.", "answer": 1}, {"article": "A new study finds that supplementing the Mediterranean diet with more olive oil or more nuts helps diminish age-related decline in cognitive function. Photo: Getty Images\n\nThe Mediterranean diet, supplemented with a handful of nuts or a few tablespoons of olive oil a day, can counteract the effects of aging on the brain\u2019s ability to function, a new clinical study suggests.\n\nThe study, published online Monday in JAMA Internal Medicine, was unusual in that it employed rigorous scientific practices to test the effect of the diet on health. Most previous evidence showing benefits from the Mediterranean diet was gathered through observational studies, a less conclusive research technique.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story describes the Mediterranean diet, which is composed of products readily available in most grocery stores.", "answer": 1}, {"article": "The comparison groups in the experiments varied as well.\nIn the latest look at various treatments, the Cochrane group evaluated studies that examined both pharmaceutical and alternative techniques, including acupuncture, acupressure (a noninvasive variation of acupuncture), ginger, vitamin B-6 and conventional anti-vomiting drugs.\n\"The onus is back to researchers to carry out studies that would stand up\" to rigorous review and that would build on what's already been tested.\nThe medicine, though never approved for use in the United States, led to birth defects in some 10,000 kids in Europe and Canada.\nAlso, inconsistencies in methodology from study to study made it difficult to pool the results and draw firm conclusions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The whole point of the story was to discuss the most commonly used treatments for morning sickness: acupuncture, acupressure, ginger, vitamin B-6 and conventional anti-vomiting drugs. \u00a0", "answer": 1}, {"article": "Radical therapy causes lifelong erectile problems and around one in five patients also suffer from incontinence.\n\"The fact that the treatment was performed so successfully by non-specialist centres in various health systems is really remarkable,\" says Professor Emberton, who is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.\nThe new treatment, 'vascular-targeted photodynamic therapy' (VTP), involves injecting a light-sensitive drug into the bloodstream and then activating it with a laser to destroy tumour tissue in the prostate.\nHe says:\n\n\"When I was diagnosed with early prostate cancer, I had the option of active surveillance but I didn't want to wait until it got worse so when I was offered a place on the trial I signed up straight away.\nWe also hope that VTP will be effective against other types of cancer - the treatment was developed for prostate cancer because of the urgent need for new therapies, but it should be translatable to other solid cancers including breast and liver cancer.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release passes the bar with this statement at the very end:\nThe VTP treatment is currently being reviewed by the European Medicines Agency (EMA), so it is likely to be a number of years before it can be offered to patients more widely.\nThe news release also quotes a researcher stating that the treatment\u2019s implementation at 47 sites \u201cwithout complication\u201d indicates it\u2019s \u201csafe, efficient and relatively easy to scale up.\u201d That\u2019s an optimistic take but we\u2019ll give the benefit of the doubt here.", "answer": 1}, {"article": "A University of Colorado Cancer Center study published today [May 3] in Oncotarget shows that combining a CPT1A inhibitors with anti-androgen therapy increases the cancer\u2019s sensitivity to the anti-androgen drug enzalutamide.\n\u201cThere is a critical need for improved therapies for this specific cancer type.\u201d\n\nMost cells use the energy of glucose (sugar).\n\u201cThis finding may have a huge impact on patients with CRPC that had very few options before,\u201d says Schlaepfer.\nHowever, there are many steps involved in lipid metabolism and researchers have been working to break prostate cancer\u2019s ability to harness this energy source.\n\u201cWe had to find a way to block this pathway so that the cancer would not be able to burn lipid in the mitochondria to acquire energy to resist therapy,\u201d explains Schlaepfer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The key drug in question, enzalutamide, (trade name Xtandi) is already widely marketed as a treatment for prostate cancer. This fact was not included in the news release.", "answer": 0}, {"article": "CHICAGO (Reuters) - The hallucinogen psilocybin \u2014 known by the street name magic mushrooms \u2014 may help ease the anxiety that often accompanies late-stage cancer, U.S. researchers said on Monday.\nEverything had to be shut down,\u201d Grob said in a telephone interview.\n\u201cIt was something of a public health crisis.\n\u201cForty to 45 years ago, the culture was going through tremendous upheaval.\nThe treatments were given in random order and neither the doctors nor the patients were told which compound was administered.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Strokes had a higher impact on the patient\u2019s quality of life, the study reported.\nThe most important message is that the overall death rate was extremely low, 0.6 percent, said one of the study\u2019s principal investigators, Dr. Gary S. Roubin, the chairman of cardiovascular medicine at Lenox Hill Hospital in New York.\nIt included 2,502 patients at more than 100 in the United States and Canada, who were randomly assigned to receive either surgery or stenting over a period of nine years.\n\u201cWe had outstanding results, and our study, we think, is representative of these treatments in the and ,\u201d said Dr. Thomas G. Brott, director for research at the campus in , Fla., and lead author of the North American study, called Crest (for Carotid Revascularization Endarterectomy versus Stenting Trial).\nThe European trial, which included 1,713 patients randomly assigned to either stent or endarterectomy, found that stent patients were at much higher risk of stroke, death or heart attack in the first 30 days after surgery, with 7.4 percent suffering one of these adverse events, compared with 4 percent of the surgery group.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that surgery has long been considered the best treatment for obstructed carotid arteries, and that Medicare is considering expanding coverage to include stents. Readers can reasonably assume from these statements\u00a0that both\u00a0treatments\u00a0are widely available.", "answer": 1}, {"article": "U.S. experts familiar with the study call it interesting but say the treatment needs more study and wonder if it would catch on in the U.S.\nDec. 13, 2010 -- Acupuncture treatments to treat one type of lazy eye proved as good as the traditional patching of the eye used to help the eyes work together, according to a new study.\nSo Dennis Lam, MD, a researcher at the Joint Shantou International Eye Center of Shantou University and Chinese University of Hong Kong, and his colleagues evaluated 88 children, ages 7 to 12, with the condition known as anisometropic amblyopia, in which there is a difference in the degree of nearsightedness or farsightedness between the two eyes.\n''These results suggest that the treatment effect of acupuncture is equivalent to that of patching for anisometropic amblyopia in older children,\" Lam writes.\n''Acupuncture could potentially become an alternative treatment to occlusion [patching] therapy for ambylopia [lazy eye], the researchers write.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Like the competing HealthDay coverage, this story\u00a0noted that acupuncture may not be widely accepted in some areas.\u00a0But it also\u00a0never cautioned that it might be impossible to find a trained acupuncturist in many places in the U.S.\u00a0It should have pointed this out and emphasized the need to check for accreditation/licensing when choosing a practitioner.", "answer": 0}, {"article": "Asthma has complicated Todd Anderson's life ever since he was 3 years old. Doing sports\u2014even stairs\u2014had been difficult. Cigarette smoke, pollen, disinfectants or a passing whiff of perfume could set off a severe asthma attack. \"It feels like your chest is clenching up like a fist,\" says Mr. Anderson, a 29-year-old music teacher in the New York City schools.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe story notes that the FDA approved this asthma treatment earlier this year and that it is available at about 30 medical centers in the U.S.", "answer": 1}, {"article": "The primary efficacy endpoint \u2013 change from baseline to day 28 in MADRS total score \u2013 was assessed among patients who received \u22651 dose of (nasal spray and oral) study medication by mixed-effects model using repeated measures using a one-sided significance level of 0.025.\nWhat makes this even more significant is that the response was rapid and this milestone was achieved in patients deemed to be treatment-resistant.\nThese statements are based on current expectations of future events.\nA bittering agent was added to placebo to simulate the taste of esketamine, to help mask the treatment assignment.\nThere were no treatment-emergent adverse events reported in >10% of patients in the placebo group.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is fairly clear that esketamine is still under investigation and is not yet clinically available.", "answer": 1}, {"article": "\"This is a very preliminary study with a small number of subjects and the results are far from conclusive,\" said Dr. Allison Reiss, head of the Inflammation Section at Winthrop-University Hospital in Mineola, N.Y.\n\nShe believes the current study lacks information on possible confounding factors -- things such as \"coexisting illnesses, medications, hydration state, tobacco use and multiple other variables\" that could influence what's found in the saliva samples.\nStill, Dr. Paul Wright, chair of neurology at North Shore University Hospital in Manhasset, N.Y., said the research \"is still in its infancy but very promising.\"\nExperts agreed that the findings held promise, but much more research will be needed.\nThey found that the saliva of people with Alzheimer's had different levels of certain substances compared to the saliva of healthy people or those with mild cognitive impairment.\nFor that reason, \"larger studies are needed to corroborate and validate their findings,\" Wright said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "At a number of different points in the story we are reminded of the preliminary nature of the research, suggesting that it is years away from prime time.", "answer": 1}, {"article": "\u201cUsing this model, we estimated mean average ages at menopause for women at different time points in their reproductive life span.\u201d\n\nTehrani said the results showed \u201ca good level of agreement\u201d between predicted and actual age at menopause for the 63 women in the group who reached menopause during the study.\n\u201cThe possibility of an accurate predictor for menopause is very exciting.\nThe researchers took two more blood samples at three yearly intervals and also collected information on the women\u2019s socioeconomic background and reproductive history.\nExperts commenting on the work agreed it was promising, but said its findings would need to be confirmed in larger trials.\n\u201cWe developed a statistical model for estimating the age at menopause from a single measurement of AMH concentration,\u201d Tehrani explained in a report on the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not describe whether the AMH test is available or not.", "answer": 0}, {"article": "Abroms and her team wanted to find out if a more intensive mobile phone program called Quit4baby would be more effective.\nThe study, \"A Randomized Trial of Text Messaging for Smoking Cessation in Pregnant Women,\" was published October 2 in the American Journal of Preventive Medicine.\nThe school also offers an online Master of Public Health MPH@GW, an online Executive Master of Health Administration MHA@GW, and an online Master of Science in Management of Health Informatics and Analytics, HealthInformatics@GW, which allow students to pursue their degree from anywhere in the world.\n\"Our findings show that a text messaging program helped some groups of pregnant women quit smoking during pregnancy,\" says lead author Lorien C. Abroms, ScD, MA, an associate professor of prevention and community health at Milken Institute School of Public Health (Milken Institute SPH) at the George Washington University.\nThe messages help educate the women about the health risks associated with smoking and they are interactive--allowing a woman to text back for more help if she is experiencing a craving or goes back to smoking.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although the release notes that this experiment took place within the confines of an \u201cestablished\u201d text messaging program (Text4baby), the availability of the \u201cQuit4baby\u201d sub-program, which is the focus of the research, is not clear.", "answer": 0}, {"article": "In an interview last spring with Psych Congress Network, an Internet news site for mental health professionals, Dr. Timothy Wilens, chief of child and adolescent psychiatry at Massachusetts General Hospital, said \u201cwe have enough data to say they\u2019re actually neuroprotective.\u201d The pills, he said, help \u201cnormalize\u201d the function and structure of brains in children with A.D.H.D., so that, \u201cover years, they turn out to look more like non-A.D.H.D.\nThe question is whether these effects can last once the drugs have left the bloodstream.\nYet the decision can be anguishing for parents who worry about both short-term and long-term side effects.\nexperts challenge this conclusion.\n\u201cThere might be quite a profound neurological benefit,\u201d he said in an interview.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that the medications being discussed are widely available.", "answer": 1}, {"article": "\"But the [overall] rate of invasive breast cancer diagnosis was no different with or without CAD,\" Fenton said.\n\"The good news is the use of CAD was related to finding invasive cancers at smaller sizes and earlier stages than before the CAD era,\" said Kopans, also a member of the American College of Radiology's Breast Imaging Commission.\n\"It's an add-on and now is used in probably three-quarters of U.S. mammograms,\" he said.\nAlthough the treatment of DCIS is debated among experts, Kopans said, \"In my mind, it is always worth it to find additional cancers.\"\n\"There should be no argument that finding invasive cancers at a smaller size and earlier stage is beneficial,\" he said, as they are more likely to be cured.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Early in the article, the study author is quoted observing that \u201cIt\u2019s an add-on and now is used in probably three-quarters of U.S. mammograms.\u201d\nWomen would have to ask if CAD is being used to read their mammograms.", "answer": 1}, {"article": "Microsoft stresses that Emma Watch is not a cure for the disease, which afflicts 10 million people.\nWhen the lights went up, Nadella welcomed both Lawton and engineer Zhang on stage, thanking them for showing that thanks \"developers can have impact.\"\nThe goal of further research is to determine whether Emma Watch could help other people with similar Parkinson\u2019s symptoms.\"\nThe watch works through a combination of sensors and AI (artificial intelligence) techniques to potentially detect and monitor symptoms like tremors, stiffness and instability, among others, according to Microsoft.\nWorking with graphic designer and Parkinson's sufferer Emma Lawton, 32, the researchers developed a watch \u2014 which they named Emma \u2014 that, according to Microsoft, \"vibrates in a distinctive pattern to disrupt the feedback loop between brain and hand.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states the device is just a prototype. More could have been said about what this means, but it\u2019s enough to rate satisfactory.", "answer": 1}, {"article": "The paper \"Real-time imaging of the resection bed using a handheld probe to reduce incidence of microscopic positive margins in cancer surgery\" is available online at http://cancerres.\n\"It is likely better to check to see if any residual tumor cells might be left behind, rather than checking the tissue mass that was taken out.\nBecause of this, excess tissue surrounding the tumor is typically removed, but the question lingers of whether any cancer cells remain to re-emerge later as tumors.\nThe interdisciplinary research team led by Stephen Boppart, a University of Illinois professor of electrical and computer engineering and of bioengineering, performed the study on 35 patients with breast cancers at the Carle Foundation Hospital in Urbana, Illinois.\nIn the clinical study, surgeons treated patients according to the standard surgical procedure, but OCT data were collected from the margin of the tumor cavity and the margin of the removed tissue mass during surgery so that the results could be compared later.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release says the device \u201ccould soon enable reliable, real-time guidance for surgeons,\u201d which may be a bit optimistic, but at least suggests that the device is not available yet. Toward the end of the release it is stated that \u201cThe researchers will continue clinical studies with the OCT device, looking at other types of solid-state tumors,\u201d which arguably suggests the same.\nIdeally the text would have been more explicit about whether and/or when the device would be commercialized, but we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "When it's functioning properly, BRCA actually helps repair damaged DNA and prevents tumors, but when BRCA1 and BRCA2 go awry, they encourage breast cancers.\nThe trial was funded by drug maker Pfizer, and the results were published Aug. 15 in the New England Journal of Medicine.\nIn January, the FDA approved the first PARP inhibitor, Lynparza, to treat BRCA-mutated breast cancer.\nIn the current trial, the women who were randomly selected to receive talazoparib had a higher response rate to treatment than women who received standard chemotherapy: 63 percent versus 27 percent, the researchers found.\nNormal cells are mostly spared.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that\u00a0talazoparib is not yet approved by the FDA.", "answer": 1}, {"article": "When it comes to the most popular type of osteoporosis treatment, bisphosphonates, the question is not so much about how much to take, but whether there are harmful consequences from long-term use.\nThe task force offers no advice for women younger than 60 or for men of any age, though men account for at least 20 percent of US patients with osteoporosis.\nEven the issues of how much vitamin D adults should take and whether calcium supplements help keep bones strong have been matters of debate.\nHowever, the most extensive study on the calcium question, done by the Women\u2019s Health Initiative as a randomized controlled trial, was inconclusive.\nIn the absence of clear guidelines, many physicians make their own judgment calls.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All the screening, prevention, and treatment approaches described in this article are widely available and their availability doesn\u2019t merit extensive discussion.", "answer": 1}, {"article": "THIS STUDY randomly assigned 60 adults with mild cognitive impairment or mild to moderate Alzheimer\u2019s disease to be given, via nasal spray, 20- or 40-milligram doses of insulin detemir (Levemir), a man-made insulin that is longer acting than natural insulin, or a placebo daily for three weeks.\nAlso, among those in the 40-milligram group, people carrying what is sometimes called the Alzheimer\u2019s gene (APOE-e4) showed more improvement than non-carriers.\nCAVEATS The study involved a relatively small number of participants and lasted a short time; a larger and longer study would be needed to adequately test effectiveness and safety.\nMemory loss is often the first sign of dementia, which in later stages can interfere with such things as the ability to solve problems, control emotions or do such daily tasks as eating and dressing.\nSome research has suggested a link between lower levels of insulin in cerebrospinal fluid and the formation of plaques often found in the brain tissue of people with Alzheimer\u2019s.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Neither this story nor the competing story by Fox News explained that\u00a0this nasally administered form of insulin is currently only available as part of research studies. The story also offers no informed opinion regarding how long additional testing might take.", "answer": 0}, {"article": "Megan L. Kavanaugh, a senior research scientist at the Guttmacher Institute, which studies reproductive health, said in an interview that \u201call new insurance plans obtained through the act\u2019s exchanges fully cover all contraceptive methods without any co-payments or other out-of-pocket costs.\u201d Title X family planning clinics and Planned Parenthood clinics are more likely than other sources to offer LARC methods, she said.\nThe risk of an unwanted pregnancy with these other methods was especially high among women under 21, whose rate of unintended pregnancy was nearly double that among older women.\nIn real-world use, these methods are associated with a one-year pregnancy rate of less than one per 100 women.\nHowever, some women develop longer, heavier periods, and some have increased spotting between periods.\nWith both implants and IUDs, fertility returns quickly as soon as the devices are removed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "You could say this story was about availability itself, and especially about why things that are widely available are not prescribed by doctors more often. All of these long-term contraceptives are available.", "answer": 1}, {"article": "Alzheimer's & dementia: The Journal of the Alzheimer's Association.\n\"We are working closely with neuroradiologists to redefine how we can reduce risk for Alzheimer's with quantitative neuroimaging that helps us pinpoint symptom-relevant volume loss in the brain and subsequent targets for tracking our lifestyle-based interventions,\" says Dr. David Merrill, a geriatric psychiatrist at UCLA Medical Center.\nThe American Journal of Neuroradiology (AJNR) is published monthly by the American Society of Neuroradiology (ASNR), a professional association of more than 5,000 members who specialize in diagnostic radiology of the central nervous system, brain, head and neck through the use of X-ray, MRI, CT and angiography.\nThe concept that cognitive decline can be identified early and prevented by applying quantitative brain imaging techniques is the focus of \"Hot Topics in Research: Preventive Neuroradiology in Brain Aging and Cognitive Decline,\" a review published online in American Journal of Neuroradiology (AJNR).\n\"I believe neuroradiology, and especially quantitative MRI technology, will have a huge impact in the future of diagnosis and treatment of Alzheimer's disease, since there is compelling evidence for the baseline size of hippocampus as a key determinant of risk for future cognitive decline, and since many lifestyle factors can cause atrophy or expansion in the volume of this critical brain structure,\" says neurologist Majid Fotuhi, M.D., Ph.D., of Johns Hopkins University.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address the availability of quantitative MRIs of the brain. MRI in general has been used since the 1970s, and its availability is not in question. But since the issue is not specifically addressed by the release, we\u2019ll rate it Not Applicable.", "answer": 2}, {"article": "The findings were reported Monday in an American Heart Association online conference.\n\"The study highlights that if one chooses to use ticagrelor in subjects with acute coronary syndromes, it would be logical to use aspirin 81 milligrams per day (and not 325 mg daily),\" said Dr. Jeffrey S. Berger, assistant professor of medicine and director of cardiovascular thrombosis at NYU Langone Medical Center in New York City.\nThe panel's recommendation was based in part on prior findings from this study, called the Platelet Inhibition and Patient Outcomes (PLATO) trial.\n\"Of note, there is little reason to ever use aspirin 325 mg except in the acute setting of a heart attack or stroke,\" he added.\n\"Patients with acute coronary syndrome have options to prevent recurrent events,\" study lead author Dr. Kenneth W. Mahaffey, co-director of cardiovascular research at the Duke Clinical Research Institute, and associate professor of medicine at Duke University Medical Center, said in an AHA news release.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We would have preferred a different tone that didn\u2019t suggest the drug is \u201cawaiting\u201d what then appears as almost inevitable FDA \u201capproval.\u201d The FDA panel that produced the 7-1 vote is not the panel that decides whether to approve drugs. It\u2019s an advisory panel. The FDA usually follows its recommendations, but it has not decided whether to approve the drug. That colors the caveat that the \u201capproval process is still ongoing\u201d as sounding somewhat perfunctory, like it\u2019s only a matter of time. It would be more balanced to suggest it\u2019s still under review.", "answer": 0}, {"article": "Why Biogen is breathing a sigh of relief with the latest Alzheimer\u2019s data\n\nWe already know Eli Lilly\u2019s big bet on Alzheimer\u2019s disease didn\u2019t work. But a deep dive into just how it failed has provided a bit of encouragement to Biogen and the many companies still hoping to succeed where their rival fell short.\n\nLilly\u2019s treatment, solanezumab, had no significant effect on the buildup of toxic brain plaques believed by many to be responsible for Alzheimer\u2019s neuron-destroying effects. The company had already disclosed that the treatment failed to improve patients\u2019 cognition and function, but the new data, released Thursday night, shed some important light on the underlying biology.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes pretty darn\u00a0clear that there will be a) no final answers to the amyloid hypothesis debate any time soon; and b) the advent of a successful anti-amyloid drug that helps those with\u00a0Alzheimer\u2019s is not close at hand.", "answer": 1}, {"article": "\u201cDespite considerable research attention, the role of specific dietary and lifestyle factors remains uncertain, although obesity and physical inactivity have consistently been reported to raise the risk of diabetes mellitus,\u201d write researcher Rachel Huxley, DPhil, of the George Institute for International Health, University of Sydney, Australia, and colleagues in the Archives of Internal Medicine.\nOverall, the studies involved nearly a million participants.\nWhen the information from the individual studies was combined, researchers found each additional cup of coffee drunk per day was associated with a 7% lower risk of diabetes.\nPeople who drank three to four cups per day had about a 25% lower risk than those who drank two or fewer cups per day.\nThe results showed that people who drink more coffee, whether it\u2019s regular or decaffeinated, or tea appear to have a lower risk of developing type 2 diabetes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The availability of coffee and tea is not in question.\u00a0 ", "answer": 2}, {"article": "OMT also reduced the in-hospital mortality rates of those with the highest severity of illness.\nWhile antibiotic therapy is the current standard of care, the emergence of resistant bacteria is a global threat and provides an incentive to explore adjunct treatments that can improve their efficacy,\" said James Bailey, DO, assistant professor in physical medicine and rehabilitation at Rowan University School of Osteopathic Medicine.\nThe data were analyzed by intention-to-treat analysis of all participants and by per-protocol analysis of participants who finished the study without missing any protocol treatments.\nThe study analyzed 375 patients ages 50 or older who were randomly assigned to three groups, either receiving OMT, a light touch or conventional care only.\nAbout the Journal of the American Osteopathic Association\n\nThe Journal of the American Osteopathic Association (JAOA) is the official scientific publication of the American Osteopathic Association.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that osteopathic manipulative therapy is established practice for osteopaths and presumably could be available in hospitals more broadly.\nBut we thought the availability of the procedure could have been made much more clear. How would a patient know if their provider was an osteopath? What would it take to implement this more broadly? Could non-osteopaths be taught to do this? Could non-physicians? It\u2019s implied that osteopathic physicians who take care of patients hospitalized with pneumonia could do this. But do patients really know whether their physician is an osteopath?", "answer": 0}, {"article": "Newswise \u2014 Women who need breast surgery to remove an abnormality that cannot be felt, also known as a non-palpable breast lesion, now may benefit from the convenience and comfort provided by an advanced new tissue locating technology offered at Rush University Medical Center.\nUsing the SAVI SCOUT system technology, which emits 50 million radar pulses per second, surgeons can target the affected tissue within 1 millimeter of the reflector.\n\u201cUltimately, this wireless technology has the potential to reduce surgical delays, and more importantly will benefit patients by increasing comfort and satisfaction during a stressful time,\u201d Madrigrano said.\nThe SAVI SCOUT Radar Localization System helps to decrease the time a woman is in the operating room, increase the success rates of lesion removal and reduce the amount of healthy breast tissue that is removed during the procedure.\nWire localization requires a high degree of coordination between radiology and surgical scheduling, which can lead to delays between placement of the wire and surgery, often requiring a woman to wait long periods of time with the wire in her breast.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the release that Rush Medical Center is now making the device available to its patients. Beyond that facility, it\u2019s unclear if the device is widely available.", "answer": 1}, {"article": "\"Beta- blocker drugs compete with stress hormones and bind to the same target receptors [on a cellular level], but unlike stress hormones, do not activate cancer cells,\" said Dr. Des Powe, a senior healthcare research scientist at Queen's Medical Centre, Nottingham University Hospital NHS Trust, in Nottingham, England.\nIt's not known, she said, whether there is a true association or whether it may be due to chance or another factor.\nThey had a 71 percent reduced risk of death from breast cancer during the study compared to those who were either taking other blood pressure drugs or weren't on any blood pressure medications.\nThose on beta blockers had a substantial reduction in the formation of distant cancers, or metastases, and of local recurrence.\nPrevious research, Lichtenfeld said, has found a reduced rate of skin cancer among men who take another type of blood pressure-lowering drug.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Beta blockers are widely used to treat a variety of conditions, including high blood pressure, and their availability is not in question.", "answer": 2}, {"article": "Of course, the chips have limitations.\nThough there still aren\u2019t enough data to prove the chips are reliable enough to put rodents out of a job, Ingber says it\u2019s only a matter of time; they hope to have them tested and ready for market in two years.\nThe sophisticated architecture of these organs-on-chips\u2014which are about the size of a thumb drive\u2014has also earned the Wyss Institute recognition in the art world with a Design of the Year award from the Design Museum and placement in the Museum of Modern Art\u2019s permanent collection.\n\u201cBiology is very complex.\u201d\n\nIncorporating the chips into drug testing could save millions of dollars and years of time on research.\nThe institute\u2019s goal is to create 10 different organ systems that can be joined together by blood vessel channels to simulate human physiology on a microscale and provide a cheaper, more reliable way to test new drugs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that this technology is still under development, with a recent grant from the Defense Advanced Research Projects Agency to create chips for all systems in the body. But we were concerned that the story allows a researcher who, according to this story is part of a team seeking to commercialize the technology, to speculate about FDA approval within two years and\u00a0to say that it\u2019s \u201conly a matter of time\u201d before these chips replace rodents. Those statements seem highly optimistic to us \u2014 another reason why the story should have consulted with an independent authority.", "answer": 0}, {"article": "\"I think people should consider it [TXA] following trauma on the basis of this study,\" he said.\nIt works by significantly reducing the rate at which blood clots break down, the researchers explained.\nAlthough there was some worry that TXA might lead to more heart attacks, strokes or clots in the lungs, the researchers observed no such increase among patients getting the drug.\nAccording to Roberts, each year about 600,000 people bleed to death worldwide.\nThe researchers believe that TXA could have even wider uses, such as reducing brain bleeds after brain injury.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that TXA is widely available around the world and easily administered.", "answer": 1}, {"article": "\"I think we need to pause and think about whether the extra information [from CT scans] really helps us make a diagnosis,\" Smith-Bindman says.\nNearly 15,000 of those cancers could be fatal.\nA low score indicates the test is unlikely to be necessary.\nIt's especially important for younger adults and parents to ask the questions.\nDoctors love the detailed pictures created by CT scans.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly CT scans are available.", "answer": 1}, {"article": "More About: The Study\n\nNathalie Scheers had looked at parvalbumin before in another context.\nWe already knew that they can meet in the gut, the blood, or the brain,\" explains Pernilla Wittung-Stafshede.\nMore About: Fish and Better Neurological Health\n\nThe link between higher consumption of fish and better long-term health for the brain has been long established.\nHerring, cod, carp, and redfish, including sockeye salmon and red snapper, have particularly high levels of parvalbumin, but it is common in many other fish species too.\nWith the parvalbumin protein so highly abundant in certain fish species, increasing the amount of fish in our diet might be a simple way to fight off Parkinson's disease.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Fish is widely available. We\u2019re told the protein of interest, parvalbumin, is found in higher concentrations in certain species, and that this concentration is seasonal and tends to peak in late summer.", "answer": 1}, {"article": "(Reuters) - Merck & Co\u2019s blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract, the U.S. drugmaker said on Wednesday.\n\u201cThis marks the sixth tumor type where Keytruda has demonstrated a survival benefit, and represents the first time an anti-PD-1 therapy has achieved overall survival for this patient population,\u201d said Roy Baynes, chief medical officer of Merck Research Laboratories.\nKeytruda, among a class of medicines called PD-1 inhibitors, is Merck\u2019s top selling drug and has already been approved to treat several forms of cancer including skin and lung cancer.\nEsophageal cancer is the seventh most commonly diagnosed cancer in the world, the company said.\nPD-1 or PD-L1 inhibitors work by blocking a mechanism of tumors that allows them to evade detection by cancer-fighting cells.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll give the story the benefit of the doubt on this one because it explained that the drug is Merck\u2019s top selling drug and has already been FDA-approved for use in other cancers.\nHowever, the story didn\u2019t explain that because Keytruda is not approved for use in gastric cancers, some providers including Medicare supplement providers, may not provide coverage.", "answer": 1}, {"article": "Less Fat.\u201d\n\nMeanwhile, Erchonia Medical, based in McKinney, Tex., has aggressively marketed its Zerona laser as \u201cthe first non-invasive body contouring procedure to effectively remove excess fat\u201d even though it has yet to receive F.D.A.\nThe low-level laser causes \u201cfat to seep out of a cell, almost like a balloon being struck by a needle,\u201d said Ryan Maloney, medical director for Erchonia Medical.\nIf you\u2019re sedentary and not eating healthy food, he said, then once fat is leaked after Zerona treatments, \u201cyour body will just store it again.\u201d\n\nHow the body rids itself of fat, and how quickly, after any noninvasive body slimming procedure is unclear, said Dr. Lawrence S. Bass, a plastic surgeon in Manhattan who started using a Zeltiq device last July.\nPart of the reason the device has made inroads during these strapped times is that doctors don\u2019t buy it outright, but pay per use.\nNonetheless, a brochure for Zerona states patients can collectively \u201close up to 9 inches without the pain or down time of surgery.\u201d Nationwide, medical spas, chiropractors, cosmetic surgeons, plastic surgeons and dermatologists now offer Zerona for $1,700 to $3,800 for six sessions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that Zerona is available nationwide through medical spas, chiropractors, dermatologists and plastic surgeons. Zeltiq, the story says, is available at over five dozen clinics identified on a website. ", "answer": 1}, {"article": "Michael Hoffer, M.D., an otolaryngologist and concussion expert at UHealth - the University of Miami Health System and lead investigator, has been using the goggle for two years, recruiting study participants from the emergency rooms of University of Miami Hospital and two military hospitals.\n\"This is the first paper demonstrating an objective method of diagnosing mTBI that relies on physiologic parameters,\" said Hoffer, who is professor of otolaryngology at the University of Miami Miller School of Medicine.\nThe goal was to identify OVRT performance metrics that differentiated between mTBI and control groups and to create a model that could accurately evaluate mTBI neurologic status in patients.\nAnother benefit for this research was that \"this next generation test has the considerable advantage of not requiring baseline testing,\" said study co-author Carey Balaban, Ph.D., of the University of Pittsburgh.\nSince the development of the goggle, researchers have hoped that the technology used by the goggle in a research setting could be translated to the sidelines of all sports - from professional leagues to amateur and little leagues.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release hints the goggle is not in widespread use \u2014 at least not yet. One of the study authors says, \u201cIt is not inconceivable that in the near future you will see the I-Portal goggle used on every sideline in America.\u201d\nIt is our understanding that this PloS One article was the first peer-reviewed paper on the only clinical study of this product. We feel it is misleading and too early to claim that this goggle could be on \u201cevery sideline\u201d in the \u201cnear future.\u201d Not only that, the wording is also vague. What does the \u201cnear future\u201d mean anyway? Until that happens, researchers need to collect more data and gain FDA approval for the device, which all take time.\nAs a result, we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "WEDNESDAY, Aug. 17, 2011 (HealthDay News) -- People who have narrowed carotid arteries in the neck and show no symptoms may be at risk for stroke and not know it, but a simple ultrasound test can identify the problem, a new study suggests.\n\"This test could be a good tool to identify the right patients for surgery,\" Topakian said.\nThese included tiny blood clots, which pass into the brain, and a type of plaque called echolucent plaque, which is fattier than other plaque and linked with an increased risk for stroke.\nAmong those in the study, 38 percent had the fattier-than-normal plaque, 17 percent had signs of blood clots and 27 percent had both the fattier plaque and blood clots, the researchers found.\nThis can cause less blood to reach the brain and, in rare cases, may also trigger a stroke if plaque breaks off and becomes lodged in the small vessels in the brain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is based on what was found with \u201ctwo ultrasound methods.\u201d\u00a0 But it never clarified whether there was something extraordinary about these methods and, if so, how well known are they?\u00a0 How widespread?\u00a0 How available?", "answer": 0}, {"article": "Cardinal says older adults need to realize that exercise can greatly improve their quality of life by maximizing function as long as possible.\nBut most Americans don't get that much exercise, and that becomes increasingly true as people age.\nPrevious findings from the same study showed that the exercise program lowered the risk of becoming disabled in the first place; this one showed that it sped recovery from an episode of disability and lowered the risk of subsequent episodes.\n\"We try to frame this as more physical activity than exercise,\" says Gill.\n\"It's the secret ingredient to successful aging in terms of quality of life.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Since walking and physical activity are available to all capable of such exercise, there is no question about availability here.", "answer": 1}, {"article": "MK-4305 belongs to a new class of sleep drugs that inhibits production of orexins in the brain, blocking stimulation of the brain\u2019s arousal system.\nNEW YORK (Reuters) - An insomnia drug being developed by Merck & Co was significantly better at improving sleep than a placebo in a mid-stage study, according to data presented on Wednesday.\nThe drug, MK-4305, helped patients sleep for a larger percentage of eight hours spent in bed at one night and at the end of four weeks of treatment, Merck said.\n\u201cWe are encouraged by these Phase II results showing positive effects of MK-4305 in patients with primary insomnia,\u201d Michelson said in a statement.\nThe company said it is testing only the 40 mg and 20 mg doses in the Phase III study among younger patients and 30 mg and 15 mg doses in the late stage trial of elderly patients.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The first sentence presents the information as coming from \"a mid-stage study,\" a vague term. Later, though, it says that Merck is going to apply for approval for the drug in 2012. This is satisfactory in the strictest sense of the word.\u00a0To really understand the origin of these results, you need to go read the press release, which calls the study a \"Phase IIb\" study and alludes to ongoing Phase III studies. The story seems to conflate these two things.", "answer": 1}, {"article": "Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others: the ability of HETIOZ\u00ae to provide significant benefit in the treatment of the symptoms of jet lag disorder; Vanda's ability to obtain marketing approval for the use of HETLIOZ\u00ae in the treatment of jet lag disorder; and other factors that are described in the \"Risk Factors\" and \"Management's Discussion and Analysis of Financial Condition and Results of Operations\" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2017, which is on file with the SEC and available on the SEC's website at www.sec.gov.\nThe results of that study were published in The Lancet in 2009.1 The observation that HETLIOZ\u00ae is effective in treating the symptoms caused by an abrupt advance of the circadian cycle of a magnitude of 5 or 8 hours suggests that HETLIOZ\u00ae will be an effective therapeutic tool in the treatment of individuals that experience symptoms of jet lag.\nIt is also reported that 8% (approximately 1.6 million) travel in Business or First class.2\n\n\"We are extremely pleased with the outcome of this study which establishes the utility of HETLIOZ\u00ae in the treatment of jet lag disorder as HETLIOZ\u00ae was shown to overcome a significant circadian challenge of an 8 hour phase advance.\nThe risk of adverse reactions may be greater in elderly (>65 years) patients than younger patients because exposure to HETLIOZ\u00ae is increased by approximately 2-fold compared with younger patients.\nThe risk of adverse reactions may be greater in elderly (>65 years) patients than younger patients because exposure to HETLIOZ\u00ae is increased by approximately 2-fold compared with younger patients.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that the drug has not been approved anywhere in the world for treatment of jet lag. However, there is a statement at the end of the news release that the company has been granted \u201cmarket authorization\u201d by the U.S. Food and Drug Administration and the European Medicines Agency. Does this mean that they have approval to start selling the drug? The Hetlioz website only lists \u201cNon-24-Hour Sleep-Wake Disorder\u201d as an indication for the use of the drug. \u00a0This is very confusing for readers.", "answer": 1}, {"article": "Primary pulmonary hypertension (PPH), a rare fatal lung disease, has been reported in patients who had taken a combination of phentermine and fenfluramine or dexfenfluramine for weight loss.\nLomaira is anticipated to be available by the end of September 2016.\nThe limited usefulness of agents of this drug class (anorectics), including Lomaira, should be measured against possible risk factors inherent in their use.\nIt has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system actions, or metabolic effects, may also be involved.\n\"Regrettably, many patients are still not covered by insurance for weight-loss medications and the low cost for Lomaira makes it an affordable treatment option.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that, \u201cLomaira is anticipated to be available by the end of September 2016.\u201d", "answer": 1}, {"article": "Thousands of heart-failure patients die each year because they aren't able to get a transplanted organ. Now, many medical experts are touting the benefits of a new mechanical pump that gives a patient's own heart a new lease on life.\n\nPatients surgically implanted with the new pump, known as a left-ventricular assist device, or LVAD, had a survival rate of 58% after two years, according to a recent study. That's not as good as a heart transplant, which offers a survival rate of about 70% after 10 years. But it surpasses the...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the Heartmate II device is currently in limited use, to keep patients alive until a heart is available for transplant. The Heartmate II clearly is available only at advanced cardiac care centers. \nYet the story fails under this criterion because it stumbles across one of the most durable trip-wires on the field of health journalism: Predicting the device is \"widely expected\" to be approved for broader use, \"possibly\" early next year. This invites the reader to assume imminent wide availability.\u00a0 ", "answer": 0}, {"article": "By the end of the study, 27 of the 183 people, or 15 percent, who took Topamax had quit drinking entirely for seven weeks or more.\nAt the start of the study, they drank, on average, 11 standard drinks daily.\nThe drug, Topamax, works in a different way than three other medications already approved for treating alcoholism.\nExperts said the drug is likely to appeal to heavy drinkers who would rather seek help from their own doctors, rather than enter a rehab clinic to dry out.\n\"It's been a miracle to me,\" Wolfe said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made clear that the drug Topamax is not FDA approved for the treatment of alcoholism but that physicians are free to prescribe it for such use.", "answer": 1}, {"article": "WASHINGTON\u2014The Food and Drug Administration questioned the clinical benefit of using GlaxoSmithKline PLC's Avodart to cut the risk of prostate cancer.\n\nAvodart is currently approved to treat benign enlargement of the prostate. The company is seeking FDA approval to market the drug to certain men to reduce the risk of prostate cancer. The drug will be reviewed by an FDA advisory panel on Wednesday along with Merck & Co.'s Proscar, a drug similar to Avodart.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that\u00a0Avodart\u00a0is approved by the FDA for treatment of non-cancerous enlargement of the prostate.\u00a0It also explains that\u00a0Glaxo Smithkline\u00a0is seeking\u00a0new approval to\u00a0market Avodart for the prevention of prostate cancer. The story could have been more clear about the fact that Avodart can\u00a0already be\u00a0prescribed off-label for cancer prevention (even though it is not officially approved for this), and that the FDA approval would\u00a0sanction this\u00a0existing use as well as\u00a0expand it to other clinicians and patients.", "answer": 1}, {"article": "(Reuters Health) - The experimental orphan drug teprotumumab significantly reduces the eye bulging associated with Graves\u2019 disease, according to results of a small trial.\nThe eyes don\u2019t have that bulging appearance, he said, and many of them return to the degree of bulging they had before they got the disease.\nThe duration of response to the autoimmune inflammatory disease, along with the quick response to initial therapy, suggests fewer infusions may be just as effective, \u201cbut future studies will sort that out,\u201d Smith said.\nThe typical treatment for Graves\u2019 eyes is glucocorticoids, which are not always effective and also have side effects, the study team notes.\nGraves\u2019 disease is the most common cause of overactive thyroid in the United States, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does state that FDA approval for this use of the drug could come sometime in 2018 so readers can easily assume the drug is not available now and won\u2019t be for the immediate future.\u00a0 It said that the next phase of the clinical trial is expected to begin within a month or two.", "answer": 1}, {"article": "Blood tests determined blood selenium, good cholesterol and bad cholesterol levels at the start of the study.\n\"Overall, the evidence is inadequate to establish a protective role of selenium in cardiovascular disease or to recommend selenium supplementation to improve cardiovascular health,\" he said.\n\"The issue is that there have been an awful lot of studies, about eight, that have looked at blood cholesterol, both good and bad, and have found an association with high blood selenium,\" said study author Margaret P. Rayman, a professor of nutritional medicine at the University of Surrey in Guildford, England.\nHowever, she cautioned that in general such supplementation has a minor impact and is not advisable as an effective means to combat high cholesterol, particularly for people who already have high blood selenium levels.\nNoting that blood selenium levels were relatively low across the board at the study's launch, the authors found that selenium levels did rise as a result of supplementation, while those taking selenium also experienced a slight drop in both bad cholesterol (LDL) and overall cholesterol levels.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t really explain what selenium is,\u00a0why someone would want to take a selenium supplement, or where one can find them. While many readers will\u00a0know the answers to these questions, selenium is obscure enough, in our view, to warrant at least some background context on these issues.", "answer": 0}, {"article": "The researchers noted that thousands of people in this final group were participants in the Women\u2019s Health Initiative, a long-term study sponsored by the National Heart, Lung and Blood Institute in the U.S. Earlier reports based on data gathered by the Women\u2019s Health Initiative found that calcium and vitamin D supplements were associated with a lower risk of fractures, but only for women who took hormone therapy after menopause. To get a clearer picture of the direct link (if any) between supplements and fracture risk, Zhao and his colleagues opted not to include data from women on hormone therapy.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We think it\u2019s safe to presume that readers know that vitamin and mineral supplements are widely available.", "answer": 2}, {"article": "(Editing by Andrew Roche)\n\u201c(This) will go some way towards reassuring patients that DBS is not just another treatment designed to fatten them up without making them feel better.\u201d\n\nDBS is used to treat several neurological illnesses including Parkinson\u2019s disease and chronic pain.\nThree months after treatment, the weight loss began to reverse in some patients, and after nine months, three patients weighed more than before treatment - the longest period of sustained weight increase since they had become ill. Around half also had better moods and less obsessive-compulsive behaviour.\nHe also said the improvements in mood and anxiety even in patients who were still underweight were \u201cespecially striking\u201d given that severely anorexic patients did not respond well to conventional medicines or psychotherapies.\n\u201cThe fact that the procedure was associated ... with improvements in affective and obsessional symptoms is of key importance,\u201d they said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story gave some hint of availability by reporting:\n\u201cDBS is used to treat several neurological illnesses including Parkinson\u2019s disease and chronic pain. Scientists are also investigating its use in depression and epilepsy, but this was the first time it had been used in patients with anorexia.\u201d", "answer": 1}, {"article": "The study started in August 2010.\nDr Emmanuel Hanon, Senior Vice President, Vaccines Research and Development, GSK, said: \"This is the first time that such high efficacy has been demonstrated in a vaccine candidate for older people and it is remarkable, as we know that these people frequently have an age-related weakening of their immune system.\nThe high efficacy is in line with the results of the ZOE-50 trial, a study in people over 50 years old which was presented and published last year showing a 97% efficacy (95% confidence interval: 93-99%)2.\nIn addition to older adults, the candidate vaccine is being evaluated in immunocompromised patient populations, including solid and haematological cancer patients, haematopoietic stem cell and renal transplant recipients and HIV-infected people.\nAnthony Cunningham, Executive Director of the Westmead Institute for Medical Research in Australia and Principal Investigator of the ZOE-70 study said: \"These data show that this investigational vaccine maintains high efficacy against herpes zoster in people over 70 and 80 years of age, the age groups who are most affected by the disease.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the press release that GSK has not yet applied for regulatory approval of the vaccine in any country. Thus, it should be obvious that the vaccine is not yet available for use.", "answer": 1}, {"article": "WEDNESDAY, April 28, 2010 (HealthDay News) -- A new drug may be the first new treatment in 25 years for a common diabetes-linked eye condition called diabetic macular edema (DME), researchers report.\nThe American Academy of Ophthalmology will review the study findings and make recommendations on whether Lucentis plus laser treatment should be the preferred treatment for a large number of patients with DME.\nFor 25 years, laser treatment has been the standard of care for DME, the main cause of vision loss in people with diabetes.\n\"First and most importantly, it provides patients an improved therapy for diabetic macular edema.\nThe condition is common in people with diabetic retinopathy, which affects up to 45 percent of people with diabetes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story never clarifies whether Lucentis is now approved and available. ", "answer": 0}, {"article": "Over the past 15 years, CHOP hematology researchers have performed clinical trials of gene therapy for hemophilia B that have helped define efficacy and dosing levels in humans.\n\"We developed a unique animal model of this disease after identifying dogs with naturally occurring factor VII deficiency,\" said Margaritis.\nThey are most commonly treated with regular infusions of clotting factor.\nThis success in large animals holds considerable potential for a safe, effective and long-lasting new treatment in humans with the same bleeding disorder.\nThe CHOP team collaborated with scientists at UNC who have a long-established colony of dogs for hematology research.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that this treatment will not be available until human clinical trials are conducted.", "answer": 1}, {"article": "A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website: http://www.\nThe medication was well tolerated, with the main adverse effects of appetite suppression and insomnia being those commonly reported for other formulations of methylphenidate.\nThe article entitled \"Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder\" is coauthored by Steven Pliszka, MD, from The University of Texas Health Science Center at San Antonio and colleagues from Massachusetts General Hospital (Boston, MA), Westside Medical Family Practice (Clinton, UT), University of Tennessee Health Science Center (Memphis, TN), Meridien Research (Maitland and Bradenton, FL), Children's Development Center (Winter Park, FL), Ironshore Pharmaceuticals & Development (Grand Cayman, Cayman Islands), and Mount Sinai Medical Center (New York, NY), on behalf of the HLD200-108 Study Group.\n\"Developing new formulations of effective medications for patients with ADHD improves the lives of children with the disorder,\" says Harold S. Koplewicz, MD, Editor-in-Chief of the Journal of Child and Adolescent Psychopharmacology and President of the Child Mind Institute in New York.\nThe drug formulation, which consists of two layers of microbeads with an inner drug-loaded core, delays release of the active ingredient for 8-10 hours and then provides controlled extended release designed to cover the early morning into the evening.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release offers no information about the possible availability of the new formulation of methylphenidate. It only mentions that the research was a \u201cphase 3 trial,\u201d which some readers will recognize must occur before a drug gets FDA approval for its use. In this case, it\u2019s unclear whether the new formulation is in the drug approval process.", "answer": 0}, {"article": "But should a woman undergoing natural menopause try acupuncture for hot flashes?\nThe results with the sham acupuncture, which bested gabapentin, suggest that \"there is more than a placebo effect with the sham acupuncture,\" said Dr. Gary Deng, interim chief of the integrative medicine service at Memorial Sloan Kettering Cancer Center in New York City.\nFurthermore, the effects of acupuncture were \"significant and enduring for hot flashes while gabapentin's effect only happened when a patient was taking the medication,\" said study first author Dr. Jun Mao, an associate professor of family medicine and community health at the University of Pennsylvania in Philadelphia.\nOne big distinction between the two populations, though, is that breast cancer survivors do not have the option of hormone replacement therapy open to them because those hormones are linked to breast cancer.\n\"For patients suffering symptoms, they can look for all kinds of possible solutions and are better off talking to their doctor to find out what's most appropriate for them,\" Deng said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Acupuncture is widely available and while the report did not establish the availability of the treatment, consumers certainly know about it. The story could have noted that insurance may not pay for acupuncture treatment, however. Gabaptentin is described as a drug that\u2019s typically used to treat nerve pain, and readers can work out from that that the drug is available.", "answer": 1}, {"article": "Previous studies have suggested a link between thrombocytosis and various cancers, with recent guidelines from the National Institute for Health and Care Excellence advising high platelet counts could be a sign of cancer of the oesophageal, stomach, lung or uterus.\nThe team add that cancer was more common among for those who had thrombocytosis for longer.\nBut it remained unclear whether the condition could signal an increased risk of all cancers, and how it ties in with factors such as age and sex.\nIn the general population about 1% of individuals over the age of 40 develop cancer each year.\nFor about a third of cases of lung and colorectal cancer in patients with thrombocytosis, there had been no other symptoms that raised the suggestion of cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "They did mention blood tests being ordered by GP\u2019s making assumptions that it is widely available.", "answer": 2}, {"article": "The change comes amid sharp controversy over new recommendations from a federal task force that women wait until age 50 before they begin having routine mammograms and that women age 50 to 74 scale back to getting the exams routinely every two years.\n\"More testing is not always more intelligent testing.\"\nThese recommendations are sound,\" she said.\nThe National Cervical Cancer Coalition, a patient advocacy group, endorsed the recommendations.\nBut in this case, if anything, we're taking money out of our own pockets.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of Pap testing is assumed. ", "answer": 2}, {"article": "The work was supported with funding from the Conrad N. Hilton Foundation, the National Institutes of Health, the California Community Foundation, the Tom Sherak MS Hope Foundation, the Rhoda Goetz Foundation for Multiple Sclerosis, and other partners of the UCLA Multiple Sclerosis Program.\nThey treated MS mice with a drug that increased expression in cholesterol synthesis genes - and this resulted in improved walking ability.\nThey hypothesized that while inflammation causes loss of myelin and synapses, it is the decrease in cholesterol synthesis gene expression in astrocytes that explains why lesions do not repair in MS.\nMS patients differ markedly from each other regarding which disability affects them the most.\nGene expression in specific cells and in specific regions can provide a more precise, neuroprotective approach than traditional treatments for neurological diseases.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This experimental treatment on mice is clearly not available to humans yet.", "answer": 2}, {"article": "\"Off-label\" refers to the practice of prescribing medicines to treat conditions not been specifically approved by the FDA.\n\"Bedtime treatment of fibromyalgia patients with low-dose cyclobenzaprine was safe and appears to be effective,\" says Seth Lederman, MD, president of TONIX Pharmaceuticals, which funded the study.\nCyclobenzaprine, marketed in higher doses by others as Amrix, Fexmid, and Flexeril, is already widely used ''off-label'' for patients with fibromyalgia, Lederman says.\nThe results of the study are published online in The Journal of Rheumatology.\nHowever, a rheumatologist not connected to the study does not expect the new drug to be a ''game-changer.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story makes clear that while this drug is available as a muscle relaxant, the dose used in this fibromyalgia trial is not available. The story also reports that the drug is not approved for treatment of fibromyalgia, but it is being prescribed \u201coff-label\u201d by some doctors. Near the bottom of the story, the researcher and company president predicts the low-dose version of the drug could be available for fibromyalgia treatment by 2015. It is hard to see what support there is for such a prediction, given the preliminary nature of this small trial.", "answer": 1}, {"article": "Gille is head of clinical and translational science strategy at CSL Limited (which funded the study) in Parkville, Australia.\nIn the year after a heart attack, about 12% of people have a second heart attack or stroke.\nAnd half of them happen in the first month, says researcher Andreas Gille, MD, PhD.\nHDL removes cholesterol from artery walls, but current HDL-boosting drugs, such as niacin and fibrates, take years to work, according to Gille.\nStandard heart attack medications, such as aspirin and anti-clotting drugs, prevent clotting but don\u2019t eliminate an underlying factor: cholesterol that has built up on artery walls, he says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Significant omission.\u00a0 How does one get IV infusions of \u201cgood\u201d HDL cholesterol?\u00a0 Where does one go for this?\u00a0 Is it only the experimental setting?\u00a0 You can\u2019t assume that readers know and understand this.", "answer": 0}, {"article": "TUESDAY, March 8, 2011 (HealthDay News) -- Acupuncture may help reduce the severity of hot flashes and other symptoms of menopause, according to a small study.\nThere were no differences between the two groups in terms of vaginal dryness and urinary tract infection.\nThe U.S. National Women's Health Information Center has more about treating menopause symptoms.\nThe findings were published online March 7 in Acupuncture in Medicine.\nThe beneficial effects of traditional acupuncture, according to the researchers, did not appear to be associated with changes in levels of hormones that trigger menopause and its associated symptoms.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This was a story about a Turkish study (not explained in the story) on Chinese acupuncture.\u00a0 If a woman doesn\u2019t know anything about acupuncture, this story told her nothing about its availability in the U.S.", "answer": 0}, {"article": "\"I think this may be changing in health care,\" said Spears, \"but because migraine affects women more than men, there is a stigma around the stereotype of a patient who comes in with multiple complaints, calls frequently and wants to see the doctor frequently.\" Men, on the other hand, have been stereotyped as going to the doctor \"only when something he has is real.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does state that, \u201cBased on the promising phase III clinical trials, the drug could be available later next year.\u201d", "answer": 1}, {"article": "Before the introduction of whooping cough vaccine in the 1940s, more than 200,000 cases a year were reported in the U.S. By 1965, that number plummeted to fewer than 10,000 a year. But the disease made a comeback in the 1990s, as the newer \"acellular\" vaccine \u2014 containing only cellular material but not whole cells \u2014 was phased in. While it is safer and has fewer side effects than the old version, studies have found that its protective effects wane more quickly than originally expected.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is widely understood that these vaccines are available to almost everyone. The story notes only half of pregnant mothers receive the vaccine, which is important and why the CDC is researching the topic.", "answer": 1}, {"article": "\"It's a very fragile organ to begin with,\" Kavaler said, \"and if you start to do all these things to it you can disfigure it...\n\"However, most men complaining of inadequate penile size do have associated sexual problems even if their penile dimensions fall within the normal range -- so-called dysmorphophobic penis,\" said Gontero, an associate professor of urology at the University of Turin.\nStudy co-author Dr. Paolo Gontero said urologists are constantly approached by men concerned about their penis size, despite the fact that the majority are average, with a flaccid length of 1 to 4 inches.\nIn a review of five evidence-based surgical studies of 121 men and six non-surgical studies of 109 men published between 2000 and 2009, the researchers found that penile extenders -- which stretch the organ over a period of months through traction -- were the most effective among non-invasive methods.\n\"All procedures aimed to increase the penile girth should be considered unsafe, leading to potentially poor cosmetic and functional results,\" Gontero added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story suggests but does not makes it clear that many \u201ctreatments\u201d are available. It implies that surgical procedures are performed by urologists and plastic surgeons. We would have liked to have seen some additional comments about the availability of and a definition of traction methods. A comment on the frequency of these procedures from one of the plastic surgery societies would have been a good addition.\nBesides the comment, \u201curologists are constantly approached by men concerned about their penis size,\u201d we are not given any idea about how widespread or available are the methods to address these concerns.\nAnd cognitive behavioral therapy isn\u2019t given much attention at all.", "answer": 0}, {"article": "(Reuters Health) - Phone support can help ease postpartum depression, a small study suggests, offering an option for mothers who are unable or unwilling to seek therapy in person.\n\u201cA lot of first-time moms wonder what\u2019s normal, what\u2019s depression, and what to do with the fact that they feel overwhelmed and alone and like their experience looks nothing like the happy moms they see smiling in all of the baby food and diaper commercials.\u201d\n\nBecause postpartum depression is the most common complication of childbirth, it makes sense to explore peer counseling and other interventions that can reach women in rural or suburban areas where access to mental health professionals may be limited, said Dr. Samantha Meltzer-Brody, director of the perinatal psychiatry program at the Center for Women\u2019s Mood Disorders at the University of North Carolina at Chapel Hill.\n\u201cPostpartum depression is a problem for one in seven women, and many of them don\u2019t get help because there\u2019s a stigma and they don\u2019t have time and it\u2019s expensive,\u201d said study leader Dr. Nicole Letourneau, a professor and research chair in parent-infant mental health at the University of Calgary.\nEven though the small study had several women drop out and lacked a control group of moms who received different treatment, the results are consistent with previous research that has proven peer counseling works, said Dr. Ruta Nonacs, a psychiatrist at the Center for Women\u2019s Mental Health at Massachusetts General Hospital in Boston.\nOn average, the women spoke more than eight times and the calls typically lasted about 38 minutes, the researchers reported in the Journal of Advanced Nursing.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is a borderline call where we\u2019ll give the story the benefit of the doubt. The story does not explicitly address availability of peer counselors, although it implies that they are not generally available for PPD. And the story does give enough detail to help the reader understand what would be necessary to create such a system of peer counselors. A comment about availability of peer counseling for other health issues would have been useful.", "answer": 1}, {"article": "March 15, 2010 -- A common pain reliever may help people with type 2 diabetes control their blood sugar levels.\nLike aspirin, salsalate is an anti-inflammatory drug derived from salicylate and is often used to treat arthritis.\nA preliminary study shows salsalate reduced blood sugar levels and helped with glycemic control at a variety of doses in people with type 2 diabetes.\nSalsalate contains the same active ingredient as aspirin but is associated with fewer side effects.\nHowever, it also has been shown to increase protein in the urine and its long-term safety will need further investigation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes that salsalate is commonly used in arthritis but it\u2019s not recommended yet for the treatment of diabetes.", "answer": 1}, {"article": "The ability to control the tightness is presumably part of the reason that patients who opt for banding lose less weight, at least initially, than gastric bypass patients -- an average of 50 to 65 percent of their excess weight in the first three years.\nThe American Society for Metabolic and Bariatric Surgery doesn't keep statistics on repeat customers, but obesity surgeons are reporting upticks.\nWhat obesity surgeons do feel confident saying is that no matter which type of surgery is chosen, and whether it's the first or second time, the patient has to meet the operation halfway.\nThe thing is, for about 20 to 40 percent of patients, the operation fails over the long term.\nAnother difference between the band and the bypass that proves both a plus and a minus is that the band doesn't cause the dumping syndrome.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story did not give any indication as to whether all bariatric surgeons perform gastric banding after gastric bypass surgery or if it was a select subset.", "answer": 0}, {"article": "\u2018What insanity is that?\u2019 Hundreds of NC children are being killed or injured by guns.\n\nDid you realize that in the past five years, hundreds of teens and youth have been killed or hurt by gunfire in North Carolina? Here\u2019s what some say you can do about it.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The AP report notes that FluMist was approved in 2003. Most readers will be familiar with flu shots and capable of determining their availability.", "answer": 1}, {"article": "People who used the device more than six days per week saw improvement, regardless of age, he added.\n\"The promise in the near term of these technologies is not only to help us reduce significantly the risk of long-term diabetic complications, but also to reduce the risk of having a catastrophic hypoglycemic event, and further help people with diabetes live easier,\" Aaron Kowalski, research director of the JDRF's Artificial Pancreas Project, said during the teleconference.\nA symposium on advances in the technology -- co-sponsored by the American Diabetes Association and the JDRF -- is slated for Sunday as part of the American Diabetes Association's annual meeting, in Orlando, Fla.\n\nFor people with type 1 diabetes, controlling their blood sugar levels is a full-time job.\n\"We have pioneered the development of a closed-loop artificial pancreas because we believe it will significantly impact the lives of individuals with both type 1 and type 2 diabetes, by providing exquisite control of blood sugar,\" Dr. Richard A. Insel, executive vice president for research at the Juvenile Diabetes Research Foundation (JDRF), said during a noon teleconference Saturday.\nSUNDAY, June 27, 2010 (HealthDay News) -- New research suggests that artificial pancreas technology can help diabetics gain greater blood sugar control overnight, even when they have eaten a big meal or had wine for dinner.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "One the one hand, the article tells us that the technology is emerging, the algorithm is still being developed, and the whole approach is still being researched in future studies. On the other hand, the article\u2019s tone and unbalanced quotes from investigators make the ultimate availability seem like a foregone conclusion, which it isn\u2019t after a 12-subject study. What\u2019s missing is at least some emphasis, ideally early, that this research is quite experimental at this point, with some discussion of the steps between this small study and the technology potentially going to market.\nThe article also takes until the third to last paragraph, after the discussion of the Ritholz study, to explain what an \"artificial pancreas\" actually is; burying that explanation and leading with an illustration of a real human pancreas does nothing but suggest to lay readers that an \"artificial pancreas\" is something like a prosthetic organ, instead of a computer link between extant devices. It could\u2019ve been clearer about how the \"closed loop\" technology is supposed to improve on the available devices. In fact, we\u2019re not sure that the description of the artificial pancreas as a single discrete \"device\" matches what was used in the study, which, according to the abstract, seems to have involved a glucose monitor, a computer, and a human being making adjustments to the patient\u2019s insulin pump.", "answer": 0}, {"article": "A few previous small trials had already suggested that giving drugs like Prozac, which belongs to a drug class known as selective serotonin re-uptake inhibitors (SSRIs), might improve motor skill recovery after stroke.\n\u201cDepression after stroke is a common enough complication to have raised the question of treating with antidepressants early after stroke,\u201d he said in an emailed comment.\nExperts commenting on the findings said they had \u201cenormous potential to change clinical practice\u201d and raised the question of whether most stroke patients with motor skill problems should be treated with this relatively cheap type of antidepressant.\n\u201cIf motor function is also more likely to improve, then treating before symptoms of depression emerge is likely to be even more beneficial.\nStroke is the single largest cause of adult disability and the third-largest cause of death in the developed world.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear\u00a0that the story is about a new use for a medicine that has been available for many years to treat depression and anxiety.", "answer": 1}, {"article": "\"If your immune system has been educated by the vaccine to recognize the tumor cells, we think it will allow the immune system to take care of any individual [cancer] cells trying to set up shop,\" explained Dr. Elizabeth Mittendorf, a surgical oncologist at the University of Texas M.D.\n\"Whether it actually has an increase in survival remains to be seen,\" he said.\nPhase 3 studies are needed before the vaccine could be approved.\nDon Diamond, director of translational vaccine research and a professor of virology at the City of Hope Comprehensive Cancer Center in Duarte, Calif., reviewed the findings and said, \"Their approach is well thought out and makes sense.\"\nThe study is a phase 2 study, meant to evaluate the vaccine's effectiveness and any side effects.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated \u201d it will take at least five years before the vaccine could conceivably be available if ongoing studies bear out.\u201d", "answer": 1}, {"article": "Volunteers had the doctored lotion slathered onto one arm and regular moisturizer on the other.\n\u201cIt does open a window for a potential new treatment.\u201d\n\nHealthy skin harbors a different mix of bacteria than skin damaged by disorders such as atopic dermatitis, the most common form of eczema.\nThis community \u2014 what scientists call the microbiome \u2014 plays critical roles in whether we stay healthy or become more vulnerable to various diseases.\nThe study couldn\u2019t address the bigger question of whether exposure to the right mix of protective bacteria might improve atopic dermatitis itself, cautioned Mount Sinai\u2019s Guttman-Yassky.\nIn lab tests and on the surface of animal skin, those substances could selectively kill Staph aureus, and even a drug-resistant strain known as MRSA, without killing neighboring bacteria like regular antibiotics do, the team reported in the journal Science Translational Medicine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear that this idea is still in the experimental stage and hence not available at your local pharmacy. Ideally the story would have explained a bit more about the many steps left in bringing this product to the marketplace (if it ever makes it there; many experimental products never do).", "answer": 1}, {"article": "Dec. 2, 2011 (Chicago) -- An experimental approach in which penile nerve tissue is frozen to knock out overactive nerves helped men with premature ejaculation last three times longer.\nAlso unknown: whether men would opt for the treatment.\nA time to ejaculation of more than two minutes is normal, he tells WebMD.\nIts supporters say the technique, or a similar one involving heat therapy, could someday become a standard treatment for the condition.\nThe findings were presented here at the annual meeting of the Radiological Society of North America.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that this procedure is not currently available to the typical patient.", "answer": 1}, {"article": "Last Wednesday, the F.D.A.\n\u201cThere are very few treatments in all of cardiovascular medicine that could claim that \u2014 I can think of heart transplant, and that\u2019s it.\u201d\n\nThe results were even more notable, he said, because the early versions of the devices were clunky, stiff and difficult to use.\nThe consensus of the group, he said, was that \u201cnot every one of the 1,150 cardiac surgery programs or the 1,600 cath labs in the U.S. should be able to do it.\u201d\n\nIn June 2014, after another company, Medtronic, did similar studies, its device was approved, too, for high-risk patients.\nThe result was a requirement that a hospital should be doing at least 50 surgical aortic valve replacements a year to have access to the technology.\nMedtronic also has a new version of its valve that cardiologists expect will soon be approved.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story summarizes the approval status of several devices. However, it doesn\u2019t explore important caveats about which patients are eligible for TAVR and implies that all comers who are too sick for surgery are eligible.", "answer": 1}, {"article": "Bone-health experts are making a new push to reduce rates of osteoporosis, with a particular focus on controlling the bone-wasting disease in men.\n\nAn important goal is to get greater numbers of men to be tested for osteoporosis when they come to a hospital or clinic with a fracture to the wrist, vertebrae or other bones that wasn\u2019t from a major accident or trauma. Doctors call this a fragility fracture\u2014one that results from a decrease in bone density.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that bone density screenings are common and done in a variety of ways.", "answer": 1}, {"article": "So, how does naltrexone work?\nThe analysis also found that another drug, acamprosate, is effective at helping people who have already stopped drinking to maintain abstinence, perhaps partly by easing the physical and emotional cravings experienced by heavy drinkers who quit.\n\"The biggest problem we have in the field is that less than 10 percent of individuals with an alcohol use disorder get any treatment whatsoever,\" says George Koob, director of the National Institute on Alcohol Abuse and Alcoholism.\nBut there's good evidence that the combination of counseling and drugs such as naltrexone can help people cut back on drinking, or move toward abstinence.\nPart of the challenge, researchers say, is that many drinkers don't realize that a medicine long used to help people addicted to opioids quit their drug habit can help alcoholics and other heavy drinkers cut back, too.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is a strong point of the story:\nAny health care provider who is licensed to prescribe medicine can prescribe naltrexone \u2014 not just mental health professionals or addiction specialists. As as long ago as 1997, a published study showed that treatment of alcohol dependence with naltrexone by primary care doctors can be effective; follow-up research has confirmed that the primary care approach not only works, but makes treatment much more accessible.", "answer": 1}, {"article": "If you'd like to find out more about this procedure, please click here\nIn less than a week, she was starting back to her regular routine, including exercise.\nThat's still the standard procedure for the 50,000 Americans who are operated on each year for this problem.\nInstead of 10 days in the hospital, there long months of recovery and a lasting scar like her mother \u2014 one that she had to have plastic surgery to repair \u2014 Barletta was out of the hospital in two days.\nDr. Bill Gray has done several of the procedures at New York Presbyterian Hospital, and he demonstrated to LaPook how the clip works to close the valve.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This piece did include a disclaimer at the end that this procedure is done only in a limited number of centers and is investigational at this time.\n\u00a0", "answer": 1}, {"article": "Ivacaftor works for people with the G551D mutation of cystic fibrosis.\n\u201cEven thought it only affects a small percentage (of patients) the hope is there that we can finally do something about this disease.\u201d\n\nThe study, published in the New England Journal of Medicine Wednesday, looked at 84 people who got the drug.\nIn an editorial accompanying the study, Dr. Pamela Davis, of Case Western University paraphrased Winston Churchill, \u201cThis study is also a great victory in the war against genetic diseases and marks the end of the beginning for the treatment of the cystic fibrosis defect.\u201d\n\nIvacaftor has been submitted to the FDA for approval, and could be available next year, according to Konstan.\nThat trial is ongoing and the treatment is at least four or five years away from approval, but if it works, Beall says, it could help 90% of the people with cystic fibrosis.\nDrug recipients could blow out more than 10% more air from their lungs compared with patients who were not taking the drug, and were about half as likely to have a \u201cpulmonary exacerbation\u201d or a worsening of their lung disease that often requires hospitalization.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nAlthough the story is clear that this drug is not yet available, it includes a claim that it could be on the market next year. The manufacturer recently applied for FDA approval, but the drug has not been reviewed, so any claim about availability is mere speculation.", "answer": 0}, {"article": "So far, however, there is little scientific proof of their effectiveness\u2014many studies of probiotics have involved less-than-rigorous...\nOne of the fastest-growing dietary supplements, probiotics are now prominent on drug and big-box store shelves.\nProbiotics are widely used to aid digestion and help restore gut bacterial balance after antibiotics.\nBut some researchers are investigating the beneficial bugs for conditions that have nothing to do with the digestive tract.\nThey are live microorganisms\u2014or \"good\" bacteria\u2014that when consumed in capsules or yogurt are said to confer a health benefit.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that probiotics are available in supplements and a variety of other products.", "answer": 1}, {"article": "\u201cOver the next couple of years, we will find out what it means.\u201d\n\nOn Oct. 23, 2008, Avid and two other companies, and , that are developing fluorine 18-based dyes for amyloid scans, got a pointed question from an advisory committee to the F.D.A.\n\u201cSomething bad happens, and now something good happens.\u201d\n\nLate last year, Avid saw the initial results of its hospice study \u2014 data from the first six patients.\nOther tests are being studied \u2014 ones that look for amyloid in cerebrospinal fluid that bathes the brain; scans that look for shrinkage of the brain in areas needed for memory and reasoning; PET scans that look for uptake of glucose, a cellular fuel, to show areas where the brain was active and where it was not.\n\u201cThe 20 percent who had amyloid, though they were still statistically in the normal range, did worse on every memory test than the control group.\u201d\n\nWhat, Dr. Skovronsky asked, did that mean?\nMost of the time, the scans were as expected \u2014 those with Alzheimer\u2019s had lots of plaque, those with normal memories had little if any and those with mild memory impairment were in between.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The whole story is about how there is nothing available right now to accurately detect Alzheimer\u2019s and how this procedure may move the ball forward. Although, as the story rightly points out, the new scan won\u2019t necessarily answer all the questions about Alzheimer\u2019s. It should make it clear up high how long it would take for this scan to go through the FDA process.", "answer": 1}, {"article": "\"I hope that people will respect the rigorous methodology used in this blinded, randomized, controlled trial and accept the result,\" study researcher Deirdre Lyell, MD, assistant professor of obstetrics and gynecology at Stanford University School of Medicine, says in a news release.\nAll of the women received therapy for eight weeks and were interviewed at the four- and eight-week marks by someone who did not know which treatment they were getting.\nThe researchers say 63% of the women who received depression-specific acupuncture reported a significant reduction in symptoms, compared to 44% of women in the other two groups combined.\nMany pregnant women who have symptoms of depression worry that taking antidepressants might harm their unborn babies -- so they stop taking their medications, say researchers at the Stanford University School of Medicine.\nSome received depression-specific acupuncture treatments, others had needles inserted in acupuncture points not known to relieve depression, and a third group received massage therapy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The acupuncture treatment appears to have been customized for depression. Depression-specific acupuncture is not likely to be available everywhere. The story didn\u2019t tell us. ", "answer": 0}, {"article": "Besides M.D.\nThe protein, known as CA-125, has not been good at identifying new early-stage ovarian cancer because it can become elevated for other reasons, leading to false positives.\nI can remember when doctors all rushed to adopt the Prostate Specific Antigen test, and we still don't know how to use it.\u201d\n\nLu acknowledged there are comparisons to the PSA test, which has come under fire in recent years for being better at detecting prostate cancer than improving survival.\nAnd if I can be saved, so can other people.\u201d\n\nThe study results were unveiled Thursday in advance of a major cancer conference next month.\nIn the last decade, hopeful of finding a better test, ovarian cancer researchers have invested much time in the investigation of other biomarkers and technologies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The CA-125 test is clearly available. What is not clear is whether the clinical algorithm used in this study to identify high risk women is available widely or only in a research setting.", "answer": 1}, {"article": "Fatty fish like salmon offer a concentrated source of the omega-3 fatty acid nutrients Tan and his colleagues looked at eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).\nA third of the brain by volume is composed of blood vessels.\nThe only people who should avoid DHA are patients on a blood thinner like Cumadin, he added.\nDHA has the added benefit of improving mood and reducing symptoms of depression, he said.\nThey controlled for such risk factors as age, smoking, gender, body mass index, physical activity and APOE, the one known gene linked to dementia risk.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of fish and fish oil supplements is not in question.", "answer": 2}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nIt is unknown how myelin-producing cells are damaged, but research suggests they may be targeted by malfunctioning immune cells and that multiple sclerosis may start as an autoimmune disorder.\nThe Center emphasizes innovation and deliverables, relying on the power of data and new technologies to develop, demonstrate and disseminate advancements in translational science that bring about tangible improvements in human health.\nThey are currently approved for use as creams or powders on the surfaces of the body but their safety administered in other forms, such as injections, in humans is unknown.\nThe mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the two drugs highlighted (clobetasol and miconazole) are available and adds the important precatuionary note, \u201c\u2026are currently approved for use as creams or powders on the surfaces of the body but their safety administered in other forms, such as injections, in humans is unknown.\u201d", "answer": 1}, {"article": "So, how might the message of this new study linking high-fiber diets to a lower risk of breast cancer be communicated to teenagers?\nThe findings are based on a long-term study of 44,000 women who were surveyed about their eating habits in high school.\nThe researchers found that women who consumed high levels of fiber (28 grams per day, on average) had a 24 percent lower risk of developing breast cancer before menopause, compared with women who ate low levels of fiber (14 grams per day, on average).\nOf course, the idea that high-fiber diets can help keep us healthy is not new.\nMost Americans don't get the 25 to 38 grams a day that's recommended, depending on age and gender.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There are no new products or services at issue in this story, and we addressed access to healthy foods under \u201cCost,\u201d so we\u2019ll rate this not applicable.", "answer": 2}, {"article": "That\u2019s called secondary prevention.\nHere\u2019s the problem: The lower an individual\u2019s risk of a future heart attack or ischemic stroke, the less he or she will benefit from taking daily low-dose aspirin.\nWith an international team of colleagues, we created an online tool that calculates whether the benefits of aspirin for primary prevention (preventing heart attack, ischemic stroke, and cancer) are greater than the harms (severe hemorrhagic stroke and severe gastrointestinal bleeds).\nAlthough the totality of evidence is incomplete, it appears that aspirin has net benefits when the absolute 10-year risk of having a cardiovascular event is greater than 10 percent.\nIt is important to keep in mind that other therapies, such as statins, have also been proven to decrease the risk of cardiovascular events.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear that aspirin is ubiquitous and sold almost everywhere as an over-the-counter drug, so we\u2019ll rate this one N/A. This story, and the other we reviewed, might have benefited from mentioning that the drug has a generic name (known as ASA or acetylsalicylic acid). Generic versions of the drug do exist, are likely cheaper than the brand name, and equally effective.", "answer": 2}, {"article": "For more information about Wolters Kluwer's solutions and organization, visit http://www.\nBefore and after surgery, patients were evaluated on a standard migraine questionnaire (the Migraine Headache Inventory, or MHI) and on the PSEQ.\n\"It seems that migraine surgery patients can recover function and ability to cope with pain very well after surgery, in stark contrast to what has been shown in other pain conditions,\" Dr. Austen and coauthors write.\nThat was much higher than in studies of patients with other types of chronic pain: for example, an average 19 percent improvement after nonsurgical treatment for low back pain.\nOne year after migraine surgery, the patients had a very large percent improvement in average PSEQ score: on average, 112 percent higher than baseline.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release made no mention of how or where patients could obtain migraine surgery. Online it seems that these surgeries are offered at many boutique plastic surgery centers around the country\u2013though interestingly it is only plastic surgeons who seem to offer this treatment, not neurologists (the doctors that most often treat migraine sufferers). The news release and the study also did not mention that not all migraine patients will be eligible for the procedure. Although we know little about migraines, it is known that they are triggered in different people through different mechanisms. A woman who has hormonal migraines, for example, might not benefit from nerve decompression.", "answer": 0}, {"article": "Guyuron, chair of plastic surgery at University Hospitals Case Medical Center in Cleveland, went on to identify four common \"trigger sites\" and publish studies showing that, in selected patients, surgical decompression of nerves in one or more of these sites provides lasting migraine relief. He has also taught 250 plastic surgeons around the world (none in the Philadelphia area) to perform the outpatient operation, which costs an average of $10,000 and is not covered by many insurers.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does make it clear that this is an experimental approach and that the surgeon in question may be one of the few practicing this technique \u2013 although he claims to have trained 250 surgeons around the world. .", "answer": 1}, {"article": "\u201cIf used perfectly, how much HIV protection could there be?\n\u201cThat individual control of prevention is so powerful.\u201d\n\nThe dapivirine ring has been in development for more than a decade, and the the new studies are the first to show that it prevents HIV transmission.\nBut 1 in 3 infections were prevented overall \u2014 and that\u2019s huge.\u201d\n\nWarren noted that other rings with antiretrovirals are also being developed, as well as rings that could offer multipurpose protection, against not only HIV but pregnancy.\nLike the other study, in this one the ring had no visible effect in women younger than 21, whereas new HIV cases dropped by 37% in women over 21.\nBut it\u2019s now known that, when taken properly, Truvada cuts new cases of HIV by at least 92%.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that the dapivirine ring \u201chas been in development for more than a decade,\u201d suggesting that it is not yet available. Some comment on when the device might become available would have been useful.", "answer": 1}, {"article": "March 21, 2011 -- Long-term results for Lap-Band weight loss surgery are relatively poor, according to a new study from Belgium.\nThe critics also point out that both the device itself and the expertise of surgeons placing it have improved greatly since the patients in the study had their bands placed, in the years 1994 through 1997.\n\"My impression is, even with the newer band, the results are not significantly better,\" he says.\nThe average weight loss was below what experts consider good results.\nNearly half of the 82 patients followed for 12 years or longer required removal of the bands and about 40% had major complications, the researchers found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the gastric banding procedure is available and provides a link to information from the National Institutes of Health.", "answer": 1}, {"article": "For more information or to obtain a PDF of any study, please contact:\n\nDawn Peters (US) +1 781-388-8408 \n\nsciencenewsroom@wiley.com \n\nFollow us on Twitter @WileyNews\n\nFull Citation: \"Dietary Isoflavone Intake and All-Cause Mortality in Breast Cancer Survivors: the Breast Cancer Family Registry.\"\nIn contrast to some previous research, high levels of isoflavone intake were not associated with greater mortality among women receiving hormonal therapy.\nA free abstract of this article will be available via the Cancer News Room upon online publication.\nOver a median follow-up of nine years, women with breast cancer who consumed high amounts of isoflavones had a 21 percent lower risk of dying than women who consumed low amounts.\nNOTE: The information contained in this release is protected by copyright.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It would have been interesting and helpful for the release to note what kinds of soy foods the participants said they ate, and which ones were most popular.", "answer": 2}, {"article": "The study was funded by the P.J.\n\"We can predict that about 15 out of every 100 people with a particular risk score will die of a heart attack, but the equations don't tell us which of those people will be one of the actual 15; they don't give us personalized information,\" says McEvoy.\nFor example, according to the researchers, those with systolic blood pressures below 140 millimeters of mercury and no calcium had an event rate of 12.7 events per 1,000 person-years, and similar people with systolic blood pressures between 140 and 159 millimeters of mercury had an event rate of 13.6 events per 1,000 person-years.\nThe scans detect levels of calcium in the heart's arteries, and the physicians suggest those people with the highest calcium levels would benefit most from aggressive blood pressure treatment, whereas those with little or no calcium may not need to be treated as intensively, depending on their other heart disease risk factors.\nThus, even though their calculated heart disease risk is relatively low and their blood pressure is below traditional cutoffs for treatment, the researchers say people in this category with calcium over 100 are high risk and may benefit from more aggressive blood pressure treatment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Though CT scans are widely available, the news release mentions that coronary artery calcium scans aren\u2019t usually covered by insurance. This seems to be an important stumbling block to widespread adoption. Could insurers be persuaded to pay for scans if the cost is outweighed by better targeting of treatments? Addressing this point would have added value to the news release.", "answer": 1}, {"article": "In fact, Dr. Weinstein's findings, released today in the Journal of the American Medical Association, conclude that surgery is only slightly more effective in some cases than a non-surgical approach.\nThe operation was a success and she's been pain-free for four years.\nBut others choose surgery to remove that bulge that causes the pain.\n\"I think that it be important for people to have good information,\" he adds.\nHis back pain was excrutiating,reports.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It's clear from the storyt that surgery for herniated disc is widely available. ", "answer": 1}, {"article": "Compared with the 16% of people who didn't drink coffee at all, those who downed two or more cups each day were about 18% less likely to have died during the study period. In addition, those who drank just one to six cups of coffee per week were 12% less likely to die. Both of these figures were calculated after taking into account known risk factors for early death, such as smoking (which is often paired with coffee drinking), diet and body mass index.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Coffee is so widely available that there\u2019s no need to make the point.", "answer": 2}, {"article": "New investigation advises doctors to recommend cranberry products as first line of defense against repeated urinary tract infections (UTIs)\n\nCARVER, Mass., September 19, 2017 - A thorough review of dozens of studies led scientists to conclude that healthcare professionals should be telling their patients to have cranberry products as a first step in reducing recurrent UTIs.\n\"Our investigation supports that cranberry products can be a powerful tool to fight off frequent UTIs,\" explains lead author, Dr. \u00c2ngelo Lu\u00eds.\nThe industry appreciates the efforts of these researchers and takes pride in the healthy attributes that cranberry products provide to consumers around the world,\" comments Terry Humfeld, executive director of the non-profit research and education-focused organization, The Cranberry Institute.\nHowever, patients with recurrent UTIs who ingested cranberry products and had undergone gynecological surgery, experienced a significant reduction in UTIs.\nLuis A, Domingues F and Pereira, L. Can cranberries contribute to reduce the incidence of urinary tract infections?\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t address this, but it can be assumed that most (if not all) readers will be familiar with the availability of products containing cranberries. Ergo, we\u2019ll rate this as not applicable. It\u2019s worth noting that the release gives readers little idea of what sort of cranberry products a patient could \u2014 or should \u2014 use to lower their risk of a UTI.", "answer": 2}, {"article": "\u201cWe think this is the first (study) to show this.\u201d\n\nMoss said women have often been overlooked in studies of heart disease, which until recently were dominated by men.\nThe original study, published in 2009 in the New England Journal of Medicine, showed patients fared better with a combination cardiac resynchronization therapy and a defibrillator rather than a defibrillator alone.\nOther studies have shown heart attack symptoms are much different in women than in men, something that has been publicized with the American Heart Association\u2019s \u201cGo Red for Women\u201d campaign.\n\u201cWe found there was a dramatic reduction not only in heart failure events, but a very dramatic reduction in death from any cause,\u201d Moss said in a telephone interview.\nThe findings come from a large Boston Scientific study of cardiac resynchronization therapy known as MADIT-CRT, in which a pacemaker is used to restore normal coordinated heart beats in people whose damaged hearts are less efficient at pumping blood.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "At the end of the story, it mentioned that what it earlier referred to as \u2018a combination pacemaker and defibrillator device\u2019 had had it use expanded by \u2018U.S. regulators\u2019 to include mild heart failure.", "answer": 1}, {"article": "LONDON (Reuters) - First results from a human trial of an Ebola vaccine from GlaxoSmithKline show it is safe and generates an immune response, scientists said on Wednesday, but larger trials are needed to see if it protects and if a booster is needed.\nThat trial is the first of several mid-stage studies planned for West Africa and aims to test GSK\u2019s vaccine and one from Merck and NewLink.\nThe data, published in the New England Journal of Medicine, were from 60 healthy volunteers given the vaccine in Britain between Sept. 17 and Nov. 18 last year.\nThe vaccine is being developed by the U.S. National Institutes of Health (NIH) and GSK against the Zaire strain of Ebola \u2014 the one circulating in West Africa \u2014 and the first doses for a larger trial arrived in Liberia last week.\nHowever, the antibody response was weaker than was found in a trial of the same Ebola vaccine in macaque monkeys, in which the animals were also found to be protected.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the vaccine is under development and that clinical trials in West Africa are under consideration. The story could have mentioned the long testing process required before such a vaccine might be available on the ground in Africa.", "answer": 1}, {"article": "\u201cThere is a great deal of interest in developing other uses of bimatoprost,\u201d Heather Katt, a spokeswoman for Allergan, wrote in an e-mail message, \u201cand Allergan is exploring ways to pursue that pathway through the F.D.A.\nIt is, however, expensive: a month\u2019s supply of Latisse can cost up to $150, and that is in amounts appropriate for use merely on the eyelashes.\nThe result is an enhanced, refortified hairline rather than a brand new head of hair.\nThough some users of Latisse have experienced skin discoloration, Dr. Bauman said he had never seen any such reaction on the scalp of his patients.\napproved a new hair-loss remedy (Propecia, in 1997), so it is understandable that anticipation for a new one might be running high.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that Latisse is a prescription product sold for eyelashes but being used off label by some doctors for hair loss.", "answer": 1}, {"article": "She noted that glitazones -- a separate class of newer drugs such as Rezulin, Avandia and Actos that also target insulin resistance -- have all shown initial promise in clinical trials before worrisome side effects began to surface in users (due to concerns around heart risks, Avandia remains on the U.S. market but under limited distribution).\nHowever, the incidence of episodes of hypoglycemia was much lower among patients taking TAK-875 (2 percent) than among those taking glimepiride (19 percent) and the same as those taking the placebo (2 percent).\nThe new drug, called TAK-875, is a pill designed to enhance the secretion of insulin in response to such changes, which means that it has no effect on insulin secretion when blood sugar levels are normal -- potentially reducing the risk for hypoglycemia.\nShe said that, \"though this study includes a small sample size followed for a short period of time, the results are promising in that TAK-875 appears to be effective for glycemic [blood sugar] control without significant risk for hypoglycemia or weight gain.\nThe incidence of treatment-related side effects was 49 percent among patients taking TAK-875, 48 percent among those in the placebo group, and 61 percent among those in the glimepiride group, according to the researchers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Right in the headline, the story shows that the drug is not widely available, calling it \u201cexperimental.\u201d Also, the lead of the story says that the findings are \u201caccording to the results of a phase 2 clinical trial.\u201d However, the story did not specifically clarify that this drug has years to go before it ever reaches the market.", "answer": 1}, {"article": "June 7, 2012 -- Drinking three cups of coffee per day may help turn the tide against Alzheimer's disease among older adults who are already showing signs of memory problems, a new study shows.\nAlzheimer's disease is the most common type of dementia.\nThis is equivalent to drinking several cups of coffee a few hours before giving blood.\nCoffee was the main, or only source, of caffeine among people in the study.\nThe findings will appear in the Journal of Alzheimer's Disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of coffee is not in question.", "answer": 2}, {"article": "Chicago \u2014 Local bans on artery-clogging trans fats in restaurant foods led to fewer heart attacks and strokes in several New York counties, a new study suggests.\n\u201cPolicies such as these when adapted on a nationwide level will be good for our entire population,\u201d said Creager, director of Dartmouth-Hitchcock Medical Center\u2019s heart center in Lebanon, New Hampshire.\nThe U.S. Food and Drug Administration in 2015 gave the food industry until next year to eliminate artificial trans fats from American products.\nThe FDA in 2006 required them to be listed on food labels and the food industry has been switching to healthier oils.\nAdmissions for heart attacks and strokes declined in all counties, going from more than 800 to less than 700 per 100,000 people, but the drop was steeper in counties that enacted bans.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story lets readers know that soon a trans fat ban will apply to the entire country:\nThe study hints at the potential for widespread health benefits from an upcoming nationwide ban, the authors and other experts say. The U.S. Food and Drug Administration in 2015 gave the food industry until next year to eliminate artificial trans fats from American products", "answer": 1}, {"article": "Tasimelteon received orphan drug status \u2014 which offers several years of marketing exclusivity for drugs developed for rare conditions \u2014 from the FDA in 2010 and from the European Commission in 2011.\nThe second trial showed that patients treated by the drug maintained their clinical benefits while placebo-treated patients showed significant deterioration in measures of night-time sleep, daytime naps and timing of sleep.\nThe study, named Reset, was a 20-patient trial designed to test the maintenance effect of a 20 mg dose of the drug, tasimelteon.\n\u201cThese results also highlight the importance of chronic therapy in treating Non-24,\u201d CEO Mihael Polymeropoulos said in a statement on Wednesday.\nThe condition, in which a person\u2019s body clock does not automatically set to the 24-hour day, affects a majority of blind people.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story referred to the drug tasimelteon as an \u201cexperimental drug.\u201d\u00a0 And it reported that the drug company plans to apply for FDA approval in mid-2013.", "answer": 1}, {"article": "Claudia Kawas, a geriatric neurologist at the University of California, Irvine, said a patient strode into her office soon after the FDA approved the procedure and asked for the \"Alzheimer's test.\" In one hand, he held an article about the approval of Amyvid. In the other, he had a document from a right-to-die group. If the test was positive, he told her, he would get his affairs in order and kill himself within 60 days.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story tells us that the PET scan/radioactive tracer approach was approved by the FDA months ago.\u00a0 It also explains some of the limitations on availability:\n\u201cRajan Agarwal, an Abington Memorial Hospital radiologist, did the country\u2019s first three commercial Amyvid scans in June and has had no referrals since. Adler also has done three. Though doctors think the test can be a blockbuster, PETNET, a Siemens subsidiary that distributes the tracer, said it had made 100 commercial doses for this region since June.\nThe tracer is made individually for each patient on test day at 15 sites around the country, then delivered within a 2\u00bd-hour radius. \u2026\nLack of coverage for the $3,000 test is the biggest barrier to it here. Medicare\u2019s decision on coverage, which often sets the standard for private insurers, is due by July.\u201d", "answer": 1}, {"article": "For more information, visit http://www.\nBased on four-month intervention data, the annual projected body weight increase in the prebiotic group would be 3 kilograms (6.6 pounds), within the expected healthy range, whereas the projected increase in the placebo group was 8 kilograms (17.6 pounds), almost triple the expected yearly weight increase.\nBethesda, MD (June 5, 2017) -- There may soon be a new tool in the fight against childhood obesity.\nGastroenterology, the official journal of the AGA Institute, is the most prominent scientific journal in the specialty and is in the top 1 percent of indexed medical journals internationally.\n\"This is a well-designed trial that demonstrates how a prebiotic could potentially help combat one of the most prevalent and costly conditions afflicting children in the developed world -- overnutrition -- by targeting the gut microbiome,\" said Geoffrey A. Preidis, MD, PhD, a member of the AGA Center for Gut Microbiome Research and Education scientific advisory board.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address availability. The supplement used in the trial is from Germany and was not easy to find online, but as noted, similar products appear to be easily available.", "answer": 0}, {"article": "She's skeptical about the Lancet study, pointing out that patients improved only moderately, and not much more than those who were counseled about pacing themselves.\nIts cause is still unknown, but over the years, researchers have identified various brain, immune system and energy metabolism irregularities involved.\n\"People need to begin to push themselves in the face of their fatigue, because if you don't, you become deconditioned and you get caught in a cycle which ... makes fatigue worse,\" says Barsky.\nNearly three decades have passed since the debate began about a series of symptoms that have come to be known as chronic fatigue syndrome.\nBut soon that level of activity often comes to a crashing end and patients can relapse dramatically, even becoming bedridden for several days or longer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions \u201ca form of talk therapy\u201d but never makes it clear how exactly the therapy works and whether any psychiatrist could provide it. This is one of many places in the story where additional detail would help. Cognitive behavior therapy (CBT) was offered for up to 14 sessions over 23 weeks. A booster session was offered at 36 weeks. CBT is a widely available and standard psychological treatment used for many conditions. Similar to CBT, details on the duration, frequency and availability of the competing interventions would be useful. Helping readers understand what might be involved in the intervention would improve understanding.", "answer": 0}, {"article": "MIT scientists find evidence that Alzheimer\u2019s \u2018lost memories\u2019 may one day be recoverable\n\n\u2019Siri, I want to commit suicide\u2019 and other statements likely to yield unhelpful responses from your phone\n\nRoots of Napoleon complex may be justified: Study finds short men get short of end stick in life.\nIn an editorial, Madhav Goyal and Jennifer A. Haythornthwaite of the Johns Hopkins University School of Medicine said that the mechanisms for why meditation might work on back pain is still a mystery but that this question is merely \"academic\" for many clinicians and their patients who need immediate relief.\nThe study did caution that 30 of the 103, or about one-third, of the participants in the meditation group reported an \"adverse event,\" most often an increase in pain due to yoga.\nThe two wrote that despite this and other unknowns, the study provides \"a compelling argument for ensuring that an evidence-based health care system should provide access to affordable mind-body therapies.\"\n\"These findings suggest that MBSR may be an effective treatment option for patients with chronic low back pain,\" the authors wrote.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear from the story whether MBSR is widely available, is available in mainly metropolitan areas, or is a relatively new field that is still uncommon. The story does quote from a separate editorial in JAMA that says health care systems \u201cshould provide access to affordable mind-body therapies,\u201d\u00a0implying that it\u2019s not widely available. Is this the case, or can it be easily accessed?", "answer": 0}, {"article": "But the limit is tricky to impose.\n\"There should be guidelines, I think, that are more clearly defined,\" says Dr. Geoffrey Sher, who heads the Sher Institutes for Reproductive Medicine and is based in Las Vegas.\nSher's ethics board said OK.\n\n\"And she went ahead and had a baby at 57 years of age without any problems whatsoever,\" Sher says.\n\"My best friend and I made a pact together that at age 38, if we were both still single, we were going to have a child on our own,\" says Robyn Ross.\nAnd the uterus doesn't decline like eggs do; in some cases, it can actually be coaxed back into working order.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story barely meets this requirement. It describes the procedure as something gaining acceptance, but still \u201cexperimental.\u201d What isn\u2019t emphasized is that this is not offered by many centers that can freeze ooccytes and far from all infertility programs have successful protocols in place.", "answer": 1}, {"article": "Related: CDC study finds opioid dependency begins within a few days of initial use\nThe animals were given three doses of the vaccine, which elicited a successful immune response that neutralized heroin given at varying doses.\n\u201cWe believe this vaccine candidate will prove safe for human trials,\u201d said Janda in a statement.\nIn this case, the vaccine introduces a piece of the heroin molecule to the immune system.\n\u201cIt\u2019s not going to be a panacea,\u201d says Thomas.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that research has not yet taken place in humans, indirectly inferring that it\u2019s not available.", "answer": 1}, {"article": "\"In this long-term study of lorcaserin for treating patients for obesity, there was good weight loss, outstanding safety profile and the drug was extremely well-tolerated,\" said lead researcher Dr. Steven Smith from the Translational Research Institute for Metabolism and Diabetes in Winter Park, Fla.\n\n\"As patients are looking for additional options and physicians are looking for new tools, [lorcaserin] provides us with a look into the future for what's going to be available for helping patients lose weight,\" he added.\n\"If weight-loss drugs are tailor-made to hit only the right receptor, based on physiological knowledge, it seems to be possible to develop weight-loss medications that do not possess any serious adverse effects,\" Astrup added.\nThe third new drug is Orexigen Therapeutic's Contrave, which is a combination of the antidepressant Wellbutrin and the addiction drug naltrexone.\nA potential player in fighting the obesity epidemic, lorcaserin is a new type of weight-loss drug that works by acting on serotonin, a chemical associated with feelings of well-being and feeling full, and does not appear to increase blood pressure or cause any other heart problems, according to the researchers, whose work was sponsored by the drug manufacturer.\nThe report is published in the July 15 issue of the New England Journal of Medicine, and was sponsored by Arena Pharmaceuticals, of San Diego, Calif., which used its own doctors as part of the study group.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this is a drug company study of a drug that is \"being considered for approval\"\u00a0by the FDA.\" It\u00a0gives a bit of a timeline but could have said\u00a0how long it might take before the drug, if approved, hits shelves.", "answer": 1}, {"article": "Although the difference between the treated patients and those given the placebo in the trial might appear modest, Dr. Joan T. Merrill, a lupus expert at the Oklahoma Medical Research Foundation, said Benlysta\u2019s safety and its ability to reduce steroid use would make it attractive to doctors.\nIt also changed the measurement of success and lengthened the trial to give the drug more time to work.\nMore patients on the drug had the required improvement in symptom severity.\nIf Benlysta gets to market, it will be the first drug from the company, and one of the first in the industry, to result from genomics.\nBecause the disease\u2019s symptoms wax and wane on their own and vary considerably from one patient to another, it has been hard to demonstrate the efficacy of drugs in clinical trials.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was clear that the drug Benlysta is currently being studied in clinical trials and is not available for use.", "answer": 1}, {"article": "Other Northwestern authors include Kate Tomasino, Emily Lattie, Hannah Palac, Mary J Kwasny, Kenneth Weingardt, Leland R Bardsley, Lauren Caccamo, Colleen Stiles-Shields and Stephen Schueller.\nIndividuals can download the apps free with no financial obligation.\nIntelliCare is a national research study.\nUsers may get bored or overwhelmed and may stop using the apps after a few weeks.\nPeople also may enroll in a study in which they will be paid to provide even more feedback.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release invites people to download the apps for free.", "answer": 1}, {"article": "The therapy continued with the parents for the next six months with less intensity.\nThe absence of any hope, as well as the very sudden regression in children\u2019s behaviour, led many parents to believe in the discredited theory of Andrew Wakefield that the MMR (measles, mumps and rubella) vaccine was the cause of autism.\nThe lifetime costs to the UK, which include health, social care and education costs as well as productivity losses, are estimated at \u00a31m to \u00a31.5m per child and between $1.4m and $2.4m in the United States.\nThere are no drugs to treat the condition, which typically sets in around the age of two, and many families have tried intensive training of their children by therapists, with mixed results.\n\u201cThis is not a cure, in the sense that the children who demonstrated improvements will still show remaining symptoms to a variable extent, but it does suggest that working with parents to interact with their children in this way can lead to improvements in symptoms over the long term.\u201d\n\nThe trial involved 152 children aged two to four.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article leads the reader to conclude that the training program is a \u201cpotential breakthrough\u201d but says nothing about a) how many children would qualify for this training program in the UK; b) whether there are enough trainers; or c) how or when people inside or outside the National Health Service can find the program and sign up.", "answer": 0}, {"article": "The study was funded in part by National Cancer Institute grant P01 CA021239.\n\"Our results indicate that proton therapy maintains excellent cure rates in pediatric medulloblastoma while reducing long-term side effects, particularly in hearing and neurocognitive function, and eliminating cardiac, pulmonary, gastrointestinal and reproductive effects,\" says Yock, who is an associate professor of Radiation Oncology at Harvard Medical School.\nIn contrast to photon radiotherapy, in which a dose of radiation is delivered all along the x-ray beam as it passes through a patient's body, in proton therapy the dose is precisely focused on the target area with little or no dose delivered to normal tissues in front of or behind the tumor.\nThe use of proton radiotherapy to treat the most common malignant brain tumor in children is as effective as standard photon (x-ray) radiation therapy while causing fewer long-term side effects such as hearing loss and cognitive disorders, according to a study receiving online publication in Lancet Oncology.\nThe paper from a team led by Massachusetts General Hospital (MGH) investigators describes patient outcomes an average of seven years after proton therapy for medulloblastoma, a fast-growing tumor that develops in the cerebellum at the base of the brain.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that the therapy is not widely available and not often used. The first quote says, \u201cProton radiotherapy is still not widely available in the U.S. or around the world, but it is increasingly recognized for its potential to reduce the side effects of treatment, particularly in the pediatric population.\u201d", "answer": 1}, {"article": "According to lead study author Felicia Cosman, MD, osteoporosis specialist and Medical Director of the Clinical Research Center at Helen Hayes Hospital, Senior Clinical Director of the National Osteoporosis Foundation and Professor of Medicine at Columbia University, who is a consultant to Radius Health, Inc., in Waltham, Massachusetts, \"Abaloparatide-SC increased bone mineral density in both the spine and hip and reduced the risk of vertebral and nonvertebral fractures consistently in postmenopausal women with osteoporosis regardless of their baseline patient characteristics, including age, bone mineral density, and whether or not they had prior fractures.\"\nThe data suggest that abaloparatide appears to be an effective treatment for a broad group of postmenopausal women with osteoporosis.\nThe drug also reduced major osteoporotic fractures by 55% compared with teriparatide and increased bone density to a greater extent in the hip region compared with teriparatide.\nThe Society, which is celebrating its centennial in 2016, has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries.\nThe study was funded by Radius Health, Inc.\n\nEndocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the drug is investigational which signifies it is not yet FDA approved and that the study was a phase 3 study.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Despite recent debate about how well antidepressants really work in people with only mild or moderate depression, a new analysis of drug studies suggests they may have some benefit across the board.\nAbout 9,000 participants were included.\nThe benefits were seen regardless of how severe patients\u2019 symptoms were before starting treatment.\n\u201cDefinitely it doesn\u2019t look like antidepressants are placebos,\u201d he concluded.\n\u201cMore than 80 percent of the patients are not getting a significant benefit from the drug \u2014 either they\u2019re not getting better or they would get the same benefit with placebo,\u201d he told Reuters Health.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of antidepressants was not in question.", "answer": 2}, {"article": "The electronic nose detected nearly 90 percent of people with asthma compared to about 70 percent who were accurately diagnosed in the traditional way with lung function tests, according to new research published in the April issue of the journal Chest.\nThe Italian researchers wanted to compare the electronic nose to the other commonly used tests -- spirometry and FENO -- to see which test was best at confirming a diagnosis of asthma.\nWhen the electronic nose and FENO were combined, the two tests together correctly identified almost 96 percent of the asthma cases.\nWhen combined with another test, called the fractional exhaled nitric oxide (FENO) test, the electronic nose did an even better job at detecting asthma, the study found.\nThis test seems relatively easy for patients and it does have potential, but they've only looked at a very narrow collection of people who have allergic asthma.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story never explicitly states that the device being discussed is experimental, comments from the experts make it pretty clear that the technology\u00a0is still in development.", "answer": 1}, {"article": "\u201cBut this is a small study, a proof of concept.\n\u201cWe can\u2019t yet say that this study means that DHEA is a viable alternative to HRT, but ... we should be looking to do larger studies to confirm these initial results.\u201d\n\nDHEA, or dehydroepiandrosterone, is a natural steroid hormone mostly made in the adrenal glands and has a variety of therapeutic uses.\nAt the start of the trial, all groups had similar sexual activity, but after the year, those taking calcium and vitamin D scored an average of 34.9 on the questionnaire scale, while those taking DHEA had a score of 48.6, showing that those on DHEA had more sexual interest and activity.\nLONDON (Reuters) - A hormone called DHEA and mostly secreted by the adrenal glands may be able to help women who are going through menopause and could also give them better sex lives, a study found on Tuesday.\nHRT, which is a combination of the hormones oestrogen and progesterone, is an approved treatment for women going through the menopause, who often experience unpleasant symptoms such as hot flushes, night sweats, loss of sex drive and mood swings.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability is implied, but the story could have been more explicit about how readers might purchase the specific drugs that were studied or whether they were in specific trial stages for this type of treatment. In fact, tibolone is not available in the U.S. though it is available in Europe.\u00a0 DHEA is sold as a supplement over the counter.\n\u00a0", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Considering having a surgeon remove your cancerous prostate using a robot?\nAnd while the robot-assisted operation is now the \u201cdominant approach\u201d to this surgery in the US and is gaining popularity in other wealthy nations, there\u2019s still too little information on how patients fare after the surgery, Dr. Declan G. Murphy of the Peter MacCallum Cancer Center in Melbourne, Australia and his colleagues write.\nThe researchers also found that surgeons who have done fewer than 20 of the robot-assisted procedures can achieve \u201cacceptable operating times.\u201d Keeping surgeries shorter is a goal because it usually means fewer complications.\nAlso, the researchers add, robot-assisted surgery is no easier to perform and has no better outcomes in patients with conditions that can worsen surgical outcomes, such as being obese, having a large prostate, or having had previous surgery in the area.\nIt may be necessary, however, for surgeons to do 80 or more procedures to ensure that they do not leave cancerous tissue behind.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story mentioned that robotic prostatectomy was the \u2018dominant approach\u2019 to this procedure in the United States.\u00a0 But that is an erroneous statement by the physician who is from Australia. It is certainly booming in popularity, but that doesn\u2019t make it the dominant approach. ", "answer": 0}, {"article": "\u201cIt provides more scientific believability that something in the brain, at a very biological level, seems to be affected by this probiotic.\u201d\n\nNo serious side effects related to the probiotic were reported, suggesting that such a supplement could be a safe way to treat both stomach- and mood-related symptoms.\nThose changes in brain activity \u201csupport the notion that this probiotic has anti-depressive properties,\u201d the authors wrote in their paper.\nThey were followed for 10 weeks; half took a daily dose of the probiotic , and half took a placebo.\nAfter six weeks, twice as many people who took the probiotic had decreased depression scores compared to those who took the placebo: 64% versus 32%.\nWhen people in the study were given functional MRI scans, the researchers found that improved depression scores were associated with changes in activity of several brain areas involved in mood regulation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although it appears close to\u00a0the end, the story does state that the probiotic used in the study is not commercially\u00a0available.", "answer": 1}, {"article": "Male infertility has a range of root causes, from low or abnormal sperm production to blockages to illness.\nThe app is similar to a fitness tracker, in a sense, in that it stores any history of previous semen samples as well.\nThe app\u2019s user experience is hard to forget: users can see vivid moving images of their sperm right on the screen.\nThe researchers tested the device on 350 clinical semen specimens in Massachusetts, including both trained and untrained users in their trial.\nThat\u2019s the question researchers at Brigham and Women\u2019s Hospital and Massachusetts General Hospital tried to answer when they went about developing a smartphone-based test that men could use to test their semen in the comfort of their homes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers are told the device is only in a prototype stage, implying it\u2019s not yet for sale. More details could have been provided, but this is sufficient for a satisfactory rating.", "answer": 1}, {"article": "PROVIDENCE, R.I. [Brown University] -- New results from a clinical trial involving more than 900 military veterans at high risk for keratinocyte carcinoma skin cancer provides evidence that using the generic skin cream fluorouacil 5 percent for two to four weeks may reduce the risk of a squamous cell carcinoma (SCC) needing surgery by 75 percent within a year.\nThe cream does have common side effects including reddened, more sensitive and often crusty skin, effects that resolve when the application of the cream stops, Weinstock acknowledged.\nBut in the new study, 5-FU appeared to provide prolonged protection after discontinuation and could be combined with sunscreen, Weinstock said.\nBut after six months and again at the end of the four-year trial, 87 percent of participants in the 5-FU group said they'd be willing to repeat the treatment if it proved effective in reducing skin cancer.\nThe experimental and control groups were very similar along all other measured characteristics, including their self- reported degree of prior sun exposure and sunburn.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the cream, available as a generic, has been used to treat other conditions. That suggests the cream is widely available.", "answer": 1}, {"article": "So, should we be referring to physical therapists, osteopaths or chiropractors from the ER?\"\nParticipants were instructed to do the exercises six to eight times per day.\nNeck pain is an extremely common problem.\nThe goal of the home-exercise program was to improve movement in the neck area.\nThe third group was assigned two one-hour sessions of home exercise.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that all of the treatments included in this trial are widely available.", "answer": 1}, {"article": "Results from a pivotal study of the treatment were reported today in the American Heart Association (AHA) journal Circulation Research.\n\"These are patients who have been on drugs and may have had multiple angioplasties or CABG surgeries,\" AHA President Gordon Tomaselli, MD, tells WebMD.\n\"Coronary artery disease involves not only the blockage of major arteries, but the death of small vessels, or capillaries, of the heart muscle,\" he says.\nJuly 7, 2011 -- An experimental therapy involving stem cell injections from the patient's own blood is showing promise in the treatment of people with chest pain that is not responsive to drugs, angioplasty, or surgery.\n\"Their activities are severely restricted by their chest pain and right now we have little to offer them.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story calls the approach \u201cexperimental\u201d\u2026says Phase III studies are planned\u2026and ends with \u201cthe next step is to prove the treatment is clinicallly useful.\u201d", "answer": 1}, {"article": "While the new study results do seem to advocate for testosterone replacement therapy, Barua stresses the need for \"appropriate screening, selection, dosing, and follow-up of patients to maximize the benefit of testosterone therapy.\"\nAccording to the FDA, \"Testosterone products are FDA-approved only for use in men who lack or have low testosterone levels in conjunction with an associated medical condition.\nFor example, the new VA study excluded men with a history of heart attacks or strokes, although it did include those with existing heart disease.\n\"Patients who failed to achieve the therapeutic range after testosterone replacement therapy did not see a reduction in [heart attack] or stroke and had significantly less benefit on mortality.\"\n... None of the FDA-approved testosterone products are approved for use in men with low testosterone levels who lack an associated medical condition.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that testosterone therapy is available to patients.\u00a0 The narrative does go to the trouble of noting that \u201coff-label\u201d use of testosterone is a no-no.", "answer": 1}, {"article": "\"The arthritis was so bad that I could barely step down without severe pain.\u201d\n\nBecause she wasn\u2019t eligible for a knee replacement she tried cortisone injections, physical therapy, medications \u2014 nothing relieved her pain.\nRecovery time is minimal, with most patients walking immediately after the procedure and resuming normal activities in a day or two.\n\"I thought I was going to limp for the rest of my life,\" she said.\n\u201cI couldn't even imagine first of all, not having the pain,\" she said.\n\u201cI had inflammation, swelling, and my knee was like the size of a golf ball, McCloden told NBC News.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Recent approval by the Federal Drug Administration means that the technique is not yet widely available, the story notes.", "answer": 1}, {"article": "Medical-device makers, venture capitalists and surgeons are racing to turn a once-controversial weight-loss procedure into the next big thing in elective surgery.\n\nOnce dismissed by some surgeons as a gimmick, gastric banding -- in which a silicone band is wrapped around the upper stomach to restrict food intake -- is now the focus of a fierce competition pitting consumer-products giant Johnson & Johnson against Botox maker Allergan Inc. Venture-capital-backed outpatient centers are popping up to implant the bands. Growing...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story provided a very complete discussion about the various venues at which gastric banding was available.", "answer": 1}, {"article": "In contrast, the risk of failure among recently recalled defibrillators has been estimated by the manufacturers at just 0.009 percent to 2.6 percent.\nAnd not every failure is deadly.\nAbout 80,000 patients received the implantable devices in 2004.\nSome patients \"might want to hang out and wait and see what happens,\" Krahn said.\nA new Canadian study provides the first estimate of the risk of major complications from replacement surgery, important information for patients facing the choice.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the article that defibrillators are available.", "answer": 1}, {"article": "\"Fasting seems to be the most beneficial for patients who have the great risk factors for disease, such as those who have high blood pressure or pre-diabetes or who are obese,\" Longo said.\nOne hundred people participated in the trial from April 2013 to July 2015.\nThe researchers had invited participants in the study for one last set of tests three months later, at the end of the diet.\nThe research team found that the beneficial effects -- from weight loss, smaller waistlines and lower glucose, blood pressure and IGF-1 levels -- were sustained.\nIn effect, the diet reduced the study participants' risks for cancer, diabetes, heart disease and other age-related diseases, according to the findings published Feb. 15 in Science Translational Medicine.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not explain whether materials used in the clinical study are widely available. The product website, however, is actively promoting the kits.", "answer": 0}, {"article": "LONDON (Reuters) - A protein in urine could be a strong indicator of prostate cancer risk, according to British scientists who say their findings could one day be developed into a quick and simple test for the disease.\nIn Britain, around 35,000 men are diagnosed with it and some 10,000 die from the disease.\nCommenting on the study, Kate Holmes of the UK\u2019s Prostate Cancer Charity, said they could prove very valuable in future.\nThe scientists took tissue and urine samples from around 350 men both with and without prostate cancer to test MSMB levels.\nProstate cancer killed an estimated 258,000 men around the world in 2008 and is the second most common cause of cancer death in men in the United States.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story was clear that the MSMB test reported on is investigational and not currently available.", "answer": 1}, {"article": "After a series of tests, the doctors made a shocking discovery.\nWhen they would open me up [the aorta] could just blow.\u201d\n\nThe bulge in the large artery that carries blood away from the heart can be immediately life-threatening if it grows large enough to rupture.\nWe can anticipate challenges by practicing the procedure beforehand.\u201d\n\nSo far doctors at Mayo Clinic have done this personalized procedure on more than 450 patients.\n\"The use of 3-D printing to personalize aortic repair is fascinating,\" said Dr. Ramesh Gowda, director of interventional cardiology at Mount Sinai Beth Israel.\nIf an AAA is found, doctors sometimes use a stent to repair the aorta, but it doesn't always work since the aneurysms are often in places where a stent can\u2019t fit.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states: \u201cSo far doctors at Mayo Clinic have done this personalized procedure on more than 450 patients. They are now training doctors nationally.\u201d It\u2019s not clear how many doctors are being trained.\nAlso, we\u2019re assuming they\u2019re referring to the 3-D printing aspect of this procedure. But regarding the endoscopic procedure, it\u2019s not clear how widely available it is. It\u2019s also not clear if this custom-printed device is\u00a0still being tested in clinical trials.", "answer": 0}, {"article": "Antioxidants neutralize unstable forms of oxygen called reactive oxygen species that can damage cells throughout the body.\nIt is unlikely that people could get too much vitamin E from food.\nHowever, the new study followed participants for a longer period than most previous studies on antioxidants and dementia.\nAnd clinical trials looking at the effects of antioxidant supplements have found no evidence that they cut Alzheimer\u2019s risk.\nOf the third with the lowest intakes, 164 were diagnosed with dementia.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story provides a list of foods that are rich in this micronutrient.", "answer": 1}, {"article": "For more information about Hebrew SeniorLife, visit http://www.\nBased in Boston, the non-profit, non-sectarian organization has provided communities and health care for seniors, research into aging, and education for geriatric care providers since 1903.\nThe Institute carries out rigorous studies that discover the mechanisms of age-related disease and disability; lead to the prevention, treatment and cure of disease; advance the standard of care for older people; and inform public decision-making.\n\"We found that that the presence of calcifications increased the likelihood of having cardiovascular disease such as heart attacks, and even the likelihood of cardiovascular deaths and mortality in general.\"\n\"Our study highlights the fact that having a bone density test not only tells women about their risk of fracture, but also their long term risk for cardiovascular disease.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that bone density scanning is routinely used to diagnose osteoporosis and presumably it is widely available. What is not clear is whether bone density scanning to determine the degree of aortic calcification is generally available.", "answer": 0}, {"article": "Tomei, a self-proclaimed animal lover, expressed that the effort is close to her heart.\nSometimes, individuals with CDE have trouble opening their eyes, but Tomei said she went to the doctor and reported mild but incessant itchiness and dryness, and was diagnosed with CDE.\n\u201cIt was as simple as going to the doctor, getting a prescription and trying RESTASIS\u00ae,\u201d Tomei, 51, who stars in the upcoming \u201cSpider-Man: Homecoming\u201d movie, told FoxNews.com.\n\u201cA whole world of freedom opens up [for these individuals] because you can move about a city like this (New York City) or anywhere much more easily, and the dogs can become your eyes,\u201d she said.\nIf you think you may be suffering from CDE, Tomei advised visiting your doctor to receive a diagnosis.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s available and as \u201csimple as going to your doctor,\u201d according to the celebrity spokesperson. (But as we discuss in the Costs criterion, it\u2019s not free nor necessarily covered by insurance.)", "answer": 1}, {"article": "Depression affects about 20 percent of people at some point in their lives.\nHONG KONG (Reuters) - Boosting the effect of acupuncture needles with small electric currents may be effective in treating depression, a study in Hong Kong has found.\n\u201cWhen the acupoints are stimulated, some brain centres responsible for producing serotonin are stimulated,\u201d explained Ng, a consultant at the department of psychiatry at the Kowloon Hospital in Hong Kong.\n\u201cThe drop (in depression scores) among the group receiving active treatment was more significant than the placebo group,\u201d said Roger Ng, another researcher in the group, which published their findings in the journal PLoS (Public Library of Science) ONE.\nHalf the patients received electroacupuncture nine times over three weeks, while the other half - the placebo group - only had needles inserted superficially into their heads.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There was no explanation of the availability of electroacupuncture. This is certainly an important issue in the USA, which is where we \u2013 and presumably many other readers \u2013 found the story online.", "answer": 0}, {"article": "The essential tremor research has been supported by InSightec, the Focused Ultrasound Foundation and the BIRD (US-Israel Binational Industry Research and Development) Foundation.\nNot only did the researchers determine that the procedure was safe and effective, they found that it offered a lasting benefit, reducing shaking for trial participants throughout the 12-month study period.\nThe site includes a list of frequently asked questions and will be updated as UVA prepares to make the treatment available.\nThe most commonly reported side effects were gait disturbances and numbness in the hand or face; in most instances, these side effects were temporary but some were permanent.\nIt can\u2019t be used in patients who cannot undergo MRI imaging, including those with implanted metallic devices such as a pacemaker.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is clear in that the medical center is preparing to make the procedure available to qualified patients but it certainly is not available to the public at this time. It also mentions the uncertainty of insurance coverage.", "answer": 1}, {"article": "Back in April the WSJ wrote about the race to develop ways of detecting Alzheimer\u2019s disease using a brain scan. Currently only a post-mortem sampling of brain tissue can provide a definitive diagnosis. But the hope is that a technology that could be used in living patients could help rule out Alzheimer\u2019s in some patients and for those that have the disease, allow its \u2026", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0This story mentioned that the company producing the labeling compound would be applying for FDA approval this year.\u00a0 ", "answer": 1}, {"article": "TUESDAY, March 13, 2018 (HealthDay News) -- A pill that combines three blood pressure-lowering drugs improves people's chances of lowering their high blood pressure, researchers report.\nThe rate of side effects was no greater among those who took the three-in-one pill than among the usual care group.\nThe findings, she said, \"should prompt reconsideration of recommendations around the use of combination therapy.\"\nThe finding stems from a study of 700 people, who averaged 56 years old.\nUsual care meant taking whatever blood pressure medicine their doctor prescribed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t explain where or even whether the \u201ctriple pill\u201d is available.\u00a0", "answer": 0}, {"article": "TUESDAY, June 5, 2012 (HealthDay News) -- A simple blood test may help gauge prognosis and tailor treatments for women who have been diagnosed with early stage breast cancer.\n\"The cells also need to have a propensity to grow elsewhere,\" she said.\nCommenting on the findings, Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, said, \"We are moving into a state where we're looking at a person's individual tumor and this is another way to do that, potentially leading to treatment.\"\nEven so, a substantial number of patients whose cancer has not spread to the lymph nodes will have a recurrence while some of those who do have lymph-node involvement won't relapse.\nThe problem is that just having circulating tumor cells may not be enough information to foretell the future, she noted.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "No information about the availability of the blood test is given.\u00a0 There\u2019s only the line about \u201cmay not be far off in terms of clinical practice.\u201d\u00a0 But readers might not pick up on that subtle note.", "answer": 0}, {"article": "For the really Type A personality, here's a chance to measure how well you are relaxing. Makers of home biofeedback devices that monitor your heart rhythms say the devices teach you to combat emotional stress. Psychologists and psychiatrists say the gadgets appear to help their stressed-out patients but warn that there isn't yet strong scientific evidence that they work.\n\nBiofeedback has long been used to treat stress in psychologists' offices -- with an expert who leads the patient in relaxing breathing exercises and...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that these devices are available and from which manufacturers.", "answer": 1}, {"article": "In 37 years as a police officer, Edwin Michel coped with a plane crash, a sniper, wildfires and three bullet wounds.\n\nNothing much rattled him until he was diagnosed with prostate cancer in November 2016. His doctor said the cancer wouldn\u2019t kill him but Mr. Michel, now 76 years old, wasn\u2019t entirely reassured. He felt more confident after a genomics test later revealed his prostate cancer was very low risk. The test, known as Oncotype DX, takes a sample from a prostate biopsy and analyzes 17 genes in it to estimate how aggressive...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that these genetic tests are currently available.", "answer": 1}, {"article": "\"Unfortunately, the majority of society looks at infertility as a women's issue, but that's just not the case,\" said Brad Imler, American Pregnancy Association president.\nThe result showed that the father of four's sperm count was below the test's threshold.\nI was really glad that the test was not ambiguous at all,\" she said.\nThe male reproductive system should not be oversimplified, Brannigan said.\nThis test, which is noninvasive, could be wake-up call for some.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the test is new to the market but now available in retail stores.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Botox injections may provide some relief from arm tremors caused by multiple sclerosis, according to a small study published Monday.\nThe study\u2019s lead researcher agreed on the need for more work.\nAnother question is whether the side effects change over time.\nLarger studies, of more-diverse groups of MS patients, are needed, he said.\nBotox gained fame for smoothing aging skin \u2014 by blocking nerve signals and relaxing muscles under the skin \u2014 but the product has a number of medical uses.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of Botox was clear in the story.", "answer": 1}, {"article": "WASHINGTON (Reuters) - An experimental drug being developed to fight influenza may fight a common but little-known virus called parainfluenza virus, researchers and the company said on Friday.\nThere is no treatment or vaccine for parainfluenza.\nAnd infection in rats does not follow the same disease course as in humans.\nAdding parainfluenza to its approved indications would provide a unique and potentially large market for San Diego-based NexBio.\nFludase is already in phase 2 clinical trials for use against influenza.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "       \n \nThe story makes it clear that this drug is not yet available. \n ", "answer": 1}, {"article": "Researchers are developing decision aids to guide physicians and consumers beginning to struggle with lung cancer screening.\nResearchers call it \u201ccompeting mortality.\u201d Finding lung cancer is a hollow victory if patients endure testing and treatment, then die of another illness before the cancer would have killed them.\nAmong the 65- to 74-year-olds getting CT scans in the national trial, moreover, many had other serious health problems \u2014 heart disease, diabetes, hypertension, pulmonary disease \u2014 which probably contributed to only 55 percent surviving five years, compared with 64 percent among those under age 65.\nThe post-surgical death rate in the national trial was just 1 percent, but that involved major medical centers with specialized radiologists and surgeons \u2014 the ideal setting.\n\u201cThe only way to prevent lung cancer or reduce your risk,\u201d Dr. Gould said, \u201cis to stop smoking.\u201d\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The issue of interest here is whether low-dose CT scans are available for older, heavy smokers to screen for lung cancer. While this is satisfactorily addressed (it\u2019s the main topic of the story), it isn\u2019t entirely clear from the story if screening has actually begun or when it will. Programs to do the shared decision-making for Medicare patients haven\u2019t been established and Medicare hasn\u2019t yet released codes for billing for the initial visit where the issue is reviewed. It\u2019s also unclear if commercial insurers are covering and for whom.", "answer": 1}, {"article": "He was fascinated by certain powerful cells of the immune system \u2014 T cells.\nStill, the approach offers promise to some people that other therapies can't, and has transformed the way doctors think about cancer treatment.\nThe company had recently developed technology that could make a human version of Allison's therapy, and was willing to give it a try.\nThough the research scientist couldn't imagine why Wolchok was in such a rush, he quickly figured it out as he opened the door and was greeted by Belvin with a huge hug.\nEach case is different, and using a patient's own cells to destroy tumors won't work in every patient or in every type of cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that ipilimumab is currently available for clinical use, marketed under the name Yervoy.", "answer": 1}, {"article": "Dozens of biotechnology and pharmaceutical companies including Alnylam, Merck, Pfizer, Novartis and Roche are looking for ways to manipulate RNA to block genes that make disease-causing proteins involved in cancer, blindness or AIDS.\n\u201cThis is the first study to be able to go in there and show it\u2019s doing its mechanism of action,\u201d said Mark Davis, a professor of chemical engineering, who led the study.\n\u201cWhen it recognizes that it\u2019s gone inside the cell, it says OK, now it\u2019s time to disassemble and give off the RNA.\u201d\n\nIn a phase 1 clinical trial in patients with various types of tumors, the team gave doses of the targeted nanoparticles four times over 21 days in a 30-minute intravenous infusion.\n\u201cWe\u2019re excited about it because there is a lot of skepticism whenever any new technology comes in,\u201d said Davis, a consultant to privately held Calando Pharmaceuticals Inc, which is developing the therapy.\nThe finding, reported in the journal Nature on Sunday, offers early proof that a new treatment approach called RNA interference or RNAi might work in people.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "An astute reader can probably figure out that this experimental approach isn\u2019t available yet.\u00a0 But the story never really says that.\u00a0 Instead, rather than calling it an \"experimental approach,\" the story calls it a treatment approach.\u00a0 We think the semantics are important.\u00a0 It\u2019s not a treatment yet.\u00a0 It\u2019s an experiment. ", "answer": 0}, {"article": "Severely premature babies are more likely to live if they receive intensive-care treatments rather than palliative care to keep them comfortable, according to a U.S. government-funded study published Thursday.\n\nWhether babies born at the extreme edge of viability, generally considered to be 22, 23 or 24 weeks of gestation, should be aggressively medically treated is a controversial issue among pediatric experts. These infants often don\u2019t survive and, even if they do, many have substantial long-term health problems.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t touch on availability, but availability isn\u2019t really an issue here. The babies received various treatments at different hospital centers. Active interventions ranged from ventilation and chest compressions to intubation.", "answer": 2}, {"article": "Wu recommended that women who are thinking about becoming pregnant should \"start prenatal vitamins and DHA supplements about three months before pregnancy and then continue them throughout the pregnancy.\nThe babies were assessed at 1, 3 and 6 months of age, and the mothers completed questionnaires about their babies' health.\nAlso at 1 month, babies whose mothers had gotten the DHA supplement had 26 percent shorter duration of cough, 15 percent less time with phlegm and 30 percent shorter duration of wheezing.\nDr. Jennifer Wu, an obstetrician and gynecologist at Lenox Hill Hospital in New York City, said, \"We've been recommending DHA intake in pregnant women for brain and nervous system development, and this study suggests another good reason to take DHA.\"\nAt times, however, babies in the DHA group experienced longer duration of rashes and vomiting, the study authors noted.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story never did explicity state whether the product used in the study was generally available or not. One might be able to assume that it is, but it would have only required a line in the story to address availability and how widespread is its use.", "answer": 0}, {"article": "Most angioplasties not necessary, study finds\n\nNEW ORLEANS \u2014 More than half a million people a year with chest pain are getting an unnecessary or premature procedure to unclog their arteries because drugs are just as effective, suggests a landmark study that challenges one of the most common practices in heart care.\nAlso, the clogs treated with angioplasty are not the really dangerous kind.\nA tiny balloon is inflated to flatten the clog and a mesh scaffold stent is usually placed.\nIn the study, only one-third of the people treated with drugs ultimately needed angioplasty or a bypass.\nThey had an average of 10 chest pain episodes a week \u2014 moderately severe.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story reported on a comparison of treatments for coronary artery disease that are used widely and described them as such.", "answer": 1}, {"article": "Coffee or tea?\nIt is high in polyphenols--compounds with strong antioxidant activity that in test-tube and animal models show anticancer and heart-protective effects.\nThere's a growing body of research to suggest that both are probably good for you.\nGood clinical studies are few, however, and although I and other physicians tell our patients to drink green tea, there hasn't been any definitive proof of the value of that advice.\nWe've heard a lot about the health benefits of tea, especially green tea.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article discusses differences in the green tea typically available in Japan and in the United States and offers suggestion sabout where Japanese green tea can be obtained. But the suggestion that the results of the study derive only from Japanese green tea and not green tea available in the US is not justified by the study cited.", "answer": 1}, {"article": "This practice isn't totally harmless.\n\"Clinical enthusiasm for supplemental vitamin D has outpaced available evidence on its effectiveness,\" JoAnn E. Manson and Shari S. Bassuk of the Division of Preventive Medicine at Brigham and Women's Hospital in Boston wrote last week in the journal's online version.\nYou should be consuming 600 international units daily if you're between the ages of 1 and 70, and 800 IU each day if you're 71 or older, according to the Institute of Medicine, the health arm of the National Academcy of Sciences.\nThese amounts are enough for 97.5 percent of U.S. and Canadian residents, according to the IOM.\nBut somehow we've arrived at a point when some physicians are prescribing large doses of Vitamin D supplements for their patients in the hope of preventing cancer, cardiovascular disease, diabetes, autoimmune disorders and other maladies, despite a lack of evidence that this works, according to a new commentary in the Journal of the American Medical Association.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t go into this, but it doesn\u2019t really need to. Vitamin D supplements are available online and have long been available in many grocery, drug, and health stores. We\u2019ll rate it not applicable.", "answer": 2}, {"article": "He presented the findings here at the annual meeting of the American Academy of Dermatology.\nResearchers used a ''microfocused\" ultrasound to target the sweat glands in 14 men and women, aged 18 to 75, says Mark Nestor, MD, PhD, a dermatologist and voluntary associate professor of dermatology at the University of Miami Miller School of Medicine.\nThe sweating can occur even when the temperature is cool and the person is at rest.\n\"Microfocused ultrasound appears to be effective and safe in the treatment of hyperhidrosis,\" Nestor says.\nThe armpits, palms, and soles are often affected.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story never does state the availability of the technology for people with hyperhidrosis.\u00a0 It does state that the FDA has approved it for eyelid lifts.\u00a0 Are many dermatologists (or others) trying it for hyperhidrosis?\nA simple few additional words would have clarified the issue.", "answer": 0}, {"article": "The Site is down for maintenance.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The experimental nature of the drug was clear in the story.", "answer": 1}, {"article": "Now Dr.\nIn the four-month study, the group randomly assigned to receive intranasal insulin twice a day either improved slightly or remained the same in tests of memory and assessments of their ability to handle day-to-day activities.\nOne hallmark of Alzheimer\u2019s disease is reduced metabolism in the brain, which shows up on scans as less use of glucose, the fuel for brain cells.\nFor years, the study\u2019s principal investigator, Suzanne Craft, has studied insulin\u2019s effects in Alzheimer\u2019s.\nAnd conditions in which the body makes too little insulin or is resistant to its effects \u2014 diabetes, prediabetes, even untreated high-blood pressure \u2014 are associated with an increased risk of Alzheimer\u2019s.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that this treatment is experimental and\u00a0that the\u00a0device used to administer insulin deep inside the nose is not on the market. It urges readers not to rush out and take\u00a0insulin for the\u00a0treatment of Alzheimer\u2019s\u00a0disease.\u00a0The story closes with\u00a0the implied promise of a larger study in which \u201cmany\u201d people might have access to the intranasal insulin therapy, which sets an overly optimistic tone. Only a small\u00a0fraction of people who might benefit from this therapy will be eligible to participate in any future studies.\u00a0On the whole, though,\u00a0the story\u2019s message on availability is correct and\u00a0merits a satisfactory.", "answer": 1}, {"article": "Predefined analyses showed significant differences between active and control study groups for hippocampal and whole-brain atrophy, and favourable effects for CDR Sum of Boxes and episodic memory (both were most pronounced in patients with high baseline cognition with regular intake).\nThe initiative benefits from funding provided by the 7th Framework Programme (FP7- 211696) of the European Commission, and follows on from previous projects in the field of dementia.\nSince its establishment, evidence has been accumulated to support the hypothesis that certain nutritional molecules are beneficial in reducing disease progression in Alzheimer's.\nSouvenaid is backed by 16 years of extensive research, based on initial preclinical research by Prof. Kiliaan (Radboud University, the Netherlands), by the LipiDiet project, coordinated by Prof. Hartmann (Saarland University, Germany) and funded by the European Union FP5 research programme and by Prof. Wurtman (formerly at the Massachusetts Institute of Technology, U.S.A) supported principally by the National Institutes of Health.\nThe primary outcome parameter was selected to assess the effect on cognitive function (a broad measure of thinking) during 24 months intake of Fortasyn Connect compared with a control product.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t state whether the product is available in the United States. It is not. However, the product is marketed widely in Europe under the brand name Souvenaid.", "answer": 0}, {"article": "Results of the vaccine were not as good in the other 25 patients.\nAs exciting as that is, he says, \"a lot of work needs to be done to prove whether this can be effective [for more patients].\"\n\"It gives us encouragement that we may be on to something here.\"\n\"In January, it will be four years [for her],\" he tells WebMD.\nNov. 8, 2011 -- A vaccine for breast and ovarian cancer that has spread to other parts of the body shows promise, according to a preliminary study of 26 patients.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We give high marks to the story for saying right in the lead that the findings are from \u201ca preliminary study in 26 patients.\u201d That tells readers both that the findings need to be interpreted with caution and that the treatment is not available to most people.", "answer": 1}, {"article": "Revenues from pharmaceutical and device corporations are available at http://www.\n\u2022 Available downloadable B-roll, animation and images to this news tip are on the right column of the tip link https:/\n\u2022 For more news at AHA International Stroke Conference 2018, follow us on Twitter @HeartNews #ISC18.\nIn the current analysis of treatment between 6 and 24 hours after symptoms were observed, or after the person was last seen to be well, researchers found:\n\u2022 each 1-hour delay reduces the chance of recovery with minimal or no disability by 11 percent; and\n\u2022 treatment remains beneficial through 24 hours, with patients who had their clots removed being 35.5 percent more likely to have minimal or no disability 90 days later, but the overall effect of treatment declines with time.\nThe international DAWN trial previously demonstrated that patients with a small area of irreversible brain damage and a large area of brain at jeopardy of being lost if the clot remains are more likely to recover with minimal disability if the clot is removed up to 24 hours after symptoms begin or were noticed.\nIt is already well-established that the benefit of clot removal declines each hour during the first 6 hours after symptoms are detected.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Unfortunately, this news release did not mention that the results from the DAWN trial contributed to updated guidelines for treatment issued by the AHA and the ASA. While thrombectomy after a stroke is already practiced in many larger centers across the country, it is unclear whether this treatment \u2014 actually an expanded indication for an existing treatment \u2014 will now be offered in more hospitals as a result. The release should have addressed that issue as well as described where the procedure is currently offered.", "answer": 0}, {"article": "Bristol-Myers Squibb\u2019s closely watched biotechnology drug ipilimumab, which enlists the help of the immune system to attack tumors, was found generally safe and showed signs that it was working on tumors in the brain, which are especially difficult to treat.\n\u201cThese findings may have implications for the use of ipilimumab therapy in the long-term management of advanced melanoma,\u201d the researchers reported in the abstract.\nThe responses lasted from three to 12 months, and patients had no serious toxic side effects.\nAll of the treatments appeared safe.\nData from a second arm of the study is still being evaluated.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story notes the drug is experimental. ", "answer": 1}, {"article": "A type of sleeping pill that several major pharmaceutical companies are racing to develop received good news yesterday when Swiss biotech company Actelion Ltd. reported positive clinical data.\n\nSleep experts say the drug class needs further study but could potentially offer some benefits beyond Ambien, the top-selling drug in the $3.8 billion global market for sleeping pills. While Ambien and similar drugs, called nonbenzodiazepine drugs, are effective and easily tolerated by most people, some insomniacs don't respond to the...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While the story did not explicitly state that this drug is not yet available, the first sentence makes it quite clear this drug is still in development and in the process of undergoing clincial trials.", "answer": 1}, {"article": "Side effects from antidepressants can include constipation, diarrhea and dizziness.\n\"Primary care clinicians and their patients may not automatically consider alternatives when discussing treatment,\" said Halle Amick, research associate at the RTI International-University of Chapel Hill Evidence-based Practice Center and lead author.\nHowever, the evidence shows that cognitive behavioral therapy can be just as effective, providing important information for patients and their physicians to consider when choosing among available treatment options.\"\n\"Bringing psychotherapy into discussions of treatment may also enhance coordination of care between primary care and mental health care providers in addition to addressing the issue of patient-centered care,\" Amick said.\n\"If primary care providers discuss psychotherapy with their patients as a valid treatment option, it may empower patients to voice their preferences and truly participate in medical decision-making and encourage them to adopt and adhere to effective treatment of their depression.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "While CBT is in wide use, the release glides over the long wait times even people with health insurance must wait to be matched with a CBT therapist. In some states, the wait can take months. In addition, the release notes that most patients see their primary care physician first. We are unclear on what percentage of primary care physicians are trained in CBT and are willing to offer it.", "answer": 0}, {"article": "EMBARGOED FOR RELEASE: 11 A.M. (ET) TUESDAY, AUGUST 16, 2016\n\nMedia Advisory: To contact Paul D. Miller, M.D., call 303-925-4514 or email millerccbr@aol.com.\nAdditional therapies are needed for prevention of osteoporotic fractures.\n: This study was funded by Radius Health.\nThe trial was conducted at 28 sites in 10 countries.\nOverall, there were no differences in serious adverse events between the treatment groups.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not make it clear whether the drugs being studied are on the market.", "answer": 0}, {"article": "Autism is characterized by difficulties in social interaction, communication, and understanding other people\u2019s emotions and behavior.\n\u201cThese results are the best yet in the search for a biological basis in terms of being able to distinguish those with and without the disease,\u201d said Nicholas Lange of Harvard Medical School, who directs the Neurostatistics Laboratory at McLean Hospital in Belmont, Massachusetts.\n\u201cHowever, it has been shown that in the early stages of development, individuals have been aided by intense one-on-one caring to help them with language, social function with their peers and also with emotional problems,\u201d he said.\nBy measuring six aspects of the brain\u2019s circuitry, the test was able to correctly pick out people who had been diagnosed with autism with 94 percent accuracy.\nCHICAGO (Reuters) - U.S. researchers are closing in on an accurate test for autism, a finding that could lead to earlier diagnosis and treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story includes this odd claim:\u00a0\u201cYou don\u2019t need any fancy equipment. This is performed around the world,\u201d Lange said in a telephone interview.\u00a0Interestingly, neither the actual published study nor the McLean press release provides any explicit information about the MRI scanner used or the way in which its programming may have been altered. And neither does the story. ", "answer": 0}, {"article": "In the study, published in the Annals of Internal Medicine, researchers reviewed 83 studies on the two methods.\nResearchers say needle biopsy has fewer complications and a shorter recovery time than open surgical biopsy, but some women and doctors may have concerns about the accuracy of the procedure compared with traditional open surgery methods of breast cancer diagnosis.\n\"Based on currently available evidence, it appears reasonable to substitute core needle biopsy procedures for open surgical biopsy given the comparable sensitivity and lower complication rates,\" write researcher Wendy Bruening, PhD, of the ECRI Institute Evidence-Based Practices Center in Plymouth Meeting, Pa., and colleagues.\nIn addition, the study showed women initially diagnosed with breast cancer with needle biopsy were more likely to be treated with a single breast cancer surgery than those initially diagnosed by open surgical biopsy.\nBiopsies may be performed via open surgery on the breast or with a less invasive core-needle biopsy in which a small sample of breast tissue from the affected area is removed through a special needle inserted through the skin.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention if all hospitals offer women core needle biopsy as an option prior to, or instead of open surgical biopsy. We are not told if recent evidence has affected clinical guidelines for suggested biopsies following an abnormal mammogram.\u00a0 We are not told that some women may not be appropriate candidates for core needle biopsies.\u00a0 The article notes:\u00a0The location and type of lesion, as well as other medical considerations, sometimes dictate the type of biopsy, but in many cases patient preference is the most important factor in the decision.", "answer": 0}, {"article": "It also allowed patients to reduce their use of antihistamines and other medications.\nThe most common side effects include itchiness and irritation in the mouth, ears and eyes, swelling of the mouth or tongue, headache and gastrointestinal problems like stomach pain and heartburn.\nIn theory, that could pay off if long-term use of allergy medications was cut, but that has yet to be shown.\nStill, Nelson said that if sublingual products do win approval in the U.S., they will likely boost the number of hay fever sufferers who want to use under-the-tongue immunotherapy.\nEven though the effectiveness is less than that of allergy shots, the convenience of an at-home version of immunotherapy is a plus, and the sublingual therapy tends to have fewer side effects than shots, according to Nelson.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>1clip_themedata.thmx\" rel=\"themeData\"/>1clip_colorschememapping.xml\" rel=\"colorSchemeMapping\"/>\n\n\n\n \nThis story makes it clear that sublingual immunotherapy is not available in the U.S.; however, this might have been mentioned sooner in the text.\u00a0\u00a0 \n", "answer": 1}, {"article": "At Cooper, cardiologist Phillip Koren said he and colleagues have used the Lariat on the left atrial appendage of about 10 patients in the last six months. The closure was unsuccessful in a few of those cases, but in those, there have been no strokes, said Koren, deputy director of the Cooper Heart Institute. None of the 10 patients suffered adverse events from the device.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There was ample explanation of the Lariat being available, even though the JAMA study authors recommend that it no longer be used for the purpose of atrial fibrillation surgery. The story also discusses recent FDA approval of the Watchman device.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070715/23knee.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes that American surgeons perform about half a million total knee replacements annually, suggesting that the operation is widely available.", "answer": 1}, {"article": "Almost 20 years ago, Gray studied how babies respond to a heel prick to draw blood, a procedure that screens newborns for genetic disorders.\nIt's not just that mother and baby are together, Gray says, but also that the mother is in some way \"programming the baby, the breathing, temperature and heart rate.\"\nThe baby gets to know their mother immediately, says Dr. Larry Gray, behavioral and developmental pediatrician at Comer Children's Hospital, University of Chicago Medicine.\nIt is as it sounds: Like a kangaroo's pouch, mothers hold their naked newborns on their bare chest for the first few hours of life.\nThis was a \"serendipitous magical finding,\" says Gray, suggesting that skin-to-skin contact acted something like a \"natural incubator.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We would have liked to see more information, such as how widely this approach is used to treat premature infants, and what some of the barriers might be in high-income countries where incubator care has been the norm. For example, how many U.S. neonatal intensive care units incorporate skin-to-skin contact in their care? Which babies don\u2019t or can\u2019t get this kind of care?\u00a0Given how many births are delivered via c-section these days, is kangaroo care an option for these moms?", "answer": 0}, {"article": "\"Migraine is one of the most disabling conditions known to man, but patients need to know that there is hope,\" says Stephen Silberstein, a neurologist at Thomas Jefferson University in Philadelphia and lead author of the guidelines from the American Academy of Neurology and the American Headache Society.\nThe guidelines do not look at the options patients have once symptoms begin.\nThey were presented at an academy meeting and published in the journal Neurology.\nNot everyone with migraines needs prevention medicine.\nStudies find that just 3% to 13% use the treatments.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s apparent from the story that these drugs are widely available.", "answer": 1}, {"article": "For more information, see www.scripps.edu.\nEven if they found a solution to one of those, the organisms would still be killed by the other two.\u201d\n\nTested against Enterococci bacteria, the new version of vancomycin killed both vancomycin-resistant Enterococci and the original forms of Enterococci.\n\u201cMaking this molecule is important, even by the current approach, if the failure of antibiotics continues.\u201d\n\nIn addition to Boger, authors of the study, \u201cPeripheral modifications of [\u03a8[CH2NH]Tpg4]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics,\u201d included first author Akinori Okano and Nicholas A. Isley, both of TSRI.\nThe researchers, led by Dale Boger, co-chair of TSRI\u2019s Department of Chemistry, discovered a way to structurally modify vancomycin to make an already-powerful version of the antibiotic even more potent.\nIn October 2016, TSRI announced a strategic affiliation with the California Institute for Biomedical Research (Calibr), representing a renewed commitment to the discovery and development of new medicines to address unmet medical needs.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release says that \u201cThe next step in this research is to design a way to synthesize the modified vancomycin using fewer steps in the lab, as the current method takes 30 steps. But [lead researcher Dale] Boger calls this the \u2018easy part\u2019 of the project, compared with the challenge of designing the molecule in the first place.\u201d Readers could be forgiven for thinking that this modified antibiotic could be in pharmacies by Christmas. But a lot of work remains to be done, in terms of both additional studies on safety and efficacy and (presumably) finding pharmaceutical industry partners who want to help this discovery move beyond the lab bench. We say presumably, because the release doesn\u2019t address either of these hurdles.", "answer": 0}, {"article": "Wall Street sees denosumab as a potential blockbuster crucial to Amgen.\nThe second study included 1,468 men with prostate cancer at increased fracture risk due to cancer hormone therapy, although 556 dropped out for reasons from side effects and cancer progression to the study being extended from two to three years.\nIn this case, it targets a molecule in bones that drives formation of cells called osteoclasts that break down bone, a strategy that greatly reduces bone loss.\nThat report comes just ahead of a meeting Thursday when outside advisers will weigh the drug's safety and effectiveness and recommend whether to approve it.\nDenosumab would be the first osteoporosis treatment that is such a monoclonal antibody \u2014 a type of immune cell cloned from the same parent cell to bind to a specific substance.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the study drug, denosumab, is not yet approved by the FDA, but indicates that it could be available this fall.", "answer": 1}, {"article": "Bissada is now conducting follow-up research to support the first study's findings.\n\"This study shows that if we treat the gum disease, it can improve the symptoms of prostatitis and the quality of life for those who have the disease,\" said Nabil Bissada, chair of Case Western Reserve's Department of Periodontics and the new study's corresponding author.\nThe researchers reported their findings in the Dentistry article, \"Periodontal Treatment Improves Prostate Symptoms and Lowers Serum PSA in Men with High PSA and Chronic Periodontitis.\"\nTreating gum disease reduced symptoms of prostate inflammation, called prostatitis, report researchers from Case Western Reserve University School of Dental Medicine and the Departments of Urology and Pathology at University Hospitals Case Medical Center.\nThe men were assessed for symptoms of prostate disease by answering questions on the International-Prostate Symptom Score (IPSS) test about their quality of life and possible urination issues.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release suggests that dental care should probably be a routine part of efforts to control prostate disease, but doesn\u2019t address the issue of financial barriers\u00a0to such care, particularly for the uninsured. But we\u2019re inclined to overlook this because of the nature of the study: it\u2019s a pilot; it was designed to add to evidence for a relationship between gum and prostate disease via an inflammatory process; and the dental care involved is widely available and commonly provided to those who have regular dental care.", "answer": 1}, {"article": "He and his colleagues are now planning a multicenter trial of fish oil for the prevention of psychotic illness in 320 at-risk people.\n\u201cAt the moment there\u2019s no state-of-the-art guideline (on) how to treat those people.\u201d\n\nPrescribing antipsychotic medications may be helpful, Amminger added, but these medications have serious side effects, and can also be stigmatizing.\nThe effect of fish oil capsules, Amminger noted, was similar to that seen in two trials of antipsychotic drugs in at-risk individuals.\nTrials of medications for treating mental illness typically don\u2019t include people younger than 18, Amminger noted, while starting minors on these medications is \u201calways very difficult, and always quite controversial.\u201d\n\nBut if future research bears out the current findings, he added, fish oil promises to offer a safe way to help prevent psychosis in at-risk people, and could also potentially be used to prevent or delay the onset of chronic depression, bipolar illness, and substance abuse disorder \u2014 all of which are far more common than psychotic illness.\nFurthermore, only about a third of people at high risk for psychotic disorders will go on to develop full-fledged mental illness in a given year.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not state that\u00a0fish oil/omega-3\u00a0PUFA\u00a0supplements are widely available. But we\u2019re not sure that\u2019s necessary, since most people are probably already aware of this. ", "answer": 2}, {"article": "NEW YORK (Reuters Health) - The inexpensive tests that look for hidden blood in a person\u2019s stool are effective for colon cancer screening, a study out Tuesday confirms.\nImmunochemical FOBT is now largely replacing the older test.\nAnd they can pick from a number of tests that have all been found to cut the risk of dying from colon cancer.\nInfection with H. pylori is associated with increased risks of stomach and throat cancers.\nAdvances in the stool tests in recent years have made them more effective.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that immunochemical FOBT is now largely replacing the older blood stool test.", "answer": 1}, {"article": "Soy may keep breast cancer from coming back\nThose who ate the most were about 11 percent less likely to die.\nThe women had all filled out questionnaires that included details of what they normally ate.\n1 cancer killer across the world.\nThe benefits may go beyond cardiac health,\u201d Patel said in a telephone interview.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of soy foods is not in question.", "answer": 2}, {"article": "\u201cThe decreased risk of breast cancer in this group is something we totally didn\u2019t expect when we started the W.H.I.\nThe women with hysterectomies who used estrogen alone had a 23 percent lower risk for breast cancer compared with those who had taken a placebo.\nNationwide, about one-third of women in their 50s have had a hysterectomy.\nNobody is suggesting that women start using estrogen to prevent breast cancer, but the finding opens a potentially new avenue of research in the prevention of the disease.\nWhile most women in the hormone study were taking combination hormone therapy, women without a uterus took estrogen alone or a placebo for about six years and were followed for nearly 11 years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Estrogen is widely available and story does not need to talk about that.", "answer": 2}, {"article": "The first problem we solved was: how do we make the hand move electronically?\n\"His main interest was to create a shocking response from onlookers by pulling it off in the grocery store,\" Falardeau wrote on CNN iReport .\n(CNN) By the time Cynthia Falardeau read about Alex Pring, a little boy who got a battery-powered robotic arm last summer, she had made peace with her son Wyatt's limb difference.\nPetresky says they ask every family about the child's favorite color, superhero and interests, so the new limb can \"not just be a piece of plastic ... but be a part of them.\"\n\"We quickly found out this is much less about fitting in and feeling normal, and much more about expressing yourself,\" Petresky said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While the story includes links to the groups developing these prosthetics, there is really no exploration of how easy it is to get one. Apparently the process involves finding a group of local volunteers, such as middle school students and Boy Scouts, who can assist with printing and assembling the limbs. Are these volunteers widely distributed throughout the country? Do they have the capacity to meet demand? We\u2019ll give the benefit of the doubt, but relying on such volunteer groups sounds like it could lead to disappointment, especially if the publicity from stories like this one leads to a surge in demand.", "answer": 1}, {"article": "Here's the scientific proof.\nThe researchers found no links to physical or mental health issues -- including depression, psychotic symptoms or asthma -- in any group, even those with very high use.\nBased on other studies in the past that seemed to allude to marijuana use and later development of psychotic symptoms such as delusions or hallucinations, the researchers had thought they might find some associations to disease or other health conditions.\nThey also found no link to a wide range of other health issues: cancer, asthma, respiratory problems, depression, anxiety, allergies, headaches or high blood pressure.\nYour office thermostat is set for men's comfort.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story leads with the \u201cwidespread availability of marijuana in recent years\u201d \u2013 especially \u201cthanks to its legalization in a growing number of states.\u201d", "answer": 1}, {"article": "Hormone therapy is a very effective treatment for menopause-related hot flashes, but concerns about risks have limited its use among women.\nThey are linked to declining estrogen levels, but it remains unclear just why the sudden lack of estrogen sends the body into thermal mayhem, and why some women are more affected than others.\n\u201cThere is certainly a need for non-pharmacologic treatments for hot flashes and night sweats,\u201d says North American Menopause Society (NAMS) Executive Director Margery Gass, MD.\nThe women were also given a recording of the hypnotic induction, and they were asked to practice self-hypnosis at home daily.\nIn the newly published study, they set out to determine if the alternative treatment would do the same in women whose symptoms were related to menopause.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It wasn\u2019t clear whether a clinician could conduct the self-hypnosis trainings, or whether the patient needed to find another certified professional. And how were the hypnotic recordings obtained?\u00a0 Towards the end, the story does include the comment about finding a qualified hypotherapist. But readers aren\u2019t given any sense of how easy/difficult that might be.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Robots may not help doctors do a better job on some surgeries, according to a new study.\nBut all I need to do is add 5 and 5.\u201d\n\nEspecially in a time of concern over rising medical costs, \u201cwe should not simply use the highly sophisticated technology just because it\u2019s there,\u201d Falcone said.\nWith the surgeon alone, \u201cthe incision is smaller (and) the manipulations are more controlled,\u201d Dr. Ceana Nezhat, an author on the study and the chair of Obstetrics & Gynecology at Northside Hospital in Atlanta, told Reuters Health.\nUsing a robot for basic surgery, like the kind studied here, would be like using a computer to do addition, he told Reuters Health.\n\u201cWe were surprised that (surgery with the robot) did not have better outcomes than (the surgeon alone), as we have always believed if you can see more and see better you can do more and do better,\u201d the authors write.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This was one of the missing elements. At a minimum, the story should have said how many companies even make these things, how long they have been in production and how many hospitals/surgical centers have them. As far as\u00a0we know, the major manufacturer is da Vinci, and we\u2019re sure they would be glad to provide some numbers. If you just do a search on the da Vinci site of how many surgeons in western\u00a0Washington use these machines for gynecological procedures, you come up with a list of 1,500 names. imagine what that would be like in an area like Los Angeles or New\u00a0York?", "answer": 0}, {"article": "\u201cThere are still lots of patients in need of transplants that are not getting them because of lack of matched donors, and that is unacceptable in the year 2016.\u201d\n\nJones estimates that about 7,500 transplants of donated stem cells were done in 2014 \u2014 primarily for leukemia and lymphoma but also for nonmalignant blood disorders such as sickle cell and aplastic anemia \u2014 but that more than 15,000 could easily be done annually if more doctors embraced the new methods now available.\nIt\u2019s an indescribable feeling.\u201d\n\nIn haploidential transplants, rather than wiping out the patient\u2019s immune system, doctors use just enough drugs to suppress it.\nThe process is dangerous because it leaves a patient vulnerable to life-threatening infection for months before the reconstituted immune system begins to work.\n\u201cMany patients who previously died for lack of a match are now cured of their underlying malignancy,\u201d said Richard Jones, director of the bone-marrow transplant program at Johns Hopkins Kimmel Cancer Center.\nIn fact, when she and her doctors scoured the registry for a match for her, only one name came up: her own.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not make it clear how frequently these treatments are performed or how widespread they are. Does one have to travel to Seattle to have this treatment? It\u2019s unclear.", "answer": 0}, {"article": "But widely prescribed sleep medications such as Ambien (zolpidem) and Lunesta (eszopiclone) can leave people feeling hung over and inattentive the next day.\nThis area of the brain releases orexins during the day to keep us awake and lowers levels at night so we can sleep.\nIn each case, the minimum dose to achieve sleep was compared with the minimum dose that altered memory and thinking.\nMore than 30 million Americans struggle to get a good night's sleep, and about one-third of these use drugs to help the process, the study authors pointed out.\nLunesta and Ambien affect GABA receptors, which are found throughout the brain and are associated with side effects, including thinking disturbances, and deficits in attention and memory, explained Uslaner.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is under study and therefore not available. The story tells readers that Merck has applied for FDA approval to market a similar drug.", "answer": 1}, {"article": "But for now this category is useful only to researchers.\nRather, the goal in creating this category is to see if scientists can define when the disease starts, and track it through biomarker tests, brain imaging, or other yet-to-be-invented tests.\nAlzheimer's Redefined, But Changes Mean Little For Patients\n\nThe definition of Alzheimer's disease just got wider and deeper, but the expansion won't change how the vast majority of people are diagnosed.\nThe guidelines say, for instance, that newly developed \"biomarker\" tests, such as assays for proteins in spinal fluid, and some specialized brain scans can be used for early diagnosis of Alzheimer's.\nBut the new criteria, which were developed by the National Institute on Aging and the Alzheimer's Association, are almost guaranteed to prompt confusion, even in people who are thinking quite clearly.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nRight from the start this story makes clear that the revised definition of Alzheimer\u2019s disease \u201cwon\u2019t change how the vast majority of people are diagnosed. It also doesn\u2019t change the very limited treatment choices.\u201d", "answer": 1}, {"article": "He recommends trying to incorporate barley into existing recipes, using it as a substitute for rice or even on its own -- just like oatmeal.\nSt. Michael's Hospital provides compassionate care to all who enter its doors.\n\"Barley has a lowering effect on the total bad cholesterol in these high-risk individuals, but can also benefit people without high cholesterol.\"\nHigh cholesterol and diabetes are major risk factors for cardiovascular disease and stroke, historically treated with medications.\nFounded in 1892, the hospital is fully affiliated with the University of Toronto.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We learn that barley is everywhere, readily available and ready to add to your food.", "answer": 1}, {"article": "The study was funded by the Veterans Health Administration's Health Services Research and Development Service\nAll 129 patients in the study, most of them men in their 40s and 50s, were receiving outpatient addiction treatment in a CBT-based, non-abstinence setting at the Ann Arbor VA. Half were randomly assigned to ImPAT sessions, the other half to support groups of peers, led by a therapist, where pain and addiction could be discussed.\nIn addition to Ilgen, an associate professor in the U-M Department of Psychiatry and member of the U-M Institute for Healthcare Policy and Innovation, the study team included Addiction Center director Frederic Blow, Ph.D., as well as Amy S. B. Bohnert, Ph.D., Stephen Chermack, Ph.D., Carly Conran, Mary Jannausch, M.S., and Jodie Trafton.\nThe sharp rise in opioid addiction in recent years - often among people who started taking the painkillers as treatment for acute or chronic pain -- has made the search for effective non-drug pain treatment options even more urgent, Ilgen notes.\nAnd the study's authors note that the ImPAT approach has the potential to be easily and inexpensively adopted by addiction treatment centers and groups worldwide, through team members trained in standard psychological techniques.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that researchers have launched a larger, follow-up study of ImPAT, and that ImPAT could potentially be widely adopted. That seems to infer that ImPAT is not currently available outside of the treatment facility where the researchers work. However, it\u2019s not clear whether that\u2019s the case. Are other facilities offering this treatment technique, or something like it? Readers really have no way of knowing.", "answer": 0}, {"article": "The U.S. Food and Drug Administration approved the first therapy to treat an underlying cause of cystic fibrosis, a pill that targets a genetic mutation affecting a small minority of patients suffering from the life-threatening breathing disorder.\n\nThe drug, Kalydeco, from Vertex Pharmaceuticals Inc., will be among the most expensive therapies on the market, costing $294,000 a year.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story focused on FDA approval.\u00a0 It also mentioned the drug company\u2019s financial assistance plan.", "answer": 1}, {"article": "American veterans coping with PTSD are traveling to lodges in the Amazon that offer ayahuasca, a hallucinogenic brew. Some say it has helped them manage emotional trauma from war, but others say it\u2019s not worth the journey. Photo: Ryan Dube/WSJ\n\nAfter surviving firefights and a roadside bomb in Afghanistan, U.S. Army veteran Asa Barrett tried antidepressant drugs and therapy to overcome depression and bouts of anger. Nothing worked.\n\nBut then, like many other foreigners, he journeyed to Peru\u2019s remote Amazonian jungle to drink ayahuasca, a centuries-old, sacred indigenous brew that some Western scientists think can help to heal psychological traumas.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story describes numerous \u201cayahuasca centers\u201d that have cropped up around the city of Iquitos in Peru\u2019s northeastern Amazon.", "answer": 1}, {"article": "For the second time, the U.S. Food and Drug Administration has approved a drug that, instead of targeting tumors by location\u2014breast cancer, prostate cancer, lung cancer\u2014attacks cancers according to specific genetic structures, known as biomarkers.\n\"This is especially true when it comes to pediatric cancers.\nThe search for a cancer cure goes on, but in the meantime, there is hope for more effective treatments.\n\"This new site-agnostic oncology therapy isn\u2019t specific to a cancer arising in a particular body organ, such as breast or colon cancer.\n\"Using our breakthrough therapy designation and accelerated approval processes, we support innovation in precision oncology drug development and the evolution of more targeted and effective treatments for cancer patients,\" the FDA stated.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that the drug has received FDA approval.", "answer": 1}, {"article": "Commenting on the Nature Medicine study, he tells Newsweek the paper is \u201cvery interesting on a number of levels.\u201d\n\n\u201cFirst of all there\u2019s clearly growing interest in the potential therapeutic role of cannabinoids and in this particular case THC on various human conditions,\u201d he says.\n\u201cTogether, these results reveal a profound, long-lasting improvement of cognitive performance resulting from a low dose of THC treatment in mature and old animals,\u201d the scientists write.\nThis is a challenge faced by anyone wanting to develop a therapy for a human disorder such as dementia.\nTHC interacts with receptors in the brain\u2019s endocannabinoid system, which is involved in many physiological functions, including pain, mood, memory and appetite.\nWe would need to assess the safety first before going into seeing whether it would improve cognition.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty widely known that cannabis products are becoming increasingly available in many states, and medicinally in some.", "answer": 2}, {"article": "But there are dangers to this approach.\n\u201cIt was not known that inflammation was a common feature of different types of epilepsy.\u201d\n\nNormal brain function is regulated by the glial cells, which protect neurons and induce an inflammatory response if the brain is injured.\n\u201cThe challenge for the next few years is to find out the limitations, the boundaries, the real mechanisms.\u201d\n\nStill, whatever the role of inflammation in epilepsy, Elisa Moller says that anti-inflammatories were a miracle intervention for her son.\n\u201cOver time, both of them may feed off each other.\u201d\n\nAbout 50 million people worldwide, including more than 2.7 million people in the United States, are struggling with epilepsy in some form.\nBut this response also can contribute to seizures, some experts believe, either because components of the immune system stimulate neurons or because the glial cells\u2019 capacity to regulate the brain is diminished when they become \u201cdistracted\u201d by an injury.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "By leaning so heavily on the William Moller anecdote, the story may confuse some readers as to whether anti-inflammatory treatments are widely available for people with epilepsy. But the story also makes clear in several places how one particular treatment being prepared for market \u2013 VX-765 \u2013 is progressing through the various clinical trials necessary for it to become a clinical application.", "answer": 1}, {"article": "Whether you've been relatively inactive or fairly athletic, age is the enemy of one of the most important sets of muscles in the body: the group of four known as the rotator cuff that surround the ball of the shoulder joint.\n\nAbout 54% of adults older than 60 have a completely or partially torn rotator cuff, compared with just 4% of those between 40 and 60. But tears are most frequently caused by degeneration of the tendon due to age, rather than injury from sports or trauma. Studies show that tears can be managed without...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe story does not tell us whether what it calls the \u201cmini-open\u201d and other less invasive surgical techniques are widely available. \u00a0It implies that they are, but by calling them \u201cnew\u201d it likewise makes one wonder whether it may take time for them to penetrate to all surgical practices.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Fast food outlets should hand out free cholesterol-lowering statin drugs to their customers to \u201cneutralize\u201d the heart risks of eating fatty foods like burgers and fries, British scientists suggested on Thursday.\nOther statins such as Pfizer\u2019s Lipitor and AstraZeneca\u2019s Crestor - which are among the biggest-selling drugs in the world \u2014 are for prescription only.\nIn the U.S., all statins are only available by prescription.\n\u201cComplimentary statin packets are prone to ... give Quarter Pounder consumers a sense of false security,\u201d he told Reuters Health by email.\n\u201cStatins are a vital medicine for people with \u2014 or at high risk of developing \u2014 heart disease,\u201d he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that statins are widely available and only by prescription in the U.S.", "answer": 1}, {"article": "To learn more about NAMS, visit http://www.\nAlthough HT is the most effective treatment for managing most menopause symptoms, some women have turned to herbal medicine because they are either not candidates for HT or are concerned about the negative publicity surrounding potential side effects.\n\"A larger, longer, randomized study is still needed to help determine its long-term benefits and side effect profile.\"\nA new study confirms that it is also effective in the management of postmenopause symptoms such as hot flashes, sleeplessness, vaginal dryness, and anxiety, without serious side effects.\nIn the end, fennel was concluded to be a safe and effective treatment to reduce menopause symptoms without serious side effects.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll rate this Not Applicable since most readers will likely be aware that fennel can be purchased and that supplements are available. However, as noted above, it\u2019s not clear at all how 100 mg doses are formulated.", "answer": 2}, {"article": "Locke said about 13 percent of patients in the trial had a severe side effect known as cytokine release syndrome, which produces high fevers, low blood pressure and other flulike symptoms.\n\u201cIt raises the potential that a cure can be possible.\u201d Some of the first patients who underwent treatment now have been in remission for three to five years, he said, although he cautioned that it's still too early to know whether those patients are cured.\n\u201cToday, marks another milestone in the development of a whole new scientific paradigm for the treatment of serious diseases,\u201d FDA Commissioner Scott Gottlieb said in a statement, adding that the approval demonstrates \u201cthe continued momentum of this promising new area of medicine.\u201d\n\nA CAR T-cell therapy involves a complicated and customized procedure in which T cells \u2014 sometimes called the foot soldiers of the immune system \u2014 are removed from the patient.\nIn addition, the agency is requiring hospitals and clinics that dispense Yescarta to be certified after undergoing special training.\nIn late August, the FDA cleared the first CAR T-cell therapy, which is designed for children and young adults whose leukemia doesn't respond to standard treatments.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The piece isn\u2019t clear on this point. It says \u201c[T]he agency [FDA] is requiring hospitals and clinics that dispense Yescarta to be certified after undergoing special training.\u201d This implies that not all places will be able to prescribe this.\u00a0", "answer": 0}, {"article": "Particularly fast increases have occurred among people older than 65 and among women 15 to 39 years old.\n\u201cYou don\u2019t need to wait for 50 percent of 675 patients to die to conclude that one drug is much better than the other,\u201d said Dr. Antoni Ribas of the University of California, Los Angeles, who was an investigator in the trial and has been a consultant to the developer of the drug.\nIn particular, the drug counters the effect of a mutation in a gene called B-RAF that was discovered in 2002 to be common in melanomas.\nThe drug, which is taken orally twice a day, would be used only by the roughly half of melanoma patients whose tumors have this mutation.\nThere were about 68,000 new cases of melanoma and about 8,700 deaths last year in the United States, up from 48,000 cases and 7,700 deaths in 2000, according to the American Cancer Society.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Vemurafenib was described as experimental and as \u201cexpected to be approved by the FDA within a few months.\u201d\u00a0 Ipilimumab was explained to be approved in March and already on the market.", "answer": 1}, {"article": "The findings build on a 2015 UCLA study that demonstrated that both green tea and black tea helped prevent obesity in mice that consumed a high-fat, high-sugar diet.\n\"For black tea lovers, there may be a new reason to keep drinking it,\" she said.\nIn the mice that consumed either type of tea extract, there was less of the type of bacteria associated with obesity and more of the bacteria associated with lean body mass.\nThe research is published in the European Journal of Nutrition.\nAccording to Henning, the molecules in green tea are smaller and can more readily be absorbed into the body and reach the liver directly, while black tea molecules are larger and stay in the intestine rather than being absorbed.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Black and green tea are widely available so mentioning that fact is unnecessary.", "answer": 2}, {"article": "The differences over when to start regular screening reflect the growing concern that the benefits of mammograms may have been oversold, and that they don't outweigh the anxiety and potential harm caused by over-diagnosis and false positives from the tests.\nFor women in their 40s, the likelihood of benefit is less and the potential harms are proportionally greater, it said.\nDespite the decades of marketing of mammography to women, \"women are capable of understanding the complexities of the issue, evaluating the evidence and making their own health decisions,\" she said in a statement.\n\"At some point we will have to decide that we are not going to pay for interventions that lack a high level of medical evidence,\" she said.\nThe most serious potential harm is unneeded treatment for a type of cancer that would not have become a threat to a woman's health during her lifetime.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the use of mammograms as breast cancer screening tools is longstanding and well established. The story also discusses insurance coverage issues that would affect availability for many women.", "answer": 1}, {"article": "Vegetables particularly high in alpha-carotene include yellow-orange vegetables, such as carrots, sweet potatoes, pumpkin, and winter squash, and dark green vegetables, such as broccoli, green beans, green peas, spinach, turnip greens, collards, and lettuce.\nResearchers wanted to see if other carotenoids may also play a role in reducing the risk of disease.\nThe study shows that eating foods rich in antioxidants, like vegetables and fruits, fights disease and may prolong life.\nAlpha-carotene is part of a group of antioxidants known as carotenoids, which also includes beta-carotene and lycopene.\nAlthough previous studies have suggested eating more fruits and vegetables is associated with a lower risk of disease, studies have not shown that taking beta-carotene supplements reduces the risk of dying from heart disease or cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story lists a number of common foods that contain relatively high levels of alpha-carotene.", "answer": 1}, {"article": "\"A clinical trial has already begun to investigate this further.\"\nIf confirmed in clinical studies, this would provide a non-surgical option to prevent breast cancer in women with elevated genetic risk.\nBy pinpointing the cells that give rise to breast cancers in women who have inherited a faulty version of the BRCA1 gene, Walter and Eliza Hall Institute researchers have identified that the drug denosumab may have potential to prevent breast cancer from developing.\n\"It is very exciting to think that we may be on the path to the 'holy grail' of cancer research, devising a way to prevent this type of breast cancer in women at high genetic risk.\"\n\"We think this strategy could delay or prevent breast cancer in women with an inherited BRCA1 gene mutation,\" Professor Lindeman said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that denosumab is already used to treat other conditions, but that clinical trials are needed to determine whether denosumab should be used to reduce breast cancer risk for women with the BRCA1 mutation.", "answer": 1}, {"article": "Women more likely to have serious mental health problems than men, study says\n\nNIH's mental health chief on why he's leaving for Google: Technology may hold key to better diagnosis\n\nMost Americans will get a wrong diagnosis at least once in their lives\nThe research, published Wednesday in JAMA Psychiatry, is significant because major depression is one of the most common mental health disorders in the United States and one of the leading causes of disability worldwide.\nThis study \"shows a new, proven-safe treatment of depression that is probably both more effective and less expensive than drug treatment or anything else,\" said Dan Kripke, a psychiatrist and professor emeritus at the University of California, San Diego, who has studied the topic but was not involved in the latest trial.\nThere's some evidence that depression, like jet lag, occurs when the biological clock is out of sync, and light helps to correct that, Lam said.\nMost people typically receive medication and psychotherapy \u2014 but medications don't work in all cases and there's a shortage of providers in many areas.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Since these lights probably aren\u2019t very difficult to find, we\u2019ll rate the story Not Applicable here.\u00a0The story doesn\u2019t specifically address availability and it could have noted what kind of light is needed and whether these lights are widely available. But we won\u2019t ding the story for not mentioning this.", "answer": 2}, {"article": "June 2, 2010 (San Francisco) -- A quick spray of a new drug may help men who suffer from premature ejaculation last nearly six times longer, new research suggests.\nA total of 358 of the men gave themselves three quick sprays of PSD502 to the head of the penis five minutes before sex and then wiped it off right before penetration.\nThe numbers aren't huge.\nNot all men with premature ejaculation suffer to the same degree as the men in the study, says researcher Ira Sharlip, MD, clinical professor of urology at the University of California, San Francisco.\nPremature ejaculation can be devastating for both a man and his partner, triggering anxiety, depression, and relationship problems, says Goldstein, who heard the results presented at the annual meeting of the American Urological Association.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that \"The drug is so new that the company has yet to give it a name under which it will be marketed\u2026. the company is preparing to apply for FDA approval based on the results of the new research.\"", "answer": 1}, {"article": "Tumors or other abnormalities show up in red.\nThe most effective screening tool for detecting breast cancer is mammography and for women of all ages to remain breast aware, reporting any changes to their [doctor].\u201d\n\u201cAlthough there is still research to be done, the system has great potential to bring a new way for breast cancer diagnosis.\u201d\n\nCarolyn Rogers, clinical nurse specialist at Breast Cancer Care in the U.K., says in an emailed statement: \u201cEvidence is needed to demonstrate the accuracy and uses of this device.\nThe Manchester team says it is far less effective for younger women, where the detection rate could be as low as 60% for women under the age of 50.\nOct. 28, 2010 -- A University of Manchester, England, engineering professor has invented a portable breast scanner that could lead to more accurate tests for younger women without the need for X-rays.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While it is briefly noted that more research and evidence are needed, we think the tone of the article\u2014\u201dNew portable scanner for breast cancer\u201d\u2014misrepresents how soon the product could be available. Any such tool would have to run the gauntlet of clinical trials and evidence evaluation. As far as we can tell, this tool may not have even entered the arena yet. Clarity about the research status is necessary to create a realistic context, to give readers a sense of the timetable and likelihood for laboratory and the real world of hospitals or home screening.", "answer": 0}, {"article": "All the women were between the ages of 18 and 45 and their contraceptives were within six months of expiring before they enrolled in the study.\nThe study is still ongoing, and the researchers plan to recruit up to 800 women and ultimately test whether the IUDs and implants were effective for up to three years after their current FDA-approved duration.\nMORE: The IUD Answer: Why The Best Form of Birth Control is the One No One Uses\n\nThe researchers followed 237 women who were using an implant like Implanon and Nexplanon and 263 women using the Mirena hormonal IUD.\nThe benefit of being able to use the implant and IUD for a longer period of time is that it could reduce costs for individuals and insurance.\nThough the data is preliminary, the researchers say they believe that the hormonal IUD and the implant can both be used for an additional year longer than the FDA recommends.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that these birth control choices are widely available in the United States. The story could have noted that access to LARCs in developing countries may be limited, and that using these devices longer might help with that problem.", "answer": 1}, {"article": "Researchers have found that delivering a fecal microbiota transplant (FMT) in a pill\u2014a poop pill, basically\u2014is no worse than a similar procedure done with a colonoscopy.\n\u201cWhat I like about this paper is that it validates the upper-GI route and demonstrates that you can get very good cure rates without doing a colonoscopy.\u201d\n\nThat\u2019s important because colonoscopies and the anesthesia required for the procedure can put a lot of stress on a person\u2019s body and can be complicated for the people most at risk for C. difficile infections, Hohmann noted\n\nKao\u2019s study also showed that people found FMTs far less unpleasant when the poop came in a pill.\nWhile the FDA said in 2013 that doctors can try fecal transplants in patients with C. difficile infections, the agency noted doctors should only use FMT for other conditions in clinical trials.\nThe 116 patients used in this study may have been selected in part because they were ideal candidates for FMTs, Dr. Elizabeth Hohmann noted, but she said the paper is solid overall.\nDespite the FDA\u2019s advice, some people have set up shop as FMT providers anyway.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Unfortunately, the story doesn\u2019t spell out whether the pill form FMT is now, or soon will be, available to the public. The story does mention that numerous other clinical trials are using FMT as a possible treatment for various diseases but it is unclear whether the pill form is an option for physicians at this point.", "answer": 0}, {"article": "Botox is now being used by men, some of whom did not even run for President. The number of men in the U.S. who paid to get a series of tiny injections in their face nearly tripled from 2001 to 2007--to 300,000, or about 7% of the total Botoxed population. And despite the recession, those numbers aren't going down yet; one of the many things the laid-off cannot afford is to look their age.\n\nMen usually get Botox to remove those two vertical lines between their eyebrows that make them look angry and confused and thus, one could argue, masculine. They...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story implies, correctly, that Botox injections are widely available. ", "answer": 1}, {"article": "Massage therapy increases the activity level of the body's white blood cells that work to combat viruses.\nThe immune changes included increased white blood cells knowns as natural killer (NK) cells, which provide rapid responses to viral-infected cells.ii\n\nAn additional randomized study found women with stage 1 and 2 breast cancer may benefit from massage therapy for enhancing dopamine and serotonin while also increasing NK cell number and lymphocytes.\nThe American Massage Therapy Association, the most respected name in massage therapy, is the largest non-profit, professional association serving massage therapists, massage students and massage schools.\nTo find a massage therapist near you, the American Massage Therapy Association (AMTA), the most trusted name in massage therapy, offers a free professional massage therapist locator service at www.findamassagetherapist.org.\n\"Researchers working with patients with compromised immune systems have found massage therapy can improve how the immune system functions,\" said Jeff Smoot, President of the American Massage Therapy Association (AMTA).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Most people are aware that massage therapy is widely available nationwide. However, the news release provides a link to the American Massage Therapy Association\u2019s locator service, presumably\u00a0 dues-paying AMTA members.", "answer": 1}, {"article": "The efficacy and safety analyses with tramiprosate published in JPAD reveal a therapeutic effect in patients who are carriers of APOE4 after segmenting them from the larger, non-genetically-defined study population in the Phase 3 clinical program, involving more than 2,000 AD patients in North America and Europe.\nThe manuscript, titled \"Clinical Benefits of Tramiprosate in Alzheimer's Disease Are Associated with Higher Number of APOE4 Alleles: The 'APOE4 Gene-Dose Effect',\" is featured in the advanced online publication of The Journal of the Prevention of Alzheimer's Disease (JPAD) with lead authors from Alzheon, Inc., a biopharmaceutical company focused on treatments for neurodegenerative and neuropsychiatric disorders.\nThe \u03b54 allele is significantly overrepresented in the Alzheimer's disease population compared to the general population: up to 65 percent of Alzheimer's patients carry one or two copies of the \u03b54 allele compared to about 25 percent of the general population.\nPeople who inherit one copy of the \u03b54 allele, APOE4 heterozygotes, have an increased chance of developing the disease; those who inherit two copies of the allele, APOE4 homozygotes, are at even greater risk and tend to have more aggressive disease.\nThis new insight shows how we can apply a precision medicine approach in AD and develop this drug for the right patients, namely patients with the APOE4 genotype, which carries the highest risk as well as the earliest onset and faster disease progression,\" said Martin Tolar, MD, PhD, Founder, President and CEO of Alzheon.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states the drug is in on-going trials and one can infer the drug is not and will not be available in the foreseeable future. It describes next steps: \u201cWe are preparing to advance ALZ-801, a promising new treatment for Alzheimer\u2019s disease, into confirmatory clinical studies in 2017.\u201d", "answer": 1}, {"article": "Nevertheless, accumulating evidence has her urging patients to get their calcium from their diet, rather than reflexively telling them to take 1,200 milligrams of calcium a day.\nA recent meta-analysis done by the same group of researchers found a 27 to 31 percent increased risk of heart attacks in women taking calcium without vitamin D.\n\nMany older women take calcium supplements with or without vitamin D to keep their bones strong, especially since that has long been standard medical advice.\nNow the increased risk for heart attack was 25 to 30 percent and, for a stroke, 15 to 20 percent.\n\"The cautious way forward seems to be to encourage people to obtain their calcium from the diet, rather than from supplements, since food calcium has not been shown to carry this increased risk of heart disease,\" Reid added.\nMoreover, the results may have been statistically significant but that doesn't mean they're clinically significant, he added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated:\u00a0\u201cMany older women take calcium supplements with or without vitamin D to keep their bones strong, especially since that has long been standard medical advice.\u201d So availability and widespread use is clear.\n", "answer": 1}, {"article": "Despite popular lore, agency won't allow labels to say drink is good for consumers' hearts\n\nWASHINGTON - There is no credible scientific evidence that drinking green tea reduces the risk of heart disease, federal regulators said last week in rejecting a petition that sought to allow tea labels to make that claim.\nUnlike black and oolong tea, it is made from unfermented tea leaves.\nGreen tea is brewed from Camellia sinensis, also known as Thea sinensis.\nThe Food and Drug Administration said it reviewed 105 articles and other publications submitted as part of the petition but could find no evidence to support claims of the beverage's health benefits.\nA health claim, in the language of the FDA, characterizes the relationship between a substance and a reduction in the risk of contracting a particular disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article explained that green tea is made from unfermented tea leaves and mentioned that its popularity had grown over the last decade. ", "answer": 1}, {"article": "Paul's group tested buckwheat honey instead of the lighter, more popular varieties because it's known to have more antioxidant and antimicrobial effects, which have been shown in other studies to help wounds heal.\nHoney also beat out no treatment at all.\nUnder the provisions of the grant, the group was not involved in the study or the published results, Paul said.\nHoney is not only cheap and readily available, it's also generally safer than cough medicine, which can have side effects or be administered in the wrong dose.\n\"(Honey) is a cheap and effective treatment,\" said Dr. Ian Paul, lead investigator for the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly honey and over-the-counter cough medicine are available.", "answer": 1}, {"article": "\"While the findings on reducing dental plaque extend a previous observation, the findings on decreasing inflammation are new and novel,\" said Charles H. Hennekens, M.D., Dr.P.H., senior author and first Sir Richard Doll Professor, and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University.\nPlaque HD\u00ae is the first toothpaste that reveals plaque so that it can be removed with directed brushing.\nThis large scale randomized trial will test whether Plaque HD\u00ae reduces risks of heart attacks and strokes.\nIn this trial, all randomized subjects were given the same brushing protocol and received a 60-day supply of toothpaste containing either Plaque HD\u00ae or an identical non-plaque identifying placebo toothpaste.\nTo assess dental plaque, all subjects utilized a fluorescein mouth rinse, and intraoral photographs were taken under black light imaging.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release implies that Plaque HD toothpaste and testing for hs-CRP are both currently available.", "answer": 1}, {"article": "In dark suits and blue shirts, with serious expressions on their round faces, they walked to stand next to their mother in a very beige room outside Washington, D.C.\nI didn\u2019t expect it to look like this.\u201d\n\nBut not everyone considers ataluren to be a miracle drug\u2014with good reason.\nThe drug, called Exondys 51 or eteplirsen, allows the genetic machinery that produces the protein to skip over the mutated part to make something that will work better.\nMany of the clinical trials failed to satisfy the statistical requirement to prove a drug works\u2014at least not for the main outcome the company was looking at.\nThe Vertins have received the drug free through the clinical trial, and expenses for their trip from Nebraska to Washington, D.C. were paid by PTC Therapeutics.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "A main point of narrative tension in the story is the family\u2019s wait to see if the FDA will approve the drug. So it is clear that the drug is not yet available.", "answer": 1}, {"article": "\"They did show a higher recurrence or progression rate with endometrial cancer than with AEH and that is consistent with other data,\" said Bakkum-Gamez, who added that the IUD method would not be appropriate for later-stage cancers, which tend to be more aggressive.\nNine of the women in the study successfully delivered babies.\nNo adverse effects from treatment were noted, according to the researchers, who declared no conflicts of interest.\nand that you may be giving higher doses of the drug directly into the uterus.\"\nOf the patients with AEH, four later relapsed and required further treatment; of the women with early-stage cancer, two who had an initial complete response relapsed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The progestin IUD is clearly available.", "answer": 1}, {"article": "He studied the extract puerarin.\nMay 17, 2012 -- An extract from the Chinese herb kudzu may help drinkers cut down on drinking, according to a new pilot study.\n\"It didn't stop the drinking,\" says researcher David M. Penetar, PhD, assistant professor of psychology at McLean Hospital and Harvard Medical School.\nIt is one of the substances known as isoflavones found in kudzu.\nThe study is published in Drug and Alcohol Dependence.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We wish the story had been clearer about the difference between the standardized kudzu extract that was tested in the study, which apparently is not yet approved for sale, and the other kudzu supplements that are widely available. Why is it ok to sell some kudzu root preparations as dietary supplements, while other extracts need approval from the FDA as though they were drugs? The story never tells us.\nThis confusion notwithstanding, the info needed to fulfill the criterion was presented in the article for those willing to puzzle it out, so we\u2019ll award a grudging satisfactory.", "answer": 1}, {"article": "And while the percentage of American adults who smoke is at the lowest level since the CDC began tracking such data, there are still an estimated 40 million adult smokers in the U.S.\nThis website is archived for historical purposes and is no longer being maintained or updated.\nThe survey results are published in the March 24 release of the journal Preventing Chronic Disease.\nAbout 80 percent of U.S. adult cigarette smokers who were surveyed reported seeing at least one television ad from Phase 2 of the 2014 campaign.\nFor every American who dies from a smoking-related disease, about 30 more suffer at least one serious illness from smoking.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release refers readers to the quit line and a web site containing the Tips ads.", "answer": 1}, {"article": "People with painfully damaged knees and hips have increasingly turned to \"minimally invasive\" joint-replacement surgery. But these relatively new procedures, though they promise shorter recuperation times, are raising concerns about potential complications.\n\nMany surgeons in recent years have performed joint replacements with ever smaller incisions. In minimally invasive surgery, the incision is typically about three to four inches long, roughly half that of traditional surgery. By cutting less of the surrounding tissue...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\nThe story says nearly half of all total joint surgeries are now being done with so-called \u201cminimally invasive\u201d approaches.", "answer": 1}, {"article": "The rats experienced overall improvement in contractile proteins and heart function too.\"\n\"The studies demonstrate that we should be able to implement a similar, safe treatment and monitoring program for use in human clinical trials.\nA 2013 study in The Journal of Translational Medicine showed thyroid hormone treatment administered to rats at the time of a heart attack led to a significant reduction in the loss of heart muscle cells and improvement in heart function.\n\"What we have tried to do here is show the effect of safe doses of thyroid hormones and we're seeing amazing results in multiple studies, with dramatic improvements in heart function, gene expression, and collagen levels, just by restoring depressed thyroid levels in the heart,\" said Gerdes.\n\"This low dose of thyroid hormone safely restored depressed cardiac tissue T3 levels to normal while largely preventing the accumulation of collagen, or scar tissue, resulting from sustained high blood pressure,\" said Gerdes.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does an excellent job of making clear that this was an animal model study and that clinical trials have not yet been approved for this treatment technique \u2014 meaning that this work is at least years away from widespread clinical use.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070520/28diet.b.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The news brief does not mention availability, but most readers will know where to find calcium and vitamin D supplements.", "answer": 2}, {"article": "Doctors in Seattle cured a late-stage cancer patient after tinkering with his body's defenses against infection, leading to cautious optimism about treating late-stage melanoma, a deadly skin cancer.\n\nThe surprising result, published in this week's issue of the New England Journal of Medicine, is the latest hopeful finding from the 30-year-old field of \"adoptive immunotherapy,\" which theorizes that the body can be taught to fight off its own cancers.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\nThe news story explains that the therapy it describes is not widely available, and probably won\u2019t be mainstream for another 5-10 years. However, the story does not say whether the therapy is FDA-approved. Numerous immunotherapies have been approved for various cancers, but this treatment for melanoma does not appear to be among them.\n", "answer": 1}, {"article": "An experimental drug has proved effective at treating an aggressive form of breast cancer in patients who aren't responding to the widely used drug Herceptin, giving hope to women with otherwise limited treatment options, said drug maker GlaxoSmithKline PLC, presenting the results Saturday at the American Society of Clinical Oncology meeting in Atlanta.\n\nWhen taken with a standard chemotherapy treatment in a clinical study, the new drug, Tykerb nearly doubled the time to 8.5 months before the average patient's breast cancer...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that lapatinib is still being tested in clinical trails and is not yet available for sale. The story says that \u201cGlaxoSmithKline plans to submit the drug for regulatory approval in the U.S. and Europe by the end of this year,\u201d and later mentions Glaxo\u2019s \u201chigh hopes for Tykerb.\u201d It would have been better to get some other perspectives about these prospects, other than comments from the company or company-sponsored researchers. ", "answer": 1}, {"article": "In years past, \"the message was that chocolate consumption might be associated with higher LDL [bad] cholesterol or perhaps higher incidence of cardiovascular disease,\" he said.\nBoth are good for heart health,\" he said.\nThe National Stroke Association has more on stroke.\n\"Today, we know that all chocolates are not the same.\"\nAntioxidants are thought to prevent cell damage.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of chocolate is not in question. ", "answer": 2}, {"article": "Ohio\u2019s roads stink. Here are 5 options to fix them\n\nNobody likes paying more. But it turns out, if we want our roads to improve, we might have to.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that estrogen and progestin pills remain available, but are to be prescribed with awareness of risk/harm tradeoffs.\u00a0 ", "answer": 1}, {"article": "(CNN) A saliva test may someday be able to diagnose a concussion and predict how long symptoms last, according to a study published Monday in the JAMA Pediatrics.\nThe saliva biomarker may be showing that neurons experienced force and not that a there is a concussion, with which the brain cannot perform its typical functions within a normal range, he said: \"I would hesitate to assign too much potential groundbreaking science.\"\n'Way too early to know'\n\nHowever, the editorial authors, Dr. William P. Meehan III of Micheli Center for Sports Injury Prevention at Boston Children's Hospital in Massachusetts and Dr. Rebekah Mannix of Brain Injury Center at Boston Children's Hospital, noted that \"the relatively small sample size in this study requires larger-scale studies to determine the reliability\" of the results.\n\"Fortunately, the technology required to measure saliva RNA is already employed in medicine; we use it to check patients for upper respiratory viruses in our hospitals and clinics every day,\" Hicks said.\nStill, \"the findings are promising, representing potential biomarkers for the diagnosis, recovery, and prognostic assessment of a sport-related concussion.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story quotes the lead author of the saliva test study as saying that many hospitals and clinics already use the technology that would be needed to assess microRNAs in saliva. This implies that the saliva test could be readily available to patients if further research confirmed the association between specific microRNAs and prolonged concussion symptoms. The story does not provide any specific discussion of how long it could take or how much further study would be needed before the saliva test would be available for use. However, the story does communicate that the saliva test is not yet available.", "answer": 1}, {"article": "PITTSBURGH, June 2, 2016 - Surgery to remove the primary tumor in women diagnosed with stage IV breast cancer, followed by the standard combination of therapies, adds months to the patients' lives, compared with standard therapy alone, an international clinical trial led by a University of Pittsburgh Cancer Institute (UPCI) professor revealed.\nAt about 40 months after diagnosis, the women who received the surgery plus standard therapy lived an average of nine months longer than their counterparts who received standard therapy alone.\nHalf the women received standard therapy, which avoids surgery and consists of a combination of chemotherapy, hormonal therapy and targeted therapy, while the other half first had surgery to remove their primary breast tumor, followed by the standard therapy.\nNearly 42 percent of the women who received surgery lived to five years after diagnosis, compared with less than 25 percent of the women who did not receive surgery.\nDr. Soran began the trial in 2007, ultimately recruiting a total of 274 women newly diagnosed with stage IV breast cancer from 25 institutions.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It should be clear to any audience that these types of basic surgeries are available, and so we are giving this criteria a pass.", "answer": 2}, {"article": "Almost all cases of cervical cancer occur as a result of infection with high risk types of HPV.\nIn the UK, all girls aged 12 to 13 are offered HPV vaccination as part of the NHS childhood vaccination programme.\nProfessor Jack Cuzick concludes: \"Following these important findings, this vaccine has been licenced in the USA and approval is currently being sought in the UK and other countries.\nThe new vaccine, Gardasil 9, is not only safe but will offer greatly improved protection against cervical and other cancers.\nIn the UK around 3,000 women a year are diagnosed with cervical cancer and in 2011 there were around 970 deaths.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that the new vaccine is available in the US but not yet in the UK.", "answer": 1}, {"article": "The potential for Clostridium novyi-NT to prompt an immune response against cancer is intriguing, said Sacha Gnjatic, who is associate director of the Human Immune Monitoring Center at Mount Sinai in New York City.\nThe bacteria also could activate the immune system to fight the cancer even if the infection didn't kill off tumor cells, Janku added.\nThe bacteria germinated in the cancers of 11 out of the 24 patients, with tumor cells dying off as a result.\nA potentially dangerous bacteria appears to target malignant cells and could provide a new means of fighting cancer, a small, preliminary study reports.\nYou would expect that the injected lesion would have some type of response because you're disrupting the tumor cells,\" Gnjatic said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that researchers are still studying this approach, implying it\u2019s not available widely.", "answer": 1}, {"article": "A three-year-old Silicon Valley start-up, Counsyl Inc., won the Bronze Innovation Award for its simple, low-cost genetic test that can alert prospective parents who might be carrying genes that could cause hereditary diseases in their children.\n\nCounsyl's technology promises a \"high quality-of-life impact for families at risk for conceiving children with familial diseases,\" says Larry Bock, an Innovation Awards judge and special limited partner at venture firm Lux Capital. \"This technology bundles previously...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story says that after a period during which the test was available only at certain clinics, it now is available nationally. That sounds like good news, but I was left wondering if \"nationally\" meant the same as \"everywhere.\" Are we just as likely to see this test in Casper, Wyoming, as we are in Manhattan?", "answer": 1}, {"article": "March 31, 2010 -- A widely prescribed drug used to shrink enlarged prostates appears to reduce the incidence of prostate cancer in men with an increased risk for the disease.\nA total of 8,231 men between the ages of 50 and 75 took part in the study, published in the New England Journal of Medicine.\nAll of the men had elevated blood levels of prostate specific antigen (PSA), which indicated an increased risk for prostate cancer.\n\"But we don't have studies saying that they decrease the risk of death from prostate cancer.\"\nScheduled biopsies were performed two and four years after they entered the trial.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Avodart, a drug commonly used to treat enlarged prostate, is clearly available. ", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5disease.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article mentions that Lucentis was approved last June for wet AMD, but doesn't tell the reader how available it is \u2013 that is, is it in widespread use?", "answer": 1}, {"article": "A Harvard researcher hopes an old arthritis drug, which he read about in a 19th century German medical journal, could be a cheap new treatment for diabetes.\n\nIn the late 1990s, Steven Shoelson's research suggested that the drug, called salsalate, might also help diabetics. The idea sent him into the basement stacks of a Harvard library to see whether anyone else had pursued the notion.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story described the drug being investigated as \u2018a cheap, generic\u2019 and as currently being sold as \u2018an inexpensive generic\u2019.\u00a0 It would have been useful to clarify whether it was available as a prescription or an over-the-counter medication.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Hormone replacement therapy (HRT) can carry serious health risks, but a new study adds to evidence that menopausal women who use the hormones may have lower odds of developing colon cancer.\nThese latest findings do not alter that advice.\nOver the next decade, 442 women were diagnosed with colon cancer.\nThe implications of that finding, if any, are not yet clear.\nMost of the women were past menopause at the outset, and 61 percent were currently using HRT.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of hormone replacement therapy is not in question. ", "answer": 2}, {"article": "For more information about Wolters Kluwer's solutions and organization, visit http://www.\nThe RTSA technique--using an implant in which the natural locations of the shoulder \"ball and socket\" are reversed--uses other muscles to move the shoulder, providing an alternative when the rotator cuff is severely damaged or destroyed.\nThe company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.\nWith refinements in technique and components in more recent years, the procedure has been used in younger, more active patients.\nThe new study focused on long-term outcomes of RTSA in patients under age 60.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Since the study is reporting the long-term results of this form of surgery in patients, readers can assume that it is available.\nThe implant is widely available to be used at the surgeon\u2019s discretion.", "answer": 1}, {"article": "Antimicrobial resistance refers to infections that have evolved the ability to withstand drugs that ought to stop them.\nFighting bacteria with drugs designed to kill them helps fuel the problem of antibiotic resistance if stronger bacteria can survive and evolve to become \u201csuperbugs.\u201d\n\n\u201cBut instead of always setting a bomb off to kill an infection, there are situations where using an anti-virulence method may be just as effective, while also helping to restore balance to the health of the patient,\u201d said Quave.\n\u201cWe\u2019re trying to answer the question: Does this work against bacteria, and how does it work, and is it safe to use?\u201d\n\nThe Brazilian peppertree, a shrubby tree native to South America, is an invasive species throughout the southern United States, particularly in Florida, where it\u2019s sometimes called the Florida holly or broad-leaf peppertree, and is considered a noxious weed.\nThe discovery may hold the potential for new ways to treat and prevent antimicrobial-resistant infections, an enormous global problem that was the focus of a rare high-level United Nations summit last fall.\nResearchers from Emory University and the University of Iowa found that extracts from the Brazilian peppertree, which traditional healers in the Amazon have used for hundreds of years to treat skin and soft-tissue infections, have the power to stop methicillin-resistant Staphylococcus aureus (MRSA) infections in mice.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the product isn\u2019t available yet:\n\u201cHer lab at Emory is doing additional research to confirm the safest and most effective way of using the plant extract. Researchers would still need to conduct pre-clinical trials to test its medicinal benefits.\u201d\nAs we noted above, the story also could have mentioned the need for expensive follow-up studies involving many patients, should those pre-clinical studies produce positive results.", "answer": 1}, {"article": "Rebecca Branstetter, psychologist who blogs at Notes from the School Psychologist, says this dyslexia brain scan could provide useful information, but it doesn't highlight environmental factors -- such as the quality of instruction in the child's classroom -- that could contribute to reading problems.\nOf course, the results of the study are only preliminary.\nBut this one found that receiving a remediation did not appear to affect improvement in reading abilities.\nThe sooner it can be detected, the better.\nA larger trial that controlled for remediations would offer more conclusive results.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story notes that the type of scan used in this study is not widely available.", "answer": 1}, {"article": "WASHINGTON (Reuters) - A new, longer-lasting \u201cmorning-after\u201d pill to prevent unwanted pregnancy appears to work with no unexpected side effects, U.S. health regulatory staff said in documents released on Tuesday.\nOn Thursday, the FDA\u2019s advisers will weigh HRA Pharma\u2019s data and offer recommendations before the agency later makes its approval decision.\nThe agency\u2019s reviewers also said the company\u2019s studies showed no unexpected side effects in women, although reports of nausea, headache and abdominal pain were common.\nProponents agree that ella is similar chemically to mifepristone but say the dose given does not interfere with a pregnancy already underway.\nEfforts in 2001 to make it available without a prescription stirred fierce opposition from conservatives, and the bid stalled under the George W. Bush administration.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that the FDA is now reviewing the drug and that it is not yet available in the US but is available in Europe.", "answer": 1}, {"article": "A new study has an intriguing finding: Advanced cancer patients who received early palliative care in conjunction with standard care for their disease not only reported better quality of life, but lived a few months longer than patients who received only standard care.\n\nThe research, published in the New England Journal of Medicine, included 151 patients diagnosed with metastatic non-small-cell lung cancer who were randomly assigned to one of those treatment plans. At 12 weeks, 86% of those who were still alive filled out assessments \u2026", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As other stories covering the study pointed out,\u00a0access to palliative care is limited by complicated reimbursement and\u00a0lack of\u00a0skilled providers in some areas. The\u00a0WSJ didn\u2019t mention\u00a0these\u00a0barriers. \u00a0", "answer": 0}, {"article": "Contrary to earlier reports, giving acetaminophen (Tylenol, etc.)\n\"We found no matter how you slice it, there was absolutely no difference between Tylenol and Motrin,\" says senior investigator and corresponding author Wanda Phipatanakul, MD, MS, of Boston Children's Hospital's Division of Allergy and Immunology.\n\u2022 The percentage of days with full asthma control were virtually the same for acetaminophen and ibuprofen: 85.8 and 86.8 percent, respectively.\n\u2022 At least one asthma exacerbation occurred in 49 percent of the acetaminophen group, vs. 47 percent of the ibuprofen group.\nThe 18-site study should settle a debate that originated when several retrospective studies seemed to indicate that children had exacerbations of their asthma when receiving Tylenol for pain and/or fever.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of acetaminophen and ibuprofen is not in question, since these are well-known, over-the-counter drugs. We rate this one Not Applicable.", "answer": 2}, {"article": "But not so fast, say experts.\nExperts describe Abbott's device as an important step in finding a better approach to treating the leading cause of death in the U.S.\n\n\"This is presumably a better technology going forward, at least that's the theory, but it will take years to prove,\" said Dr. George Vetrovec, professor emeritus at Virginia Commonwealth University.\nThe Food and Drug Administration approved the device Tuesday for patients with coronary artery disease, the artery-narrowing condition that causes about 370,000 U.S. deaths each year, according to government figures.\n\"The key for the stent market will be whether pricing returns to rational levels and the success of the new bio-absorbable stent platforms,\" states Evercore ISI analyst Vijay Kumar, in an investment note.\n\"We have good theoretical reasons to believe that by getting rid of the stent, and allowing the coronary artery to restore its normal shape, that will prevent many of those late events,\" said Dr. Gregg Stone, of Columbia University Medical Center, who helped conduct the pivotal trial of Absorb.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The news peg for this story was FDA approval of the device for patients with coronary artery disease.\u00a0 But although the Abbott Labs\u2019 press release suggests that the dissolvable stent is available worldwide (\u201cin more than 100 countries, including the United States\u201d), the story does not mention U.S. access to the device. The Reuters story covered this criterion better.", "answer": 0}, {"article": "Ulcerative colitis is a chronic inflammatory bowel disease.\nWhether Xeljanz should be used as a first treatment is still not clear, said Dr. Arun Swaminath, director of the inflammatory bowel disease program at Lenox Hill Hospital in New York City.\nFor more information on ulcerative colitis, visit the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.\nWEDNESDAY, May 3, 2017 (HealthDay News) -- A new study finds that people with moderate to severe ulcerative colitis who haven't done well on other treatments may find relief with Xeljanz (tofacitinib), a drug currently used to treat arthritis.\n\"There is still a substantial unmet need for new treatments for patients with ulcerative colitis,\" said study lead author Dr. William Sandborn.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear both that Xeljanz is already on the market for treating arthritis and that it has not yet been approved by the FDA for use in treating ulcerative colitis.\u00a0It would have been helpful to note if some doctors currently prescribe Xeljanz as an off-label treatment for ulcerative colitis.", "answer": 1}, {"article": "When prebiotics are working the way they should, good bacteria increase in abundance.\nThe article, \"Dietary polydextrose and galactooligosaccharide increase exploratory behavior, improve recognition memory, and alter neurochemistry in the young pig,\" is published in Nutritional Neuroscience.\nThe researchers hypothesize that the prebiotics may alter levels of tryptophan, serotonin's amino acid precursor, but it's too early to say.\nIn a recent study from the Piglet Nutrition and Cognition Lab at U of I, scientists worked with piglets to show prebiotics included in infant formula can enhance memory and exploratory behavior.\nAlthough more work is needed to tackle remaining questions, the study adds to the growing body of research suggesting a strong and potentially modifiable link between the gut and the brain: a link that makers of infant formula should strongly consider.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This published study (but not the release) mentions that infant formula supplemented with prebiotics are currently available.", "answer": 0}, {"article": "Amid a dry spell for breakthrough cancer drugs, recent U.S. approval of Eisai Co.'s Halaven represents some vindication for a small group of researchers who believe, contrary to recent pharmaceutical fashion, that molecules from nature hold promise against hard-to-treat diseases.\n\nThe Food and Drug Administration's approval of Halaven in November for treating late-stage breast cancer was a triumph of chemistry and tenacious research. Its path, extending nearly three decades from the first studies, demonstrates not only potential...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "UTMB is a part of the University of Texas System and a member of the Texas Medical Center.\nThe goal of the study was to find out whether testosterone replacement therapy reduced the risk of respiratory hospitalizations in middle-aged and older men with COPD.\nChronic obstructive pulmonary disease, or COPD, is predicted by the World Health Organization to be the third-leading cause of illness and death internationally by 2030.\nUsing the Clinformatics Data Mart, a database of one of the largest commercially insured populations in the U.S., Baillargeon and colleagues examined data of 450 men aged 40 to 63 with COPD who began testosterone replacement therapy between 2005 and 2014.\n\"Previous studies have suggested that testosterone replacement therapy may have a positive effect on lung function in men with COPD,\" said Jacques Baillargeon, UTMB professor in preventive medicine and community health.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is pretty obvious that TRT is available to men, so the fact it wasn\u2019t mentioned as available is a moot point.", "answer": 1}, {"article": "The brain controls how long we live.\n\u201cHowever, if the mechanism is fundamental, you might expect to see effects when an intervention is based on it.\u201d\n\nPrevious experiments had already hinted that the hypothalamus, an almond-sized part of the brain in humans, played some role in the ageing process, but what it was remained unclear.\nThe work, described as a tour de force and a breakthrough by one leading expert, suggests that ageing across the body is controlled by stem cells that are found in the hypothalamus region of the brain in youth, but which steadily die off until they are almost completely absent in middle age.\n\u201cThe mechanism is partially due to these cells secreting certain miRNAs which help maintain youth, and the loss of these leads to ageing\u201d said Cai, whose study is published in Nature.\nTo test whether the decline in stem cells was causing ageing, and not itself a result of old age, the researchers injected mice with a toxin that wiped out 70% of their neural stem cells.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that this research is preliminary. The story clearly says, \u201cThe next step is to create human neural stem cells in the lab for testing.\u201d\u00a0 It also states that, \u201cResearchers at Albert Einstein College of Medicine in New York hope to launch clinical trials of the procedure soon, but must first produce supplies of human neural stem cells in the lab which can be implanted into volunteers.\u201d", "answer": 1}, {"article": "Calcium intake from food has been rising, he says, with recent surveys finding averages around 1,000 mg a day \u2014 close to or meeting the 1,000 mg. to 1,200 mg recommended for adults (the higher level is advised for women over 50 and men over 70).\nMost recently, researchers at Johns Hopkins University tracked nearly 3,000 adults and found that those who took calcium supplements at the study outset were 22% more likely to show artery calcification 10 years later.\nThe mineral found in popular supplement pills \u2014 and in dairy foods, leafy greens and many fortified foods \u2014 is unquestionably good for your bones.\n\u201cThe public has been receiving very confusing and alarming messages about calcium supplements,\u201d says JoAnn Manson, a professor of medicine at Harvard Medical School and chief of preventive medicine at Brigham and Women\u2019s Hospital, Boston.\n\u201cIf you look at the overall totality of the evidence, there\u2019s a lack of association between supplement use and heart attack and other cardiovascular events,\u201d says Manson, who co-wrote an editorial accompanying the review.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not address calcium supplement availability. However, given that these supplements are not new, and are widely available, we\u2019ll rate this as not applicable.", "answer": 2}, {"article": "\"There are a lot of pundits who remain skeptical or feel we need to research this ad infinitum before it's ready, which doesn't make sense to me,\" Feifel says.\nIt's been used for decades as an anesthetic that can rapidly stop pain without affecting vital functions like breathing.\nAnd ketamine's safety record is so good that it's often the painkiller of choice for children who arrive in the emergency room with a broken bone.\nInsurers don't cover the cost because the treatment is still considered experimental.\nOthers have been started by entrepreneurial anesthesiologists and emergency room doctors, who are familiar with ketamine but may not know much about depression.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that ketamine is not approved for treatment of depression, but it is widely used as an anesthetic.", "answer": 1}, {"article": "TUESDAY, Aug. 16, 2016 (HealthDay News) -- An experimental drug appears to reduce the risk of bone fractures in postmenopausal women with osteoporosis better than a placebo and the currently available drug, a new study finds.\n\"I am hoping that having a second drug available, that it will help reduce the cost,\" he said.\n\"Everybody is going to want to know if this is inferior or superior to Forteo,\" she said, adding that this is an early study.\nAlong with building bone density, they are the only ones that increase bone quality, he said.\nThere were no differences among the groups in other serious side effects, such as nausea and heart palpations, Miller said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that abaloparatide is currently in a Phase 3 trial stage.", "answer": 1}, {"article": "The American Heart Association recommended more than a year ago using induced hypothermia for cardiac arrest patients who are stable.\nThe idea is that cooling a comatose patient after a heart attack prevents brain damage.\nIt's a story that still gives Cowles chills.\nResearch has shown it can improve the survival rate by 14 percent.\n\"He started rendering the compression and I started mouth to mouth.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned that this treatment is not available at most hospitals.", "answer": 1}, {"article": "But a P.P.I.\nBut while certain common foods \u2014 like raw onions, garlic, citrus juices, coffee and chocolate \u2014 are likely to cause reflux in most people with the condition, Dr. Aviv and other experts emphasize that everyone is different, and trial and error is the most effective way to determine an individual\u2019s trigger foods and drinks.\nOne characteristic often associated with acid reflux \u2014 being overweight, especially with abdominal obesity \u2014 largely explains why the condition has become so common in Western countries.\nSmoking and alcohol can loosen tension of the upper esophageal sphincter and cause symptoms of reflux like hoarseness, postnasal drip and shortness of breath by irritating the mouth, larynx and trachea, Dr. Aviv reports.\nEating big meals, lying down before a meal is digested, and exercising too soon after eating can also trigger symptoms.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t address availability\u2013but it doesn\u2019t need to: lifestyle changes are not products or services. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\nCurrently approved in the U.S. for treating major depression, dTMS is being studied in some countries for the treatment of other neuropsychiatric disorders, especially addiction.\nIn their study, funded by the Italian Ministry of Health, the investigators recruited three men and 11 women, ages 22 to 65, with obesity as shown by a body mass index (BMI) of 30 to 45 kg/m2.\nThey randomly assigned the study subjects to two groups for five weeks to receive 15 sessions--three times per week--of either dTMS (to the insula and prefrontal cortex deep in the brain) or a sham stimulation as a control.\n\"These changes suggest a beneficial effect of dTMS on both weight loss and change in microbiota composition,\" Luzi said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not discuss the availability of this treatment and the treatment does not appear to be available for obesity at this time. Since dTMS is only approved in the U.S. for treatment of depression, it\u2019s unlikely that it would be available to people without a formal diagnosis of depression.", "answer": 0}, {"article": "And, he promised, \u201cI will get on the skates again.\u201d\n\nLike Smith, many boomers endured months or years of pain before surgery, pain caused by \u201cbone-on-bone\u201d friction when cartilage deterioration eroded their bone cushioning.\nSome took multiple cortisone shots, hoping to avoid surgeries.\nWe want to keep going till we\u2019re in our 80s or 90s.\nI can run in the snow and ride my bike.\nI have complete range of motion .\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made it clear that knee replacements are widely available and covered by insurers.", "answer": 1}, {"article": "Men who received the combination of surgery and radiotherapy had higher rates of erectile dysfunction (28 percent vs 20 percent) and higher rates of urinary incontinence (49 percent vs 19 percent).\nA comparison of 2 of the most common combination therapies for locally advanced prostate cancer show the more aggressive option is linked with a higher rate of survival\n\n(Philadelphia) - High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies.\nSeveral large clinical trials are nearing completion that should validate these retrospective findings of the benefits of primary radical prostatectomy followed by additional therapies such as adjuvant radiation,\" said Leonard Gomella, Chair of the Department of Urology at Jefferson (Philadelphia University + Thomas Jefferson University), who was not involved in this research.\nIt's not just the risk of side effects.For some men, especially those who are not fit enough for the surgery, prostatectomy is not an option.\n\"For high-risk prostate patients we started the use of aggressive radiation therapy after surgery 20 years ago,\" said Adam Dicker, Senior Vice President and Chair of the Department of Enterprise Radiation Oncology at Jefferson Health, who was not involved in the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s evident these treatment options are widely available. However, the news release said researchers found many men aren\u2019t getting treatment that\u2019s recommended in medical guidelines.", "answer": 1}, {"article": "Scientists are inching closer to a drug that may protect peanut allergy sufferers from potentially life-threatening complications that can occur due to accidental consumption.\nIf that happens, people who receive and are able to tolerate this treatment should be protected from accidental exposures.\nThe study\u2019s authors noted that patients would need to stay on the drug in order to receive protection against the allergy.\nThe hope would be to have a treatment available in the second half of 2019.\nAll participants, who mostly fell between ages 4 and 17, had a peanut allergy, but one third received a placebo while the rest were given a peanut protein powder that increased in dose over time.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the treatment is not yet FDA-approved, and is not currently commercially available.", "answer": 1}, {"article": "The review identified a handful of drugs that \u201care probably effective and should be considered for migraine prevention.\u201d These include the antidepressants amitriptyline (Elavil, Endep or Vanatrip) and venlafaxine (Effexor); the beta blockers atenolol (Senormin or Tenormin) and nadolol (Corgard); and for menstrual migraines, naratriptan (Amerge) and zolmitriptan (Zomig).\nYou can read the new guidelines here, or check out the patient-friendly summary here.\nThe guidelines will be published in Tuesday\u2019s edition of the journal Neurology.\nThey were developed in conjunction with the American Headache Society.\nIt can cause throbbing pain in the head.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that these drugs are widely available.", "answer": 1}, {"article": "This mutation tells the cell to continue to grow.\nResearchers compared this new drug, which comes in pill form, to the only FDA-approved chemotherapy drug for melanoma, dacarbazine: It has been used to treat melanoma patients since 1975, but is only effective in about 10% of patients.\nChicago (CNN) -- For the first time, patients with the deadliest form of skin cancer have two new treatment options that prolong survival, according to new research presented at a cancer conference in Chicago on Sunday.\n\"This is an unprecedented time of clinical options -- it is truly practice-changing,\" said Dr. Lynn Schuchter, who heads the Melanoma Center at the University of Pennsylvania and is not involved with the research.\n\"Twenty-one percent of (the Yervoy) population was alive after three years,\" lead study author Dr. Jedd Wolchok said, compared to 12% who got the placebo and chemo.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that vemurafenib is experimental and Yervoy is commercially available. Unfortunately, the story includes a prediction from the ASCO President and others that , \u201c\u2026vemurafenib will almost certainly get FDA approval this year.\u201d While this may occur, it is not certain. And a little shoe leather journalism would easily find someone who would remind readers that FDA approval is not a fait accompli.\u00a0 Because of this, we judge this unsatisfactory.", "answer": 0}, {"article": "MONDAY, Jan. 11, 2010 (HealthDay News) -- As a major organization of pediatricians considers revising its recommendations on circumcision of newborn boys, two new reviews of existing research offer conflicting conclusions about the bitterly debated procedure.\n\"There are some clear benefits to circumcision,\" he said.\n\"These may be considered unacceptable for an elective procedure,\" she said.\n\"There are some risks to circumcision, although the significant ones appear to be rare.\"\nTwo studies involved neonatal circumcision, and six involved older males, roughly 14 to 49 years old.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 2}, {"article": "The human collagen used to develop the corneas was provided by biotechnology company FibroGen Inc.\n\u201cWe are still in the prototype stage, but this shows that regenerating a human cornea is possible.\u201d\n\nTwo years after having the corneas implanted, six of the 10 patients had improved vision .\n\u201cThis is the first time we have been able to regenerate a cornea in humans,\u201d researcher May Griffith, PhD, of the Ottawa Hospital Research Institute and the University of Ottawa tells WebMD.\nIn a newly released study, investigators from Canada and Sweden reported results from the first 10 people in the world treated with the biosynthetic corneas.\nA shortage of human donor tissue coupled with the threat of graft rejection from donor corneal transplants has driven the search for other ways of treating corneal damage.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Of the three stories, this one does the best job making it clear how preliminary this study is. The second sentence says that the results are from \"the first 10 people in the world treated with the biosynthetic corneas,\" signaling that much more work needs to be done. To underscore that point, two paragraphs later the first quote in the story, from one of the lead researchers in the study, says \"We are still in the prototype stage, but this shows that regenerating a human cornea is possible.\" This is the best quote in any of the stories.", "answer": 1}, {"article": "A birth-control pill that eliminates women's monthly periods could hit pharmacy shelves later this year, marking the latest effort by a drug company to expand a contraceptive's features beyond preventing pregnancy.\n\nSince \"The Pill\" was introduced nearly a half-century ago, most regimens have mimicked a woman's cycle by having a pill-free week each month when women can have bleeding and other symptoms.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states that the drug maker has applied to FDA for approval, and expects a response by the end of June. The story also claims that the new birth control pill could be on the market by year\u2019s end. However, there is no independent source cited in support of these claims. The trail of past baseless predictions of FDA approval and market availability is long. ", "answer": 0}, {"article": "Nature publishes broad review articles, called Primers, that cover global aspects of various diseases and describe all aspects from epidemiology, disease mechanisms, diagnosis, screening and prevention, management and quality of life.\nLike all medical foods, IBgard\u00ae does not require a prescription, but it must be used under medical supervision.\nAdditionally, the support from the medical community builds on a previously important review article about the use of peppermint oil in IBS.\nIt included a favorable review of IBgard\u00ae, a novel formulation of peppermint oil developed as a medical food specifically for the dietary management of IBS.\nThe researchers also concluded that, \"A novel formulation of peppermint oil, designed to cause sustained release in the small bowel, was superior to placebo in causing a reduction in total symptoms.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that IBgard is for sale without a prescription at many pharmacies and other stores.", "answer": 1}, {"article": "Folic acid -- a synthetic version of folate found in many supplements and multivitamins -- has been shown to lower homocysteine in previous studies, but its effect on disease risk is disputed.\n\"A healthy diet likely remains important,\" Seshadri says.\n\"The role of supplementation remains unclear.\"\n\"Good nutrition should minimize the risk of Alzheimer's disease, but we can't say that any specific food has been proven to reduce this risk.\"\nHealth.com: 9 foods that may help save your memory\n\nOver the next seven years, 17 study participants were diagnosed with Alzheimer's disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Boutot and Bertone-Johnson suggest that more prospective studies of their findings are warranted, including studies that compare soy-based and non-soy vegetable proteins.\n\"A better understanding of how dietary vegetable protein intake is associated with ovarian aging may identify ways for women to modify their risk of early onset menopause and associated health conditions,\" write first author and then-graduate student Maegan Boutot, with her advisor, professor Elizabeth Bertone-Johnson.\nBoutot and Bertone-Johnson add, \"Though relatively few women in our study consumed very high levels of vegetable protein and our power for analyses of more extreme intake levels was limited, women consuming 9 or more percent of their calories from vegetable protein had a hazard ratio of 0.41 (95 percent confidence interval = 0.19-0.88)\" compared to those eating less than 4 percent.\nBoutot, Bertone-Johnson and colleagues in the School of Public Health and Health Sciences at UMass Amherst, with others, evaluated the relationship between diet and risk of early menopause among members of the Nurses' Health Study II (NHS2), an ongoing prospective study of 116,000 women aged 25-42 when they entered it in 1989.\nFor a woman with a 2,000 calorie per day diet, the authors explain, this is equal to three to four servings of such foods as enriched pasta, breakfast cereal, tofu and nuts, or about 32.5 grams a day.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Availability isn\u2019t an issue. Adding vegetable protein to your diet in the modest amounts involved in this study is a fairly easy thing to do. A completely vegetarian diet is more challenging, but that\u2019s not what the study suggests.", "answer": 2}, {"article": "Feb. 7, 2011 -- Giving your sweetie chocolate for Valentine's Day may show you care for their health as well as their heart.\nAntioxidants are a group of compounds known to fight the damaging effects of oxidative stress on cells within the body and are increasingly thought to have many heart-healthy properties.\nTwo groups of antioxidants in particular, polyphenols and flavonols, which are found in various fruits and seeds, have been the focus of much research due to their potentially healthy effects.\n\"These substances help keep the arteries healthy and are protective against cardiovascular disease,\" says preventive cardiologist Suzanne Steinbaum, MD, of Lenox Hill Hospital in New York City, in an email.\nDark chocolate generally has a higher percentage of cocoa content than milk chocolate.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of dark chocolate isn\u2019t really in question, but it is important to point out that health benefits\u00a0are associated with specialty chocolates that have a high concentration\u00a0of cocoa solids and are minimally processed.\u00a0Milk chocolate and other sweeter chocolates undergo a \u201cdutching\u201d process that softens the bitter taste of the cocoa but also destroys many of the antioxidants.\u00a0The story was relatively clear on this point, so we\u2019ll award a satisfactory.", "answer": 1}, {"article": "The population studied was relatively homogenous, and \"the [body mass] findings were not the object of the study (wheezing or asthma in children was the primary objective), growth was a secondary finding,\" Rabin explained.\n\"The use of fish oil in the latter part of the pregnancy has an impact on bone and muscle mass.\nThough these children are larger, they do not have increased rates of obesity,\" Wu added.\n\"For the past decade, the importance of fish oil and the omega-3 fatty acids have been stressed to patients,\" explained Wu, who was not involved in the study.\nBut Rabin, who was not involved in the study, did add a few caveats about the findings.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Fish oil supplements are readily available.", "answer": 1}, {"article": "Combining ursolic acid with either curcumin or resveratrol prevents cancer cells from gobbling something that they need to grow, glutamine.\n\"After screening a natural compound library, we developed an unbiased look at combinations of nutrients that have a better effect on prostate cancer than existing drugs,\" says corresponding author Stefano Tiziani, assistant professor in the Department of Nutritional Sciences and Dell Pediatric Research Institute at UT Austin.\nThe most promising active ingredients were then tested on model animals: ursolic acid, a waxy natural chemical found in apple peels and rosemary; curcumin, the bright yellow plant compound in turmeric; and resveratrol, a natural compound common to red grapes or berries.\n\"These nutrients have potential anti-cancer properties and are readily available,\" says Tiziani.\nNew research from The University of Texas at Austin identifies several natural compounds found in food, including turmeric, apple peels and red grapes, as key ingredients that could thwart the growth of prostate cancer, the most common cancer afflicting U.S. men.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "These foods can be obtained at most grocery stores; availability is not a question. The release could have lent more clarity by telling readers whether supplements are available. For example, resveratrol supplements are available and have been extensively studied for diabetes, obesity, and cardiovascular disease.", "answer": 2}, {"article": "Replacement, by contrast, preserves some range of motion.\n\"Some of the newer implant designs save a lot of the bone stock,\" said Collins, who performs about 10 wrist replacements a year.\n\"Our hand is our working instrument,\" said Dr. Evan D. Collins, an orthopedic surgeon with the Methodist Center for Sports Medicine.\nFor questions or comments on the Health & Medicine page, contact matthew.schwartz @chron.com.\nSome form of wrist replacement surgery has been available but seldom used for decades.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article explains that wrist replacement has been available for decades. But why is the procedure \u201cseldom used\u201d? Is the device FDA-approved? Is the operation widely available in the U.S., offered in the local community hospital, or mostly consigned to large or academic medical centers? The article does not say.", "answer": 0}, {"article": "\u201cThe journal knew it.\u201d\n\n\u201cThe question for the journal, given that the authors worked for the company, is, \u2018Do we publish something like that?\u2019\u201d\n\nJohnston said there was an ongoing debate about whether or not scientists who review studies should know about potential industry interests.\n\u201cIt sounds like opinion and nothing more.\u201d\n\nThe only published data on the tanning pill\u2019s ability to reduce sunburns came out last month in the British Journal of Dermatology.\nThe pill combines lycopene and beta-carotene \u2014 the red and orange substances in tomatoes and carrots, respectively \u2014 with a probiotic reported to impact the skin\u2019s response to UV light.\nDr. Tobias W. Fischer, a dermatologist at the University Lubeck in Germany, offered this rationale for why he didn\u2019t: \u201cI don\u2019t give interviews, criticizing other researchers\u2019 work, even if industrial.\u201d\n\nThe editor of the journal that published the study, Dr. Tanya Bleiker, said it had been reviewed by experts before acceptance, as are all the journal\u2019s reports.\nAs a result, said Schalock, the company\u2019s claim that women taking their product can sunbathe with less concern of getting burned might be a stretch.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no question about the availability of the beauty product in question.\u00a0 The story states the company is preparing to \"present this product to dermatologists\" and that it \"has already been launched in Europe and South America.\" ", "answer": 1}, {"article": "It appears to be that fasting is causing some major stress, and the body responds to that by some protective mechanisms that potentially have a beneficial long-term effect on risk of chronic disease.\u201d\n\nDr. Horne noted that patients shouldn\u2019t take up fasting without discussing it first with their doctor.\nRegular fasting may be good for your heart.\nThe patients were asked if they engaged in regular fasting, and the researchers compared the answers to whether they eventually received a diagnosis of heart disease.\nThe scientists used blood tests before and after the fasting period to look at a number of different metabolic markers.\nThe hormone is released by the body in times of starvation to protect lean muscle mass and trigger the body to start burning fat stores.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 Anyone can fast.", "answer": 2}, {"article": "The requested URL /usnews/health/articles/070225/5laser.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions LASIK is a common surgery, accounting for 87% of all laser eye surgeries last year. The story notes that more surgeons are tailoring techniques and procedures as laser eye surgery grows in popularity,\u00a0but the story also notes that\u00a0corrective eye surgery is not a \"one size fits all\".\u00a0 The story\u00a0 mentions newer tools to improve the LASIK and PRK procedures, but it does not mention if these are widely available. ", "answer": 1}, {"article": "He is an associate professor in the department of infection and obesity at the Pennington Biomedical Research Center in Baton Rouge, La.\nScientists suspect that egg protein may be better at making people feel full longer compared to the protein found in wheat.\nFor people hoping to shed some pounds, changing the type of protein in the diet, rather than the amount of it, is an idea the researchers think deserves more study as a weight loss strategy.\nOne large egg has about 70 calories, and it contains about 6 grams of protein, 5 grams of fat, and 186 milligrams of cholesterol.\nIn a small study, it took longer for people who ate eggs for breakfast to show signs of hunger than it did for those who had a bowl of ready-to-eat cereal.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of eggs and cereal is not in question.", "answer": 2}, {"article": "Equally important, the response was long-lasting for most patients.\nThe results of the larotrectinib trial in adult patients - a 75 percent response rate - were published last month in the New England Journal of Medicine.\nThe selectivity of the drug means it does not cause the severe side effects associated with many traditional cancer treatments, and none of the patients with TRK fusions had to quit the study because of a drug-induced side effect.\nTo date, the response to this drug seems to be durable in most patients,\" said Dr. Laetsch, who investigates the use of tumor molecular profiling to guide therapy in UT Southwestern's Pediatric Hematology and Oncology Division.\nThe TRK-fusion mutation can be present in many types of cancers, including lung, colon, thyroid, and breast cancer, as well as certain pediatric tumors.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not make it clear that the drug is not yet available in the US beyond clinical trials.\nThe company recently completed its application for fast track approval from the FDA but it is not yet approved.", "answer": 0}, {"article": "Whether it is encouraging people to eat right or to exercise, they said, the hardest part is not getting them to start doing the right things but getting them to keep doing the right things.\nThe results, being published today in the Journal of the American Medical Association, are heartening, but Willis and Marsiske cautioned that the biggest challenge lies ahead, in getting people to apply the findings to their lives.\n\"If you think you have come to a time in your life when new learning is impossible and there are no benefits of continuing mental activity, the study shows that for a large number of people that this is not true,\" added Marsiske, a clinical and health psychologist at the University of Florida at Gainesville.\nIf anything, the study suggests, there is a bigger payoff to mental exercise, because the brief training sessions seemed to confer enormous benefits as many as five years later.\nAlthough it did not examine the effects of mental exercise on people who had begun to show signs of Alzheimer's or other brain disorders, previous studies have pointed toward the conclusion that anyone can benefit.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story did contain advice (from the lead author of the study) about working on puzzles that are more difficult, something new, and stretch the mind \u2013 the nature of the three distinct interventions used with the ACTIVE study participants was not clear, nor was the\u00a0difficulty of\u00a0finding people to work with on these specific sorts of mental training activities mentioned.\u00a0 How one might access the interventions used in the study was not clarified for the reader.\u00a0 It is also not clear how the study interventions actually relate to the kinds of examples given in the story such as doing puzzles.", "answer": 0}, {"article": "\u2022 In the randomized controlled trial, 38 men with abdominal obesity followed a dietary pattern high in either carbohydrates (53 % of total energy, in line with typical official recommendations) or fat (71 % of total energy, of which about half was saturated).\nTotal energy intake was within the normal range.\nRather, the \"good\" cholesterol increased only on the very-high-fat diet.\nIt may even be healthy,\" says Ottar Nyg\u00e5rd.\n\"The fat sources were also lowly processed, mainly butter, cream and cold-pressed oils.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Both high-carbohydrate and high-fat foods are widely available.", "answer": 2}, {"article": "'This is not the end': Using immunotherapy and a genetic glitch to give cancer patients hope\n\u201cOne man who came in a wheelchair is now out of a wheelchair and is coaching Little League.\u201d\n\nPeople with hemophilia B inherit a gene mutation on the X chromosome that interferes with their ability to produce normal levels of blood-clotting factor IX.\nSo far, with a full year, it doesn\u2019t look like that is happening.\u201d\n\nLindsey George, the lead investigator and a hematologist at Children's Hospital of Philadelphia, said that nine of the 10 men in the trial didn't experience any bleeding episodes after the gene therapy treatment.\nThe hemophilia study \u201cis small but very promising, and it gives me the sense that gene therapy for hemophilia B is going to be at our disposal in no time, maybe a few years from now,\u201d said Aric Parnes, who is associate director of the Boston Hemophilia Center at the Dana-Farber/Boston Children's Cancer and Blood Disorders Center and wasn't involved in the study.\nIn addition, he said, researchers need to find ways to provide the therapy to a broader group of people, including children, and to figure out how to reduce the costs involved.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Since the story notes that the research is at an early stage with only 10 participants, a reader can easily infer that the treatment is not yet available. However, additional information about remaining evaluation stages for this treatment would have been a useful reinforcing addition. Hemophilia B sufferers who see this story will likely be contacting their doctors.", "answer": 1}, {"article": "In a first, U.S. trial to test Cuban lung-cancer vaccine\nHe said the results established the double-immunotherapy combination as a first-line treatment for patients with a high \u201ctumor mutational burden,\u201d but that it was too early to know whether the treatment leads to longer survival.\nExperts said it was especially significant that the study showed that patients benefited from the Keytruda-chemo combination regardless of the levels of a protein, called PD-L1, found on their cancer cells.\nLast week, in a related development, Merck, which makes Keytruda, reported that a different trial showed that the medication prolonged survival even when used alone, compared with chemo.\nBut the disease is so lethal that many patients don\u2019t survive long enough to try second- or third-line treatments, so researchers are trying to develop and use more effective approaches earlier.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the FDA approved the Keytruda-chemo combination last May based on an early-stage trial, but many doctors did not adopt it because the trial was small and didn\u2019t initially show a survival benefit.", "answer": 1}, {"article": "\"It is a huge step\" and a first for the field of genetics, said John Rossi, a researcher at City of Hope in Duarte, Calif., where he and Zaia plan another study to test Sangamo's approach.\nThe only side effect was two days of flulike symptoms.\nThe results announced Monday at a conference in Boston left experts cautiously excited.\nThe research was only meant to show that, so far, it seems feasible and safe.\nHe treated his first patient with it in July 2009.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story\u00a0 made it clear that this was a very preliminary report.", "answer": 1}, {"article": "\"\nIt can be hard to view those everyday decisions in light of more distant consequences, like having another heart attack or not living as long a life as desired.\nIt can't tell us whether text messaging could eventually lead to fewer subsequent heart attacks among the patients receiving those messages or whether the positive health outcomes would continue past the six-month study window.\nBy the end of the six-month study, patients who had received the text messages had reduced their cholesterol, blood pressure and body mass index.\nThe texts that patients received were semi-personalized, based on background information about each person, such as smoking status and preferred name.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It was fairly clear from the story that this was a clinical trial, and that this particular service doesn\u2019t seem to be available to offer customized, encouraging text messages for heart disease patients.", "answer": 1}, {"article": "The results so far are very promising.\n\"We are delighted to have received further funding from the Wellcome Trust and Department of Health to test whether adalimumab will work for patients with early stage Dupuytren's disease,\" said Professor Sir Marc Feldmann, co-author and former director of the Kennedy Institute.\n\"Our data have shown that a concentrated formulation of adalimumab injected directly into the diseased tissue may be effective in targeting the cells responsible for Dupuytren's disease,\" said Jagdeep Nanchahal, MD, PhD, University of Oxford Professor of Hand, Plastic and Reconstructive Surgery, who led the study.\nThe researchers are continuing to investigate the use of this drug to treat Dupuytren's disease in a phase 2b trial called the RIDD trial, which is currently running in Oxford and Edinburgh.\nThe team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection, suggesting this drug could be used to stop the growth of disease causing myofibroblast cells.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s noted that this treatment approach is in phase IIa trial; that is, preliminary evaluation of short-term safety and efficacy.\nHowever, the language used in the release: \u201cThe team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection\u201d\u00a0suggests this drug (which is commercially available for other conditions) could be used to stop the growth of disease causing myofibroblast cells. A simple statement in the release noting the preliminary nature of the research would have gone a long way into placing the the drug\u2019s availability into proper perspective.", "answer": 1}, {"article": "\u201cNo matter how sophisticated, they shouldn\u2019t trump data from real people who participated in the randomized trials\u201d \u2014 which in PLCO found zero lives saved from PSA screening.\nAmong other drawbacks, the tests lead to overdiagnosis (meaning a biopsy finds malignant cells but they are so innocuous they would never harm, let alone kill, the man) as well as incontinence and impotence from treatment (including of harmless cancers).\nIn April, however, the task force proposed instead that men aged 55 to 69 discuss PSA\u2019s pros and cons with their doctor and then decide what to do, factoring in that if 1,000 men get regular PSA screening for a decade it will save about one life.\nDr. Kenneth Lin of Georgetown University Medical Center, a former staffer at the USPSTF, said crediting PSA tests with reducing prostate cancer mortality by around 30 percent was probably an overstatement, especially since mathematical models are only models.\nFor a man in the U.S., the risk of dying of prostate cancer is about 2.5 percent.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the article that PSA testing is ubiquitous in America. Mentioning that it is covered by most insurers, and for those on Medicaid/Medicare, still would have been helpful, however.\n\u00a0", "answer": 1}, {"article": "The P-Cure gantry-less system significantly reduces many factors associated with proton therapy including the capital cost of equipment and construction, the size of a single room center or multi-room expandable center and the time from center planning to treatment.\nP-Cure works both with the existing and new cancer centers to establish advanced proton therapy capabilities.\nBecause of the high capital costs, proton therapy is currently only available to less than one percent of patients who could potentially benefit from it.\n\u201cWe are excited to receive FDA clearance for our upright imaging technology.\nAdult and pediatric patients who will initially benefit from this clinical breakthrough will be those treated for cancers of the lung, breast, chest, the head and neck, and lower torso.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that this therapy has just been cleared and that proton therapy is currently not widely available.", "answer": 1}, {"article": "POPGis one of several lipids found in the fluid that lines the air sacs of the lungs.\n\"Our findings demonstrate that POPG is a potent antiviral agent both as\n\na prophylactic and after infection has occurred,\" researcher Dennis Voelker, PhD, professor of medicine at National Jewish Health in Denver, says in a news release.\nThe findings also suggest that POPG\u2019s role in the lungs may be to help the lungs tolerate the daily barrage of inhaled irritants.\n\"While these are still early studies, several characteristics of POPG make me believe that it has real potential as both an antiviral and anti-inflammatory treatment.\"\nDec. 21, 2009 -- A fatty substance found naturally in the lungs may provide a natural defense against respiratory syncytial virus (RSV) infection.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not until the sixth paragraph does the story explain that this work was done in the lab \u2013 not in people.\u00a0 But later, the story says that the substance in question \"is already used in other treatments and has been safely given to millions of premature infants to protect their lungs.\" So is that a substance that doctors would use (have used?) off-label?\u00a0 This is not at all clear. ", "answer": 0}, {"article": "Prescribing testosterone for age-related deficiency \u2014 which is only vaguely defined \u2014 took off in 2000. The trend was driven not by solid scientific evidence, but by the introduction of convenient, rub-on testosterone products, the first being Androgel. Many men are put on testosterone with no tests of their levels or despite tests showing normal levels, a study of Medicare claims found.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s made clear that testosterone is available. It would have been\u00a0helpful to clearly state that this requires a prescription, but this is a minor quibble.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/09/national/a005536S75.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability is clear from the statement that nevirapine \u201chas become a mainstay in the effort to prevent mother-to-child HIV transmission in poor countries\u201d. ", "answer": 1}, {"article": "Now genomics may have provided an answer.\nWorking on the theory that cigarettes harm not only the lungs but a \"field of injury\" extending to other areas of the respiratory tract, the study authors surmised that evidence of existing or soon-to-develop lung cancer might be available further up in the airway.\nThe researchers also need to explore whether or not the PI3K pathway is active in non-smokers, as well as what other pathways might also trigger lung cancer.\nWEDNESDAY, April 7, 2010 (HealthDay News) -- Researchers may have found an easy way to detect lung cancer in its early or even pre-cancerous stages, as well as a way to reverse the start of the deadly disease with a readily available, over-the-counter drug.\nThe minimally invasive procedure involves using a small brush to collect a smattering of cells from the windpipe (a bronchoscopy), explained study co-author Andrea Bild, an assistant professor of pharmacology and toxicology at the University of Utah in Salt Lake City.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The opening line of the article \u2014 \"Researchers may have found an easy way to detect lung cancer in its early or even pre-cancerousstages, as well as a way to reverse the start of the deadly disease with a readily available, over-the-counter drug\" \u2013 overstates the evidence for inositol\u2019s effectiveness, and implies that it is available in a form that could reverse the development of lung cancer.\u00a0 ", "answer": 0}, {"article": "\u201cThere\u2019s been a longstanding fear of skin testing, and it turns off a lot of allergy sufferers from getting help,\u201d said Dr. Mitchell, the author of \u201cAllergy and Asthma Solution\u201d (Marlowe, 2006), which advocates oral immunotherapy, or allergy drops, instead of shots.\nThe blood test, which is not without its own ouch factor, measures levels of circulating IgE.\nBecause the test comes with a small risk of a serious reaction, it should not be performed in very young children and pregnant women, among others.\nThe blood test is also part of a larger debate about who should be treating allergy sufferers.\nA patient typically gets 15 to 20 skin pricks, but sometimes many more.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does say that the test is available and comments that its use is limited in the U.S.", "answer": 1}, {"article": "Johansson and her colleagues used data from nationwide Swedish health registries to compare pregnancies between nearly 600 women who had given birth after bariatric surgery and more than 2,300 women who hadn't had the surgery but had the same BMI.\nWEDNESDAY, Feb. 25, 2015 (HealthDay News) -- After undergoing weight-loss surgery, women are significantly less prone to diabetes during pregnancy but twice as likely to deliver smaller-than-normal infants, a new study suggests.\nWhile various techniques may be used, the surgery restricts the amount of food the stomach can hold and/or reduces the intestines' absorption of calories and nutrients from food.\n\"The number of women who are obese in early pregnancy has increased dramatically over the last decades,\" said study author Kari Johansson, a postdoctoral researcher and nutritionist at Karolinska Institute in Stockholm.\nBecause obesity is linked to poor outcomes for expectant mothers and babies -- including birth defects, gestational diabetes, high blood pressure, premature birth and even childhood obesity -- efforts to lose weight before pregnancy are important, said Dr. Aaron Caughey, chair of the department of obstetrics and gynecology at Oregon Health and Science University's School of Medicine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article provides nice context for the scope and nature of bariatric surgery in the U.S.: \u201cNearly 179,000 obese people underwent weight-loss surgery in the United States in 2013, according to the American Society for Metabolic and Bariatric Surgery. While various techniques may be used, the surgery restricts the amount of food the stomach can hold and/or reduces the intestines\u2019 absorption of calories and nutrients from food.\u201d", "answer": 1}, {"article": "MRI uses a powerful magnetic field and pulses of radiowave energy to create images.\nBut doctors do not always want to run the risks that can be associated with that technique, and the leading candidates for less invasive assessment are CT and MRI.\n\"This article holds no surprises whatever,\" said Dr. Uwe Joseph Schoepf, a professor of radiology and cardiology at the Medical University of South Carolina.\nThough that difference is well established among radiologists, the new study may be of assistance in the general medical community, including general cardiologists, because \"it summarizes the advantages of CT at this point in time,\" he said.\nIndeed, CT appears to be better for assessment of coronary artery disease, matched against not only MRI but other methods, such as echocardiography, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that CT and MRI are currently used in clinical practice. Both techniques are routinely available for imaging of the heart in most academic and large community hospitals.", "answer": 1}, {"article": "\"What we found was a very coherent pattern of less cervical cancer among people who\u2019ve used the IUD based on thousands of women \u2014 and the pattern wasn't subtle at all, it was stunning,\" Dr. Victoria Cortessis, the study's lead author and associate professor of clinical preventive medicine at the Keck School of Medicine at the University of Southern California, told BuzzFeed Health.\n\nIUDs are small, T-shaped devices that are placed in the uterus to prevent sperm from reaching an egg. They are a highly effective form of birth control and they can offer protection against pregnancy for up to three, five, or ten years.\n\nThe study is the first of its kind to combine and analyze data from multiple studies to look at the issue. \"We went through all of the relevant human epidemiological data on this topic and narrowed it down to 16 high-quality observational studies of over 12,000 women from all over the world,\" Cortessis says.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "IUDs have been available to women for decades. The only issue the story might have considered further is how available they are in low-income nations where vaccines and regular screening are not accessible to many women.", "answer": 1}, {"article": "The team of scientists at Imperial was funded by Cancer Research UK.\nProfessor Charles Coombes, from the Department of Surgery & Cancer, said: \"Treatment-resistant tumours represent a significant threat for patients, as once a cancer stops responding to treatments there is increasingly little clinicians can do.\nThe drug may not become available to patients for a number of years yet, but researchers believe that if clinical trials are successful, it could be used to tackle a variety of treatment-resistant cancers.\nProfessor Tony Barrett, from the Department of Chemistry, said: \"This work is the result of extensive collaboration between chemists, biologists and clinicians, which has helped to bring a new treatment from discovery to clinical testing in record time, streamlining the process.\"\nIn addition, laboratory studies showed ICEC0942 worked better in combination with traditional hormone therapies for estrogen receptor positive breast cancer cells, which have not yet become resistant.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We applaud the news release for stating in the second paragraph that the \u201cdrug may not become available to patients for a number of years yet.\u201d Of course, the \u201cyet\u201d is optimistic; it remains to be seen whether this will ever become available.", "answer": 1}, {"article": "Researchers agree there is a strong genetic component.\n\u201cWe would hope that it would work just as well ... there is no reason why not.\u201d\n\nThe ability to base a diagnosis on an objective biological test, rather than having to rely on personality traits, should mean patients get treatment more quickly, he added.\nLONDON (Reuters) - A 15-minute brain scan could in future be used to test for autism, helping doctors diagnose the complex condition more cheaply and accurately.\nThe speed of the test makes it some 20 times cheaper than traditional tests, which can take a team of doctors four to eight hours to conduct.\nThe new scanning method \u2014 which picks up on structural changes in the brain\u2019s grey matter \u2014 could be ready for general use in a couple of years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although it is clear that this technology is not yet available to the public, the story\u00a0predicts the new scan \"could be ready for general use in a couple of years.\" Really?\u00a0Who says? It seems unlikely that any knowledgeable researcher would make such a wildly optimistic prediction on the basis of a 40-person study.\u00a0But the story\u00a0treats\u00a0this forecast\u00a0as an established fact\u00a0requiring no attribution, so\u00a0we can\u2019t tell where it came from.\u00a0\u00a0In any case, we think such\u00a0pie-in-the-sky guesstimates are usually wrong and should be avoided in health journalism. \u00a0", "answer": 0}, {"article": "Further,Dr.\n\u201cIf you take the core patients who are at highest risk, it makes you appreciate how important this drug class is,\u201d said Dr. Amit Khera, Director of the Preventive Cardiology Program and Associate Professor of Internal Medicine at UT Southwestern.\n\u201cIn the world of cholesterol patients, most are well-controlled with statins, and they should stay on those,\u201d said Dr. Khera.\nUsing data from the Dallas Heart Study, a population-based study that gathered extensive medical data on 6,000 Dallas residents, the two researchers showed that certain mutations to the gene that codes for the protein PCSK9 lead to low levels of cholesterol in the blood.\n\u201cThere are many more Frank Browns out there \u2013 patients who can\u2019t control their cholesterol with the standard drugs,\u201d said Dr. Khera.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the drugs have been approved by the FDA, and that at least one of them was available to the patient described in the release. The reader can infer that the drugs are available to the public.", "answer": 1}, {"article": "\u201cFor antidepressants in adolescents, this equation will rarely favor prescribing; in younger children, almost never.\u201d\n\nTo be clear, Jureidini believes there is almost never a justification for prescribing antidepressants to children or adolescents.\n\u201cOnly if the discounted benefit outweighs the boosted harm should the treatment be prescribed,\u201d he writes.\nGiven the U.S. population, that works out to more than a million children and adolescents.\nOf course, having an effective intervention once it is recognized would help.\nI called him to be sure.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says all the 14 antidepressants studied were \u201ccommercially available.\u201d", "answer": 1}, {"article": "Armed with her previous research, Bahn and her team detailed a panel of blood biomarkers in individuals who have an increased risk of schizophrenia but have no visible symptoms yet.\nThe team took urine samples from patients who had been diagnosed with one of the two disorders and looked for differences between the two groups.\nThe brain, however, is also vulnerable to many more, much less visible ailments.\n\u201cPsychiatric disorders often present with other diseases such as diabetes and some immune disorders,\u201d says Bahn.\nThose working on these sorts of tests see them being implemented in a different setting entirely: when a patient comes into their internist seeking treatment for other conditions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story goes into some detail about how experimental these diagnostic tests are and even some of the difficulties entailed in bringing them to market.", "answer": 1}, {"article": "Media Advisory: To contact corresponding author Susan L. McElroy, M.D., call Jennifer Pierson at 513-536-0316 or email jennifer.pierson@lindnercenter.org\n\"In the primary analysis of this study of adults with moderate to severe BED, lisdexamfetamine dimesylate treatment with 50 and 70 mg/d, but not 30 mg/d, demonstrated a significant decrease (compared with placebo) in weekly BE days per week at week 11.\nThe one-week BE episode response status was improved in the 50- and 70-mg/d treatment groups, and a greater proportion of participants achieved four-week cessation of BE episodes and global improvement of symptom severity with all lisdexamfetamine dosages.\nAt some doses, the medication lisdexamfetamine dimesylate, a drug approved to treat attention-deficit/hyperactivity disorder, was effective compared with placebo in decreasing binge-eating (BE) days in patients with binge-eating disorder (BED), a public health problem associated symptoms of mental illness and obesity and for which there are no approved medications, according to a study published online by JAMA Psychiatry.\nResults also indicate the percentage of patients who achieved four-week BE cessation was lower with the placebo group (21.3 percent) compared with the 50-mg/d (42.2 percent) and 70-mg/d (50 percent) treatment groups.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release\u00a0clearly indicates that the drug is already approved to treat other medical problems. It also indicates that the next step in making the drug available for the need at hand rests on \u201cconfirmation of these findings\u201d in additional clinical trials. This release was issued in January 2015, and the drug has subsequently been approved for the treatment of binge-eating disorder.", "answer": 1}, {"article": "MONDAY, Aug. 6, 2012 (HealthDay News) -- Treatment with growth hormone-releasing hormone improves memory and focus in healthy adults and in those who already show some signs of mental decline, new research finds.\nAll of these hormones are believed to play a role in brain health, and decreasing levels of these hormones are suspected to play a role in the development of Alzheimer's disease.\n\"IGF1 is a hormone we all have from birth that increases through development until it starts to decline in our early 50s.\nThey saw improvement in \"planning, organizing, focusing and shifting from one task to another\" -- tasks collectively known as executive function.\n\"It stimulates a whole cascade of hormones in the body and brain; it stimulates normal function of a system that was working at a younger age so that cells can do what they were programmed to do at birth.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There could have been a line or two about how GHRH is used now in medicine and whether there is much off-label use of the injections.", "answer": 0}, {"article": "But these methods alone don't give reliable results.\nAnother problem is that the test results find signs of cancer, but often fail to pinpoint which part of the body is affected.\nThe scientists at Hopkins have already launched their next study, which could involve tens of thousands of apparently healthy volunteers who are enrolled in the Geisinger Health Plan in Pennsylvania.\nFor example, the test was successful only about 40 percent of the time in the patients the researchers studied with the earliest stage 1 cancers.\nOf course, the ultimate goal of this test is to find cancer in people who haven't already been diagnosed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s mentioned the authors of the study are \u201choping their idea would eventually lead to a $500 test \u2026 but they have a long way to go.\u201d Future studies of the screening test are also discussed, so it seems clear this test is not currently available.", "answer": 1}, {"article": "Nov. 24, 2016.\nThis information opens the door to using decitabine in a more targeted fashion to treat not just older patients, but also younger patients who carry TP53 mutations.\u201d\n\nFirst author John Welch, MD, PhD, an assistant professor of medicine, added: \u201cIt\u2019s important to note that patients with an extremely poor prognosis in this relatively small study had the same survival outcomes as patients facing a better prognosis, which is encouraging.\n\u201cThe findings need to be validated in a larger trial,\u201d Ley added, \u201cbut they do suggest that TP53 mutations can reliably predict responses to decitabine, potentially prolonging survival in this ultra high-risk group of patients and providing a bridge to transplantation in some patients who might not otherwise be candidates.\u201d\n\nIn an accompanying editorial, Elihu Estey, MD, an AML expert at the University of Washington Medical Center and Fred Hutchinson Cancer Research Center in Seattle, noted that AML is not one disease but many, each driven by different genetic mutations.\n\u201cIt\u2019s exciting to think we may have a therapy that has the potential to improve response rates in this group of high-risk patients.\u201d\n\nThe research is supported by an AML-SPORE grant and the Genomics of AML Program Project grant, both from the National Cancer Institute at the National Institutes of Health (NIH), grant numbers P50 CA171963 and P01 CA101937.\n\u201cThe challenge with using decitabine has been knowing which patients are most likely to respond,\u201d said co-author Amanda Cashen, MD, an associate professor of medicine who led an earlier clinical trial of decitabine in older patients with AML.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that decitabine is an existing FDA-approved drug. However, its off-label use in this trial does not mean that it is now available for other AML patients. The researchers note repeatedly that larger trials are required.", "answer": 1}, {"article": "The study's authors acknowledged that their preliminary data offers \"promise for the use of time-restricted feeding as a weight loss technique in obese adults, but longer-term, large-scale randomized controlled trials [are needed].\"\n\"There are also many studies that either report no overall effect or sometimes the opposite.\nFor 12 weeks, the scientists measured various factors, including the participants' fat mass, blood pressure and cholesterol and glucose levels.\nNow, researchers have shed light on what one type of time-restricted eating does to the body.\nFurther research is now needed to uncover whether 16:8 works better than other fasting diets in terms of weight loss and health benefits.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is an intervention tied to eating schedules, not a product. There\u2019s no question of availability.", "answer": 2}, {"article": "UnitedHealthcare's medical policy for TMS says it is unproven for treating depression.\nThe device makes a clicking noise while delivering the magnetic pulses.\nThe cost, however, is less than an extended hospital stay.\nIt can cost as much as $400 for a 37-minute session and require multiple treatments.\nIt's an alternative to electroconvulsive therapy \u2014 shock treatments \u2014 for patients who have not responded to drugs or psychotherapy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the device and thus the treatment is available. \u00a0The story does provide some insight into insurance coverage as well.", "answer": 1}, {"article": "Over two years, both groups showed steady improvement.\nBut by the end, those who had been in the combined program had more symptom relief, and were functioning better as well.The researchers expect to have lowered average doses in the combined program but had not yet finished analyzing that data.\nThe sprawling research team, led by Dr. John M. Kane, chairman of the psychiatry department at Hofstra North Shore-LIJ School of Medicine, randomly assigned 34 community care clinics in 21 states to provide either treatment as usual, or the combined package.\nFor example, some patients can learn to defuse the voices in their head \u2014 depending on the severity of the episode \u2014 by ignoring them or talking back.\n\u201cI\u2019m very favorably impressed they were able to pull this study off so successfully, and it clearly shows the importance of early intervention,\u201d said Dr. William T. Carpenter, a professor of psychiatry at the University of Maryland School of Medicine, who was not involved in the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story touches on availability when it says, \u201cIn 2014, Congress awarded $25 million in block grants to the states to be set aside for early-intervention mental health programs. So far, 32 states have begun using those grants to fund combined-treatment services, Dr. Heinssen said.\u201d That doesn\u2019t provide as much detail as readers might like as to when and where they might find these services, but it gives a general idea of where things stand.", "answer": 1}, {"article": "Ellis also is a McNair Scholar at Baylor.\nThe results of the clinical trial were encouraging in that about 30 percent of the 16 patients treated with neratinib had a meaningful clinical response showing significant disease stabilization or regression.\nThere is a group of metastatic breast cancers that has the HER2 gene amplified - the cells have many copies of it - which leads to enhanced activity of the product enzyme, a tyrosine kinase.\nBased on the estimate that the new mutation is present in 2 to 3 percent of cases, the researchers calculated that approximately 4,000 to 6,000 patients with metastatic breast cancer carry a HER2 mutation and are therefore potential candidates for neratinib treatment.\nHER2 has been established as a therapeutic target in breast cancer, and breast cancers in which the HER2 gene is not amplified do not, in general, respond to HER2-directed therapeutic approaches.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release didn\u2019t make it clear that more research is needed following the phase 2 trial. The release could have mentioned that neratinib has already been approved by the FDA for women with early-stage HER2+ breast cancers as a follow-on therapy.", "answer": 0}, {"article": "However, Reid believes theirs is the first study to model the long-term effects of eating dark chocolate in reducing cardiovascular risk.\nThey did not study actual people eating actual chocolate.\nMaybe, according to a new study from Australia.\nReid and his team constructed a mathematical model to predict the long-term health effects of eating dark chocolate daily in high-risk people.\nSeveral studies have found that dark chocolate, with its heart-healthy flavonols, can lower blood pressure and improve cholesterol.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of dark chocolate is not in question.", "answer": 2}, {"article": "Can a high-tech scan reveal whether Alzheimer's disease is the cause of your forgetfulness? Advocates of Positron Emission Tomography scans for the diagnosis of Alzheimer's say the scans significantly aid in the early and accurate diagnosis of the memory-robbing disease. Neurologists say PET is useful in distinguishing between Alzheimer's and a similar-acting dementia. However, opinions differ on whether the scans are useful in predicting the likelihood of Alzheimer's in people with only mild memory problems.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not comment on the availability of PET scanners.", "answer": 0}, {"article": "Lee believes ibuprofen strips could be useful for sports participants, helping alleviate conditions such as tendonitis, and repetitive strain injuries.\nWe\u2019ve tested them in our polymers with very good results, we\u2019ve been able to get increased loadings of drugs in the polymer and we\u2019ve shown almost across the board that we can get a steady release rate of that drug from the polymer as well.\u201d\n\nThe team says TEPI patches could go on sale within three years, and Medherant is working with some large, unnamed, pharmaceutical companies to get them ready for market.\nWe\u2019re controlling the dosage and we\u2019re keeping it there for a prolonged period of time.\u201d\n\nThe patches could help treat conditions like chronic back pain, neuralgia and arthritis without the need to take potentially damaging doses of the drug orally.\nAccording to Andrew Lee, co-founder of Medherant, \u201cwe\u2019ve only been in the lab about 12 months, but in the 12 months we\u2019ve essentially assessed about 90 percent of the drugs that are currently available as either creams or patches.\n\u201cOne of the interesting areas that we plan to explore in partnership with large companies is actually using our platform technology to include other drugs that previously maybe haven\u2019t been suitable for topical or transdermal delivery - or drugs which may have not got through the regulatory filings because, for instance, they might have caused stomach irritation or other side effects when taken orally,\u201d said Lee.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story tells us the the patches are expected to hit the market in three years, but the information comes direct from the company and isn\u2019t independently verified. Given the stage of development for this technology, three years sounds like a very aggressive timeline given the need for clinical validation of the assumptions made and the need for regulatory approval.", "answer": 0}, {"article": "Seventy-four subjects with type 2 diabetes were randomly assigned to follow either a vegetarian diet or a conventional anti-diabetic diet.\nThe vegetarian diet consisted of vegetables, grains, legumes, fruits and nuts, with animal products limited to a maximum of one portion of low-fat yoghurt per day; the conventional diabetic diet followed the official recommendations of the European Association for the Study of Diabetes (EASD).\nUsing magnetic resonance imaging, Dr. Kahleov\u00e1 and colleagues then studied adipose (fat-storage) tissue in the subjects' thighs to see how the two different diets had affected subcutaneous, subfascial and intramuscular fat (that is, fat under the skin, on the surface of muscles and inside muscles).\nLosing muscle fat improves glucose and lipid metabolism so this finding is particularly important for people with metabolic syndrome and type 2 diabetes, says lead author, Dr. Hana Kahleov\u00e1, Director of Clinical Research at the Physicians Committee for Responsible Medicine in Washington DC.\nThe vegetarian diet was found to be almost twice as effective in reducing body weight, resulting in an average loss of 6.2kg compared to 3.2kg for the conventional diet.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes no statement about availability, but it seems at first blush that the\u00a0diet would be readily available. Then again, perhaps that\u2019s not the case since people who eat a conventional diet containing a lot of processed foods are very likely to turn to processed foods for their vegan or vegetarian meals, as well. Prepared vegetarian foods might be hard to find and expensive, not to mention not very tasty to everyone. To help clarify, the release could have pointed to resources that would help readers eat like participants in the study.", "answer": 2}, {"article": "Although tenecteplase appears to be more effective for stroke patients, it's not approved for that use in the United States, according to Dr. Rohan Arora, director of stroke at Long Island Jewish Hospital in Forest Hills, N.Y.\nThe investigators found that 22 percent of the patients treated with tenecteplase had more than 50 percent of blood flow return to the brain, compared with 10 percent of those treated with alteplase.\n\"Tenecteplase is likely to become the preferred medication for clot-dissolving in stroke patients,\" said lead researcher Dr. Bruce Campbell, head of the stroke department at the Royal Melbourne Hospital in Parkville.\nTHURSDAY, April 26, 2018 (HealthDay News) -- After a stroke, many patients are given the clot-busting intravenous drug alteplase, but another drug may be more effective, Australian researchers report.\nAmong more than 200 stroke victims, TNKase (tenecteplase) was about twice as effective as alteplase in restoring blood flow to the brain, and it also resulted in less disability, the scientists found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story said tenecteplase is not approved for stroke in the United States, though it used for other purposes like heart attacks and blood clots in the lungs.\nIt also notes that \u201cfor either drug to be most effective, it needs to be given as soon as possible after a stroke occurs,\u201d and in this study patients were given the drug within 4.5 hours of the onset of a stroke.", "answer": 1}, {"article": "(CNN) -- The use of mammograms has dipped since a medical task force made controversial recommendations that women in their 40s may not need to get breast cancer screenings every year, according to one of three small studies to be presented Monday.\n\"There are whole lots of assumptions that are not supported by the data they presented.\"\n\"This is a decision that should belong to the woman with appropriate info on hand.\"\nThey do not appear in peer-reviewed journals.\nIt's obvious that annual screenings would catch cancers before they progress, she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of mammograms is not in question.", "answer": 2}, {"article": "\u201cIt\u2019s very muddy now exactly how long we need to treat patients,\u201d George said.\n\u201cIt looks as if from this trial you at least need to try three weeks and maybe even six weeks before you would give up.\u201d\n\nPatients who got better were prescribed venlafaxine - marketed as Effexor \u2014 and a small dose of lithium, noted George, a combination that\u2019s been shown to help people stay well after their depression has remitted.\nSomething similar is likely happening, he added, with electroconvulsive therapy (ECT), or what is sometimes referred to as \u201celectroshock treatment.\u201d Sixty to 70 percent of depressed people who undergo ECT, in which electrodes placed on the front of the brain induce a convulsion while the patient is anesthetized, will recover.\nWhile there\u2019s evidence that this technique, known as transcranial magnetic stimulation (TMS), helps depressed people get better-and the US Food and Drug Administration has approved TMS for this purpose-many skeptics have questioned whether it really works, notes Dr. Mark S. George of the Medical University of South Carolina in Charleston, the lead author of the new study.\nThe biggest issue with studies so far, he explained, has been that it\u2019s tough to fake the sound and sensation of the real device in order to run a gold standard clinical trial in which some people get the treatment, and others get a sham treatment, no one knowing which.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that TMS is approved by the FDA for the treatment of depression, but this characterization may give the impression that TMS is more widely available than\u00a0is actually the case.\u00a0TMS is cleared\u00a0for use only in patients with major\u00a0depression who don\u2019t get better after treatment with an antidepressant medication.\u00a0Also,\u00a0while we couldn\u2019t locate data as to how widely available TMS treatment is, it is safe to say that most practitioners don\u2019t have a TMS device in their office.\u00a0Obtaining access to the machine\u00a0and trained operators is likely to be a challenge for\u00a0many patients,\u00a0especially those in rural areas. The story should have pointed out these important restrictions on the treatment\u2019s availability. \u00a0", "answer": 0}, {"article": "More women were still using the intrauterine system after two years than were still taking standard medical treatments -- 64 percent compared to 38 percent.\n\"If women suffer with heavy periods and do not want to get pregnant -- as the levonorgestrel intrauterine system is a contraceptive -- then having the levonorgestrel intrauterine system is a very good first-line treatment option that does not require taking regular, daily oral medications,\" said the study's lead author, Dr. Janesh Gupta, professor of obstetrics and gynecology at the University of Birmingham and Birmingham Women's Hospital in England.\n\"This study really adds to the evidence that shows how useful this intrauterine system is for heavy menstrual bleeding,\" said Dr. Eve Espey, professor of obstetrics and gynecology at the University of New Mexico School of Medicine in Albuquerque.\nWEDNESDAY, Jan. 9, 2013 (HealthDay News) -- Women with heavy menstrual bleeding may find some relief using an intrauterine device, or IUD, containing the hormone levonorgestrel, according to new research.\nFor women who do want to get pregnant, Gupta said, taking the blood-clotting drug tranexamic acid during periods is an alternate method of treating heavy periods.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We are only told that the IUD is \u201csold under the brand name Mirena.\u201d\nWe\u2019ll give the story the benefit of the doubt, although it didn\u2019t discuss anything about how widespread is the use of this IUD.", "answer": 1}, {"article": "Prostate cancer begins when cells in a man\u2019s prostate gland mutate and start to grow uncontrollably.\nLooking back, the experience was even better than I was expecting, and I hope to see nanoparticle therapy advance into an option for anyone diagnosed with prostate cancer in the future.\u201d\n\nThe gold nanoparticles were invented by Naomi Halas, the head of Rice University\u2019s Laboratory for Nanophotonics.\nThe fusion of MRI and ultrasound imaging technology that we use to accurately identify and diagnose the cancer, combined with the extreme precision of the gold nanoshells in targeting the diseased cells, allows us to be incredibly accurate at obliterating them.\n\u201cThis therapy could be life-changing for men diagnosed with prostate cancer and I\u2019m honored to be among the first doctors the U.S. Food and Drug Administration approved to put it to the test,\u201d said Steven Canfield, M.D., chair of the division of urology at McGovern Medical School at UTHealth, who recognized the possibility of the nanoparticles to treat prostate cancer and helped developed the trial to test the theory.\nI am excited as we continue tracking the progress of this groundbreaking improvement to prostate cancer care.\u201d\n\nDoug Flewellen, the first patient in Texas to receive the new method of care, says for him, the procedure was a no-brainer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release gives the sense that this new technique is very experimental, and being done inside the bounds of a trial, but that is never made very clear. The trial will enroll only 45 patients and the follow up (a repeat biopsy) is only for 3 months.", "answer": 0}, {"article": "Responding to the research, Yale Child Study Center director Fred Volkmar told WebMD: \u201cThe question remains, \u2018Is fluoxetine better than risperidone for this symptom?\u2019 It would be interesting to see studies comparing these two drugs head to head.\u201d\n\nHollander has previously received funding from pharmaceutical companies, but the current study was paid for by a grant from the Food and Drug Administration\u2019s \u201corphan\u201d drug program.\nIt is not known if the differences between these studies are due to differences between the medications or other factors.\nThe antidepressant Prozac may alleviate repetitive behavior and obsessive-compulsive symptoms in adults with autism, reducing these defining symptoms of the disorder, according to new research.\nA previous, larger study of a similar medication, Celexa (citalopram), in autistic children did not find a reduction in repetitive behaviors, but the drug did reduce irritability and was superior to placebo among children who had the highest levels of irritability.\nWhen the research was originally funded, Hollander says, autism was considered to be a rare condition.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that Prozac is widely available and that other drugs are approved for use in autistic patients.\n\u00a0\n\u00a0", "answer": 1}, {"article": "[On average] \"22 grams (about .78 ounces) of new heart tissue grew,\" which he says is quite remarkable considering this had never been done before and the average weight of the part of the heart that is responsible for pumping the blood through the body is about 150 grams (about 5.3 ounces).\nThe damaged area also doesn't conduct electric current as well, leading to an abnormal heart rhythm, which can cause more problems.\nNot only did this show that the procedure was safe, it also showed that the cells can help reduce scarring and even cause new heart muscle to grow.\nAfter 12 months, researchers report only one patient appeared to have a serious side effect that may have been connected to the experimental cells.\nAll patients were followed for six months and researchers have 12-month data for 21 patients.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear not only that the treatment is experimental but that it has to clear many more hurdles before becoming a clinical option.\n\u00a0", "answer": 1}, {"article": "To move this into treatment, controlled trial such as the one by Dollfus and coworkers are important.\nSecondly, we have shown that treatment with high frequency TMS makes a difference to at least some sufferers, although there is a long way to go before we will know if TMS is the best route to treat these patients in the long-term\".\nUsing magnetic resonance imaging (MRI), the pulses were targeted at a specific brain area in the temporal lobe, which is associated with language (the exact area is the crossing of the projection of the ascending branch of the left lateral sulcus and the left superior temporal sulcus)\n\nAfter 2 weeks, the patients were re-evaluated.\nNOTE: The full title of this release is \"Scientists discover brain area which can be targeted for treatment in patients with schizophrenia who 'hear voices'\" It has been shortened in some versions to comply with Eurekalert title limits.\nThe researchers found that 34.6% of the patients being treated by TMS showed a significant response, whereas only 9.1% of patients in the sham group responded ('significant response' was defined as a more than 30% decrease in the Total Auditory Hallucinations Rating Scale score).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not address availability of TMS for treatment of AVHs specifically. The release does note that TMS \u201chas been shown to be effective in several psychiatric conditions.\u201d However, it\u2019s not clear from the release how widely available TMS is, or even whether it is clinically available at all. This may be because the release is aimed more at practitioners (who are aware of TMS\u2019s availability) than at a more general audience. However, since many reporters and news consumers don\u2019t have that professional background and insight, it would be much better to simply address the issue of availability head on.", "answer": 0}, {"article": "Cancer experts said Tuesday that the actress and filmmaker Angelina Jolie Pitt was wise to have had her ovaries and fallopian tubes removed last week because she carries a genetic mutation, BRCA1, that significantly increases the risk of ovarian cancer, a disease so difficult to detect that it is often found only at an advanced, untreatable stage.\nIt is unclear how common the mutations are in other racial and ethnic groups.\n\u201cProphylactic removal of ovaries and fallopian tubes is strongly recommended in women before age 40 in BRCA1 and BRCA2 mutation carriers,\u201d said Dr. Susan Domchek, executive director of the University of Pennsylvania\u2019s Basser Research Center, which specializes in BRCA mutations.\nThey also said Ms. Jolie Pitt\u2019s decision to discuss her own choices so frankly will encourage women in similar situations to consider their own options.\nBRCA mutations cause about 5 to 10 percent of breast cancers and 10 to 15 percent of ovarian cancers among white women in the United States.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The comments of Drs. Domchek, Offit, and Bakkum-Gamez make it clear that the surgical procedure is widely available.", "answer": 1}, {"article": "The National Academy of Sciences says adults between 19 and 50 years old need 1,000 milligrams of calcium each day.\nIt's important to note that calcium intakes on food labels are based on adult requirements of 1,000 milligrams per day.\nResearchers studied the effect of 600-milligram calcium supplements twice a day on women over 70 and found that only those women who took 80 percent or more of their pills were less likely to experience fractures.\nThe message here, Senay says, is that calcium supplements are useful for bone health \u2014 but you should only take them if you do so regularly, as directed by a doctor.\nThe study earlier this year also found that women who took supplements regularly reduced their chance of fracture more than those who didn't.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention if the supplements are available, if they are available over the counter and if you can buy them in the formulation used in the study (600mg 2x/day).", "answer": 0}, {"article": "Inside the brightly lit storefront in Brooklyn, N.Y., business was brisk as employees combed, washed and blow-dried little heads.\n\n\u201cDo I have a lot of lice?\u201d a boy asks the woman combing his hair slathered in Pantene conditioner.\n\nIt\u2019s the busiest time of the year for companies like Lice Busters, a family-run business Dalya Harel started in...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Good job on this. It\u2019s clear\u00a0that businesses that assist with combing are easy to find, and over-the-counter\u00a0shampoos are even easier.", "answer": 1}, {"article": "Both groups lost about four pounds over the six months.\n\"The question one had to address was how does this play out with people in the real world,\" Jenkins said in a telephone interview.\nTo put the diet to the real-world test, participants received a one-hour counseling session with a dietitian and an illustrated study booklet at the outset and, later, received a 30-40 minute follow up session.\nA control group advised to eat a vegetarian, low-saturated diet but not with the cholesterol-lowering foods a saw a slight dip in total cholesterol, from 249 to 246, and in LDL, from 167 to 161.\nResearchers in Canada have shown that a special cholesterol-lowering diet works well \u2013 even with only two nutritional counseling sessions over six months.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no\u00a0discussion of the difficulty people in poor urban and rural areas may have finding some of the vegetarian foods called for in this diet, which includes some fairly exotic soy products (e.g. soy deli slices) as sources of protein. Also, considering the lack of physician reimbursement for dietary advice, patients may\u00a0have trouble finding a health professional who can\u00a0counsel them on this approach.", "answer": 0}, {"article": "Researchers around the world are seeking ways to regenerate damaged hearts, spines and skin with stem cells. At an operating table here recently, Kotaro Yoshimura leaned over a 51-year-old woman and put stem cells to use for a different purpose: cosmetic breast surgery.\n\nDr. Yoshimura jabbed the underside of the woman's left...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story focuses on this fat injection with stem cells as a procedure for cosmetic augmentation or reconstruction following breast cancer surgery.\u00a0 The story notes that while some plastic and cosmetic surgeons are experimenting with this procedure, it is a \"biologic product\" (due to mixture of a person\u2019s own fat w. additional stem cells) which is not currently approved by the FDA.\u00a0 ", "answer": 1}, {"article": "A number of new multiple-sclerosis medications are beginning to hit the market that promise to make it easier for patients to control flare-ups of the disease and slow its progression.\n\nThe drugs, designed to be taken orally, represent a new generation of treatment for MS. Currently, people with the disease can choose from a range of drugs that are administered by injection.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Good job explaining which oral drugs are pending approval, and which is approved. The story says 6,000 patients are already taking Gilenya, the oral drug that is first in this family to win FDA approval.", "answer": 1}, {"article": "Byrd said it is more common in men than in women.\nThis is a marked uptick from a decade ago, when Ochiai said the single course in hip arthroscopy was nearly canceled due to lack of interest.\nIn the past 10 to 15 years, doctors have discovered one specific cause of hip pain: a tear in the acetabular labrum, a condition in which the cartilage that lines the hip socket is damaged.\nAs a result, surgeons are trying to find remedies for problems that, Byrd said, had received \"no treatment at all\" in the past.\nWhile that is still done, restorative techniques have been introduced that allow for the preservation of the labrum instead of its removal.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\n \nThe news story explains that orthopaedic surgeons are performing increasingly more hip arthroscopy procedures, and are taking increasingly more courses to learn how to do them. Readers are likely to correctly infer that the procedures are commonplace in some centers around the U.S. and less common in others.", "answer": 1}, {"article": "The ancient art of applying suction cups to the body has gotten a boost from several new studies that show it helps relieve a variety of painful conditions. But scientists say larger, more rigorous studies are needed.\n\nCupping, as the practice is called, was performed traditionally in China and other countries, and is now available from acupuncturists, and some chiropractors and massage therapists in the U.S. In the traditional method, called fire cupping, a ball of burning cotton is briefly placed inside a glass cup to heat...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that cupping treatment is available through acupuncturists, chiropractors and massage therapists.", "answer": 1}, {"article": "MILAN (Reuters) - An established targeted therapy for bowel cancer may also help women with an aggressive form of breast cancer, a mid-stage clinical study revealed on Monday, opening up a potential new market for the medicine.\nNo question,\u201d he said.\nSales last year were $1.7 billion.\n\u201cThis study clearly opens the field ...\n\u201cWe are very excited by these results,\u201d lead researcher Jose Baselga of the Massachusetts General Hospital Cancer Center in Boston told the European Society for Medical Oncology (ESMO) \u2014 Europe\u2019s biggest cancer meeting.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Doctors who have turned surgery into a popular treatment for obesity are setting their sights on a burgeoning new market: diabetes patients.\n\nA growing amount of research suggests that bariatric surgery, which shrinks the stomach and sometimes reroutes the intestines, has a lasting effect on the most common form of diabetes, and not just because patients lose weight. Studies have found that more than 75% of patients with this type of diabetes who undergo the surgery see their disease disappear. They can go on to live diabetes-free...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that the surgery is widely available and increasing in frequency. It also indicates\u00a0the populations for which it is currently recommended. ", "answer": 1}, {"article": "DALLAS, Oct. 20, 2015 -- Botox -- known for reducing facial wrinkles -- may also prevent irregular heart rhythms when injected into fat surrounding the heart after bypass surgery, according to research in the American Heart Association journal Circulation: Arrhythmia and Electrophysiology.\n\"About a third of all patients undergoing bypass surgery will develop atrial fibrillation, putting them at higher risk for cardiovascular complications,\" said Jonathan S. Steinberg, M.D., senior study author and Adjunct Professor of Medicine at the University of Rochester and Director of the Arrhythmia Institute in the Valley Health System in Ridgewood, New Jersey.\nThe results must be replicated in larger studies before Botox injections are routinely used to prevent AF after bypass surgery, researchers said.\n\"In the near future, botox injections may become the standard of care for heart bypass and valve patients, but we're not quite there yet.\"\nAtrial fibrillation (also called AFib or AF) is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Since the release makes no claim that this therapy is ready to be used outside of clinical trials we\u2019ll give this a satisfactory. The story makes it clear that botulinum toxin is available and is routinely used in cosmetic dermatology. For that use it\u2019s sold under the trade name Botox Cosmetic. However, there are four different FDA approved strains of the toxin. Various formulations of the toxin have received\u00a0 FDA approval for use in treating excessive sweating, migraines, dystonia, bladder control issues, and several other non-cosmetic conditions. Those formulations have been available for many years as well. Since this is the first time botulinum toxin has been tested in human hearts, it\u2019s safe to say that it could be several years before it receives approval as a preventative for heart complications. The release is clear that larger studies are needed.", "answer": 1}, {"article": "For example, Chinese medicine paired with selective serotonin reuptake inhibitors (SSRIs) increased IELT by two minutes longer than SSRIs alone and nearly three minutes longer than the Chinese medicine alone.\nA man\u2019s \u201clatency time\u201d can also become reduced later in his sexual life, and this secondary form is usually defined as ejaculation within three minutes or less.\n\u201cThere are a range of treatments available for premature ejaculation, including drug treatments, behavioral techniques and counseling, however, some men may not want to visit the doctor, take drugs long-term or be on a long wait list for counseling,\u201d said lead author Katy Cooper of the University of Sheffield in the UK.\n\u201cAlthough it is not openly discussed in the media - at least not as much as erectile problems have been discussed in the post-Viagra era - numerous studies report men feel frustrated, depressed and anxious because of this problem,\u201d said Ege Can Serefoglu of the Bagcilar Training and Research Hospital in Istanbul, Turkey.\nThe improvements were small, and the studies were of varying quality, but preliminary evidence suggests that acupuncture, Chinese herbal medicine, Ayurvedic herbal medicine and a Korean topical cream may all have desirable effects, researchers conclude in the journal Sexual Medicine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear how available these products are.\u00a0Considering how many products are sold online for this problem, some information on what these products are, and how available they are, would be useful.", "answer": 0}, {"article": "\"I have successfully raced in 20 triathlons since I started taking sildenafil, including five ultra events that require 10-kilometer swims,\" Calder-Becker said.\nWhen the SIPE participants were given sildenafil and then performed the same underwater exercise, the pressures were no longer as elevated.\nThe drug -- best known as Viagra\u2122 -- is normally used for treatment of male impotence, but also for pulmonary arterial hypertension.\nMany don't know they are prone to the problem until they are in the water and quickly develop symptoms.\nIt dilates blood vessels, giving it the potential to ease an abrupt cold water-induced constriction of blood vessels in the arms and legs that can lead to blood pooling in the heart and lungs.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The very first sentence of the release characterizes sildenafil as \u201creadily available.\u201d Indeed it is. It is Viagra \u2122.", "answer": 1}, {"article": "The patient had no prior history of high blood pressure or cirrhosis, the drugmaker said.\n(Reuters) - Johnson & Johnson said on Tuesday its blockbuster drug Stelara was found to be effective in treating a chronic bowel disease in a late-stage trial.\nTwo doses of Stelara, already approved for psoriasis, psoriatic arthritis and Crohn\u2019s disease, was tested in 961 patients with moderate-to-severe ulcerative colitis (UC) who had failed prior therapy.\nThe treatment and the placebo arms reported similar proportion of side effects, with one patient on the 6 mg/kg dose dying following excessive bleeding, J&J said.\n\u201cMore than half of UC patients have not experienced remission with currently available treatment options,\u201d the study\u2019s lead investigator Bruce Sands said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that Stelara is already on the market. However, it\u2019s not clear whether Stelara could currently be prescribed \u201coff label\u201d to patients suffering from UC. Nor is it clear whether the \u201clate-stage\u201d trial is still ongoing or has been completed. Is there a pathway to FDA approval? If so, what might the timeframe be?\nThe complexity of the drug approval process is such that news reports should help the public understand that this use of the drug is still experimental. that although the drug may be used \u201coff-label,\u201d it is not clear whether the company is seeking to broaden the FDA-approved indications or drum up interest among clinician researchers to design their own clinical trials.", "answer": 0}, {"article": "Dr. Vijay B. Vad, a sports medicine specialist at the Hospital for Special Surgery in Manhattan, compares the problem to a thermostat in a cool room.\nThe study, which was financed by the implant maker Medtronic, followed 100 patients who had undergone spinal surgery and had developed chronic pain in one or both legs.\nThe implants cost about $20,000, and the procedure, hospital care and follow-up can bring the total bill to about $40,000.\nStill, most patients accept this vibrating version of white noise, says Dr. Richard North, a retired neurosurgery professor at Johns Hopkins who developed several patents related to the technology, although he no longer receives royalties.\n\u201cSometimes efficacy wanes over time, but I still believe in them,\u201d said Dr. Kaufman, also an assistant professor of anesthesiology at the New Jersey Medical School.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that spinal stimulation devices \u201care not widely used,\u201d though it does not mention that they are approved by the FDA for the treatment of chronic pain.", "answer": 1}, {"article": "A government panel of experts released updated guidelines today spelling out who should be taking a daily low-dose aspirin for heart health, which also offers the added benefit of protection against colorectal cancer.\n\"As with any drug, patients and their doctors must balance the benefits and risks of taking aspirin,\" Dr. Kirsten Bibbins-Domingo, chair of the task force and professor of medicine, epidemiology and biostatistics at the University of California, San Francisco, told CBS News.\nColorectal cancer is the third most common cancer diagnosed in both men and women (excluding skin cancers) and a leading cause of cancer death, the American Cancer Society reports.\n\"The task force recommends that all patients talk to their doctor to evaluate their risk for cardiovascular disease and bleeding before making a decision about aspirin use, but this is particularly important for people in their 60s,\" Bibbins-Domingo said.\n\"The evidence shows that there's really no incremental benefit of going over 81 milligrams, and in fact, you may increase bleeding risk by going over,\" CBS News medical contributor Dr. Tara Narula, a cardiologist at Lenox Hill Hospital in New York City, told \"CBS This Morning\" when the draft guidelines were released last September.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear that aspirin is ubiquitous and sold almost everywhere as an over-the-counter drug, so we\u2019ll rate this one N/A. This story, and the other we reviewed, might have benefited from mentioning that the drug has a generic name (known as ASA or acetylsalicylic acid). Generic versions of the drug do exist, are likely cheaper than the brand name, and equally effective.", "answer": 2}, {"article": "The visor that allows legally blind people to see is no longer Star Trek fiction.\nLeaps in augmented-reality technology are being used to help people with severely low vision gain back enough sight to function, and then some.\nBut when the Toronto-based artist and mother puts on a new kind of camera-equipped headgear, she looks at me like no one has before.\nGeoffrey A. Fowler discusses the headset with Yvonne Felix, a blind artist and supporter of the technology.\nA next-generation visor from eSight can improve vision for many legally blind people.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the eSight is cleared by the FDA as a Class I\u00a0device \u2014 something that\u2019s presumably about as safe as dental floss (which is also a Class I device, according to the FDA). The story mentions that most insurance carriers reject compensation, which itself implies the eSight 3 is freely available to anyone as long as they have $10,000.", "answer": 1}, {"article": "A key difference, Schubiner said, is that affective self-awareness asks people to \u201cdirectly engage\u201d the emotions that may be helping to drive their symptoms.\nThere is also evidence that they are relatively less aware of their own emotions and more reluctant to express their feelings, particularly anger.\nThey randomly assigned 45 women with the condition to either undergo the therapy or go on a wait-list for treatment, serving as a control group.\nPatients are also encouraged to get back to any exercise or other activities that they have been avoiding due to pain.\nPast studies have found that compared with people without fibromyalgia, those with the disorder have higher rates of stressful life events, such as childhood abuse, marital problems and high levels of job stress.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that only a small number of healthcare providers practice affective self-awareness, suggesting that the treatment is not widely available. ", "answer": 1}, {"article": "She tried decongestants, antihistamines and steroid nasal sprays.\nTo avoid poking through to the brain or into the orbit of an eye, there's a device around the patient's head with a guidance system that tells Metson, in three dimensions, exactly where his sharp instruments are on a CT scan of Butler's head.\n\"And if we can use those as novel targets for, let's say, nasal sprays or medications, we may be able to treat people like Judy without surgery,\" Metson says.\n\"The next time she gets a cold,\" he says, \"her membranes are not going to swell and block the sinuses the way they have in the past.\nBut they can't stop the inflammation some people are prone to, and that inflammation can cause new obstructions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that about\u00a0300,000 people a year\u00a0undergo sinus surgery, making it one of the most commonly performed\u00a0procedures in the U.S.\u00a0 However, it does not provide statistics on the number or percentage of those procedures that are performed endoscopically and the type of hospital setting in which they are done. Enodoscopic surgery with CT guidance as described in the story may be out of the reach of smaller community based practitioners.\u00a0We\u2019ll call this satisfactory, but some additional detail\u00a0would have been appropriate.\u00a0", "answer": 1}, {"article": "Everyone loses some bone with aging - women abruptly at menopause when estrogen levels decline, men more slowly as male hormones decline over time.\n\"All bones - spine bones and big leg bones - will respond to pressure from weight by forming more bone.\"\nIf a person simply stands, the muscles accommodate and do most of the work, he said - with no benefit to the bone.\nAnother 34 million are at risk because they have low bone density.\n\"Anything that makes bone bear weight is good for bone quality,\" said Dr. Kirkham Wood, head of orthopedic spine surgery at Massachusetts General Hospital.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "not applicable in this case", "answer": 2}, {"article": "NEW YORK (Reuters Health) - Hormone replacement therapy may work slightly better than soy at reducing menopausal hot flashes, a new study says.\nThey compared the average number of hot flashes in 760 women who had treatment with 770 who did not.\nThat means that if women do take hormones, Bachmann told Reuters Health, it should be the lowest dose and for the shortest possible period of time.\nIt\u2019s thought to have similar effects to estrogen on the brain, bones, and blood vessels, Bolanos-Diaz told Reuters Health by email.\nThe study did not look at whether eating soy in food has the same effect on hot flashes as supplements, Bolanos-Diaz said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of soy supplements or of hormone replacement therapy is not in question.", "answer": 2}, {"article": "Liver cancer is the second-leading primary cause of cancer-related deaths worldwide.\nThe success of this trial opens the field for testing drugs in third-line treatment of HCC and provides a rationale to test regorafenib as a first-line treatment or in combination with therapies administered directly into the tumor or diseased liver in patients in an earlier stage of HCC, according to Dr. Llovet.\n\"This study represents a breakthrough in the management of hepatocellular carcinoma, since it provides evidence for clinical benefits in an area that was an unmet medical need,\" said Josep M. Llovet, MD, founder and Director of the Liver Cancer Program and Professor of Medicine and Liver Diseases at the Icahn School of Medicine at Mount Sinai.\nIn January, Bayer announced that the U.S. Food and Drug Administration (FDA) had granted priority review status for Stivarga (regorafenib) as a second-line systemic treatment for patients with hepatocellular carcinoma.\nThis trial provides evidence that regorafenib is the first systemic treatment for patients whose HCC progressed during treatment with sorafenib, the only other drug with proven clinical benefit.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does tell readers that \u201cIn January, Bayer announced that the U.S. Food and Drug Administration had granted priority review status for Stivarga (regorafenib) as a second-line systemic treatment for patients with hepatocellular carcinoma.\u201d However, the release doesn\u2019t tell readers that regorafenib has already passed FDA review for treatment of other cancers, nor does it explain to readers what \u201cpriority review status\u201d means in terms of when the drug might be used for HCC treatment on a widespread basis.", "answer": 0}, {"article": "Although colon cancer is the second leading cause of cancer death for men and women in the U.S., many adults don't undergo the screenings once they reach age 50 (or earlier for those with a family history), Ahlquist told a news conference.\n\"We were pleased by the results of this first clinical study,\" he says.\nPatients must often take time off work and need transportation home from the procedure.\nThe research was presented at the American Association for Cancer Research's special conference, Colorectal Cancer: Biology to Therapy.\nOne screening test, the colonoscopy, in which a flexible, lighted tube with a video camera is inserted to examine the colon, requires dietary restriction and preparation of the colon.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that a clinical trial may begin in 2011 and said that the lead researcher believed that \u201cif all goes well the test could be available soon after that.\u201d", "answer": 1}, {"article": "With the memory of Memorial Day cheeseburgers and bratwursts still lingering, many of us may be relieved to hear that a new study suggests that a meaty, high-fat, Atkins-style diet can do more than contribute to rapid weight loss.\nBut a unique worry raised by these regimens, extending back to the heyday of the original Atkins diet in the 1970s, was that indulging in repeated fatty, glistening meals would lard your arteries and cause heart disease.\nAnd like most of the recent studies about the health effects of low-carbohydrate diets, \u201cthese are very short-term results,\u201d said Dr. Dena Bravata, an internist and research associate at the Center for Primary Care and Outcomes Research at Stanford University, who was not involved with this experiment but has conducted dietary studies.\n\u201cBut what about in 5 or 10 years, if they remain on the diet?\u201d\n\nThis study also reported on a single marker of cardiovascular health, she continued.\nThe sessions lasted for at least 30 minutes three times a week.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story referred to the diets studied in broad terms including avoidance of trans fats and indicated that study participants reduced their daily caloric intake by about 750 calories. The Atkins diet is broadly available and widely recognized.", "answer": 1}, {"article": "All patients were interviewed about diet, health habits and medical history.\nFor this case-control study, researchers recruited 5,307 colonoscopy patients, 60 percent of them men, at two Tennessee hospitals over a seven-year period ending in April 2010.\nThe researchers found no effect in men, and no effect of omega-3 consumption on hyperplastic polyps, which are more likely to be benign.\nAfter controlling for age, race, body mass index, smoking and other factors, the researchers found that women in the highest fifth for omega-3 consumption \u2014 those who consumed three or more servings of fish a week \u2014 were 33 percent less likely than women in the lowest fifth to have adenomatous polyps, a type likely to become cancerous.\nA new study has found that consumption of omega-3 fatty acids from fish is associated with a reduced risk for one kind of colon polyp, but only in women.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability of fish is not currently in question, although its future availability has been questioned considering the rate we are overharvesting wild stocks. Stories that don\u2019t critically evaluate these kinds of studies might conceivably contribute to the problem.", "answer": 2}, {"article": "Washington University School of Medicine\u2019s 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children\u2019s hospitals.\nThe average cost of treating those cesarean-related infections in the hospital is $3,500 and may be much higher for severe infections.\nTuuli and his colleagues also pointed out that the superiority of the chlorhexidine-alcohol combination was consistent whether the C-section was scheduled or unscheduled, whether or not the patient was obese, whether staples or sutures were used to close the wound and whether the patient had chronic medical conditions, including diabetes.\nIn addition, past trials comparing antiseptics before surgery included relatively few participants and often compared a chlorhexidine-alcohol combination with iodine alone.\nAlthough the new study was conducted at only one hospital, the researchers said the patient population was racially diverse and that more than 60 percent received public insurance.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We believe both skin-cleaning agents are widely available. So while the release never explicitly addresses availability, we don\u2019t dock points for this.", "answer": 2}, {"article": "Sacco notes that both the AHA and the American Academy of Pediatrics now recommend cholesterol screening in children with risk factors for heart disease other than family history, such as obesity, high blood pressure and diabetes.\nSee TIME's Pictures of the Week.\nSee the Cartoons of the Week.\n\"It's something we would become more aware of if more children were screened.\"\nAnd 1.7% had levels high enough (above 160 mg/dL) to warrant cholesterol-lowering medications.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe availability of cholesterol screening is not at issue.", "answer": 2}, {"article": "\"For high-risk people, those with heart disease or [who] have had a stroke who are taking a standard dose of a statin, further reduction in LDL cholesterol will give them extra benefit,\" said Dr. Colin Baigent of the Clinical Trial Service Unit and Epidemiological Studies Unit at University of Oxford in the United Kingdom, who was involved in both studies.\nThe muscle disease, known as myopathy, can cause pain, weakness, and in its rare but most severe form, destruction of the muscle tissue leading to kidney failure.\nThis benefit was seen even among those whose cholesterol levels were already low, researchers say.\nThe researchers noted that the higher dose of Zocor (simvastatin) did result in a risk of a muscle disease 10 times higher than that associated with the lower dose.\n(All statins carry the risk of myopathy, but lower dosages are associated with a reduced risk.)\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The class of medications, statins, discussed in the story are commercially available as indicated.", "answer": 1}, {"article": "CHAPEL HILL - University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that mailing self-collection kits to test for high-risk human papillomavirus infection has the potential to boost cervical cancer screening - especially for low-income women who are overdue for testing.\n\"We found in this sample, all of the women who had high-grade lesions had HPV-positive home self-collection results,\" Smith said.\nFinancial disclosure: High-risk HPV and sexually transmitted disease tests, sample preservation media, ThinPrep processor slides, and other equipment were donated by Hologic, Inc. Self-collection brushes were donated by Rovers Medical Devices.\nThis will allow us to determine the effect that self-collection has on screening uptake.\"\n\"We didn't miss any of those high-grade cases by conducting home self-collection.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the release that at-home, self-collected screening samples are not even close to being adopted for widespread use.", "answer": 1}, {"article": "Dr Ishwar Singh, a specialist in novel drug design and development from the University of Lincoln's School of Pharmacy, is leading the research team.\nWith this new knowledge, synthesised versions of teixobactin can be more easily developed, taking the process from up to 30 hours to just ten minutes for a single coupling step - a significant step towards turning teixobactin into a viable new drug.\nThe breakthrough by researchers at the University of Lincoln, UK, marks another important step to realising the potential of teixobactin in aiding the global fight against antibiotic-resistant pathogens.\nImportantly, the two new simplified forms of teixobactin have also proven to have identical potency against superbugs as the natural form of teixobactin.\nThe development of new antibiotics which can be used as a last resort when other drugs are ineffective is therefore a crucial area of study for healthcare researchers around the world.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that this work is a step closer toward creating drug treatments. There are no claims about how long subsequent testing and development may take. However, the failure to point out that this work is confined to laboratory tests and that human clinical trials have yet to begin implies a shorter path to potential clinical use than seems likely.", "answer": 1}, {"article": "Two classic laboratory measures of inflammation are sedimentation rate \u2014 the ability of red blood cells to clump together, which isn't a factor in ME/CFS \u2014 and C-reactive protein, which reflects levels of a single cytokine that wasn't one of those linked to severity in this study.\nThat typically happens to people with the mysterious illness commonly known as chronic fatigue syndrome.\n\"Inflammation is much more complicated than two imperfect old measures,\" Montoya says.\nMiriam E. Tucker is a freelance journalist specializing in medicine and health.\nYou can follow her on Twitter @MiriamETucker.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that both this type of test and proposed treatments are still experimental.", "answer": 1}, {"article": "He said his team is now working with other scientists to try to design a drug which could interrupt the gene\u2019s activity.\nSurinder Soond, who worked on the study, said it was a \u201cnovel and exciting approach to treating cancer and the spread of tumors which holds great potential.\u201d\n\n\u201cThe challenge now is to identify a potent drug that will get inside cancer cells and destroy the activity of the rogue gene,\u201d said Andrew Chantry of UEA\u2019s school of biological sciences, who led the research.\nThe culprit gene, called WWP2, is an enzymic bonding agent found inside cancer cells, the researchers explained in their study, published in the journal Oncogene Monday.\nLONDON (Reuters) - British scientists have discovered a \u201crogue gene\u201d which helps cancer spread around the body and say blocking it with the right kind of drugs could stop many types of the disease in their tracks.\nIf a drug was developed that deactivated WWP2, he said, conventional therapies such as chemotherapy and radiotherapy could be used on primary tumors with no risk of the disease taking hold elsewhere.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that \u201cthe findings mean drugs could be developed in the next 10 years that could be used to halt the aggressive spread of many forms of cancer, including breast cancer, brain, colon and skin cancer.\u201d The story says nothing about all the hoops that remain for a finding to go from the lab to the drug store. Nor does it mention anything about the many cancer \u201cbreakthroughs\u201d that have failed to fundamentally alter the rates of cancer incidence or mortality over many decades.", "answer": 0}, {"article": "Dr. Durado Brooks, director of colorectal cancer at the American Cancer Society, agreed.\n\"There are 150,000 new cases of colon cancer each year in the United States, treated at an estimated cost of $14 billion,\" noted Dr. David A. Ahlquist, professor of medicine and a consultant in gastroenterology at the Mayo Clinic in Rochester, Minn.\n\n\"The dream is to eradicate colon cancer altogether and the most realistic approach to getting there is screening,\" he said.\n\"You would intuitively think that the G variant would be associated with a poorer prognosis, as it is in late-stage colorectal cancer, but that is not the case,\" Smits said in a statement.\nIn addition, the test is the only one that is able to identify cancer in all locations throughout the colon, something which other tests either can't or don't do well, Ahlquist said.\nThe search for a highly accurate, noninvasive alternative to invasive screens such as colonoscopy or sigmoidoscopy is a \"Holy Grail\" of colon cancer research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that \u201cCologuard is not yet available for sale. Clinical trials comparing the test with colonoscopy are slated to start next year.\u201d\u00a0But then it allows the lead researcher to get away with saying he \u201chopes that the test will be approved and available within two years.\u201d\u00a0 Sure he does.\u00a0 That doesn\u2019t make it a prediction you can bank on.", "answer": 1}, {"article": "The use in spine surgery of bone-growth proteins like Medtronic Inc.\u2019s product Infuse has led to widespread nationwide increases in hospital charges ranging from 11% to 41% above conventional surgical costs, researchers found.\n\nThe researchers studied the results of a broad U.S. sample of 328,000 spine surgeries from 2002 through 2006. They report their findings this week in JAMA, the Journal of the American Medical Association.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states correctly that about 25 percent of spinal fusion surgeries use bone-growth proteins [BMPs].", "answer": 1}, {"article": "As of last month, 354 people who got CTs had died of lung cancer, compared to 442 who got ordinary X-rays.\nIt is also possible the scans will turn up tumors that would never have killed the patients, and that some people will undergo unnecessary surgery if they are screened.\nThe study sponsored by the U.S. National Cancer Institute is the first to show that people can be screened for lung cancer, akin to mammograms for breast cancer and tests for colon and prostate cancer.\nIt is not clear when or how guidelines for lung cancer screening could be drawn up, and until they are, insurers including government programs such as Medicare are unlikely to pay the average $300 cost of a scan.\nAlmost all advanced CT scanners can perform a spiral CT, and about 60 percent of U.S. hospitals have such a machine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story did a better job than others in actually spelling out how commonly used these spiral CT scans are, noting that \u201cAlmost all advanced CT scanners can perform a spiral CT, and about 60 percent of U.S. hospitals have such a machine. Makers include General Electric Co\u2019s GE Healthcare Siemens AG, Toshiba Corp, Hitachi and Philips.\u201d", "answer": 1}, {"article": "Weight loss drugs are recommended supplements to diet and exercise \u2014 included, for example, in 2013 guidelines by the American Heart Association, the American College of Cardiology and the Obesity Society, Bohula said.\nThat\u2019s how we need to start looking at drugs for obesity.\u201d\n\nWhat many don\u2019t understand is that weight gain leads to changes in the brain that may not be reversible, Aronne said.\nSo the challenge is to keep it off long term.\u201d\n\nWhile a 5 percent weight loss may not seem like a lot, \u201cthat is the point where there is a very significant reduction in the risk of diabetes,\u201d said Dr. Louis Aronne, a professor of metabolic research at Weill Cornell Medicine.\n\u201cThe process of weight gain makes it hard to lose weight,\u201d he explained, adding that in certain areas of the brain nerve cells are actually damaged and sometimes die.\nBut within a couple of years some patients began to develop very scary side effects: damage to heart valves that could lead to heart failure and a kind of high blood pressure, pulmonary hypertension, that proved to be fatal in some cases.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that, in general, the \u201clatest generation\u201d of weight loss drugs are FDA approved. But it never explains which ones fall under that category. There are at least nine weight loss drugs on the market.", "answer": 1}, {"article": "There are no currently approved treatments for agitation, and we\u2019re very enthusiastic about this finding.\u201d\n\nCorrection: October 8, 2015 \n\nA report in the In Brief column on Sept. 29 about a combination drug that could ease the agitation of Alzheimer\u2019s disease described incorrectly a disorder treated with the combination drug, dextromethorphan and quinidine.\nThen the researchers re-randomized those who did not respond to placebo to receive either drugs or placebo, and found similar encouraging results for the drug combination.\n\u201cFifty-five percent of the people who were on drugs had a 50 percent reduction in their agitation,\u201d said the lead author, Dr. Jeffrey L. Cummings, director of the Cleveland Clinic Lou Ruvo Center for Brain Health.\nThe drug is approved for treating pseudobulbar affect, a neurological disorder that involves involuntary crying, laughing and other emotional displays as its main symptom \u2014 not involuntary movement of the facial muscles.\nIn combination, they are used to treat pseudobulbar affect, a neurological disorder involving involuntary crying or other emotional displays.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the drug tested is \u201calready in use for treating certain neurological problems,\u201d and we think most readers can work out from that that the drug is available.", "answer": 1}, {"article": "A new method for performing a \u201cvirtual\u201d colonoscopy that requires less unpleasant preparation was shown in a new study to accurately detect larger precancerous polyps\u2014and was a better experience for patients.\n\nThe second-leading cause of cancer deaths in the U.S., colon cancer can be prevented if precancerous polyps\u2014known as adenomas\u2014are found and removed during a colonoscopy\u2026.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is relatively clear from the story that while virtual colonoscopy is available as a treatment option, this method of preparing for a scan is not (\u201cmay become a useful alternative\u201d).", "answer": 1}, {"article": "The games are based on the work of Japanese neuroscientist Ryuta Kawashima, M.D.\nThe modifications in functional connectivity shown in the video game group after training corresponded to significant improvements in test scores assessing sustained attention and executive function, the higher-level cognitive skills that help organize our lives and regulate our behavior.\n\"Functional MRI allows you to study which brain areas are simultaneously active and gives information on the participation of certain areas with specific brain circuits,\" Dr. De Giglio said.\n\"This means that even a widespread and common use tool like video games can promote brain plasticity and can aid in cognitive rehabilitation for people with neurological diseases, such as multiple sclerosis.\"\nThey used a collection of video games from the Nintendo Corporation, called Dr. Kawashima's Brain Training, which train the brain using puzzles, word memory and other mental challenges.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does identify the specific video game used in the study and its manufacturer, Nintendo, allowing readers to do a quick web search showing both it and accompanying equipment are readily available on the market.", "answer": 1}, {"article": "The review covered only carefully controlled trials.\n\u201cAlthough the randomized controlled trial is the gold-standard methodology in comparing between conditions,\u201d said Thomas G. Brown, an assistant professor of psychiatry at McGill University, \u201cit washes out a factor that may be important in potentiating A.A.\u2019s benefits, namely patient choice and preference.\u201d In other words, having a patient choose the form of treatment, rather than being assigned to it as in most studies, could be an important factor.\nBut observational data can.\u201d\n\nIt is unlikely that substance abuse experts will widely reject A.A. on the basis of these findings.\nDespite the largely negative findings, John F. Kelly, a clinical psychologist at Harvard, said he still believed that A.A. and other 12-step programs were effective.\nA.A. and other 12-step programs \u201care not cure-alls,\u201d Dr. Kelly said, \u201cbut I would say at a minimum, they help.\u201d\n\nDr. Edward V. Nunes, a professor of clinical psychiatry at Columbia, said research had demonstrated that certain elements of A.A. were effective.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains Alcoholics Anonymous (AA) and similar 12-step self-help programs for reducing alcohol dependence. The story does not mention that A.A. groups are widely available to anyone regardless of finances, and many groups allow people to attend any meeting without prior membership in the group. This would be important to note when discussing comparisons with more time-limited and potentially costly psychological treatments. ", "answer": 0}, {"article": "However, Richmond says patients considering viscosupplementation should discuss this as a treatment option with their doctor.\nThe authors of the study discourage patients from getting this treatment.\nThe researchers in Switzerland reviewed the existing studies and concluded that viscosupplementation was associated with an increase in these and other adverse events.\n\"This is not a first line treatment, but it's a reasonable treatment in those people who have been appropriately screened.\"\n\"This needs to remain one of those limited treatment options and should be used appropriately by the physician giving it.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story never explained the availability of the viscosupplementation approach.", "answer": 0}, {"article": "Millions of Americans suffer from pet allergies that prevent them from enjoying the benefits of owning a dog or a cat.\n\u201cBut now I don\u2019t really feel allergy symptoms anymore.\u201d\n\nTo find a prescribing doctor for Allerdent in your area or to find more information, visit Allovate.com.\n\u201cThe patients who came in were treated for the very things that they were sensitive to, and that included indoor allergens, like dustmite and pet dander, as well as outdoor allergens such as tree pollen, grass pollen, ragweed pollen,\u201d Dr. William Reisacher, an associate professor of otolaryngology and director of allergy services at Weill Cornell Medicine/New York-Presbyterian Hospital, told FoxNews.com.\nI was really uncomfortable and miserable.\u201d\n\nJoyce tried over-the-counter medications but couldn\u2019t find relief.\nThe toothpaste, called Allerdent, works to keep breath fresh and fight cavities while also offering the same benefits as an allergy shot or drops.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions the product price tag, the fact that it\u2019s not covered by insurance, and includes a link to the company website that can link readers to a prescribing doctor.\nWhile the promotional aspect of this information in a news story is somewhat troubling, it does satisfy the criterion.", "answer": 1}, {"article": "The research, supported by the European Research Council and titled Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells, is published by PNAS.\nOur new compounds work by attacking the energy balance in cancer cells\u201d.\nThe new drug works by forcing cancer cells to use their mitochondria, the \u2018power house\u2019 of a cell, to generate the energy necessary to function.\nBy stopping this switch of energy source, the drug causes the cancer cell to die.\nSimilar results were obtained by the National Cancer Institute USA in tests conducted on 60 cell lines.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that the compounds are not available to human patients yet.", "answer": 1}, {"article": "And yet, a new study published in JAMA Internal Medicine has found something that may seem counterintuitive: More breast cancer screening didn't actually save lives.\nThe authors of the newest study don't advocate no screening.\nAnd not all mass screening programs are bad.\nFor women under 50 and over 75 \u2014 who aren't at a high risk of breast cancer \u2014 the benefits of mass screening are less clear.\nIn other words, we don't actually know how bad the problem is.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s obvious from the story that mammography is widely available.", "answer": 1}, {"article": "By contrast, he said by e-mail, Asclera \u201cis very safe for skin.\u201d\n\nAn injector\u2019s experience matters, because if the injection misses the vein, (or open sores) can occur.\n\u201cMy wife looked at me, and my veins had disappeared,\u201d said Mr. Emerick, 68.\nShe is still due for treatments, so some veins remain visible, but they are no longer raised.\nShe now wears sundresses instead of just selling them in her boardwalk shop.\nA series of sessions is usually required for a large area.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story provides very specific information as to the availability of\u00a0different treatments for varicose veins in the U.S.", "answer": 1}, {"article": "Doctors tell patients who are at risk of developing stones to drink lots of water and avoid foods rich in oxalate, such as rhubarb, okra, spinach and almonds.\nThe findings are the result of a combination of experimental studies, computational studies and human studies, Rimer said.\nHCA is chemically similar to CA and is also available as a dietary supplement.\nHCA was also tested in human subjects, as seven people took the supplement for three days, allowing researchers to determine that HCA is excreted through urine, a requirement for the supplement to work as a treatment.\nThis finding could lead to the first advance in the treatment of calcium oxalate stones in 30 years.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that, like citrate, hydroxycitrate is available as a dietary supplement.", "answer": 1}, {"article": "He started taking a daily dose of aspirin a couple of years ago as the results of his study emerged.\nThe benefits of daily low-dose aspirin can exceed the risks for many middle-aged and older people when it comes to preventing heart attacks and strokes, the task force says.\nTo be sure, the U.S. Preventive Services Task Force's currently recommends against taking aspirin to prevent colorectal cancer, the type of cancer for which there is the largest body of scientific work.\nRothwell says the \"sensible time\" to start taking aspirin \"would be before the risk of cancer starts to rise, at about 45.\"\nStill, none of the big guns in cancer and prevention -- the National Cancer Institute, the American Cancer Society, or the U.S. Preventive Services Task Force -- are ready to advise healthy people to start taking aspirin to prevent cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of aspirin is widely known. What is unique here is how common is it to be used as a cancer prevention method. This story, like others, makes clear that it is commonly used for other reasons but not for cancer prevention. \u201cTo be sure, the U.S. Preventive Services Task Force\u2019s currently recommends against taking aspirin to prevent colorectal cancer, the type of cancer for which there is the largest body of scientific work. The benefits of daily low-dose aspirin can exceed the risks for many middle-aged and older people when it comes to preventing heart attacks and strokes, the task force says.\u00a0So for those already taking prophylactic aspirin for this reason, the possible anticancer effects are just icing on the cake.\u201d\u00a0", "answer": 1}, {"article": "If it gets to that point, then clearly things will change.\u201d\n\nStroke is the fourth-leading cause of death in the United States.\nThe three trials demonstrated how hard it is to test things once they\u2019re in widespread use.\nWe wanted the superiority of endovascular treatment.\u201d\n\nWhether the findings will cause physicians to abandon the practice is uncertain.\nIf flow isn\u2019t restored quickly, brain tissue and the functions it controls \u2014 movement, speech, cognition \u2014 are damaged or can die.\nOne study took eight years to complete because it was so difficult to enroll patients willing to take the chance that they would be randomly assigned to get the older treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Beyond establishing general availability of the different approaches. the story provided this important big picture context:\u00a0 \u201cThe three trials demonstrated how hard it is to test things once they\u2019re in widespread use.\u201d", "answer": 1}, {"article": "Without strong evidence for its efficacy, the American Congress of Obstetricians and Gynecologists does not include the treatment in its Practice Bulletin for Urinary Incontinence in Women. L. Elaine Waetjen, professor of obstetrics and gynecology at the University of California, Davis Medical Center, who has spent more than 15 years treating women for this problem, said that there is \"no scientific evidence that the O-Shot works for incontinence and there is also no clear biological mechanism for why it should treat this condition.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story provides a website link and features one practitioner in the Philadelphia Inquirers\u2019s readership area. Readers will get the hint that there aren\u2019t a lot of front-line gynecologists and urologists offering this therapy, especially since the story explains that\u00a0insurance will not pay for it.", "answer": 1}, {"article": "Newswise \u2014 Baltimore, Md.\n\u201cBy continuing to develop a comprehensive thermal oncology program, we are giving patients more effective treatment options and therefore another reason to hope for better outcomes.\u201d\n\n\u201cThe Maryland Proton Treatment Center has achieved another milestone by becoming the first center to offer both deep-thermal therapy and proton therapy,\u201d says E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs at UM Baltimore and the John Z. and Akiko K. Bowers Distinguished Professor and dean at UMSOM.\nIt\u2019s this type of innovation that sets MPTC apart from other proton treatment centers.\u201d\n\nAbout the University of Maryland School of Medicine\n\nCommemorating its 210th Anniversary, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States.\nThe acquisition of the deep-tissue thermal therapy system was made possible by donations from Jack and Emily Howell and the Middendorf Foundation, Inc.\n\n\u201cWithin the Department of Radiation Oncology and throughout our cancer center, we strive to make every available tool in the cancer-fighting toolbox available to our patients,\u201d says William F. Regine, MD, FACR, FACRO, the Isadore & Fannie Schneider Foxman Endowed Chair and Professor of radiation oncology at UMSOM and chair of radiation oncology at UMGCCC.\n\u201cWe are very pleased to be able to offer deep-tissue thermal therapy, which can be combined with standard radiation therapy as well as proton-beam therapy to enhance the cancer-killing effects of the radiation,\u201d says Zeljko Vujaskovic, MD, PhD, a professor of radiation oncology and director of the Division of Translational Radiation Sciences (DTRS) in the Department of Radiation Oncology at the University of Maryland School of Medicine (UMSOM).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release says that the Maryland Proton Treatment Center, \u201cis the only proton treatment center in Maryland.\u201d While this is technically true, they neglect to mention that there is another proton treatment center in the region, an hour\u2019s drive away in Washington, D.C. Nor do they mention any of the other 28 proton centers currently open around the country, or the 10 more under development.\u00a0", "answer": 0}, {"article": "March 29, 2011 -- A minimally invasive procedure that cuts off the blood supply to an enlarged prostate may help when medications fail, and it appears to provide good symptom control without sexual dysfunction, a new study shows.\nDespite the promising results of this small trial, experts said it was far too early to recommend PAE to patients.\n\u201cWe don\u2019t know how well these particles are localized to the prostate or if they\u2019re going to the pelvis or other parts of the body.\u201d\n\nMalizia notes that in one serious complication reported in the study, the particles appeared to migrate and kill a small part of the bladder wall.\nWe really don\u2019t know what the short- and long-term success or complication rates are,\u201d says Anthony Malizia Jr., MD, president and director of the Malizia Clinic, a nonprofit urology specialty center in Atlanta.\nA similar procedure is sometimes used to treat another kind of benign growth, uterine fibroids, in women.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story did not establish whether prostatic artery embolization was currently performed in the US and if so, whether it was widely available or an option only at particular centers.", "answer": 0}, {"article": "The majority of cases are caught at around 66.\nThe resulting test hones in on these and the existing 100 known markers to pinpoint the 1 percent of men who are at six times greater risk of developing the condition, and the 10 percent of men who have a threefold greater risk of developing the disease, a study author told The Guardian.\nThe next steps should be to understand how this research can be developed into tests that could identify men who might be more likely to develop aggressive cancers, and how this could be rolled out to patients.\u201d\n\nDr. Iain Frame, the director of research at the charity Prostate Cancer UK, highlighted that men with a family history of prostate cancer are two-and-a-half times more likely to be diagnosed with the disease compared to a man with no family history.\nRosalind Eeles, an author of the study at the U.K.-based Institute of Cancer Research (ICR) who specializes in finding genetic variants that increase the risk of prostate cancer, told The Guardian the team is \u201cexcited by the test\u201d because it can be used by doctors to offer patients targeted screenings.\nThe new method is being trialed on 300 men in doctors' offices across London, and is due to be expanded to 5,000 next year, according to BBC News.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made it clear this test isn\u2019t available but would have served readers better by explaining that higher. It stated the test \u201cis being trialed on 300 men in doctor\u00a0surgeries across London, and is due to be expanded to 5,000 next year.\u201d\nIt also provided this quote: \u201cIf it is found to be effective, it could be an important tool for physicians.\u201d [emphasis ours]", "answer": 1}, {"article": "Ultimately, four (27%) achieved the proposed end point, a PSA of 150 ng/dL at 20 months after the start of ADT, which remained undetectable in two patients for 27 and 46 months, respectively.\nSuch results could not have been achieved with any single therapy alone.\nLonger follow-up is needed to determine whether these patients were in fact cured.\nIt is expected that an upcoming Phase 2 trial will further test this endpoint and combined modality approach.\nThe combined treatment regimen including surgery was well tolerated.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that all of the treatment options are currently available.", "answer": 1}, {"article": "So Dr. Jianfeng Xu, a professor of epidemiology and cancer biology at Wake Forest University School of Medicine, and his colleagues studied a Swedish population of 2,893 men with prostate cancer and 1,781 men who did not have it.\nBut the men in this study had an average age of about 65, when the disease is less common and more likely to kill.\nThe next step was to ask whether those variants really could predict who had prostate cancer.\nThat led to their finding that each of the five variants independently predicted prostate cancer risk.\nIn fact, no one knows what their effect is.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reported that the company that would be offering the test estimated that it would be available in a matter of months.", "answer": 1}, {"article": "A lot changed in between the births of my second and third daughters. For one thing, this time around I really am getting no sleep; for another, the pediatrician recommended something for our 1-month-old that is different from what had been suggested for our other children. She said we needed to pick up a liquid multivitamin that contains 400 international units (IUs) of vitamin D. It was a little confusing, because with our first daughter, now almost 4, the doctor told us to simply get her out in the sun from time to time to let her body produce vitamin D,...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story described a recommendation to \u2018pick up a multivitamin\u2019 with a given level of vitamin D, suggesting that this is a simple over the counter purchase. \u00a0That said \u2013 the article failed to distinguish among the types of vitamin D available and whether this made any difference.", "answer": 1}, {"article": "\"In health as elsewhere, if something looks too good to be true, it should be treated with great caution,\" says an editorial published this week in the medical journal BMJ.\nFor some people, even moderate drinking is clearly risky.\nNo health agency or major medical group recommends drinking for health.\nAlcohol raises blood pressure and thins blood, he say.\n\u2022 Age matters too.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of alcohol is not in question.", "answer": 2}, {"article": "Our research shows for the first time that mefenamic acid, a simple [NSAID] can target an important inflammatory pathway called the NLRP3 inflammasome, which damages brain cells,\u201d David Brough, lead author of the study said, in a statement.\nBut, they also warned that these \u201cdrugs are not without side effects and should not be taken for Alzheimer\u2019s disease at this stage - studies in people are needed first.\u201d\n\nThe research was published in the journal Nature Communications on Thursday.\nResearchers, who conducted the study on mice, found that mefenamic acid \u2014 a common Non-Steroidal Anti Inflammatory Drug (NSAID) used to relieve menstrual pain \u2014 can completely reverse memory loss and brain inflammation that are hallmark changes of Alzheimer\u2019s, which currently affects over five million Americans.\nBecause this drug is already available and the toxicity and pharmacokinetics of the drug is known, the time for it to reach patients should, in theory, be shorter than if we were developing completely new drugs,\u201d Brough said.\nAlzheimer\u2019s disease, the most common form of dementia, can be fully cured with an anti-inflammatory drug commonly used for period pain, a new research by the University of Manchester shows.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It says that the drug being studied is\u00a0\u201ca common Non-Steroidal Anti Inflammatory Drug (NSAID).\u201d This\u00a0is\u00a0true for readers in the UK (where the study originates), so we\u2019ll rate this Satisfactory. However, for readers in the U.S. (Medical Daily is an American-owned news site), this is not the case, and it would have been helpful to explain the drug is available by prescription in the U.S., though it is not commonly used.", "answer": 1}, {"article": "\"The truth is that quit smoking programs, like other programs that treat addictions, often have fairly low success rates. But that doesn't mean they're not worthwhile or that you should be discouraged. Your own success in quitting and staying that way is what really counts, and you have some control over that. Even if you don't succeed the first few times, keep trying. You can learn from your mistakes so that you'll be ready for those pitfalls next time.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of cigarettes or smoking cessation products is not in question, which is why we rate this one Not Applicable.", "answer": 2}, {"article": "reconstructions\u201d currently being conducted on injured knees \u201ccould be avoided without adversely affecting outcomes.\u201d\n\nThis possibility should reverberate across playing fields nationwide, where, at the moment, preseason high school, collegiate and adult-league sports practices are under way, with a concomitant surge in A.C.L.\nTwenty-three subjects of that group did eventually have the operation.\nAt the time of the original injury, the knee also had been scored.\nThe surgically repaired knees were notably more stable.\nAt the same time, the urge to treat the injury with surgery appears to be growing.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that ACL\u00a0surgery and physical therapy are available.", "answer": 1}, {"article": "Aug. 17, 2011 -- German researchers say that highly trained dogs are able to reliably sniff out lung cancer in human breath.\nHe was not involved in the research.\nIn its early stages, lung cancer has few symptoms, making it difficult for doctors to catch it early, when it's still treatable.\nBut that test has caused controversy because it falsely detects cancer in about one out of four people, leading to further invasive procedures.\nRecently a large, government-funded study found that longtime smokers at high risk for lung cancer who received annual rapid computed tomography (CT) scans of their lungs cut their risk of dying of the disease by 20%.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that this very preliminary research procedure with dogs is not available yet.", "answer": 1}, {"article": "About half of all patients should be suitable for a partial replacement, but an analysis of data routinely collected by the National Joint Registry showed that of 98,147 knee replacements undertaken in 2016, only 9% were partial.\nThe main reason for the surgery is osteoarthritis.\nThey can be carried out with a smaller incision using minimally invasive surgery, but they are only suitable for people whose ligaments inside the knee are strong.\nMany more people facing surgery for knee problems would be better off with a partial rather than total knee replacement, which should allow them to recover faster, say experts.\nThose surgeons who carried out more partial replacements had better outcomes from them than surgeons who did fewer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that partial knee replacement surgery is available.", "answer": 1}, {"article": "The machine costs around $30,000, but would be priced under $20,000 in poor countries, he told the AP.\n\"The test that we developed finally makes it possible to detect TB in a single clinic visit,\" Dr. David Alland, chief of infectious diseases at the UMDNJ-New Jersey Medical School, said in a university news release.\nTHURSDAY, Sept. 2, 2010 (HealthDay News) -- An experimental test that can diagnose tuberculosis in less than two hours, making only one doctor visit necessary before treatment starts, is being hailed as a potentially significant advance against a disease that kills nearly 2 million people annually, most of them in developing countries.\nThe test, known as the \"Xpert MTB/RIF\" test for Mycobacterium tuberculosis and resistance to rifampin (RIF), appears to be more than 97 percent accurate and is even able to diagnose drug-resistant TB, researchers said.\nFor the study, a research team led by Dr. Catharina C. Boehme, of the Foundation for Innovative New Diagnostics in Geneva, Switzerland, used the Xpert MTB/RIF test on 1,730 patients suspected of having drug-sensitive or multidrug-resistant pulmonary tuberculosis.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states the new test is available in Europe and will soon be submitted for FDA approval in the U.S. But this information doesn\u2019t tell readers\u00a0when or if the test will be available in the developing world, where need for it is greatest. In developing countries, which often have rudimentary health care systems, deployment of this test may\u00a0be hampered by any\u00a0number of systemic barriers.\u00a0Cost is\u00a0certainly\u00a0one important issue. but so are management expertise and human resources and availability of reliable electricity.\u00a0The importance of these issues is demonstrated in our experience with malaria and HIV, where fast and accurate tests are\u00a0available but significant segments of the population do not have access to them.\u00a0The story doesn\u2019t do enough to provide this context.\u00a0", "answer": 0}, {"article": "New research from BYU exercise science professors finds that pro-inflammatory molecules actually go down in the knee joint after running.\nRunning may also slow the process that leads to osteoarthritis\n\nWe all know that running causes a bit of inflammation and soreness, and that's just the price you pay for cardiovascular health.\nIn other words, it appears running can reduce joint inflammation.\nThe researchers found that the specific markers they were looking for in the extracted synovial fluid--two cytokines named GM-CSF and IL-15--decreased in concentration in the subjects after 30 minutes of running.\n\"What we now know is that for young, healthy individuals, exercise creates an anti-inflammatory environment that may be beneficial in terms of long-term joint health,\" said study lead author Robert Hyldahl, BYU assistant professor of exercise science.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Obviously, running is available to anyone who\u2019s able to do it for no cost. The release could have pointed out that areas with sidewalks and dedicated trails make this activity more accessible.", "answer": 2}, {"article": ".\nAnd, though the compound is apparently well tolerated without significant side effects, the benefit is modest and limited to the motor symptoms of the disease and it is unknown how long the improvement observed could last,\" he added.\nThe only drug currently approved for Huntington's is tetrabenazine, which treats only involuntary movements and can cause serious side effects.\nThe results of the phase 3 clinical trial, conducted by Spanish researchers led by Dr. Justo Garcia de Yebenes, of the department of neurology, Hospital Ramon y Cajal in Madrid, appear in the Nov. 7 online edition of The Lancet Neurology.\n\"However, this is the first large study to show evidence of a positive result in treating the motor symptoms of this devastating disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that study results are from a phase III clinical trial, but it does not clearly comment on the availability of pridopidine, or the class of dopidine drugs in general. The story could have simply said that this drug is investigational and is not available yet.", "answer": 0}, {"article": "THURSDAY, July 20, 2017 (HealthDay News) -- A laser treatment can reduce spots in people's vision known as \"floaters,\" a new study finds.\n\"Floaters often arise as the vitreous -- a gel-like substance that fills the eye -- contracts and pulls away from the back of the eye,\" explained ophthalmologist Dr. Naomi Goldberg, who reviewed the new research.\n\"Greater confidence in these outcomes may result from larger confirmatory studies of longer duration,\" the study authors wrote.\nA limitation of the study was its small size and short follow-up period, the researchers said.\nThey explained that, currently, there are three management options for floaters: patient education and observation; surgery; and a laser procedure known as YAG vitreolysis.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t discuss the availability of this laser treatment approach. Is it available through most ophthalmic practices? Is the equipment standard in most eye hospitals?", "answer": 0}, {"article": "Ellison has written a book about living with ADHD called Buzz: A Year of Paying Attention.\n\"The hope for neurofeedback is that after training ends, the benefits that resulted from training will persist -- that in some sense there's been more enduring change in the child's ability to focus and attend and to regulate their behavior,\" he says.\nFor kids who got neurofeedback, he says, \"The ability to speed up the car and steer it was contingent on maintaining your brain waves in a more favorable ratio.\"\n\"There has been a need for some time to have the kind of carefully controlled study that would provide more definitive answers for parents and for the field,\" he says.\nThe team had hoped to announce results last week at a scientific meeting in New York, but Gene Arnold, one of the scientists in charge of the study, says they had to delay that announcement because \"we weren't able to get the results analyzed in time,\" he says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that this type of treatment is available to the general public.\u00a0We like that the story cautioned readers to look out for\u00a0unqualified therapists and\u00a0gave tips\u00a0for finding reputable clinicians. The story could have been more specific about how many trained professionals there are and how easy\u00a0it is\u00a0to find them outside of large population centers.", "answer": 1}, {"article": "Wilmington, DE, December 17, 2018 - The CRISPR-Cas9 gene editing system may be able to restore the effectiveness of first-line chemotherapies used to treat lung cancer by deleting or \"knocking out\" a gene in cancer tumors that helps the tumors develop resistance to the drugs.\nYou can find the Gene Editing Institute on Twitter and Facebook.\nYou can find Christiana Care Health System on Twitter and Facebook.\nIt was originally a defense mechanism found in bacteria that allows the bacteria to recognize and slice up the DNA of invading viruses.\nThis multidisciplinary clinical/scientific team has been working together to develop a compassionate bench-to-bedside approach.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release makes it clear that this is not yet a treatment option.", "answer": 1}, {"article": "As part of the research for the World Journal of Surgery study, 108 patients with early-stage breast cancer were prospectively implanted with the marker during \"reconstructive lumpectomy,\" a method of oncoplastic surgery to remove the cancer while reconstructing the remaining breast to improve cosmetic outcomes.\nIt is the first and only device that identifies in a reliable way the 3-D region where the tumor was removed.\nThe tiny marker clips stay in place so the surgical site can be viewed for long-term monitoring such as mammograms.\nIt is particularly effective because by suturing the implant to the tumor bed, the surgeon can more precisely indicate to the radiation oncologist where the cancer was located.\nThe BioZorb device is placed during lumpectomy surgery, which removes the cancer and preserves the breast.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We aren\u2019t told where the device is available or whether it\u2019s covered under most insurance plans. It was noted that the implant has received clearance by the FDA.", "answer": 0}, {"article": "Former NASA astronaut Mark Kelly announced that he is running for John McCain's Senate seat in Arizona in the 2020 election.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "In the lead-in to her interview with the reporter, the CNN anchor states in passing that \"as always with things that are seeking approval, and there are benefits and there are of course risks.\"\u00a0She is alluding to the fact that this\u00a0asthma treatment involves an investigational device that has not yet been approved by the FDA. However,\u00a0this is never directly stated. We\u00a0think there\u2019s a good chance the average\u00a0viewer will think that this\u00a0treatment\u00a0is already available, but it isn\u2019t.\u00a0\u00a0", "answer": 0}, {"article": "In a 2014 CDC report, the U.S. infant mortality rate (6.1 per 1,000 births) put it in 26th place among a selection of developed countries.\nAs with any change in standard medical care, extensive research is needed before it can be safely and widely adopted.\n\u201cThere is no benefit to the fetus waiting beyond 39 weeks in well-dated pregnancies,\u201d he told the doctors.\nLabor can begin immediately or take a day or two; if it becomes too lengthy, Caesareans are performed.\n\u201cStillbirth is a hugely underappreciated problem,\u201d he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Since the discussion centers on when to induce labor, it is clear that treatments to induce labor are widely available.", "answer": 1}, {"article": "Because the prostate is small and tiny shifts in position can make accurately targeting tumors difficult, OU Physicians has software and a real-time machine that allow doctors to place the seeds exactly where they are needed.\nAlthough there are no large-scale national results, doctors say studies have shown brachytherapy to be as effective as traditional radiation therapy.\nThe procedure requires a hospital stay, at the end of which the needles and pellets are removed.\nAlthough long-term data are unavailable, results have been positive.\nIn the multiple-catheter method, a doctor places 10 to 20 \"needles\u201d about one centimeter apart around the tumor cavity, and a machine inserts the radioactive pellet.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article does not indicate whether brachytherapy is available at any hospital that provides cancer treatment or only at specialized facilities. ", "answer": 0}, {"article": "\u201cWe found that patients generally can resume normal activities the following day with typical side effects.\u201d\n\nThe study, which appeared in the Red Journal\u2019s January 2017 issue, presented the results of a nonrandomized, prospective clinical trial of 58 patients with low- or intermediate-risk (non-metastatic) prostate cancer, with a median follow-up period of 2.9 years.\nThe median patient age was 63 years (range 43-73), and 91 percent of the patients presented with stage T1 disease.\n\u201cThis study illustrates that a potentially curative dose of radiation may be delivered safely to the prostate entirely in a single administration,\u201d said Dr. Krauss.\nTypically, HDR brachytherapy is administered in four to as many as nine treatment sessions, which generally requires multiple invasive procedures to insert the implants.\nThe study is available online in the International Journal of Radiation Oncology \u25cf Biology \u25cf Physics, the flagship journal of the American Society for Radiation Oncology (ASTRO).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address availability but high dose brachytherapy has been available for years\u2013and a Google search reveals many sites offering this treatment.", "answer": 2}, {"article": "The method enables researchers to identify and define the glymphatic pathway, where cerebrospinal fluid (CSF) filters through the brain and exchanges with interstitial fluid (ISF) to clear waste, similar to the way the body\u2019s lymphatic system clears waste from organs.\nIn humans and many animals the lateral sleeping position is the most common one.\nIt is during sleep that the glymphatic pathway is most efficient.\nIt is increasing acknowledged that these sleep disturbances may accelerate memory loss in Alzheimer\u2019s disease.\nTheir finding is published in the Journal of Neuroscience.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Because everyone sleeps this criteria doesn\u2019t apply for this particular release.", "answer": 2}, {"article": "The drug used in the study was manufactured by Organix Inc. in Woburn, Mass.\nHe also says \u201cPsilocybin therapy may not work for everyone, and some groups, such as people with schizophrenia, as well as adolescents, should not be treated with it.\u201d\n\nBoth the NYU Langone and Johns Hopkins studies were principally funded by the Heffter Research Institute, a non-profit, scientific institution with the principal mission of helping to design, review and fund studies on the use of psilocybin for a wide range of ailments (Ross previously served as a board member).\n\u201cAnd if it\u2019s true for cancer care, then it could apply to other stressful medical conditions.\u201d\n\nBossis cautions that patients should not consume psilocybin on their own or without supervision by a physician and a trained counselor.\n\u201cOur results represent the strongest evidence to date of a clinical benefit from psilocybin therapy, with the potential to transform care for patients with cancer-related psychological distress,\u201d says study lead investigator Stephen Ross, MD, director of substance abuse services in the Department of Psychiatry at NYU Langone.\n\u201cIf larger clinical trials prove successful, then we could ultimately have available a safe, effective, and inexpensive medication \u2014 dispensed under strict control \u2014 to alleviate the distress that increases suicide rates among cancer patients,\u201d says Ross, also an associate professor of psychiatry at NYU School of Medicine.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not specifically address drug availability. However, the release does note that psilocybin is a banned substance, and makes clear that larger clinical trials would have to be successful before psilocybin could be used as a \u201csafe, effective and inexpensive medication \u2014 dispensed under strict control.\u201d That\u2019s sufficient to merit a satisfactory rating.", "answer": 1}, {"article": "In Manhattan some raw-milk drinkers hire a mule to bring the white stuff to an agreed-upon location in...\nCarol Peterson, an IT manager at Xerox, drives almost two hours each month to her favorite farm in upstate New York for her unpasteurized supply.\nAnd they consider themselves lucky.\nNo biggie--just zip to your local supermarket and pick up a carton.\nNow that's trickier.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While the story did not list the states by name, it did mention that six states allow the sale of raw milk in stores and that 28 states allow the sale of raw milk on the farms where it is produced.", "answer": 1}, {"article": "The best moment in Rene\u00e9 Ford's life came the day her son Chase, then 2, tried to kick his doctor. It was July 2005, and that angry gesture marked the first time the boy had moved below the neck in more than a month.\n\nThese days when you look at Chase, you don't at first notice any sign of what happened to him that year--not the fall he took while jumping on the couch nor the paralyzing blow to the neck as he hit the wooden armrest. More and more, Chase can do the kinds of things any other 4-year-old can...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that locomotor training is only available in a handful of centers in the U.S.\u00a0and access is limited. The story should not have implied that the treatment has gone \"mainstream\" because it is only available in 17 hospitals in the US.", "answer": 1}, {"article": "\"The easier it is to detect CF, the earlier it can be diagnosed, and the better people's chances are at living a longer, healthier life\", says Joanna Valsamis, Chief Healthcare, Research and Advocacy Officer at Cystic Fibrosis Canada.\nThe test is commonly used in universal newborn disease-screening programs and measures the concentrations of salt.\n\"Sweat contains lots of information related to human health that researchers have not fully analyzed and we found some unexpected chemicals associated with CF,\" he says.\nTesting for these biomarkers could be done in cases in which the chloride sweat test result is unclear, say researchers.\nBut life expectancy rates have risen dramatically in recent decades with the median age of survival now over 50 years, due to better treatments to improve lung function, better nutrition and lung transplants.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is not clear how far these research findings are from making their way into clinical use.", "answer": 0}, {"article": "The state's most comprehensive health sciences university, LSU Health New Orleans includes a School of Medicine, the state's only School of Dentistry, Louisiana's only public School of Public Health, and Schools of Allied Health Professions, Nursing, and Graduate Studies.\nThis relationship strengthens the researchers' hypothesis that the lower pole ligaments stretch at a significantly slower rate than the upper pole ligaments.\nIn all patients, only one reduction technique was performed per patient.\nThis occurs when breast tissue drops to the lower portion of the breast independent of nipple position.\nA horizontal membrane of dense connective tissue originating at the level of the fifth rib that divides the breast into segments at the level of the nipple has been described.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release mentions standard therapy and a modified technique but doesn\u2019t tell us how widely available the modified technique is, whether it is new or how many plastic surgeons are skilled in the procedure.", "answer": 0}, {"article": "Data from nearly 9,500 people on five continents shows that amyloid can appear 20 to 30 years before symptoms of dementia, that the vast majority of Alzheimer\u2019s patients have amyloid and that the ApoE4 gene, known to increase Alzheimer\u2019s risk, greatly accelerates amyloid accumulation.\nThe findings also confirm that amyloid screening, by PET scan or cerebral spinal fluid test, can help identify people for clinical trials of drugs to prevent Alzheimer\u2019s.\n\u201cThe papers indicate that amyloid imaging is important to be sure that the drugs are being tested on people who have amyloid,\u201d said Dr. Roger Rosenberg, the director of the Alzheimer\u2019s Disease Center at the University of Texas Southwestern Medical Center at Dallas, who wrote an editorial about the studies.\nThe largest analysis to date of amyloid plaques in people\u2019s brains confirms that the presence of the substance can help predict who will develop Alzheimer\u2019s and determine who has the disease.\nExperts say previous trials of anti-amyloid drugs on people with dementia failed because their brains were already too damaged or because some patients, not screened for amyloid, may not have had Alzheimer\u2019s.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Dr. Gandy\u2019s quote implied scans were available, although expensive and not covered by many insurance plans. We consider this a satisfactory recognition that the scanning technology is available now.", "answer": 1}, {"article": "While a positive test result is highly suggestive of IBS, only 44 percent of patients with IBS tested positive, meaning that many people who test negative could in fact still have the condition.\nMaking it worse for many patients, there hasn't been a conclusive test to diagnose what's wrong with them.\nShe got the new blood test to confirm her diagnosis, and when it came back positive, she said she felt a sense of relief knowing IBS wasn't all in her head.\n\"We now have a test to say, you have a disease,\" Pimentel told CBS News.\nThe tests, which measure antibodies in the blood, were based on research suggesting that IBS may develop after infection from a bacterial toxin found in food poisoning.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We don\u2019t know if the tests are available, and we don\u2019t learn anything about how far away from commercialization they might be.", "answer": 0}, {"article": "\u201cOur study is the first to contribute multi-center data that support the use of SBRT as front-line therapy for men with prostate cancer.\u201d\n\nA total of 309 men with newly diagnosed prostate cancer were enrolled in the trial at 21 community, regional and academic hospitals across the U.S.\nThe 2016 Annual Meeting is expected to attract more than 11,000 attendees from across the globe, including oncologists from all disciplines and members of the entire radiation oncology team.\nThere were no reported grade four or five toxicities nor any grade three GI toxicities.\nThe technique has become the standard of care for many non-surgical lung cancer patients, as it limits exposure to the heart and surrounding lungs.\n\u201cAfter following patients for more than five years, we found that serious side effects from a brief course of SBRT were uncommon and that cancer control rates were very favorable compared to historical data.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states that patients in the trial were treated at 21 academic, regional, and community medical centers, which suggests that SRBT is widely available.", "answer": 1}, {"article": "After her mother unexpectedly died from a tear in the wall of her heart at age 63, Patricia Walters talked to her doctor, Leslie Cho, about how to better monitor her own heart health.\n\nPregnant at the time with her own daughter, Ms. Walters, now 46, says she was \"a nervous wreck\" worrying that she, too, might face serious cardiac risk.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the test is available and most insurers will pay for it.", "answer": 1}, {"article": "Your cells might be aging faster than you are, and new tests purport to help you find out.\n\nA few companies are offering mail-order testing to measure the length of people\u2019s telomeres, the protective caps of DNA on the ends of chromosomes that have been likened to the plastic tips that prevent shoelaces from fraying. Telomeres gradually shorten as people age and eventually may disappear, leaving cells vulnerable to disease and death.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that these tests are available through the mail from a number of companies.", "answer": 1}, {"article": "\u201cHowever,\u201d she added, \u201cunlike a pill, which always has the same ingredients, acupuncture, like psychotherapy, varies from one provider to the other.\u201d\n\nSo while the specific regimen used in this study appeared effective, Manber said, \u201cI do not think we can say that our study proves that acupuncture is effective for depression during pregnancy.\u201d\n\nIt\u2019s estimated that 3 to 5 percent of pregnant women are diagnosed with depression, Manber and her colleagues note in their report.\nThe study, which followed 150 pregnant women with major depression, tested \u201cdepression-specific\u201d acupuncture against massage and acupuncture sessions that, according to traditional Chinese medicine, does not specifically target depression.\nAccording to traditional medicine, specific acupuncture points on the skin are connected to internal pathways that conduct energy, or qi (\u201cchee\u201d), and stimulating these points with a fine needle promotes the healthy flow of qi.\nResearchers found that after eight weeks, women who received depression-specific acupuncture were more likely to have a treatment response \u2014 meaning the severity of their symptoms fell by at least half and they no longer met all of the criteria for diagnosing major depression.\nSSRIs include drugs like sertraline (Zoloft), paroxetine\n\nBecause of the potential for harm from medications, many pregnant women with depression may prefer psychotherapy or other non-drug options.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t address whether any acupuncture therapists are trained in the \"depression-specific\" acunpuncture methods that were used in one arm of this study.\u00a0 ", "answer": 0}, {"article": "The research falls short of concluding marijuana helps wean people off opioids - Vicodin, Oxycontin and related painkillers - and heroin, though.\nIt's a tempting sell in New England, hard hit by the painkiller and heroin crisis.\nThe growing number of patients who claim marijuana has helped them drop their painkiller habit has intrigued lawmakers and emboldened advocates.\nSubstance abuse experts argue there are already approved medications.\n\"We are in the midst of a serious problem.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article adequately\u00a0discusses that availability varies widely from state to state.", "answer": 0}, {"article": "In a separate analysis published in the same issue of JAMA Cardiology, researchers used data from the PARADIGM-HF trial to model the health consequences and cost-effectiveness of Entresto over a 30-year time period.3 They compared Entresto to the ACE-inhibitor enalapril and found Entresto was associated with more than a year longer average survival time, and that it was cost-effective compared to enalapril when these medications were used with other standard of care therapies.3 For every 1,000 patients treated with Entresto vs. enalapril, potentially 59.7 HF hospital admissions could be averted per each year alive in the model.3 In addition, Entresto increased life expectancy at an incremental cost-effectiveness ratio consistent with other high-value widely accepted cardiovascular interventions such as implantable cardioverter defibrillators (ICDs) and cholesterol-lowering statins before they became generic.3\n\nAbout Heart Failure\n\nHeart failure is a debilitating and life-threatening condition, which impacts nearly 6 million Americans and is the leading cause of hospitalization among Americans over the age of 65.4,8 About half of people with heart failure have heart failure with reduced ejection fraction (HFrEF).5 Reduced ejection fraction means the heart does not contract with enough force, so less blood is pumped out.9 Heart failure presents a major and growing health-economic burden that currently exceeds $30 billion in the United States, which accounts for both direct and indirect costs.10\n\nAbout Entresto\n\nEntresto is a twice-a-day medicine that reduces the strain on the failing heart.\n2006;355:251\u2013259.\n2013;6:606-619.\n2002;347(18):1397-1422.\n\u2022 Owan TE, Hodge DO, Herges RM, et al.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s noted that the drug is FDA approved.", "answer": 1}, {"article": "Still, even starting the trial could be a boost to Advanced Cell, which often makes headlines but has struggled to raise money.\nAfter a year, roughly 95 percent of the patients in all the arms of the trial maintained their vision, meaning their ability to read an eye chart declined by no more than 15 letters, or three lines.\nAlso, he said, there is less chance of rejection of the implanted cells because the eye is shielded somewhat from the body\u2019s immune system.\nIt sells one drug for a rare disease and has garnered hundreds of millions of dollars from licensing deals with big pharmaceutical companies.\nIt is likely to be several years before such a treatment can reach the market, if it works.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story calls VEGF Trap-Eye \u201cexperimental\u201d and says the drug\u2019s developers\u00a0plan to\u00a0apply for approval of the drug in the first half of 2011.", "answer": 1}, {"article": "Sonata uses a probe that is inserted through the cervix into the uterus. The probe not only allows the doctor to see the fibroid using ultrasound, but it also has a radio-frequency device at the tip. The doctor hits a foot pedal to send energy through the probe to heat the fibroid, shrinking it over time. The body absorbs the dead tissue, so it does not have to be surgically removed.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that Sonata is undergoing clinical trials and is otherwise unavailable in the United States \u2014 though it is approved in Europe.", "answer": 1}, {"article": "SILVER SPRING, Md., May 18, 2016 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma.\nThis is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type of cancer.\nThe study also looked at the difference in effect based on \"positive\" versus \"negative\" expression of the PD-L1 protein on patients' tumor-infiltrating immune cells.\nTecentriq is the first FDA-approved PD-L1 inhibitor and the latest in the broader class of PD-1/PD-L1 targeted biologics approved by the FDA in the last two years.\nWhile patients who received Tecentriq experienced a tumor response across the study, the greater effect in those who were classified as \"positive\" for PD-L1 expression suggests that the level of PD-L1 expression in tumor-infiltrating immune cells may help identify patients who are more likely to respond to treatment with Tecentriq.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The FDA\u2019s approval of a drug clears the way for the drug sponsor to scale up production and begin marketing and selling the product. (The FDA doesn\u2019t state this explicitly but it can be inferred.)\u00a0 A NYT article said the drug would be available in about two months.", "answer": 1}, {"article": "MONDAY, April 16, 2018 (HealthDay News) -- People with chronic back pain often try painkillers and other treatments without success.\nIt's rarely used for back pain, she said.\nPatients in the program reported 50 percent less pain after the treatment.\nNow, a new study suggests a program of education and exercise may provide relief.\nThey also reported paying less attention to pain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that this is an experimental therapy.", "answer": 1}, {"article": "Utian is now an independent consultant and was a co-author of one of the studies.\nHormone therapy is the only FDA-approved treatment for hot flashes related to menopause, but many women are reluctant to undergo hormone therapy because its long-term use has been linked to an increased risk for breast cancer and stroke .\nIn one study, the number of daily hot flashes experienced by postmenopausal women taking 1,800 milligrams of the drug per day declined from around 10 to around 2.\nMichael Sweeney, MD, who is vice president of research and development for Serada manufacturer Depomed Inc., says the company\u2019s slow-release gabapentin formulation avoids many of these side effects.\nIn earlier studies, immediate-release gabapentin was shown to be an effective treatment for hot flashes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The oblique reference to this drug perhaps being \"one step closer to becoming the first approved nonhormonal treatment for menopause-related hot flashes\" is likely to leave many readers unsure about whether this drug is not yet available or whether it is just not approved specifically for treatment of hot flashes.\nThe standard formul gabapentin, which is approved for treatment of seizures and pain,\u00a0can be prescribed off label for treatment of hot flashes even though it isn\u2019t FDA approved for this use. (In fact, Pfizer has recently been slapped with large fines for promoting unapproved off-label uses of the drug.) However, the slow-release form of the drug discussed here is not available commercially. Although it calls the new drug \"experimental,\"\u00a0the story\u00a0doesn\u2019t\u00a0explicitly address\u00a0the\u00a0availability of the immediate-release vs. slow-release forms of the drug.\u00a0The article should have been clearer that the FDA has not approved this new slow release form, and that it is not available.\u00a0\u00a0", "answer": 0}, {"article": "All of these study participants \u2014 largely people in their 70s, all with a diagnosis of either \"mild cognitive impairment\" or atypical dementia \u2014 are living with the unconfirmed suspicion that they have Alzheimer's. The study is underwritten by the Centers for Medicare & Medicaid Services and the Alzheimer's Assn. It set out to find out whether knowing \u2014 getting the costly test that would offer either confirmation or reprieve \u2014 would change the way that patients with cognitive troubles are treated, or the way that they plan their lives.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This was a close call. In general, PET scans are widely available, if costly. The story also made it clear that Medicare doesn\u2019t cover this scan. But, the story could have gone a step further and explained without Medicare coverage, it\u2019s unlikely to become widely available.", "answer": 1}, {"article": "Developed in the laboratory of UHN transplant surgeon Dr. Markus Selzner, with the help of UHN transplant surgeons Drs.\n\u201cThis can make a difference to other patients, so I am glad to be the first one helping them with my experience.\u201d\n\nAs soon as the donor kidney was reattached to the patient, it turned ruby-red and started to pour out urine, indicating that it was functioning well.\n\u201cIt behaved like a normal kidney, despite it being an extended criteria donor kidney.\u201d\n\nHe points out blood tests within 48 hours showed that the kidney was removing wastes and excess fluid from the blood normally.\nThe technique, unique solution, and device are part of a Phase I clinical trial at Toronto General Hospital (TG), University Health Network (UHN), assessing the safety of the device, with subsequent phases examining its efficacy.\n\u201cThis new technology can help us answer the critical question, \u2018What\u2019s the best way to improve function and recover and repair the kidney before transplantation to get the best results for our patients?\u2019\u201d\n\nDr. Grant, who is also Professor of Surgery at the University of Toronto, emphasized that high-impact research projects such as this require strong collaborative teams \u2013 including researchers, surgical residents, nurses, Canadian Blood Services, perfusionists, colleagues at SickKids - working together on experimental and clinical trials.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "As noted above, the release does tell readers that this work was done as part of a phase 1 clinical trial, so we\u2019ll rate this Satisfactory. However, many \u2014 if not most \u2014 readers are not familiar with clinical trials, and we think the release would have been stronger had it translated that.", "answer": 1}, {"article": "The requested URL /2011-08-30/business/29945941_1_mark-kris-cancer-cases-lung was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that crizotinib recently received FDA approval for use \u201calong with a companion diagnostic test for just a small subset of lung cancer patients.\u201d However, while the story refers to ongoing research, the actual status of the drug is not explained. The FDA approval letter warns that, \u201cIf postmarketing trials fail to verify that clinical benefit is conferred by XALKORI (crizotinib) Capsules, 200 mg and 250 mg, or are not conducted with due diligence, we may, following a hearing in accordance with 21 CFR 314.530(b), withdraw or modify approval.\u201d \nReaders should have been clearly told that this drug is still very much on trial.", "answer": 0}, {"article": "This study was presented at a medical conference.\n\"A key question now is to work out which patients will benefit from the drug -- clearly, some patients do and some don't,\" Johann de Bono, MD, PhD, of the U.K.'s Royal Marsden NHS Foundation Trust, says in a news release.\nAnd while the average patient survived only four months longer than those on standard chemotherapy -- 14.8 months vs. 10.9 months -- some patients did much better.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\nOct. 12, 2010 -- Even when medical or surgical castration fails, a potent drug extends survival by four months in patients with metastatic prostate cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The reader is given no information about whether this drug is available now, or, if not, what stage of research it is in.\u00a0 There\u2019s a hint \u2013 in the line that Johnson & Johnson is \"developing\"\u00a0the drug but news organizations shouldn\u2019t play guessing games with readers on the topic of the availability of prostate cancer drugs \u2013 or any topic. \nThe competing Wall Street Journal story, by contrast, reported:\u00a0\"Johnson & Johnson plans to file for new-drug approval in the U.S. and Europe by year-end, raising prospects that the drug could be on the market next year.\"\u00a0 There\u2019s no doubt about availability when you read that. (Although one could doubt the prediction of when it could be on the market.)\u00a0", "answer": 0}, {"article": "In the Swiss research, animals took a drug that dissolved a barrier around the part of the brain where mammals store their fear memories. Afterward, they stopped being afraid of noises that were linked to electric shocks, which meant their bad memories had been erased, according to the Mail. Human brains, explains NYU neuroscience Prof. Joseph LeDoux, could actually \"overwrite\" memories with happier thoughts if the medication is developed for people, according to the Daily Mail.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this \u201cmind-cleansing\u201d drug is not available. ", "answer": 1}, {"article": "Harvard T.H.\n\"This work on the role of nutrition in early life and breast cancer incidence suggests one of the very few potentially modifiable risk factors for premenopausal breast cancer.\"\n\"From many other studies we know that breast tissue is particularly influenced by carcinogens and anticarcinogens during childhood and adolescence,\" said Walter Willett, Fredrick John Stare Professor of Epidemiology and Nutrition at Harvard Chan School and senior author of the study.\nThe researchers looked at a group of 90,534 women who participated in the Nurses' Health Study II, a large long-running investigation of factors that influence women's health.\n\"Previous studies of fiber intake and breast cancer have almost all been non-significant, and none of them examined diet during adolescence or early adulthood, a period when breast cancer risk factors appear to be particularly important,\" said Maryam Farvid, visiting scientist at Harvard Chan School and lead author of the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll give this a Not Applicable since it\u2019s commonly assumed that fresh dietary fiber is widely available in various products at many grocery stores.\u00a0 We discussed problems with this assumption under the \u201ccosts\u201d criteria.", "answer": 2}, {"article": "In an earlier pilot study supported by Life Extension, Drs.\n\"It's an important trial,\" says Dr. Steven Hirsh, director of clinical research for Life Extension in Fort Lauderdale, Fla. \"The findings are very noteworthy and support further study in randomized controlled trials with larger sample sizes and durations.\nThe team of researchers, led by Dr. Rafael de la Torre, program director of IMIM Hospital del Mar Medical Research Institute and study co-principal investigator, and Dr. Mara Dierssen, group leader at Center for Genomic Regulation, Barcelona, Spain, and study co-principal investigator, proposed that EGCG might have conferred these benefits by inhibiting an enzyme called DYRK1A, which has been implicated in Down syndrome and neurodegenerative conditions including Alzheimer disease.\n\"We are excited that the benefits observed in the early pilot and preclinical research extended to this larger trial,\" says Luke G. Huber, ND, MBA, vice president of product innovation and scientific development at Life Extension.\nIn acknowledging the novelty of their findings and calling for more research, the Spanish research team noted that \"\u2026this study is the first well-powered trial that shows improvement in adaptive behavior (functional academics) and brain-related changes in young adults with Down's syndrome.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release could have been more explicit in pointing out that green tea extract supplements are easily available online or at the local health foods store. However, we give it here the benefit of the doubt, since it disclosed Life Extension\u2019s support in this study. Furthermore, the availability of green tea is not in question.\nWe rate this one Not Applicable.", "answer": 2}, {"article": "CHICAGO (Reuters) - A new analysis of evidence used by a U.S. advisory panel to roll back breast cancer screening guidelines suggests it may have ignored evidence that more frequent mammograms save more lives, U.S. researchers said on Tuesday.\nThey were meant to spare women some of the worry and expense of extra tests needed to distinguish between cancer and harmless lumps.\nBreast cancer is the second-leading cause of cancer death among U.S. women, after lung cancer.\nThose guidelines recommended against routine mammograms for women in their 40s and said women in their 50s should get mammograms every other year instead of every year.\n\u201cIt\u2019s like a weather man using a computer model to see what the weather is rather than looking outside the window,\u201d Lee said in a telephone interview.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 There\u2019s no question about the availability of mammograms.", "answer": 2}, {"article": "Other Phase 2 data presented over the weekend showed that treatment with cabozantinib led to significant tumor shrinkage in 24 percent of patients with metastatic ovarian cancer.\n\u201cMen with late-stage prostate cancer usually die from bone disease.\u201d\n\nAfter 12 weeks of treatment, 31 patients were randomly selected to receive either a placebo or cabozantinib.\n\u201cFor the first time, cabo is showing dramatic activity against both soft tissue and metastatic bone lesions,\u201d said Exelixis Chief Executive Officer Michael Morrissey.\nThe disease remained stable in 23 other patients, or 21 percent, and worsened in three.\nThe drug reduced by 87 percent the risk of disease progression or death.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says the drug is \u201cexperimental.\u201d\u00a0 We wish it had provided more details than that.\u00a0 But we\u2019ll give it the benefit of the doubt.", "answer": 1}, {"article": "\u201cIt\u2019s not a randomized controlled trial, so you always wonder, are there other things going on that you weren\u2019t able to control for?\u201d she said.\nThose in the bottom third \u2014 less than 173 micrograms folic acid per day for girls and 227 for boys \u2014 had an average score of only 120.\nBecause a lack of the nutrient during pregnancy can cause severe birth defects in babies, certain foods are fortified with folic acid, also called folate, in North America.\n\u201cThere is very little deficiency of folic acid in North America,\u201d Deborah O\u2019Connor, a nutrition researcher who was not involved in the study, told Reuters Health.\nMost of the population is thought to get adequate amounts for that reason.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that folic acid is one of the \u2018B\u2019 vitamins and that at least in the US, is found in fortified foods.\nThe story could have also mentioned that folic acid is a common ingredient in multivitamin formulations.", "answer": 1}, {"article": "Dr. Shari Lusskin, director of reproductive psychiatry at the New York University Langone Medical Center, echoed that sentiment.\nThe depression-specific protocol was designed just for this study, and the control acupuncture was specifically designed to avoid using acupuncture needles in any areas known to affect depression.\nThe researchers found a 63 percent response rate in women who received the depression-specific acupuncture, while the response rate was 44.3 percent in the control acupuncture and massage groups.\nBut, she added, because this is the first study of its kind, and the acupuncture protocol used was specifically designed for this study, \"you always need replication of the findings.\"\nThe quality of what you get can differ from one practitioner to another,\" said Manber.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stresses that the type of pressure points used were specifically designed for this study, yet the story makes no mention of whether or not this method is available to any practitioners and if so, where to find them. ", "answer": 0}, {"article": "For more information, visit http://www.\n\"Our study highlights the fact that laparoscopic anti-reflux surgery is as effective as the open approach, and in 2017, with all its advantages, should be the standard of care,\" said senior study author Marco G. Patti, MD, FACS, a surgeon and Director of the Center for Esophageal Diseases and Swallowing, University of North Carolina, Chapel Hill.\nCHICAGO (January 26, 2017): Patients with gastroesophageal reflux disease, known as GERD, who undergo laparoscopic anti-reflux operations compared with traditional \"open\" operations suffer fewer postoperative complications, experience faster recovery, and incur lower health care costs, according to study results published online as an \"article in press\" on the Journal of the American College of Surgeons website, ahead of print publication.\n\"Patients with GERD have an incompetent lower esophageal sphincter, which allows gastric acid to go back up into the esophagus,\" said lead study author Francisco Schlottmann, MD, a surgeon at the Center for Esophageal Diseases and Swallowing, University of North Carolina, Chapel Hill.\nFor the study, researchers analyzed data in the National Inpatient Sample (NIS) database of more than 75,000 adults who underwent either laparoscopic or open fundoplication for GERD between 2000 and 2013.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the release that both methods of surgery have been widely available nationally and the outcomes of 75,000 surgeries were tracked by the National Inpatient Sample (NIS) database.\nThe release also notes that \u201curban academic or teaching hospitals\u201d perform laparoscopic anti-reflux surgery more often than \u201copen\u201d procedures, 54.4 percent versus 45.6 percent. And it recommends that anti-reflux surgery should be performed laparoscopically in specialized centers.", "answer": 1}, {"article": "Then President Richard Nixon declared drugs \u201cpublic enemy No.\n\u201cThose kinds of changes are not delusional, because blinded interviews with family members, friends and work colleagues [confirm these reports].\u201d\n\nSimilar work has shown psilocybin can help treat anxiety associated with cancer, at UCLA and New York University.\nGrob says work by his group and others has shown that psilocybin can help treat \u201cterminal cancer patients with overwhelming existential anxiety, an area that traditional medicine struggles with.\u201d And a study in late 2014 found that LSD permanently reduced anxiety in a small number of patients.\nThe idea that you can take a medicine one or a few times and become \u201ccured,\u201d or at least significantly helped, conflicts with current standard practices, which often involve taking medications every day for years, or life.\nHe points out that psychedelics should never be used carelessly, and that the \u201cset and setting\u201d (meaning the dose, mood, environment, company and surroundings) where a person takes them are of paramount importance.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Magic mushrooms and MDMA may be \u2018available\u2019 in our society, but hardly through channels that one would consider reliable or trustworthy. While we might want more details on how to obtain these substances, in the interests of public service, it may be just as well that the story didn\u2019t delve into this issue too far.", "answer": 1}, {"article": "Reductions in pancreas, stomach and brain cancers were difficult to quantify because of smaller numbers of deaths.\nThe researchers added, however, that treatment with aspirin during the trials lasted for only for between four and eight years on average, so the effects on risk of deaths due to cancer may underestimate possible results of longer-term treatment.\nAspirin protected people against gastrointestinal cancers the most, the study found, with rates of death from these cancers around 54 percent lower after five years among those who took aspirin compared to those who did not.\nLONDON (Reuters) - Taking low doses of aspirin can reduce the risk of many kinds of cancer, scientists said on Tuesday, and the evidence is strong enough to suggest people over 40 should take it daily as protection.\nIn Rothwell\u2019s study, published in The Lancet, researchers found the 20-year risk of death was reduced by about 10 percent for prostate cancer, 30 percent for lung cancer, 40 percent for colorectal or bowel cancer and 60 percent for oesophageal cancer in those taking aspirin.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story notes that aspirin is widely used to relieve pain and reduce fever. Oddly, it does not highlight the use of aspirin by certain people to reduce their risk of heart attacks even though it was trials looking at those effects that provided the data for this analysis. While this story technically meets this criterion because aspirin is indeed available on store shelves and home medicine cabinets, the drug is specifically intended for use as an analgesic and, in certain individuals, to reduce the risk of certain heart-related problems; notwithstanding this one study, aspirin is not widely recognized or officially approved as a cancer prevention agent.\n", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061105/13healy.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention that lung cancer screening is already being offered and advertised by many hospitals and imaging centers across the country. We're told the study was done in 38 centers around the world but are given no idea of the availability of spiral CT scanners.\u00a0 ", "answer": 0}, {"article": "LaCroix says her new study refutes that research and shows that older adults can still benefit at levels below the moderate-to-vigorous guidelines.\n\u201cBut what we have here is solid evidence that light physical activity reduces a woman\u2019s risk of dying over the next three to four years\u2014and we see the benefits are substantial and independent of moderate-to-vigorous physical activity.\u201d\n\nThe study could not show a cause-and-effect relationship between activity level and risk of death, only an association.\nBut the link was present in all types of women in the study, including those of all races and ethnicities, women who were obese and those who were not, women with high and low functional abilities and women older and younger than 80.\nAnd recent analyses, compiled from studies in which adults self-reported their levels of physical activity, have suggested that older adults have to log moderate-to-vigorous exercise in order to reduce their risk of early death.\n\u201cThey throw up their hands and think, \u2018that\u2019s not for me.\u2019 But everyone does light physical activity, and the idea that doing more of it can have substantial health benefits should be welcome news.\u201d\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a good job of defining what light activity means, which is important for understanding how accessible it is. Bike riding is a moderate activity, for example, whereas \u201cstrolling around the neighborhood\u201d is a light activity.", "answer": 1}, {"article": "For more information, go to http://www.\n\"We were pleasantly surprised to see that just a small increase in dietary zinc can have such a significant impact on how metabolism is carried out throughout the body,\" says King.\nThis was a novel approach, different from the commonly used method of looking at zinc in the blood or using stunting and morbidity for assessing zinc status.\nThe study, published in the American Journal of Clinical Nutrition, was led by CHORI Senior Scientist Janet King, PhD.\nOakland, CA (January 3, 2017) - A new study by researchers from the UCSF Benioff Children's Hospital Oakland Research Institute (CHORI) shows that a modest 4 milligrams of extra zinc a day in the diet can have a profound, positive impact on cellular health that helps fight infections and diseases.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We wish the news release could have talked more about existing zinc fortification efforts around the world, since it\u2019s not clear in the release whether zinc fortification practices are already in place.\nIn the original journal article, researchers mention the zinc fortification programs initiated in more than 30 countries and point out how Bangladesh increased its rice zinc concentration by 50 percent through its biofortification methods.\nFor this reason, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": "The main reason to take a multivitamin is to correct or prevent a deficiency, \"but there may be a modest benefit in reducing the risk of cancer in older men,\" Gaziano said.\nThe National Institutes of Health paid for most of the study.\nThey are marketed as a kind of insurance policy against bad eating.\nScience on vitamins has been skimpy.\nSide effects were fairly similar except for more rashes among vitamin users.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of multivitamins is not in question.", "answer": 2}, {"article": "What's the point of a runny nose?]\n\u201cIt's almost symbiotic,\u201d Navarro said, \u201cbecause in order for it to survive and thrive, it needs its host to be happy and healthy.\u201d\n\nPerhaps the adaptations that help the parasites stay hidden also benefit their host by reining in overactive immune systems.\nThis suggests that AIP-2 might also help humans, since dendritic cells have the same function in us that they do in mice.\nThe study is the latest from a surprising field of research into the potentially positive sides of parasites, one of the most maligned groups in the animal kingdom.\n\u201cBut what we need is to find what's good in them,\u201d she said, \u201cand try to restore that missing component.\u201d\n\nThe vocal tricks political candidates use to sound like leaders\n\nThis lab can re-create the sounds of any space\n\nThese monkeys are creating tools thought to be unique to humans \u2014 by accident\n\nThe tiny genetic tweak that helped snakes lose their legs\n\nThe mysterious \u2018Planet Nine\u2019 might be causing the whole solar system to wobble\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does\u2019t address availability. As we explain in the quantified benefits criterion above, the most readers get is an\u00a0erroneous statement about the next steps: \u201cNavarro said their next step is a phase one clinical trial, which would test the effectiveness of an AIP-2 pill.\u201d A phase one trial is actually to test safety\u2013not effectiveness\u2013and this error may have the effect of making this pill seem closer to reality than it is.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - A new study bolsters the case that daily aspirin may help protect against cancer, although the effect seems weaker than previously thought.\nBut it didn\u2019t seem to matter whether people had been on aspirin for more or less than five years.\nOther researchers are more skeptical.\nRay called for trials that specifically check people for new cancers at given intervals to weed out the selection bias marring the previous research.\nThe effect was strongest for gastrointestinal cancers, such as colon cancer and stomach cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of aspirin is not in question.", "answer": 2}, {"article": "So when the government advisory panel \u2014 the U.S. Preventive Services Task Force \u2014 recommends against routine PSA testing, it\u2019s making a judgment call.\nThe rate of new diagnoses of all cancer types combined has been falling consistently in recent years.\nMany doctors do have very strong opinions, though.\nIn the U.S., a large randomized trial found no mortality benefit of screening.\nBut an even larger randomized clinical trial in Europe has found a benefit.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that PSA screening is widely available.", "answer": 1}, {"article": "Aug. 10, 2011 -- Two of three patients dying of chronic lymphocytic leukemia (CLL) appear cured and a third is in partial remission after infusions of genetically engineered T cells.\nExcitement is spreading as oncologists learn about the findings.\nA manmade virus-like vector is used to transfer special molecules to the T cells.\nThe treatment uses a form of white blood cells called T cells harvested from each patient.\n\"Within three weeks, the tumors had been blown away, in a way that was much more violent than we ever expected,\"June says in a news release.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Previous studies have found women's monthly hormone fluctuations can affect everything from food cravings and digestive problems to joint pain and a whole host of other health issues.\n\"This result emphasizes the need for gender-specific programs to quit smoking, as well as taking into consideration a menstrual cycle phase during addiction treatment in women,\" the researchers conclude.\n\"One of the factors contributing to these differences may be that women crave cigarettes more than men and that their desire to smoke is influenced by hormonal fluctuations across the menstrual cycle.\"\n\"While overall more men than women smoke cigarettes, women and girls take less time to become dependent after initial use and have more difficulties quitting the habit,\" the researchers write in their study.\nAccording to small study conducted by researchers at the University of Montreal, women are more likely to crave cigarettes and have trouble quitting when in the follicular phase of their monthly cycle.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story ends with a call for emphasis on \u201cgender-specific programs to quit smoking.\u201d Are such programs available? \u00a0The headline and the first sentence might suggest to some readers that the proof is in and that women can already get help with this. Accordingly, we\u2019ll rate this as unsatisfactory. \u00a0", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a131601S24.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There is no mention of whether this device is still in testing or whether it has garnered FDA device approval. (In fact, the FDA has determined that the device may be marketed as of August 18, 2005; the company was FDA approved to market it for \u201cfailed diuretic therapy\u201d not as an alternative for heart failure patients \u2013 FDA Feb 2, 2006 .)", "answer": 0}, {"article": "Molecular Psychiatry; 18 Oct 2016; DOI: 10.1038/mp.2016.167\nAlthough the trials reviewed by the team involve physical illnesses that trigger inflammation - and hence potentially contribute to depression - their previous work found a connection between depression and baseline levels of inflammation in healthy people (when someone does not have an acute infection), which can be caused by a number of factors such as genes and psychological stress.\nBy looking at additional beneficial side-effects of the treatments, the researchers were able to show that there was a significant antidepressant effect from the drugs compared to a placebo based on a meta-analysis of seven randomised controlled trials.\nIn other words, regardless of whether a drug successfully treated rheumatoid arthritis, for example, it would still help improve a patient's depressive symptoms.\nNew types of anti-inflammatory drugs called anti-cytokine monoclonal antibodies and cytokine inhibitors have been developed recently, some of which are now routinely used for patients who respond poorly to conventional treatments.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "While this meta-analysis was done on clinical trials data, all of the drugs involved are currently available for treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis, and the release makes this clear.\n\u00a0", "answer": 1}, {"article": "In their commentary, the FAU researchers emphasize that, until recently, the totality of randomized evidence on varenicline had been restricted to eight small trials, which did not demonstrate a hazard.\ndegree.\nMore than 35 million Americans are trying to quit smoking.\n\"For reducing risks of cardiovascular disease it's never too late to quit, but to reduce risks of cancer, it's never too early,\" said Hennekens.\nThere were plausible alternative explanations including that nearly half of the subjects had psychiatric histories, 42 percent were taking psychotropic drugs and about 42 percent were suffering from depression.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that Chantix is commercially available.", "answer": 2}, {"article": "If studies show the same thing in humans, the heart hormone may hold the key to an effective weight loss treatment, says researcher Sheila Collins, PhD, of Sanford-Burnham Medical Research Institute in Orlando, Fla.\nThe study appears online in the Journal of Clinical Investigation.\n\u201cThese hormones are involved in fluid regulation, but we showed in this study that they also play a role in breaking down fat,\u201d she says.\nAdults don\u2019t have much brown fat, but a new study suggests that hormones produced by the heart just might help them make more.\nResearchers found that the hormones, known as cardiac natriuretic peptides, caused regular energy-storing white fat cells to turn into energy-burning brown fat in mice.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable; there\u2019s no product or treatment that can increase brown fat.", "answer": 2}, {"article": "Those are also symptoms of a deficiency of B12, a key nutrient needed to make red blood cells and DNA and keep the nervous system working right.\n\nVitamin B12 deficiency is officially considered rare, affecting about 1 in 1,000 Americans, according to a 2005 study. But the incidence...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The text mentioned that vitamin B12 supplements were available in pill and injectable form; \u00a0a table listing food sources of B12 was included.", "answer": 1}, {"article": "The results were published in January in Nature Medicine.\nThe purpose was to determine whether the antibody was safe and whether it had antiviral activity in humans.\nThe study of 10-1074, an early-stage clinical trial, included 19 individuals who were infected with HIV and 14 who were not.\nThese antibodies are a major area of study in the laboratory of Rockefeller University investigator Michel Nussenzweig, who is Zanvil A. Cohn and Ralph M. Steinman Professor and head of the Laboratory of Molecular Immunology.\nThe drug belongs to a class of molecules called broadly neutralizing antibodies, which are naturally found in HIV-infected people whose immune systems have a rare ability to fight off the virus.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We can assume that this is preliminary data collection but it would have been useful if the release included information about how long the research process may be before eligible patients might have access to this new therapy. Next steps regarding future clinical trials are mentioned in the last paragraph.", "answer": 1}, {"article": "The scientists hypothesized the cancer could use this molecule to render chemotherapy ineffective.\nDr. Dean A. Fennell, professor and consultant in thoracic medical oncology at the University of Leicester, who was not involved in the study, told Newsweek the study presents an \u201cexciting result.\u201d\n\nHe was particularly surprised by the magnitude of the response triggered by vistusertib combined with paclitaxel, which is closely related to standard chemotherapy.\nWe need to wait for these results, expected later this year, to see how effective this approach is compared to chemotherapy alone.\u201d\n\nProfessor Udai Banerji\u200b, author of the study and deputy director of the Drug Development Unit at The ICR and Royal Marsden, acknowledged in an interview with Newsweek the cohort of patients was small, \"however anything more than 20 patients usually gives one a rough idea [of the effectiveness of a treatment].\"\nThe cocktail also stopped the cancer growing for almost six months, which is unexpected for patients with advanced-stage cancers who were unresponsive to currently available treatments, including chemotherapy, the authors said.\nConfirmatory studies will be essential and if positive would broaden our armamentarium for fighting this cancer.\u201d\n\nThis article has been updated with comment from Professor Udai Banerji\u200b.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned a larger trial with 140 ovarian cancer patients that will test the drug\u2019s effectiveness versus chemotherapy alone, with results \u201cexpected later this year.\u201d This is enough information that a reader can infer that it\u2019s not available yet.\nHowever, the story didn\u2019t explain what scientific and regulatory hurdles would have to be overcome for this drug to become available.", "answer": 1}, {"article": "The study included 60 adults with TBI symptoms lasting an average of eight years.\nA recent study from the Center for BrainHealth at The University of Texas at Dallas shows that a certain type of instructor-led brain training protocol can stimulate structural changes in the brain and neural connections even years after a traumatic brain injury (TBI).\nBuilding upon previous research, the study challenges the widely held belief that recovery from a TBI is limited to two years after an injury.\nThe findings, published in Brain and Behavior, further suggest that changes in cortical thickness and neural network connectivity may prove an effective way to quantitatively measure treatment efficacy, an ability that has not existed until now.\nThe knowledge-based training group learned information about the structure and function of the brain as well as the effects of sleep and exercise on brain performance.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "From the news release alone, it is not entirely clear if the brain training program already existed and was simply now applied to those with chronic TBI for the first time.", "answer": 0}, {"article": "The trial reported today \u201cis a major study that may substantially change our approach to treatment of PDR,\u201d summed up Dr. Sun.\n\u201cWe know that this drug will help treat both conditions at the same time, so this is an especially appealing treatment alternative for these patients,\u201d Dr. Aiello noted.\n(Their work followed a distinguished Joslin tradition\u2014the basic laser photocoagulation technique was developed in the 1960s by Dr. Aiello\u2019s father, Lloyd M. Aiello, M.D., and grandfather, William P. Beetham, M.D.)\nBecause Lucentis is commonly injected to treat diabetic macular edema (DME)\u2014a build-up of fluid in the center of the retina\u2014the study permitted the use of Lucentis for DME in the laser group, if necessary.\nThese new vessels are prone to bleeding into the center of the eye, sometimes requiring a surgical procedure called a vitrectomy to clear the blood.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that Lucentis is already used to treat other diabetes-related eye problems, and \u201cshould be considered a viable treatment option for people with PDR.\u201d", "answer": 1}, {"article": "MONDAY, July 6, 2015 (HealthDay News) -- A scan of calcium deposits inside your arteries can help doctors deduce how long you're likely to live, a new study has found.\nThe findings appear in the July 7 issue of Annals of Internal Medicine.\n\"It can be a very potent motivator,\" she said.\nResearchers then tracked the participants for roughly 15 years, taking special note of the 936 patients who died.\nThis study confirms their usefulness in that regard, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that CAC testing is widely available.", "answer": 1}, {"article": "A compound in raspberries is being touted as the next new fat burner. But people looking to lose a few pounds may not want to go running to the produce aisle just yet. Scientists say there are no major human studies to support the idea that a berry holds the secret to weight loss.\n\nRaspberry ketones, the organic compounds that give raspberries their aroma, raised hopes as a weight-loss aid after a 2005 study by Japanese researchers found the ketones boosted fat-burning processes in rat cells in a laboratory as long as those...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that supplements containing raspberry ketones are widely available.", "answer": 1}, {"article": "\u201cThe length of statin use, both greater than six months and greater than five years of use was associated with reduction in colorectal cancer risk.\u201d\n\nThe group of statins that showed the greatest effect in reducing risk are classified as lipophilic: atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Altocor, Altoprev, Mevacor), pitavastatin (Livalo), and simvastatin (Zocor),\n\nColorectal cancer is the third most common type of cancer in the U.S.; 102,900 new cases of colon cancer are diagnosed in men and women every year, and about 39,670 new cases of rectal cancer are diagnosed annually.\n\u201cThis effect was largely consistent across study design with both case control and cohort studies showing a strong correlation,\u201d he says in a news release.\nAlso, the longer patients used statin drugs, the greater their reduction in risk for colorectal cancer.\nThe analysis shows there was a 12% reduction of colorectal cancer risk among statin users.\n\u201cObservational studies have suggested that long-term use of statins is associated with reduced risk of several cancers, including breast, prostate, lung, pancreas and liver,\u201d says Samadder in the news release.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There isn\u2019t any question about the availability of statins.\u00a0", "answer": 1}, {"article": "For advice, information and support, visit http://www.\nThis is a real breakthrough in reducing the risk of falls for people with Parkinson's.\"\nThis takes us a step closer to improving the quality of life and finding better treatments for people with Parkinson's.\"\nThe main symptoms of the condition are tremor, slowness of movement and rigidity.\n\"This trial shows that there may be drugs already available, being used for other purposes, that can be tested to help treat Parkinson's.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the drug is already available as a treatment for Alzheimer\u2019s disease patients.", "answer": 1}, {"article": "The new study ''adds to the trickle of evidence that cannabis may help some of the patients who are struggling [with pain] at present,\" Henry McQuay, DM, an emeritus fellow at Balliol College, Oxford University, England, writes in a commentary accompanying the study.\nThe research is published in CMAJ, the Canadian Medical Association Journal.\n\"About 10% to 15% of patients attending a chronic pain clinic use cannabis as part of their pain [control] strategy,\" he tells WebMD.\n''It's been known anecdotally,\" says researcher Mark Ware, MD, assistant professor of anesthesia and family medicine at McGill University in Montreal.\nBut Ware's study is more scientific -- a clinical trial in which his team compared placebo with three different doses of cannabis.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "ACOG already recommends that women who are at high risk of preeclampsia take a low-dose baby aspirin beginning between 12 and 28 weeks of pregnancy.\nJust 13 women in the aspirin group developed preeclampsia, while 35 women in the placebo group developed the complication, the findings showed.\nThis is important because it will reduce the need for preterm delivery, which is risky for the baby.\"\nThey continued taking the pills until they were 36 weeks' pregnant, or sooner if they delivered the baby early.\nThere were no serious side effects for expectant mothers, or adverse events for the babies related to aspirin use during pregnancy, the researchers noted.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As mentioned above, aspirin is ubiquitous in the modern world so there is hardly a problem with its availability.", "answer": 1}, {"article": "It\u2019s easy to get into the habit of popping a pill to have a good night\u2019s sleep. Insomnia, which affects a third of adults, becomes more common as we age.\n\nBut as evidence has mounted about the risks of drugging the brain to induce or maintain slumber, more doctors are steering patients away from sleep aids, including over-the-counter medications, and are offering innovative behavioral-change solutions.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that CBT can be provided by any trained therapist or nurse. The story could have been more\u00a0helpful if it had specified how common this training is and how a patient seeking CBT could go about finding a health care professional trained in the technique. The article also might have mentioned that systematic analysis of studies has shown that even web-based versions of cognitive behavioral therapy can effectively treat insomnia, making it even more widely available.", "answer": 1}, {"article": "Other researchers will be analyzing economic data.\nThey include people like Danielle Denlein, who, to her total shock, developed a serious heart problem.On October 20, 2008, at 1:50 p.m., Ms. Denlein was driving to a drug store to buy formula for her 5-day-old baby girl.\nThe hope is that the devices, now being tested in clinical trials, will save lives, reduce medical expenses and nudge heart patients toward managing their symptoms much the way people with diabetes manage theirs.\nThe data are stripped of patient identifiers and analyzed, a task requiring the company to become more like a Google or a Microsoft, handling enormous amounts of information.\nThere are, for example, more than four million recordings of weights and blood pressures and over 60,000 instances when the defibrillators went off, shocking a patient\u2019s heart.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was a tapestry of information about devices that are currently available, devices in clinical studies, and the potential benefit from devices to be developed in the future. \u00a0The story could have been clearer about products that are and are not readily available to patients.\u00a0 We had to read the piece several times in order to reflect on which device, from which company, was at which stage of research or development. ", "answer": 0}, {"article": "Revenues from pharmaceutical and device corporations are available at http://www.\nEvery second counts, in the current standard of care, patients who experience stroke-like symptoms and call 9-1-1 arriving to the hospital by ambulance are assessed by clinical examination and imaging (CT or MRI scan) in the Emergency Department.\nPast research showed the sooner that a clot-busting tPA drug is given after an ischemic stroke - one in which a clot is blocking blood flow - the better patients fare.\n\"Time is brain in acute stroke after vascular collaterals fail, and faster treatment yields better outcomes,\" said May Nour, M.D., Ph.D., lead researcher, interventional neurologist and director of UCLA's Mobile Stroke Rescue Program.\nNour's team used data from Berlin's PHANTOM-S study, which took place from 2011 to 2015 and included 427 participants (median age 72) which were compared to 505 patients who received conventional care with in-hospital clot busting.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Availability is not addressed beyond UCLA\u2019s Mobile Stroke Rescue Program, which collected the data for the study.\nIt would have been good to mention that specialist-staffed mobile stroke units have been popping up in different parts of the country over the last 3-4 years. They are mainly affiliated with larger medical centers and funded by private donations. ", "answer": 0}, {"article": "\"Doctors are already doing these [glucose and HbA1c] tests together -- if a patient is obese, for example, and has other risk factors for diabetes, the physician is likely to order tests for both glucose and HbA1c from a single blood sample.\nThe study began in the 1980s, and along the way has recorded valuable data from participants, including diabetes test data.\nThe new study \"helps us move quicker to treat diabetes,\" he said.\nBut taking the test twice takes up time and money and could still result in missed diagnoses, said a team from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\nNow we can educate the patient sooner and start treatment earlier to prevent complications of diabetes such as heart attack, dialysis and amputations.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained that both blood tests are routinely performed for diabetes.", "answer": 1}, {"article": "Hamilton, ON August 11, 2016 - A study led by McMaster University researchers has found that, contrary to recent reports, flu nasal sprays provide similar protection against influenza as standard flu shots.\nThis study was funded by the Canadian Institutes for Health Research.\nPublished today in the scientific journal Annals of Internal Medicine, the study shows that the nose spray had a similar effect to the standard flu shot.\nThen, subsequently, it was no longer preferred and now not recommended at all.\nIn fact, as late as June 2014, the live vaccine was preferred.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Both forms of immunization \u2014 shots and nasal spray \u2014 have been around for some time, their availability is widely known, earning the release a Satisfactory in this category.", "answer": 1}, {"article": "Scientists from the University of Gothenburg\u2019s Sahlgrenska Academy have developed a portable pocket-sized vestibular, or balance, stimulation device in a bid to improve the lives of Parkinson\u2019s sufferers.\nThe difference is that we use a particular current profile which you can stimulate the balance organs with without creating a balance disturbance.\nIt is a current device which is very similar to the ones that people use for pain relief with electrical stimulation of muscles and nerves, what\u2019s called TENS.\nThe effectiveness of oral levodopa reduces as Parkinson\u2019s disease progresses in the patient and can lead to involuntary movements, or dyskinesia.\nThe plan is now for the device to be tested in a longer-term study, where patients will be using it at home.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the device is experimental and, as a result, not available to the public. For comparative purposes, the story could have cited the cost of other devices that use the TENS technology.", "answer": 1}, {"article": "\"The study found an interesting protective association between low-dose aspirin and breast cancer,\" said lead author Christina A. Clarke, Ph.D., M.P.H., from the Cancer Prevention Institute of California.\nIt was also able to look in detail at subtypes of breast cancer.\nThis study differed from other studies that have looked at aspirin and cancer risk because it focused on the dose levels of the aspirin women had taken and tracked the frequency of the use of low-dose aspirin as opposed to regular aspirin.\nIn the ensuing years before 2013, 1,457 of these participants developed invasive breast cancer.\nOther collaborating authors include Alison J. Canchola, M.S., and Lisa M. Moy, M.P.H., from the Cancer Prevention Institute of California, and Susan L. Neuhausen, Ph.D., The Morris & Horowitz Families Professor in Cancer Etiology & Outcomes Research, Nadia T. Chung, M.P.H., and James V. Lacey Jr., Ph.D., M.P.H., from City of Hope.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release explicitly states that low-dose aspirin is \u201creadily available\u201d and that\u2019s widely known to be the case.", "answer": 1}, {"article": "WEDNESDAY, Feb. 15, 2012 (HealthDay News) -- The quit-smoking drug Chantix may also help problem drinkers cut their alcohol consumption, a small new study suggests.\n\"We need a lot more options in terms of medicines to help curb drinking,\" he said.\nChantix costs roughly $3 per pill.\nMore research is needed, he noted, but \"this medication may be helpful for people with a drinking problem who are also smokers.\"\nThe study included 15 healthy participants who took part in six sessions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that Chantix is currently available to help smokers quit.", "answer": 1}, {"article": "A new study raised questions about the benefits of a relatively common procedure for heart patients\u2014implanting tiny devices that prop open clogged arteries to relieve chest pain.\n\nThe 200-patient study conducted by U.K. researchers found that patients with stable chest pain, or angina, who received stent devices experienced no significant improvement in exercise time on a treadmill, compared with similar patients who received no stents during sham procedures.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that stent insertion is widely available and frequently done.", "answer": 1}, {"article": "NeuroVision was formed in 2010 and is headquartered in Sacramento, California.\nSACRAMENTO, Calif. (Aug. 22, 2017) - A study led by researchers at Cedars-Sinai and NeuroVision Imaging LLC provides the scientific basis for using noninvasive eye imaging to detect the pathological hallmarks of Alzheimer's.\nHere are several highlights:\n\u2022 The first histologic quantitative analysis of retinal plaque clusters, or \"hot spots,\" containing the most toxic forms of beta-amyloid with specific distribution patterns in superior peripheral regions that were previously unexplored.\n\"This is the first study demonstrating the potential to image and quantify retinal findings related to beta-amyloid plaques noninvasively in living patients using a retinal scan with high resolution.\n\"We know that Alzheimer's begins as many as 10 or 20 years before cognitive decline becomes evident, and we believe that potential treatments may be more effective if they can be started early in the process.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although not as clearly stated as it could be, it does come across in one of the quotes that this is a technology that is not yet available for use.\n\u201cIt\u2019s exciting to see these studies demonstrating the power of the technology applied to the Alzheimer\u2019s field. Our goal is to develop a product that is easy to use, affordable and widely accessible. We look forward to the potential of retinal imaging playing a vital role in solving the problem of Alzheimer\u2019s, both in identifying and monitoring those who may be affected by the disease. Our next step is to continue with clinical trials, building upon the existing pharmaceutical company collaborations, to ensure our technology is ready for the medical community to help manage this disease.\u201d", "answer": 1}, {"article": "Sorry. The page you requested is not available", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that the drug is currently on the market and approved for other uses. But it did not state whether Rituxan is, or may become, used off-label for relapsing-remitting MS. And, as noted in our summary comment below, there are issues surrounding off-label use that could have been addressed.", "answer": 0}, {"article": "In more than 22% of cases, implantable defibrillators are given to heart patients who don\u2019t meet the guidelines for receiving the pricey devices, according to a study just published in JAMA.\n\nThe research, based on 111,707 cases submitted to a national registry over a three-and-a-half-year period, also finds that those patients who didn\u2019t meet the guidelines had a higher risk of dying in the hospital and of complications from the implantation.\n\nICDs, which can cost north of $30,000, monitor the rhythm of the \u2026", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Like the LA Times story we reviewed, this story shows how widespread these implants are by explaining the scope of the study. \u201cThe research, based on 111,707 cases submitted to a national registry over a three-and-a-half-year period, also finds that those patients who didn\u2019t meet the guidelines had a higher risk of dying in the hospital and of complications from the implantation.\u201d Both stories could have benefited from a sentence about how likely hospitals in less populated areas are to have access to the implants and to have properly trained staff.", "answer": 1}, {"article": "Researchers here quantified the detection of cervical precancer and cancer by cotesting compared with HPV testing alone at Kaiser Permanente, where 1,208,710 women have undergone triennial cervical cotesting since 2003.\nThis remains the most extensive experience of HPV testing incorporated into routine screening in the world.\nThe analysis found that HPV testing identified more women subsequently diagnosed with cancer and precancer than the Pap test.\nHPV testing is more sensitive than the Pap test for detecting precancer.\nDespite more research into HPV, and the introduction of preventive HPV vaccines, screening will remain important and comprise many millions of tests annually for decades to come.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is implied that these tests are widely available in the US.", "answer": 1}, {"article": "The results were just published online by the medical journal The Lancet.\nThe drug is used to reduce bleeding during surgery and is also approved in the U.S. to prevent bleeding in hemophiliacs who have teeth pulled.\nA study of more than 20,000 patients with traumatic injuries and at risk of bleeding to death found those who were treated with tranexamic acid were significantly less likely to die than those who got a placebo.\nSome 14.5 percent of patients who got the drug were dead within a month of being injured compared with 16 percent of those who got the dummy medicine.\nIt works by keeping the body from breaking down clots.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that TXA is a 25-year-old medicine that is approved in the U.S. to prevent bleeding in hemophiliacs who have teeth pulled.", "answer": 1}, {"article": "Four people taking curcumin, and two taking placebos, experienced mild side effects such as abdominal pain and nausea.\nIt also has been suggested as a possible reason that senior citizens in India, where curcumin is a dietary staple, have a lower prevalence of Alzheimer\u2019s disease and better cognitive performance.\n\u201cExactly how curcumin exerts its effects is not certain, but it may be due to its ability to reduce brain in\ufb02ammation, which has been linked to both Alzheimer\u2019s disease and major depression,\u201d said Dr. Gary Small, director of geriatric psychiatry at UCLA\u2019s Longevity Center and of the geriatric psychiatry division at the Semel Institute for Neuroscience and Human Behavior at UCLA, and the study\u2019s first author.\nThe research, published online Jan. 19 in the American Journal of Geriatric Psychiatry, examined the effects of an easily absorbed curcumin supplement on memory performance in people without dementia, as well as curcumin\u2019s potential impact on the microscopic plaques and tangles in the brains of people with Alzheimer\u2019s disease.\nThe study was supported by the Ahmanson Foundation, the Marshall and Margherite McComb Foundation, the McMahan Foundation, Bob and Marion Wilson, the Fran and Ray Stark Foundation Fund for Alzheimer\u2019s Disease Research, the U.S. Department of Energy and the National Institutes of Health.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Theracurmin is available from several sources not mentioned in the news release. The initial comments in the release give the reader the erroneous impression that eating Indian food is equal to the form used in the study. (We also discuss this under Unjustified Language.)\nThe lead sentence of the news release \u2014 \u201cLovers of Indian food, give yourselves a second helping \u2026\u201d \u2014 implies that the alleged benefits of curcumin might be achieved through diet alone, thus making availability a no-brainer. But the dosages used in the study (which we\u2019re not told are about three times the commonly recommended dose) require oral supplements, which certainly are widely available in health stores and online, but at a much greater cost than the kitchen spice.", "answer": 0}, {"article": "THURSDAY, Oct. 12, 2017 (HealthDay News) -- Breast cancer is the second leading cause of cancer death among women in the United States, and routine screenings remain the most reliable way to detect the disease early, a breast cancer expert says.\nThis is an important part of breast health,\" she said.\n\u2022 Mammogram: An X-ray of the breast used to examine breast changes.\nNot all women with breast cancer experience the same warning signs of the disease.\nIn some cases, women never develop any of these symptoms, Evers noted.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that all of these screening methods are available.", "answer": 1}, {"article": "This test might help.\n\"Those molecules will circulate in the blood for some time, they can be measured, and you can see the contributions from essentially every tissue in the body,\" senior investigator Stephen Quake told BuzzFeed News.\n\"When you are pregnant you can see the contribution from the placenta and the fetus,\" said Quake, a professor of bioengineering and applied physics at Stanford University in Palo Alto, California.\nThe study was funded by the March of Dimes and other nonprofit sources, although Quake and his colleagues have filed for a patent on the test.\nHowever, a new blood test \u2014 which is still experimental and not yet available outside of a research lab \u2014 can pick up on gene activity in the body that suggests a pregnancy is at risk for preterm delivery, according to a study published Thursday in the journal Science .\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear about the test\u2019s availability in above-the-fold copy, stating it \u201cis still experimental and not yet available outside of a research lab.\u201d There\u2019s even a reference to it being experimental in the story summary. (But why not include \u201cexperimental\u201d in the headline, too?)", "answer": 1}, {"article": "This research was designed to explore recovery in acute stroke, or the period immediately following stroke - in mice, that is five days; in humans, that is two months.\nThe study was supported by funds from the National Institutes of Health.\n\"This study indicated that new brain tissue can be regenerated in what was previously just an inactive brain scar after stroke.\"\nIn addition to Carmichael and Segura, other authors of the paper are Lina Nih and Shiva Gojgini, both of UCLA.\nThe brain has a limited capacity for recovery after stroke and other diseases.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s made fairly clear that the gel used in this study was developed by the authors, is experimental, and most likely not available for widespread use.", "answer": 1}, {"article": "Chemotherapy and other cancer therapies can wreak havoc on the taste buds and olfactory senses, depriving recipients of the intricate interplay between taste and smell that is critical to grasping flavors and enjoying foods.\nThe transdisciplinary team, including William Ray, Department of Biochemistry; Andrea Dietrich, of the Charles E. Via Jr. Department of Civil and Environmental Engineering in the College of Engineering; and Glenn Lesser, from Wake Forest Baptist Medical Center, previously identified the role of lactoferrin, a specific milk protein, in diminishing the metallic flavor stimulated by chemotherapy medications.\nThe substance is well-known as a first-line defense, aiding the body's immune response, but little is known about its ability to impact salivary proteins.\n\"The prevailing symptom described by patients undergoing chemotherapy is a persistent metallic flavor or aftertaste, with or without food intake.\nThe team's findings will make it possible for cancer patients to taste foods properly and to enjoy a healthier appetite, enabling more optimal nutrition during a critical period of recovery.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It wasn\u2019t made clear enough in the release that lactoferrin supplements are available online. Many readers might erroneously think the only source is drinking milk.", "answer": 0}, {"article": "Science has so far identified about 1800 human miRNAs.\n\"This is the first demonstration that micro-RNAs associated with circulating exosomes in blood are informative biomarkers not only for the diagnosis of MS, but in predicting disease subtypes with a high degree of accuracy,\" said Associate Professor Michael Buckland, Head of the Department of Neuropathology at RPA Hospital and the Brain and Mind Centre, University of Sydney.\n\"This, in turn may lead to fewer relapses and a slower loss of brain volume, resulting in slowing or potentially halting progression of the disease for the person living with MS.\nGiven exosomes can cross the blood-brain barrier, it is likely that some of the circulating exosomes in MS patients come from affected central nervous system cells or the associated inflammatory milieu.\n\"In studying the blood exosomes of healthy volunteers and patients with MS, the research team identified a 'molecular signature' of MS that not only correctly diagnoses MS, but also discriminates between patients with different stages of disease,\" Associate Professor Buckland said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This research is basic, so one might expect a reader to infer that the blood test is not yet available.\u00a0 But the text could have reinforced that by indicating what next steps need to be taken in order to validate this discovery and move it into clinical use.", "answer": 2}, {"article": "Was this research necessary -- and ethical?\n\"One of the things ALS has going for it is, since it has no effective treatment or cure, you throw anything you can at it,\" he said.\nThe results of one new study may be less than hoped for, but the science is sound: The study concluded that injecting stem cells into the spinal cords of patients with amyotrophic lateral sclerosis is safe in most, though not all, cases.\nThese early stages may be painful for some of the \"medical heroes\" involved, but the goal is clear: providing an effective and safe treatment for future patients who suffer from a devastating condition.\n\"People who do these studies should be considered medical heroes,\" Goldstein said, adding, \"The selflessness of these people when they're told they're gonna die.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story quotes a lead researcher saying, \u201cwe are just now getting started with testing our hypotheses about using stem cells as therapeutics. \u2026 We do not know if these treatments\u00a0will work, and it will take time\u00a0to test these therapies in a systematic and safe way.\u201d", "answer": 1}, {"article": "Buck scientists strive to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer\u2019s and Parkinson\u2019s, cancer, cardiovascular disease, macular degeneration, osteoporosis, diabetes and stroke.\n\u201cFollow up testing showed some of the patients going from abnormal to normal.\u201d\n\nOne of the more striking cases involved a 66-year old professional man whose neuropsychological testing was compatible with a diagnoses of MCI and whose PET scan showed reduced glucose utilization indicative of AD.\n\u201cWe think addressing multiple targets within the molecular network may be additive, or even synergistic, and that such a combinatorial approach may enhance drug candidate performance, as well.\u201d\n\nWhile encouraged by the results of the study, Bredesen admits more needs to be done.\nBy 2050, it\u2019s estimated that 160 million people globally will have the disease, including 13 million Americans, leading to potential bankruptcy of the Medicare system.\n\u201cEven though we see the far-reaching implications of this success, we also realize that this is a very small study that needs to be replicated in larger numbers at various sites.\u201d Plans for larger studies are underway.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Some of the MEND interventions, such as dietary changes and exercise, may be readily available. But the intensiveness that this approach requires would make it hard for most people to access financially and logistically. Perhaps the book about the program, when it publishes, will make this clear, but the news release does not.", "answer": 0}, {"article": "(Reuters) - Pivotal trial results for Merck & Co Inc\u2019s immunotherapy drug Keytruda show that it lengthened survival by three months, or nearly 40 percent, for patients with advanced bladder cancer who had stopped responding to chemotherapy.\nThe study did not detect a difference in the length of time patients lived without their disease getting worse.\nThe company is currently enrolling patients in a phase three trial of Keytruda, combined with chemotherapy, as an initial treatment for bladder cancer.\nAccording to the FDA approval letter, the company has until December to submit the full trial data to the agency.\nAfter 18 months, 36 percent of Keytruda patients were alive, compared with 20.5 percent of chemotherapy patients, according to research published by ASCO.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is not currently approved for this type of cancer, but is approved for other types.", "answer": 1}, {"article": "Minimally invasive procedures increased to 31 percent of all radical prostatectomies in 2005 from 12.2 percent in 2003.\n\u201cThis paper,\u201d Dr. Hu said, \u201cdemonstrates that there are hidden risks for patients who opt for laparoscopic or robotic surgery.\u201d\n\nIn laparoscopy, a surgeon inserts instruments through small cuts in the skin instead of making large incisions to expose the organs.\nThe study, published on May 10 in The Journal of Clinical Oncology, examined a sample of 2,702 Medicare patients undergoing radical prostatectomy, the complete removal of the prostate, from 2003 to 2005.\nThe widely advertised procedure is becoming more popular, said Dr. Jim C. Hu, the lead author of the study and an instructor in surgery at Harvard.\nLaparoscopic operations for prostate cancer, a minimally invasive surgery that is in rising demand, result in fewer immediate complications and quicker recovery than the more common open procedure, a new study reports.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story implies that laparoscopic prostatectomies are widely available, and in fact are done about a third of the time in the studied population.\nBut it would have been useful to state how difficult it is (or is not) to find a surgeon experienced with laparoscopic procedures. ", "answer": 1}, {"article": "LONDON -- GlaxoSmithKline PLC said it has produced an effective bird-flu vaccine for humans and could begin producing the shots at year's end, leaving it to governments to decide whether to begin ordering the shots.\n\nGlaxo, the world's second-biggest drug maker by sales behind Pfizer Inc., called the findings a breakthrough but said it needs to gather additional data before it can answer several important questions, including how much of the vaccine it will be able to manufacture.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that Glaxo expects to submit the vaccine for FDA approval in the future. ", "answer": 1}, {"article": "strongly supports the basic rationale being pursued at Sirtris, which focuses on the development of small-molecule compounds that directly activate the enzymatic activity of SIRT1 as a new therapeutic approach to many diseases of aging,\" Vlasuk wrote in an email to the journal.\nThe study is in the May 1 issue of Cell Metabolism.\nSeveral studies, including work with yeast, worms and flies, have found that resveratrol acts on a class of seven genes known as sirtuins and, in human cells, SIRT1 in particular.\nMice that have their SIRT1 gene deleted are born with developmental defects and are unsuitable for experiments, he explained.\nThere was no effect on AMPK in mice given a lower dose of resveratrol.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The preliminary nature of these findings was clear in the body of the story (although not in the headline).", "answer": 1}, {"article": "Asked if the 34% improvement in cognitive decline is meaningful to a patient, Carrillo said, \"I have a family member with AD.\nThe drug is designed to prevent those clumps from forming.\nThere was even a hint that the drug helped to slow the decline in functioning.\nI would be happy with a sustained cognitive benefit for my mother-in-law.\"\nLarger studies in many more patients are needed before the drug will be available, though, she says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that the drug is still being tested.", "answer": 1}, {"article": "Depression risk was assessed using the Edinburgh Postnatal Depression Scale (EPDS) six weeks after childbirth.\n\u201cLabor pain matters more than just for the birth experience.\nJoin the ANESTHESIOLOGY\u00ae 2016 social conversation today.\nLike ASA on Facebook, follow ASALifeline on Twitter and use the hashtag #ANES16.\nIn the study, researchers reviewed the medical records of 201 women who used epidural analgesia and had their pain assessed using a 0-10 scale during labor.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Epidurals are so widely available we don\u2019t think the availability needs to be stated.", "answer": 2}, {"article": "The blood test that millions of men undergo each year to check for prostate cancer leads to so much unnecessary anxiety, surgery and complications that doctors should stop testing elderly men, and it remains unclear whether the screening is worthwhile for younger men, a federal task force concluded yesterday.\nThe PSA test, which measures a protein in the blood produced by prostate tissue, has significantly increased the number of prostate cancer cases being diagnosed at very early stages.\n\"If it turns out that PSA screening and aggressive treatment saves lives, maybe all the harm that it has caused is worth it,\" said Otis W. Brawley, chief medical officer at the American Cancer Society.\nIn fact, there are several ways in which screening can actually be harmful,\" said Howard L. Parnes of the National Cancer Institute.\n\"We have seen a dramatic drop in mortality,\" said J. Brantley Thrasher, chairman of the urology department at the University of Kansas and a spokesman for the American Urological Association.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned that it was about routine screening of men for prostate cancer. \u00a0As the story lead with \"The blood test that millions of men undergo each year\", it accurately indicated that this test is readily available.\n\u00a0", "answer": 1}, {"article": "Can these tiny tumors affect the lymph nodes and spread cancer to other areas of the body?\n\"These findings allow surgeons to select which patients with microinvasive tumors may actually benefit from lymph node sampling, while sparing other patients from this procedure,\" said Tamera Lillemoe, M.D, pathologist and a study co-author.\nThe study, funded by Engelsma Family Foundation and Abbott Northwestern Hospital Foundation, was published recently in The Breast Journal, the official journal of the National Consortium of Breast Cancers.\nOnly 1.5 percent had positive lymph nodes - indicating the rare possibility of metastatic cancer.\nThey examined the outcomes of 294 patients who were treated between 2001 and 2015.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does not address availability specifically but readers can glean from the release that lymph node biopsy is a common surgical procedure. The release summarizes the study\u2019s research question: Should lymph node biopsies in tumors that are 1mm or less in size remain common practice?", "answer": 1}, {"article": "\"In conclusion, gemcitabine did not result in improved overall survival compared with fluorouracil plus folinic acid in patients with [surgically removed] pancreatic cancer,\" the authors concluded in their report.\n\"So this is not a revolutionary finding, but it's part of an effort to look at what we have and even to find newer regimens with more combinations of drugs,\" he noted.\nThe study authors noted that, currently, the prognosis for pancreatic cancer is very poor, with a five-year survival rate of less than 5 percent.\nThe finding, reported in the Sept. 8 issue of the Journal of the American Medical Association, stems from work conducted by Dr. John P. Neoptolemos, of the Cancer Research U.K. Liverpool Cancer Trials Unit at the University of Liverpool in England, and colleagues.\nThe pool of nearly 1,100 patients that the researchers focused on were part of the large European Study Group for Pancreatic Cancer trial that took place across 159 pancreatic cancer centers located in Europe, Canada, Australasia and Japan.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not clearly establish whether gemcitabine or the other drugs mentioned are currently on the market. (They are.)", "answer": 0}, {"article": "\u201cKangaroo mother care is care of preterm infants carried skin-to-skin with the mother.\n\u201cKangaroo mother care may change the behavior of less well-educated mothers by increasing their sensitivity to the needs of their children, thus making them equivalent to mothers in more favorable environments.\u201d\n\nTwenty million babies are born at a low birth weight every year around the globe, the World Health Organization reports.\nRelated: More U.S. Moms are Breastfeeding Their Babies\n\n\u201cThe effects of kangaroo mother care at one year on IQ and home environment were still present 20 years later in the most fragile individuals, and kangaroo mother care parents were more protective and nurturing,\u201d Dr. Nathalie Charpak and colleagues at the Kangaroo Foundation in Bogota, Colombia, wrote in their report.\nIts key features are: early, continuous and prolonged skin-to-skin contact between the mother and the baby; exclusive breastfeeding (ideally); it is initiated in hospital and can be continued at home; small babies can be discharged early; mothers at home require adequate support and follow-up,\u201d WHO said.\nThe U.S. has one of the highest rates of pre-term and low-weight births \u2014 about one in 12 births, according to the March of Dimes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that KMC requires parents to receive adequate support and follow-up. But we would have liked to see more information, such as how widely this approach is used to treat premature infants and what some of the barriers might be in high-income countries where incubator care has been the norm. For example, how many U.S. neonatal intensive care units incorporate skin-to-skin contact in their care? Which babies in intensive care don\u2019t or can\u2019t get this kind of care?", "answer": 0}, {"article": "Antidepressants frequently prescribed to help treat bipolar depression do little to help patients recover, according to a new study that adds fuel to a long-running debate over how to best treat an affliction that affects an estimated eight million Americans.\n\nBipolar disorder, also known as manic depression, is a serious mental illness that involves dramatic swings in mood, including frequent and lengthy periods of depression. Along with mood-stabilizing drugs like lithium, many physicians also treat the disorder with common...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It's clear from the story that the drugs in question are commonly prescribed and available.\u00a0\u00a0 \n\u00a0", "answer": 1}, {"article": "Michael Burk found walking increasingly painful last year. Crossing the street and tying his shoes became challenges, and colleagues noticed he was limping at work.\n\nOn a recent morning, Mr. Burk reported to the Hospital for Joint Diseases, part of NYU Langone Medical Center in New York City, for hip-replacement surgery. His surgeon had promised him a better quality of life, and said both the operation and recovery would be quick.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that the procedure is at least 20 years old and is practiced in a significant percentage of hip-replacement operations, implying that it would not be too tough to find a surgeon who does the anterior procedure. Of course, learning a bit about what the learning curve is for this procedure and how many procedures any given surgeon has done are key questions", "answer": 1}, {"article": "\"LaVonne has had Alzheimer's disease longer than anybody I know, and that sounds negative, but it's really a positive thing because it shows that we're doing something right,\" Moore said.\nIt's \"much too early\" for patients or caregivers to seek out DBS, said Fargo, who was not involved in the study.\nAnd there were \"signals\" that it was slowing down two of the patients' decline, said lead researcher Dr. Douglas Scharre, director of cognitive neurology at Ohio State University's Wexner Medical Center.\nThe theory behind trying DBS for Alzheimer's patients, Scharre said, is similar to the \"use it or lose it\" principle: If key brain areas can be stimulated to form new connections among cells, it might slow decline.\nMore than 5 million Americans have Alzheimer's -- a number that could rise to 16 million by 2050, according to the Alzheimer's Association.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We like the prominent placement of the caveat that \u201cit\u2019s far too early to know whether it has value for people with Alzheimer\u2019s\u201d and it\u2019s \u201cnot something patients can ask their neurologist for.\u201d It also mentions DBS \u201cwould not be for everyone\u201d including people who are frail or have other serious medical conditions.", "answer": 1}, {"article": "\"If five types of the disease exist, how does this change popular medical opinion on prostate cancer screening?\n\"These findings could lead to more optimized diagnostic testing on all aspects of the prostate cancer diagnosis process and brings full circle the coming approach to cancer being an individual disease based very much on the patient's individual genetic profile,\" said Dr. Samadi.\nFor men with a family history of the disease, contact Dr. Samadi to learn more about your risk factors and to get a baseline PSA blood test.\nThis may mean that each type of the disease needs its own approach to screening, diagnosis, treatment and even recurrence,\" noted Dr. Samadi.\nPrior research had shown six of the genes were linked to prostate cancer, however researchers noted in the published study that it turns out the other 94 genes had not been associated with prostate cancer until now.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We can\u2019t be sure if the testing protocol discussed in the release is available or not. One might reasonably assume that genetic cancer screening for the five identified genetic types of prostate cancer is available at the specialist\u2019s hospital. However, the release isn\u2019t clear on this point.", "answer": 0}, {"article": "Tens of thousands of patients a year undergo the procedure \"off-label,\" however, paying around $5,000 out-of-pocket, based on the claims of doctors who say it can cure everything from Alzheimer's to autism.\nAn investigation by the federal Office for Human Research Subject Protections, which is charged with protecting patients, found that patients may not have been properly informed of chelation's risks.\nIn a statement after the study was presented, Antman, a cardiologist at Boston's Brigham and Women's Hospital and professor of medicine at Harvard Medical School, added, \"Intriguing as the results are, they are unexpected and should not be interpreted as an indication to adopt chelation therapy into clinical practice.\"\nAt least 30 patients have died from off-label chelation therapy since the 1970s, including an autistic 5-year-old Pennsylvania boy, according to a 2008 report in The Medscape Journal of Medicine.\nGary Gibbons, director of the National Heart, Lung, and Blood Institute, says the study was a \"breakthrough\" not for proving that chelation works, but for \"establishing that this chelation therapy regimen can be administered in a safe manner in the context of a clinical trial.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Another mixed bag for which we\u2019ll give a satisfactory score.\nThe story is not clear about exactly what chelating agent was used in this study, or where one would go to find a practitioner who can prescribe it.\u00a0 (But, to its credit, it mentioned problems with off-label prescribing.) It was relatively easy to find out online that EDTA was the agent used in the study.\nWe give the story for credit for reporting that \u201cthe Food and Drug Administration had taken the study drug off of its list of approved medications.\u201d", "answer": 1}, {"article": "He divided a group of rats into galantamine and donepezil cohorts.\nThere's no data to suggest that a clinician treating a smoker should prescribe one of these AChEIs now.\n\"At the doses shown to reduce nicotine self-administration, the AChEIs did not make our animals sick,\" Schmidt said.\n\"We know from the literature that upward of 30 percent of patients will report nausea and vomiting [when taking these drugs], and this will limit their compliance,\" he said.\n\"We're very interested in screening potential efficacy of anti-addiction medications in our models,\" said Schmidt, a professor in Penn's School of Nursing and Perelman School of Medicine.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that galantamine is FDA approved which speaks to its availability. The release responsibly points out that \u201cThere\u2019s no data to suggest that a clinician treating a smoker should prescribe one of these AChEIs now,\u201d according to the lead investigator.", "answer": 1}, {"article": "The drug lorcaserin works on the serotonin receptor -- the same appetite-controlling hormone targeted by the notorious drug fenfluramine, the \"fen\" component of combination medication fen-phen.\nBut lorcaserin is far more selective than the drug fenfluramine and much safer, its manufacturer says, because it specifically targets the serotonin receptor associated with hunger while having no impact on the heart.\nBy the end of year one, 55% of the patients in the placebo group and 45% of those taking the diet drug had dropped out of the study.\nDiet Drug Users Lost Twice as Much Weight The study included about 3,200 obese or overweight adults who were randomly assigned to take 10 milligrams of the diet drug or placebo, twice a day for a year.\nPeople who continued on the drug for two years were able to maintain their weight loss better than those switched to placebo after one year, researcher Steven R. Smith, MD, of the Florida Hospital and the Sanford-Burnham Institute tells WebMD.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is still in trials although it could have done a better job explaining how far it has come and what steps it still has to take to win approval. ", "answer": 1}, {"article": "This study is really a proof of concept.\nThe result: The breath test correctly identified all the patients with heart failure, clearly distinguishing them from those cardiac cases where heart failure was not an issue.\n\"And that print can tell us a lot about a person, what they've been exposed to and what disease they have,\" he added.\nAnd the blood work that would be taken in a doctor's office might not come back until the next day, delaying identification,\" he noted.\nBut by subjecting a patient's breath to a rigorous but fast analysis of the hundreds of so-called volatile organic compounds contained therein, the study team said it has so far been able to correctly diagnose heart failure among newly hospitalized patients with a 100 percent accuracy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that this test is experimental and quotes a researcher saying, \u201cThere is much more work that needs to be done to get it to the point where it would become widely available.\u201d", "answer": 1}, {"article": "About 3.3 million people are allergic to peanuts or tree nuts.\nBecause even a minor exposure can set off a reaction, many people at risk strictly avoid foods that contain an allergen or were prepared in places where nuts or other allergens might have been used.\nThe findings, presented on Sunday at a meeting of the American Academy of Allergy, Asthma and Immunology in Washington, suggest that a treatment for peanut allergy may be developed in two or three years, said Dr. Wesley Burks, the chief of the division of pediatric allergy and immunology at Duke University Medical Center, who helped conduct the research.\nNearly half of the 150 deaths attributed to food allergies each year in the United States are caused by peanut allergies, according to Duke University.\nWhile drugs can be used to treat an allergic reaction, there are no approved treatments for food allergies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that this experimental treatment for peanut allergy is in the early stages of human research, and not available. \nIdeally it would have made this plain earlier in the story.\u00a0 \n\u00a0", "answer": 1}, {"article": "The effect of the newer-generation medications, gonadotropin-releasing hormones, is similar to bicalutamide, according to other trials.\nThe drug, a type of androgen-depleting therapy, is a frontline treatment for men who opt not to have surgery for the cancer.\nMen with medium-grade tumors and those who may not have had their entire cancer removed during surgery also survived significantly longer if they received the drug.\n\u201cYou don\u2019t want to treat a patient if he doesn\u2019t need to be treated,\u201d Shipley said.\n(While that is a relatively low level for most men, PSA levels should be close to zero after a prostatectomy.)\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story implies hormone blockers have been around as a technique for decades, but have not been widely used due to their side effects and uncertainty surrounding their actual efficacy.", "answer": 1}, {"article": "Lupron critics said autism parents may not understand the dangers.\nThe drug mainly is used to treat endometrial cancer in women and prostate cancer in men, and sometimes to chemically castrate sex offenders.\nThe area's largest autism treatment center jointly run by the University of Miami and Nova Southeastern University, as well as another at Florida Atlantic University, frown on Lupron and other untested therapies, officials at the centers said.\n\"It has not been tested so there's no way to know if it has adverse effects in the long run,\" Berkovitz said.\nIn addition, the Food and Drug Administration is investigating complaints that Lupron causes diabetes in adults.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that Lupron is already used to treat endometrial cancer and prostate cancer.\u00a0 The story might have addressed more directly its current off-label use.\u00a0\u00a0 \nIt\u2019s also clear that this is about a Maryland medical group taking its idea on the road to South Florida.\u00a0 Ideally, the story might have addressed whether it\u2019s being tried elsewhere. ", "answer": 1}, {"article": "And if patients are given a choice of catheterization sites, what factors should they consider?\nThe approach allows patients to sit up immediately afterward and even walk, an impossibility in femoral procedures, which require that they lie flat on their backs for several hours to prevent severe bleeding.\n\"I don't think it's worth going across the river to do it.\nThe radial artery is thinner and offers a much more circuitous path, more like driving on a two-lane mountain road with frequent switchbacks.\n\"There's an inherent conservatism in medicine for many reasons,\" he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that radial catheterization is most likely not routinely available and that a low percentage (1%) of catheterizations are performed this way.", "answer": 1}, {"article": "For more information about our products and the organization, visit http://www.\nJanuary 30, 2018 - For older women undergoing mastectomy for breast cancer, direct-to-implant (DTI) breast reconstruction provides good outcomes in a single-step procedure, while avoiding some of the inconvenience and risks of staged approaches to breast reconstruction, reports a study in the February issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\n\"The DTI approach is a powerful tool for breast reconstruction in elderly patients,\" comments ASPS Member Surgeon Andrea Moreira, MD, of the Cleveland Clinic.\n\"Half of all breast cancers occur in women over 65, yet only four to 14 percent of these women undergo reconstruction,\" Dr. Moreira and coauthors write.\nThe authors note some important limitations of their study--particularly the fact that it was a review study of one hospital's experience with a relatively new procedure.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although the release does mention that the tissue expander approach is more established and widely used, it could have been more explicit \u2014 as the authors of the study were \u2014 in letting us know \u201cthis is relatively new technique.\u201d\nWe\u2019re told\u00a0 that DTI \u201chas emerged as a single-stage approach to immediate breast reconstruction after mastectomy\u201d and we get this quote from one of the lead authors:\nThe DTI approach is a powerful tool for breast reconstruction in elderly patients.\nTaken together these two quotes could give readers an erroneous sense that this is an established and proven option. It\u2019s not.", "answer": 0}, {"article": "The results of the Women's Health Initiative (WHI)--the largest, most scientifically rigorous study of older women's medical issues ever conducted--continue to startle researchers, confuse the public and frustrate headline writers. Case in point: last week's report that taking estrogen for seven years does not increase the risk of breast cancer for many women. There is a lot of good news in that finding, as well as some important caveats.\n\nIn many ways, the story began four years ago when researchers halted a different part of the WHI--one that looked at the long-term health effects of taking the hormone combination estrogen and progestin...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the article that estrogen is readily available.", "answer": 1}, {"article": "Still, the authors say the study strengthens the growing body of evidence that spicy food may have protective health properties that can lead to a longer life.\nLike spicy foods?\nParticipants were followed for an average of 18.9 years.\nThe research is observational, so no cause and effect relationship can be established.\nhad lower HDL-cholesterol, lower income, and less education,\u201d in comparison to participants who did not consume red chili peppers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Red hot chili pepper are widely available in American supermarkets.", "answer": 2}, {"article": "Their conclusion?\nAnd a lot of running (i.e., ultramarathon training) can well be harmful, while the same is never true for walking.\nJogging even 5 to 10 minutes per day can reduce the risk of death from all causes I also learned about some of the incredible health benefits of going fast: Even five to 10 minutes per day of jogging at around 6 miles per hour can reduce the risk of death from cardiovascular disease and other causes.\nAs this study described, \"Running produces ground reaction forces that are approximately 2.5 times body weight, while the ground reaction force during walking is in the range of 1.2 times body weight.\"\nRunning has greater health benefits than walking (Sarah is super fit), but it also carries a much bigger risk of injury (see Sarah\u2019s foot brace).\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While it\u2019s certainly true that some people in the United States\u00a0might have a harder time finding space places to run or walk, it\u2019s reasonable to argue that both activities are available to most everyone.", "answer": 2}, {"article": "JACC is ranked No.\nThe latest research and clinical practice updates in cardiology are at your fingertips with the JACC Journals app for iPhone/iPad and Android.\nIn addition, as many as 20 percent of people hospitalized with a heart attack report symptoms of depression, while patients with heart disease have three times the risk of developing depression compared to the general population.\n\"There are many patients with heart disease who also experience depression - we need to study whether encouraging them to exercise will reduce their risk of adverse outcomes.\"\nThe Journal of the American College of Cardiology, which publishes peer-reviewed research on all aspects of cardiovascular disease, is the most widely read cardiovascular journal worldwide.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "With the \u201ctreatment\u201d being physical exercise, availability is a given. There are countless ways to exercise and there need not be any cost involved.", "answer": 1}, {"article": "Switching to AstraZeneca PLC's breast-cancer drug Arimidex after treatment with older drug tamoxifen not only helps women live longer, but also increases their chances of staying cancer-free after initial therapy for breast cancer, according to a study in the online edition of the Lancet Oncology medical journal.\n\nThe data, which come from more than 4,000 patients in three clinical trials, have shown that switching treatment from tamoxifen to Arimidex reduces the risk of dying by 29%.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that a hormone therapy, anastrozole (trade name Arimidex), was FDA-approved in 2005 for the treatment of early-stage breast cancer (after surgery). What is important, but is not\u00a0emphazied\u00a0is that this drug is only for post-menopausal women. ", "answer": 1}, {"article": "Greek researchers offered fresh evidence of the health benefits of the Mediterranean diet, reporting in a large study that it helps improve several risk factors linked to diabetes, obesity and heart disease.\n\nThe Mediterranean diet is high in monounsaturated fats such as olive oil and also relies heavily on whole-grain cereals, fruits and vegetables, fish and low consumption of animal fats. It has been shown in numerous studies and clinical trials to reduce mortality from such causes as cardiovascular disease and cancer.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story included an outline of the foods that are included in a \u2018Mediterranean diet\u2019 , enabling readers to appreciate that these foods are available in grocery stores.", "answer": 1}, {"article": "Vericel shares were down $2.01, or 33 percent, at $4.02 on Nasdaq.\n\u201cFor patients, this is a really hopeful thing.\u201d\n\nHenry, who presented the data at the ACC meeting, stressed the need for larger trials to prove the benefit of ixmyelocel-T\n\nFor the treatment, bone marrow is taken from the patient and enhanced over two weeks to increase two types of cells associated with healing.\n\u201cPeople were looking for downside and they had one.\u201d\n\nThe data compared Vericel\u2019s bone marrow-derived ixmyelocel-T stem cells with placebo in 109 well-treated patients with advanced heart failure who had exhausted medical and device therapies.\nThe result was primarily driven by the difference in deaths of 13.7 percent in the placebo group, or 7 deaths, compared with 3.4 percent, or 2 deaths, for the ixmyelocel-T group.\nIf the disease worsens despite all available medicinal and interventional therapies, the only options are heart transplant or a pumping assist device.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The doctor and lead investigator who was interviewed in the story noted the need for larger trials, meaning this therapy is nowhere close to being available to the general public. Although the audience is aware this is early testing, it would have been helpful to know how the study will address the limitations of failing to meet the secondary goals, such as the walk test and heart pumping efficiency.", "answer": 1}, {"article": "Will it help avoid back surgeries, for example, that may or may not have great outcomes?\nWhile the study results are promising, much more work needs to be done, Munk said: \"The fact of the matter is that chronic lower back pain is very complex and often requires a maintenance-type approach versus a short-term intervention option.\"\n\"The study can give primary care providers the confidence to tell patients with chronic low back pain to try massage, if the patients can afford to do so,\" Munk said.\nINDIANAPOLIS -- In the first study of its kind, researchers found real-world massage therapy to be an effective treatment for chronic low back pain.\nThe study, \"Real-World Massage Therapy Produces Meaningful Effectiveness Signal for Primary Care Patients with Chronic Low Back Pain: Results of a Repeated Measures Cohort Study,\" was published online March 14 in the journal Pain Medicine.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that massage is widely available. We give the release credit for noting that it\u2019s not covered by insurance and therefore not accessible to everyone.", "answer": 1}, {"article": "Another expert, however, said that scenario is likely overoptimistic.\nTheir systolic blood pressure -- the top number in a blood-pressure reading -- remained dangerously high at 160 millimeters of mercury (mmHg) or above despite having taking three or more drugs to control blood pressure, the researchers noted.\nFor the study, an international team lead by Dr. Murray Esler, professor and senior director of the Baker IDI Heart and Diabetes Institute in Melbourne, Australia, assigned 35 patients to renal denervation and compared them to 47 patients who had already had the procedure.\n\"You may have to take less medication and you may have to take lower doses of medication, but we all expect that patients will still have to take some medication,\" he said.\n\"This is a very promising approach for managing medication-resistant hypertension,\" said Dr. Gregg Fonarow, a spokesman for the American Heart Association and professor of cardiology at the University of California, Los Angeles.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained that the procedure is used in other countries but not yet approved in the US.\nHowever suggesting it is used in other countries doesn\u2019t really provide the reader with enough information.\u00a0 Here is what the UK\u2019s National Institute for Health and Clinical Excellence (IPG418 Percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension: guidance ) had to say about the approach:\n\u201cCurrent evidence on percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension is from limited numbers of patients, but there is evidence of efficacy in the short and medium term. There is inadequate evidence on efficacy in the long term; this is particularly important for a procedure aimed at treating resistant hypertension. The limited evidence suggests a low incidence of serious periprocedural complications, but there is inadequate evidence on long-term safety. Therefore this procedure should only be used with special arrangements for clinical governance, consent, and audit or research.\u201d\nThese evidence-based questions will have some impact on availability \u2013 whether in other countries or in the US.\u00a0 And the story should have dug a bit deeper.", "answer": 0}, {"article": "For more information visit http://www.\nThe drug, a type of treatment called a PARP inhibitor, was licensed last year for women with ovarian cancer and inherited BRCA mutations, but so far has not been approved for use on the NHS by NICE or the Cancer Drugs Fund.\nThe results have led on to the start of TOPARP-B, a second part of this trial in which only men whose prostate cancers have detectable DNA repair mutations will receive olaparib.\nThe development of olaparib, which is now owned by AstraZeneca, was underpinned by scientific research carried out with funding from Cancer Research UK at The Institute of Cancer Research (ICR) and the University of Cambridge, and clinical trials led by the ICR and The Royal Marsden, and other institutions in the UK and overseas.\nThere was also support from the Investigator-Sponsored Study Collaboration between AstraZeneca and The NIHR Biomedical Research Centre at The Royal Marsden and the ICR, the NIHR Cancer Research Network, and Experimental Cancer Medicine Centre (ECMC) funding to the ICR and Royal Marsden, and several other ECMC sites.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The story nods to the availability of the drug used in the study in the UK when it says it \u201cwas licensed last year for women with ovarian cancer and inherited BRCA mutations, but so far has not been approved for use on the NHS by NICE or the Cancer Drugs Fund.\u201d However, we aren\u2019t left with any idea if the gene testing carried out here is widely available. That\u2019s a critical point that should have been addressed.", "answer": 0}, {"article": "As a nicotine-gum addict, Mike Metzger used to worry about the warning on its label: \"Stop using the nicotine gum at the end of 12 weeks.\"\n\nBut that was before a prominent smoking-cessation scientist, K. Michael Cummings, told him to keep chewing the gum as long as it helped him stay off cigarettes. So 15 years after quitting smoking, Mr. Metzger, a 63-year old retired New York telephone worker, still chews 16 pieces of nicotine gum a day.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that these over-the-counter drugs are widely available and that Nicorette is the market leader. \u2018Glaxo products\u2014which include Nicorette gum and lozenges and NicoDerm patches\u2014account for more than half of the $835 million market in annual U.S. retail sales of over-the-counter smoking-cessation aids, according to market-research firm Euromonitor International. Pfizer Inc. and Novartis AG also market NRT.\u201d", "answer": 1}, {"article": "Qi Sun of the Harvard School of Public Health and his colleagues analyzed data collected from 13.984 female nurses participating in the Nurses\u2019 Health Study, an ongoing study examining a variety of health issues.\nThat was after accounting for other factors, such as smoking.\nGood overall health was defined as having no major chronic diseases, such as heart disease or diabetes, as well as having no significant decline in their thinking or physical abilities.\nThose who drank between one-third and 1 drink per day five to seven days a week were almost 50 percent more likely to be in good health when they got older compared with those who did not imbibe.\n\u201cThese data suggest that regular, moderate consumption of alcohol at midlife may be related to a modest increase in overall health status among women who survive to older ages,\u201d the researchers wrote.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of alcoholic beverages isn\u2019t in question.", "answer": 2}, {"article": "People who have two or more type 1 antibodies have between a 50 and 100 percent risk of developing type 1 diabetes, according to background information in the study.\nWEDNESDAY, Nov. 10, 2010 (HealthDay News) -- Offering your baby a special formula when weaning off breastfeeding may offer some protection against the development of the antibodies associated with type 1 diabetes, if you have a family history of the disease, new research suggests.\nAfter adjusting the data to try to account for the duration of exposure to one of the study formulas, the researchers found that the extensively hydrolyzed formula reduced the risk of having one diabetes autoantibody by 49 percent, and the risk of having two or more autoantibodies by 53 percent.\n\"I think this is an important study because we need to understand what causes type 1 diabetes,\" said Harlan, who added the caveat: \"In this study, while there is an apparent signal, there are also some causes for withholding complete faith in the conclusion that the formula caused diabetes.\"\nThe current study was randomized and double-blind (meaning neither the parents nor the researchers knew who was getting what), and compared regular baby formula to one that was made easier for babies to digest because the proteins were broken down (extensively hydrolyzed).\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Various infant formulas are available when weaning infants from breast milk, or when breastfeeding is not an option.\u00a0 The story discusses research that compared regular infant formula with a type of extensively hydrolyzed formula that helps break down proteins during digestion.\nThis formula may not be available to some parents due to greater expense.", "answer": 0}, {"article": "July 7, 2010 -- The FDA says it has approved the use of micro-sized implantable telescopes to improve vision in patients with end-stage, age-related macular degeneration.\nIt is designed to magnify and project images onto a healthy portion of the afflicted person's retina.\nTraining would also be needed to verify that there is sufficient peripheral vision in the untreated eye.\nThe tiny device, called an Implantable Miniature Telescope (IMT), is designed to replace the natural lens.\nThere are two forms of AMD, a wet form and a dry form.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The focus of the story was on FDA approval of the device. ", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nThis difference in cardiovascular rates has not been seen across all other studies, and therefore may be due to chance.\nIn many states, a corrected visual acuity of 20/40 or better in at least one eye is required for a driver\u2019s license that allows both day- and nighttime driving.\nThe drugs are injected into the eye and work by inhibiting vascular endothelial growth factor (VEGF), a substance that can promote abnormal blood vessel growth and leakage.\nThe risk of heart attack, stroke, or death from a cardiovascular condition or an unknown cause by end of the trial was higher among participants in the Lucentis group.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that all three drugs compared are available and in use. It could have noted that payers may not cover them all.", "answer": 1}, {"article": "(Editing by Pravin Char)\n\u201cThis is one of the first handful of examples of drug repurposing, where a new use has been found for an existing drug,\u201d Vasudevan said.\nBut it is very toxic - at only twice the right dose it could kill a patient, Churchill said - and its adverse side-effects mean many people stop taking the drug and relapse into episodes of mania and depression.\nScientists say the drug, ebselen, may be a swift answer to long-sought after better medications for patients with the manic depressive disorder, since it is already known to be safe.\nIf the drug could be \u201crepurposed\u201d and licensed for the treatment of bipolar disorder, it could reduce the unpleasant side effects of weight gain, thirst and potential kidney damage that patients risk when taking lithium.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the drug is not available by noting, \u201cEbselen is an antioxidant originally developed up to late stage, or phase III, clinical trials by the Japanese firm Daiichi Sankyo for the treatment of stroke, but which never reached market and is now out of patent.\u201d", "answer": 1}, {"article": "For most patients the cravings really do disappear.\nIt can force type 2 diabetes into almost instant remission and it appears to reduce the risk of cancer.\nA big reason the operation works is because it seems to suppress appetite.\nIt used to be that roughly one in 100 people died from this operation.\nIt's pretty well known to doctors that the most successful treatment for obesity is surgery, especially the gastric bypass operation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The segment makes clear that the gastric bypass operation is widely available and done as many as 200,000 times per year. ", "answer": 1}, {"article": "AOSSM is also a founding partner of the STOP Sports Injuries campaign to prevent overuse and traumatic injuries in kids\nAfter treatment with an arthroscopic bankart repair, the postoperative dislocation rate in the first-time injury group was 29%, compared to 62% in those who did not have surgery after their initial injury.\nThe Society works closely with many other sports medicine specialists, including athletic trainers, physical therapists, family physicians, and others to improve the identification, prevention, treatment, and rehabilitation of sports injuries.\n\u201cPhysicians should counsel those with first time injuries on these benefits moving forward.\u201d\n\nThe American Orthopaedic Society for Sports Medicine (AOSSM) is a global leader in orthopaedic sports medicine education, research, communication and fellowship, and includes national and international sports medicine leaders.\nOf this group, 68 patients had experienced their first dislocation, while 53 had recurrent dislocations after being initially treated non-operatively.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does not say how available either procedure is. The release would have been stronger if it had clarified whether all orthopedic surgeons perform this procedure or if it is a specialized procedure only available at certain clinics. ", "answer": 0}, {"article": "Staying sexually active\u2014and considering sexuality an important part of life\u2014may be linked to higher cognitive functioning as people age, according to a study in the March issue of the American Journal of Geriatric Psychiatry.\n\nOlder men and women who were satisfied with their sexual relationships and considered sexuality an essential component of aging performed better on tests of cognitive function than those who felt sexuality and intimacy were unimportant, the research showed.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t address any of the health problems or other issues that can make sex less available or fulfilling for older adults. For example, the death of a spouse, erectile dysfunction, arthritis, chronic pain, etc. Then again, these factors may not affect availability of sex for the elderly as much as we think \u2014 what goes on in assisting living facilities may surprise us all.\u00a0Regardless, we\u2019d like to see the story explore this. We\u2019d reiterate that people in worse overall health are also likely to have worse brain function and have less ability to perform sexually. This is an example of where our EVIDENCE and AVAILABILITY criteria comments overlap, but build on each other.", "answer": 0}, {"article": "Acupuncture designed to treat depression appears to improve symptoms in pregnant women, suggesting it as an alternative to antidepressant medication during pregnancy, a study found.\n\nThe study, published Monday in the journal Obstetrics & Gynecology, is the largest to date examining the effectiveness of acupuncture to treat depression in pregnant women. It was funded by a grant from the government's Agency for Healthcare Research and Quality. \"Acupuncture that we have tested works for pregnant, depressed women,\"...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While acupuncture is widely available, the story doesn\u2019t clearly point out that the regimen used in the study was specially developed for this study. Where could a woman seeking this treatment find it? How many practitioners are trained on this regimen?", "answer": 0}, {"article": "A biopsy involves the removal of tissue or fluids to test for disease.\nIn fact, the use of these minimally invasive biopsies increased from 59 percent to 67 percent of all biopsies between 1997 and 2008, a trend which is likely to continue, one expert noted.\n\"We also found that the use of imaging guidance increased over this time period, most likely because the technique enables more efficient and safe targeting of lesions,\" Kwan said in a news release.\nTUESDAY, Aug. 17, 2010 (HealthDay News) -- Less invasive biopsies done with the help of imaging to guide the needle now make up the majority of biopsies being done, a new study finds.\n\"In time, I would expect 80 to 90 percent of biopsies will be image-guided biopsies,\" he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability \u2013 and growing use of \u2013 less invasive biopsies is the whole point of the story. But the story didn\u2019t clarify how broad the study sample was \u2013 and how representative of different health care settings large and small, urban and rural, etc.. For this information to be truly meaningful and helpful to readers all over the US, such scrutiny is vital. ", "answer": 0}, {"article": "The research was carried out in association with the University of the West of England, and the concentrated blueberry juice (BlueberryActive) and some funding for the study was provided by CherryActive Ltd, which produces cherry, beetroot and blueberry products in concentrate and capsule form.\nThe study was also supported by the charity BRACE, which raises funds to support dementia research.\nBlueberries are rich in flavonoids, which possess antioxidant and anti-inflammatory properties.\nBefore and after the 12-week period, participants took a range of cognitive tests while an MRI scanner monitored their brain function and resting brain blood flow was measured.\nFlavonoids, which are abundant in plants, are likely to be an important component in causing these effects.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We know blueberry juice is widely available but what about the concentrated blueberry juice used in the study?", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070603/11back.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "A reader might reasonably conclude that the treatments the story describes are generally available. Whether the same outcomes are equally obtainable at all hospitals is unclear. The studies were performed at some of the leading spine centers in the world.", "answer": 1}, {"article": "\"Are you angry?\"\nThese results provide strong evidence for using advanced technology as a decision-support tool to help clinicians and caregivers identify and prevent suicidal behavior, says John Pestian, PhD, professor in the divisions of Biomedical Informatics and Psychiatry at Cincinnati Children's Hospital Medical Center and the study's lead author.\nThe study is published in the journal Suicide and Life-Threatening Behavior, a leading journal for suicide research.\nThe scientists also noticed that the control patients tended to laugh more during interviews, sigh less, and express less anger, less emotional pain and more hope.\nThis methodology easily can be extended to schools, shelters, youth clubs, juvenile justice centers, and community centers, where earlier identification may help to reduce suicide attempts and deaths.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Availability of the algorithm isn\u2019t made clear in the release, though the study notes that an \u201cunexpected\u201d lack of predictive power means \u201cadditional research\u201d is required.", "answer": 0}, {"article": "But researchers say the preliminary findings could one day lead to diabetes treatments.\n\u201cSurgery puts the diabetes into remission.\nAnd the patients in both groups had lost just a fraction of the weight they needed to lose at the time of the analysis.\nMost of the research has focused on changes in gut hormones, but we have shown that a decline in specific circulating amino acids also occurs.\u201d\nNow a new study from Duke University Medical Center and Columbia University may help explain why.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that gastric bypass is a readily available surgical procedure.", "answer": 1}, {"article": "We showed that the islets [cells] can start to work again,\" said Dr. Yong Zhao, an assistant professor in the section of endocrinology, diabetes and metabolism at the University of Illinois at Chicago.\nThe study participants, who were 15 to 41 years old, had had type 1 diabetes for an average of nine years.\nThe average daily dose of insulin dropped almost 39 percent after 12 weeks for the group with some beta cell function and 25 percent in those with no beta cell function, suggesting that the group with no beta cell function now produced insulin.\nAlthough the treatment didn't wean anyone off insulin completely, average blood sugar levels dropped significantly, which would reduce the risk of long-term complications.\nThe researchers measured C-peptide, a protein fragment that's a byproduct of insulin production, and found that the educator therapy group had improved levels of C-peptide at 12 weeks.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that this type of treatment is not yet available and no claims were made about a timetable for reaching the market.", "answer": 1}, {"article": "TUCSON, Ariz., Nov. 10, 2016 /PRNewswire/ -- HSRx Biopharmaceutical, a leading developer of proprietary OTC drugs, announced that an independently conducted clinical study has demonstrated its new product, OsteoRx\u2122, outperformed Osteo Bi-Flex Triple Strength\u00ae in alleviating pain and increasing range of motion in patients suffering from joint pain.\nMeasurements in the level of pain and range of motion in the affected knee were recorded over a 14-day period for each patient.\nAfter 14 days of treatment, the average improvement was still nearly twice as large as the competition.\nAfter 14 days of treatment, average pain reduction was more than twice as large as the competition.\nAfter 48 hours, the average pain reduction for OsteoRx\u2122 users was nearly three times greater than for patients using the competing brand.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The point of the release appears to be an advertisement for a product that is already available. The supplement was readily found online.", "answer": 1}, {"article": "\"Given walnuts are a high-energy food, a prevailing concern has been that their long-term consumption might be associated with weight gain,\" said study author Dr. Emilio Ros, director of the Lipid Clinic, Endocrinology & Nutrition Service at the Hospital Clinic of Barcelona, in a press statement.\nEat walnuts mindfully,\" she said.\nThey're rich in fiber, folic acid, and potassium.\nIt's still important to remember portion control, especially for people on weight loss programs, warned Politi.\n\"Try a serving in a snack bag.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Walnuts are widely available everywhere, so this is not applicable.", "answer": 2}, {"article": "Each carries problems.\n\u201cOur new method is far more accurate and also allows us to identify the difference between cancerous and benign tissue in the prostate without the need for invasive surgery.\u201d\n\nThe prostate is a small gland in the male reproductive system and is normally about the shape and size of a walnut.\n\u201cWith an average of one man dying every 45 minutes from prostate cancer in the UK, the need for a more reliable test that can identify dangerous forms of the disease earlier is greater than ever.\u201d\n\nIn the past few years, a number of celebrities have revealed that they had been diagnosed with prostate cancer and have joined campaigns to raise awareness of the disease, including Michael Parkinson, Ian McKellen and most recently Stephen Fry, the comedian and former rector of Dundee University, who this year described how he had surgery to deal with a prostate tumour.\n\u201cThe technique now needs to be tested in a much larger number of men to confirm just how well it can detect the aggressive cancers, while also ruling out those who do not have prostate cancer,\u201d said Simon Grieveson, head of research funding at Prostate Cancer UK, which funded the Dundee project (with support from the Movember Foundation).\nPSA results can be unreliable; a DRE is not good at identifying which cancers are benign and which need treatment; MRI scans cannot always give a definitive answer; while a biopsy carries a risk of infection and is expensive.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While the story doesn\u2019t explicitly deal with the availability of shear wave elastography (SWE), it\u2019s fairly clear that the new approach is experimental, has only been used on no more than 200 patients, and would require larger clinical trials to prove its efficacy \u2014 all points that suggest that it may not be available to most patients now.\u00a0 It also states that, \u201cSWE technology is already used in diagnosing breast cancer and liver diseases.\u201d", "answer": 1}, {"article": "Tumor cells make PD-L1 turn on PD-1 when immune cells approach.\n\"I suspect the findings were significant enough that this will be a practice-changing finding,\" Dr. Pasi Janne, lung cancer specialist at Harvard Medical School and the Dana-Farber Cancer Institute, told NBC News.\nLung cancer is the top cancer killer in the U.S. It\u2019s diagnosed in more than 220,000 people a year and it killed nearly 160,000 people last year, according to the National Cancer Institute.\nRelated: Keytruda Keeps Some Patients Alive For Three Years\n\n\"Immunotherapy is a whole new way of treating cancer, including lung cancer,\" said Janne, who was not involved in the study.\nThe drug, Keytruda, is the same drug that former president Jimmy Carter says helped stall advanced melanoma that had spread to his brain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does establish availability, though it is confusing.\nIt calls the drug \u201cthe Jimmy Carter drug\u201d in the headline, leading readers right away to believe this is an available drug that the former president took. But then it provides a\u00a0tidy\u00a0summary of drug trials and why the halting of this particular trial matters, saying:\n\u201cCancer research goes forward in slow steps. In tests of new drugs, patients always get either the very best therapy already available, or the new drug. Often they get both. Usually, cancer drugs are only tested at first in patients who have tried everything else available and their cancer has come back, anyway. So\u00a0it\u2019s an important break for a company if its drug is the first one a patient gets and it works better than the so-called standard of care.\u00a0The company now can ask the Food and Drug Administration if it will approve Keytruda to use as the first treatment a lung cancer patient tries.\u201d\nThe nuance there might be missed by readers. But we are giving the story a pass here because later, the story says more clearly that Keytruda was \u201capproved October last year for lung cancer and in 2014 for melanoma.\u201d", "answer": 1}, {"article": "However, for a study that lasts this long, \u201cthose are acceptable numbers,\u201d noted Arber.\nStill, the results are \u201cvery promising,\u201d Arber told Reuters Health by e-mail, adding he is now working to identify people who could benefit from the drug without experiencing the side effects.\nThis is not the first study to suggest Celebrex and similar drugs \u2014 known as COX-2 inhibitors - may reduce the risk of developing colon cancer, he said, but people need to balance that potential benefit with the higher risk of cardiovascular complications.\nColorectal cancer is the third most common cancer in men and women, and strikes 1.2 million people each year.\nAs a result, he said he suspects most people would choose to rely on regular colonoscopies to catch the disease in its early stages, rather than take a potentially risky drug for years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that Celebrex is the only COX-2 inhibitor remaining on the market in the U.S., so readers should know it\u2019s available. The story could have been more clear that the drug is available only by prescription and can\u2019t be purchased over the counter.", "answer": 1}, {"article": "TUESDAY, Jan. 19, 2010 (HealthDay News) -- DNA testing for the human papillomavirus should replace the Pap smear as the main way to screen women for cervical cancer, according to Italian researchers.\nThis results in many more callbacks for women to undergo further testing.\nThe HPV test should become the screening tool of choice for women 35 and older, the researchers said.\nThe HPV test works a step further back in the process, looking to see if women are infected with HPV.\n\"It does make sense, it's cost-effective and effective.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly the HPV DNA test and pap tests are both available in the US.", "answer": 1}, {"article": "\u201cOur results suggest that the same dietary recommendations that are made to the general population primarily for the prevention of cardiovascular disease may also decrease the risk of dying from prostate cancer among men initially diagnosed with nonmetastatic disease (cancer that has not spread),\u201d said Dr. Jorge Chavarro of Brigham and Women\u2019s Hospital and Harvard Medical School, who led the study.\nProstate cancer survivors who eat a typical American diet loaded with red meat, cheese and white bread are far more likely to see their cancer come back and kill them, and they\u2019re more likely to die sooner of any disease than patients who eat a healthier diet, researchers reported Monday.\nIt\u2019s yet another piece of evidence showing that the so-called Western diet can worsen the risks for cancer, as well as all sorts of other diseases from heart disease to Alzheimer\u2019s.\nMany studies have shown it doesn\u2019t take a whole lot of adjustment to greatly lower the risks.\nSo-called Mediterranean-style diets, with plenty of fresh vegetables and fruit, olive oil instead of saturated fat, whole grains and more fish than meat, ward off these same diseases.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "With some notable exceptions, such as \u201cfood deserts\u201d in areas of high poverty, prudent diets are widely accessible and the article spells this out pretty well.", "answer": 1}, {"article": "Dong notes that pulse wave velocity and blood pressure measures are complimentary but not interchangeable.\nWhile heart disease is the leading cause of death in the United States, according to the Centers for Disease Control and Prevention, blacks have higher rates of cardiovascular disease and death than whites and the disease tends to occur earlier in life.\nThe varying doses, as well as the placebo participants took, were all packaged the same so neither they or the investigators knew which dose, if any, they were getting until the study was complete.\nThe test essentially measures the speed at which the blood is moving, and in this case, fast is not good, Raed says.\nNow it's time to do a larger-scale study, particularly in high-risk populations, and follow participants' progress for longer periods, Dong and Raed say.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that it would be simple for almost anyone seeking to increase their vitamin D intake to do so. They can drink more milk, eat more yogurt, eat more greens like kale, take a supplement and so forth.", "answer": 1}, {"article": "Records covered the use of both low- and high-dose aspirin (ranging from 75 milligrams to 500 milligrams), so-called \"nonselective\" NSAIDs (such as ibuprofen [Advil] and naproxen [Aleve]), and both older and newer types of COX-2 inhibitors.\nOver-the-counter NSAIDs are used to control pain, fever and swelling.\nThe study appears in the May 29 online issue of the journal Cancer.\nIn turn, prescription histories were gathered for both the cancer patient group and almost 179,000 healthy Danes.\nTing also advised that people consult with their doctor before starting on any blood thinner.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of NSAIDs isn\u2019t in question.", "answer": 2}, {"article": "Potluri cautioned, however, that this study can't prove that statins actually extended life in cancer patients.\n\"Regardless of whether or not a person has cancer, statin use should be discussed with a health care provider,\" said Eric Jacobs, strategic director of pharmacoepidemiology at the American Cancer Society.\n\"There is little evidence that statins affect cancer risk or survival, but clear evidence that they can help some people lower risk of heart attacks and strokes,\" he said.\n\"We need to further investigate the reasons for patients with high cholesterol having improved mortality in four of the most common cancers,\" said senior researcher Dr. Rahul Potluri, a clinical lecturer at Aston University School of Medicine in Birmingham.\nFRIDAY, July 8, 2016 (HealthDay News) -- Some cancer patients who take cholesterol-lowering statins may live longer than those not on these heart medications, a study from Britain suggests.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s obvious from the story that statins are widely available. If research shows they can lower risk, they are available already for that purpose.", "answer": 1}, {"article": "\u201cThe potential for a nutritional lifestyle intervention to counter obesity driven by high-carbohydrate food, though we don\u2019t know yet how significantly, is fascinating,\u201d Arciero says\u2014especially when it\u2019s as simple and delicious as reheating your pasta.\nIt\u2019s too soon to tell if resistant starch can help people weight.\nMost intriguing and surprising of all is that so many leftovers contain resistant starch.\nThere, they\u2019re fermented and turned into short-chain fatty acids, which the body burns as energy.\n\u201cCooking the carbohydrate starch alters the chemical bonds in the food,\u201d Arciero explains.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All of these foods are widely available.", "answer": 2}, {"article": "Maryjane Wraga , associate professor of psychology at Smith College in Northampton, tested 54 women for spatial reasoning skills -- the ability to solve problems related to shape and measurement.\nDifferent activities -- such as speech or music -- may be affected differently by stereotypes.\nCAUTIONS: The study looks only at spatial reasoning.\nA second group received a positive message, and the control group received no message.\n\"It's the difference between a B and an A\" on a test, says Wraga.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly alcoholic drinks are available.", "answer": 2}, {"article": "While the procedure may look straightforward, it's extremely delicate, said Linda Cormier, a sales representative for Cambridge Endo, whose headquarters is in Framingham, Mass.\nThe hook, grasper and scissors are on the ends of shafts less than one-fifth of an inch wide.\nInstead, he chose cold.\nThe recovery has been pain-free, and the cancer hasn't returned, he said.\nAbout 12,980 die of the cancer each year.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes no mention of how widely available cryotherapy is.", "answer": 0}, {"article": "(Reuters) - Johnson & Johnson said its drug, Tremfya, was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study.\nAbout 7.5 million Americans live with plaque psoriasis, of which 20 percent have moderate-to-severe form of the disease, J&J said.\nTremfya, first approved in July 2017 as a plaque psoriasis treatment in the United States, is also being tested as a for psoriatic arthritis and Crohn\u2019s disease.\nU.S.-listed shares of Novartis closed up 1.2 percent .\nShares of J&J closed up marginally at $148.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability is implied but it should have been made more clear when these drugs received FDA approval, and what they\u2019re approved for.", "answer": 1}, {"article": "Now two new studies (bolstered by an accompanying editorial) in the New England Journal of Medicine demonstrate what we parents have suspected for years: When it comes to ear infections, antibiotics are in order.\nInterestingly, antibiotics were no more effective at reducing pain, as reported by parents or children, than placebos.\nBut please give some to my kid anyway.\nBy Christmas morning, the pain had subsided.\nEar infections hurt, and waiting for them to run their course can be excruciating.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of antibiotics isn\u2019t in question, so this is not applicable.", "answer": 2}, {"article": "WASHINGTON -- A U.S. Food and Drug Administration panel of outside medical experts backed a Novartis AG drug, Exelon, for treatment of dementia in patients with Parkinson's disease.\n\nExelon is currently on the market to treat mild to moderate Alzheimer's disease. The FDA said it wasn't sure whether dementia associated with Parkinson's was much different than dementia associated with Alzheimer's. Dementia is a condition that typically first presents itself as memory loss greater than what would be expected as part of the normal...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story fails to mention a projected date for or the next steps in obtaining FDA approval. While the FDA usually follows the advice of the advisory panel, which in this case recommended the drug\u2019s approval for treatment of dementia associated with Parkinson\u2019s Disease, the FDA does not have to follow the panel\u2019s recommendation. There is no discussion of when the FDA might approve the drug for this indication. ", "answer": 0}, {"article": "For the study, Lumeng's team collected data on more than 43,700 Michigan preschool-age children between 2005 and 2013.\n\"Even though children in the Head Start group began the observation period more obese, equally overweight, and moreunderweight than children in the comparison groups, at the end of the observation period the initially obese and overweight Head Start children were substantially less obese andoverweight than the children in the comparison groups,\" the authors wrote.\n\"Perhaps the program fosters better mental health in the children, which in turn leads to better eating,\" he said.\nAt the study's start, about one-third of the Head Start kids were obese or overweight, compared to 27 percent of those on Medicaid and less than 20 percent of kids not on Medicaid.\nInformation on the others -- 5,400 of whom were on Medicaid, the publicly financed insurance program for the poor -- came from two primary health care groups.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that Head Start is available to children ages 3-5 who live in poverty. We\u2019ll rate this good enough for a satisfactory grade. \u00a0Detail about how to enroll in the program would have helpful.", "answer": 1}, {"article": "The trial was funded by Mayo Clinic.\nIn this group, the rate of heart attack, stroke and revascularization and death was 3.7 percent among those with a low ceramide score, but 16.4 percent in people with the highest ceramide levels.\nThe test, released commercially by Mayo Medical Laboratories in August 2016, measures blood concentrations of plasma ceramides, a class of lipids that are highly linked to cardiovascular disease processes.\n\u201cOur research suggests that evaluating ceramide levels in patients who are not at immediate risk for coronary artery disease events may help cardiologists decide who could benefit from proactive and preventive treatment, such as statins, or lifestyle changes to prevent a serious cardiac event down the road,\u201d says Jeff Meeusen, Ph.D., a clinical chemist, co-director of Cardiovascular Laboratory Medicine at Mayo Clinic and the study\u2019s lead author.\nBut the risk of having an event became higher as ceramide level increased; for each 1-point increase in the ceramide risk score, the risk rose by 9 percent.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states that the \u201cnew test is available to health care providers worldwide through Mayo Medical Laboratories.\u201d It is not entirely clear whether this is the only commercially available test of its kind.", "answer": 1}, {"article": "It\u2019s not the first study to show a potential anticancer effect of aspirin and other similar painkillers \u2014 a class of medications known and nonsteroidal anti-inflammatory drugs, or NSAIDs.\nEach case was compared to 10 matched controls who did not develop the disease.\nThe longer people took the drugs, and the higher the dose, the greater the anticancer benefit.\nFind her on Twitter at @aliceparkny.\nAn aspirin a day could keep skin cancer away, according to a new report in the journal Cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of NSAIDs is not in question.", "answer": 2}, {"article": "Give these a click:\n\nPersonalized cancer vaccines have already helped treat three patients\n\nSmartwatches might cause cancer, says article based on \u2018expert\u2019 who pushes holistic breast cancer treatments\n\nSun damage keeps happening even after you go inside, new study says\nWhen the latest trial was started, Harrington explained, there was no standard of treatment for melanoma -- so it's compared to a treatment that no one expected to outpace T-VEC.\nNow that other therapies -- ones that target specific mutations in patients' cancer cells -- are showing more success than what was available when the trial was formed, researchers will have to see how T-VEC compares.\n[Personalized cancer vaccines have already helped treat three patients]\n\nIn a study of 436 patients with inoperable melanoma, Talimogene Laherparepvec had 16.3 percent of patients showing results at the six-month mark, compared to 2.1 percent taking the control therapy.\nA modified version of the Herpes Simplex 1 virus (known for causing cold sores and some cases of genital herpes) called T-Vec has successfully been used to treat melanoma in a phase III clinical trial.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a bit too much crystal ball-gazing as to when this drug might become available. The start of the article refers to the drug as being months away from approval. Later in the story, the Amgen-affiliated researcher says he expects approval within the year. But his optimism might not be shared by those outside the company \u2014 the story should at least have asked for an independent take. While it\u2019s true that an FDA advisory panel has recommended approval of the drug, the researcher can\u2019t know if the FDA will in fact approve the drug or when. One analysis suggested that the FDA does not follow the advice of its advisory panels\u00a0about a quarter of the time.", "answer": 0}, {"article": "Prior to this, Yu\u2019s team had performed targeted MRI biopsies with the patient being moved in and out of the MRI scanner as the needle was guided to the target area \u2014 a sort of stop-motion procedure that could take up to an hour.\nThat\u2019s one of our strengths.\u201d\n\nYu has seen how MRI technology has changed prostate patients\u2019 care.\n\u201cIf we put those characteristic features together from each sequence then we can say with a high degree of confidence that this area is concerning for cancer and potentially target it for biopsy,\u201d said Sarah Winks, M.D., an attending physician in the Department of Radiology.\nHe ends up diagnosed with cancer only after the tumor has spread to his bone or lymph nodes years later.\u201d\n\nMagnetic resonance imaging and targeted biopsy for the prostate have provided relief for patients like Harder who have not been able to get an accurate diagnosis.\nWhen I went back to my urologist, he said, \u2018Why spend money flying around the country when we can take care of you here?\u2019 I said, \u2018Because 85 percent is better than 40 percent.\u2019\u201d\n\nVCU Medical Center was one of the places Grandon had researched to get his diagnostic testing done, and a few phone calls later, he was on a plane flying across the country to see Yu.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states that \u201cVCU Medical Center is one of the major teaching hospitals in the country doing advanced multiparametric MRI.\u201d That appears to be accurate.\nIt would have helped readers not in the VCU vicinity if the release had included more information about where tests could be done. Is it generally available at major teaching hospitals? If not, how many have it?", "answer": 0}, {"article": "After taking into account other factors that might affect health and disease risk, like smoking, researchers found women who drank light or moderate amounts of alcohol were less likely to develop chronic diseases as they aged.\nThe women filled out questionnaires about what they ate and drank at midlife, about age 58.\nFor example, compared to nondrinkers, women who drank up to one alcoholic drink per day were 20% more likely to be disease-free at age 70 than nondrinkers.\nResearchers then analyzed health status information collected after the women turned 70.\nA new study shows women who drank the equivalent of a beer or small glass of wine each day were less likely to develop chronic diseases like heart disease, cancer, and diabetes as they got older compared to nondrinkers or those who drink four or more drinks at one time.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of alcoholic drinks is not in question.", "answer": 2}, {"article": "But there are reasons to think aducanumab may succeed where other drugs have failed.\nThe results are encouraging for pharmaceutical companies that have spent billions of dollars on efforts to come up with the first drug to treat the underlying cause of Alzheimer's.\n\"It was surprising, encouraging and thought-provoking to see such a striking reduction of existing plaques,\" Reiman says.\nResults from a small number of patients who received a high dose of the drug, called aducanumab, hint that it may also be able to slow the loss of memory and thinking.\n\"If that hint of a clinical benefit is confirmed, it would be a game changer in the fight against Alzheimer's disease,\" says Dr. Eric Reiman, executive director of the Banner Alzheimer's Institute in Phoenix.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story calls the drug experimental and says that it will take several years for larger studies to report results. It\u2019s apparent that the drug won\u2019t be available outside of a research study any time soon.", "answer": 1}, {"article": "A 33-year-old Queens woman who was treated by Batzofin last week fits that bill. Married for two years, she failed to get pregnant through intercourse, with and without drugs. When Batzofin told her about his new procedure, she said, \"Let's go for it.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that IVM (in vitro maturation) treatments are not widely available and this method is not as successful or widely accepted in the medical community as IVF (in vitro fertization) treatments.\u00a0 The story notes that Dr. Batzofin is one of the first doctors in Manhattan to offer the treatments and is conducting a clincal trial on IVM.\u00a0 ", "answer": 1}, {"article": "\"Sometimes [the mother] is a bit uncomfortable, or sometimes Dad has to go on a business trip or Grandma wants to fly in,\" Lavin said.\n\"This happens to me every day,\" Lavin said.\nAll of the women had previously had C-sections.\nOf those, more than 13,000 had elective C-sections.\nThe Associated Press and McClatchy Newspapers contributed to this story.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The \"growing number of planned C-sections\" is clear from the story. ", "answer": 1}, {"article": "ISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (\"Volition\") today announced preliminary data from a prospective, multi-centered Proof of Concept Study of 84 men into the utility of Volition's Nu.Q\u2122 assays to diagnose men with high-grade prostate cancer.\nThe funding provided by the region has enabled this study and will support our continued research.\"\nEarly diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.\nWe will further investigate the data in relation to disease stage as well as additional factors used for pre-treatment risk stratification.\"\nIf these results are validated in larger trials, they will present a potentially significant new market opportunity.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that this blood test is experimental and one can safely assume it is not yet available.", "answer": 1}, {"article": "Petersen and his team wanted to develop a test that any physician can administer to patients, without the need for any new technology or expensive equipment.\n\u201cBut what\u2019s nice about it is that it\u2019s a nice non-cognitive, motor factor so it\u2019s looking at another aspect of brain function.\u201d\n\nMORE: This Alzheimer\u2019s Breakthrough Could Be a Game Changer\n\nPetersen suggests that every physician should get this information on their patients at age 65; that way, they can have a baseline against which to compare any changes as their patients age.\n\u201cIf we had a simple blood test, a cholesterol test for Alzheimer\u2019s disease, that would help,\u201d says Dr. Ronald Petersen, director of the Alzheimer\u2019s Disease Research Center at the Mayo Clinic, \u201cbut we don\u2019t.\u201d But Petersen has a potential solution, and according to a new paper released Wednesday in the journal , his Alzheimer\u2019s test has promise.\nCurrently, the only way to truly separate out those on the road to Alzheimer\u2019s is to conduct expensive imaging tests of the brain, or to do a spinal tap, an invasive procedure that extracts spinal fluid for signs of the amyloid protein that builds up in the disease.\nIn the first phase of the test, his researchers simply collected information from 1,500 patients\u2019 medical charts\u2014their age, family history of Alzheimer\u2019s, factors such as diabetes or smoking that have been linked to Alzheimer\u2019s, and whether the patient had ever reported problems with memory.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although not explicitly stated, the story makes it clear that the test could be performed now. That\u2019s technically accurate, and we\u2019ll award a satisfactory on that basis. However, we wonder how many general practice clinics are equipped both staff- and resource-wise to begin testing their patients. Even without the need for \u201cnew technology and expensive equipment,\u201d as stated in the article, one assumes clinics and hospitals much smaller than the Mayo Clinic (which developed the test procedures) would require at least some training and additional resources in order to introduce multi-part testing.", "answer": 1}, {"article": "TUESDAY, Nov. 27, 2018 (HealthDay News) --What if a simple zap to the spine could relieve the debilitating lower back and leg pain brought on by a herniated disk?\nAnd the new research suggests the treatment could prove a boon to back pain patients for whom standard therapies have failed to do the trick.\n\"Steroid injections are effective only in portion of the patients, and generally require more sessions,\" he noted.\nThe process, said Napoli, requires no hospital stay, is noninvasive, far cheaper and less risky.\nSuch research is considered preliminary until published in a peer-reviewed journal.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story mentions this treatment has been FDA-approved, but doesn\u2019t explain whether it\u2019s widely available, particularly for treating spinal disk herniation with spinal nerve compression.", "answer": 0}, {"article": "\"Adolescence is the key time for bone growth.\n\"Although we didn't study other sports, it's reasonable to suppose that weight-bearing, high-impact, high-intensity exercise like tennis, badminton, basketball and handball will have similar effects to football.\"\nAdolescence is the key period for bone development, and poor development at this stage is linked to reduced peak bone mass (the amount of bone mass at the end of the skeletal maturation, around age 30), increased fracture risk and osteoporosis later in life.\nThough swimming and cycling have proven health benefits, the scientists said their study \"raises a question\" about whether they are good for bone development due to the non-weight bearing training - and they say young swimmers and cyclists could benefit from more weight-bearing exercise in training regimes.\nDr Gracia-Marco said: \"The sports we studied are the three most popular in the UK, and it's important to know what effects they have in relation to bone health.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t mention availability. True, soccer is the world\u2019s most popular sport and there are opportunities to play \u2014 but not all families are able to invest the time and expense required for intense participation in a sport.", "answer": 2}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\nHowever, MRI also detected additional disease in 19 percent of patients with fatty or scattered fibroglandular tissue.\nIn addition, the MRI-detected multicentric cancers were greater than 1 centimeter in size in 25 percent of the 73 patients.\nResearchers said that in some cases MRI findings of additional cancers not seen on mammography may necessitate a change in treatment.\nTo learn more, Dr. Iacconi and colleagues reviewed records from 2,021 patients with newly diagnosed breast cancer who underwent biopsy after preoperative MRI.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that MRI is widely used for screening high-risk patients and for pre-surgical planning.", "answer": 1}, {"article": "\u201cIf this is the case, dosage shouldn\u2019t matter.\nBut the fact that the fewest recurrences were seen in men who took the highest statin doses is compelling, says senior investigator Stephen J. Freedland, MD, of the Duke Prostate Center.\n\u201cStatin users may see their doctors more often and may be more health conscious in general, and it has been suggested that this could explain the observed reduction in risk,\u201d Freedland tells WebMD.\nIn a new study from Duke University Medical Center, men who took statins for their hearts were 30% less likely to have their cancers come back after their prostates were removed than men who did not take the drugs.\nJune 28, 2010 -- Cholesterol-lowering statin drugs appear to reduce the risk for prostate cancer recurrence in patients who have had a surgical procedure called radical prostatectomy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Statins are widely available under several brands, many of which are mentioned in the story. At the same time, the reporter does explain that additional study would be needed before doctors would know whether to prescribe statins to prostate cancer patients and at what point in their treatment regimen.", "answer": 1}, {"article": "Both involve radiation.\nIn this study, the average age was about 59 years old - six years younger than the age at which the U.S. Preventive Services Task Force, a government-backed panel, recommends all women begin being screened for osteoporosis.\nThe idea, say the researchers, is doctors can use patients\u2019 CT scans that are ordered for another reason - such as looking for tumors - to also check for signs of osteoporosis.\nThe researchers, who published their findings in the Annals of Internal Medicine on Monday, compared patients\u2019 CT scans to their dual-energy X-ray absorptiometry (DXA), which is traditionally used to diagnose osteoporosis.\nDr. Sumit Majumdar, who wrote an editorial accompanying the new study, said a lower threshold for bone density would catch most cases of osteoporosis and limit \u201cincidentaloporosis\u201d - incorrect osteoporosis diagnoses \u201cdiscovered\u201d while doctors were looking for something else.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story touched on availability and use patterns in this succinct statement:\n\u201cDespite DXA scans being safe and cost effective, Pickhardt and his colleagues say the test is underused. CT scans, however, are considered overused \u2013 with more than 80 million performed in the U.S. during 2011.\u201d", "answer": 1}, {"article": "In devising their models, the researchers updated assumptions that have cast doubt on the relevance of existing breast-cancer risk calculators, which relied on the experiences of women who got an earlier generation of screening mammograms and were more likely to die of breast cancer than is currently the case. Here, teams of modelers from Erasmus University in the Netherlands, Albert Einstein College of Medicine in New York and Harvard Pilgrim Healthcare assumed that women were getting digital mammograms, which offer improved cancer detection rates at lower radiation dosages than earlier mammographic methods. They took into account improved rates of breast cancer treatment effectiveness, and changing causes of mortality for women older than 50. They also took account of the fact that breast density decreases in older women.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Digital mammography is available across the United States, so we\u2019ll rate this N/A.\nHowever, the news story would have been stronger had it more clearly explained that these findings were based on an assumption of all-digital mammography. Not all women have access to digital mammography and\u00a0may have to travel farther for digital screening. Travel is often a barrier to screening in the first place, especially for those who rely on public transportation.", "answer": 2}, {"article": "LONDON (Reuters) - A non-surgical treatment for low-risk prostate cancer in which doctors inject a light-sensitive drug derived from deep-sea bacteria into a patient\u2019s bloodstream was shown in a trial to kill cancer cells without destroying healthy tissue.\n\u201cThis is truly a huge leap forward.\u201d\n\nThe treatment, called vascular-targeted photodynamic therapy or VTP, was developed by scientists at the Weizmann Institute of Science in Israel in collaboration with the privately-owned STEBA Biotech.\n\u201cThese results are excellent news for men with early localized prostate cancer, offering a treatment that can kill cancer without removing or destroying the prostate,\u201d said Mark Emberton, a University College London consultant urologist who led the trial.\n\u201cThe fact that the treatment was performed so successfully by non-specialist centers in various health systems is really remarkable,\u201d Emberton said.\nIn the trial, only 6 percent of patients treated with VTP needed radical therapy compared with 30 percent of patients in the control arm who were under active surveillance.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says the treatment is \u201cbeing reviewed by the European Medicines Agency (EMA) for possible license, but it is likely to be several years before it can be offered to patients more widely.\u201d\nStill, we\u2019re left wondering what \u201cmore widely\u201d means here. Is it already available to some patients? The story doesn\u2019t say.", "answer": 1}, {"article": "For further information, please visit: http://www.\nAlthough detection has been improving, most patients have lost a third of vision by the time they are diagnosed.\nIt invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from laboratory to market.\nResearchers hope that eventually it may be possible for opticians to do the tests, enabling even earlier detection of the disease.\nFurther studies will now be carried out to into DARC and how it can be used not only to diagnose and treat glaucoma patients but also for other neurodegenerative conditions.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Despite the enthusiasm about its future uses, it\u2019s pretty clear this test is in early trials and unavailable to the public. ", "answer": 1}, {"article": "Fried said sensory experiences that eventually become memories pass through this hub before they are stored in the hippocampus, the brain\u2019s chief memory center.\nThe current study was done at the University of California at Los Angeles in seven epileptic patients awaiting surgery who had electrodes implanted deep in their brains to help pinpoint the source of their seizures.\nDespite costly efforts, no drug has been found that can keep Alzheimer\u2019s from progressing, and policymakers are growing increasingly worried about the swelling ranks of dementia patients as the population ages.\nPacemaker devices known as deep brain stimulators made by Medtronic and St. Jude Medical are already used to calm muscle tremors in patients with Parkinson\u2019s disease and other movement disorders, and are being tested for a host of other conditions such as treatment-resistant depression.\n\u201cAlthough the current evidence is preliminary, is based on small samples and requires replication, the potential application of deep-brain stimulation in amnestic disorders is enticing,\u201d Black wrote.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story describes how brain stimulation is now used to treat some patients with Parkinson\u2019s disease and other disorders, while making clear that more research is needed before anyone will know if it offers any benefits to people with Alzheimer\u2019s disease.", "answer": 1}, {"article": "Researchers analyzed the men\u2019s hormones and cholesterol with blood tests at the start and end of the study.\nPage has high hopes for the results, calling them \u201cunprecedented in the development of a prototype male pill.\u201d Longer-term studies are the next step toward a once-daily male contraceptive pill, she said.\nThe \u201cundecanoate\u201d in DMAU, however, is a long-chain fatty acid that can slow the drug\u2019s journey out of the body, Page said.\nRead more: Male birth control pill could be made from heart-stopping poison in ancient African arrows\n\nThe once-daily prototype pill suppressed certain hormones to the low levels you'd expect to see with effective longer-term contraceptives, results from an ENDO 2018, the Endocrine Society\u2019s annual meeting in Chicago, abstract show.\nThe prototype pill\u2014dimethandrolone undecanoate (DMAU)\u2014is somewhat similar to the combined female pill, which contains estrogen and a steroid hormone.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does state that \u201cLonger-term studies are the next step toward a once-daily male contraceptive pill.\u201d However, most people are not familiar with how clinical trials work. A little additional information here would have gone a long way. Realistically, these \u201clonger-term studies\u201d will take years \u2014 and that\u2019s if everything goes perfectly. Readers expecting to see a male birth control pill in the relatively near future will certainly be disappointed.", "answer": 1}, {"article": "But even that can be helpful.\nIt remains far from clear, however, what proportion of children will benefit, how long the benefit might last and what proportion will need to continue to consume at least some milk or peanuts every day to maintain their protection.\n\"There's been a substantial uptick in the amount of research,\" said Marshall Plaut of the National Institute of Allergy and Infectious Diseases, which has more than doubled the funding for food-allergy research since 2007.\nAlthough the approach appears to be highly effective for some children with milk and peanut allergies, the researchers conducting the studies and others caution that much more research is needed to prove and perfect the approach and that it is far from ready for widespread use.\n\"There's definitely been a spike in the amount of work going on,\" said Hugh A. Sampson, a professor of pediatrics, allergy and immunology at the Mount Sinai School of Medicine in New York who leads a federally funded consortium studying food allergies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story described positive results from a couple of studies and indicated that desensitization in this manner is the realm of research and not widely available clinically. \u00a0\nThat said \u2013 it could have provided readers with some ideas for where they could go to learn about studies in their area. (www.clinicaltrials.gov)\u00a0", "answer": 1}, {"article": "In a study suggesting that red wine might be the next big thing in breast cancer prevention, a study has found that women who drank just under two servings of red wine daily experienced hormonal changes that mimic the effects of a drug used to prevent malignant breast tumors from coming back.\n\nThe study, published Friday in the Journal of Women's Health, found that consuming the same amount of white wine did not have the same effect in premenopausal women participating in the study.\n\nWomen intent on warding off breast cancer have been warned about alcohol consumption: as recently as November, a study found that women who consumed as few as three servings of alcohol a week increased their risk of developing the disease, which strikes one in eight American women at some point in life.\n\nWhite wine and other alcoholic beverages are believed to promote the conversion of androgens--\"male hormones\" such as testosterone, which circulate in all women's blood--into estrogen. And the greater a woman's lifetime exposure to estrogen--whether her own or estrogen that comes from medication or environmental sources--the higher her risk of developing breast cancer.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of red wine is not in question.", "answer": 2}, {"article": "LOS ANGELES -- Researchers have demonstrated for the first time that the progression of Type-1 diabetes can be halted -- and possibly reversed -- by a stem cell transplant that preserves the body's diminishing ability to make insulin, according to a study published today.\nBut other doctors said that even if the benefits of the therapy are temporary, the research provides valuable insight into the mechanism behind the disease.\nIn the study, 15 Brazilian patients were treated within a few months of their diagnosis, before their immune systems had the chance to eradicate all of their insulin-producing cells.\nThe study suggests a new avenue for treating the intractable disease, in which the immune system destroys insulin-producing beta cells in the pancreas.\nThe researchers also cautioned that the process is not without risk, with patients vulnerable to infection during part of the therapy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states the treatment is experimental, letting readers know this procedure is not available at your local doctor's office just yet.\u00a0 ", "answer": 1}, {"article": "Cancer is the No.\nIt was even more accurate in finding late-stage cancers, but the goal would be to catch cancer in its earliest, easiest-to-treat stage.\n\u201dThe survival difference between late stage and early stage disease in these cancers would account for more than a million lives each year worldwide,\u201d Velculescu said.\nThe first goal would be to try it in people at high risk of cancer but no symptoms yet \u2013 such as smokers, or people with cancer-causing gene mutations like BRCA mutations, Velculescu said.\n\u201cThere is a lot of excitement about liquid biopsies, but most of that has been in late-stage cancer or in individuals where you already know what to look for,\u201d said Dr. Victor Velculescu, professor of oncology and pathology at the Johns Hopkins University Kimmel Cancer Center.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that the potential use of this technology as a cancer-screening tool is some time off in the future, if its usefulness is further proven. Based on the story, readers should understand that this isn\u2019t a tool currently available.", "answer": 1}, {"article": "Dr. Louis Jacques, director of the coverage and analysis group at the Centers for Medicare and Medicaid Services, said cost was not a factor and that the agency had reviewed products approved by the F.D.A.\nSo it cannot be completely ruled out that XL184 somehow stopped bone growth without killing the cancer.\nIt reviewed the clinical trial data and then rated the strength of the data on a scale of 1 to 5.\nHowever, Dr. Smith said he doubted that was the case because there were signs the drug also controlled tumors outside the bones.\nXL184 is believed to block the formation of blood vessels that feed tumors and also inhibits a protein called MET that helps spur tumor growth.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story provided clear information about the availability of Provenge and XL184.", "answer": 1}, {"article": "On The Early Show Friday, Family Circle magazine Editor in Chief Linda Fears discussed everyday lessons that can make a big difference.\nEarly Show national correspondent Hattie Kauffman did a two part series, \"Up and Running,\" in which she spoke to moms with home businesses, doing what they love.\nFor more information about the businesses featured in the series, click on:\n\nThe Consumer Product Safety Commission wishes to remind you that using camp stoves, portable camping heaters, or lanterns or charcoal grills inside your home produces dangerous levels of carbon monoxide, as does using a portable generator inside your home.\nTo watch the segment,\n\nFor much more on folic acid, from the federal Centers for Disease Control and Prevention, click here.\nIt's a tremendous challenge for parents to teach their teenagers and \"tweens\" everything they ought to know.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story discussed folic acid supplements,\u00a0but would have been better if it had explicitly mentioned that these are available over the counter.\u00a0 The story mentioned multivitamins, but would have been better had it included the caveat that consumers need to check the label to determine whether the product contained 400 mcg.\u00a0 The story also discussed food sources (leafy green vegetables, liver, dried beans, citrus fuits, whole grain bread and cereals); however this\u00a0was somewhat incomplete because\u00a0without mention of the amounts of folic acid or the % of the recommended 400 mcg they might get in a single serving a person does not know how to use these foods to insure\u00a0sufficient folic acid\u00a0intake.\nIncluding guidance, such as reading labels, would have made this story more useful for the viewer interested in meeting the recommended intake.", "answer": 1}, {"article": "This news-agency article is no longer available on nytimes.com.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that these apps are available in pilot programs and studies. It also refers to Skype, which most readers will know is generally available. One issue that remains to be seen is how accessible these apps will be to lower-income or homeless people, or those who have limited technology experience and/or limited eyesight.", "answer": 1}, {"article": "[But] Kalydeco controls CF at the basic defect, so I'm OK with the other 'c' word, control, because I'm living it and I've never felt better in my life.\"\nThe time from gene discovery to successful drug may be shortening, but there are only a handful of successful drugs so far, and for a while at least, the appearance of new ones will be slow.\nThe only way to fix that would be gene therapy, where a healthy form of the gene would supplant the damaged one.\nAs a result, sticky mucus builds up in a patient's lungs, causing infections and making it hard to breathe.\n\"I was with my brother in Florida, and we were walking down the street, and I took a deep breath, and when I took a deep breath in and I let it out, I didn't cough,\" says Schaller.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers can infer that this drug is available from the final sentence that establishes cost. It would have been easy for the story to specify clearly that the drug is now available by prescription, with some estimate of how widespread is the use.\u00a0 Nonetheless, we\u2019ll give the story the benefit of the doubt.", "answer": 1}, {"article": "Previous surgical treatment was performed on 31 of 38 knees in the study group and 37 of the 42 knees in the control group.\n\"Our findings note that patients older than 40 may benefit from using a fresh osteochondral allograft transplantation to treat focal cartilage defects, a common cause of knee pain in adults,\" said lead author, Dennis Crawford, MD, PhD from the Oregon Health and Science University in Portland, Oregon.\nThe study group consisted of 38 patients, 10 women and 28 men who were at least 40 years of age and a control group with 42 patients (27 men and 15 women) who were 39 years of age or younger.\nThe American Orthopaedic Society for Sports Medicine (AOSSM) is the premier global, sports medicine organization representing the interests of orthopaedic surgeons and other professionals who provide comprehensive health services for the care of athletes and active people of all ages and levels.\n\"This type of osteochondral allograft transplantation has traditionally been used in younger active patients with cartilage disorders.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that \u201costeochondral allograft transplantation has traditionally been used in younger active patients with cartilage disorders.\u201d Readers can infer from this that the technique is already available, although it may not be available everywhere and not all insurers will cover these procedures.", "answer": 1}, {"article": "Lap-banding, introduced in 2001, involves separating the stomach into two sections with a band so, simply speaking, eating too much becomes more difficult.\nIn the bypass group, patients lost an average of 64 percent of their excess weight, vs. 36 percent for those in the lap-banding group.\nThere are various theories to explain why gastric bypass may be superior, including one that attributes the success to changes in hormones that control the metabolism of blood sugar.\nLater complications may include malnutrition, hernias and a tendency in about one in 10 people to regain much of the weight they lost as a result of the procedure.\nAn editorial accompanying the studies noted the results should be interpreted with caution since longer-term data is not yet available.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story did not fully explain who might be a candidate for these procedures \u2013 which is a matter of availability. A brief explanation of the criteria for weight loss surgery would have dispelled any confusion.", "answer": 0}, {"article": "Newswise \u2014 Anew gastric balloon that can be swallowed like a pill and then filledwhile in the stomach, helped patients lose more than 37 percent oftheir excess weight over four months, according to new researchpresented here at ObesityWeek 2015, the largest international eventfocused on the basic science, clinical application and prevention andtreatment of obesity.\nThe catheteris then removed, while the balloon remains in the stomach for fourmonths.\nSimilar to othergastric balloons, the most common adverse events reported were nauseaand vomiting.\nvi\n\nTheASMBS is the largest organization for bariatric surgeons in thenation.\nThe FDA also approved threeweight-loss drugs since 2012.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that the device is not yet commercially available.", "answer": 1}, {"article": "LOS ANGELES (Reuters) - Amgen Inc\u2019s experimental drug AMG145 reduced levels of bad cholesterol by as much as 55 percent in combination with statin drugs in patients genetically predisposed to high cholesterol, according to data from a midstage trial presented on Monday.\nThe most common side effects seen in the trial were injection-site reactions, cold-like symptoms and headache.\nPatients treated with a placebo saw a 1 percent increase in LDL cholesterol.\nThe disorder is estimated to affect about one in 500 people and causes extremely high cholesterol.\nAMG145, along with other PCSK9 inhibitors being developed by companies like Pfizer, Regeneron Pharmaceuticals Inc in partnership with Sanofi and Roche, is a man-made antibody.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story points out that the drug is still experimental.", "answer": 1}, {"article": "\"There is some limited evidence from my study and others that fish oil may be good for preventing breast cancer, but there is not sufficient evidence to make a public health recommendation right now,\" cautions study researcher Emily White, PhD, an epidemiologist at the Fred Hutchinson Cancer Research Center in Seattle.\nLobular breast cancer forms in the milk glands.\nDuctal breast cancer is the most common type of breast cancer and forms in the milk ducts.\nExactly how fish oil may affect breast cancer risk is not fully understood, but it may be related to its strong anti-inflammatory properties.\nIn the study, 880 women developed breast cancer during six years of follow-up.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of fish oil supplements is not in question.", "answer": 2}, {"article": "Intrarosa is marketed by Quebec-based Endoceutics Inc.\nAlthough DHEA is included in some dietary supplements, the efficacy and safety of those products have not been established for diagnosing, curing, mitigating, treating or preventing any disease.\nThe U.S. Food and Drug Administration approved Intrarosa (prasterone) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nIntrarosa is the first FDA approved product containing the active ingredient prasterone, which is also known as dehydroepiandrosterone (DHEA).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release doesn\u2019t disclose how soon consumers can expect to find Intrarosa at their local drug store. However, it does make clear that DHEA is already out on the market as a dietary supplement, although these have not been FDA approved for safety and efficacy for \u201cdiagnosing, curing, mitigating, treating or preventing any disease.\u201d\nWe feel this mention is good enough for a Satisfactory rating here.", "answer": 1}, {"article": "Taylor discovered that the study participants who received in-person cognitive behavioral treatment for their insomnia reported significantly greater improvements in sleep quality -- as determined by the sleep diaries and activity monitors -- than those who received the Internet therapy.\nBoth the in-person and Internet therapy had the exact same content, with the Internet lessons presented as audio recordings accompanied by visual graphics and animations.\nFor deployed military personnel, the side effects such as grogginess, slowed cognitive processing and slowed reaction time can be dangerous,\" Taylor said.\n\"The online program can also be done from home rather than at a military behavioral health clinic, which some service members may avoid due to concerns about stigma,\" said Pruiksma, an assistant professor of psychiatry at the University of Texas Health Science Center at San Antonio (UT Health San Antonio).\nAll completed one week of sleep monitoring by keeping sleep diaries and wearing activity monitors.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The extent to which Internet-delivered CBTi is available for military personnel or the general public isn\u2019t mentioned.", "answer": 0}, {"article": "Surgery isn't the answer for all older lung cancer patients, according to Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society.\nI thought it was a death sentence,\" he says.\nLung cancer is the second most common cancer in men and women.\nOne year after surgery, more people had died from other causes than died from lung cancer.\nPatients with heart or other health problems may not be candidates.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The surgery is clearly already available.", "answer": 1}, {"article": "But there are still a lot of unanswered questions about immune therapy.\n\"It is early days for the successes of immune therapy,\" said Mark Fishman, president of the Novartis Institutes for BioMedical Research, a research arm of drug company Novartis, which is taking a different approach to turning the immune system against cancer.\n\"We are feeling more and more confident that we are on the cusp of a treatment revolution,\" said Roger Perlmutter, president of Merck Research Laboratories, which has its own, similar drug called Keytruda.\n\"We as a lung cancer community are incredibly excited about the activity of immunotherapy in various aspects of the disease,\" said Pasi Janne, director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute in Boston.\nThere have been no other recent treatment breakthroughs in squamous cancer, which most commonly occurs in smokers or former smokers, so this advance is particularly welcome, said Janne.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that Opdivo is approved to treat advanced melanoma. And Pasi Janne, a professor at Harvard Medical School and director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, says more research is needed before \u201cpatients should be routinely treated with Opdivo\u201d and that \u201cit\u2019s a little premature to start treating people today\u2026but I don\u2019t think we\u2019re far away from that.\u201d That\u2019s all very useful context. However, it\u2019s not clear at the end of the day what any of this means for patients. Could Opdivo, given it\u2019s melanoma approval, now be used off-label to treat lung cancer? Should patients expect this treatment to become available in six months? Six years? Ten years? The story also doesn\u2019t note that the study being halted by Bristol-Myers Squibb is a Phase III trial.", "answer": 0}, {"article": "Repatha, with a list price of more than $14,000 a year, was approved based on its ability to dramatically lower \u201cbad\u201d LDL cholesterol in patients who require more intensive therapy on top of widely-used statins, such as Lipitor, or who are unable to tolerate statins.\nThe company said Repatha would be well on its way to becoming a $1 billion seller if all prescriptions written had been filled.\nThe primary goal also included need for a new artery-clearing procedure and hospitalization for angina.\nThe primary and secondary goals of the study are composites of several adverse outcomes.\nIt also said Repatha\u2019s effect on mental function was similar to placebo, likely alleviating concerns that it might impair cognition in some patients.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the drug Repatha is already on the market and available for use.", "answer": 1}, {"article": "TUESDAY, Sept. 11, 2012 (HealthDay News) -- A new device meant to help surgeons determine in the operating room if they have removed all cancerous breast cancer tissue may help reduce repeat surgeries after lumpectomy without compromising cosmetic effects, according to a new study.\nThe patients were followed for two months to see if they needed a repeat surgery.\nDoctors wait for the pathology report to find that out, which can take a week or two.\nData and conclusions presented at meetings should be considered preliminary until published in a peer-reviewed medical journal.\nIf the results are repeated in larger studies, it could be a welcome addition to doctors' techniques, she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers are told that an FDA advisory panel recommended that the FDA approve the device, which has been used for several years in Europe.", "answer": 1}, {"article": "\"There is a fear among clinicians that if you ask questions about suicide, you are giving the patient an idea that this could be an option,\" says Espiritu, \"and if you ask about guns or pills, that you are giving them some hints on how they can carry out a plan.\"\nThe rate is five per 100,000 in the organization's general population, which is well below the national average and has remained steady despite an increasing rate of suicide statewide.\nWhile the homicide rate in the U.S. has dropped 50 percent since the early 1990s, the suicide rate is higher than it was a decade ago.\n\"There is no question that the message I got from Day 1 is that they knew they could help me, and they would help me,\" Lynn says.\nThere's reason to think a full-bore effort to treat depression could reduce health costs, because untreated depression is associated with higher medical bills for chronic illnesses such as diabetes and hypertension.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that \u201cperfect depression care\u201d has been either adapted or adopted by other health systems, and names two of them. It also says that health insurers and other health systems have expressed an interest in the approach. In short, the approach is not yet in widespread use, but may eventually be adopted in additional areas. Given that the story can\u2019t be expected to incorporate a list of every health system currently using the approach, this earns a Satisfactory.", "answer": 1}, {"article": "For those with early stage breast cancer, \"lumpectomy is just as effective if not more effective than mastectomy,\" said researcher Dr. Shelley Hwang, chief of breast surgery at Duke Cancer Institute in Durham, N.C.\n\n\"There are lots of women who think the more [treatment] they do, the better they will do,\" she said.\nIn this procedure, just the tumor and some healthy tissue are removed, sparing the rest of the breast.\n\"We wanted to look at early stage disease, and those patients typically don't get radiation after mastectomy,\" she said.\nAmong the exceptions are those whose cancers are too large, or those who have different cancers in the same breast.\n\"They broke it down by year of diagnosis and by age category,\" she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "No discussion of availability of either approach, but we don\u2019t think that was necessary in this case.", "answer": 2}, {"article": "For the current study, she and her colleagues sent out questionnaires to a representative sample of about 600 office-based doctors and hospital departments around the country.\n\u201cOften a provider just does the HPV test\u201d without telling the patient.\nFirst, they might not know about the guidelines.\n\u201cA woman should know what test is being used,\u201d said Dr. Mona Saraiya, a co-author on the new study.\nThey asked doctors and staff what tests they used for cervical cancer screening and presented them with three patient scenarios.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The entire story was about cervical cancer screening being made TOO available too often.", "answer": 1}, {"article": "Surgical removal of cancerous tissue also can spur the spread of cancer in the body.\nWhile there are drugs given to patients after surgery to prevent cancer cells from adhering to each other or other tissues, these drugs do not rid the body of cancer cells or collect them to allow an assessment of the patient\u2019s status.\n\u201cWe have made a nano-sized device that we can put under the skin using an injection needle to recruit the cancer cells into a small area where we can treat them with less overall side effects to the whole body,\u201d Tang said.\n\u201cThis method is effective for both diagnosing and treating metastasis cancer and can be used in combination with traditional chemotherapy and radiation therapy,\u201d he added.\n\u201cOur cancer trap works just like a roach motel, where you put in some bait and the roach goes there and dies,\u201d said Liping Tang, UTA bioengineering professor and leader of the research.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release appears to be in conflict with itself here. On the one hand, the first paragraph talks about the patenting of an implantable medical device. On the other hand, the release also tells us that the researchers are \u201choping to move toward clinical trials in the next few years.\u201d The first paragraph may make many readers think this is a prototype that may be close to the market. But the lack of a timeline for clinical trials suggests that this could be many years away from clinical use (if it reaches clinical use at all). This lack of clarity is problematic.", "answer": 0}, {"article": "\"If you are a patient and someone says, 'There is an 85% chance of you spending $120,000 on a drug, and spending four months of your life being sick, with no benefit,' you're not going to be so excited.\"\nAll improve survival by a few months.\nNone of the new drugs works for everyone.\nPatients with a limited time to live may not be so positive, Turnham says.\nFor the first time, however, patients such as Herry have options.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The varying stages of availability of the various drugs was made clear in the story.", "answer": 1}, {"article": "\"We think it will be a very important tool in the toolbag of surgeons and physicians treating obesity and its co-morbidities,\" said Gregory S. Lea, senior vice president and chief financial officer of EnteroMedics. \"When patients leave the diet, counseling and drug world and have nothing more, they turn to surgical procedures, and only 1% to 2% of patients who might be eligible for bariatric surgery are getting it.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although vague, the story reports when the procedure will likely be available based on the best source available \u2014 the manufacturer. The main reference to availability is a quote by the company spokesperson stating that the company hopes to have successful negotiations with insurers and Medicare concluded \u201clater this year.\u201d We\u2019ll rate this sufficient for a satisfactory, but we\u2019d note that the availability will also hinge on patient shared costs and hospital and physician training and location. In addition, low income and minority populations have higher rates of obesity and higher rates of Medicaid use. State Medicaid programs will likely not cover this or will at least establish some pretty restrictive criteria.", "answer": 1}, {"article": "A complex and expensive pacemaker-defibrillator can significantly improve the chance for survival among the tens of thousands of heart-failure patients with only mild symptoms, according to a major, multiyear clinical study.\n\nThe research, regarded as likely to change medical practice, showed that the device to \"resynchronize\" the hearts of such patients lowered the death rate by 29% in such patients over 40 months, compared to those who had a standard defibrillator implanted.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story makes it clear that the device studied is in clinical trials for the targeted patient population and that a similar device is on the market. \u201cJust over a month ago, Boston Scientific won federal approval to treat mild-symptom heart-failure patients with such devices. Medtronic is seeking such approval, but already sells it for more severe heart failure patients.\u201d We would have liked to have seen some estimate of how many people have these devices implanted every year.", "answer": 1}, {"article": "Nov. 18, 2012 -- Researchers say they've been able to use nanoparticles to stop multiple sclerosis (MS) in mice that are bred to have the disease.\nWhat remains to be seen is whether the researchers have picked the right proteins that might turn off the disease in humans, he says.\nThe study was funded by grants from the National Institutes of Health, the Myelin Repair Foundation, the Juvenile Diabetes Foundation, and the Australian government.\nWhen researchers attach specific proteins to the particles, they say they're able to teach the body not to attack its own tissues.\nIt\u2019s rational, but we won\u2019t know until we get it into people,\u201d says Coetzee, who was not involved in the research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this is an experimental treatment being tested in mice and says, perhaps optimistically, that trials in humans would be at least two years away.", "answer": 1}, {"article": "DOI: 10.4172/2155-6105.1000290 \n\nhttp://www.\nThe results, published in the Journal of Addiction Research & Therapy, show that 66 per cent of respondents reported an improvement in respiratory symptoms, 29 per cent reported no change and 5 per cent reported worsening.\nFor more information, please contact: \n\nJoel Winston \n\nPublic Relations Manager (School of Medicine and Dentistry) \n\nQueen Mary University of London \n\nj.winston@qmul.ac.uk \n\nTel: +44 (0)20 7882 7943 / +44 (0)7970 096 188\n\n* Research paper: 'Changes in the Frequency of Airway Infections in Smokers who Switched to Vaping: Results of an Online Survey'.\nSenior author Professor Peter Hajek from QMUL said: \"There is no doubt that e-cigarettes are much safer than conventional cigarettes, but smokers are still led to believe that they're dangerous.\nDespite the limitations, the researchers say that the study provides a reasonable reassurance that vaping does not promote respiratory infections and may in fact reduce them.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "E-cigarettes are widely available at nearly every drug store and gas station convenience store in the United States and are widely available in the\u00a0 UK where the study was conducted. The release could have mentioned that, in the U.S. at least, new rules require buyers to be at least 18 years old to purchase them.", "answer": 2}, {"article": "Sales of herbal cleansing products tripled last year to $28 million, according to Spins, a market research company.\n\"When I'd come home from work, I'd be very tired and have to go take a nap for like an hour and a half,\" Rick said.\nLike many on the various detox plans, she couldn't stomach the all-liquid diet and craved solid food.\nIt includes no caffeine, sugar, animal products, gluten or alcohol.\n\"If you need to get into a dress in two weeks, you'll lose weight,\" Roslin said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The \u2018treatments\u2019 mentioned ranged from concoctions you could prepare yourself with ingredients in your kitchen to products you could purchase on-line or at a local drug store.", "answer": 1}, {"article": "(Reuters) - Medtronic Inc, a manufacturer of pacemakers, heart stents and spine products, has developed a device to tackle another common health problem: erectile dysfunction.\nIt is the inception of an entirely new way of treating ED that has never been seen before,\u201d he said.\nThere are an estimated 30 million men in the United States who have ED and 300 million worldwide.\nThere were no adverse events reported up to three months later, but Rogers acknowledged that risks may become evident much later.\nThe medical device maker said it completed an initial feasibility study of 30 men, average age of 60, who suffered from erectile dysfunction (ED).\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was clear that \u201cit could be several years before Medtronic undertakes a much larger late-stage trial\u201d and that \u201cthis is still investigational.\u201d", "answer": 1}, {"article": "Sept. 17, 2010 -- The FDA has approved Krystexxa (pegloticase) for the treatment of gout.\nThe drug is administered to patients every two weeks as an intravenous infusion.\nThe condition is associated with obesity, high blood pressure, high cholesterol, and diabetes.\nThe drug is associated with some serious side effects.\nKrystexxa, which is made by Savient Pharmaceuticals Inc. of East Brunswick, N.J., is an enzyme that lowers uric acid levels by metabolizing it into a chemical that does not cause bodily damage and is then passed through the urine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is about new FDA approval of the drug.\u00a0 It notes that the manufacturer expects it to be available by prescription later this year. ", "answer": 1}, {"article": "But therapies have been improving steadily.\n``The proof of the pudding is always what happens when you give it to people and look at what the potency of the antiviral effect is,\" said Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.\n``We can, once again, get control of virus replication in patients with the most advanced disease who are resistant to other drugs and really have a major impact on the course of disease and on survival in these patients,\" said Kuritzkes, who is a paid consultant to Panacos.\nIn 2003, roughly 1.2 million Americans lived with acquired immune deficiency syndrome, and another estimated 40,000 Americans are newly infected with the human immunodeficiency virus each year, according to the Centers for Disease Control and Prevention.\nThe therapy is exciting, AIDS specialists say, even though it is at least three years from market, because it could offer a completely new tool to combat a 25-year-old foe.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The drug, bevirimat, is derived in part from the herb syzigium claviforum. This herb is currently used in traditional Chinese medicine to treat diarrhea and stop bleeding. Bevirimat is a manufactured drug, using certain components of this herb to potentially inhibit HIV replication. The story does mention that the drug is at least 3 years from market and still in early clinical trials.", "answer": 1}, {"article": "In effect, those guidelines say there's no particular benefit from working out harder, other than saving time.\n(It's unclear whether the 9 percent improvement seen will be enough to cut their risk of heart disease, though.)\nNow we have some answers: You may want to go just a tad longer and harder than you'd thought.\nBut there was also a benefit from going just a bit faster: Only participants in the higher-intensity group saw an improvement in glucose tolerance, a risk factor for heart disease.\nAt the end of the study, members of all three exercise groups lost an average of about 2 inches from their waist circumference.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Walking and other forms of exercise are widely available for most. As noted above, however, some mention of the cost of a gym membership would have been helpful in a story like this.", "answer": 1}, {"article": "When treating a patient suffering from depression, Brent Forester considers which anti-depressant to prescribe\u2014ideally, one that will ease psychic pain without side effects.\n\nIt can be a tough call.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that the test, marketed as GeneSight, is available.", "answer": 1}, {"article": "The difference?\nIt\u2019s a process, but hormone replacement therapy is helping women have a better life in an era when they live longer.\u201d\n\nJohnson, Firouzbakht and other experts will tell you that hormone therapy protects against heart disease, a much more common killer of women than breast cancer, as well as against dementia, colon cancer, osteoporosis and other health issues.\nIf a doctor won\u2019t work with you, then find another doctor,\u201d says Dr. Marina Johnson, a Dallas endocrinologist and pharmacist and author of Outliving Your Ovaries: An Endocrinologist Weighs the Risks and Rewards of Treating Menopause With Hormone Replacement Therapy.\nIt\u2019s no longer that you need to stay away from hormone replacement therapy, it\u2019s that you need to use it wisely.\u201d\n\nThat wisdom comes from a careful medical assessment and ongoing surveillance of blood pressure, blood work, breast changes, side effects and effectiveness.\nDr. Noushin A. Firouzbakht, an obstetrician-gynecologist at Texas Health Harris Methodist Hospital Fort Worth, says that despite the alarm provoked by the Women\u2019s Health Initiative study, much was learned, especially about the ideal candidate for hormone replacement.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "HRT is available from your doctor, but at the end of the article, there is a statement that Dr Firouzbakht \u201cprescribes pharmaceutical hormones and also works with a pharmacy she trusts to develop bio-identical hormone combinations for some patients. Such custom compounds are not FDA-approved.\u201d The article goes on to state:\n\u201cIt doesn\u2019t matter what formulation of the hormones you are using, it\u2019s the surveillance of it all that is very important,\u201d Firouzbakht says.\nThese statements are confusing about the actual availability of HRT and hormones and dismisses the importance of FDA approval.", "answer": 0}, {"article": "This abstract can be found at sirmeeting.org.\n\"A majority of our patients with osteoarthritis of the knee saw significant pain reduction, not only just a few days after the procedure, but a month after as well, making this an accessible treatment for patients looking to improve their quality of life without surgery,\" said Sandeep Bagla, M.D., director of interventional radiology at the Vascular Institute of Virginia and lead author of the study.\nOne month later, researchers followed the progress of eight patients and found that GAE significantly decreased pain (-58 mm on the Visual Analog Scale), reduced stiffness and increased physical function (-36.3 on the Western Ontario and McMaster University Osteoarthritis Index).\nLOS ANGELES (March 19, 2018)--A nonsurgical treatment could improve quality of life for patients with knee pain due to osteoarthritis, according to new research presented today at the Society of Interventional Radiology's 2018 Annual Scientific Meeting.\nBut GAE provides another option for patients struggling with pain and may even allow patients to avoid the painful recovery of knee surgery and the need for the kind of opioid pain medications associated with the dangerous epidemic in the United States.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is confusing for readers on this point. The release suggests that GAE is an intervention already in current use when it states:\n\u201cInterventional radiologists perform GAE for knee pain by inserting catheters through a pinhole-sized incision, blocking the very small arteries or capillaries within the lining of the knee, reducing the inflammation caused by osteoarthritis. As an outpatient treatment, GAE does not require open surgery or physical therapy, and takes 45-90 minutes to perform.\u201d\nHowever, further down in the release its noted that the procedure has \u201conly been used in a clinical trial setting.\u201d", "answer": 0}, {"article": "Bianchi said one study had estimated the blood test costs about 255 pounds in the UK (about $413), all included.\nSome European hospitals already rely on the method, called cell-free fetal DNA, although it\u2019s not available from doctors in the U.S.\n\n\u201cWhat they are finding in England is that many women are not going on to have the invasive tests,\u201d Bianchi told Reuters Health.\nThat leaves some room for error, which could be important if parents are making medical decisions based on the results \u2014 such as whether or not to get an invasive procedure to look for genetic disorders.\nBecause such disorders mostly strike boys, knowing that the baby is a girl could spare the mother diagnostic procedures, such as amniocentesis, that carry a small risk of miscarriage.\n\u201cRemember, gender is not a disease.\u201d\n\nThe test looks for small pieces of the male sex chromosome in the mother\u2019s blood, which would mean she is carrying a baby boy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The test to determine fetal gender is available in the United States, as an unregulated procedure outside a doctor\u2019s purview. The Reuters story does not mention this. The competing NY Times story was explicit on this.", "answer": 0}, {"article": "The test measures five chemicals in the breath.\nThis study suggests that we may be able detect these differences and use a breath test to indicate which patients are likely to have cancer of the esophagus and stomach, and which do not,\" he explained.\nThis method is expensive, invasive and has some risk of complications,\" study author Dr. Sheraz Markar said in an ECC news release.\nEach year, 1.4 million cases of cancer of the stomach and esophagus (the tube leading from the throat to the stomach) are diagnosed worldwide.\n\"A breath test could be used as a noninvasive, first-line test to reduce the number of unnecessary endoscopies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a good job here. It not only notes that \u201cthe test needs to be validated in a bigger group before it could be used on patients,\u201d but makes clear that the study findings were presented at a conference. Further, the story explains that \u201cStudy results presented at meetings are generally considered preliminary until they\u2019ve been published in a peer-reviewed journal.\u201d That\u2019s valuable context for readers.", "answer": 1}, {"article": "TUESDAY, March 20, 2018 (HealthDay News) -- Tiny pellets could treat arthritic knee pain, delaying the need for knee replacement surgery, a small study has found.\n\"This therapy is very well-targeted to that particular mechanism, and certainly it should be investigated further,\" said Vedantham, who wasn't involved with the study.\nThe small pilot study -- the first U.S. clinical trial of this procedure -- involved 20 patients with moderate to severe arthritis pain.\nOnly 13 had undergone the procedure by the time of Monday's annual meeting, and only eight had made it to the one-month follow-up, Bagla said.\n\"It's an outpatient procedure, and no physical therapy is required before or after this procedure,\" he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does acknowledge the need for further research. But this is a bit of an extreme case, in terms of how preliminary the research is, and so we feel the story should have made it very, very clear that we have no idea how this will pan out. Another more skeptical source would have helped on this one.", "answer": 0}, {"article": "\"Strikingly, these fasting-stimulated changes in the growth of vascular cells and subsequent immune alterations occur even after a single cycle of 24-hour fasting, and are completely reversed when mice start eating again,\" adds Yun Hye Kim.\nSuch fasting already shows benefits after only six weeks.\nA type of white blood cell known to play a role in fighting inflammation is triggered.\nTheir glucose and insulin systems also remained more stable.\nThere are changes in certain gene pathways involved in the immune system and the body's reaction to inflammation.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Fasting is widely available.", "answer": 2}, {"article": "\"A lot of the time, people have quite painful and challenging experiences revisiting the trauma, and [MDMA] can help them do it without being overwhelmed or numbed out,\" he says.\nThis was the first clinical trial to explore the therapeutic potential of MDMA since the drug was outlawed in 1985, and the researchers required the permission of the National Institutes of Health, the Food and Drug Administration , and the Drug Enforcement Administration.\nThe drug MDMA\u2014better known by its street name, Ecstasy\u2014may be illegal, but a new study suggests that it\u2019s also a promising treatment for post-traumatic stress disorder.\nThe study, which appears in the Journal of Psychopharmacology, included 20 people with PTSD stemming from traumas such as sexual assault and combat stress.\nThe use of MDMA in psychotherapy has been studied for decades, but research in the U.S. all but ground to a halt after the drug became illegal.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The first sentence states that \"The drug MDMA\u2014better known by its street name, Ecstasy\u2014may be illegal, but a new study suggests that it\u2019s also a promising treatment for post-traumatic stress disorder.\" The story underscores the point several times that the drug is illegal and currently unavailable for therapeutic use.", "answer": 1}, {"article": "Panel Says Aspirin Lowers Heart Attack Risk For Some\n\nMillions of Americans take baby aspirin every day to prevent a heart attack or stroke.\n\"With all the good therapies, better blood pressure control, better cholesterol control, all the things we do in modern medicine,\" he says, \"over the last couple of decades, we've had nearly a 50 percent reduction in the rate of cardiovascular disease.\"\nIf people don't have a significantly increased risk of having a heart attack or stroke over the next decade, Nissen says, they may be \"causing more harm than benefit.\"\nSeveral groups including the American Heart Association offer online calculators to help people figure out their risk, which, along with discussion with a health care provider, can help determine whether daily aspirin might be useful.\n\"It's just not prudent or safe,\" he says, noting that bleeding in the abdomen or brain is extremely dangerous and can be fatal.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Low-dose aspirin is readily available, of course, and the story makes this clear. \u00a0The story suggests that the typical healthy American NOT avail him/herself of this resource.", "answer": 1}, {"article": "+3582944 54542\n\nIntake of fermented and nonfermented dairy products and risk of incident CHD: the Kuopio Ischaemic Heart Disease Risk Factor Study Timo T. Koskinen, Heli E. K. Virtanen, Sari Voutilainen, Tomi-Pekka Tuomainen, Jaakko Mursu, Jyrki K. Virtanen.\nSour milk was the most commonly used low-fat fermented dairy product.\nAll the mechanisms are not understood yet, but they may be linked to compounds forming during the fermentation process.\nDuring this follow-up, 472 men experienced an incident coronary heart disease event.\nLower consumption levels were not associated with the risk.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Fermented dairy products are widely available and the news release does clearly outline several types.", "answer": 1}, {"article": "And there's another potential problem with existing treatments.\nFor now, much of the attention in the world of liver disease is on two drugs -- telaprevir and boceprevir -- that Schiff expects will become available within the next year and a half.\nThe side effects, particularly of the treatment component known as interferon, can be \"pretty hard to deal with,\" said Nicholas A. Meanwell, a co-author of the study and a researcher with the Bristol-Myers Squibb pharmaceutical company.\nIt's too early to tell if the drug actually works, and it will be years before it's ready to seek federal approval to be prescribed to patients.\nThe greater possibility of a cure and fewer side effects, in turn, will lead more people who think they have hepatitis C to \"come out of the woodwork,\" said Schiff, who's familiar with the study findings.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story\u00a0points out that BMS-790052 is in an early phase testing and nowhere near being available to patients, it improperly relayed\u00a0the prediction of a researcher who said that\u00a0two other investigational drugs were expected to become available by 2011. The prediction is especially troubling given the undisclosed financial ties between the researcher and the manufacturers of the investigational agents (see source/conflict of interest criterion below). ", "answer": 0}, {"article": "At dinner one recent evening at their yellow brick townhouse in the Georgetown neighborhood in Washington, his wife, Pura, admitted to worrying, but said, \u201cWe don\u2019t talk about it a lot.\u201d She served Indian takeout \u2014 saffron rice, tandoori chicken, eggplant.\nOtherwise, lots of people would have early heart disease but no obvious risk factors.\nOr the change might be in a poorly understood region of DNA that controls genes rather than in a gene itself.\nSo he left for the gym before dawn on a recent chilly morning.\n\u201cOur main job is to find the gene,\u201d Dr. Biesecker said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. Any\u00a0tests or treatments based on this research are many years away.", "answer": 2}, {"article": "At the end of six months, LDL cholesterol was cut 81 milligrams per deciliter (mg/dl) of blood to 45 mg/dl, a reduction of about 40 percent.\nIn the new trial, anacetrapib actually showed a tendency toward fewer cardiovascular problems and fewer angioplasty or bypass procedures, although the study only lasted 18 months.\n\"Torcetrapib raised HDL astoundingly but that was entirely neutralized by the increase in cardiovascular events.\"\nOther experts are intrigued by the findings, but note that the research is still in very early stages.\nStill, he added, \"the trial demonstrated safety and it demonstrated a tremendous effect on altering the lipid profile in a good direction.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story points out that anacetrapib still must be tested in a large clinical trial and is years away from being considered for approval.", "answer": 1}, {"article": "The page you are looking for has either moved or is not available (error 404).\n\nPlease return to the homepage or use the search box above to see if the page is available in a new location.\n\nIf you think this message is in error or need assistance, please email the webmaster.", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s understood that the drug is already being used in sickle cell treatment and is FDA approved.", "answer": 1}, {"article": "Newly postmenopausal women who received estrogen via a skin patch had reduced beta-amyloid deposits, the sticky plaques found in the brains of people with Alzheimer\u2019s disease, a Mayo Clinic study published this month in the Journal of Alzheimer\u2019s Disease found.\nIn the U.S., the average age of menopause is 51.\nResearchers investigated the brain amyloid deposition in 68 women ages 42 to 59 who participated in the Kronos trial during this critical window.\nThe researchers used positron emission tomography, also known as a PET scan, to look for the brain amyloid deposits three years after the trial ended.\nA rapid decline in estrogen with menopause may be associated with an increased risk of Alzheimer\u2019s disease risk in women.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that numerous estrogen supplements \u2014\u00a0 including those delivered via patch \u2014 are readily available.", "answer": 2}, {"article": "Examining more than 500,000 Facebook posts from both groups, researchers determined which words, post lengths, frequency of posting and timing of posts were most associated with a depression diagnosis. They found people with depression used the words \"I, my, and me,\" as well as such words as \"hurt, tired, and hospital,\" more often than others in the months preceding their diagnosis. Using indicators such as these, they built a computer model that could predict which people would receive a depression diagnosis with comparable accuracy to commonly used clinical surveys.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the social media diagnostic model is not close to being viable for clinical use.", "answer": 1}, {"article": "George E. Jordan may be reached at gjordan@starledger.com or (973) 392-1801.\n\"It is still possible that CETP inhibitors without off-target effects of torcetrapib could be viable as a therapy for cardiovascular disease,\" said an editorial published in today's edition of the New England Journal of Medicine, which concluded: \"It is possible that CETP inhibition might be better suited to certain subgroups of patients, such as those with impaired clearance of LDL cholesterol or low levels of HDL cholesterol at base line,\" the editorial said.\nThe study said there were still many unanswered questions about Pfizer's pill, torcetrapib, the first in a new class of heart medicines known as a CETP inhibitors, which raise HDL, or good cholesterol, and lower LDL, or bad cholesterol.\n\"In any case, it is premature to announce the death of CETP inhibitors on the bases of the torcetrapib experience alone.\"\nThe study suggested a \"clean\" version of torcetrapib could increase so-called good cholesterol without raising blood pressure and causing adverse cardiovascular events.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that the HDL-targeting drugs are still in the early stages of development. The story does not make any claims about when a new drug would be available, however whether it will ever happen is still highly theoretical. However, atorvastatin was studied along with torcetrapib and a note that it is available commercialy and is the largest selling cholesterol lowering drug would have been useful to the readers.", "answer": 1}, {"article": "Feb. 15, 2011 -- Taking zinc, either as a syrup or lozenge, through the first few days of a cold may shorten the misery of an upper respiratory infection, a new research review shows.\n\u201cThe evidence from the recent trials does support the use of zinc lozenges in treatment of common cold,\u201d says study researcher Meenu Singh, MD, a pediatric pulmonologist at the Post Graduate Institute of Medical Research in Chandigarh, India.\n\u201cWe really don\u2019t have interventions for colds that work.\u201d\n\nThe review of 15 studies with 1,360 participants was published by the Cochrane group, an international collaboration of researchers that reviews evidence behind therapeutic interventions.\n\u201cThis is great news,\u201d says Kay Dickersin, PhD, an epidemiologist with the Johns Hopkins School of Public Health and director of the U.S. Cochrane Center.\nThe review also found that zinc cut the number of days that kids missed school because of being sick and reduced the use of antibiotics by cold sufferers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not make it clear where zinc treatments are available. One could assume that most readers would know, but we think the Reuters Health story did a better job here by actually pointing out that zinc lozenges are sold in most drug stores and even adding the important detail that a specific zinc nasal spray, Zicam, was removed from the market.\u00a0To its credit however, the story does emphasize that additional research is needed to identify the right zinc preparation and dose.", "answer": 0}, {"article": "The process can take several years.\n\"These findings need to be replicated in larger trials, and you have to be able to predict whether improved heart function from cimaglermin will help people live longer and feel better,\" she noted.\nTUESDAY, Dec. 27, 2016 (HealthDay News) -- Heart failure patients have weakened hearts, but researchers say an experimental drug used for the first time in humans may repair heart cells and improve heart function.\nThe study was funded by Acorda Therapeutics, the maker of cimaglermin, and the report was published online Dec. 26 in the journal JACC: Basic to Translational Science.\n\"It's a remarkable thing that you could give a drug once and have it affect heart function three months later -- it's really extraordinary,\" she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll rate this category satisfactory, given that the story admits that it is reporting on a phase one trial, and includes the following information:\n\u201cBefore cimaglermin could be used to treat patients, it must prove its worth in a series of progressively larger and challenging trials and then be approved by the U.S. Food and Drug Administration. The process can take several years.\u201d", "answer": 1}, {"article": "June 22, 2010 -- Drinking lots of coffee probably isn't entirely good for you, but it does lower your risk of mouth and throat cancer.\nInterestingly, the protective effect of coffee was not diminished in drinkers and smokers.\nThe protection was seen for oral and pharyngeal cancer, but not for cancer of the larynx.\nDrinking less than five cups of coffee a day had a smaller but statistically significant protective effect: about 4% lower odds of mouth and throat cancer for each cup drunk daily.\nGaleone and colleagues note that coffee contains more than a thousand chemicals.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable \u2013 the availability of coffee is not in question. ", "answer": 2}, {"article": "Newswise \u2014 SAN FRANCISCO \u2013 A diet rich in vitamin C could cut risk of cataract progression by a third, suggests a study being published online today in Ophthalmology, the journal of the American Academy of Ophthalmology.\nThe fluid inside the eye is normally high in vitamin C, which helps prevents oxidation that clouds the lens.\nAbout the American Academy of OphthalmologyThe American Academy of Ophthalmology is the world\u2019s largest membership association of eye physicians and surgeons.\nOur EyeSmart\u00ae program is a preeminent source of eye health information for the public and empowers people to preserve their vision.\nParticipants answered a food questionnaire to track the intake of vitamin C and other nutrients, including vitamins A, B, D, E, copper, manganese and zinc.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that Vitamin C-rich foods are widely available, although in different types and costs, so we rated that Not Applicable.", "answer": 2}, {"article": "Strawberries have the potential to prevent esophageal cancer, according to a preliminary study released Wednesday.\n\nResearchers, led by Ohio State University, were able to show that freeze-dried strawberries slowed the growth of dysplastic, or precancerous, lesions in about 30 people who consumed the fruit for six months.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of strawberries is not in question. The story notes that a strawberry-industry-funded agency supplied the fruit for the study.\u00a0 One online commenter on the WSJ site wrote, \u201cIf you need someone to \u2018contribute\u2019 strawberries for research .. you already know the outcome.\u201d", "answer": 2}, {"article": "The subjects were divided into two groups.\nThe clinical trial was a randomized, double blinded study of 24 adult males who smoked 11 or more cigarettes per day, indicating a high level of nicotine dependence.\nFor example, 75% of all smokers reach for their first cigarette within 30 minutes of waking up.\nThe Chrono Solution is designed to deliver the first dose of nicotine replacement therapy (NRT) shortly before a smoker wakes up and then creates a pattern of \"peaks and troughs\" of nicotine delivery throughout the rest of the day to assure the smoker has more nicotine support when cravings are predicted to be strongest.\nIn fact, most people try 8 to 10 times and this includes quit attempts with standard cessation medications like nicotine patch and gum and prescription drugs like varenicline,\" said Alan Levy, Ph.D., chairman and CEO of Chrono Therapeutics.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There is no mention of the availability of this device, such as next steps in testing or application for FDA approval. The news release also does not discuss whether this device would require a prescription.", "answer": 0}, {"article": "If that feels a little onerous, consider new findings out of Baylor College of Medicine in Houston suggesting that love of physical activity may start in the womb.\nThe research in question involved mice, not women.\nThe offspring of those mothers turned out to be about 50 percent more physically active than those born to mothers that hadn\u2019t had the exercise wheel option.\n\u201cI think our results offer a very positive message.\nThe mice with running wheels voluntarily ran an average of more than six miles a night, decreasing to about two miles late in pregnancy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Running as an activity is presumably accessible to\u00a0women.", "answer": 2}, {"article": "Italian researchers conducted a phase three study that included 281 women with breast cancer, aged 18 to 45 years and who had not experienced menopause.\nWhile most breast cancer is diagnosed at later ages, about 6% of women learn that they're ill before age 40 - when they are still of childbearing age.\nAn accompanying editorial by Dr. Hope S. Rugo and Dr. Mitchell P. Rosen of the University of California-San Francisco says that trptorelin therapy should not be recommended as a standard treatment and should be approached with caution in women with hormone-sensitive disease.\nAmong the women who had received triptorelin, the rate of early menoapuse was 8.9%, which is 17% lower.\nEarly menopause is often a side effect for women treated with chemotherapy for breast cancer, but a new study reveals some guarded promise for preventing early menopause breast cancer patients.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There is no statement in the article as to availability of the treatment, although the information is correctly identified as arising from a \u201cphase three study.\u201d But are readers really supposed to know what a Phase Three study means?\u00a0 Want to do a reader poll to test how many do?", "answer": 0}, {"article": "Zarate and his colleagues had previously demonstrated that ketamine shots helped some patients with treatment-resistant unipolar depression, meaning they did not cycle through manic episodes.\nIn the US, research is continuing on the drug, he added, and some physicians are likely trying the drug in their patients with bipolar illness or depression who aren\u2019t helped by standard treatments.\nBut, according to Zarate, more research is needed on how to use the drug in the safest and most effective way.\nIn 1999, US regulators classified ketamine as a Schedule III controlled substance, meaning it has the potential for abuse but is also useful medically.\nAnd as a person waits for their medications to kick in, he added, they will continue to have difficulty working and coping with social and family life; they may even be having thoughts of suicide.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that ketamine is not currently widely prescribed for depression but that it is available for other purposes, thereby lending itself to off label use.\u00a0", "answer": 1}, {"article": "And the results, just published by The Cochrane Library, are likely to disappoint people who swear by vitamin C.\n\nAccording to their analysis, daily vitamin C basically had no effect on the incidence of the common cold in the general population, except for very specific groups of people, all of them small groups.\nPreventing colds just isn't one of them.\nFor women, it's 75 milligrams.\nIt makes us look toward other methods, aside from vitamin C, Senay concluded.\nFor adult males, the recommended amount is 90 milligrams per day.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Vitamin C supplements are widely available.", "answer": 1}, {"article": "CHICAGO (Reuters) - A study in rats and monkeys suggests an experimental Merck & Co sleep drug may help induce sleep without causing the memory loss and attention problems sometimes seen in the commonly used drugs Ambien and Lunesta, company researchers said on Wednesday.\nThe most common side effects from Suvorexant have been headache and sleepiness.\nLevels of this compound rise during the day and fall at night.\nIn the study, rats given GABA blockers were less likely to recall the objects than those given DORA-22.\nInsomnia affects about 10 percent of U.S. adults, and roughly a third of these individuals take drugs to help them sleep.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that Merck has applied for FDA approval of a similar drug.", "answer": 1}, {"article": "For further information, please contact:\n\nThis information was brought to you by Cision http://news.cision.com\n\nThe following files are available for download:\nThe results of our study clearly support the use of SBRT for elderly patients, especially those who may not be able to tolerate longer courses of radiotherapy or more invasive treatment options,\" says Meredith Giuliani, MBBS, FRCPC, MEd, a radiation oncologist in the Cancer Clinical Research Unit at Princess Margaret Cancer Centre, University Health Network in Toronto and lead study author.\nTo date, they have accumulated data on close to 1,200 such patients and identified medical and technical factors that affect tumor control and toxicity.\nStudy results show no significant differences among the three age groups with respect to 2-year local recurrence, regional recurrence, distant metastases or the incidence of grade 3 or higher toxicity.\nThe results, which were based on data from more than 1,000 patients across five institutions that comprise the Elekta Lung Research Group, are available online and will be published in the July 15 print issue of International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the release that the treatment is available at the five sites that participated in the observational study, but whether it is available outside of major academic cancer treatment centers isn\u2019t spelled out.", "answer": 0}, {"article": "(CNN) Corey Thomas admitted to his pharmacist that he hated the blood pressure medications a previous doctor had prescribed for him.\nThe history of barbershops as havens for health\n\nIn the years to come, as racial segregation laws limited the spaces where black Americans could gather, the barbershop served as a safe meeting space for the black community.\nBy the end of the study, the researchers found that the barbers' role in encouraging the men to monitor and improve their health resulted in a significant reduction in blood pressure, when coupled with medication from the pharmacists.\nShape your hair and your blood pressure\n\nThe new study included 319 black men across 52 black-owned barbershops in California's Los Angeles County.\nAdditionally, more research is needed to determine whether similar study results would occur on a national level, since the study was conducted only in the Los Angeles area.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that this research was conducted in the Los Angeles area and cautions that a national study would be needed to show the approach\u2019s applicability in other locales. Readers would not assume that this kind of health care assistance was available in black-owned barber shops elsewhere.", "answer": 1}, {"article": "\"Although there was no significant difference in either physician visits or antibiotic use, as might be expected over only a 6-month follow-up period, our findings concerning consultations are important in the longer term, given antibiotic use increases the risk of antimicrobial resistance.\"\nSteam inhalation did not appear to alleviate symptoms of sinusitis.\nPatients who were instructed to use nasal irrigation showed improvement at 3 and 6 months, as measured by the Rhinosinusitis Disability Index.\nMore than 25 million people in the United States and about 2.5 million Canadians suffer from chronic rhinosinusitis, or sinus infection, and experience compromised quality of life.\nTo alleviate symptoms, steam inhalation and nasal irrigation are widely suggested as an alternative to common treatment with antibiotics, which are often not effective and contribute to antibiotic resistance.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Nasal irrigation and steam are both widely available.", "answer": 2}, {"article": "Foods to avoid\n\n Dairy: Milk, ice cream, yogurt, cottage and ricotta cheeses (except for lactose-free versions)\n\n Fruits: Apples, peaches, pears, watermelon, cherries, figs\n\n Vegetables: Garlic, onions, leeks, asparagus, cauliflower or large servings (more than \u00bd cup) of broccoli and Brussels sprouts\n\n Grains: Wheat (except in sourdough bread), rye, barley\n\n Legumes and nuts: Cashews, kidney beans, soy beans and soy milk\n\n Sweeteners: Honey, fructose, xylitol, agave syrup\n\nFoods to include \n\n Dairy and dairy substitutes: Kefir, almond milk, coconut milk\n\n Fruits: Bananas, blueberries, grapes, oranges, strawberries\n\n Vegetables: Carrots, green beans, bell peppers, potatoes, tomatoes\n\n Grains: Rice, oats, gluten-free bread (but check labels for high-FODMAP ingredients)\n\n Legumes and nuts: Peanuts, pecans, walnuts\n\n Sweeteners: Cane sugar, aspartame, stevia\n\u201cOur goal is for them to be on the most varied, nutritious diet possible.\u201d\n\nThe trickiest part is avoiding onions and garlic, the dietitians say.\nIt found that 52% of low-FODMAP patients and 41% of patients on a less-restrictive diet reported \u201cadequate relief.\u201d The difference was not statistically significant, says study co-author William Chey, a professor of gastroenterology.\nThe diet is aimed primarily at people with irritable bowel syndrome, a common condition in which abdominal pain and irregular bowel habits \u2014 with diarrhea, constipation or both \u2014 can wax and wane for years.\nShe credits the diet, along with medication, with a big reduction in her symptoms, but says \u201cit has not been a miracle cure.\u201d\n\nThe diet has generated enough interest to prompt some food companies to introduce low-FODMAP products \u2014 hoping for a market surpassing that for gluten-free foods, according to some industry reports.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The text offers links to online explanations of the diet, as well as to lists of foods that would be eliminated initially as part of it. Anyone could give this a try, though the article recommends that IBS sufferers implement the diet under a dietitian\u2019s supervision.", "answer": 1}, {"article": "Finzi notes previous studies show between 50 to 60 percent of patients may benefit from the treatment.\nCosts vary widely, but the American Society for Aesthetic Plastic Surgery said the average price for a Botox treatment in 2016 was $376.\n\u201cI found overall my mood was better on a day-to-day basis,\u201d she said.\n\u201cOur hope is eventually it will form a place as one of the tools to treat depression,\u201d he said.\nWhile Botox is commonly used for cosmetic purposes, doctors say the reasoning behind the treatment for depression may not be what you expect.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "No statement is made about the availability of botox, but readers can reasonably\u00a0assume that it will continue to be widely available.", "answer": 2}, {"article": "Their improvement was significantly more than the average seen in patients taking just medication, he said.\n\u201cIf out of 10 years the patients have left to live we can keep them at home in a relatively mild state of the disease for three, four, five years, it\u2019s a lot.\u201d\n\nAccording to Alvaro Pascual-Leone, director of the hospital\u2019s Berenson-Allen Centre for Non-invasive Brain Stimulation, brain stimulation - or transcranial magnetic stimulation - involves a very low current applied to a specific part of the brain and is approved by the FDA for treatment of a variety of ailments and diagnostic applications.\nThe device, which consists of a chair containing an electronic system and software in the back and a coil placed at the head, has been tested on mild to moderate Alzheimer\u2019s patients who suffer from dementia but are not totally dependent.\nThe device, which combines electromagnetic stimulation with computer-based cognitive training, is already approved for use in Europe, Israel and several Asian countries such as Singapore.\nTEL AVIV (Reuters) - Israel-based Neuronix, which has developed a non-invasive medical device to help to treat Alzheimer\u2019s disease, expects the system to be approved by the U.S. Food & Drug Administration in late 2014.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Mixed bag here.\nThe story explained that the the device is approved for use in several other countries.\u00a0 But it also said the company \u201cexpects the system to be approved by the U.S. Food & Drug Administration in late 2014.\u201d\nNo basis for that projection was given.\u00a0 Later the story stated that \u201cUS trials are expected to run till the end of 2013.\u201d\nSo the entire projection of approval and availability is based on a hope and a prayer and a crystal ball of unknown clarity and certainty.", "answer": 0}, {"article": "Gonzalez said the new trial addressed a serious medical need.\n\"Even under the best current treatments, ICAD carries high rates of recurrent stroke and death, compared with other causes of stroke,\" he said.\nThe trial, led by Nestor R. Gonzalez, MD, professor of Neurosurgery and director of the Neurovascular Laboratory at Cedars-Sinai, enrolled 52 patients with severe brain atherosclerosis, also known as intracranial atherosclerotic disease, or ICAD, who showed symptoms of either a recent stroke or a mini-stroke, called a transient ischemic attack.\n\"This clinical trial moves us significantly closer to preventing strokes and death in high-risk populations,\" said Keith Black, MD, professor and chair of the Department of Neurosurgery.\nAfter one year, 9.6 percent of the patients treated with the surgery experienced another ischemic stroke or died, compared with 21.2 percent of patients in a matched control group who received only intensive medical management.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This procedure is currently available, as explained here:\u00a0 \u201cEDAS has been used for moyamoya disease, a rare cerebrovascular disorder that affects younger patients.\u201d However,\u00a0 there are relatively\u00a0few facilities that treat moyamoya disease.\u00a0 Saying how many sites have the ability and expertise to do the EDAS procedure would\u00a0have been more helpful.", "answer": 0}, {"article": "Cowen & Co estimates that use of DNA blood tests for cancer screening will exceed $10 billion a year by the end of the decade.\n\u201cFor any given test, the rate of false positives causing unnecessary alarm and false negatives that provide false security should be known,\u201d said Dr. Keith Stewart, an oncologist who heads Mayo Clinic\u2019s Center for Individualized Medicine.\nBut the move by Pathway, a privately owned maker of genetic tests ranging from cancer risk and heart health to drug response, underscores a growing debate over how much genetic information should be made available to healthy people if it is not yet clear how it can improve their health.\n\u201cIf we are relying on a test that can only detect cancer after it has formed, we miss a huge opportunity to intervene,\u201d said Dr. Scott Kopetz of the University of Texas MD Anderson Cancer Center.\nCHICAGO (Reuters) - Pathway Genomics, a company known for pushing the boundaries of direct-to-consumer genetic testing, on Thursday will launch a cancer screening test designed to detect bits of cancer DNA in the blood of otherwise healthy people.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that \u201cThe tests must be ordered by a doctor, based on a patient\u2019s risk profile.\u201d However, it\u2019s not clear that this fully describes the process. While the tests can be ordered through the patient\u2019s physician, the Pathway website also suggests that patients can order them autonomously online through Pathway\u2019s \u201conline physician network.\u201d Here\u2019s the text:\nPatients can also order CancerIntercept\u2122 Detect online through Pathway Genomics\u2019 online physician network.\u00a0After speaking with a client services representative, the patient must create a personal account with Pathway\u00a0Genomics Member Site (members.pathway.com) and enter all personal health information into the website for\u00a0physician review. It will take up to 1-2 business days for physician review, at which time a sample collection kit\u00a0will be sent to the patient\u2019s provided shipping address if the test is approved.\nThis process seems essentially to be a direct consumer purchase with the involvement of an online physician middleman \u2014 something which is not fully conveyed by the text. We\u2019ll give the benefit of the doubt since it\u2019s debatable whether the story is technically wrong on this point or not. But we wish more detail had been provided.", "answer": 1}, {"article": "Overall, research is suggesting that CT scans of people at risk of lung cancer might make a dent in cancer mortality, and it\u2019s possible that more frequent screening might make an even bigger dent, Hanley noted.\nThe data are \u201cconsistent\u201d with earlier studies but there are still many issues to resolve regarding lung cancer screening, Johnson said.\nIt is not clear when or how guidelines for lung cancer screening could be drawn up, and until they are, insurers including government programs such as Medicare are unlikely to pay the average $300 cost of a scan.\nA new study finds that regular smokers who received three-dimensional X-rays to look for the presence of early tumors had a significantly lower risk of dying over a 10-year period.\nThe three groups of people had some important differences, such as in average age and how long and heavily they had smoked, so the researchers had to use mathematical tools to try to eliminate the influence of those differences, said Hanley.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nAlthough this story does not directly address the availability of CT screening specifically designed to identify lung tumors, it does point out that such screening is generally not covered by insurance.", "answer": 1}, {"article": "People with cluster headaches can have as many as eight per day in bouts that last for weeks or months.\n\"To our knowledge, this is the first adequately powered trial of high-flow oxygen compared with placebo, and it confirms clinical experience and current guidelines that inhaled oxygen can be used as an acute attack therapy for episodic and chronic cluster headache,\" wrote Anna S. Cohen, of the National Hospital for Neurology and Neurosurgery in London, and colleagues.\nTUESDAY, Dec. 8, 2009 (HealthDay News) -- High-flow oxygen appears to be an effective treatment for cluster headaches, British researchers have found.\nThis new study included 76 adult patients, aged 18 to 70, with either episodic cluster headache (57) or chronic cluster headache (19).\nThe study found that 78 percent of patients reported being pain-free or having adequate relief within 15 minutes of receiving high-flow oxygen, compared with 20 percent of patients after they received high-flow air.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says high-flow oxygen is in \"limited use\" to treat cluster headaches. But it fails to say where or how it is available \u2013 or even what \"limited\" really means.\u00a0 Two places in the US?\u00a0 Twenty?\u00a0 ", "answer": 0}, {"article": "\"The study by Schwartz and colleagues in this issue of JAMA Pediatrics adds to a growing body of evidence supporting the importance of providing drinking water access in schools.\n\"Even a small, straightforward, relatively inexpensive policy intervention was associated with a small but statistically significant drop,\" Elbel told CBS News.\nModern water dispensers may be more effective than old-fashioned water fountains since water quality and cleanliness may deter kids from using older fountains, and they're not as efficient at serving large numbers of children, experts noted in an accompanying editorial.\nThe large, clear, electrically cooled jugs with a push lever for fast dispensing were placed in 483 school cafeterias, about 40 percent of schools during the 2008-2009 and the 2012-2013 school years.\nWater jets also were linked with a decrease in the amount of half-pints of milk students bought, which could be a potential mechanism of weight reduction, the researchers found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of water dispensers is not in question, which is why we rate this Not Applicable.", "answer": 2}, {"article": "Previous attempts to find an Alzheimer's vaccine either caused harmful side effects, such as brain inflammation, or used less effective approaches, she said.\n\u201cThe number of dementia cases could drop by half.\u201d\n\nNov. 20: MRI scan may predict which people will develop Alzheimer's disease\n\nLambracht-Washington said the study marks major progress toward a safe and effective vaccine.\nMore: The hidden side of dementia: Families fight over care, end-of-life decisions, finances, estates\n\nDementia is a term used to broadly describe symptoms of cognitive decline; Alzheimer's disease is the most common cause of dementia.\n\u201cIf the onset of the disease could be delayed by even five years, that would be enormous for the patients and their families,\u201d Lambracht-Washington said in a statement.\nThe vaccine works by prompting the body to produce antibodies inhibiting the buildup of amyloid and tau, two proteins that are hallmarks of the degenerative brain disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the vaccine is not available and has not even begun clinical research in human patients. However, it would have been appropriate to give a sense of the time frame. Even if trials started in humans and the vaccine was shown to be safe and effective, it would be years before this became widely available.", "answer": 1}, {"article": "\u201cYou can say, \u2018O.K., let\u2019s dismiss the observational studies because they have all these problems.\u2019 \u201d But, he said, despite the virtues of a randomized controlled clinical trial, such a study \u201cwill never ever be done.\u201d It would be impossible to keep people on a low-sodium diet for years with so much sodium added to prepared foods.\nDr. Alderman said that he once was an unpaid consultant for the Salt Institute but that he now did no consulting for it or for the food industry and did not receive any support or take any money from industry groups.\nBut that study, others say, will never happen.\n\u201cIt\u2019s a problematic study,\u201d Dr. Sacks said.\nDr. Briss adds that it would not be prudent to defer public health actions while researchers wait for results of a clinical trial that might not even be feasible.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 2}, {"article": "For 6.7 million American women of child-bearing age, getting pregnant is not an easy task.\nSpecialists now have a way to test the parents-to-be that may not only increase their chances of getting pregnant but also reduce the risk of them passing on certain genetic diseases.\n\u201cWe can\u2019t fix the embryos yet, but we can determine which embryos are affected by the disease and which aren\u2019t and only transfer back those that are not affected,\u201d Robbins, who is also a fertility doctor at Northwestern Memorial Hospital, said.\n\u201cAll it does is allow us to choose the best embryos to transfer so that we can get the patients pregnant faster,\u201d he said.\n\u201cWe have the technology and ability to eradicate diseases that have ravaged families for decades,\u201d Dr. Kaylen Silverberg, of Texas Fertility Center, told Fox News.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that preimplantation genetic screening is available, but it doesn\u2019t make clear that it is available only for pregnancies resulting from IVF.", "answer": 0}, {"article": "Loyola's department of urology is ranked 39th in the country by U.S. News and World Report.\n\"It is important to conduct these trials before widespread adoption of technology, as has been the case with robotic prostatectomy (removal of the prostate),\" he said.\nBut apart from the RAZOR trial, there have been no prospective, randomized multicenter trials to assess how robotic surgery compares to open surgery in cancer survival.\nThe RAZOR trial found that two years after surgery, 72.3 percent of patients in the robotic surgery group were alive, with no disease progression and essentially cured, compared with 71.6 percent in the open surgery group.\nResearchers wrote that the findings \"underscore the need for further high-quality trials to assess surgical innovation before this surgical technique is widely adopted in clinical practice.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that both techniques are available\u2026 including at the institution that issued the release. The release could have informed readers that, according to the published paper, that all of\u00a0the operators in this study had\u00a0done at least 10 robot-assisted cystectomies before being allowed to participate in the study. When widespread adoption of the robot-assisted procedure occurs, it would be possible that many surgeons would not have completed that many robotic cystectomies.", "answer": 1}, {"article": "For more information please visit http://www.\n\"We've long heard anecdotal evidence that singing in a choir makes people feel good, but this is the first time it's been demonstrated that the immune system can be affected by singing.\nRosie Dow, Head of Sing with Us at Tenovus Cancer Care and co-author of the research, added: \"This research is so exciting, as it echoes everything all our choir members tell us about how singing has helped them.\nSinging in a choir for just one hour boosts levels of immune proteins in people affected by cancer, reduces stress and improves mood, which in turn could have a positive impact on overall health, a new study by Tenovus Cancer Care and the Royal College of Music published today in ecancermedicalscience has found.\nFollowing on from this research, Tenovus Cancer Care is launching a two year study looking in more depth at the longitudinal effect of choir singing over several months.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We think choir-singing is widely available. The news release provides a link to 17 Tenovus Cancer Care centers that offer group singing in England and Wales. However, it\u2019s worth noting that most people do not have access to choirs that are meant to support people in cancer treatment and their caregivers.", "answer": 1}, {"article": "March 4, 2010 -- A new urine test may reduce unnecessary biopsies for prostate cancer.\nThe test, which is approved in some European countries but not in the U.S., detects genetic material -- RNA -- from prostate cancer gene 3 or PCA3.\nIt showed that the test accurately predicts whether a prostate biopsy will reveal cancer in high-risk men.\nIf a man has any type of damage to the prostate, his PSA level can go up.\nBut it improves the ability to diagnose prostate cancer, Groskopf says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story does mention that this test is not approved for use in the US but that is approved for use in several European countries. \u00a0It closes by indicating that the company that makes the test is hoping to file for approval later this year.", "answer": 1}, {"article": "\u201cThis makes sense, but we\u2019ll see if it holds up in future studies.\u201d\n\nFuture studies should look at the habits, activities and nutrition that affect lifestyle and glaucoma risks, said Idan Hecht of Tel-Aviv University in Israel, who wasn\u2019t involved in the research.\nAbout 1,700 participants were over age 40, had no other known eye diseases and had full eye examination results from the survey.\n\u201cPatients can and should be involved and take an active role in the management of their ailments,\u201d Hecht said.\nAlmost half of participants reported drinking coffee often, but less than 10 percent drank hot tea daily.\nOverall, both medical and non-medical approaches are key to treating the disease in the future, Aref added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Other than water, tea is the most widely consumed beverage in the world.", "answer": 2}, {"article": "Surgeons sometimes fly blind when operating on hard-to-reach anatomical parts or hard-to-see conditions. For visual references inside the brain or body, they often rely on images and scans taken before an operation.\n\nA growing number of hospitals are equipping operating suites with magnetic resonance imaging, CT scanners and other technology that enables surgeons to scan a patient in real time, without having to move them from the operating table.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story discusses the relatively new Center for Surgical Innovation in New Hampshire and the program at\u00a0Brigham and Women\u2019s Hospital in Boston. But it\u2019s not clear from the story whether these real-time imaging surgical techniques are being implemented elsewhere. Is it widespread? Do we expect it to become widespread? If so, when? And at what cost?", "answer": 0}, {"article": "Spinal fluid can also reveal the disease but that can be a difficult and painful test.\nThere is still plenty of lab work to be done, more rigorous research before it's proven a simple blood test can diagnose Alzheimer's, but those working on the test are hopeful it can be approved for use by 2009, adds Blackstone.\nAccording to a paper published in the online edition of the British journal Nature Medicine, preliminary studies by a team of scientists led by a Stanford neurology professor show the test is yielding promising results in predicting which patients with mild memory loss are at high risk of developing Alzheimer's disease.\nIn a study of 259 blood samples, the test identified early markers for Alzheimer's with 90 percent accuracy, reports CBS News correspondent John Blackstone.\nBrain scans and spinal taps are helpful but they're not certain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The report clearly states that \"plenty of lab work\" still remains before it\u2019s proven that a simple blood test can diagnose Alzheimer\u2019s.\u00a0 Even though this is tacked on as a disclaimer as the last sentence of an otherwise exuberant report, we\u2019ll give it the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "\"We found that, in general, African-American breast cancer patients exhibit increased likelihood for tumor recurrence, particularly to regional and distant sites, after receiving any combination of adjuvant therapy (treatment following surgery) compared to European-American breast cancer patients.\nDifferences in recurrence rates and patterns between the races following various forms of treatment have not been thoroughly investigated.\nRecurrent breast cancer has hindered the successful management of this disease for decades and is one of the primary factors for the racial disparity in prognosis and outcomes.\nWhen breast cancer recurs, it is more challenging to treat regional and distant tumors than local tumors (in the breast), Wright explained.\nThe researchers also found that among early stage patients (noninvasive or minimally invasive breast cancer), African-Americans displayed higher tumor recurrence than European-American patients.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "None of the treatments given are new or experimental and it\u2019s clear they\u2019re readily available within cancer treatment facilities.", "answer": 1}, {"article": "At the start, about 12% said they didn\u2019t exercise, and the rest said they exercised anywhere from \u201cup to 30 minutes\u201d to \u201cmore than 4 hours\u201d a week.\nFor people who worked out more, no additional benefits were observed.\nMORE: A New Hope For Depression\n\nThe authors write that the combined physical and social benefits of exercise are likely responsible for its ability to help stave off depression.\nIf their hypothesis is right, they say, 12% of depression cases could be prevented if everyone got just one hour of exercise a week.\nBoth the American Heart Association and the World Health Organization recommend getting at least 150 minutes of moderate- to high-intensity physical activity a week for cardiovascular and overall health.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While it makes no statements about availability, most readers will realize that exercise, such as walking and cycling, are usually readily available.", "answer": 2}, {"article": "In five weeks of trying the diet, Pelsser says, parents will know if their child is responding or not; if not, they can move on to other treatments.\nU.S. experts had some caveats, saying that the results of the study, which included 100 children, should be repeated in other populations to see if the findings hold up.\nFeb. 3, 2011 -- Children with attention deficit hyperactivity disorder (ADHD) should be offered a special ADHD diet to see if eliminating certain foods might reduce their symptoms, Dutch researchers say.\nIn the study, published in The Lancet, 78% of children who stuck with the diet did respond by having fewer symptoms.\n''I am of the opinion that every child deserves this diagnostic intervention,\" researcher Lidy Pelsser, PhD, of the ADHD Research Centre in Eindhoven, the Netherlands, tells WebMD.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both the HealthDay story and the WebMD story described the diet in broad strokes, allowing readers, especially parents, to understand the basic components. There are two problem with both stories, though. First, they did not say anything about food preparation. Is serving a child fried chicken the same as grilled? Are french fries as good as a baked potato?\u00a0The other key point is that a dietician has to \u201ctailor\u201d the diet for each child. If there were no experienced dietician available, that would be problematic.\u00a0Still, we thought enough detail was presented to warrant a satisfactory rating.", "answer": 1}, {"article": "Santen and colleagues reviewed controlled clinical trials, observational studies, evidence-based guidelines, and expert opinion from professional societies to address the gap in treatment recommendations for management of menopausal symptoms after breast cancer.\n\u2022 Smoking cessation, weight loss (if indicated), limiting or avoiding alcohol, maintaining adequate levels of vitamin D and calcium, eating a healthy diet, and regular physical activity are suggested for all women with prior breast cancer\n\u2022 Non-pharmacologic therapies for VMS such as cognitive behavioral therapy, hypnosis, and acupuncture may be helpful as are vaginal lubricants and moisturizers\n\u2022 Several emerging approaches such as selective estrogen receptor modulators (SERMs), Tissue selective estrogen complex (TSECs), estetrol, and neurokinin B inhibitors show promise as useful agents to expand options for symptom relief with less breast cancer risk but have not yet been tested to confirm safety in women with prior breast cancer\n\nOther authors of the study include: Cynthia A. Stuenkel of the University of California, San Diego in La Jolla, Calif.; Susan R. Davis of the School of Public Health and Preventative Medicine, Monash University in Australia; JoAnn V. Pinkerton of the University of Virginia in Charlottesville, Va.; Ann Gompel of Paris Descartes University in France; and Mary Ann Lumsden of the University of Glasgow School of Medicine, Dentistry, and Nursing in Scotland.\n\"Following breast cancer, women should generally not be treated with menopausal hormone therapy but should instead focus on lifestyle modifications such as smoking cessation, weight loss, and regular physical activity,\" said the study's first author, Richard J. Santen, M.D., of the University of Virginia Health System in Charlottesville, Va. \"Pharmacologic agents are also available to treat women with severe symptoms.\nMenopause is a normal part of a woman's aging process but pre-menopausal women treated with chemotherapy can also develop premature menopause, and consequently, severe menopausal symptoms including sleep disorders, vulvovaginal atrophy (VVA), vasomotor symptoms (VMS), mood changes, depressive symptoms, cardiovascular disease, osteopenia, and osteoporosis.\nThe study, \"Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors\" is published online at https:/ , ahead of print.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although lifestyle changes are readily available, it\u2019s unclear if the emerging approaches (\u201cselective estrogen receptor modulators (SERMs), Tissue selective estrogen complex (TSECs), estetrol, and neurokinin B inhibitors\u201d) listed in the release are even available. Some of the recommended lifestyle changes aren\u2019t available to women with limited access to healthy foods which are often more costly even if they are available. \u00a0Lack of insurance coverage and lack of availability of alternative treatments like cognitive behavior therapy, acupuncture and hypnosis put these modifications out of reach for many women.", "answer": 0}, {"article": "MONDAY, Nov. 16, 2015 (HealthDay News) -- Breast-feeding a premature infant may help reduce the risk of a serious eye problem known as retinopathy of prematurity (ROP), new research suggests.\nThe studies included more than 2,200 preterm infants, comparing how often babies had been fed human milk or formula, and whether or not they developed ROP.\nThe takeaway from this study, Llanos said, is to breast-feed as long as possible, if possible.\nHe added that in China, a previous study showed the incidence of ROP was 50 percent in infants with a birth weight under 1,000 grams (2.2 pounds).\nIn re-evaluating the studies, Chen's team found that breast-feeding in any amount appeared to reduce the risk of ROP.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We won\u2019t dock points from the story for not discussing the availability of formula and breast milk. Although those topics could certainly sustain such a discussion had the story chosen to address them.", "answer": 2}, {"article": "For more information, visit http://www.\nWith educational activities representing the entire spectrum of radiology, ARRS will host leading radiologists from around the world at the ARRS 2018 Annual Meeting, April 22-27, at the Marriott Wardman Park Hotel in Washington, DC.\nThe study results showed that there was a higher number of callbacks among women ages 40-49 compared to women ages 50-59 (17% compared with 12.5%) and to women ages 60-69 (17% compared with 10.2%).\nBy adding the women ages 40-49 to the screening population of 50 and over, the overall callback rate increased 1.5%, the biopsy rate increased 0.1% and 19.3% more cancers were detected.\nFounded in 1900, ARRS is the first and oldest radiology society in the United States, and is an international forum for progress in radiology.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Mammograms are a widely available intervention. However, like all medical care, women in rural areas far away from clinics or hospitals may have trouble accessing mammograms.", "answer": 2}, {"article": "Alzheimer's disease is the most common age-associated neurodegenerative disorder that has no cure.\nHowever, the question of whether such a strategy would prevent the onset and progression of Alzheimer's in people is challenging because treatment with a calcineurin-blocking agent suppresses the immune system.\n\"Taken together, our findings from these people confirm the data obtained with animal models and support, for the first time in human subjects, our notion that calcineurin inhibition has a protective effect on the development and possible progression and even reversal of Alzheimer's disease,\" said senior author Giulio Taglialatela, Professor and Vice Chair for Research in the department of neurology and director of UTMB's Mitchell Center for Neurodegenerative Diseases.\nTo bypass this issue, the UTMB team analyzed data from the medical records of 2,644 patients who received organ transplants and must take calcineurin inhibitor-based medications, such as Tacrolimus or cyclosporine, for the rest of their lives to prevent rejection of the transplanted organ.\nThe UTMB study data was compared with national data obtained from the 2014 Alzheimer's Association Facts and Figures dataset on age-matched patients to compare the prevalence of Alzheimer's.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although not explicitly stated, it is clear that the drugs in question are available. That raises a possible concern, as their availability and the news release\u2019s enthusiasm may result in patient demand for access to this as-yet unproven strategy.", "answer": 1}, {"article": "Dr. Scolnick has not seen the results of the Novartis trial, but was told of them and concluded that if the drugs work in fragile X, \u201cthere\u2019s nothing to say that they won\u2019t work in some cases of broader autism-spectrum disorders.\u201d\n\nThe roots for the Novartis results began in 1982 when Stephen T. Warren, then a graduate student in genetics at Michigan State University, was looking for a job and something to research.\nThe discovery was front-page news around the world, and experts predicted that widespread fetal testing and therapies were in the offing.\nThose with 55 to 200 repeats are considered carriers, and recent research shows they can have severe neurological declines late in life that mimic Alzheimer\u2019s and Parkinson\u2019s.\nThe Novartis drug and others like it are intended to lower the volume of this noise so memory formation and high-level thinking can take place, allowing children to develop normally.\nIt mostly affects boys and earned its name because, under a microscope, one arm of the X chromosome seems nearly broken, with part hanging by a thread.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no question that the\u00a0drug discussed in the story is years away from being available and may never get approved by the FDA.\u00a0\u00a0", "answer": 1}, {"article": "Researchers at the University of Pennsylvania engineered patients\u2019 own pathogen-fighting T-cells to target a molecule found on the surface of leukemia cells.\nThe engineered T-cells were detected in patients\u2019 blood for several months afterward, and a portion of them turned into \u201cmemory T-cells,\u201d which could provide ongoing protection against cancer recurrence, researchers surmised.\nThe results provide \u201ca tumor-attack roadmap for the treatment of other cancers,\u201d including those of the lung and ovaries as well as myeloma and melanoma, researchers said.\n\u201cWe put a key onto the surface of the T-cells that fits into a lock that only the cancer cells have,\u201d said Dr. Michael Kalos, director of translational and correlative studies at the University of Pennsylvania\u2019s Perelman School of Medicine and an investigator on the study.\nFurther study will show whether the latest results \u201creflect an authentic advance toward a clinically applicable and effective therapy or yet another promising lead that runs into a barrier that cannot be easily overcome,\u201d Urba said in an NEJM editorial.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does note the study is a Phase 1 trial iin the 4th sentence and also notes that\u00a0researchers intend to enroll\u00a0four more\u00a0subjects. WebMD did a better job showing that, even for people hoping to enroll in a trial for this therapy, the odds will be long.\nWe wish stories would take for granted that readers know what Phase I and Phase II means.", "answer": 1}, {"article": "A capsule of Probiotic Immunity from New Chapter Inc., based in Brattleboro, Vt., contains 1 billion each of 10 different organisms, including Streptococcus salivarius subsp. thermophilus and Lactobacillus acidophilus, two species of bacteria often found in yogurt. Other ingredients include herbs such as cumin, ginger and spinach. Users are instructed to take two capsules each day, preferably one in the morning and one in the evening, on an empty stomach. You can buy a bottle of 90 capsules for about $20 at many health food stores.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of these products is clear from the story.", "answer": 1}, {"article": "An experimental spray improved sex for some men who regularly experience premature ejaculation, according to the results of two studies set to be presented Tuesday at a urology conference.\n\nMen who applied the aerosol spray, a mixture of the anesthetics lidocaine and prilocaine, reached orgasm a mean of 3 minutes 18 seconds after beginning sex, compared with about 56 seconds for those who got a placebo spray. The 539 men completing the two studies, who were randomly assigned to the real drug or the fake version, had an average...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear, even in the headline, that these are the results of a trial and that there currently is no product even in the FDA pipeline. It also talks about a drug therapy from Johnson &\u00a0Johnson and where it is being sold. It says at one point in the story that the \"findings of both trials had previously been made public.\" It would have been nice to know where, how and why. Presumably at previous conferences, and, if so, why is this treatment not already in the FDA\u00a0pipeline. Reporters should always be wary of scientists, especially corporate ones, who are using the trade show circuit to build momentum for their product instead of following a rigorous peer review process.", "answer": 1}, {"article": "This showed that they \u201cvalue the relationship more than being right,\u201d Williams said.\nA relationship is obviously so much more than that.\u201d\n\nMembers of Williams\u2019s research team visited 15 couples in their home once a week for 10 weeks.\nPrevious research has found that communication decline among people with dementia is a significant source of stress to caregivers, and most say they need education about communication.\nIn analyzing the recordings, Williams identified 10 communication patterns that caregiving spouses used to connect with their partners and show affection.\n\u201cNo one is looking at it from the perspective of what these couples are doing right, what is helping,\u201d said Williams, whose findings were published in the International Journal for Human Caring.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The behavioral approaches derived from this study seem to be easily adoptable by caregivers. However, the story mention that the couples were receiving specific training on these communication techniques. Is such training widely available? The story doesn\u2019t say, and the average reader probably doesn\u2019t know.", "answer": 0}, {"article": "But since then several new studies - known as randomized controlled trials - have been completed.\nAlthough the precise estimate is still uncertain, researchers found that people who started taking zinc-loaded lozenges or syrups within 24 hours of showing symptoms \u2014 a sore throat, say, or runny nose \u2014 shortened their cold by one day.\nExactly how well zinc works is a matter of future research, and the one day estimate may well change, the researchers note.\nWhile the episodes usually aren\u2019t serious, the resulting visits to the doctor alone cost the U.S. an annual $7.7 billion, according to the new report.\nSingh said the side effects of zinc lozenges, which can be bought for a few dollars in any drug store in the U.S., come down to bad taste and some cases of nausea.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story, unlike the WebMD story, made it clear exactly what the review looked at and where those supplements could be found. \u201cSingh said the side effects of zinc lozenges, which can be bought for a few dollars in any drug store in the U.S., come down to bad taste and some cases of nausea. The researchers did not study nasal zinc remedies, however.In 2009, the U.S. Food and Drug Administration warned Matrixx Initiatives to stop selling its widely used supplement Zicam after more than 130 users reportedly lost their sense of smell.\u201d", "answer": 1}, {"article": "Surgery for a painful, common back condition known as spinal stenosis resulted in significantly reduced back pain and better physical function than treatment with drugs and physical therapy, according to the latest findings from a large federally funded research effort.\n\nThe results from the Spine Patient Outcomes Research Trial, or Sport, echo findings it reported last April involving degenerative spondylolisthesis, another common spinal problem. A separate, earlier report from the same study found nonsurgical treatment for...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The news story notes that laminectomy is one of the most common operations performed in the U.S., suggesting that it is widely available. Most readers are likely aware of the availability of nonoperative treatments such as pain medications and physical therapy.", "answer": 1}, {"article": "The day after the article was released, the Mayo Clinic removed the headline, replacing it with the still misleading statement that smokeless tobacco was \u201cnot a safe product.\u201d\n\n\u201cPeople can only make as good a decision as the information available to them allows,\u201d said Sweanor, an adjunct professor in the University of Ottawa\u2019s Faculty of Law who has spearheaded the development of world-leading tobacco control initiatives in Canada since the early 1980s.\n\u201cThe public is dramatically misinformed about the relative risks of substitutable tobacco and nicotine products.\nThe risk differentials are huge, but this is simply not known by a vast majority of those whose lives are at risk,\u201d adds Sweanor.\nIt is as if tobacco consumers were blindfolded and not allowed to see dramatic differences in harm from different products.\u201d\n\u201cIt would be scandalous, even criminal, to keep such facts from consumers,\u201d the researchers write.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Anyone who has been to a drug or convenience store knows that smokeless tobacco products are readily available.", "answer": 1}, {"article": "CHICAGO \u2013 Initial findings from a randomized phase III clinical trial show that patients with advanced squamous non-small-cell lung cancer (NSCLC) benefit more from initial treatment with PD-L1 targeted immunotherapy atezolizumab (Tecentriq\u00ae) and chemotherapy than from chemotherapy alone -- 29% had a reduced risk of disease worsening or death compared with those who received chemotherapy alone.\nOutcomes for only two of the groups, however, are being reported in this presentation:\n\nOutcome data for the third treatment group, which received atezolizumab with a slightly different chemotherapy regimen (carboplatin and paclitaxel), are not yet available.\nAlthough the rate of severe side effects was higher with the combined modality treatment than with chemotherapy alone (68% vs. 57%), it had a manageable safety profile, consistent with known safety risks of the individual therapies.\nAlthough the difference between treatment groups is modest, a statistically significant improvement shows that, overall, people with advanced squamous lung cancer can benefit when immunotherapy is added to standard treatment, according to the authors.\nThe researchers will explore tumor PD-L1 expression and other molecular markers, such as tumor mutational burden (TMB), that may predict whether a patient will benefit from this treatment regimen.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release refers to the brand name of the immunotherapy drug, which would be enough to alert most journalists covering the ASCO meeting that that this drug is approved for other uses.\nHowever, given the cost and marginal benefit, many insurers will not pay for it which would make it prohibitive for most.", "answer": 1}, {"article": "This research, titled \"Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular Degeneration,\" was supported by National Center for Advancing Translational Sciences, National Human Genome Research Institute, Research to Prevent Blindness, Bright Focus Foundation, The Edward N. & Della L. Thome Memorial Foundation, Wisconsin Genomics Initiative, National Eye Institute, Marshfield Clinic and University of Arizona.\n\"We need more research, but this first step is promising.\"\nThe disease attacks the macula of the eye, where the sharpest central vision occurs, causing central blindness.\n1 cause of legal blindness in adults over 60, is a progressive eye condition affecting as many as one in three adults.\nIn those people who got L-DOPA before being diagnosed with AMD, their AMD diagnosis occurred eight years later than those without L-DOPA.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "L-DOPA is readily available to patients now and the story makes this clear.", "answer": 1}, {"article": "This increases the risk of diabetes.\nThe most widely accepted treatment for sleep apnea is continuous positive airway pressure (CPAP), a device that blows a constant pressure of air into the lungs through a tube and face mask during the night.\n\"Our study showed that CPAP in patients with prediabetes can lower their risk of progressing to diabetes when CPAP is used for eight hours, a full night's sleep,\" said the study's lead author, Sushmita Pamidi, MD, a former fellow at the University of Chicago who is now on the faculty at McGill University in Montreal, Canada.\nUsing a simple device for eight hours a night to treat sleep apnea can help people with prediabetes improve their blood sugar levels and may reduce the risk of progressing to diabetes, according to a new study published online in the April 21, 2015, issue of the American Journal of Respiratory and Critical Care Medicine.\n\"Despite the demonstrated efficacy of lifestyle interventions and the availability of many drug treatments, the economic and public health burden of diabetes remains enormous,\" said Esra Tasali, MD, assistant professor of medicine at the University of Chicago and senior author of the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does not establish how easy or difficult it is to obtain treatment with a CPAP machine. Many people with prediabetes do not know they have sleep apnea. Diagnosis requires either an expensive overnight sleep study (not widely available) or sometimes, with a cheaper home sleep monitor (becoming more available). There are many insurance limitations on testing for sleep apnea. Once the condition is diagnosed, treatment is usually covered by insurance and provided by respiratory care supply companies in the home. Some discussion of this context would have been helpful.", "answer": 0}, {"article": "Dr. Jae Jung, a dermatologist at City of Hope cancer center in Duarte, California, agreed.\n\"It's safe, it's almost obscenely inexpensive, and it's already widely commercially available,\" Dr. Diona Damian, the senior author of the study and a professor of dermatology at the University of Sydney, told HealthDay.\nIt doesn't involve any high-priced new pharmaceuticals -- the key may be an over-the-counter vitamin supplement that costs less than $10 a month.\nThe two most common forms of the disease, basal cell carcinoma and squamous cell carcinoma, can usually be treated successfully.\nFor the study, researchers in Australia looked at nearly 400 people who had had at least two non-melanoma skin cancers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article\u2019s first paragraph establishes that nictotinamide is an \u201cover-the-counter vitamin supplement\u201d and thus readily available \u2014 at least in theory. The study\u2019s lead author also adds: \u201cIt\u2019s safe, it\u2019s almost obscenely inexpensive, and it\u2019s already widely commercially available.\u201d\nWe\u2019ll award a Satisfactory, but we\u2019d note that the competing AP story dug deeper, cautioning that \u201cA check of one major drugstore chain found only other forms of B3, such as niacin, or combination B vitamins.\u201d", "answer": 1}, {"article": "MONDAY, Feb. 20, 2017 (HealthDay News) -- Stem cell transplants may halt the progression of aggressive multiple sclerosis (MS) in nearly half of those with the debilitating disease, but picking the right patients for the treatment is key, a new study suggests.\nA trial that compares stem cell transplants with other therapies to see whether stem cell transplants can become a treatment for patients who have progressive MS is about to start, added Racke, who co-authored an editorial that accompanied the study.\nMost people are diagnosed between the ages of 20 and 50, although individuals as young as 2 and as old as 75 have developed the disease, the society says.\nThose deaths are a major concern, one neurologist said, because MS is not in itself life-threatening.\n\"There may be a population of MS patients that could be identified that might do well with transplant,\" he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not explain if stem cell transplants are currently available to MS patients. The National MS Society states they are not FDA approved, and are considered experimental.", "answer": 0}, {"article": "Line Kessel, an ophthalmologist at Glostrup Hospital of the University of Copenhagen in Denmark, and colleagues have come up with what they say is a promising alternative to replacement surgery.\nThe pulses are so fast, Dr. Kessel said, that two photons hit a target molecule simultaneously, with the same effect as if UV light was used.\nMuch more research and development work remains, Dr. Kessel said, but the goal is a relatively simple procedure that would last half an hour at most and use largely automated equipment in mobile clinics.\nCataracts are the leading cause of blindness in the world, and are often related to aging.\nTo make cataract treatment available to more people around the world, a less-invasive, less-expensive technique is needed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The final line \"much more research and development work remains\" may help readers understand that this is not a readily available approach. ", "answer": 1}, {"article": "\"The results and especially the rapidity of the effects observed in the gantenerumab trial went beyond our expectations,\" Luca Santarelli, MD, study co-author and Roche senior vice president of neuroscience, writes in an email.\nIn the study, patients who received monthly gantenerumab injections showed reductions in such brain plaques.\nThe experimental compound, known as gantenerumab, is being developed by Roche, the Swiss pharmaceutical company.\nTherefore, it's not known if reducing the amount of them will slow or stop the disease.\nThe study is published in the online edition of Archives of Neurology.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story ends with an appropriate send-off:\u00a0 \u201cWe need more studies to know if it is safe or effective.\u201d\u00a0 The early, experimental nature of the research is clear.", "answer": 1}, {"article": "CHICAGO - Screening patients for diabetes based solely on their age and weight - a recommendation from a leading medical expert group - could miss more than half of high-risk patients, according to a new Northwestern Medicine study of a nationwide sample.\nThe other co-authors were from the CDC.\nDr. Ronald Ackermann is the study's senior author.\nThese limited screening criteria also missed more racial and ethnic minorities, most notably Asians.\nThe study was published today, Friday, April 13, in the Journal of General Internal Medicine.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "More intensive screening is obviously available.", "answer": 2}, {"article": "Feb. 1, 2010 -- Twelve weeks of fish oil pills made teens at high risk of psychosis much less likely to become psychotic for at least one year.\nIt may be that fish oil works better in young people with pre-psychotic conditions than in older people with more established psychiatric disorders.\nThis happened to only two of 41 teens who began the year with 12 weeks of fish oil capsules rich in omega-3 fatty acids.\nDespite having worrisome symptoms, none of the teens in the Amminger study had ever had a full-blown psychosis.\nThe study suggests that to prevent one case of psychosis, four high-risk young people must be treated.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Fish oil pills sold as dietary supplements are widely available; however, supplement formulations can vary widely and some may only be available with a prescription. More information on the specific formulation used in the study, as well as the dosage would have been useful. \n\u00a0", "answer": 1}, {"article": "(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG\u2019s relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents.\n\nMS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body and is among the most common causes of neurological disability in young adults.\n\nGilenya is the first FDA-approved drug to treat pediatric patients suffering from relapsing MS, the U.S. health regulator said.\n\nIn a clinical trial 86 percent of patients receiving Gilenya remained relapse-free after 24 months of treatment, compared to 46 percent of those who were administered another MS drug.\n\nGilenya was first approved by the FDA to treat adults with relapsing MS.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned that Gilenya has already been approved to treat adults with MS. However, it would have been stronger it had mentioned that the expanded indication is for ages 10 and older.", "answer": 1}, {"article": "\"The potential is huge.\"\nBeing able to clear the blockage just as well without stents reduces possible complications and gives greater flexibility to doctors later, said Brian Verrier, vice president and general manager of peripheral vascular for Covidien.\nAtherectomy is only used in about 15 to 20 percent of PAD cases, but Dr. Lawrence Garcia, a principal investigator in the study, said he expects that to change with these results.\nThe study is the largest to look at the effectiveness of atherectomy, Covidien said, and enrolled 800 patients at 47 centers in the U.S. and Europe.\nThe results showed that atherectomy, the practice of trimming away the plaque that causes peripheral artery disease (PAD), is just as effective at restoring blood flow as traditional angioplasty and stents.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story never established if the device is approved by the FDA, and, if so, how widely it is used and available. There\u2019s a quote from the principal investigator that atherectomy is \u201conly used in about 15-20% of PAD cases\u201d but that he expects that to change with these results.\u00a0 But not all atherectomy is done with these tools.\u00a0 We actually aren\u2019t told how many are done with these tools.", "answer": 0}, {"article": "The trial was funded in part by Karo Bio, a small commercial spinoff of the institute.\n\"We knew that thyroid hormone could lower lipid [cholesterol] levels but would have side effects on the circulation and bones and cause diarrhea,\" Angelin said.\nHowever, he added, \"if we can get the thyroid effect in the liver [where cholesterol is metabolized] but not in other organs, we would be OK.\"\n\nFrequent monitoring showed no ill effects on the hearts and bones of those taking the drug, the report said.\n\"But if there is one thing we've learned about drugs in this arena, it's that we need large trials to see how they measure up in terms of risk and benefit.\"\nWEDNESDAY, March 10, 2010 (HealthDay News) -- A thyroid-derived cholesterol-lowering drug that could be an alternative to the widely used statin medications has done well in a small, early trial, Swedish and American researchers report.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We really never learn the status of the drug eprotirome.\u00a0 Is it approved?\u00a0 Is it used for anything else now?\u00a0 Readers may assume that it is because the headline already labels it as an \"alternative to statins.\"\u00a0 ", "answer": 0}, {"article": "[Added June 10] So Gokhale studied findings from anthropologists, such as Noelle Perez-Christiaens, who analyzed postures of indigenous populations.\nBack pain is a tricky beast.\nAnd it's quite different than American spines.\nIt's good design,\" Gokhale says.\nGokhale had a herniated disc.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the Gokhale Method is available.", "answer": 1}, {"article": "Dr. Beth Karlan, director of gynecologic oncology at Cedars Sinai Medical Center in , said the results of the new trial would \u201cmake us all rethink the approach to treating patients with recurrent ovarian cancer.\u201d\n\nDr. Karlan, who was not involved in the study but presented a commentary on it, said CA125 testing should be done less frequently.\n\u201cMany women often say they live from one CA125 to the next,\u201d she said.\nOther were resistant to chemotherapy and would not respond to treatment no matter when it was given.\n\u201cI was in a constant state of , waiting for the test, waiting for the results,\u201d she said.\n\u201cI\u2019ve had patients who wouldn\u2019t dream of not being treated,\u201d Dr. Berchuck said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly CA-125 is available.", "answer": 1}, {"article": "\"F.E.S.\nWith the touch of a button, Annette turns on a device much like a pacemaker that's implanted in her chest.\n\"If it hadn't been for my sister by my side 24-7,\" Annette says.\n\"I basically ... just wanted to close my eyes and not wake up again,\" remembers Annette Coker, who was paralyzed in a car accident.\nSo when the implant is turned on, it electrically stimulates the nerves in order to cause the muscles to move in motions, for example, to open and close the hands.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention if the device is available anywhere other than this clinic in Cleveland. In addition, it isn\u2019t clear whether it is investigational or FDA-approved. Is the woman in the story a study subject or is this part of routine care?", "answer": 0}, {"article": "(Reuters Health) - Getting too little sleep during the week can increase some risk factors for diabetes, but sleeping late on weekends might help improve the picture, a small U.S. study suggests.\nAnd it doesn\u2019t prove that catching up on sleep will prevent diabetes.\n\u201cBy catching up on sleep on the weekends, people are reducing average extent and severity of the effects of sleep deprivation,\u201d Gangwisch added by email.\nAfter the four nights of sleep deprivation, the volunteers\u2019 insulin sensitivity had fallen by 23 percent and their bodies had started to produce extra insulin.\nThe volunteers were given a calorie-controlled diet to limit the potential for their food and drink choices to influence the outcomes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of sleep is not in question.", "answer": 2}, {"article": "\"Ovarian cancer is notoriously difficult to detect in its early stages, when there are more options for treatment and survival rates are better.\nThe new blood test has the potential to dramatically improve early detection of the disease, although it will require further testing before it is available for clinicians.\nOur new test is therefore a potential game changer,\" says Professor James Paton, Director of the University of Adelaide's Research Centre for Infectious Diseases.\nA paper published this month in Biochemical and Biophysical Research Communications has shown that the new test detected significant levels of the cancer glycan in blood samples from over 90% of women with stage 1 ovarian cancer and in 100% of samples from later stages of the disease, but not in any of the samples from healthy controls.\nThe team has now engineered a harmless portion of the toxin to enhance its specificity for the cancer glycan and used this to detect it in blood samples from women with ovarian cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Here\u2019s the last sentence of this very brief news release:\n\u201cThe [research] team is currently seeking scientific and commercial partners to further test the technology with larger numbers of patient samples and to adapt it for mass screening.\u201d\nIt doesn\u2019t completely clarify for readers whether the test is currently available, but suggests it isn\u2019t.", "answer": 0}, {"article": "For those who have resolved to get fit in the New Year, O\u2019Donovan recommends to start with moderate exercise, such as brisk walking, and then to set realistic, incremental goals to boost confidence without running the risk of setbacks due to injury.\nMen and women benefited equally, according to the study published in the Journal of the American Medical Association: Internal Medicine.\n\u201cA middle aged or older person should do as much as 12 weeks of moderate exercise before introducing vigorous exercise,\u201d he said.\nNearly 9,000 of the study participants died in the period.\nThere are doing a large proportion of vigorous exercise and that makes you fitter than moderate exercise,\u201d said O\u2019Donovan.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The ability to exercise is generally available, so this is N/A.", "answer": 2}, {"article": "The control group received information about depression but was under no obligation to read it.\nFor the problem-solving therapy, people were asked to create a list of the things that matter most to them in their lives and brainstorm on how to incorporate those things into daily life.\nIt took the trainers about 30 minutes to provide feedback for each session, and they also stayed in touch with participants via instant messaging, Buntrock says.\nIn this experiment, half of the participants were asked to do six half-hour-long exercises that were based on cognitive behavioral therapy and problem-solving therapy, which are techniques commonly used for in-person therapy.\nThey next were asked to categorize problems and worries into \"manageable\" and \"unmanageable\"; the main focus in problem-solving therapy is to tackle those problems that are considered manageable.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story not only makes clear that this preventive approach to online interventions is fairly novel, but that there are significant questions about whether it could be scaled up.", "answer": 1}, {"article": "Cole's own research deals with fish oil, which is relevant because fish is a component in the Mediterranean diet.\nIt is complicated in general to compare the benefits of a particular diet with the benefits of not following a different food regimen.\nIt would be easier for people to focus on adding particular elements to their diets -- for example, by taking fish oil capsules -- rather than trying to readjust their eating habits altogether.\nThis study looked at people who had never had a clinical stroke, but may have had smaller strokes that went unnoticed.\nThe study shows association, not causation, meaning there could be some other factors linking the Mediterranean diet to resilience against this form of brain damage.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There isn\u2019t any question about the availability of the \u2018mediterranean diet\u2019 so this criterion is not applicable for this story. ", "answer": 2}, {"article": "Vincent said she and her colleagues were disappointed by the results of the study, which was funded by Mayo and prompted in part by the findings from the Women's Health Initiative (WHI), a federally funded study of more than 36,000 women ages 50 to 79.\n\"We were hoping for something better,\" she said.\nSome herbs and supplements seem to work, she added, but improvement has proven to be temporary.\n\"Hot flashes are one of the most placebo-responsive conditions,\" she said.\nResearchers knew who was receiving sham treatment, but the women, who completed questionnaires detailing the extent of their hot flashes, did not.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that acupuncture is used worldwide.", "answer": 1}, {"article": "SUNDAY, Sept. 19, 2010 (HealthDay News) -- For asthma patients whose condition is not controlled with standard inhaled steroids, the addition of Spiriva -- a medication already approved for lung disease -- appears to improve breathing, a new study finds.\nThe results need to be confirmed in a much larger pool of patients, Peters said, and he noted that the patients were not followed long enough to see if Spiriva was able to reduce the severity of asthma attacks and hospitalizations.\nDr. Shirin Shafazand, an assistant professor of pulmonary, critical care and sleep medicine at the University of Miami Miller School of Medicine, said that \"perhaps there is a role for Spiriva in these poorly controlled asthmatics.\"\nThe researchers found that Spiriva plus an inhaled steroid was more effective than giving a double dose of steroids in improving breathing and controlling asthma for these tough-to-treat patients.\nThese included: Spiriva plus an inhaled steroid; a double dose of the inhaled steroid; and an inhaled steroid plus Serevent, a long-acting beta agonist that relaxes the muscles in the airway.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The headline and early sentences establish that Spiriva is available for COPD. It\u2018s not clear about the availability of Severent, one of the comparator regimens used in the study.", "answer": 1}, {"article": "Abbott Laboratories is betting heart patients will benefit from a new type of arterial stent that dissolves away when it is no longer needed.\n\nStents are scaffold-like devices used to prop open clogged heart arteries. Most stents are made of metal. But Abbott's new device, called Absorb, is made from a plastic-like material called polylactide that is commonly used in surgical sutures. The Absorb scaffold\u2014Abbott doesn't call it a stent\u2014is designed to completely fade away in two years and to cease supporting arteries at six...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that while the absorbable stent is available in Europe, Abbot will not be seeking approval for marketing in the United States until 2015.", "answer": 1}, {"article": "It's a \"close call,\" says H. Gilbert Welch, MD, MPH, of the Dartmouth Institute in Lebanon, N.H.\n\n\"This is a test that women who want it should be able to have,\" Welch tells WebMD.\nHow many lives?\n\"Because we don't know which cancers these are, all cancers are treated.\n\"Some will benefit in a very large way.\n\"The vast majority will turn out not to have cancer, but all of them will worry.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\nMRI screening has not been considered necessary for women at average risk, and there has been resistance to expansion of MRI into this population due, in part, to concern over higher costs.\nThe new study showed that, consistent with previous research, breast MRI can depict these rapidly growing cancers with high reliability.\nThe results also highlight the ability of MRI in the detection of more aggressive types of cancer.\nOf the 60 cancers detected in the study group over the observation period (7,007 screening rounds), 59 were found only using MRI, one was found also by mammography, and none by mammography or ultrasound alone.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that MRI screening is already available. The release notes that there\u2019s been a resistance to expand MRI screening to average risk women because of the cost.", "answer": 1}, {"article": "Malmgren, a breast cancer survivor, says more focus should be placed on the benefit of early diagnosis, because it often means less treatment is needed.\n\"They have an earlier diagnosis, earlier stage, better prognosis,\" said study author Judith Malmgren, an affiliated professor of epidemiology at the University of Washington School of Public Health and Community Medicine.\nIt also suggests that women aged 40 to 49 at average risk discuss the pros and cons with their doctors and decide on an individual basis if and when to start screening.\nAmong them, according to the 2009 guidelines, are false-positives, which can lead to anxiety and unnecessary biopsies.\n\"That's where the money is,\" Malmgren said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 Availability of mammograms is not in question although access to care is dependent upon many factors including distance to facility with instrument, insurance coverage, etc.", "answer": 2}, {"article": "2018;59:160-172.\nThe researchers speculate that it may be due to the polyphenols (anthocyanins and other flavonoids) in Montmorency tart cherries, the varietal of tart cherries grown in the U.S. Polyphenols in plant-based foods are broken down by microbes to stimulate growth of good bacteria.\nWhile the dietary intervention was based on a limited number of human volunteers and more research is needed to support these conclusions, the results help build the foundation for future research and suggest Montmorency tart cherries can play a role in positively shaping the microbiome and maintaining gut health.\nThe microbiome has been the focus of multiple studies in recent years due to its potential role in maintaining digestive health, as well as its impact on immunity, heart health, blood sugar control, weight management and even brain health.\nThe individuals who ate a more plant-based diet, with higher intakes of carbohydrates and fiber, responded with an increase in Bacteroides and Bifidobacterium, presumably because of the specific combination of polysaccharides and polyphenols.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We can presume that tart cherry juice is widely available, and the news release does mention that Montmorency cherries are a common domestic variety \u201cavailable year-round in dried, frozen, canned, and juice forms.\u201d", "answer": 1}, {"article": "First published on June 22, 2006 at 12:00 am\nBut \"the line between disease and the disability baggage that accompanies aging is sort of arbitrary,\" he said, pointing out that many interventions, such as prescribing glasses, have been developed to counteract the effects of aging.\nThe study he led randomly assigned 395 men and women ages 65 to 84 with mild functional limitations to receive either sugar pills or various oral doses of the growth hormone stimulator capromorelin, an investigational medication developed by Pfizer Global Research and Development.\n\"There are no short-term fixes,\" he said, saying diet and exercise remain preferred approaches to avoiding many health problems associated with aging.\nDr. Julia Zehr, a Michigan State University researcher who led the study, said the findings suggest that biological factors may influence those behaviors, not just the psychological effect of changes in body composition during puberty.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that growth hormone to counteract the effects of aging is controversial and it is not FDA approved for this use. However, the story also subtly suggests it is available for non-approved use. \u201cAnti-aging\u201d clinics may administer growth hormone, but federal law states that distributing or administering human growth hormone for age-related health problems or for cosmetic use is illegal. Growth hormone is currently only approved for adults with Growth Hormone Deficiency (GHD) and for children with pituitary disorders. The American Association of Clinical Endocrinologists does not recommend growth hormone to prevent age-related muscle loss in otherwise healthy adults, due to a lack of information on long-term safety: http://www.aace.com/pub/pdf/guidelines/hgh.pdf ", "answer": 0}, {"article": "But it is increasingly clear that DTI can also be used to identify very small structural changes in the gray matter of the brain, which is critical for learning and memory, researcher Giovanni A. Carlesimo, MD, PhD, of Italy's Tor Vergata University tells WebMD.\n\"This might help doctors when trying to differentiate between normal aging and diseases like Alzheimer's.\"\nIn a study published in the Jan. 19 issue of Neurology, Carlesimo and colleagues found that DTI scanning predicted declines in memory performance with more accuracy than traditional MRI.\nThe technique, known as diffusion tensor imaging (DTI) or diffusion MRI, is used to assess changes in the white matter regions of the brain.\n\"This type of brain scan appears to be a better way to measure how healthy the brain is in people who are experiencing memory loss,\" Carlesimo says in a news release.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story provided no insight about whether hospitals have the facilities needed for this test.", "answer": 0}, {"article": "Eight foods account for 90 percent of all reactions: milk, eggs, peanuts, tree nuts, soy, wheat, fish and shellfish.\nThe skin patch \u2014 intended to desensitize patients to peanuts by exposing them to tiny amounts of the allergen \u2014 may be particularly appealing to children who are too frightened to try oral or under-the-tongue therapy.\n\u201cThe goal for most practicing allergists and for most parents is to get a child to the point where if there is an accidental ingestion of peanut it would not be as risky or life-threatening,\u201d said Dr. Amy Stallings, an assistant professor of pediatrics in the division of allergy and immunology at the Duke University Medical Center who is not affiliated with the new study.\nIt means that \u201cthey are not going to have to worry about traces of peanut in a package that came from a plant where peanuts were used or minor contamination of food in a restaurant,\u201d said the study\u2019s lead author, Dr. Hugh Sampson, a professor of pediatrics at the Icahn School of Medicine and director of the Jaffe Food Allergy Institute at Mount Sinai.\nAbout 15 million Americans have food allergies, including 1 in 13 children, according to the Food Allergy Research and Education (FARE) group.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story lede uses cautionary wording\u2013\u201cprotection may eventually come\u201d\u2013and then, at the bottom of the text, gets reasonably specific about the \u201cseveral more years\u201d needed before a product could become available.", "answer": 1}, {"article": "ISI Group analyst Mark Schoenebaum said although the vemurafenib results look the most encouraging, the findings are unlikely to make a difference for current sales estimates, since virtually all eligible patients will be treated with both drugs, either in sequence or in combination.\n\u201cWe don\u2019t know what dacarbazine did to the ipilimumab, but we do know even in the presence of dacarbazine, ipilimumab still produced a durable response and extended survival.\u201d\n\nDoctors said taken together the new studies offer new options for patients.\n\u201cThat is a drug that can take a while to work, so if the person has time I would rather give him essentially two shots on goal rather than one.\u201d\n\nFor advanced patients who need a quick response, he would use vemurafenib first.\n\u201cWhat was interesting about this study was not only was it the second one to show a benefit,\u201d but that the improvement \u201ctook place even in the presence of dacarbazine chemotherapy,\u201d Dr. Jedd Wolchok of Memorial Sloan-Kettering Cancer Center in New York, who presented the study at the meeting, said in a telephone interview.\n\u201cEven if it diminishes over time, who cares?\u201d\n\n\u201cNearly half of patients treated with the Roche drug had tumor shrinkage, compared with 5.5 percent with chemotherapy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Adequately described. The story appropriately notes that vemurafenib is experimental and Yervoy has been approved for use in the US.", "answer": 1}, {"article": "For more information about featured studies, as well as a schedule of availability for featured researchers, please visit http://www.\n\"For years, patients seeking weight-loss interventions had limited options because they could not tolerate or did not want surgery, or it was not even an option for them,\" added Dr. Sharaiha.\nWhile endoscopic sleeve gastroplasty is performed with an endoscopic device through the mouth, laparoscopic sleeve gastrectomy involves a small surgical incision in the belly to place a tube in the abdomen, allowing doctors to reduce the stomach's volume.\nPatients who underwent ESG -- a procedure performed through the mouth with an endoscope to \"accordion\" the stomach by suturing pleats to reduce its size -- achieved greater weight loss than laparoscopic banding, but less weight loss than laparoscopic sleeve gastrectomy surgery.\nThe team also reported that endoscopic sleeve gastroplasty patients customarily left the hospital on the same day of treatment, while laparoscopic sleeve gastrectomy patients stayed for about three days and laparoscopic banding patients for a day and a half.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "For someone reading the news release who is unfamiliar with weight loss treatment procedures, ESG may sound like an entirely novel treatment that is not yet clinically available. However, while it is relatively new, it is already in use. The release doesn\u2019t give us any idea of how many facilities perform any of these procedures.", "answer": 0}, {"article": "For Patients and the General Public:", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Both neratinib and veliptarib are described as \u201cexperimental\u201d so it is clear that neither are\u00a0currently\u00a0available outside of clinical\u00a0trials.", "answer": 1}, {"article": "Actually, nitrous is making a comeback in U.S. maternity circles. It has remained a staple of childbirth in Canada, Australia, and Britain \u2014 Catherine, Duchess of Cambridge (the former Kate Middleton), who welcomed her third royal baby, Louis Arthur Charles, last month, reportedly has used it. But it basically disappeared in the United States in the 1970s. American women preferred to be numbed below the waist with epidural anesthesia, or at least that became the gold standard for pain relief.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s mentioned that currently \u201can estimated 500 U.S. hospitals and birthing centers offer nitrous \u2014 up from a handful less than a decade ago.\u201d", "answer": 1}, {"article": "Adamas is also testing the drug to treat walking impairment in patients with multiple sclerosis.\nThe company said the drug is expected to be available in the fourth quarter, and formally launched in January 2018.\nThe main ingredient of Gocovri, amantadine, has been available in the market as an antiviral drug for several decades.\nAn estimated 90 percent of levodopa-treated patients, about 200,000 people in the United States, suffer from LID, the company said.\nA majority of patients diagnosed with Parkinson\u2019s are treated with levodopa, whose use often leads to dyskinesia - involuntary movements that are non-rhythmic, purposeless and unpredictable.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes this clear: \u201cThe company said the drug is expected to be available in the fourth quarter, and formally launched in January 2018.\u201d", "answer": 1}, {"article": "The findings are mixed on substance abuse.\nA recent review by Canadian researchers, focusing specifically on mindfulness meditation, concluded that it did \u201cnot have a reliable effect on depression and anxiety.\u201d\n\nTherapists who incorporate mindfulness practices do not agree when the meditation is most useful, either.\n\u201cIt\u2019s a shift from having our mental health defined by the content of our thoughts,\u201d Dr. Hayes said, \u201cto having it defined by our relationship to that content \u2014 and changing that relationship by sitting with, noticing and becoming disentangled from our definition of ourselves.\u201d\n\nFor all these hopeful signs, the science behind mindfulness is in its infancy.\n\u201cWhat concerns me is the hype, the talk about changing the world, this allure of the guru that the field of psychotherapy has a tendency to cultivate.\u201d\n\nBuddhist meditation came to psychotherapy from mainstream academic medicine.\n\u201cAfter a while, we put enough studies out there that people became more comfortable with it.\u201d\n\nOne person who noticed early on was Marsha Linehan, a psychologist at the University of Washington who was trying to treat deeply troubled patients with histories of suicidal behavior.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that mindfulness training in psychotherapy and for the management of chronic conditions is not standardized; thus, practicioners may have different interpretations of the practice in the clinical setting.\u00a0 The story notes that practitioners who use elements of mindfulness meditation and related therapies may do so with different types of patients and for different conditions; there is not yet agreement or clear evidence for which patients are most helped by mindfulness mediation.\u00a0 The article does a good job of explaining elements of the practice and listing resources (in the form of books, experts, clinical training centers and accessible home-based practices). Readers could practice or learn more about mindfulness mediation on their own based on information presented in the article. ", "answer": 1}, {"article": "WASHINGTON (Reuters) - It may be possible to predict which women will develop a dangerous complication of pregnancy called pre-eclampsia weeks before they ever show the first symptoms, an international team of researchers reported Monday.\nThe babies are usually born prematurely and suffer complications all their lives.\nThey found a series of 45 different compounds linked with metabolism that were different in the women destined to develop the condition, and said that could form the basis of a test.\nIf mothers and their babies survive, the women later have a higher risk of high blood pressure, heart disease, stroke and diabetes.\nFrom this series of compounds they narrowed down a list of 14 sugars, fats and amino acids that were different in the women who developed the condition.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is an experimental diagnostic test and not available beyond research settings. The story makes that clear.", "answer": 1}, {"article": "\"It's known that EPA and DHA can inhibit breast tumour growth, but no one has looked directly at how effective these omega-3s are compared to ALA.\"\n\nMa found overall exposure to marine-based omega-3s reduced the size of the tumours by 60 to 70 per cent and the number of tumours by 30 per cent.\nEPA and DHA are found in marine life, such as fish, algae and phytoplankton.\nHER-2 affects 25per cent of women and has a poor prognosis.\n\"It seems EPA and DHA are more effective at this.\nALA is plant-based and found in such edible seeds as flaxseed and in oils, such as soy, canola and hemp oil.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Fatty fish is widely available.", "answer": 2}, {"article": "\u201cFollowing a 'healthy diet' emerges as an important strategy for prevention of neurological disease, but remains to be proved.\u201d\n\nCathy A. Sila, MD, the George M. Humphrey II Professor of Neurology and the director of the Stroke & Cerebrovascular Center at the Neurological Institute Case Medical Center of Case Western Reserve University School of Medicine in Cleveland, Ohio, says the benefits of diet and lifestyle choices in disease prevention are more important than ever, given the rising costs of health care.\n\u201cWe do not know for sure, and we do not know which particular aspect of olive oil is the most relevant to stroke,\u201d he says.\n\u201cNow, we see it may reduce stroke risk in people older than 65.\"\n\u201cMaybe olive oil improves vascular risk factors such as hypertension, dyslipidemia, diabetes, heart disease, obesity, which may in turn reduce stroke risk, or it may be that olive oil is anti-inflammatory or an antioxidant.\u201d Scarmeas writes an accompanying editorial.\n\u201cOlive oil is a healthy fat and it can reduce cholesterol and inflammation, and has been shown to help reduce the incidence of heart disease,\u201d she says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of olive oil is not in question.", "answer": 2}, {"article": "SUNDAY, Oct. 23, 2011 (HealthDay News) -- Older women who take nonsteroidal anti-inflammatory drugs -- such as aspirin or ibuprofen -- appear to have a lower risk of death from colorectal cancer than women who don't use these medications, a large new study suggests.\nThe researchers confirmed 2,119 cases of colorectal cancer and 492 deaths due to the disease.\nThe findings were slated for presentation on Sunday at the AACR International Conference on Frontiers in Cancer Prevention Research, in Boston.\nExperts say that for studies presented at medical meetings, data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nWhile the study found an association between NSAID use and a reduced risk of colorectal cancer, it did not prove a cause-and-effect.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Aspirin and ibuprofen are widely available in US pharmacies.", "answer": 2}, {"article": "CHICAGO (Reuters) - Radiation from CT scans done in 2007 will cause 29,000 cancers and kill nearly 15,000 Americans, researchers said on Monday.\nThe researchers said efforts need to be taken to minimize CT radiation exposure, including reducing the number of unnecessary tests, cutting the dose per study, and standardizing the doses across facilities.\nThey found radiation dosage varied widely between different types of CT studies, from a median or midpoint of 2 millisieverts for a routine head CT scan to 31 millisieverts for a scan of the abdomen and pelvis, which often involves taking multiple images of the same organ.\nThat is a lot of excess deaths.\u201d\n\nCT scans give doctors a view inside the body, often eliminating the need for exploratory surgery.\n\u201cIt\u2019s estimated that just from the CT scans done in one year, just in 2007, there will be 15,000 excess deaths,\u201d Redberg said in a telephone interview.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly CT scans are available. The story does a good job of describing the\u00a0dramatic increase in the use of CT scanning in the past 20 years.", "answer": 1}, {"article": "Doctors can slow macular degeneration with vitamins, laser surgery, stem cell treatments, and even implantable miniature telescopes.\nThese promise that patients could become more independent.\u201d\n\nWhen healthy, retinal cells transmit visual information to the brain.\nBut Dr. Grazia Pertile, director of ophthalmology at the Sacred Heart Don Calabria in Negrar, Italy and one of the Italian researchers, said in a written statement that her team's device could be \u201ca turning point in the treatment of extremely debilitating retinal diseases.\u201d\n\nShe\u2019s not alone in that assessment.\nThe researchers were unable to determine how well the rats were able to see, if at all, but they noted that the animals\u2019 eyes continued to react to light more than six months after the implant was installed.\nThe new prosthesis is designed to be implanted onto the back wall of the eye, where it absorbs light and transforms it into an electrical signal that stimulates the still-active retinal cells to restore vision.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story\u00a0makes quite clear that the new devices are not yet available and likely won\u2019t be for several years. We especially liked that this was brought up near the beginning of the story, versus at the end.", "answer": 1}, {"article": "This article is featured in Newsweek's Special Edition: Nature's Remedies\u2014Heal Your Body.\nThe brain\u2019s synapses control how much of these chemicals are released, and drugs like Zoloft effectively prevent the little serotonin being produced from reabsorbing back into the nerve cells from which they were released, resulting in a higher concentration of serotonin.\nIn fact, the only clue TMS treatment contains magnets at all is that patients must remove any jewelry and stow their credit cards (to prevent demagnetization) before treatment.\nThough it was approved by the FDA in 2008, its use is federally restricted with exemptions only for those with severe depression, autism or Parkinson\u2019s.\nIts efficacy varies from patient to patient and, like most prescriptions for depression, TMS has its own set of side-effects.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states\u00a0\u201cits use is federally restricted with exemptions only for those with severe depression.\u201d\nThis is incorrect and a misinterpretation/misunderstanding of the FDA approved indication for depression. The FDA (the \u201cfederal\u201d\u00a0we assume here) approved TMS for the treatment of depression after a patient fails to respond to one antidepressant, whatever his or her\u2019s degree of depression severity (moderate, severe\u2026). A physician makes the judgement of whether TMS is indicated and can do so even before trying a drug if there is some reason a person cannot tolerate drugs. The FDA does not regulate the practice of medicine.", "answer": 0}, {"article": "Her report is the latest warning from researchers who suspect that stents are being overused and may even be causing heart attacks and deaths.\nThe median time since the heart attack was eight days.\nBy late afternoon, the rally had wiped out all the morning losses.\nAbout a third of heart attack patients show up after 12 hours.\nIt can sometimes save the muscle after 12 hours, but then doctors decide case by case whether it is worthwhile.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It's clear from the story that this is a widely used procedure.\u00a0", "answer": 1}, {"article": "In an editorial that accompanies the JAMA study, they write that the discrepancy \u201cmay be attributable to changes in diagnosis and surveillance but also may reflect a concurrent real increase in the risk of ASDs attributable to as-yet undescribed risk factors and exposures.\u201d They also note that data from the National Health Examination and Nutrition Survey published in 2009 show that the typical American consumes only 150 mcg of folic acid per day even with mandatory fortification.\nIt\u2019s unclear how these findings apply to mothers and children in the United States.\nThe study also looked at folic acid use later in pregnancy but found no correlation between that and the chances of a child developing an autism spectrum disorder.\nMothers who took folic acid supplements around the time they became pregnant were less likely to have children with an autism spectrum disorder, a new study has found.\nThose who did were more likely to have attended college, to be nonsmokers, to be first-time mothers and to have planned their pregnancies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that folic acid supplements are widely available and have long been recommended for women considering pregnancy.", "answer": 1}, {"article": "The researchers from Harvard's T.H.\nThe findings showed that breast cancer risk was 12 to 19 percent lower among women who ate more dietary fiber in their youth, depending on how much more they ate.\n\"The results of this study emphasize the role of an early life high-fiber diet on prevention of breast cancer in later life.\nThis is just one mechanism by which we can reduce risk and it does warrant further study.\"\n\"Having the recommended 25 to 30 grams of fiber daily would decrease the risk by 30 percent and potentially even greater with higher fiber intake,\" Farvid said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There are no new products or services at issue in this story, and we addressed access to healthy foods under \u201cCost,\u201d so we\u2019ll rate this not applicable.", "answer": 2}, {"article": "Australian researchers have completed the world's first randomised control trial (RCT) assessing the efficacy and safety of ketamine as a treatment for depression in elderly patients.\nThe results, published in the latest American Journal of Geriatric Psychiatry, provide preliminary evidence suggesting ketamine's effectiveness as an antidepressant when delivered in repeated intravenous doses.\n\"These findings take us a big step forward as we begin to fully understand the potential and limitations of ketamine's antidepressant qualities,\" said lead author UNSW Professor Colleen Loo, who is based at Black Dog Institute.\n\"Our results indicate a dose-titration method may be particularly useful for older patients, as the best dose was selected for each individual person to maximise ketamine's benefits while minimising its adverse side effects.\"\nMore broadly, little is known about ketamine's potential side effects at different doses, which include cognitive and dissociative effects, elevated blood pressure and heart rate, liver inflammation and urinary problems.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address the availability of ketamine for depression head-on. We\u2019re not sure what regulatory issues may apply in Australia, where the release was issued from, but since the information is being distributed to a worldwide audience via a news wire, some comment on this issue would have been appropriate and helpful. The implication is that ketamine is not yet in general clinical use for treatment geriatric depression. But in the U.S., at least, clinics are starting to pop up around the country that offer this therapy. Are these treatment centers reputable? Readers aren\u2019t given any guidance.", "answer": 0}, {"article": "But after treatment, the group exposed to the bright light was scoring sexual satisfaction scores of around 6.3.\n\u201cThe increased levels of testosterone explain the greater reported sexual satisfaction,\u201d he said.\nAndrea Fagiolini, a professor who led the study and presented it at the European College of Neuropsychopharmacology conference in Vienna on Monday, said the treatment may prove useful during the Northern hemisphere\u2019s darker winter months.\n\u201cBefore treatment, both groups averaged a sexual satisfaction score of around 2 out of 10.\nAfter taking baseline readings, they divided the men into two groups and gave one regular treatment with a bright light box, while the control, or placebo, group was treated with a light box adapted to give out significantly less light.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Many people are aware that light boxes are available and relatively commonplace, so we\u2019ll rate this N/A. However, the story would have been stronger had it discussed what kind of light box the researchers used, and if it\u2019s available, etc.", "answer": 2}, {"article": "\u2022 Even among patients with hypertension, a longer median overall survival was observed among users of NSBBs compared with nonusers (90 months versus 38.2 months).\nThere are currently two clinical trials, one led by MD Anderson, evaluating the combination of chemotherapy and propranolol (a type of NSBB) on cancer biology and on stress modulators in patients with newly diagnosed EOC.\nAlthough further study is needed, these results highlight the importance of adrenergic receptor-\u03b22 (ADRB2), a signaling pathway important to ovarian carcinogenesis and targeted by NSBBs (versus the ADRB1 pathway targeted by SBBs).\nAn estimated 21,290 new cases are diagnosed, and some 14,180 women die from the disease each year in the U.S., according to the American Cancer Society.\n\"The ability to show improved survival using nonselective agents - which inhibit a specific stress pathway - is the culmination of years of research into ovarian cancer biology and pathogenesis.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This is a close one. Yes, the release notes that beta blockers are already in widespread use. Yes, the release mentions the two ongoing clinical trials and how they\u2019ll be used to design additional clinical trials. But the information on clinical trials is in the penultimate paragraph and the ramifications aren\u2019t necessarily clear to lay readers \u2014 it will be years before researchers can determine whether beta blockers should be incorporated into clinical treatment of EOC patients.", "answer": 1}, {"article": "The California Walnut Commission (CWC) prohibits discrimination in all programs and activities on the basis of race, color, national origin, age, disability, sex, marital status, familial status, parental status, religion, sexual orientation, genetic information, political beliefs, reprisal, or because all or part of an individual's income is derived from any public assistance programs.\n#250, Folsom, CA 95630\n\n1.\nshould contact the CWC offices at (916) 922-5888.\nCWC is an equal opportunity employer and provider.\nJ Nutr.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Walnuts are known to be widely available.", "answer": 2}, {"article": "Nov. 28, 2011 (Chicago) -- Researchers are using high-energy waves similar to those used to make microwave popcorn to destroy inoperable lung tumors.\nThe procedure, which costs about $2,000, takes about an hour, and the patient is typically kept overnight in the hospital for observation.\nIn a preliminary study, the technique, called microwave ablation, eliminated lung tumors in 19 of 28 patients.\nBut more patients have to be followed for far longer to see if they stay in remission, they say.\nDuring microwave ablation, radiologists place a thin microwave antenna directly into the tumor.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers are really only told that this was a study in Italy and that \u201cUS researchers say the technique certainly shows promise.\u201d The story does not make it clear whether a patient could expect to have this technique performed in a typical hospital or how many clinical trials are currently ongoing involving microwave ablation.", "answer": 0}, {"article": "Behind that common piece of advice is a complex series of physiological processes that calm the body, slow the heart and help control pain.\n\nBreathing and controlling your breath is one of the easiest ways to improve mental and physical health, doctors and psychologists say. Slow, deep and consistent breathing...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story includes a link to the Spire web site. It\u2019s clear that the device can be purchased.", "answer": 1}, {"article": "\u201cHospitalization is often necessary when patients start to retain fluid, develop congestion and experience shortness of breath.\nThis is a big game-changer.\u201d\n\nFunded by the Ted Rogers Centre for Heart Research, the device called CardioMEMS\u2122 HF System was successfully implanted by interventional cardiologists at the Peter Munk Cardiac Centre in March 2017.\nWhen the patient lies on an accompanying antenna-equipped pillow device, the sensor provides important data \u2013 including the patient\u2019s lung pressure readings to clinicians \u2013 via a secure website.\nEach year, approximately 55,000 patients receive innovative and compassionate care from multidisciplinary teams in the Peter Munk Cardiac Centre, and the Centre trains more cardiologists, cardiovascular surgeons and vascular surgeons than any other hospital in Canada.\n\u201cNever before have we had the ability to obtain a patient\u2019s accurate lung pressure data while they are outside the hospital,\u201d said Meredith Linghorne, nurse practitioner, Peter Munk Cardiac Centre.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release makes it clear that this device is not widely available in Canada, since it\u2019s a \u201cnovel\u201d sensor and not yet approved by Health Canada.\nIn the last sentence, it states that CardioMEMS was approved by the US FDA, implying that the implantation procedure is more widespread there.\nWe rate this one Satisfactory.", "answer": 1}, {"article": "The biopharma company Amarin is making some heart-medicine history Monday with its proprietary, prescription formulation of fish oil, called Vascepa.\n\nIn a stunning clinical trial result that upends years of skepticism about the long-term heart benefit of products containing omega-3 fatty acids, Amarin\u2019s Vascepa significantly reduced the risk of deaths, heart attacks, strokes, and other serious cardiovascular events compared to a placebo.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that Vascepa is available by prescription to treat high triglyceride levels.", "answer": 1}, {"article": "\"Although media coverage of the early release of data from the STAR trial suggests a clear 'winner' in raloxifene, the data from clinical endpoints and patient-reported symptoms suggest a less clear conclusion,\" Dr. William J. Gradishar and David Cella of Northwestern University wrote in an editorial in the medical journal.\nThe new information presented here and published in the medical journal included a detailed analysis of the side effects of the drugs and the results of a survey of about 10 percent of the 19,747 women in the trial concerning their physical and mental well-being.\nThe editorial in the journal said the new data \"still may not be enough to convince primary care physicians to be more aggressive than they have been to date in breast cancer chemoprevention.\"\nWhile both drugs reduced cases of breast cancer by about half from what would have been expected for the women in the study, raloxifene caused fewer cases of blood clots, cataracts and uterine cancers, making it initially appear the winner.\nAs for the data on vaginal and vulvar cancer prevention, they came from combining data from three trials used to test the ability of the vaccine, Gardasil, made by Merck & Company, to prevent cervical cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes that both tamoxifen and raloxifene are currently available, and notes the conditions for which they are approved.", "answer": 1}, {"article": "Antibodies \"are easily accessible in the blood, so it provides a fantastic test to identify an early-stage cancer,\" said project lead Professor Mel Ziman, leader of the university's Melanoma Research Group on Monday.\nSurgery to remove the growth is the most common form of treatment.\n\"We're in the wrong place with the wrong skin color.\nPatients who returned a positive result would still need a biopsy to confirm the blood test and determine how far the cancer had developed, Ziman said.\n\"In order for it to be valued by clinicians we would need to get to 90% accuracy in detection,\" she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that the tests are in the experimental stages and not available commercially.", "answer": 1}, {"article": "New clinical research published today in PLoS One shows that over-the-counter magnesium appears safe and effective to treat mild to moderate depression.\nCritical to such body functions as heart rhythm, blood pressure and bone strength, the mineral magnesium plays a role in combating inflammation in the body and has been proven to have an association with depression.\nParticipants in the active arm of the study received 248 milligrams of elemental magnesium per day over six weeks, while those in the control arm received no treatment.\nThe study participants, who were currently experiencing mild-to-moderate depression, had a mean age of 52, with 38 percent of them male.\nHowever, few clinical trials have studied the supplement's effects.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release mentioned that magnesium can be found over-the-counter.", "answer": 1}, {"article": "U.S.\nFigure 1a shows a tear at baseline on the posterior horn of the medial meniscus, while Figure 1b, taken 9 months after the first injection shows complete resolution of the tear.\n\"Use of one's own healing cells to help repair damaged tissue rather than having to cut open or manipulate the damaged area to try to reduce pain and restore function is the most elegant form of regenerative medicine we have today.\"\nStem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product Adipocell\u2122, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.\nResults are published in the scientific publication the Journal of Medical Cases, and is authored by USRM Chief Science Officer Dr. Kristin Comella and colleagues Dr. Scott Greenberg of the Magaziner Center for Wellness, and Dr. Laura Ross of Ross Orthopedic.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release never emphasizes the early stage nature of this work.\u00a0 Knowledgeable readers might know that news of a single case study\u00a0may be\u00a0just the beginning of a long-term research effort, but nothing in the release expresses that to readers who may be less knowledgeable.", "answer": 0}, {"article": "For the work, a cohort of 541 9- to 11-year-olds in China, 54 percent boys and 46 percent girls, completed a questionnaire about how often they consumed fish in the past month, with options ranging from \"never\" to \"at least once per week.\"\n\"It really has to be a concerted effort, especially in a culture where fish is not as commonly served or smelled.\n\"Children should be introduced to it early on.\"\n\"This area of research is not well-developed.\nThose whose meals sometimes included fish scored 3.3 points higher.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear that fish is a common food source, available everywhere.\n\u00a0", "answer": 2}, {"article": "Post-traumatic stress disorder (PTSD) is a term for a broad range of psychological symptoms that can develop after someone experiences or witnesses a traumatic event.\nOur results support this theory, opening up an exciting avenue of research that might help us to find treatments for PTSD.\nMatrix enzymes are found throughout the body, and their over-activity is involved in certain immune diseases and cancers.\nThis is called 'reconsolidation', and we now plan to test the effect of doxycycline on reconsolidation of fear memories.\n\"The theory is based on the recent discovery that our brains need proteins outside nerve cells, called matrix enzymes, to form memories.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that \u201cmore realistic models\u201d of clinical PTSD are needed and any testing of doxycycline in those models is years away.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/060723/31robot.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states the robotic tool is available at selected hospitals throughout the country and that availability is expected to increase. ", "answer": 1}, {"article": "\u201cIt\u2019s one and done,\u201d he said.\nIt has been shaking for years and they look at it as though, \u2018Hmm, is this really my hand?\u2019 It\u2019s really a remarkable moment.\u201d\n\nFor Samuels, who underwent the procedure on June 29, the recovery has been surprising.\nThe therapy, called focused ultrasound thalamotomy, uses the energy generated by sound waves to burn off certain cells in the thalamus, a region of the brain where the essential tremor is thought to originate.\nIt has been developed by InSightec, which is funding the trial along with the Focused Ultrasound Foundation and the Binational Industrial Research and Development Foundation.\nThe doctors at Brigham will follow up with Samuels \u2014 and others who undergo the treatment \u2014 for up to five years and run more MRI scans and neurological exams to find out for how long the lesion lasts and keeps the tremor suppressed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the device was approved by the FDA in July. The story could have done readers a service by giving a sense of how many medical centers around the country are geared up to perform the procedure, or will be soon.", "answer": 1}, {"article": "The study of nearly 32,000 people in eight countries boosts hope that early detection by CAT scans may reduce the death toll of lung cancer, much as mammography has done for breast cancer.\nA new study has found that it is possible to find a large number of \"silent\" cancers in the lungs of heavy smokers by periodically screening them with CAT scans.\nSuch early lung cancers can usually be cured; the problem is that they are usually found at that \"asymptomatic stage\" only by chance when someone has a CAT scan or chest X-ray for an unrelated reason.\nOthers, including researchers and policymakers in the government, say it is a question that will not be settled for five or six years, when other studies are complete.\nWhen the tumors are then surgically removed, most people live five years or more, in striking contrast to patients whose cancers are found only after they experience symptoms.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not discuss if the lung cancer screenings are available, or how widely available the screening scanners may be. The story should have mentioned that the tests are being advertised by private\u00a0screening centers and some hospitals, but are not generally covered by insurance.", "answer": 0}, {"article": "The remaining subjects were divided randomly into four groups.\nThe good news, according to a Brazilian study published by the journal PLoS One, is that two relatively simple measures can help to reduce the incidence of POCD: administering a small dose of the anti-inflammatory drug dexamethasone immediately before an operation and avoiding profound anesthesia during the operation.\n\"The results reinforce recent evidence of the importance of avoiding deep anesthesia,\" Carmona said.\nIf so, the use of an anti-inflammatory drug may have a protective effect,\" said Maria Jos\u00e9 Carvalho Carmona, a professor of anesthesiology at the University of S\u00e3o Paulo's Medical School (FM-USP) and principal investigator for the study.\nThe researchers evaluated 140 patients aged between 60 and 87 who underwent surgery under propofol-induced general anesthesia at the Central Institute of Hospital das Cl\u00ednicas, FM-USP's teaching hospital, in most cases for removal of gallstones.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the release that the relevant tools involved in this particular intervention \u2014 the use of dexamethasone and avoidance of \u201cdeep\u201d anesthesia \u2014 are currently available. However, as noted above, this is a relatively small study, and we suspect that more research would be needed before this approach was considered for widespread clinical practice. Since we already dinged it for that point earlier, we\u2019ll give it a satisfactory here.", "answer": 1}, {"article": "In the Atlas trial, it appears that roughly 40 percent of the patients assigned to take tamoxifen for the additional five years stopped prematurely.\nSome small studies in the 1990s suggested that there was no benefit to using tamoxifen longer than five years, so that has been the standard.\nOther doctors were not so sure.\nThere was virtually no difference in death and recurrence between the two groups during the five years of extra tamoxifen.\n\u201cIf it can keep the cancer away, I\u2019m all for it,\u201d said Ms. Behrend, 39, a single mother in Tomball, Tex.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicates the drug has been available, studied, and inexpensive.", "answer": 1}, {"article": "Malignant mesothelioma is an aggressive and almost uniformly fatal tumor caused primarily by exposure to asbestos.\nor e-mail info@oncoblotlabs.com\n\nIf you'd like to read the clinical study, please visit http://clinicalproteomicsjournal.\nAlthough the fight against cancer often appears to be an overwhelmingly intransigent problem, significant progress is being made regarding the development of additional tools for cancer detection, such as the ONCOblot Test.\n\"The completion of this trial is an exciting new chapter for our work,\" says Nick Miner, Vice President of Business Development.\nIn this study, the serum presence of a mesothelioma-specific form of the ENOX2 protein (a recently identified marker of malignancy) was found within the serum of asbestos-exposed individuals an average of 6.2 years in advance of clinical symptoms by using the ONCOblot tissue of origin cancer detection test.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release notes that the ONCOblot test is FDA approved as a \u201cLaboratory Developed Test.\u201d It also includes a link to a company web site with more information on the test and how to get it.", "answer": 1}, {"article": "He'd read about advances in targeted therapies \u2014 drugs that go after cancer cells at the molecular level.\nOur series is produced with member station WNYC, and with Ken Burns Presents: Cancer: The Emperor of All Maladies, which will air on PBS starting March 30.\nBut in the meantime, patients like Anselmo are grateful to have time they wouldn't have had otherwise.\nWhy Doctors Are Trying A Skin Cancer Drug To Treat A Brain Tumor\n\nMaryAnn Anselmo feared for the worst when she was diagnosed with a brain tumor called a glioblastoma in late 2013.\nCalled a basket trial, the study is designed to include people whose tumors have the same kind of genetic fingerprint regardless of where in the body the tumors are found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The skin cancer drug this patient received is stated to be available through a clinical trial, at least for GBM. The article also links to NIH-curated information about the drug. But this story is mainly about cancer treatment that is guided by genetic testing of the tumor, and the availability of that testing and related treatment is not satisfactorily established. The story states that the patient\u2019s\u00a0family sent samples of her tumor to several leading cancer hospitals, suggesting that this is not something that would\u2019ve been done as a routine part of her care. But what about patients whose families may not be savvy enough to coordinate this kind of testing? And how much does it cost and would the testing be covered by insurance? This story is going to create interest and demand for such testing, so a few more details about the logistics of having it carried out would have been very useful.", "answer": 0}, {"article": "A leading biologist at the Massachusetts Institute of Technology, with backing from five scientists who are Nobel prize recipients, is wading into the murky world of dietary supplements with a new antiaging pill that is said to restore muscle tissue, improve brain function, and increase energy levels by improving \u201cmetabolic health.\u201d\n\nLeonard Guarente, one of the best-known antiaging researchers in the region, and the roster of eminent scientists have formed Elysium Health, which on Tuesday will debut its first product, a pill called Basis.\nBoth substances are available individually as dietary supplements.\nThey say it will enable the body to produce more of a natural compound that supports a healthy metabolism.\n\u201cAs soon as we have analyzed the data, we will publish them on our website,\u201d he said.\nWith Elysium, Guarente and his colleagues are entering an industry with a mixed reputation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article mentions the pill will be available online and debuted on Tuesday.", "answer": 1}, {"article": "Using the immune system to beat cancer is quickly becoming a promising new strategy for battling tumors.\nThe patient is one of nine in the trial, and so far, many of the other people are having similar experiences on the therapy.\nIt\u2019s also becoming clear that more than one type of modified immune cells may have to be enlisted.\nIt\u2019s possible that the immune cells had destroyed most of the cancer cells expressing the original protein, so other cancer cells with other proteins began to proliferate and survive.\nThe tumors in the first patient remained under control for almost eight months, but the cancer returned after that in new parts of the brain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that the therapy is experimental, that complexities are numerous, that much is still unknown, and the trial is ongoing.", "answer": 1}, {"article": "\u201cThe findings published today substantially increase our optimism for the potential for the development of a Zika vaccine for humans.\u201d\n\nBeyond that, \u201cthis is a promising [vaccine] candidate that can be easily produced in large quantities,\u201d said coauthor, Col. Nelson Michael, an Army doctor who specializes in flaviviruses, such as Zika and dengue.\nThe urgency for a vaccine to protect against Zika infection has intensified as the virus spreads rapidly across Latin America and the Caribbean.\nResults are expected by December and if they are promising, a bigger phase II trial will be launched in Zika endemic countries\n\nThat puts the project ahead of schedule, since the original launch of the phase I trials was expected to start in September, Fauci said.\nRelated: New Study Shows Just How Tricky the Zika Virus Is\n\nThe two other experimental vaccines described in the new report also sparked an immune response in monkeys.\nTrials of that vaccine in people, which is also based on man-made copies of virus proteins, began on August 2, when the first study volunteer was given a vaccination through a needle free injector, said Dr. Anthony Fauci, head of the National Institute for Allergy and Infectious Diseases.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story offers information about possible timetables for clinical testing and availability. It could have been more emphatic that there are a lot of unknowns here, though.", "answer": 1}, {"article": "Contact Professor Ole G. Mouritsen, head of Centre for Biomembrane Physics (MEMPHYS) at University of Southern Denmark, head of center Taste For Life, President of the Danish Academy of Gastronomy.\nThe men's reaction was that the bread tasted acceptable as long as the seaweed content was kept under 4%.\n\u2022 Some species may contain large amounts of iodine.\nOne suggestion is to replace 5% of the flour in pizza dough with dried and granulated seaweed.\n\u2022 Never eat seaweed that is washed up on the beach.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We are going to assume here that most people think seaweed is widely available as a food product.", "answer": 1}, {"article": "The study was divided into three parts.\nThe authors report no other relevant potential conflict of interest.\nIt was published in the December 2018 issue of the journal.\nAn additional six older healthy controls were recruited for full-body scanning.\nThese three most promising tracers were previously tested in nonhuman primates, and the results looked promising enough to test in people.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not make clear that this work is still far removed from widespread clinical application.", "answer": 0}, {"article": "\"Our concern is there are so many CT scans being done right now that we should really be starting to think: Do we need to all of these CT scans?\"\nThe radiation and risk from one CT scan is low, but it carries a dose 50 to 100 times greater than a traditional X-ray, reports LaPook.\n\"The CT scan is a wonderful tool for examining internal organs, organs that are below the depth of where a poking finger or a listening stethoscope can hear, and yet don't show up on routine X-rays,\" Dr. Michael Brant-Zawadzki, a clinical professor of radiology at Stanford University tells CBS News.\nThe report estimates the percentage of cancers caused by CT scans -- currently 0.4 percent -- will increase to as much as 2 percent in a few decades because the number of scans has increased so dramatically, reports CBS News medical correspondent Dr. Jon LaPook.\nThe average American's total radiation exposure has nearly doubled since 1980, largely because of CT, or computed tomography, scans.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story did not include information about availability of CT scans (i.e. in hospital setting, in free standing imaging centers).\u00a0 However, the point of the story was that the technology is over used.\u00a0 While not meeting our usual standard of describing availability, the context of the news spot makes this less important.\nAlthough the story mentioned that patients ought to make sure that the doctor gives you \u2018the least possible dose\u2019, it did not inform the viewer that this option is not available on all CT equipment.", "answer": 1}, {"article": "All said they had taken MDMA for recreational purposes at least twice in their lives.\nIn July, another study reported that MDMA might be useful in treating post-traumatic stress disorder (PTSD), based on the drug's apparent boosting of the ability to cope with grief by helping to control fears without numbing people emotionally.\nIn a study involving a small group of healthy people, investigators found that the drug -- also known as MDMA -- prompted heightened feelings of friendliness, playfulness and love, and induced a lowering of the guard that might have therapeutic uses for improving social interactions.\nTUESDAY, Dec. 21, 2010 (HealthDay News) -- The recreational drug known as ecstasy may have a medicinal role to play in helping people who have trouble connecting to others socially, new research suggests.\nThe findings \"suggest that MDMA enhances sociability, but does not necessarily increase empathy,\" noted study author Gillinder Bedi, an assistant professor of clinical psychology at Columbia University and a research scientist at the New York State Psychiatric Institute in New York City.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that \u201cMDMA is part of a family of so-called \u201cclub drugs,\u201d which are popular with some teens and young at all night dances or \u201craves.\u201d\nBut it doesn\u2019t tell readers anything about whether this is MDMA\u2019s only use, and how it might be made available/distributed.", "answer": 0}, {"article": "For more information, visit http://www.\nPears are an excellent source of fiber (24% DV) and a good source of vitamin C (10% DV) for only 100 calories per medium sized pear.\nThe USDA Dietary Guidelines for Americans state that people who eat more fruit as part of an overall healthy diet are likely to reduce their risk of some chronic diseases, although little is published on the health outcomes associated with individual fruits, including pears.\nIn addition to discovering a correlation between fresh pear consumers and lower body weight, the study found that pear consumption was associated with higher diet quality (as defined by the Healthy Eating Index).\n\"The association between pears and lower body weight is very exciting,\" said Dr. Carol O'Neil.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release goes into some detail about the wide availability of pears in the United States.", "answer": 1}, {"article": "Fish-oil supplements don't appear to help pregnant women prevent post-partum depression or boost the baby's brain development as previously believed, according to a large trial published Tuesday in the Journal of the American Medical Association.\n\nThe 2,400-woman, randomized study complicates the advice for pregnant women. It adds to a body of mixed research on some potential benefits of the popular omega-3 fatty acid known as DHA, or docosahexaenoic acid. DHA, which can move from the mother to the baby during pregnancy, accumulates...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that fish oil is widely available and has been widely used for the described uses.\u00a0 However, it would have been helpful for readers/consumers if the story had discussed the challenge of assessing product purity, quality control, etc. \u2013 that it\u2019s not just a simple matter of \"just take fish oil.\"\u00a0", "answer": 1}, {"article": "Today\u2019s action supports the FDA\u2019s Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging\u2014an effort to ensure that each patient is getting the right imaging exam, at the right time, with the right radiation dose,\u201d said FDA Commissioner Scott Gottlieb, M.D.\n\u201cThe FDA\u2019s review team worked closely with the test developer and the U.S. Department of Defense to expedite a blood test for the evaluation of mTBI that can be used both in the continental U.S. as well as foreign U.S. laboratories that service the American military.\u201d\n\nThe Brain Trauma Indicator works by measuring levels of proteins, known as UCH-L1 and GFAP, that are released from the brain into blood and measured within 12 hours of head injury.\nThese findings indicate that the test can reliably predict the absence of intracranial lesions and that health care professionals can incorporate this tool into the standard of care for patients to rule out the need for a CT scan in at least one-third of patients who are suspected of having mTBI.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\n\u201cA blood test to aid in concussion evaluation is an important tool for the American public and for our Service Members abroad who need access to quick and accurate tests,\u201d said Jeffrey Shuren, M.D., director of the FDA\u2019s Center for Devices and Radiological Health.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release announces that the test is \u201capproved\u201d for use, so we assume it will be widely available. It also quotes an official who says the test \u201ccan be used both in the continental U.S. as well as foreign U.S. laboratories that service the American military.\u201d", "answer": 1}, {"article": "The study appears in the September issue of the journal PLoS Medicine.\nSeveral studies have suggested a role for statins in slowing the progression of disease among patients with rheumatoid arthritis, but others failed to find a protective benefit for statin use.\nThere is also a suggestion that statins reduce systemic inflammation and may be protective against RA and other chronic inflammatory diseases.\nThe analysis revealed that patients who took statins for at least eight years during the decade-long study period were roughly 40% less likely to develop rheumatoid arthritis than people who did not take statins at all or who took them less persistently.\nBut it is not driven by inflammation, so statin use is not as likely to affect its development or progression.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story notes that statins are the most commonly prescribed class of drugs in the world, which is an even better description than the one used in the HealthDay story.", "answer": 1}, {"article": "New medtech apps put specialist knowledge in patients' pockets\n\nDeep-learning networks have already been applied to produce algorithms capable of diagnosing diseases like melanoma and blindness caused by diabetes.\nThe researchers concluded: \u201cThe opportunity to one day readily understand the health of a patient\u2019s blood vessels, key to cardiovascular health, with a simple retinal image could lower the barrier to engage in critical conversations on preventive measures to protect against a cardiovascular event.\u201d\n\u201cHowever, some of these parameters may be unavailable\u2026We therefore explored whether additional signals for cardiovascular risk can be extracted from retinal images, which can be obtained quickly, cheaply and non-invasively in an outpatient setting.\u201d\n\nRead more: Can smartphones replace your GP?\nThe risk factors include the person\u2019s gender, smoking status, blood pressure and age\u2014estimated to within four years of the patient\u2019s actual age.\nThe method\u2014detailed in a paper published on Monday in the Nature journal Biomedical Engineering\u2014involves analyzing blood vessels in an area of the eye called the retinal fundus.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicates that \u201cfurther tests\u201d are needed, but readers are left with no idea as to when, if ever, this new approach to determining risk might be available.\u00a0 There\u2019s no mention of when, if ever, clinical trials might be done to gauge its efficacy.", "answer": 0}, {"article": "Paul J.D.\n\u201cThis new technology may also provide physicians with a safer, more controllable option for treating patients.\u201d\n\nThe team co-authored the paper, \u201cUltrasonic modulation of tissue optical properties in ex vivo porcine skin to improve transmitted transdermal laser intensity,\u201d which recently was accepted for publication by the society\u2019s journal, Lasers in Surgery and Medicine.\n\u201cWe\u2019ve named the technique \u2018sonoillumination,\u2019 and we\u2019re hopeful that the procedure will be available widely in the near future.\u201d\n\nWhiteside and his team, including adviser, Heather K. Hunt, an assistant professor of bioengineering in the MU College of Engineering, tested the sonoillumination system on porcine skin tissue samples.\n\u201c\u2018Sonoillumination\u2019 will be extremely beneficial for clinicians and the ASLMS presentation allowed us to demonstrate the system to the people who actually will be using the technology once it\u2019s commercialized.\u201d\n\nNicholas Golda, associate professor of dermatology and director of dermatology surgery at the MU School of Medicine, echoed the merits of the sonoillumination system and the effect it will have on dermatology.\nIn 2016, the Office of Technology Management and Industry Relations reported that Mizzou received $14.9 million in revenue from more than 40 technology licenses.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although the release is clear that the device is not yet available, there is no support for the claim that the device, which has yet to be tested on tattoos or other skin markings, \u201cwill be available widely in the near future,\u201d especially since clinical trials have yet to be performed.", "answer": 0}, {"article": "Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance.\nThe Oncotype DX DCIS Score result provides patients with an individualized estimate of local (in the same breast) recurrence, which could be either invasive breast cancer or DCIS.\nNOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.\nThe company's flagship product, the Oncotype DX breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.\nThe company is based in Redwood City, California, with European headquarters in Geneva, Switzerland.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There was no mention on how available the Oncotype DX DCIS Score test is in clinical offices and no mention on whether it is covered by insurance. The test is, in fact,\u00a0widely available \u2014 the physician sends a\u00a0requisition form either to the pathology department, which will send the tissue to Genomic Health, or to Genomic Health, who will then request the tissue samples from pathology.", "answer": 0}, {"article": "To contact Editor's Note author Mitchell H. Katz, M.D., email mediarelations@jamanetwork.org\nThe women were an average age of 67.7 years old, had an average body mass index of 30.4, most of them had undergone menopause before the age of 55 and less than 3 percent used hormone therapy.\nThe authors report that women eating a Mediterranean diet supplemented with EVOO showed a 68 percent (multivariable-adjusted hazard ratio of 0.32) relatively lower risk of malignant breast cancer than those allocated to the control diet.\nThis one has a small number of outcomes (only 35 incident cases of breast cancer), the women were not all screened for breast cancer with mammography, they were not blinded to the type of diet they were receiving, and all were white, postmenopausal and at high risk for cardiovascular disease.\nThe study was conducted within the framework of the large PREDIMED (Prevenci\u00f3n con Dieta Mediterr\u00e1nea) trial, which was designed to test the effects of the Mediterranean diet on the primary prevention of cardiovascular disease.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the release that the foods in the Mediterranean diet are widely available. However, it might be harder to find certain component foods like fish, fresh fruits and vegetables, and extra virgin olive oil in some places in the U.S. (i.e. \u201cfood deserts\u201d). The release could have acknowledged this.", "answer": 1}, {"article": "AUGUSTA, Ga. (March 9, 2017) - The first year of free lung cancer screening in the Augusta, Georgia area found more than double the rate seen in a previous large, national study as well as a Massachusetts-based screening for this number one cancer killer.\nThe combination technology is often used to visualize other tumor types throughout the body and many patients require an injection of sugar dye, which will be taken up by the tumor but must first circulate for about an hour before the scan is done.\nAs examples, smoking rates were highest among those without a graduate education degree certificate and lowest among those with a graduate degree; higher among those living below the poverty level versus above it; and higher among some minorities such as American Indians and Alaska Natives, multiple- race individuals and blacks.\nThey may follow up on smaller nodules in six months, then if the nodule is stable, go back to annual reviews.\n\"We want to reach as many people as we can as early as we can,\" he said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that the relevant diagnostic techniques are in widespread use; that there is limited access to the screening initiative (based on availability); and that there is an effort underway to expand the screening initiative.", "answer": 1}, {"article": "All had high-functioning autism or Asperger's syndrome.\nWhile there are drugs for the secondary symptoms of autism, such as irritability and aggression, doctors have nothing yet for the core symptoms in the areas of language, social interaction and intellectual deficits.\nAlthough there are many kinks to be worked out, experts feel the strategy holds promise to treat one of the core symptoms of autism spectrum disorder.\nIt's almost like a designer drug, a drug which has a selective effect on a behavior in the normal range,\" said Keith Young, vice chairman of research in psychiatry and behavioral science at the Texas A&M Health Science Center College of Medicine in Temple and the neuroimaging and genetics core leader at the VA Center of Excellence for Research on Returning War Veterans at the Central Texas Veterans Health Care System.\n\"In the absence of intellectual deficits, the areas where they have the greatest struggle is around social communication and social connectedness,\" she continued.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that the strategy used in this laboratory study is uNPRoven in the real world, particularly in children and young adults. They even note the issues in translating the delivery method to clinical practice.", "answer": 1}, {"article": "\u201cThat effect might be even greater over the long term if they are drinking it day upon day.\u201d\n\nResearchers say that drop may seem small, but on a public health level a reduction like that would equate to a 10% reduction in deaths due to heart disease .\nThey were then monitored for 24 hours.\nThe results appear in Nutrition Journal.\nAmong both men and women, the results showed a trend to lower systolic blood pressure six hours after drinking the beet juice.\nThe same procedure was repeated two weeks later, with those who drank the placebo on the first round receiving beetroot juice on the second.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of beet juice is not in question.", "answer": 2}, {"article": "What if doctors had a pill that prevents breast cancer and nobody wanted to take it? That has pretty much been the situation with tamoxifen, an estrogen-like drug that was proved in 1998 to cut in half the chance of developing breast cancer if taken for five years by women with increased risk of the malignancy. The trouble is, tamoxifen also triggers menopausal symptoms like hot flashes and slightly increases the chances that a woman will develop blood clots and uterine cancer. As a result, women haven't been too eager to take the medication--nor have many doctors been all that enthusiastic...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that raloxifene is currently available for use in post-menopausal women to prevent osteoporosis and that use in chemoprevention has only been in clinical trials\u2013more data is needed prior to FDA approval for use as chemoprevention. Use as chemoprevention would be off-label and only women with an increased risk of breast cancer.", "answer": 1}, {"article": "\"The [brains of] children who received the ESDM looked virtually identical to typical 4-year-olds,\" Dawson says.\nIt also calls for many more hours of the treatment, in the form of structured play, with a parent trained in the technique.\n\"We jump-started and improved the responses of children's brains to social information,\" says Dawson, professor of psychiatry at the University of North Carolina and chief science officer at Autism Speaks.\n\"The children that received the interventions normal in their communities continued to show the reversed pattern.\"\nBy age 4, children given the treatment had higher IQ scores, more adaptive behavior, better coordination, and a less severe autism diagnosis than kids given the standard autism treatments offered in their communities.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is not clear from the story whether this therapy is being used anywhere or whether it is something that only Dawson and her colleagues are testing out in small settings.", "answer": 0}, {"article": "Read more at The Wall Street Journal.\nThe drugmaker plans to apply for approval in the U.S. this summer; however, the drug likely wouldn't be available here until next year.\nIn a clinical trial, a single dose of the drug made by the pharmaceutical company eliminated the virus from people's bodies in a median time of 24 hours, The Wall Street Journal reported.\nA Japanese drug company is offering up a big claim: Shionogi & Co. says it has an experimental pill that can kill the flu virus within a single day, according to news reports.\nThe experimental drug, however, kicks into action earlier, working to block the virus from hijacking cells in the first place, the Journal said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article, again as noted above, seems to assume that the FDA will automatically approve this anti-viral drug and do so quickly. Neither assumption is necessarily the case.", "answer": 0}, {"article": "Scientists have used a form of stem-cell therapy to improve survival rates for the most severely sick lupus patients, a group that usually has no remaining treatment options.\n\nLupus is an autoimmune disease that attacks an individual's own organs, causing symptoms that range from swollen joints and skin rashes to severe damage to kidneys, lungs and other parts of the body.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The results presented are acknowledged to be preliminary, with the next step being a second, larger trial. \nThis suggests that use of HSCT for treatment of lupus is not likely to be widely available for some time.", "answer": 1}, {"article": "The drug could be game-changing for certain women, said Dr. Alice Police, regional director of breast surgery at Northwell Health Cancer Institute in Sleepy Hollow, N.Y.\n\n\"This is a really important advance in survivorship and compassionate cancer care,\" added Police, who wasn't involved in the study.\nThe drug is oxybutynin (Ditropan XL), long used to treat urinary incontinence.\nThe study found that women taking the medicine had an average of five fewer hot flashes a week, compared with three fewer among women taking a placebo.\nWith insurance, copays would be less, he added.\nThe patient said she was willing to stop her hormone therapy and risk the return of breast cancer rather than live with her current symptoms, she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states that the drug, which is approved to treat incontinence, is readily available.", "answer": 1}, {"article": "Dr. Douglas Fraser, a physician in the Paediatric Critical Care Unit at Children's Hospital, London Health Sciences Centre and Lawson scientist, led the study with his co-investigator Mark Daley, a professor in the Departments of Computer Science, Biology and Statistics & Actuarial Sciences at Western University.\nThe scientists measure a panel of metabolites - small molecules that are the products of the body's metabolism - in the blood to search for distinct patterns that indicate a concussion has occurred.\nIn the relatively inexpensive test, blood is drawn from an individual that may have suffered a concussion as the result of a sudden blow to the head (or from transmitted forces from a sudden blow to the body) within 72 hours of the incident.\nThis new method, fully funded by the Children's Health Foundation and conducted by the Western Concussion Study Group, is unique in that previous attempts have looked unsuccessfully for a single highly accurate protein biomarker that can distinguish concussed from non-concussed adolescent patients.\nThe technology is subject to a patent application filed through WORLDiscoveries\u00ae, the joint technology transfer office of Lawson and Western.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We aren\u2019t told if it is available or not or even when it might become available. The release could have been much more transparent about its availability. When we assessed the release it appears that there isn\u2019t a test per se, but a series of chemicals that could be combined into a future commercial test.", "answer": 0}, {"article": "The antidepressants can cause headache, nausea, dry mouth, dizziness and insomnia or sleepiness.\nThough hormones cause small increases in the risks for breast cancer and heart disease, a short course may still be the best choice for women with very severe symptoms, she said, though she added that women who have had breast cancer should definitely not take hormones.\nFor women with a lot of hot flashes, that is not a very impressive performance, Dr. Nelson said, but she added that the drugs may also lessen their severity.\n\"There's a lot of hype around trying things that we haven't proven effective and, sadly, we haven't proven they're safe,\" said Dr. Heidi D. Nelson, the first author of the journal article and an internist and professor at the Oregon Health and Science University.\nThe drugs include the antidepressants Paxil (paroxetine), Effexor (venlafaxine), Prozac (fluoxetine) and Celexa (citalopram), the blood pressure drug Catapres (clonidine), and the seizure drug Neurontin (gabapentin).\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Medications listed in the story are available with a prescription, but they are not yet FDA approved for the treatment of hot flashes. Supplements such as soy and red clover are available without a prescription, however, these are not regulated and the active ingredient (i.e. plant estrogens) in these supplements may vary by manufacturer.", "answer": 1}, {"article": "The study, \"The Impact of Preoperative Statin Therapy on Open and Endovascular Abdominal Aortic Aneurysm Repair Outcomes,\" recently was published in Vascular, the official publication of the International Society for Vascular Surgery.\nIn an effort to prevent cardiovascular disease they take statin medications.\nPatients who took statins and had traditional open procedures also did better, but the difference was not nearly as significant as with endovascular repair.\n\"Most patients with this disease are older and tend to have other health conditions such as high cholesterol.\nWe wanted to understand the impact statin use has on surgical outcomes when repairing this type of aneurysm.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s assumed that the public is aware that statins are widely available as a prescription drug.", "answer": 1}, {"article": "Additionally, change in IRLSSGS score was significantly greater for the RLS device (17.22) compared to historic reports for ropinirole versus the placebo (12 versus 8.9 respectively).\nResearchers indicate that the pressure produced by the device may also stimulate a dopamine release, similar to massage therapy or acupressure.\nUntil recently, potent drugs including opioids, depressants and dopamine agonists have been used to ease symptoms, but each of these is accompanied by negative side effects such as dizziness, nausea, vomiting and the added risk of addiction.\nDisclosures: Dr Kuhn worked without compensation through Lake Erie Research Institute (LERI) during the 5 years of the study of the device and is now receiving compensation for that work.\nNone of the other study authors reported any conflict of interest or financial disclosure relevant to the topic of this study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Oddly, the release does not say that this foot wrap was cleared for sale by the FDA in 2013 and is already on the market (brand name restiffic).", "answer": 0}, {"article": "Most of the women had a personal history of breast or ovarian cancer already.\n\u201cThe interpretation of these tests is not a simple color-by-numbers thing.\u201d The vast majority of uncertain genes will be benign, but a misinterpretation could lead a patient to a drastic, unnecessary surgical procedure, he said.\nBut new tests for breast cancer risk mutations beyond the well-known BRCA genes would offer actionable information for many women and their doctors, a new study finds.\n\u201cThere\u2019s a lot of controversy even among experts,\u201d said the senior author of the new study, Dr. Leif W. Ellisen of Massachusetts General Hospital Cancer Center in Boston.\nThough these results indicate that additional genetic screening is clinically useful, some genetic test results will be uncertain, and it can be psychologically difficult for patients to deal with this uncertainty, Ellisen said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although availability isn\u2019t explicitly addressed, the story does note that women and their physicians are \u201cordering a wide selection of multiplex tests daily,\u201d from which one can infer that they are available. The story could have been more specific as to which panels were tested here and what others are available from physicians and even online. A good review is included in a table in this recent article from the NEJM.", "answer": 1}, {"article": "If a pill could prevent teenagers from taking dangerous risks, would you consider it for your children?\n\nI\u2019d be tempted. My skateboard- and bicycle-riding son was hit by a car\u2014twice\u2014when he was a teenager. I would have welcomed anything that could have averted those dreadful phone calls from the emergency room.\n\nWhile some bumps and scares...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear in the story that the drugs in question are available for prescription. However, the U.S.\u2019s complex behavioral health system and prescription drug payment policies makes obtaining them difficult for many, and the story would have served readers better if it discussed this barrier to access.", "answer": 1}, {"article": "CAM2038 is also being developed for treatment of chronic pain.\nThe CAM2038 products have been evaluated in three Phase 1/2 clinical trials, which evaluated the safety and tolerability as well as pharmacokinetic and pharmacodynamic properties of the products in a total of 176 individuals (opioid-dependent patients and healthy volunteers under naltrexone blockage).\nAbout CAM2038\n\nThe investigational CAM2038 buprenorphine subcutaneous injection products for treatment of opioid use disorder are being developed as once-weekly and once-monthly formulations, each with multiple doses, to cover all phases of treatment from initiation through maintenance.\nThe ability of CAM2038 to produce a long-lasting and robust blockade of hydromorphone-induced Drug Liking is especially encouraging,\" said Sandra D. Comer, Ph.D, Professor of Neurobiology, Columbia University.\nIn September 2015 the Food and Drug Administration (FDA) accepted for review Braeburn's New Drug Application for its lead candidate, Probuphine\u00ae, a six-month buprenorphine implant for treatment of opioid addiction.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release doesn\u2019t provide a time frame for when the drug, which is still under development, will be available but suggests it will be \u201ca future treatment alternative.\u201d We don\u2019t fault them for not providing a date following a phase 2 trial. There are many steps to be completed before or if it is approved and marketed.", "answer": 1}, {"article": "Robert Maclaren, a professor of Ophthalmology at Britain\u2019s Oxford University and a consultant retinal surgeon at the Oxford Eye Hospital, who was not involved in this trial, said he was \u201cvery excited\u201d by Zrenner\u2019s results.\n\u201cTo go from being completely blind for many years, to being able to read a few letters and see shapes is an amazing step.\u201d\n\nRetinitis pigmentosa in a genetic eye condition that leads to blindness and affects about 1 in 4,000 people worldwide.\nHe was cautious about possible wider applications, but said that if it was developed further, the device may someday be used to help people with severe cases of age-related macular degeneration, the leading cause of blindness in older people.\nAccording to the study published in the Proceedings of the Royal Society B journal, one blind patient who had the device implanted was able to identify and find objects placed on a table in front of him, and was able to walk around a room independently.\nExperts described the study results as phenomenal and said the device, developed by German researchers, could eventually change the lives of up to 200,000 people worldwide who suffer from blindness due to a degenerative eye disease called retinitis pigmentosa.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a credible job noting that the device is under study and not commercially available. Unfortunately it also suggests, based on the manufacturer\u2019s statement, that the device in a very early stage of development will be available in 5 years. The hyperbole used is indefensible \u2013 \u201cthe device could become routine for some kinds of blindness in five years\u201d\u00a0and \u201ccould eventually change the lives of up to 200,000 people worldwide.\u201d\u00a0 This comes after a test in 3 people.", "answer": 0}, {"article": "Two drugs once widely used to treat Parkinson's disease sharply increase the risk of heart-valve damage, researchers have found. The studies immediately prompted calls for the treatments to be discontinued or patients more closely monitored.\n\nPatients who take the drugs, pergolide or cabergoline, are four to seven times as likely to suffer damage to their heart valves as patients who don't take either one, according to two studies published in today's New England Journal of Medicine.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The Wall Street Journal article provides accurate information about the availability and stormy history of two Parkinson\u2019s drugs that may increase the risk heart valve disease.", "answer": 1}, {"article": "Nothing worked.\nShe enrolled in a trial, and by the third treatment session, \u201cI noticed a dramatic difference,\u201d she said.\n\u201cIt was receding.\u201d\nAs an adult, she faithfully performed facial exercises purported to tighten the area under the chin.\nThen she discovered another option: a series of fat-reducing injections intended to slim down a double chin.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the treatment will be available in late summer after doctors are trained to give the injections.", "answer": 1}, {"article": "TUESDAY, Nov. 16, 2010 (HealthDay News) -- By substituting a healthy gene for a defective one, scientists were able to partially restore the heart's ability to pump in 39 heart failure patients, researchers report.\nAfter that, the only option is a transplant.\nFor this phase 2 study, 39 patients with advanced heart failure were randomly chosen to receive either the gene therapy (through cardiac catheterization) or a placebo.\nThe American Heart Association has more on heart failure.\nAt both six months and a year later, the patients who had received the new gene saw their risk for death, cardiac transplantation, worsening heart failure and hospitalization decline by half.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that this gene therapy is experimental and not available to patients.", "answer": 1}, {"article": "Dec. 1, 2011 (Chicago) -- An experimental treatment that involves spinal injections of ozone gas and steroids relieved pain in over two-thirds of 327 people with back problems related to a herniated disc.\nNone of the people in this study had been helped by other nonsurgical therapies, and supporters say the new therapy could become a standard treatment for such patients.\nBefore the treatment, patients had tried everything without success and were considering an operation, he says.\nAnd 7% had no improvement or their pain got worse.\nAnother 22% reported only a little improvement, with pain persisting.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made clear that this treatment is available in Europe, but not in the United States.", "answer": 1}, {"article": "Check out more than one clinic and make sure you know what it defines as a \u201csuccess\u2019\u2019 \u2014 a viable transferring of an egg leading to a baby, or just a safely thawed egg.\n\u25a0 After a woman\u2019s mid-30s, her eggs may not be of high enough quality to produce a baby.\nDiscarding an unused embryo, which has the potential to develop into a baby, has weightier implications for many than discarding unused eggs.\n\u25a0 A woman who freezes eggs rather than embryos avoids potential custody problems if she and her partner split up.\nThings to consider before freezing your eggs\n\n\u25a0 Beware of a false sense of security.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear about the availability:\u00a0 \"half of 282 US fertility centers surveyed offer egg freezing.\" ", "answer": 1}, {"article": "FRANKFURT (Reuters) - Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in combination with Pfizer\u2019s Inlyta drug in a late-stage study.\n\nThe drug combination led to longer progression-free survival in patients with advanced renal cell carcinoma (RCC) when compared with a control group on older Pfizer drug Sutent, the German drugmaker said in a statement on Tuesday.\n\nThe trial will continue to show whether Bavencio plus Inlyta also prolongs patients\u2019 lives.\n\nWhile the company said the benefit was statistically significant, they did not specify the duration of progression-free survival. A detailed analysis would be submitted for presentation at a medical congress, it added.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not make clear that Bavencio and Inlyta are already on the market, much less that Bavencio\u2019s current use is for treatment of a skin cancer called Merkel cell carcinoma.", "answer": 0}, {"article": "Subsequent actions by PGC1-alpha then stimulate cells to produce more mitochondria.\nNoting that he is a scientific advisor to Sirtris, a company developing drugs that activate the sirtuins, Dr. Kahn said, \u201cCertainly, drugs that act on this class of proteins have the potential to have major effects on human disease.\u201d\n\nDr. Auwerx\u2019s study complements one published earlier this month by Dr. David Sinclair of the Harvard Medical School, who found that much more moderate doses of resveratrol protected mice from the metabolic effects of a high-calorie diet.\nThe two studies were started and performed independently, Dr. Auwerx said, though he obtained supplies of resveratrol from Sirtris, which was co-founded by Dr. Sinclair, and he has become a scientific advisor to the company.\nThe developing buzz over sirtuin activators has captivated some scientists who do research on the aging process, several of whom are already taking resveratrol themselves.\nThe principal theory developed by Dr. Guarente and others is that the sirtuins somehow sense the level of energy expenditure in living cells and switch the body\u2019s resources from reproduction to tissue maintenance when food is low.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story did not mention that reservatrol is not a substance approved by the FDA.\u00a0 It mentioned an available capsule product but then mentioned that this product's volume of resveratrol \"would have to be gulped in almost impossible quantities for a human to obtain doses equivalent to those used in mice.\"\u00a0 So the true availability issue was unresolved. \u00a0 ", "answer": 0}, {"article": "IRE uses strong electric fields that cause cells to die without exposing the tissue to radiation or heat.\n\"The patients we have treated at The Prostata Center have had their cancers destroyed without the need for surgery, with a low incidence of side effects and in most cases have been back on their feet the next day,\" said Dr. Michael K. Stehling, an internationally recognized expert on image guided tumor ablation treatments and primary author of the study.\nInitial tumor control was achieved in all patients, and during the follow-up period of up to 4 years, the recurrence rates were 0/55 (Gleason <7), 3/117 (Gleason 7) and 10/67 (Gleason >7).\nThe study which was conducted at the Prostata Center of Offenbach, Germany (www.prostate-center.org) will be presented today at the annual meeting of the Radiological Society of North America (RSNA).\n\"The data from this study confirms what we see every day, we have a very attractive approach for patients who are concerned about quality of life challenges and are considering options for the treatment of localized and late stage prostate cancer,\" he said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "When a release is all about a \u201cnew\u201d therapy, it is important to establish whether this technology and expertise is available only in academic centers or more widely in the community or hardly at all and only in clinical research. This release does not tell us anything about when and where this might be made available.\u00a0If the investigator is just now reporting up to 4 years of data on only 265 subjects then this is not widely available.", "answer": 0}, {"article": "Obesity-related health conditions include high blood pressure, type 2 diabetes and high cholesterol.\nBut the device can only be used for six months at a time, and it is not likely to be an alternative for people who require lap-band surgery, stomach stapling or other forms of bariatric surgery, said Dr. Mitchell Roslin, chief of obesity surgery for Lenox Hill Hospital in New York City.\n\"It's going to be effective for short-term weight-loss,\" Roslin said, \"but there is still an overwhelming question whether these devices provide any long-term benefit for obesity.\"\nThe people who initially will use the ReShape are people who can afford to pay for it out-of-pocket and need to drop some pounds quickly, Roslin said.\n\"The first few days are associated with a fair amount of nausea, and you will need some coaching to get through that,\" Roslin said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear the device has just won FDA approval, and has been available in Europe.\u00a0But the story doesn\u2019t comment on what might be the obstacles to use in the US. \u00a0What training is required? \u00a0How many physicians have been trained? \u00a0How might availability be held back if (as the story appropriately suggests) patients have to pay cash for it? Are there any lessons from Europe that would educate American consumers?\n\u00a0", "answer": 0}, {"article": "\u201cHowever,\u201d the researcher said, \u201cthere is a lack of clinical studies of the effect of vitamin D supplementation for preventing respiratory infections.\u201d\n\nFor the current study, Laaksi\u2019s team randomly assigned 164 male military recruits to take either 400 international units (IU) of vitamin D or inactive placebo pills every day for six months \u2014 from October to March, covering the months when people\u2019s vitamin D stores typically decline and when respiratory infections typically peak.\nSome researchers believe that people need more vitamin D than is currently recommended, and that intakes above 2,000 IU per day are safe.\nExcessive vitamin D in the blood can also raise blood pressure or trigger heart rhythm abnormalities.\nThe upper limit is currently set at 2,000 IU per day; higher intakes may raise the risks of side effects.\nWhile recruits in the vitamin group were more likely to have no days missed from duty, they were no less likely to report having cold-like symptoms at some point during the study period.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe availability of vitamin D supplementation is really not in question. ", "answer": 2}, {"article": "But in a new study the kids who consumed the fermented dairy product did no better, based on number of stools produced, than youngsters in a comparison group.\nIt seemed logical that probiotics, live microorganisms that are often called \u201cfriendly\u201d or \u201cgood\u201d bacteria, might work for children.\nThe finding is significant, the researchers say, because probiotics have helped some adults with constipation.\nMay 23, 2011 -- Researchers in Europe say a fermented dairy product containing a specific bacterium known as a probiotic did not relieve constipation in children more than a dairy product without a probiotic.\nThe study examined 159 children with constipation for at least two months with a defecation rate of less than three times per week.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story opened by informing readers that it was about \u201ca specific bacterium, known as a probiotic\u201d and although the story did indeed name the particular bacterium used in the study, it neglected to inform readers whether it was currently available to the public. And, since this was a European study, it raises even more questions in readers\u2019 minds about how the findings relate to American products.", "answer": 0}, {"article": "Before the trial, one 40-year-old, who said he had fears starting at age 10 that he was going to die in his sleep, rated his certainty that he was suffering from a serious illness as an 8 on a scale of 1 to 10.\nThe study found that hypochondriacs who got cognitive behavior therapy, which encourages people to challenge the validity of their disabling beliefs, also improved -- as much as those given the drug.\nAccording to the standard manual of mental disorders, hypochondriasis is a potentially serious condition that can prompt people to go doctor shopping, abuse sick time at work and become complete invalids.\nIn the first controlled study that compared a group of hypochondriacs given the drug with a group that got psychological talk therapy and another group that received sugar pills, the medication significantly reduced people's fears about imaginary illnesses.\nMen who had only daughters were more likely to have developed the disease than those who had at least one son, researchers found, and the relative risk of prostate cancer decreased as the number of sons increased.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is about the\u00a0medication Paxil, which is a\u00a0readily available prescription medication\u00a0though the piece failed to mention this and the fact that\u00a0the use of Paxil in the treatment of hypochondriasis has not been approved by the FDA.", "answer": 0}, {"article": "For more information about NIH and its programs, visit http://www.\nTo assess the impact of acetaminophen use on children's asthma, AsthmaNet investigators studied 300 children, aged 1 to 5 years old, who had mild, persistent asthma, defined as symptoms on more than 2 days out of a week but not daily.\nAs the primary pediatric affiliate of Case Western Reserve University School of Medicine and the only Level I Pediatric Trauma Center in the region, UH Rainbow Babies & Children's Hospital offers access to novel therapies, advanced technologies and clinical discoveries long before they are available nationwide.\nThe study, funded by the National Heart, Lung, and Blood Institute's (NHLBI) asthma network (AsthmaNet), appears in the August 18, 2016, issue of the New England Journal of Medicine.\nCLEVELAND, Ohio - A new study finds young children with mild, persistent asthma, can tolerate acetaminophen without the worsening of asthma, when compared with ibuprofen use.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of acetaminophen and ibuprofen is not in question, since these are well-known, over-the-counter drugs. We rate this one Not Applicable.", "answer": 2}, {"article": "\u201cBut if adults believe in echinacea, they\u2019re going to get benefits \u2014 maybe from placebo \u2014 but they\u2019ll get benefits.\u201d\n\nDr. Coleman, who described himself as \u201cnot much of a pill taker,\u201d hedged a bit when asked if he planned to use echinacea himself.\nIn addition, some studies might not use large enough doses of the herb; others might use a species of echinacea that is less effective.\n\u201cBut here every one of those things fails.\u201d One of Dr. Barrett\u2019s papers on echinacea was included in the analysis.\n\u201cThere\u2019s some danger of kids getting a rash, and it would be inadvisable to give it to women in the early stages of pregnancy,\u201d he said.\n\u201cIf you\u2019re testing the same intervention on the same population using the same outcome measures, then meta-analysis is a very good technique,\u201d Dr. Barrett said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article fails to say\u00a0how widely the herb is used and where it\u2019s available. But it\u2019s probably safe to assume that most Americans know how to find it.\u00a0 ", "answer": 2}, {"article": "Also unknown: Will insurers pay for the expensive test without evidence it leads to better care or saves lives?\nThe results suggest the test could triple the number of men thought to be at such low risk for aggressive disease that monitoring is a clearly safe option.\nIndependent experts say such a test is desperately needed but that it's unclear how much information this one adds or whether it will be enough to persuade men with low-risk tumors to forgo treatment, and treat it only if it gets worse.\n\"I would suspect that having cancer and having to live with it would be very difficult for them,\" but it doesn't bother him, Smith said.\nA new genetic test to gauge the aggressiveness of prostate cancer may help tens of thousands of men each year decide whether they need to treat their cancer right away or can safely monitor it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained that one test goes on sale today and that another recently came on the market. And it raised the questions about whether availability/use will be limited if there isn\u2019t evidence it leads to better care or saves lives.", "answer": 1}, {"article": "A study in the United States last year found that routine prostate cancer screening had resulted in more than a million being diagnosed with tumors who might otherwise have suffered no ill effects from them.\nThe study found that the predictive value of screening these men \u2014 expressed as the number of cancers detected relative to the number of tissue samples taken \u2014 was 48 percent, far higher than the 24 percent achieved in population-wide screening.\nThe findings suggest that by narrowing the focus of prostate cancer screening to those whose genes put them at most risk, doctors would catch more cancers early as well as reducing the potential for costly and damaging overdiagnosis.\nBut fears about overdiagnosis, which can lead to treatments such as surgery, radiation or hormone therapy that can cause serious side-effects such as impotence and incontinence, have so far dissuaded many European countries from nationwide screening.\n\u201cAlthough these are early results, it appears that (prostate cancer) screening is reasonably accurate at predicting potentially aggressive prostate cancer among men at higher risk of the disease due to a genetic predisposition,\u201d said Ros Eeles, who led a research team from Britain\u2019s Institute of Cancer Research (ICR) and Royal Marsden hospital.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that PSA testing is the standard screening for men, saying, \"U.S. doctors routinely recommend PSA screening in men over 50 on the assumption that early diagnosis and treatment is better than doing nothing.\"", "answer": 1}, {"article": "This page either does not exist or is currently unavailable.\n\nFrom here you can either hit the \"back\" button on your browser to return to the previous page, or visit the ABCNews.com Home Page. You can also search for something on our site below.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Mentioned that statins are widely used and considered safe. Mentioned that use as cancer \npreventative would be an off-label use (i.e. drugs not approved for this purpose)", "answer": 1}, {"article": "The main stages of NAFLD are:\n\n1.\nIt is the first time an epigenetic signature in blood has been discovered which is diagnostic of the severity of fibrosis for people with Non-alcoholic Fatty Liver Disease (NAFLD).\nCirrhosis - the most severe stage, occurring after years of inflammation, where the liver shrinks and becomes scarred and lumpy; this damage is permanent and can lead to liver failure (where the liver stops working properly) and liver cancer\n\nIt can take years for fibrosis or cirrhosis to develop and the presence of this scarring predicts those people with the worse prognosis.\nNon-alcoholic steatohepatitis (NASH) - a more serious form of NAFLD, where the liver has become inflamed; this is estimated to affect up to 5% of the UK population \n\n3.\n\"We know that the presence of even mild fibrosis of the liver predicts a worse long-term outcome for patients with NAFLD and so it's important to be able to detect liver scarring at an early stage.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release includes a quote that says \u201cWe are now working on confirming these findings in a larger group of patients.\u201d Based on that, readers can infer that the technique is not yet available \u2014 so it gets a pass. However, it would have been better to state that more explicitly. As the paper itself says: \u201cWith validation, this blood-based biomarker could become an important contributory clinical tool alongside other epigenetic, genetic and biochemical biomarkers, mitigating the future need for biopsy to evaluate fibrosis.\u201d", "answer": 1}, {"article": "Some doctors are raising concerns about a new cancer-treatment device that uses electrical jolts to zap tumors but that hasn't been through a large clinical trial to prove it's safe and effective in people.\n\nThe device, called NanoKnife, is currently being used in about 13 U.S. hospitals including Baptist Health Medical Center in Little Rock, Ark., University of Louisville, and Shands Hospital/University of Florida in Gainesville, Fla. Each machine costs as much as $300,000. Some of the hospitals are aggressively promoting...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that the NanoKnife is \"currently being used in about 13 U.S. hospitals including Baptist Health Medical Center in Little Rock, Ark., University of Louisville, and Shands Hospital/University of Florida in Gainesville, Fla.\" It later says, \"The NanoKnife, which is also available in five hospitals outside the U.S., has so far been used to treat about 300 cancer patients world-wide.\"", "answer": 1}, {"article": "So his team designed a randomized controlled clinical trial to see if short-term use of a curcumin supplement could reduce inflammation in people with metabolic syndrome, a cluster of risk factors for heart disease.\nThe researchers didn\u2019t examine the effect of curcumin on any diseases, and it was a fairly brief study, so it\u2019s not clear what the long-term implications may be they caution in their report.\nThe study team also analyzed data from eight previous studies and confirmed that curcumin had shown a significant reduction of CRP concentrations in a total of 281 patients.\n\u201cCurcumin is the active ingredient of the famous spice turmeric and has a long history of culinary and medicinal use in the Asian countries,\u201d said the study\u2019s senior author Amirhossein Sahebkar.\n\u201cCurcumin is a very safe natural supplement, and there is no severe adverse event associated with its use, even at high doses,\u201d Sahebkar said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that one of the study co-authors is affiliated with companies that make curcumin supplements, so it is easily inferred that such supplements are available.", "answer": 1}, {"article": "That myelin increases the speed of neural transmission is one of the most well-established concepts in neurobiology, and combined with the clear evidence from Chan's preclinical research showing that clemastine fumarate promotes myelin formation, myelin regeneration is the only plausible explanation for the VEP results, the authors said.\nThe effect persisted in the group that had switched to placebo, suggesting that durable repair of myelin had been induced by the drug.\nTo enhance the power of their study, the researchers used a \"crossover\" design: they divided the patient population in two and gave the drug, blinded to both participant and researcher, to one group, and a placebo to the other for 90 days; then they switched between the two groups, giving a placebo to the first group and the drug to the other for the next 60 days.\nThe new results are particularly notable, Chan said, because patients in the trial had suffered from MS symptoms caused by injury to myelin for years.\nThe researchers said that the Phase II results, published online on 10 October, 2017 in The Lancet, are the first in which a drug has been shown to reliably restore any brain function damaged by a neurological disease in human patients.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release reports that clemastine was first approved by the US FDA in 1977 for allergies and that its generic form has been available over the counter since 1993.\nWe rate this Satisfactory.", "answer": 1}, {"article": "\"Our idea was to ask, 'What are the most important proteins we could find in Alzheimer's patients?'\nThe test has also shown promise in predicting which patients with mild memory loss are at high risk of developing the dreaded syndrome, which each year kills 66,000 Americans and inflicts incalculable heartache on the families of its victims.\nIn one experiment using stored blood samples, the test was positive for Alzheimer's disease in 38 out of 42 patients who had been independently diagnosed by clinicians as having the disease - a 90 percent accuracy rate.\n\"\n\nThe Stanford professor and his team screened 120 such proteins that commonly circulate in the blood, and settled on 18 that showed the signature of Alzheimer's.\nAlthough the studies were small in scale, researchers said the experiment proved that the concept of screening for chemical signals was promising and that the first Alzheimer's blood test might be within reach after further large scale studies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story used words like \"proves\" and \"promising\", it also included estimates for the time needed for further testing\u00a0that made it clear that this was not something that was currently available.", "answer": 1}, {"article": "\"Although alemtuzumab [Lemtrada] treatment is associated with safety risks, those risks are manageable in most patients,\" Miskin said.\n\"Some patients have been going 12 years without any evidence of disease activity,\" he said.\nMoreover, patients receiving Lemtrada were 2.5 times more likely to have their thinking skills improve compared to those given interferon.\nThe report was published online Oct. 12 in the journal Neurology.\nNow we can tell our patients that a significant number can actually improve by reversing their disability,\" said lead researcher Dr. Gavin Giovannoni.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states\u00a0that the drug is approved in the U.S. for patients who have failed other treatments.", "answer": 1}, {"article": "Neither method yields an entirely satisfactory outcome in older adults.\n\"The results reported by Willett et al demonstrate that most unstable ankle fractures in older patients can be treated with a cast without the need for surgery,\" writes David W. Sanders, M.D., M.Sc., F.R.C.S.C., of Western University, London, Ontario, Canada, in an accompanying editorial.\nAmong older adults with an unstable ankle fracture, the use of a modified casting technique known as close contact casting (a molded below-knee cast with minimal padding) resulted in similar functional outcomes at 6 months compared with surgery, and with fewer wound complications and reduced intervention costs, according to a study appearing in the October 11 issue of JAMA.\n\"Close contact casting was delivered successfully for most participants, substantially reducing the number of patients requiring invasive surgical procedures at the outset and additional operations during a 6-month period,\" the authors write.\nEditor's Note: The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release quotes an accompanying editorial stating that \u201cclose contact casting may be unfamiliar to some orthopedic surgeons.\u201d Although that\u2019s a vague statement, we can assume it\u2019s not in widespread use.\nIn the U.S., most orthopedists are not trained in close contact casting nor do they feel comfortable using it. \u00a0Most patients will not be offered this treatment as an option for their fracture care.", "answer": 1}, {"article": "But Cytori\u2019s machine hasn\u2019t been approved by the .\n\u201cAnyone can take fat and inject it into the breast, and the patient will look good immediately afterwards,\u201d Dr. Khouri said, but a few months later, the fat injected by a doctor with sub-par skills may result in \u201coil cysts, masses, and scarring.\u201d\n\nTo some, this kind of fat recycling seems simple.\nThe study, which Dr. Khouri plans to publish in a peer-reviewed journal, found that the procedure does not impede the reading of mammograms and that on average, 85 percent of transplanted fat survived to give patients natural-feeling larger breasts.\nThat hasn\u2019t stopped Dr. Todd Malan, a board-certified ob-gyn in , Ariz., who is the surgeon in the ABC news clip, from anointing himself the \u201cFirst in U.S. to perform Stem Cell Enhanced Breast Augmentation!\u201d on his Web site.\nBut Dr. Michael F. McGuire, the president of the American Society of Plastic Surgeons, cautioned: \u201cHow you take the fat, how you process it, how you inject it are all factors in how successful fat survival is going to be.\u201d\n\nIn some cases, radiologists can distinguish between innocuous and suspicious calcifications, said Dr. Sameer A. Patel, a plastic and reconstructive surgeon at Fox Chase Center in .\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nThis story points out that only a handful of surgeons across the country offer breast augmentation using fat grafts and that the results are highly dependent on the skill and experience of the surgeon. The story also warns about doctors who promise unrealistic results.\n However, the story offers readers no information about how to locate a surgeon who has a good track record.", "answer": 1}, {"article": "Chattoo also offers patients a nutritionist and trainer with the procedure.\nIt is meant for people looking for an extra jumpstart on a diet, whether the purpose is cosmetic or for health reasons.\nThe hope is that patients can train their body to eat in a much healthier fashion without feeling overly hungry.\n\u201cThe beauty of the procedure is that it is a nonsurgical procedure,\u201d Chattoo said.\nThe balloon remains in the patient\u2019s stomach for six months and is then removed the same way it was inserted, through the mouth.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t tell readers that Orbera is available, but it can be inferred from the patient\u2019s testimonial, so we\u2019ll give it a pass.", "answer": 1}, {"article": "One was a low-fat diet that included lots of fruits, low-fat dairy, poultry, whole grains and small amounts of red meat.\nThe only difference between the two was the avocado \u2014 the other diet had the same amount of fat from other sources.\nAnd given the reduction in funds available for research, it's become increasingly common for researchers to carry out these kinds of industry-supported studies.\nIt was also supported by a grant from the Hass Avocado Board, an industry group that the researchers say had no role in the design of the study or the interpretation of the data.\nAt the end of the study, the researchers found that the avocado diet led to significant reductions in LDL cholesterol, compared with the other two diets.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Avocados are widely available, so we won\u2019t ding the story for not discussing availability. As with the competing stories, we would have liked to have seen some acknowledgment that there are areas where avocados may be more difficult to find.", "answer": 1}, {"article": "Devenish manufactures pre-mix and special feed for pigs, poultry, cattle, sheep, equine, game, companion animals and aquaculture.\nThe Devenish strategy, 'One Health, From Soil to Society, focuses on the importance of optimising nutrient utilisation in soil, plant, animal, environmental and human health, as key and interlinked components of the value chain.\nThe findings were presented by Professor Alice Stanton of The Royal College of Surgeons in Ireland:\n\n\"Greater consumption of oily fish has long been linked to a reduced incidence of heart attack, stroke, diabetes and cancer and improved brain health, vision, muscle and joint health,\" said Professor Alice Stanton.\nThe results from the clinical study saw an increase in omega-3-PUFA levels in blood and a positive shift in what is described as the 'omega-3 Index'-a test that measures the amount of the omega-3 fatty acids, Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) in red blood cell membranes, which reflects the levels in your heart and other tissues.\nThe 161 subjects involved in the study consumed at least three portions of chicken and eggs per week, that were naturally enriched with omega-3 Polyunsaturated Fatty Acids (PUFA), the same nutrients found in oily fish.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although it isn\u2019t made clear in the release whether the new chicken feed is on the market yet, one might assume that it will be shortly, based on the fact that the release seems aimed more at promoting a commercial product than it does describing actual clinical research.", "answer": 2}, {"article": "These weekend warriors cram the recommended amount of exercise into one or two days, while the rest of us faithfully head to the gym multiple times a week for a half-hour hamster run on the treadmill.\nThis could be something as simple as a brisk walk or other low-impact options for vigorous exercise about 20 minutes a day.\nHowever, there are also some limitations to this study, the researchers say.\nThe coronary heart disease patients who stuck with the recommended 150 minutes a week had the lowest risk for heart attack and stroke.\n\u201cIn theory, someone who did one bout of 150 minutes of moderate exercise is a weekend warrior,\u201d says O\u2019Donovan.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We think that the ability to exercise is generally available, so this is N/A.", "answer": 2}, {"article": "Autism is a group of complex brain developmental disorders characterized by impairments in social interaction, communication, and stereotypical and repetitive behaviours.\nThe study, led by researchers at the University's Brain and Mind Centre, is thought to be the first evidence of a medical treatment for social impairments in children with autism.\n\"The potential to use such simple treatments to enhance the longer-term benefits of other behavioural, educational and technology-based therapies is very exciting,\" he said.\n\"We found that following oxytocin treatment, parents reported their child to be more socially responsive at home, and our own blind independent clinician ratings also supported improved social responsiveness in the therapy rooms of the Brain and Mind Centre,\" he said.\n\"We used some of the most widely used assessments of social responsiveness for children with autism,\" said autism expert, Associate Professor Adam Guastella of the Brain and Mind Centre.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t mention that synthetic oxtocin (in this trial Syntocinon was used) has been widely available for many years. It was first synthesized by American Nobel prize-winning biochemist Vincent du Vigneaud in 1955. It is most frequently used as an injectable to induce labor in pregnant women.", "answer": 0}, {"article": "The medical community has called for an increase in colorectal cancer screening overall, both through the recent recommendations of the Cancer Moonshot Blue Ribbon Panel and the National Colorectal Cancer Roundtable's call for 80% screening by 2018,\" said Joshua Korzenik, M.D., a co-founder of ColonaryConcepts, and Faculty Member at Harvard Medical School and the Director of the Brigham and Women's Hospital Crohn's and Colitis Center.\nThe primary outcome was the proportion of subjects with an endoscopic visibility rating of excellent or good based on the Aronchick scale.\nThe investigational prep is designed to be good-tasting, with no fasting and lower fluid requirements than standard preps.\nThere were no serious adverse events across any of the treatment groups.\nThe study tested six formulations of ECP, using different doses of the active ingredients integrated within different meal kit menus, randomized against two U.S. Food and Drug Administration-approved active comparators.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release makes it clear that the results reported come from a Phase 2 clinical trial and that Phase 3 trials may begin in early 2017. Put another way, the prep is not yet available.", "answer": 1}, {"article": "The boxes are a new idea for many Americans.\n\u2018\u2018They do it because they want to be nurturing and they are, but it\u2019s not safe.\u2019\u2019\n\nTo get the boxes, prospective moms can register through babyboxuniversity.com, watch a handful of videos on sleep safety and pass a quiz.\nBut when they\u2019re linked to a practice that started in Finland decades ago to help babies sleep safely, they\u2019re taking on a new purpose as so-called baby boxes make their way to the U.S.\n\nParents are beginning to take baby boxes home from hospitals along with their newborns.\nThe idea for baby boxes started in Finland in the 1930s, and is tied to a sharp drop in sudden infant deaths, according to Dr. Kathryn McCans, a pediatrician who chairs New Jersey\u2019s Child Fatality and Near Fatality Review Board.\nMcCans says the complimentary items like diapers and onesies are nice, but the more important objective behind the boxes is bringing down infant deaths and grounding parents on safe sleep practices: Place babies on their backs to sleep; Don\u2019t use bumpers in cribs; Keep stuffed animals and blankets out of infants\u2019 sleep spaces; Avoid sleeping in the same bed as infants.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The boxes are given away, but parents have to \u201cregister\u201d through babyboxuniversity.com.\nThey must \u201cwatch a handful of videos on sleep safety and pass a quiz. Parents can then take their digital or printed-out certificates to a participating hospital for their boxes. The boxes can also be sent in the mail, if a nearby hospital is not designated as a distribution center.\u201d\nWe are left unsure whether any parent can get a box from the company without registering or can a parent watch the educational material without registering and giving away his or her identity?", "answer": 0}, {"article": "By contrast, previous BCG vaccination subverted TST specificity [62% (67/108) in BCG vaccinated compared to 95% (99/104) in BCG unvaccinated persons; (p<0.001)].\nThe TST is the most commonly used test to detect TB infection, with about 50 million tests worldwide each year, according to the World Health Organization.\nThe test is easy to administer but produces too many false positives to achieve the WHO's goal of reducing TB deaths by 95 percent and new cases by 90 percent by 2035, Dr. Ruhwald said.\nThe study, conducted in South Africa, enrolled 1,090 participants, including 299 patients with HIV and 402 children as young as 28 days.\nCayla2, H. Aggerbaek1, K. Dheda3, P. Andersen1 \n\n1Statens Serum Institut - Copenhagen/DK, 2Public Health Agency of Barcelona - Barcelona/ES, 3UCT Lung Institute, Lung Infection & Immunity Unit - Cape Town/ZA\n\nRenewed emphasis on the detection and preventive treatment of M. tuberculosis-infected individuals at risk is required to reach the goals of the WHO post-2015 global tuberculosis strategy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release informs readers that the test still faces a regulatory and commercial path, which strongly implies it is not yet available: \u201cRegulatory approval for C-Tb is currently being sought and Statens Serum Institute is actively seeking a commercial partner for marketing of C-Tb. The cost of a C-Tb test is to be determined; however, it is expected to be significantly less than an IGRA.\u201d", "answer": 1}, {"article": "Dr. P. Murali Doraiswamy, a biological psychiatrist at Duke who had helped recruit patients for the study, called the results among \u201c the most highly anticipated data from the entire meeting.\u201d\n\nTo compare the scans with autopsy results, the company scanned the brains of 35 people in hospices who were expected to die within six months.\nAnd the data showed that the scans were completely accurate in ruling out Alzheimer\u2019s pathology: unlike doctors, they never said people had Alzheimer\u2019s pathology when they did not.\nAlthough the scans looked promising, the companies needed to show that what they revealed was the same as what a pathologist would see on autopsy.\nIn 34 of the 35 patients, the PET scan, the pathologists\u2019 report and the computerized pathology report agreed.\nIn one patient who had Alzheimer\u2019s, the pathologist and the radiologist analyzing the scan did not see much plaque, but the computerized analysis of the scan and the two autopsy reports did.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story was clear that it was reporting on a screening test for Alzheimer\u2019s disease that is undergoing study. That said \u2013 it would have been better to state explicitly that this test is currently unavailable to patients.", "answer": 1}, {"article": "For more information, please see www.arthrokinex.com\nTypically, the treatment process is painless and just takes a few minutes and consists of one injection per week for three weeks, followed by quarterly injections, as needed.\nSignificantly better concentration, healing/pain reduction durability, faster production (just one hour), one-fifth the price, and chemical additive free, IRAPjoint\u2122 is now available in multiple physician practices throughout the United States.\nThe cost of the USA-based IRAPjoint\u2122 treatment is $2,000 compared to the reported price of $10,000 for a foreign competitor.\nFinally, a U.S. based company has a solution for America's professional and weekend athletes as well as those struggling with aching or arthritic joints.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The specific treatment in the news release is only offered at one clinic in the U.S., but the news release didn\u2019t mention if any other clinics or companies offer a similar therapy. The release also makes it sound like this treatment is available for anyone with bad joints, though theoretically there would be people who do not qualify for the treatment based on their symptoms or medical history. ", "answer": 0}, {"article": "Related: New Test Detects Heart Disease Risk, Especially for Black Women\n\nIt\u2019s not just the fat cells that lead to heart disease, the No.\nSometimes a heart attack or stroke is the very first symptom.\nAbout 750,000 Americans have a heart attack every year.\nIt\u2019s inflammation, also.\n1 cause of death in the United State.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that more research is needed before the technology might be available to everyone.", "answer": 1}, {"article": "The medications, which include Requip (ropinirole), levodopa, Neurontin (gabapentin) and Lyrica (pregabalin), appear to reduce symptoms of the syndrome in more than 60 percent of patients, researchers report.\nThe most common side effects of these drugs include fatigue, swelling in the legs, dizziness and weight gain.\n\"This may be due to restless legs syndrome or other conditions.\nThe harms of medications may outweigh benefits for these individuals, Wilt said.\nThe same is true for levodopa, Wilt said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the drugs discussed are all approved by the FDA.", "answer": 1}, {"article": "He contended that kratom does not act on the brain's opioid receptors the way prescription painkillers and heroin do. But back in 2016, the Journal of the American Chemical Society reported that kratom indeed works this way. Last month, an FDA study found that 22 of the 25 of the most prevalent compounds in kratom do bind to opioid receptors, and so should be considered an opioid. The study also said most deaths did occur in people who used kratom in addition to other drugs, though in one case, only kratom was detected.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that kratom is widely available in Philadelphia at gas stations and convenience stores, but that a number of states have banned kratom or\u00a0have legislation to ban it pending.", "answer": 1}, {"article": "Migraines are throbbing, one-sided headaches that can be accompanied by nausea as well as sensitivity to light, sound, smell, and movement.\nRight now, the only available preventive treatments are accidental discoveries: A number of people prescribed medications for depression, high blood pressure and epilepsy discovered migraine relief, too.\n\"There's a big hole to fill, both in prevention and acute therapies,\" says Alexander Mauskop, director of the New York Headache Center in New York City.\nIn women of childbearing age, who are the ones most prone to frequent migraines, \"you can imagine that might have effects on fertility or placental function.\"\nBut then he says that, since I'd previously shown some response to Botox, perhaps I might want to give it another try.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear these injections aren\u2019t available yet:\nTwo manufacturers, Amgen (in collaboration with Novartis) and Teva Pharmaceuticals, have completed clinical trials and expect to hear from the FDA by June whether the therapies have been approved. Two more companies, Eli Lilly and Alder Biopharmaceuticals, plan to file for FDA approval later this year.\nIt also cautions that their high cost means insurance companies might \u201crequire patients to have tried just about everything else first.\u201d", "answer": 1}, {"article": "\u201cSo this is a possible fringe benefit.\u201d\n\nResearchers studied 2,447 men over 12 years, examining them every other year.\nThe study, published online by The American Journal of Epidemiology, had limited data on dosage, but scientists believe that even low doses of anti-inflammatory drugs reduce the risk of urological problems.\nOther nonsteroidal anti-inflammatory drugs, or Nsaids, like naproxen (Aleve) or ibuprofen (Advil or Motrin), have the same effect.\nTaking aspirin every day may lower the risk for prostate enlargement, a new study has found.\nAfter adjusting for age, diabetes, hypertension and other factors, men who took a daily aspirin or another Nsaid reduced their risk of moderate or severe urinary symptoms by 27 percent, and their risk of an enlarged prostate by 49 percent.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article mentions medications like aspirin, naproxen, and ibuprofen, all of which are currently available (and available without a prescription, although this is not explicitly stated). ", "answer": 1}, {"article": "Why?\nThis is an indication of the standardization of hospital care regardless of the time/day that patients seek care.\u201d\n\nStudies on the potential for a \u201cweekender effect\u201d in care and outcome for urgent conditions such stroke and heart attack have yielded mixed results.\nFor example, in one study examining stroke outcomes in Canada, researchers found that patients with stroke admitted to the hospital on weekends were at greater risk of dying than those admitted on weekdays.\nOverall, Kazley added, this study offers \u201cgood news that indicates that the quality of care is similar regardless of when patients present at the hospital for treatment.\nIn this study, weekend admissions for heart attack were associated with much higher death rates, leading the researchers to conclude that more appropriate hospital staffing or regionalized care of heart attack patients may prevent some of these deaths.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Similar to the story from HealthDay, this report\u00a0emphasizes\u00a0that\u00a0an early diagnosis\u00a0is a critical\u00a0factor in the availability of\u00a0tPA for stroke patients. Although more detail could have been provided, this is the key point.", "answer": 1}, {"article": "But overall, the median length of survival was 12.5 months for patients treated with poliovirus, compared with 11.3 months for a similar group of patients treated in the past, the researchers report.\nIn the study, only 21 percent of patients experienced a prolonged survival.\nBetween 2012 and 2017, the researchers treated 61 patients, trying various doses of the modified virus to determine which was safest and most effective.\nGlioblastoma is the most common and aggressive malignant brain tumor in adults.\nAnd starting at two years after treatment, the two groups' survival rate began to diverge, the researchers reported.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made clear this is an experimental therapy and thus not yet widely available.", "answer": 1}, {"article": "A recent Canadian study looked at the issue, but the analysis had a caveat: Each of the more than 3,400 clinical trial patients received rivaroxaban the first five days after surgery.\nThese days, most patients have a generally low risk of blood clots after knee replacement for a number of reasons.\nSome patients are even going home the same day.\nThat was true for 1.42 percent of anticoagulant patients, according to the Michigan study.\n\"Aspirin is easy to take and much less expensive,\" Hallstrom says.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that many knee replacements surgeries are performed every year.", "answer": 1}, {"article": "While the American Cancer Society, the American College of Physicians and other gastroenterology experts recommend virtual screening every five years, the U.S. Preventive Services Task Force, a congressionally mandated but non-federal, independent group of medical experts, concluded the evidence wasn\u2019t strong enough to justify Medicare coverage of the service.\nBut according to Dr. Marc Gollub, director of CT and gastrointestinal radiology at Memorial Sloan-Kettering Cancer Center, \u201cthe radiation is much lower than a regular CT scan and has not been proven to be of any risk.\nThe prep for both the virtual and actual colonoscopy is the same \u2014 the dreaded \u201ccolon cleanse\u201d that many patients find is the worst part of the procedure.\nBut in spite of those challenges, Megan McHugh at the Health Research and Educational Trust in Chicago and her team report that about 17% of hospitals in the U.S. now offer the screening test, up from 13% in 2005.\nOr, the images can be combined to generate a 3D view of the colon, allowing the doctors to \u201cfly through\u201d the organ looking for any suspicious growths or protrusions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is based on estimates of the rising use of virtual colonoscopy and cites one estimate that 17% of US hospials now offer it. The story suggests that the availability of CT colonoscopy is \u201con the rise.\u201d In reality the study in question actually demonstrated only a 3% increase over a 3 year period.\u00a0 Is that high or low?", "answer": 1}, {"article": "Drinking cow\u2019s milk produced at night may be a treatment for anxiety and insomnia, suggests an animal study in the Journal of Medicinal Food.\n\nA glass of milk at bedtime has long been touted as a sleep aid. But the study found that milk collected at night, or night milk, had enhanced sedative effects in mice compared with milk produced during the day. Night milk significantly decreased the rodents\u2019 physical activity, balance and coordination and increased sleep time compared with day milk, the research showed.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes an effort to establish the availability of night milk by\u00a0providing a hyperlink\u00a0to a company that sells night milk. But the website obviously caters to German customers and seems like it could be a headache for US consumers to navigate. And we couldn\u2019t find any other online sources of night milk besides this company that would be more accessible.", "answer": 1}, {"article": "Then what, Dr. Nigg asked in series of studies, do orthotics actually do?\nThe men selected five of the six inserts with equal frequency.\nEach made a different type of insert to \u201ccorrect\u201d his pronation.\nEach man chose the insert he found most comfortable and wore it for four months.\nBut they can have large effects on muscles and joints, often making muscles work as much as 50 percent harder for the same movement and increasing stress on joints by a similar amount.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both off-the-shelf and custom shoe inserts are widely available. This doesn\u2019t merit discussion.", "answer": 1}, {"article": "The panel evaluated 38 of the most popular or trendy diets this year.\nOn the opposite end of the list, the Whole30 diet -- a 30-day program that bans processed foods, legumes, grains, dairy, alcohol and added sugar -- ranked as the worst overall diet on the list, the new report said.\nWhen it comes to speedy weight loss, the HMR program and Biggest Loser diet shared the top ranking, followed by the Atkins diet in second place and Weight Watchers in third.\nThe MIND diet includes some features of the DASH diet and Mediterranean diet, such as high consumption of fruits, vegetables and fish, but focuses on foods that promote brain health.\nThe DASH (Dietary Approaches to Stop Hypertension) diet was designed to lower blood pressure and cholesterol levels by limiting fats, red meat and sugar in favor of healthy grains, poultry, low-fat dairy and nuts, the U.S. National Heart, Lung, and Blood Institute says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s understood that the DASH diet is widely available. It has been available and promoted to the public for many years. There are books, public and private websites, shopping lists and menus devoted to it. It has been named the \u201cTop Overall Diet\u201d by one magazine six years in a row.\nThe concern that a broad swath of the public does not have the financial means or a neighborhood grocery store they can walk into and acquire the menu items is another matter.", "answer": 1}, {"article": "Master said each participant was asked to carry an accelerometer to record movements and an iPod Touch loaded with an app that would ping them prompts at intervals during each day to report any symptoms they were feeling. They also completed activity questionnaires and summaries. In addition, they wore a device called an ActiGraph to monitor sleep.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers may feel mislead about the availability of the app, given the story\u2019s headline (\u201cHow to heal head injuries? Try new app\u201d) which very strongly indicates that not only is this app publicly available, but also that it\u2019s capable of healing head injuries. Neither are true. \u00a0", "answer": 0}, {"article": "The average age was 53 when the study began.\nDuring the next seven years, the cancer returned in 256 women (16.7 percent) in the special diet group and 262 women (16.9 percent) in the comparison group.\nThe government study found no benefit from a mega-veggie-and-fruit diet over the U.S. recommended serving of five fruits and vegetables a day -- more than most Americans eat.\nAn additional 1,551 women were given only materials about the importance of eating five servings of fruits and vegetables a day.\nHopes that a diet low in fat and chock-full of fruit and vegetables might prevent the return of breast cancer have been dashed by a seven-year experiment in more than 3,000 women.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not specifically mention the availability of a fresh fruits and vegetables for all populations, but the focus of the story is on the lack of evidence that a diet concentrated on these foods has any benefit for breast cancer recurrence.\u00a0 No preventative behavioral modification related to diet is advocated.\u00a0 The story was also suffienciently clear about what the \"treatment\" was (number of servings of vegetables and fruits, etc) such that if a person wanted to \"treat\" themselves in this manner they could replicate the intervention.\n\u00a0\n", "answer": 1}, {"article": "Yin Cao, an instructor in the Medicine, Clinical and Translational Epidemiology Unit at Massachusetts General Hospital and Harvard Medical School, presented the information Monday at the American Association for Cancer Research meeting in Washington.\n\"This study found strong evidence that aspirin use may reduce cancer death.\nThe study was well conducted and was able to control for a number of important confounders.\nMen's risk of dying from lung cancer was also lower.\nEven the ancient Egyptians used the natural form of it for pain relief centuries ago.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Aspirin is\u00a0widely available.", "answer": 2}, {"article": "\"We estimate that use of [Brilinta] instead of [Plavix] for one year in 1,000 patients with acute coronary syndromes and who are planning to undergo an invasive strategy at the start of drug treatment would lead to 11 fewer deaths, 13 fewer myocardial infarctions, and six fewer cases of stent [clotting] without an increase in the rates of major bleeding or transfusion,\" conclude study researcher Christopher P. Cannon, MD, and colleagues.\nThat's probably why the 6,732 study patients who got Brilinta were 16% less likely to die, or have a heart attack or stroke, than were the 6,676 patients who got Plavix.\nAnd since the drugs irreversibly bind to blood-clotting platelets, a patient has to stop taking these drugs for five to seven days before the body can make enough new platelets.\nThe new kid on the block is AstraZeneca's ticagrelor, to be named Brilinta if the experimental drug gets FDA approval.\nStone has in the past received honoraria from the makers of both Plavix and Brilinta and serves on the advisory boards of Boston Scientific and Abbott Vascular.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was clear that ticagrelor is not yet have FDA approval.\nHowever, the story stated that \u2018approval was likely\u2019 and that the drug will be marketed as Brilinta. \u00a0Both pieces of information are more akin to marketing than reporting. \u00a0It would be more accurate to state that the drug is currently under consideration for FDA approval and that the name Brilinta has been proposed.", "answer": 1}, {"article": "\u201cIf you\u2019re a busy surgeon, you have a volume to maintain,\u201d Bollinger says, \u201cand it\u2019s hard to go from doing three a day to one during the learning period.\u201d\n\nChristopher Chen, a surgeon who uses the anterior approach at Alta Bates Summit, adds that most doctors \u201cstill use the posterior approach because it\u2019s the one they were taught.\u201d And, he says, the majority of younger surgeons learn the older approach because established surgeons are typically the ones who staff the residency training programs and demonstrate the method they know best.\nBut with a relatively new procedure, surgeons enter from the front and only stretch the muscles aside, avoiding the cutting and minimizing pain and recovery time.\nAnother obstacle to the widespread use of the newer approach is that if established surgeons want to switch, they face time and cost constraints.\nThe surgery is extensive: As its name suggests, it involves removing the joint \u2014 the damaged bone and cartilage \u2014 and replacing it with prosthetic parts made of metal, plastic or ceramics.\nHe says that \u201cnurses love the anterior approach\u201d because there\u2019s less worry about dislocating the joint.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story spends a lot of time discussing why this technique is still only practiced by a minority of physicians, but it is clear that it is a widely available option.", "answer": 1}, {"article": "Peer-reviewed clinical studies show that the Proove Opioid Risk\u00ae profile accurately identifies patient risk for opioid abuse.\nDr. Ashley Brenton, Associate Director of R&D for Proove states, \"This validation study builds on the peer-reviewed evidence supporting Proove Opioid Risk\u00ae and its components as an optimal model to predict opioid abuse risk.\"\nThis study, entitled \"Evaluation of a Predictive Algorithm that Detects Aberrant Use of Opioids in an Addiction Treatment Centre\", is published in the peer-reviewed Journal of Addiction Research and Therapy (Impact Factor: 1.4).\nFurthermore, the sensitivity of the \"moderate risk\" cut-off score was 98%, while the specificity of the \"high risk\" score was 100%.\nThis study evaluated 186 patients, comparing 94 Medicaid patients at an addiction treatment facility with confirmed cases of opioid abuse, and 92 healthy patients with no history of opioid use.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release quotes one of the study authors as saying he has used the \u201ctechnology\u201d for six years, suggesting that it should be available. However, the news release does not provide information about any use of the POR algorithm by health professionals not affiliated with Proove or this specific study. The release neglects to mention whether the FDA has cleared the device for marketing.", "answer": 0}, {"article": "Please use our search feature and update your bookmarks. Thank you!", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that estriol is widely available now for other uses and that researchers have yet to complete Phase lll trials and apply for FDA approval for application in MS patients. However, it should be noted that estriol is far more commonly used in topical skin creams and not in tablet form as was the case with this study.", "answer": 1}, {"article": "Regular aspirin use can also cause side effects, like stomach bleeding and ulcers.\nIt\u2019s believed that aspirin, and possibly other nonsteroidal anti-inflammatory drugs, may reduce or head off that process.\nOne of the most prominent followed more than 6,000 older women for nearly a decade and found that those who regularly took 100 milligrams of aspirin did no better on cognitive tests, over time, than those who were given a placebo.\nAnother study in 2003 in The European Journal of Clinical Pharmacology found a similarly beneficial effect for aspirin and other nonsteroidal anti-inflammatory drugs.\nThe claim that aspirin can prevent the disease stems from the notion that Alzheimer\u2019s is caused by inflammation that disrupts proteins in the brain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story did not explicitly state that low-dose aspirin is a readily available, over-the-counter product, this information is common knowledge.", "answer": 2}, {"article": "It's been assumed that people with mild strokes \"generally [do] well and the risk of tPA treatment, which includes a slight but significant risk of life-threatening bleeding in the brain, would not be worth the benefit,\" she says.\nThose parts of the brain soon start to die.\nIn fact, one in three people who suffer a mild stroke are disabled three months later, Khatri says.\nA stroke occurs when a clot cuts off blood flow to parts of the brain.\nBut people with mild strokes are typically denied tPA because the studies that established its effectiveness excluded mild cases, says Pooja Khatri, MD, of the University of Cincinnati.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story isn\u2019t crystal clear on the widespread availability of the drug tPA but it can be inferred from the story.", "answer": 1}, {"article": "Abbott Diagnostics developed both the new and the conventional troponin tests used in the study.\nThe issue with available troponin testing has been that they must be repeated two more times over the next 12 to 16 hours for accurate readings.\nThis means that if a test result is negative, the person is not having a heart attack.\n\"We need a blood test that can tell people when they walk in or soon thereafter that they are having a heart attack because the sooner you make the diagnosis, the sooner you can start the right therapy.\"\n\"We can rule out heart attacks more quickly with the new test,\" said Dr. Sandra Chaparro, a cardiologist at the University of Miami Hospital in Florida.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of the new test is left as a mystery by this story.\nIs it experimental?\nIs it growing in use already?\nIs it in widespread use?\nWe\u2019re not told a thing about its availability or use.", "answer": 0}, {"article": "He cites clinical data showing stroke and death rates of more than 10 percent within one year among those getting stents -- not much different from the results in the same study for surgery.\nDr. Alberts and some other doctors say that both procedures are done too often and that the advent of carotid stenting seems to be making the problem of over-treatment worse.\nThen there are the interventional radiologists, who have extensive experience with stenting in arteries not near the heart, and neurologists, who specialize in treating brain diseases.\n\"My memory and energy levels are better now,\" she said.\nMedicare restricts coverage to patients who have a blockage of at least 70 percent of an artery, who have already had a stroke or displayed some other clear symptom of carotid disease and who have conditions that make surgery highly risky.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Very clear presentation of FDA \napproval of devices made by two manufacturers and that others are awaiting full approval.", "answer": 1}, {"article": "About the University of Louisville Physicians Group and The James Graham Brown Cancer Center:\n\nThe James Graham Brown Cancer Center is a key component of the University of Louisville Health Sciences Center.\nThe centers that collaborated on the study included University of Louisville, Louisville, KY; Henry Ford Hospital, Detroit, MI; Cleveland Clinic, Cleveland, OH; Piedmont Hospital, Atlanta, GA; Swedish Medical Center, Denver, CO; and Cancer Treatment Centers of America, Atlanta, GA.\n\nFrom July 2010 to October 2014, patients with radiographic Stage III LAPC were treated with IRE and monitored under a multicenter, prospective IRB-approved registry.\nPancreatic cancer has one of the highest mortality rates of all cancers and is expected to climb from the fourth leading cause of cancer-related death in the U.S. to the second by 2020.\nAs part of the region's leading academic, research and teaching health center, the cancer center provides the latest medical advances to patients, often long before they become available in non-teaching settings.\nThe NanoKnife\u00ae IRE system is a tool that destroys cancerous cells by subjecting them to a series of short electrical pulses using high-voltage direct current that does not injure surrounding cells, blood vessels and other vital structures.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told the NanoKnife\u00a0system \u201cis approved by the U.S. Food and Drug Administration for the surgical ablation of soft tissue\u201d and that it \u201cis not approved for use in specific cancers.\u201d So does that mean a pancreatic cancer patient could ask for this treatment? It\u2019s unclear. It\u2019s also unclear if insurance will pay for it.", "answer": 0}, {"article": "Comparing states with and without medical marijuana laws\n\nIn order to evaluate whether medical marijuana could function as an effective and safe alternative to opioids, the two teams of researchers looked at whether opioid prescriptions were lower in states that had active medical cannabis laws and whether those states that enacted these laws during the study period saw reductions in opioid prescriptions.\nThe impact of these laws also differed based on the class of opioid prescribed.\nSince then, 29 states and the District of Columbia have approved some form of legalized cannabis.\nThe method of procurement also had a significant impact on opioid prescription patterns.\nThe first state in the United States to legalize marijuana for medicinal use was California, in 1996.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article included information about the number of states that have legalized certain types of marijuana use.", "answer": 1}, {"article": "Though randomized controlled clinical trials of bright light are difficult to do properly \u2014 one expert is fond of saying that it is difficult to \u201cblind\u201d studies of bright light \u2014 the American Psychiatric Association considers bright-light therapy an effective low-risk treatment for both S.A.D.\nFace the light but do not stare at the light.\nPatients generally sit in front of the light box, which can be as small as 9 by 11 inches and 5 inches deep, with the bright light emanating from the square surface, in the morning.\nSome say their patients don\u2019t have the patience to sit in front of a light for 30 to 45 minutes every morning.\n\u201cIt can help you from falling into a deep depression, but it won\u2019t help you climb out of one,\u201d he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear how widely used are the light boxes and that they are sold online and available for rent.", "answer": 1}, {"article": "The findings don't confirm that the ancient Chinese discipline relieves hot flashes, and only 14 men participated in the study, which was conducted by researchers at New York Methodist Hospital and Weill Cornell Medical College of Cornell University.\nHormone therapy designed to reduce levels of testosterone in the body is one of the standard treatments for prostate cancer.\nTheir reported level of hot flashes dropped markedly.\nIt's also possible, he said, that the symptoms went away on their own, which commonly happens to men on hormone therapy.\n\"It is a definite nuisance.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of acupuncture isn\u2019t in question.", "answer": 2}, {"article": "Patsalis\u2019 method takes advantage of differences in the DNA methylation patterns \u2014 which are important to control levels of genes \u2014 between mother and fetus.\nThe risk of having a baby with Down\u2019s \u2014 which occurs when a child has three copies of chromosome 21 instead of the normal two \u2014 increases sharply as women get older.\nPhilippos Patsalis, medical director of the Cyprus Institute of Neurology and Genetics, who led the study, said the results were \u201cvery exciting\u201d and the test now needed to be trialed in a larger study of about 1,000 pregnancies, but could lead to changes in clinical practice within two years.\n\u201cWe believe we can modify this test and make it much easier and simple... (and then) we can have something ready to be introduced into the clinic,\u201d he told Reuters in Nicosia.\nIn a small trial, Patsalis\u2019 team were able to correctly diagnose 14 cases where there were extra copies of the chromosome, and 26 normal fetuses \u2014 results they said highlighted its clinical potential.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Allowing researchers to claim that a test \u201cmay soon be\u201d available after a study in just 40 pregnancies is not wise journalism.\u00a0 If the story had turned to an independent expert, perhaps this enthusiasm may have been put into a better perspective. The path to commercialization is likely years in the making.", "answer": 0}, {"article": "The California Walnut Commission (CWC) prohibits discrimination in all programs and activities on the basis of race, color, national origin, age, disability, sex, marital status, familial status, parental status, religion, sexual orientation, genetic information, political beliefs, reprisal, or because all or part of an individual's income is derived from any public assistance programs.\nResearchers conducted the randomized study with two groups of mice.\nJ Nutr Biochem.\nWorld cancer research fund/american institute for cancer research.\nALA is an essential fatty acid critical to various body processes and is known to reduce inflammation.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We accept that walnuts are widely available.", "answer": 1}, {"article": "But confirmation would be good news for the prevention and control of gonorrhea.\n\u201cGonorrhea rates have been going down in the vaccine group whereas in the non-vaccine group it\u2019s following the rest of the province.\u201d\n\nIt is not clear how long the protection \u2014 if it\u2019s real \u2014 will actually last.\nThe research, conducted in New Zealand, found that the gonorrhea rate among teens and young adults there who had received a meningitis B vaccine during an emergency campaign in the early 2000s was significantly lower than the rate seen in people of the same age who weren\u2019t vaccinated.\n\u201cMathematical modeling has shown that even a vaccine of moderate efficacy and duration could have a substantial effect on the transmission and prevalence of gonorrhea, if coverage in the population is high and protection lasts during the highest risk period,\u201d Kate Seib, of Australia\u2019s Institute for Glycomics, wrote in a commentary that accompanied the study.\nDespite the fact that gonorrhea and meningitis are quite different from one another, the bacteria that cause Neisseria gonorrhoeae and Neisseria meningitidis are actually related.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says the single-component vaccine used in New Zealand is no longer made but that the component is part of GSK\u2019s Bexsero vaccine, which is on the market. The story also distinguishes the B vaccine from others on the market: \u201cMeningococcal vaccines that protect against the other strains do not seem to have the same effect (on gonorrhea).\u201d", "answer": 1}, {"article": "Even so, Allen says more research is needed to determine the specific strains of bacteria that are most effective.\nThe review confirms the findings of another review in 2004, which also showed that probiotics had some effect against diarrhea.\nHowever, the impact of the probiotics varied greatly from study to study, researcher found.\n\"Surprising thing was it didn't really matter what type of probiotic was used or in which setting,\" Allen says.\nAmong the different bacteria tested were L. acidophilus, S. boulardii, and L. casei, which occur naturally or are added to products like supplements, yogurt, miso, soy milk and some juices.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story listed several different types of products containing \u2018probiotics\u2019, indicating that they may normally be found in some products while others represent supplemented products.", "answer": 1}, {"article": "The results showed no differences in IQ.\nLorch also pointed out that this study involved a mostly homogenous population in a country outside the U.S.\n\n\"We should see whether similar effects are seen in higher-risk populations, such as the low socioeconomic population, racial and ethnic minorities and those at higher risk for neurodevelopmental delay,\" Lorch said.\n\"There is growing evidence from a number of studies that all infants, those born at term and those born early, benefit from receiving extra blood from the placenta at birth,\" said Dr. Heike Rabe, a neonatologist at Brighton & Sussex Medical School in the United Kingdom.\n\"The extra blood at birth helps the baby to cope better with the transition from life in the womb, where everything is provided for them by the placenta and the mother, to the outside world,\" Rabe said.\n\"We don't know exactly why, but speculate that girls receive extra protection through higher estrogen levels whilst being in the womb,\" Rabe said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Hypothetically, a delay in cord-clamping is something equally available to all those who deliver babies and their patients. But in the real world it\u2019s different: A delay is only available to a woman if her doctor/health system decides to offer it (barring the role of patient advocacy). The story didn\u2019t explore how common delayed cord-clamping is, or how willing doctors are to consider it. And unlike the competing USA Today story, it didn\u2019t suggest that women might want to raise the issue with their doctors.", "answer": 0}, {"article": "The studies were reported at an American Heart Association conference this week in New Orleans.\nNow, more are getting open-heart surgery, with remarkable survival rates rivaling those of much younger people, new studies show.\nNEW ORLEANS \u2014 Eighty-year-olds with clogged arteries or leaky heart valves used to be sent home with a pat on the arm from their doctors and pills to ease their symptoms.\nIn Florida, Dr. Paul Kurlansky led a study of 1,062 octogenarians who had heart bypass surgery at Mount Sinai Medical Center in Miami Beach from 1989 through 2001.\nEven more impressive: 65 percent survived without any long-term complications \u2014 a \u201cvery, very remarkable\u201d result, Kurlansky said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story sketched out the possibilities and potential merits for individuals in the 80\u2019s and 90\u2019s to undergo open heart surgery to repair valves and vessels. \u00a0While these types of procedures are widely available, there was no discussion about whether all facilities admitted or were suited to handle older individuals for these sorts of procedures. \u00a0", "answer": 0}, {"article": "Wenzel said dupilumab was well tolerated, with side effects similar to placebo.\n(Reuters) - A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage trial, making it a potential game changer for patients with moderate to severe disease, researchers said on Tuesday.\n\u201cOverall, these are the most exciting data we\u2019ve seen in asthma in 20 years,\u201d said Dr. Sally Wenzel, lead investigator for the 104-patient study of dupilumab, an injectable treatment being developed by Regeneron Pharmaceuticals Inc and French drugmaker Sanofi.\n\u201cThis asthma data and the data we already have in atopic dermatitis really raises the possibility the scientific community has finally hit upon the key pathway across all these allergic diseases,\u201d George Yancopoulos, Regeneron\u2019s research chief, said in an interview.\n\u201cWe do not know whether dupilumab will be effective in other patient populations,\u201d the editorial said, including patients that stay on their standard therapies and who do not have high levels of eosinophils.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Right in the lead, the story signals that this drug is not currently available, and, to the knowledgeable reader, shows where it is in the regulatory process, referring to a \u201cmid-stage trial.\u201d\u00a0 Later, it also says that \u201cfar larger trials will be needed to confirm findings from the \u201cproof of concept\u201d study.\u201d\nHowever, calling this \u201ca potential game changer for patients with moderate to severe disease\u201d may imply a more imminent definitive answer than actually exists.", "answer": 1}, {"article": "The drug, known chemically as denosumab, is widely considered to be Amgen\u2019s most important future growth driver and the FDA decision comes nearly two months ahead of the agency\u2019s expected action date of July 25.\nAmgen said the drug will be available within the next two weeks and cost $825 per 60 milligram injection based on wholesale acquisition cost.\n\u201cMost of us certainly expected this drug to be approved,\u201d said Cowen and Co analyst Eric Schmidt, adding it was \u201ca surprise that it happened before\u201d July 25.\nHe estimates U.S. annual peak sales of $750 million to $1 billion in osteoporosis.\n\u201cIt\u2019s also superior to Zometa in its ability to delay subsequent events,\u201d Perlmutter said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\n\"The nerve root is a sensitive structure that when pinched becomes inflamed and causes pain,\" said lead investigator Alessandro Napoli M.D., Ph.D., an interventional radiologist at Sapienza University of Rome.\nThe single-center prospective study included 80 patients experiencing at least three months of low back pain due to a herniated disk that had not responded to conservative treatments including exercise and medication.\n\"The body reacts with muscle constriction, which decreases the distance between vertebrae, and a vicious cycle is created.\"\n\"The probe delivers a gentle electrical energy, so there's no thermal damage,\" Dr. Napoli said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does a nice job of explaining the procedure and, we feel, gives readers enough detail to understand how it would work. But it does not make it clear how widely this procedure is available and the type of technical skill necessary to administer it.", "answer": 0}, {"article": "New research is helping Pfizer Inc. build a case for getting an important drug in its portfolio approved to treat a mysterious pain condition that could offer a big additional source of sales.\n\nThe New York drug maker said Tuesday that Lyrica, already on the market to treat certain types of pain, reduced painful symptoms among sufferers of fibromyalgia, a chronic and controversial condition that may affect as many as six million Americans. And today, it will unveil results from another study that it says shows Lyrica has a lasting...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained that Lyrica is available for the treatment of pain, but that it is not yet approved for fibromyalgia.\u00a0 \nThe story stated that \"Pfizer is expecting word form the Food and Drug Administartion on its application this year\".\u00a0 However a search through www.clinicaltrials.gov shows that there are two phase\u00a0III (trials to\u00a0look at effectiveness of a treatment)\u00a0trials of this drug for the treatment of fibromyalgia that are currently recruiting patients.\u00a0 This would suggest that it will take more time than till the end of this year before the FDA will make a decision about approving this use of the drug.\nNonethless, we'll give the story the benefit of the doubt on this criterion.\u00a0 ", "answer": 1}, {"article": "This new approach to drug discovery is a promising technology that is rapidly moving in the translational research space , .\nDry eye can be treated with cyclosporin drops or autologous serum, but there is as yet no specific product for chronic treatment of the ocular pain related to dry eye syndrome; oral analgesics or anaesthetics are used in general.\nTivanisiran is a product under development for the treatment of signs and symptoms related to dry eye syndrome and has the potential to be developed for other pathologies that cause ocular pain (corneal lesions, refractive surgery, etc.)\nIn this respect, Jim\u00e9nez points out that \"this is a significant step forward in the development of innovative drugs in different therapeutic areas through a novel technology of genetic silencing based on the RNA.\"\nIn this context, the phase III \"Helix\" study is being carried out in more than 30 hospitals in Spain, Germany, Estonia, Portugal, Slovakia and Italy, in 300 patients to evaluate the efficacy of this compound in the treatment of the sign and symptoms of dry eye syndrome.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "A scientist working for the drugmaker says she hopes \u201cthat tivanisiran will soon become a real alternative.\u201d Savvy readers will note that the drug is still in development and that the drug is not yet ready for patient use outside of a research setting.", "answer": 1}, {"article": "But the scientific evidence has been slim.\nWhat was lacking was clear evidence that taking melatonin in supplement form had the same sleep-inducing effect.\nMillions of jet-lagged and sleep-deprived Americans--citing countless self-help articles--insist they do.\nThere's no question that the hormone helps the brain tell a.m. from p.m.--regulating sleep cycles and circadian timing--when it is produced naturally by the body at night.\nThat's why there's so much interest in a study in the current issue of the journal Sleep.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article did not mention that melatonin is sold as a dietary supplement and as such, the FDA neither approves the claims made nor monitors the content of the product.", "answer": 0}, {"article": "She notes that using trastuzumab to selectively treat uterine serous carcinoma that express HER2/neu is part of a broader trend at Johns Hopkins and other cancer centers to use the tools of tailored therapy, or precision medicine, based on the molecular and genetic makeup of tumors and patients.\n\"The fact that these tumors grow rapidly, but also have a propensity to spread to lymph nodes and other organs very early, is a double whammy for women,\" says Amanda Fader, M.D., associate professor of gynecology and obstetrics at the Johns Hopkins University School of Medicine, and first author of the new study.\nThe results of the trial, published online ahead of print on March 27 in the Journal of Clinical Oncology, show that the drug extended the length of time to tumor progression by four to eight months in the seven-year trial.\nThe difference, Fader says, may be that these patients have been heavily treated in the past, are more likely to have overall poorer health and are more likely to have mutated or heterogeneous tumors, or tumors with different levels of HER2 expression.\nBut the results of the trial, they add, were strong enough to warrant submission to the National Comprehensive Cancer Network, which guides the design of standard treatment plans around the country.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that researchers have submitted their findings to the National Comprehensive Cancer Network, \u201cwhich guides the design of standard treatment plans around the country.\u201d However, it\u2019s not clear when or whether USC patients may have access to trastuzumab \u2014 either through FDA approval or via off-label prescriptions by health care providers. More importantly, though, the release could be a bit more clear on the percentage of patients with uterine cancers who may benefit from trastuzumab. There are bits and pieces of information scattered throughout the release, but it would be good to pull them together and add up what it all means. Here\u2019s what we\u2019re talking about (bear with us): according to the American Cancer Society, there are expected to be about 63,230 new cases of uterine cancer diagnosed in the U.S. in 2018; about 92 percent of those uterine cancers are likely to be endometrial, bringing the number to around 58,171; approximately 10 percent of those endometrial cancers will be USC, bringing the number to 5,817; and about 30 percent of those patients with USC test positive for HER2/neu receptor proteins that trastuzumab blocks. In other words, of the 5,817 women who may be diagnosed with USC in 2018, only 1,745 of them may be able to benefit from trastuzumab. That\u2019s an important idea to get across clearly.", "answer": 0}, {"article": "To find out, they studied 79 adults with chronic insomnia.\nNEW YORK (Reuters Health) - A few short visits and phone calls with a nurse may be enough to help insomniacs get their zzz\u2019s, suggests a new study of sleep-deprived older adults.\nAnd if you wake up in the middle of night and don\u2019t fall back asleep easily, get out of bed.\u201d\n\n\u201cYou don\u2019t want to have any linkage between the experience of lying in bed and being awake,\u201d he said.\n\u201cMore consolidated sleep is more refreshing.\u201d\n\nBased on questionnaires and sleep diaries, the researchers found that two out of every three participants receiving the behavioral intervention responded favorably by the end of 4 weeks, while just one out of every four receiving the printed material experienced substantial improvement in their sleep.\nThe key ingredient in the therapy, according to lead researcher Dr. Daniel Buysse of the University of Pittsburgh School of Medicine, was a simple, somewhat counter-intuitive lesson: \u201cWhen you are sleeping poorly, the most important thing you can do is spend less time in bed.\u201d\n\nInsomnia affects about one in every five Americans, rising to one in three among the elderly, and has been linked to a range of physical problems, from accidents to hypertension.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story says this form of \u201cbrief behavioral treatment for insomnia is not yet generally available\u201d. It also described this study as being a first step in the process of making such an intervention available without making predictions about a timetable.", "answer": 1}, {"article": "TUESDAY, Feb. 23, 2010 (HealthDay News) -- A popular nutritional supplement -- extract of bitter melon -- may help protect women from breast cancer, researchers say.\nThe next step is to see if the team can repeat these findings in animals, Ray said.\n\"The results of this laboratory study are intriguing,\" McCullough said.\nThe extract slowed the growth of these breast cancer cells and even killed them, the researchers found.\nThe bitter melon extract killed only the cancer cells, not the healthy breast cells.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that bitter melon extract is a popular nutritional supplement and is a common vegetable in India, China and South America. ", "answer": 1}, {"article": "CHICAGO\u2014For patients facing a choice between bypass surgery and a popular, less-invasive procedure to treat heart blockages, surgery improves chances of long-term survival, researchers said Tuesday.\n\nIn a study that analyzed data on nearly 190,000 Medicare patients treated between 2003 and 2007, 16.4% of surgery patients had died after four years, compared with 20.8% treated with angioplasty and a stent to prop open diseased vessels.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story did not explicitly note the general availability of bypass surgery and angioplasty/stent, there are sufficient hints to allow the reader to appreciate that they are routinely offered.", "answer": 1}, {"article": "The FASEB Journal, June 2018.\nIn the study, 24 healthy postmenopausal women consumed 330 grams (2 cups) of mango daily for 14 days.\nSix of the 24 participants produced methane, and of these six, three shown significant reduction after consuming mango, which is considered a favorable outcome for gut health.\nMangos contain a mix of polyphenols, including mangiferin, quercetin, gallotannins, and gallic acid, that have been the focus of previous investigations exploring the potential health-protecting properties of mangos.\nYet once mango was consumed, systolic blood pressure was significantly lower two hours after mango intake compared to baseline values.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t mention this, but presumably people know that mangoes are already available to the public. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "Jan. 25, 2010 -- A low-carbohydrate diet may have health benefits that go beyond weight loss.\n\"It's important to know you can try a diet instead of medication and get the same weight loss results with fewer costs and potentially fewer side effects,\" Yancy says.\n\"I expected the weight loss to be considerable with both therapies but we were surprised to see blood pressure improve so much more with the low-carbohydrate diet than with orlistat,\" researcher William S. Yancy, Jr., MD, an associate professor of medicine at Duke University Medical Center, says in a news release.\nA new study shows that a low-carbohydrate diet was equally good as the weight loss drug orlistat (the active ingredient in Alli and Xenical) at helping overweight and obese people lose weight, but people who followed the low-carb diet also experienced a healthy drop in their blood pressure levels.\nResearchers say studies have already shown that the two weight loss methods are effective at promoting weight loss, but it's the first time the health effects of each have been compared head to head.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The\u00a0story mentioned that\u00a0orlistat, the weight loss medication tested in the study,\u00a0is the active ingredient in Xenical and\u00a0Alli. Unlike the competing piece in HealthDay, however, it did not specify that Xenical is a prescription drug and that Alli is available over the counter. Although this information would have been helpful, providing the trade names for both drugs is probably enough to orient most readers.", "answer": 1}, {"article": "Servan-Schreiber offered more words of wisdom to LaPook -- words he says doctors rarely impart to their patients -- and LaPook discussed with co-anchor Harry Smith on The Early Show Friday why he thinks it is that cancer survivors aren't offered more guidance by the medical establishment:\n\nServan-Schreiber appears in the joint CBS, NBC, ABC special \"Standing Up To Cancer\" Friday night.\n\"Help it with the right nutrition, with physical exercise, with managing stress better, and avoiding contaminants that feed cancer.\n\"Your body knows how to fight cancer,\" Servan-Schreiber observed to LaPook.\nTo read an excerpt, click here.\nThen, he discovered in one of his own brain scanner experiments that he -- had brain cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly fruits and vegetables, spices and green tea, and physical activity \u2013 mentioned in the story \u2013 are all widely available.", "answer": 1}, {"article": "THURSDAY, Feb. 24, 2011 (HealthDay News) -- Blood tests that indicate prostate-specific antigen (PSA) levels are rising rapidly over time are of little use in detecting aggressive prostate cancer and should not be done, a new study indicates.\nThe National Cancer Institute has more on the PSA test.\nThe men in the study were all from the placebo arm, meaning they had not received the drug.\n\"It's something that has become almost a community standard.\nPSA is a protein produced by cells of the prostate gland.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that PSA tests are readily available.", "answer": 1}, {"article": "Safety, tolerability and response were assessed every eight weeks for the first six months and every 12 weeks thereafter.\nDr. Mehnert, who is also a medical oncologist in the Melanoma and Soft Tissue Oncology Program at Rutgers Cancer Institute, shares more about the research:\n\nQ: How was the study structured?A: At the time our abstract was submitted, 22 patients with a diagnosis of advanced or metastatic papillary or follicular thyroid cancer who failed prior standard therapy were accrued from multiple international sites.\nNewswise \u2014 New Brunswick, N.J. \u2013 June 2, 2016 \u2013 According to the American Cancer Society, the chance of being diagnosed with thyroid cancer has risen rapidly in the United States in recent years.\nThe clinical benefit of pembrolizumab in advanced thyroid cancer will be further studied in a follow-up phase II clinical trial that is now ongoing to try to discover biomarkers which predict response to treatment with pembrolizumab.\nJanice M. Mehnert, MD, director of the Phase I and Developmental Therapeutics Program at Rutgers Cancer Institute of New Jersey, is the lead author of research highlighting the immunotherapy drug pembrolizumab and its effect on advanced thyroid cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that\u00a0pembrolizumab is under study in an early clinical trial. It does not, however, point out that the drug is in fact commercially available under the trade name Keytruda, a drug we have heard a great deal about in the past few months related to its use in melanoma.", "answer": 0}, {"article": "The controls have had twice the death rate from aging-related diseases like heart failure and diabetes.\n\"There's never been a study like this one,\" said Dr. Evan Hadley, director of geriatrics and clinical gerontology at the National Institute on Aging, which paid for the study.\n\"There is no data on non-obese humans,\" said Eric Ravussin, chief of health and performance enhancement at the Pennington Biomedical Research Center at Louisiana State University.\nIt was probably preserved by evolution because it saved people from starving to death when food was scarce, but it is the bane of dieters because it means that the more weight they lose, the harder it is to keep reducing.\nBut Dr. Ravussin and Dr. Hadley cautioned that the study was preliminary, and that it did not prove that calorie restriction could make people healthier or add years to their lives.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions \u2018people experimenting on themselves\u2019, indicating the potential for anyone to self-impose calorie limitations on themselves. However, the article failed to explain that all the food consumed by the research subjects in the study was provided for them thus ensuring nutritional adequacy while restricting calories. That\u2019s beyond the reach of the average American. People were paid $7,000 to be in the study!", "answer": 0}, {"article": "Attorney James Tuffin followed his usual daily routine last week: He ran five miles and drove to his office on suburban Long Island. In between, he stopped at Advanced Radiation Centers in North Hills, N.Y. There, he drank a quart of water, lay down on a treatment table and watched as a high-tech linear accelerator rotated around him for 90 seconds, blasting his cancerous prostate with radiation.\n\n\"On a good day, I'm in and out in a half-hour,\" says Mr. Tuffin, 54 years old, who was midway through his scheduled 45...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that the highlighted device, the RapidArc, was currently in use in only 30 locations in the US. \u00a0\n\u00a0", "answer": 1}, {"article": "With the FDA's announcement, drugs like pembrolizumab have also begun to change the way that physicians, patients and government regulators think of cancer. No longer will they see all cancers of the lung, breast, colon, brain, liver, pancreas and prostate as distinct from one another. Instead, they will look for the common genetic mutations that give rise to cancers no matter where they're found. And they'll treat those cancers with a drug that uses that common signature as a homing beacon, either for the immune system or for targeted cancer drugs to attack.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that pembrolizumab is currently being sold under the brand name Keytruda.", "answer": 1}, {"article": "In one of his own studies, Wong found no effect on soy germ isoflavones among women who took the supplements for two years.\n\u201cThere is a major cultural difference in how we deal with menopause symptoms,\u201d he mused.\n\u201cIt is something they need to gauge, is it worth the risk?\u201d Wong told Reuters Health.\nBut a U.S. expert wasn\u2019t convinced by the results, which run counter to other published studies.\nWhile the same pattern was seen in the placebo group, it was less pronounced.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 Soy supplements are over-the-counter products sold in most health stores.", "answer": 2}, {"article": "SATURDAY, March 31, 2012 (HealthDay News) -- A noninvasive scan might someday help doctors track the progress of prostate cancer and help guide treatment, researchers report.\nIf a specific change did not occur, that treatment could be abandoned and another tried instead.\nEncouraged by their findings, the study's authors said they hope to begin a human trial next year.\nIf a treatment showed a marked change, it could continue to be used in that patient, hence \"personalized\" medicine.\nThe U.S. National Cancer Institute provides more information on prostate cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that the researchers \u201chope to begin a human trial next year.\u201d", "answer": 1}, {"article": "Agatston says relatively new imaging tests give real-time pictures showing whether plaque is building up in key blood vessels, alerting doctor and patient to an increased risk of a potentially deadly heart attack.\nMost hospitals now offer the imaging tests, some at less than $100 for both, and they are often covered by insurance.\nThey have very large particles, and they don't get into the vessel wall,\" Agatston says.\nA calcium score would answer that question, she says.\nIt's doable,\" Agatston says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story makes it clear that the three tests discussed are available at most hospitals.", "answer": 1}, {"article": "Newswise \u2014 Fresh thyme and oregano offer a savory touch to a tasty dish, but a University of Iowa researcher recently discovered natural compounds in the herbs that may offer a treatment for cachexia or \u201cwasting syndrome\u201d as it is more commonly known.\nIn pre-clinical studies, compounds in thyme and oregano have demonstrated a greater than 37 percent increase in exercise tolerance and a 15 percent increase in muscle mass of certain body muscles.\n\u201cWe tested these compounds in sedentary mice and found a dramatic improvement in exercise endurance and a mild increase in muscle size of certain muscle groups,\u201d Sah says.\nIt is a miserable, frequent event that every physician knows about and many patients experience, but there is simply little available against it and nothing to prevent it.\u201d\nThe discovery was a \u201cserendipitous finding\u201d in the lab of Rajan Sah, M.D., Ph.D., assistant professor of Internal Medicine and Molecular Physiology and Biophysics at the University of Iowa.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll give the release a Satisfactory in this category since it states that a company has been licensed to develop a drug based on this research, and therefore readers know that it isn\u2019t available yet.", "answer": 1}, {"article": "NEW YORK (Reuters Life!)\n\u201cThe human cost of shingles is enormous,\u201d said Michael Oxman, who studies infectious diseases at the University of California, San Diego, and was involved in a previous study of the vaccine.\nMost shingles patients are older adults, but people with a weak immune system or those under stress may also develop it.\nEveryone in the study, published in the Journal of the American Medical Association, was at least 60 years old, and the researchers didn\u2019t include anybody for whom the live vaccine is not recommended.\nIn 2006, the U.S. Food and Drug Administration approved a vaccine against shingles \u2014 a painful and potentially serious condition \u2014 for adults over 60.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story notes that this shingles vaccine was approved in 2006. It also makes reference to stringent requirements for storage and handling, which have been cited (along with cost) as barriers to access.", "answer": 1}, {"article": "This measure of metabolic health is called \u201cinsulin sensitivity,\u201d and it is one of many metabolic functions that goes awry in people with obesity. In those who develop type 2 diabetes, sensitivity to insulin becomes so impaired that the body is tricked into believing less insulin is needed, and it pares back its production. The insulin-producing cells in the pancreas will often atrophy and die in response. As a person\u2019s insulin production declines, an external supply of insulin is needed to control blood sugar and deliver fuel to muscles and organs.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that deep brain stimulation is a current therapy, though not yet for diabetes.", "answer": 1}, {"article": "In a related editorial, Drs.\nThe study included 508 women who were given eribulin and 254 women who received treatment of the physician's choice, which was defined as: any single-agent chemotherapy, hormonal or biological treatment approved for cancer treatment; radiotherapy; or symptomatic treatment alone.\n\"It would be interesting to see if the drug offers the same benefit in women that have not been treated with multiple drugs before exposure to eribulin,\" she added.\nWEDNESDAY, March 2, 2011 (HealthDay News) -- The new chemotherapy drug eribulin extends the lives of metastatic breast cancer patients who have received extensive treatment, according to a new study.\nNumbness and pain stemming from nerve damage were the most common adverse event connected to eribulin that led women to drop out of the study (24, or 5 percent).\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article does not report that eribulin, the drug studied, received approval in the United States based on the results of the study.\u00a0 Eribulin is approved for patients who have previously\u00a0been treated for metastatic breast cancer with at least two chemotherapies, including an anthracycline and a taxane.\nAs a result, the availability of the drug is unclear to readers.\u00a0 Information about drug approval and availability is valuable for patients with metastatic breast cancer.", "answer": 0}, {"article": "There were also big improvements in their parenting style.\nThe international research project into the impact of depression on pregnant mothers and their babies, led by Professor Sonia Bhalotra from the Institute for Social and Economic Research at the University of Essex, could have major implications for public policy.\nThe study, one of the largest randomised control trials to be held in the developing world, followed women diagnosed with depression mid-pregnancy in 40 communities in rural Pakistan.\nThe NHS website explains that it is \u201cbased on the concept that your thoughts, feelings, physical sensations and actions are interconnected, and that negative thoughts and feelings can trap you in a vicious cycle\u201d.\nThe study found that women who had least social support such as those who were not living with or near their mother or mother-in-law, benefited most from the therapy intervention, both in the short and long term.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t address availability.\nAs explained in the original clinical trial, the researchers used an existing system of Lady Health Workers who are specially trained to do the intervention, making the treatment available in an area where it normally wouldn\u2019t be.\nBut even in nations with more resources, spotty insurance coverage and lack of providers limit access to this type of care. The story should have at least touched up on the availability issue. This is an area an independent source likely could have given some context on.\n\u00a0", "answer": 0}, {"article": "Iowa Democrats may have saved the caucuses\n\nIf the proposed Democratic plan is adopted, the Iowa Democratic caucuses will be both familiar and new and may well endure as first in the nation.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that although this is a new technology, it is not available everywhere.", "answer": 1}, {"article": "Texas rep expects Trump to make case for a border wall at State of the Union\n\n\"We're going to keep working to secure the border, and not blink until we either get it done or the voters get to speak in 2020\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that this is an existing drug for osteoporosis that has not been approved by the FDA for use in breast cancer prevention. The story does not make claims about when it may be approved for that purpose.", "answer": 1}, {"article": "A new study offers a fresh strategy for treating patients suffering from both coronary artery disease and heart failure, afflictions linked to poor quality of life and high risk of death that affect as many as two million Americans.\n\nThe 1,212-patient study calls into question the need for immediate bypass surgery in these patients\u2014an approach commonly recommended by doctors. The study, called Stich, found benefits in treating people with medication only, and in treating people with a combination of bypass surgery and medication....", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the range of treatments studied by the authors are widely available.", "answer": 1}, {"article": "For the study, researchers looked at data on 27,347 women ages 50 to 79 who joined two WHI trials between 1993 and 1998 and were followed through 2014.\nThey took hormones or a placebo for five to seven years and were followed for a total of 18 years altogether.\nYounger women in the study appeared to have better survival odds with HRT.\nWomen were 63 years old on average when they joined the trials and had already gone through menopause.\nOne trial tested estrogen alone against a placebo, or dummy pill, while the other trial tested estrogen taken in combination with progestin.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "These therapies are widely available and that\u2019s implied in the story.", "answer": 1}, {"article": "\"It was becoming unacceptable to just take tonsils out because they were there or you had a few infections,\" says Richard Rosenfeld, an ear, nose and throat doctor at SUNY Downstate in Brooklyn, N.Y. \"People were growing up with their tonsils.\"\nAbout 530,000 tonsillectomies are performed in the United States each year.\nGetting your tonsils out used to be just part of childhood \u2014 a rite of passage for children in the 1950s and '60s.\nTyler still hears snoring at night, he says.\nIt's usually done as an outpatient procedure now, but with general anesthesia.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a great job explaining how tonsil surgery as a first resort has evolved over the years.", "answer": 1}, {"article": "These studies used tablet computers to test navigational tasks.\n\u201cBy pinpointing those who are beginning to lose their navigational skills, we hope to show that we can target people at a much earlier stage of the condition and one day become far more effective in treating them.\u201d\n\nThe discovery that loss of navigational skills was associated with Alzheimer\u2019s disease was made several years ago by Chan and colleagues based at several centres in the UK.\n\u201cThe aim of the study is very simple: can we detect changes in brain function before people are aware that they have them?\u201d\n\nResearchers recently pinpointed the significance of a tiny area of the brain known as the entorhinal cortex, which acts as a hub in a widespread brain network that controls navigation.\n\u201cThe entorhinal cortex is the first brain region to show degeneration when you get Alzheimer\u2019s, and that is where we shall be focusing our research,\u201d said Chan, whose work is funded by the Alzheimer\u2019s Society.\n\u201cIt is usually thought memory is the first attribute affected in Alzheimer\u2019s,\u201d said project leader Dennis Chan, a neuroscientist based at Cambridge University.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "On the one hand, the story does tell readers that there will be a forthcoming study to evaluate whether VR technology can be used to test people\u2019s navigation ability in order to determine whether it is an effective technique for diagnosing Alzheimer\u2019s. (In other words, they don\u2019t even know if this is something that will work yet.)\nOn the other hand, earlier in the story, readers run across sentences like: \u201cVirtual reality to help detect early risk of Alzheimer\u2019s\u201d and \u201cThose who do worse in the tests will be the ones most likely to succumb to Alzheimer\u2019s later in life, scientists now believe.\u201d That makes it sound like this is already a useful tool, and availability could be right around the corner. Ultimately, the story never explicitly tells readers that any possible VR tool is years away, at best. That tips the scales for us, and we lean in the direction of \u201cnot satisfactory\u201d on this criterion. One wonders how many people read this story and contacted their general practitioner about taking a VR test to assess their Alzheimer\u2019s risk.", "answer": 0}, {"article": "Kerry Aldrich, 15, suffered a concussion playing varsity soccer for The Potomac School in McLean, Va., three weeks ago when she did a face-first dive and violent somersault.\nBut, Regan adds, diagnosing them can be daunting: While there are some physical symptoms such as headaches, nausea, dizziness and blurred vision, concussions don't cause bleeding or swelling in the brain and don't show up on X-rays.\n\"The brain, in its development, while it is actively developing, seems to be less able to take these forces and to really rebound from these forces,\" Dr. Gioia observed.\n\u2026 It's like a sophisticated video game, but the numbers that are generated from the report are critical in helping to better identify the severity and recovery from the injury.\"\nBut for students such as Aldrich, who don't know their baseline, extra caution is the doctor's order.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\nThe report describes the widespread availability of the Impact system in the U.S., but fails to describe how an athlete would gain access to such neurocognitive testing systems.\n", "answer": 0}, {"article": "Newswise \u2014 LOS ANGELES (Dec. 5, 2018) - Vascular surgeon Ali Azizzadeh, MD, was the first to use a newly approved, minimally invasive device to perform a series of innovative surgeries on patients with aneurysms of the aorta, the main vessel that delivers blood from the heart to the rest of the body.\n\u201cThis was a difficult surgery, but I knew I was in good hands,\u201d said Angelino, 85, of Culver City.\nCompared to other technologies, the stent graft can travel through smaller, curvy vessels and better adjust to a patient\u2019s anatomy.\nThough aneurysms can happen anywhere in the body, they most commonly happen in the brain, or in the main vessels that lead to the heart, legs and arms.\n\u201cI feel very lucky to have benefited from this new and improved surgical technique and for the great doctors who cared for me.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We are given no indication whether the procedure is in use in other hospitals outside the clinicians who were involved in the clinical trial.", "answer": 0}, {"article": "Medical researchers are well aware that the dummy pills used in clinical trials often provide as much relief as the actual drugs being tested. This is what's known as the placebo effect, and it's quite common in people with Parkinson's, a movement disorder that causes tremors, stiffness and balance problems. A 2008 meta-analysis found that placebos used in clinical trials of Parkinson's treatments improved symptoms by an average of 16%.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of sugar pills is not in question. However, many physicians would not consider it ethical to prescribe a placebo. The story does not convey this nuance.", "answer": 0}, {"article": "Jaffe said the study focused on time to treatment failure because delaying or preventing inflammation is the key to successful treatment.\n\u201cSince each of these signs can be associated with different types of uveitis, the study\u2019s results broaden the applicability of treatment for patients.\u201d\n\nThe study authors note, however, that patients in the adalimumab group reported serious adverse effects, such as respiratory tract infections and allergic reactions, more frequently than those in the placebo group.\nThe studies also looked at whether an alternative would be better tolerated or more effective, yet still safe.\u201d\n\nThe study consisted of 217 adults who had active, non-infectious intermediate or posterior uveitis, or panuveitis.\nIn addition to Jaffe, co-authors include Andrew D. Dick, Antoine P. Br\u00e9zin, Quan Dong Nguyen, Jennifer E. Thorne, Philippe Kestelyn, Talin Barisani-Asenbauer, Pablo Franco, Arnd Heiligenhaus, David Scales, David S. Chu, Anne Camez, Nisha V. Kwatra, Alexandra P. Song, Martina Kron, Samir Tari, and Eric B. Suhler.\n\u201cPatients may have many unwanted side effects when taking steroids long-term, as many uveitis patients do,\u201d Jaffe said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The level of detail is good here, noting that the FDA recently approved adalimumab for noninfectious uveitis, how it was previously approved for other conditions, and in which types of uveitis it\u2019s generally ok to treat.", "answer": 1}, {"article": "Source: Brightling C, et al.\nAs the researchers tracked the participants over the course of 12 weeks, they found that those taking the drug saw a decrease in their sputum eosinophil reading from an average of 5.4 percent to 1.1 percent.\nBy measuring the sputum eosinophil \u2014 the inflammation marker that shows how white blood cells increase during asthma attacks \u2014 the researchers were able to track the effects of the drug.\nWe already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.\u201d\n\nUltimately, the researchers hope that the drug \u201ccould likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms \u2013 making it a \u2018game changer\u2019 for future treatment,\u201d said Brightling.\nIn the study, the researchers examined 61 participants who were divided into two groups: The first was given 225mg of the drug twice a day for 12 weeks, and the second group was given a placebo.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The headline makes it sound as if the pill is readily available, with no mention that further trials and approvals are necessary before the drug could be marketed.", "answer": 0}, {"article": "CHICAGO -- Many patients treated with Byetta, a diabetes drug by Amylin Pharmaceuticals Inc. and Eli Lilly & Co., were able to maintain good blood-sugar control and also lose weight after three years on the drug, according to a study.\n\nThe study, described at the American Diabetes Association's annual meeting here, examines clinical data from the longest trial involving Byetta presented to date.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states the drug studied, Byetta, was approved by the FDA for selected people with type 2 diabetes in 2005.\u00a0 ", "answer": 1}, {"article": "But scientists also realized it could have other uses.\nIn trials on mice, the antibody was found to increase bone mass and reduce adipose tissue (fat)\u2014and while human studies are some way off, the findings could lead to new treatments for weight loss and osteoporosis.\nTheir next step is to \u201chumanize\u201d the antibody, so it can be tested without triggering an immune response.\nTen years ago, scientists started looking at the hormones made in the pituitary gland to see how they act on certain targets.\nAs a result, they started considering it as a potential treatment for osteoporosis, particularly in post-menopausal women\u2014a period when women lose bone mass fairly quickly.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly notes all of the steps that need to be taken before the antibody could even begin human trials, in three to four years at the earliest.", "answer": 1}, {"article": "\"Parents often say that their biggest concern is, 'When is my child going to be back to normal again?'\nIf the experimental test pans out, \"a pediatrician could collect saliva with a swab, send it off to the lab and then be able to call the family the next day,\" says Steven Hicks, an assistant professor of pediatrics at Penn State Hershey.\n\"When they came to our medical center and received the diagnosis of concussion, we evaluated them with some standard survey-based tools and then we also got a sample of their saliva,\" Hicks says.\n\"A lot of children get mild concussion and oftentimes it goes ignored,\" he says.\nThe team measured levels of many different microRNAs in the samples, and eventually they identified a handful that let them predict how long symptoms would last.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that the spit test is still being studied. There were no predictions about when or if it would be available.", "answer": 1}, {"article": "Just one center in the north of the country offers proton therapy for certain types of eye tumors.\nWhile the proton therapy market is expected to more than double by 2018, with an estimated 300 proton therapy rooms, Jongen's Brussels-based company IBA is working on a smaller and cheaper model they hope will make proton therapy more accessible.\n\"In this space we accelerate the protons and we give them a higher and higher velocity until they reach two thirds of the speed of light -- that's 200,000 km per second and this acceleration takes place in the shape of a spiral,\" he said.\n\"I started to designing equipment (for) proton therapy of cancer -- that was a radically new idea,\" Jongen told CNN.\n\"I have a number of letters from parents of young kids saying if it had not been for this treatment we would have lost our kid,\" he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The reader is told that there are a limited number of sites (and none in England) offering proton beam therapy, but that hope is on the way in the form of a less expensive device from Mr. Jongen\u2019s company. The story states that \u201cthe proton therapy market is expected to more than double by 2018, with an estimated 300 proton therapy rooms,\u201d but it doesn\u2019t explain where they are.\nNonetheless, we\u2019ll give the story the benefit of the doubt for supplying a general overview.", "answer": 1}, {"article": "Although we know quite a bit about it, it's still not that well understood,\" said Steven Silverstein, professor of psychiatry at Rutgers Robert Wood Johnson Medical School and director of research at Rutgers University Behavioral Health Care (UBHC), who designed the study.\nA tiny skin electrode was placed on the skin under the eye to record the retina's electrical activity.\n\"Schizophrenia is a devastating disorder, probably the most disabling disorder long term.\nThe participants were tested in normal light and after sitting in the dark for 10 minutes to assess activity in different types of retinal cells.\nThis was the first time a portable device was used for these tests.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release said the device is \u201ccommon in optometrists\u2019 offices.\u201d", "answer": 1}, {"article": "\u201cWhat about long-term safety issues?\u201d he asked.\n\u201cThe trial did not last long ... so the authors cannot really say whether any response would be sustained,\u201d Dr. Henry McQuay, who studies pain and pain relief at the University of Oxford, wrote in an editorial accompanying the study.\nNEW YORK (Reuters Health) - In a small study, people who had chronic pain as a result of damage to the nervous system reported feeling less pain, as well as less depression and anxiety, when they smoked marijuana compared to when they smoked a drug-free placebo.\nFor that reason, the finding that marijuana may actually help improve patients\u2019 sleep, she said, is \u201cparticularly noteworthy.\u201d\n\nThe cannabinoid family, which includes marijuana, is \u201cemerging as an interesting new class of drugs for pain management,\u201d Ware said.\n\u201cA lot of the treatments that are used for neuropathic pain ...might also be associated with disruptions in sleep,\u201d Dr. Andrea Hohmann, who studies marijuana and pain at the University of Georgia and was not involved with the current study, told Reuters Health.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Strangely, neither story we reviewed pointed out that marijuana is illegal in most states and in Canada, where the study took place. The story could have, at a minimum, mentioned which states have medical marijuana laws or talked about whether any other countries currently allow cannabis to be sold in pill form the way it was used in this study.", "answer": 0}, {"article": "Celgene\u2019s drug Abraxane prolonged the lives of patients with advanced pancreatic cancer by almost two months in a clinical trial, researchers reported Tuesday, signifying an advance in treating a notoriously difficult disease but not as big a leap as some doctors and investors had hoped.\n\n\u201cIt was not the breakthrough we were anticipating,\u201d said Dr. Andrea Wang-Gillam, an assistant professor and pancreatic cancer specialist at Washington University in St. Louis, who was not involved in the trial.\n\nStill, Dr. Wang-Gillam and others said any progress was welcome against metastatic pancreatic cancer, which has defied most treatments, with patients tending to live only about six months after diagnosis.\n\nPancreatic cancer is the fourth most common cause of cancer death, with 38,000 Americans expected to die this year, almost as many deaths as from breast cancer, according to the American Cancer Society. Yet there are only 45,000 new cases of pancreatic cancer a year compared with more than 230,000 new breast cancer cases.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that Abraxane is already used to treat advanced breast cancer and non-small-cell lung cancer.", "answer": 1}, {"article": "Feb. 17, 2011 (Orlando, Fla.) -- Taking a pomegranate pill a day may help slow the progression of prostate cancer, preliminary research suggests.\nAfter six months of taking the capsules, it took 19 months for their PSA levels to double.\nThe new study involved 92 men with cancer that had not spread beyond the prostate and rising PSA levels.\nThe men took either one capsule containing 1 gram of pomegranate extract or three pomegranate capsules daily.\nThe study was presented at the Genitourinary Cancers Symposium.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story never explained whether capsules containing pomegranate extract are available.", "answer": 0}, {"article": "The quality of life survey measured overall functioning (physical, emotional, cognitive, etc.\nThe study is titled \u201cQuality of Life in Patients Undergoing Pleurectomy and Decortication for Malignant Pleural Mesothelioma.\u201d The surgeries were performed by Dr. Vigneswaran at University of Chicago Medicine, where he practiced before recently joining Loyola.\nPrior to surgery, 31 percent of the patients had a performance status score of 0 (fully functional); 65 percent had a performance status score of 1 (able to do light house work or office work); and 4 percent had a performance status of 2 (ambulatory and capable of self-care, but unable to work).\n\u201cThe net benefit of pleurectomy and decortication justifies the procedure in the majority of patients with malignant pleural mesothelioma,\u201d Dr. Vigneswaran concluded.\nBut a study led by a Loyola Medicine thoracic surgeon has found just the opposite: Patients who underwent an operation called pleurectomy and decortication (PD) generally reported their quality of life improved after surgery.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We rated this as satisfactory, but just barely. The release notes that surgery in the opening paragraph:\u201dAlthough surgery can prolong the lives of patients with an aggressive type of cancer called malignant pleural mesothelioma, many patients avoid the operation for fear it will degrade their quality of life.\u201d\u00a0 This makes it clear that surgery is a routine option for treatment although not specifically pleurectomy and decortication. We appreciate that the release is intended for a sophisticated audience but think that the wording could have been a bit clearer. ", "answer": 1}, {"article": "Only about half the patients who were screened qualified for treatment, known as thrombectomy, which uses a mechanical device to pull clots out of a blood vessel.\n\u201cThese striking results will have an immediate impact and save people from lifelong disability or death,\u201d Dr. Walter J. Koroshetz, director of the National Institute of Neurological Disorders and Stroke, said in a statement.\nThe study showed that the time window could be expanded to 16 hours.\n\u201cI really cannot overstate the size of this effect.\u201d\n\nThe key finding is that there is often more time than doctors realized in which brain cells can still be rescued by a procedure to remove the clot.\nThe researchers used a special type of brain imaging to identify the patients who still had live brain tissue that could be saved if the blood supply was restored.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While it\u2019s not clear when the new 16-hour guideline will take effect, the article makes it clear that this procedure is currently available.", "answer": 1}, {"article": "Aging is never easy, particularly during menopause. But for 30 years women could at least depend on estrogen and progestin supplements, a comforting hormonal hand to hold that would not only ease the uncomfortable symptoms of getting older but also keep skin supple and hair lustrous. Doctors even encouraged women well into their 70s to take the treatments, on the basis of studies showing that they protected against heart disease and cushioned bones against osteoporosis-related fractures.\n\nIt seemed almost too easy--and it was. In 2002 the quick pharmaceutical fix was all but snatched away when a large government study found that...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that hormone therapy has been around for a long time and is very common.", "answer": 1}, {"article": "One of the top research universities in the world, MSU focuses its vast resources on creating solutions to some of the world's most pressing challenges, while providing life-changing opportunities to a diverse and inclusive academic community through more than 200 programs of study in 17 degree-granting colleges.\nIn a proof-of-concept study, published in the journal Neurobiology of Disease, the drug nortriptyline, which has been used to treat depression and nerve pain, stopped the growth of abnormal proteins that can build up in the brain and lead to the development of the disease.\nThe idea that this clustering effect is controlled by how fast or slow a protein reconfigures itself is typically not a standard way of thinking in research on proteins, but our work has been able to show these changes.\"\n\"We found that those on a certain class of antidepressant, called tricyclics, didn't need the levodopa therapy until much later compared to those who weren't on that type of antidepressant medication,\" Collier said.\n\"By using a test tube model, we found that by adding nortriptyline to the alpha-synuclein proteins, they began to move and change shape much faster, preventing the proteins from clumping together.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is about a \u201cproof of concept\u201d and no therapy is available based on this research. We\u2019ll rate this Not Applicable but note that the release should have been more clear in the headline and lede that this therapy hasn\u2019t been tested in humans.", "answer": 2}, {"article": "NEW YORK (Reuters Health) - Taking multivitamins may help women without cardiovascular disease to ward off a heart attack, new research shows.\n\u201cEven if we have controlled for many of those factors that are associated with a healthy behavior we cannot exclude the possibility that we might measure a healthy lifestyle via multivitamin use.\u201d\n\nIn industrialized countries, Rautiainen and her team note in the American Journal of Clinical Nutrition, multivitamin use is widespread.\nAmong the women with heart disease, 13 percent of the non-supplement-users had heart attacks, compared to 14 percent of women who took multivitamins only, which wasn\u2019t a statistically significant difference (meaning it could have been due to chance).\nThe results don\u2019t settle the question of whether it\u2019s actually the vitamin pills that are protective, Rautiainen told Reuters Health via e-mail.\nTo investigate the relationship between vitamin use and heart disease in women, Rautiainen and her team followed 31,671 women with no history of heart disease and 2,262 women who did have cardiovascular disease for about 10 years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of multivitamins is assumed. However, the researchers did not collect deatiled data about which vitamins the women took or in what amounts, so it is unknown whether the results truly reflect on typical multivitamins or possibly other products.", "answer": 1}, {"article": "Amgen has partnered with Novartis AG to co-commercialize Aimovig in the United States, while Amgen has rights to the drug in Japan and Novartis has rights to commercialize in rest of world.\nA decision by the FDA is due by May 17.\nThe drug, a monoclonal antibody, was given monthly by injection at a dose of 140 mg for the trial.\nReuter said the 17-point gap between the treatment and placebo groups was in line with previous Aimovig studies.\nHe said previous studies excluded patients who had tried more than two other treatments.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the drug is under review by the FDA and that a decision is expected in May.", "answer": 1}, {"article": "MONDAY, Oct. 31, 2011 (HealthDay News) -- Doctors who listen to Mozart while performing colonoscopies may spot more precancerous growths, researchers suggest.\nResearchers set out to determine if this phenomenon, called the \"Mozart Effect,\" played a role in the detection rates of precancerous polyps during colonoscopies.\n\"Anything we can do to get those rates up has the potential to save lives.\nHowever, the second doctor had an adenoma detection rate of nearly 37 percent with Mozart and 40 percent without the music, compared with a baseline detection rate of 27 percent.\n\"Adenoma detection rate is linked to a reduction in colorectal cancer incidence, so it is an important quality indicator for colonoscopy,\" said O'Shea.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 There\u2019s no question about the ability of anyone to listen to any of kind of music while doing colonoscopies.", "answer": 2}, {"article": "Compared with the 35 stroke patients who got clot-dissolving medicine alone, the 35 who got the two-pronged treatment were nearly twice as likely to regain some neurological function after three days. Imaging results revealed that for those who got both treatments, 100% of the brain tissue initially affected by a clot had blood flowing to it after 24 hours. Among the subjects who only got alteplase, the median level of restored blood flow was 37%.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a wonderful job highlighting concerns about the availability of the treatment offered in these studies. \u00a0We are told that only specialized centers have the expertise and technology available to perform the procedures, \u00a0and that insurance coverage has been spotty. The story also mentions the three clot retrieval devices that are approved for use in the United States.", "answer": 1}, {"article": "Previous reports22,23 of the overall randomized clinical trial found locoregional control and survival advantages associated with the addition of cetuximab to radiotherapy.\nFurthermore, there were greater severe acute toxic effects from the chemoradiotherapy treatments compared with radiotherapy alone,13 but no significant differences in severe late toxic effects were noted in the comparison of the 3 treatment arms.14 Unfortunately, the concomitant chemoradiotherapy arm had an increase in deaths not attributable to cancer compared with the other 2 arms; this finding needs to be explored further to determine whether undetected fatal late treatment toxic effects are greater with concomitant regimens.\nIn a recent trial from France, 269 patients were queried about the treatment choices they might make if they faced the diagnosis of advanced laryngeal cancer.30 Only 29% stated that they would not consider options with a lower chance of cure if told that the best option, with respect to survival, was total laryngectomy.\nHistorically, locoregionally advanced squamous cell cancers of the larynx or hypopharynx have been treated with surgical resection, usually involving laryngectomy with or without postoperative radiotherapy.1 Although laryngectomy is an effective treatment, investigators have sought therapeutic strategies that result in voice preservation.\nThe TREMPLIN (Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation) trial compared the efficacy and safety of induction chemotherapy using docetaxel, cisplatin, and fluorouracil, followed by chemoradiotherapy with cisplatin (n = 60) or cetuximab (n = 56), for laryngeal preservation.33 No differences were found in laryngeal preservation, laryngeal function preservation, or overall survival between the 2 regimens.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This release notes that more research, on a larger scale, needs to be done to \u201cassess the potential value\u201d of interventions like CRT in treating cancer while preserving the larynx. However, the release would have been much better if it had clearly noted that cetuximab is not currently eligible for insurance coverage for this particular condition and a result will not be available to many patients.", "answer": 0}, {"article": "* Researchers involved in this study are affiliated to the following:\n\nSchool of Medicine, University of East Anglia, Norwich, UK \n\nNorfolk and Norwich University Hospital, Norwich, UK \n\nBristol Medical School, University of Bristol, Bristol, UK \n\nDepartment of Rheumatology, University Hospitals Bristol, Bristol, UK \n\nMedical Research Council Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK \n\nCollege of Medical and Dental Sciences, University of Birmingham, UK \n\nCentre for Endocrinology, Diabetes and Metabolism, Queen Elizabeth Hospital, Birmingham, UK \n\nLeicester Medical School, Centre for Medicine, University of Leicester, UK \n\nNational Institute of Health Research Manchester Musculoskeletal BRU, Central Manchester University Hospitals NHS Foundation Trust & \n\nArthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, UK \n\nDepartment of Health Sciences, University of York, York, UK \n\nCentre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK \n\nMellanby Centre for Bone Research, Centre for Integrated Research into Musculoskeletal Ageing, University of Sheffield, Sheffield, UK \n\nAustralian Catholic University, Melbourne, VIC, Australia\nThe team used a University of Sheffield developed tool called FRAX, which predicts the probability of a hip fracture or a major osteoporotic fracture (a hip, spine, upper arm or lower arm fracture), to identify older women at high risk.\nThe study suggests that one hip fracture could be prevented for every 111 women screened and early analysis suggests the approach is likely to be cost-effective.\nFor further information or interviews contact Emma McKinney, Press Office, University of Birmingham, at +44 (0)121 414 6681 or contact the Press Office out of hours on 44-0-7789-921165.\nWhile screening did not reduce the incidence of all osteoporosis-related fractures, there was strong evidence for a reduction in hip fractures.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This was a clinical trial of the proposed adoption of a screening procedure which the researchers hope will contribute to national healthcare policy. The risk calculator used in screening, FRAX, is already widely available.", "answer": 2}, {"article": "Researchers reviewed data on all patients who have been exposed to JCV who are enrolled in TOUCH, the U.S. Food and Drug Administration-mandated Risk Evaluation and Mitigation Strategy (REMS) program for natalizumab that requires manufacturers to document all uses of a medication to ensure that the benefits of a drug outweigh its risks.\nThere have been 756 PML cases reported worldwide as of January 2018, with a global incidence rate of 4.19 per 1,000 PML cases in people treated with natalizumab.\nThe new study, however, reports safety data through up to 72 months, or 6 years, when the extended dosing regimens were applied, with risk reduction for PML as high as 94 percent.\nA commonly-prescribed multiple sclerosis (MS) infusion medication linked to a rare but serious side effect is safer to use when dosing intervals are extended, according to a new study led by MS specialists NYU Langone Health.\nThe new research showed that extending dosing of natalizumab from every 4 weeks to every 5 to 12 weeks significantly reduced the risk of developing progressive multifocal leukoencephalopathy (PML), a rare but potentially fatal brain infection.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does mention that natalizumab is a \u2018commonly-prescribed multiple sclerosis (MS) infusion medication linked to a rare but serious side effect \u2026 \u201d\nIt should have been made more clear, however, that the drug has been pulled from the market before (over PML concerns) and is now FDA-approved only for\u00a0highly active, relapsing remitting MS.", "answer": 1}, {"article": "Earlier this year, dementia overtook heart disease as the leading cause of death in England and Wales.\nDavid Reynolds, chief scientific officer at Alzheimer\u2019s Research UK, said: \u201cIt is conceivable that changing brain cell rhythms could be a future target for therapies, but researchers will need to explore how light flickering approaches could not only reduce amyloid in the visual area of the brain but in those areas more commonly affected in Alzheimer\u2019s.\u201d\n\nThe authors suggest that it may be possible to take a multi-sensory approach, using a combination of flashing lights and vibrating chairs.\nEd Mann, an associate professor of neuroscience at the University of Oxford, said: \u201cI was surprised, and it\u2019s exciting, that such a simple stimulus can target a molecular pathway and have such an effect in an hour.\u201d\n\nQuestions remain, however, about whether boosting gamma oscillations and sweeping amyloid plaques out of the visual brain region would help with memory, which is centred in the hippocampus, or broader cognitive abilities.\nThe latest intervention, scientists predict, should be quicker and cheaper to confirm in humans than pharmaceuticals, which typically take more than a decade to develop and assess for safety before the clinical efficacy is even examined.\nThe study, published on Wednesday in the journal Nature, hinges on the observation that Alzheimer\u2019s patients show a loss of synchronised brain activity, known as gamma oscillations, which is linked to attention and memory.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story address availability with this\u00a0statement: \u201cThe latest intervention, scientists predict, should be quicker and cheaper to confirm in humans than pharmaceuticals, which typically take more than a decade to develop and assess for safety before the clinical efficacy is even examined.\u201d OK, quicker and cheaper \u2014 but does that mean a year from now or five years or 10?", "answer": 0}, {"article": "Hare was not involved in the study.\nIt's the first time tissue-specific stem cells, other than bone-marrow cells, have been tested in humans, Hare says.\n\"This is a groundbreaking study of extreme importance,\" Joshua Hare, MD, director of the University of Miami's Interdisciplinary Stem Cell Institute, tells WebMD via email.\nIt's early -- results are in for only the first 16 patients -- but the results already are drawing praise from experts not easily impressed by first reports.\nThese adult stem cells already are committed to becoming heart cells, but they can transform into any of the three different kinds of heart tissues.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that these findings are from a small study early in the development of a stem cell therapy and that the treatment is not going to be available in the near term. It says that a \u201clarger, phase II study is planned.\u201d More important, it clearly states \u201cthe experimental treatment simply will not be available to other patients in the near future.\u201d ", "answer": 1}, {"article": "Or are these symptoms merely the consequence of the violence of the shock, of which will ultimately only leave a bump behind?\nHis team has developed a rapid diagnostic test (POCT) called TBIcheck, inspired by the principle of pregnancy testing: by placing a single drop of blood on the well of a small 5cm plastic case, the patient knows within 10 minutes whether there is a risk of mild trauma, namely whether or not his H-FABP level is higher than 2.5 nanograms per millilitre of blood.\nResearchers from the University of Geneva (UNIGE), in collaboration with the Hospitals of Barcelona, Madrid and Seville, have developed a small device - Point-of-Care Test (POCT) - that analyses the level of proteins in the blood and allows, using a single drop of blood, to diagnose the possibility of a mild traumatic brain injury.\n\"Our idea was to find a way to do a quick examination that would allow, during a boxing or American football match for example, to determine whether the athlete can return to the field or if his condition requires hospitalization.\n\"We wondered if it was possible to isolate certain proteins whose presence in the blood increases in the event of mild traumatic brain injury,\u00bb explains Jean-Charles Sanchez, professor at the Department of Internal Medicine of Specialties and the Biomarkers Centre of the Faculty of Medicine of the UNIGE.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release stated that the device will be marketed starting in 2019 by a company called ABCDx. However, it would have been helpful to readers to point out whether or not the device must receive regulatory approvals or any details about the types of patients for whom it is recommended.", "answer": 1}, {"article": "\u2022 3 diet shakes per day and 240 grams of non-starchy vegetables taking in between 600 and 700kcal a day for 8 weeks\n\u2022 volunteers then gradually returned to eating normal food over the next two weeks with very careful instruction on how much to eat\n\u2022 volunteers were seen once a month and supported with an individualized weight maintenance programme over the next 6 months\n\u2022 to keep weight steady after the weight loss, they were eating around one third less than before the study\n\nAllan Tutty, 57, from Sunderland, transformed his health by taking part in the study.\nThis caused international interest, but the study was very short as it was only eight weeks and the question remained whether the diabetes would stay away.\nIf you have had the diagnosis for longer than that, then don't give up hope - major improvement in blood sugar control is possible.\nIn this new study, 30 volunteers with Type 2 diabetes embarked on the same diet of 600 to 700 calories a day.\nA previous study led by Professor Taylor, published in 2011, showed that diabetes could be reversed by a very low calorie diet.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Given that the approach of this study focuses on specific foods as key to maintaining weight, and that these foods are commonplace, one assumes that they are readily available in the marketplace.", "answer": 2}, {"article": "A 6-month supply of vitamin D supplements can be bought for less than $10, and many multivitamins contain the recommended daily dose of vitamin D.\n\nAs for calcium, the NIH advises 1,000 mg per day for men ages19-70, and then 1,200 mg per day for men older than 70.\nMore than 40 million people in the US are affected by osteoporosis.\nTo build bone density, weight-bearing exercise is needed, such as running or weight-lifting, according to the NIH.\n\u201cAdding more might not strengthen the wall, but you have to take enough to keep the wall strong.\n\u201cYou\u2019ve got to have it to build a wall,\u201d he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of calciium and vitamin D are not in question.", "answer": 2}, {"article": "\"How bulging is the eardrum?\nBut here's the rub \u2013 diagnosing ear infections in very young children, who tend to squirm, is not easy.\nIf many children in prior studies didn't really have ear infections, then it's not surprising the antibiotics didn't work for them, says Dr. Jerome Klein of Boston University, who wrote an editorial that accompanies the new studies.\nMuch of the confusion, experts say, has been caused by studies that weren't careful enough about the diagnosis.\nBut the new studies, from the United States and Finland, come down firmly on the side of early antibiotic therapy for kids under age 2 or 3.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made it clear that the \u201cwait and see\u201d approach to ear infections is widely recommended. The accompanying radio piece reported that there are \u201c13 million prescriptions every year for ear infections,\u201d in part because only about 20% of doctors actually follow that approach.\n", "answer": 1}, {"article": "Ankle replacement has been around for three decades, but it has been slow to catch on.\nStill, Dr. Deland said, \u201cwe\u2019re getting fewer and fewer failures.\u201d\n\nThe new models require that less bone be removed, so the bone to which the device is affixed is stronger.\nFour models are commonly used in the United States, with Food and Drug Administration approval.\nThe bodies of many older Americans are practically bionic: more than 770,000 hip and knee replacements are performed each year in the United States.\nUntil lately, such patients have had only one surgical option: ankle fusion surgery, in which the worn-out part of the joint is removed and the bones are permanently locked together with screws and plates.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story correctly notes that ankle replacement has been available for\u00a0several\u00a0decades but is not\u00a0widely performed.\u00a0 However, there was an omission in not indicating that\u00a0that knee and hip replacement are\u00a0most often associated with osteoarthritis, the most common form of arthritis, while ankle replacement is largely\u00a0performed in patients with post-traumatic osteoarthritis and the much less common rheumatoid arthritis.\u00a0\u00a0 In addition, the article inaccurately states that 4 models are FDA\u00a0approved.\u00a0 A fifth model, the STAR,\u00a0which has\u00a0a unique design, was FDA approved in May 2009.", "answer": 1}, {"article": "Study Limitations: Imbalances caused by matching groups of obese patients for comparison based on age, sex, body mass index and diagnoses of diabetes.\nWhy The Research Is Interesting: Much is known about the short-term outcomes of bariatric surgery for weight loss but relatively little is known about its long-term effects.\nResults: The rate of death from any cause over about 4.5 years was lower among obese patients who underwent bariatric surgery compared with patients who managed their obesity with nonsurgical care.\nSome previous research has been limited by a number of factors, including the lack of a comparison group of obese patients who did not undergo bariatric surgery.\nThe following related elements from this issue of JAMA are also available on the For The Media website:\n\n-- Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity\n\n-- Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity\n\n-- Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A , LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study\n\n-- Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities\n\n-- Editorial: Comparing the Outcomes of Sleeve Gastrectomy and Roux-en-Y Gastric Bypass for Severe Obesity\n\nFor more details and to read the full study, please visit the For The Media website.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address availability. However, bariatric surgery for obesity is becoming increasingly common and is now available worldwide. The release would have been stronger had it informed readers about the eligibility criteria for the surgery.", "answer": 2}, {"article": "\u201cThere\u2019s really no doubt that there have been cold feet in the industry about this issue.\u201d\n\nBut investigators around the world have shown they can carry out these \u201cfood challenge\u201d trials safely \u2014 which could help hasten the development of new drugs.\nThe idea is to create resistance to an allergen without ever having to expose the patient to that substance.\nThis timeline becomes untenable for patients with multiple allergies \u2014 and about 70 percent of people who have an allergy to one type of food will also be allergic to another, Long said.\nIf it works, it\u2019d be fairly easy to swap out the cedar pollen DNA for a different allergen \u2014 for instance, the genetic material that codes for peanut or cat antigens \u2014 and tack it onto this vaccine template.\nOnce there, it revs up an aggressive immune response and imprints an \u201cimmunological memory,\u201d which means the immune system will respond even more quickly to future exposures to the allergen.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article, admirably, makes clear that movement through the new drug pipeline is likely to be slow for most of the newly envisioned therapies.", "answer": 1}, {"article": "Use of osteoporosis drugs, once heavily advertised by celebrity spokeswomen, has dropped by more than 50% in recent years amid reports of such serious side effects as sudden bone fractures.\n\nYet many experts say the benefits of the drugs, known as bisphosphonates, far outweigh the risks for many users.\n\nAn analysis in the New England Journal...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that bisphosphonates are in widespread use, and the article at least implied that the generic versions were generally available at the low quoted price \u2014 giving readers the tools to select the drug and look at reasonable pricing.", "answer": 1}, {"article": "\"Weight loss was similar but substantial in both groups we studied, but blood pressure improved more in the low-carb dieters,\" said study author Dr. William Yancy Jr., an associate professor of medicine at Duke University Medical Center and a staff physician at the Department of Veterans Affairs Medical Center in Durham, N.C.\n\n\"There are options out there.\nThe researchers found that combining the DASH diet with weight management and exercise resulted in a 16.1 mm Hg drop in systolic blood pressure compared to 11.2 mm Hg on the DASH diet alone.\nAdditionally, those in the exercise, weight management and DASH plan lost an average of 19 pounds over four months vs. less than one pound for the DASH diet alone.\nThe third study compared an Internet weight-management program with a physician-managed program for extremely obese people that included a liquid diet component, followed by a structured diet, behavioral counseling and diet medications.\nSimilar reductions were seen for diastolic blood pressure.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that orlistat is available via prescription as Xenical and over the counter as Alli. The availability of the low-carb and low-fat diet options is not in question.", "answer": 1}, {"article": "What does that mean for men today?\nThose with a higher PSA velocity \u2014 the level rose more than a count of 0.35 a year \u2014 had a 54 percent survival rate, while those whose PSA rose more slowly had a 92 percent survival rate.\nThe work is \"another step on the road to more sophisticated\" prostate cancer screening and treatment, Dr. Timothy Church of the University of Minnesota wrote in an editorial accompanying the work.\nBut Carter contends the findings suggest that men should consider getting a baseline PSA test around age 40, instead of the more usual 50, to use as a comparison for future changes.\nIt diagnoses prostate cancer that's going to actually cause harm,\" said Dr. H. Ballentine Carter, urology chief at Johns Hopkins University, who led the research published Tuesday in the Journal of the National Cancer Institute.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states this latest study could help change how PSA (or prostate specific antigen) tests are currently used, implying that PSA testing is available.\u00a0 The article also states that many doctors already use PSA velocity to help determine which men need biopsies, also implying that the use of PSA velocity, a particular way to use PSA testing, is available\u00a0although not necessarily used by all at this time.\u00a0 ", "answer": 1}, {"article": "The Ache: Common cholesterol-lowering drugs called statins can have unpleasant side effects, including muscle aches and weakness.\n\nThe Claim: An extract from a bitter, fragrant citrus fruit called bergamot, commonly known as a flavoring in Earl Grey tea, can lower cholesterol with minimal side effects, some scientists say. It also boosts good cholesterol, reduces fatty deposits in the liver and lowers blood sugar, they add.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The supplements are already on the market and the story makes that clear.", "answer": 1}, {"article": "Jordan says the new findings will quickly change care for some patients.\nBreast cancer survivors have mixed reactions to the results.\nIn the U.K., tamoxifen costs only $5 a month.\nSome switch to an AI, although these drugs can also cause problems, such as joint pain and osteoporosis.\nGray noted that tamoxifen has risks.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability is well-established in the story.", "answer": 1}, {"article": "\u201cLet\u2019s talk about your test results,\u201d my neurologist said.\n\nShe looked as if she had good news. Instead, it was shocking.\n\nThe carotid artery on the left side of my neck, one of the brain\u2019s two main sources of blood and oxygen, was clogged with fatty plaque, the doctor said. The artery was almost completely blocked.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that carotid endarterectomy is widely available.", "answer": 1}, {"article": "No doubt you have heard that yogurt is teeming with bacteria--and no doubt you try not to think about that as you dig into a cup of the stuff. Yes, they're supposed to be good bacteria, ones that not only don't make you sick but actually improve your health. Still, a spoonful of critters with unlovely names like Lactobacillus reuteri, Lactobacillus rhamnosus and Bifidus regularis will never sound like a palate pleaser to even the most dedicated health nut.\n\nWhether or not you've ever developed a taste--or even a tolerance--for living things in your lunch, more are on the way. Food...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that there are current products for sale in grocery stores that contain probiotic bacteria and that in addition, there are new products being developed. \u00a0However \u2013 the story should have mentioned that there is no evaluation process to ascertain that the products sold as probiotics actually contain the organisms in the doses advertised. So true \"availability\" is difficult to ascertain.\u00a0 Consumers should know this. \nIt should be noted that the table that is a part of this story provides an inadequate listing of sources of probiotic containing foods.\u00a0", "answer": 0}, {"article": "; Jerrold H. Levy, M.D.\nThe new results are part of a large on-going phase III study testing idarucizumab in a range of patients who take dabigatran and have dangerous bleeding or need urgent surgery or other procedures that carry serious bleeding risks.\nIn patients who received two 2.5-gram of idarucizumab infusions in a 15-minute period, blood tests revealed that dabigatran's blood-thinning effect was 100 percent reversed in all 18 patients with brain bleed.\nPatients on blood-thinning drugs, such as dabigatran (Pradaxa), who suffer a type of bleeding that occurs inside the skull (intracranial hemorrhage) are at high risk of complications or disability.\nIdarucizumab (Praxbind) is an antibody that chemically binds and neutralizes the blood-thinning effects of dabigatran.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that idarucizumab was approved by the FDA in October 2015, so readers can assume that it\u2019s available (and it is).", "answer": 1}, {"article": "He's also on Twitter: @BretStetka.\n\"We also know that in patients who receive stimulation there is an increase in glucose utilization in memory areas of the brain,\" he says, a finding that could mean there's a way to overcome some of the damage from Alzheimer's.\nYet the fact that the therapy can in some people rescue recollections \u2013 albeit random ones \u2013 and possibly induce new neuron growth in memory regions of the brain seems reason enough to pursue it further.\nThe technique is also approved for obsessive-compulsive disorder and is being looked at for a number of other brain disorders, including depression, chronic pain and, as in Lozano's work, dementia.\nThough no bigger than a pea, the hypothalamus is a crucial bit of brain involved in appetite regulation and other bodily essentials such as temperature control, sleep and circadian rhythms.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story acknowledges the preliminary nature of the research, but we\u2019d have liked to see it near the top rather than in the third-to-last paragraph, which states: \u201cDBS for treatment of Alzheimer\u2019s and other dementias is a field in its infancy. Unlike on TV, in all likelihood it won\u2019t be widely used anytime soon to retrieve specific memories.\u201d", "answer": 1}, {"article": "WEDNESDAY, July 13, 2011 (HealthDay News) -- For men who have prostate cancer that's considered \"intermediate risk,\" radiation plus four months of hormone therapy appears to improve survival, a new study finds.\nHe noted that the radiation treatments in use today differ from those given in 1994 when the trial began.\nYou need to give long-term androgen deprivation therapy in addition to radiation to have the best results,\" Jones said.\nOn the other hand, hormone therapy plus radiation was most effective in patients with intermediate-risk prostate cancer.\nThe hormone therapy is known as androgen deprivation therapy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained about the treatment used in the study reported on as well as how radiation therapy has changed since the men in the study were treated.", "answer": 1}, {"article": "A female testosterone patch showed promise at boosting older women's enjoyment of sex, but concerns about the cancer risk of hormone therapies mean U.S. women won't be getting an equivalent of Viagra anytime soon.\n\nProcter & Gamble Co., the Cincinnati consumer-products giant, has worked since 1999 to secure U.S. approval for its Intrinsa patch, intended to increase sex drive and satisfaction in women after menopause.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes plain that the female testosterone patch is not available in the United States but is on the market in Europe. ", "answer": 1}, {"article": "The frequency of screening mammograms -- and the appropriate age to begin them -- has been debated since the U.S. Preventive Services Task Force in 2009 recommended that women routinely get screening mammograms every other year starting at age 50.\n\"Hopefully, there will be less anxiety about getting a recall.\"\nInformation about the women and their mammograms came from the Breast Cancer Surveillance Consortium, funded by the National Cancer Institute.\nThey found a small but not significant increase in the chance that women diagnosed with breast cancer had a more advanced case if they underwent screening every other year instead of every year.\nThose false-positives may cause inconvenience and anxiety, and biopsies can cause pain and scarring, the researchers note.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Screening mammography is widely available throughout the United States.", "answer": 2}, {"article": "Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.\nIt's unclear why the three remaining patients didn't have good improvement, although Dr. Peled notes that two of the three had had temporal headaches for decades before surgery.\nApril 29, 2016 - A modified surgical technique may provide a simpler approach to the surgical treatment for one type of chronic headache, according to an \"Ideas and Innovations\" paper in the May issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\nDuring these operative procedures, surgeons seek to relieve pressure on these nerves or to disconnect the nerves in order to prevent them from triggering future headaches.\nThe simplified approach using the Gillies incision combines the advantages of other approaches to chronic temporal headache surgery while minimizing the disadvantages, Dr. Peled believes.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release isn\u2019t clear whether or not the surgery is currently available specifically for chronic headache patients. From an online search, it seems that some centers do offer surgery to treat chronic headaches, although it isn\u2019t always clear\u00a0 what techniques the surgeons use.", "answer": 0}, {"article": "All of the babies born by C-section were slightly more likely to use an asthma inhaler at age 5: 10.3 percent of planned C-section babies and 10.19 percent of unscheduled C-section babies wound up using an inhaler, compared with 9.6 percent of vaginally born babies.\nThe remaining 252,917 were vaginal births.\nOver all, the differences between a scheduled C-section and an emergency C-section were slight.\nIn the United States, nearly one in three babies are born by C-section.\nThere were no significant differences in cancer and irritable bowel disease among any of the types of births.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All three of the birth methods described are widely available.", "answer": 1}, {"article": "The CDC says the next step is to fully review all the data and begin to develop guidelines for the use of these drugs in heterosexual men and women here in the U.S.\nThe risk of infection was reduced 63% overall, but for participants who actually got the drugs, that risk decreased by 78%.\nIn fact, an interim review of the Partners data on effectiveness was so compelling that the trial was stopped early and the placebo arm was discontinued.\nHeterosexuals who are HIV negative can significantly reduce their risk of infection by taking a daily dose of an antiviral drug, according to a new study by the Centers for Disease Control and Prevention.\nThe news comes at the same time a second study looking at PrEP in heterosexual couples in Kenya and Uganda also found significant reductions in infection rates.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Unlike the competing AP story, this story didn\u2019t make it clear that there will be issues in getting this strategy implemented in Africa and in the US.", "answer": 0}, {"article": "A new study by researchers at Wake Forest University suggests combining weight training with a low-calorie diet preserves much needed lean muscle mass that can be lost through aerobic workouts.\nThe participants were randomly assigned to one of three groups: a weight-loss-only group, who followed a calorie-restricted diet with no exercise regimen; a weight loss plus cardio (i.e., walking) group; and a weight loss plus weight-training group.\nPut another way, the percentage of weight loss coming from muscle mass was 20% in the weight loss plus walking group, 16% in the weight loss alone group, and 10% in the weight loss plus weight training group.\nThese results may be even more important for older adults who gain and lose weight with frequency, because seniors typically don't regain muscle - they regain fat mass - which is \"all the more reason for older adults to try and preserve muscle mass during weight loss,\" Beavers said.\nLoss of lean mass could have important consequences given the high risk of physical disability among the growing population of older adults.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "As mentioned above, weight lifting classes are offered at most gyms and there are online tutorials as well, making it extremely available. However, it would have been nice to include some organizations that specifically offer weight training for elders.", "answer": 2}, {"article": "March 20, 2011 -- Elevated levels of a group of five amino acids may predict the development of diabetes years before any noticeable symptoms occur, according to a new study.\n\"These findings could provide insight into metabolic pathways that are altered very early in the process leading to diabetes,\" says researcher Thomas Wang, MD, of Massachusetts General Hospital's Cardiovascular Research Center, in a news release.\n\"They also raise the possibility that, in selected individuals, these measurements could identify those at highest risk of developing diabetes so that early preventive measures could be instituted.\"\nFor example, insulin resistance, where the body does not use insulin effectively, occurs long before blood sugars reach the level seen in type 2 diabetes.\nResearchers found that blood tests that screened for these amino acids accurately predicted risk of type 2 diabetes in otherwise healthy adults as well as in those with traditional risk factors such as obesity.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article says that further studies will be needed. It would have been useful to state that any clinically available screening test would be years off. The article doesn\u2019t give readers a sense of how far away this hypothetical test is from practice. Are the tools even being used in blood labs, or is this all being done purely in a research setting?", "answer": 1}, {"article": "Until today, researchers were not sure that fixing the mitral valve would do much to help these patients.\nIn the new trial, 614 patients with severe heart failure in the United States and Canada were randomly assigned to receive a MitraClip along with standard medical treatment or to continue with standard care alone.\n(The clip is made by Abbott, which funded the study; outside experts reviewed the trial data.)\nThe leaky mitral valve makes the heart enlarge even more, as it tries to compensate, and heart failure worsens.\nIn the new study, a device called the MitraClip was used to repair the mitral valve by clipping its two flaps together in the middle.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This was a strong point.\nThe story stated: \u201cIf the device is approved by the Food and Drug Administration for treatment of severe heart failure, as expected, then insurers, including Medicare, most likely will cover it.\u201d\nIt also stated, \u201cNot every cardiologist is equipped to insert the clip.\u201d", "answer": 1}, {"article": "Colitis, inflammation of the colon, is the second most common side effect from ICIs, occurring in up to 40 percent of patients, explained Wang.\n\u201cWe have a limited amount of time to fix the problem so they can resume ICI treatment, but I feel that we\u2019ve made great progress in this area.\u201d\n\nThe researchers chose to investigate the potential for FMT as an alternative, compassionate-use therapy for patients suffering from refractory, or unresponsive, ICI-associated colitis.\nThe current data further suggests there is the potential for many molecular studies to better understand the role of the microbiome in driving ICI-colitis and immunotherapy response more broadly.\n\u201cBased on these results, this should be evaluated even as a first-line therapy for ICI-associated colitis because it\u2019s safe, quick, and the effect is durable - from one treatment.\u201d\n\nImmune checkpoint inhibitors, which release a block on the immune system to attack cancer, have been successful in providing durable responses for patients with several cancer types.\nThe study was supported by the Andrew Sabin Family Fellowship Program; the American Association for Cancer Research \u2013 Stand Up to Cancer; the National Institutes of Health (CA219896-01A1, HL124112); the Cancer Prevention & Research Institute of Texas; and the Melanoma Moon Shot\u2122, part of MD Anderson\u2019s Moon Shots Program\u2122, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients\u2019 lives\n\nIn addition to Wang, other MD Anderson authors include: Diana Wiesnoski, Christopher Sanchez, and Chia-Chi Chang, Ph.D., all of Genomic Medicine; Beth Helmink, M.D., Ph.D., and Vancheswaran Gopalakrishnan, Ph.D., both of Surgical Oncology; Hamzah Abu-Sbeih, M.D., Gottumukkala Raju, M.D., and John Stroehlein, M.D., all of Gastroenterology, Hepatology & Nutrition; Edwin Parra, M.D., Ph.D., and Alejandro Francisco-Cruz, Ph.D., both of Translational Molecular Pathology; Matthew Campbell, M.D., Jianjun Gao, M.D., Ph.D., and Sumit Subudhi, M.D., Ph.D., all of Genitourinary Medical Oncology; Dipen Maru, M.D., of Pathology; Jorge Blando, DVM, and James Allison, Ph.D., both of Immunology; Padmanee Sharma, M.D., Ph.D., of Genitourinary Medical Oncology and Immunology; Michael Tetzlaff, M.D., Ph.D., of Translational Molecular Pathology and Pathology; Jennifer Wargo, M.D., of Genomic Medicine and Surgical Oncology; and Robert Jenq, M.D., of Genomic Medicine and Stem Cell Transplantation.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Determining this will be confusing to someone reading this release.\u00a0 Fecal transplant procedures are in use to treat a variety of gastrointestinal issues, so this would suggest that the procedure is available.\u00a0 But its employment to subdue inflammation caused by immunotherapy treatment is just being explored and has not even been subjected to clinical testing yet.\u00a0 So whether the procedure would be available to cancer patients receiving immunotherapy is an open question.", "answer": 0}, {"article": "(Chicago) - Eating a meal of seafood or other foods containing omega-3 fatty acids at least once a week may protect against age-related memory loss and thinking problems in older people, according to a team of researchers at Rush University Medical Center and Wageningen University in the Netherlands.\nPeople who ate more seafood had reduced rates of decline in the semantic memory, which is memory of verbal information.\nThey also had slower rates of decline in a test of perceptual speed, or the ability to quickly compare letters, objects and patterns.\nThose in the lower group ate an average of 0.5 meals per week.\nAt study enrollment, none had signs of dementia.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "People have been eating fish for rather a long time, so we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "But as for whether they\u2019ll help a client prepare for an important presentation?\nThe other \u2014 which was also missing a placebo group \u2014 involved just seven patients and showed only short-term improvement in symptoms.\nThe company claims liquid vitamins, minerals, and amino acids delivered straight to the bloodstream can protect users from getting a cold, boost athletic performance, \u201cannihilate toxins,\u201d and stave off headaches.\nThe author, Dr. Alan Gaby, has long promoted the use of intravenous vitamins for a wide range of clinical conditions.\nThe infusion treatments can be traced back to an intravenous supplement known as the Myers\u2019 cocktail, a slurry of magnesium, calcium, B vitamins, and other products developed decades ago by a Baltimore physician.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained that several different companies are selling nutritional supplements delivered by intravenous drip. But it was not clear how easy these are to obtain and the potential for insurance coverage was not mentioned, so this is a marginal satisfactory rating.", "answer": 1}, {"article": "\u201cUsually everything is developed first for adults,\u201d he noted recently, \u201cand children are an afterthought.\u201d\n\n\u2018This is not the end\u2019: Using immunotherapy and a genetic glitch to give cancer patients hope\n\nThis 8-year-old is free of cancer \u2014 for now \u2014 after a \u2018breakthrough\u2019 treatment\n\nFor a 6-year-old with cancer, a future staked on medicine\u2019s hottest field\n\u201cThe efficacy takes care of itself, but safety takes a lot of attention.\u201d\n\nOne of the most common side effects is called cytokine release syndrome, which causes high fever and flulike symptoms that in some cases can be so dangerous that the patient ends up in intensive care.\n\u201cNobody was hoping for zero cancer.\u201d\n\nThe pioneering therapy administered to Ludwig and a few other adults at the University of Pennsylvania hospital paved the way for clinical trials with children.\n\u201cI said, \u2018Surely, this has been tried on kids somewhere else in the world,\u2019 \u201d recalled her father, Thomas Whitehead of Philipsburg, Pa. \u201cBut Steve said, \u2018Nope, some adults got it, but that was a different kind of leukemia.\u2019 \u201d\n\nAfter she received the therapy, Emily\u2019s fever soared, her blood pressure plummeted, and she ended up in a coma and on a ventilator for two weeks in the hospital\u2019s intensive care unit.\nThe CAR T-cell treatment, manufactured by the drug company Novartis, initially would be available only for the small number of children and young adults whose leukemia does not respond to standard care.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly lays out where this treatment is in the FDA review process, how that process may unfold, and what this may mean for future availability. In addition, the story explains that CAR T-cell treatment would not be rolled out universally, but \u2014 if approved \u2014 would be available only through designated treatment facilities that have the relevant expertise.", "answer": 1}, {"article": "He applied for funding of the research a few years ago, to no avail.\n\"When our insulin is very high, we can't get to sleep,\" he says.\nIf your teen has to get up at, say, 6:30 to be at school by 7:30, that means bedtime's at 9:15 or 9:30 p.m.)\n\nVorona says he'd like to delve deeper into the sleep-obesity question.\nIf sleep extension could have a salutary effect on helping people lose weight,\" he says, we'd have another tool in the fight against obesity.\n-- Avoid what are commonly called simple carbohydrates and \"sugary stuff\" at that meal or at bedtime.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The criterion is not applicable. The story\u2019s focus is on the connection between sleep and weight, and the lifestyle interventions mentioned are available to everyone.", "answer": 2}, {"article": "One expert agreed that the results were encouraging.\nThe study was conducted at 14 sites in the United States and Australia and included 162 patients who received different dose combinations of the drugs: two daily 150 milligram (mg) doses of dabrafenib plus one 2 mg dose of trametinib; the same dabrafenib dose with a 1 mg dose of trametinib; or treatment with dabrafenib alone.\nThe drug combination is now being tested in a larger phase 3 study, which is required for U.S. Food and Drug Administration approval.\n\"We investigated this (drug) combination because of research we and others have conducted into the molecular underpinnings of resistance to BRAF inhibitor therapy,\" study lead author Dr. Keith Flaherty, of the Massachusetts General Hospital Cancer Center, said in a hospital news release.\nBut the response is temporary in most cases, and tumor growth resumes in six or seven months, the researchers explained.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that the drug combination is\u00a0being tested in a larger phase 3 study, which is required for FDA\u00a0approval. While this is true, it could also have noted that the drugs individually have already been submitted for approval as monotherapies. If they are approved, oncologists could presumably use the drugs in an off-label\u00a0combination treatment similar to the one studied here.", "answer": 1}, {"article": "It is a bold move, but bold moves are what our patients deserve.\"\nWith a goal of enrolling 82 patients, those in the trial will be treated with a combination of anti-myeloma agents and immunotherapy that have a proven record of eliminating minimal residual disease, including the drug carfilzomib and the monoclonal antibody daratumumab, agents that are currently only approved to treat patients whose disease has returned.\n\u201cI believe for the first time that we have treatments that are effective enough to make it possible to eradicate multiple myeloma definitively in a substantial proportion of patients, along with having the technology to detect that the disease has been targeted and that treatment can be stopped,\u201d said Luciano Costa, M.D., Ph.D., scientist at the UAB Comprehensive Cancer Center, lead of the Hematologic-Malignancy Working Group, and principal investigator of the MASTER study.\nThe clinical trial Monoclonal Antibody Sequential Therapy for Deep Remission in Multiple Myeloma, also known as MASTER, utilizes next generation sequencing technology to detect minimal residual disease down to a level of one cancer cell in 100,000 \u2014 or 100- to 1,000-fold more sensitive than traditional methods to evaluate response.\nAs it stands, patients with billions of cancer cells in their bodies and patients with true disease eradication will both appear to be in complete remission using current methods to measure disease response to therapy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the trial uses drugs that are already available, though some are approved for only patients who have relapsed after initial treatment. It makes clear that the \u201cminimal residual disease\u201d testing regime to be used is not routinely available.", "answer": 1}, {"article": "And the chunky monkeys?\n\"If the promise holds true, I think this has the chance to change healthcare,\" Dr. Christoph Westphal tells\n\nDr. Westphal says we all may soon be taking a drug that just might beat the clock, a simple pill that could delay the inevitable.\nTo maintain their sterile environment, the 60 Minutes team had to suit up to visit them with Ricki Colman, the \"project leader.\"\n\"When I Googled this resveratrol, I was shocked to find that red wine was the top hit,\" Sinclair remembers.\nThe important thing is that we passed a milestone where we can now make drugs based on this knowledge and we can potentially slow down aging itself,\" Sinclair explains.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Here\u2019s an excerpt of the story taken from the CBS website: \nBut the question that most of us want answered is: when do we get this pill? \n\"I would say five years to be conservative that this\u2019ll happen within our lifetimes. I\u2019m fairly certain about that,\" Sinclair says.\u00a0 \n\u00a0Sinclair is one of the co-founders of the company working on the drug.\u00a0 His 5-year estimate should have been checked with at least one independent source for comment.\u00a0 Also, note how that comment \u2013 as transcribed by CBS \u2013 makes no sense.\u00a0 ", "answer": 0}, {"article": "Matthews: \u2018It\u2019s only going to get better\u2019\n\nIn his first game with the Pacers, he only made two shots but they came in the fourth quarter to pull out the victory vs. the Hornets.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The treatment highlighted in this piece is about expanding the use of \u00a0a material already approved for other medical problems as a means for dealing with a variety of problems with heart muscle. \u00a0So although the piece mentioned that the material was currently being tested in animals for this new purpose, the story blurs this distinction because it goes on to include a quote from a patient in whom the material was used to repair a leak due to valve repair.\nSo\u00a0the CorMatrix Extracellular Matrix may be able to solve more problems than it is currently applied to, but we don\u2019t yet know. \u00a0This means the treatment is available for some medical problems, though not the one highlighted in the story. \u00a0The story was a little confusing on this one.\u00a0", "answer": 0}, {"article": "THURSDAY, June 8, 2017 (HealthDay News) -- Scary pit vipers may need an image upgrade: Their venom might end up helping human heart patients, research suggests.\nStill, experiments in animals often don't translate to success in humans, so further research is needed.\nThe snake's venom contains a protein called trowaglerix, the researchers explained.\nThe study was published June 8 in the journal Arteriosclerosis, Thrombosis and Vascular Biology.\nHowever, it is often at the cost of serious bleeding complications,\" he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicates more research is needed before this compound will be available (if ever).", "answer": 1}, {"article": "\u201cThat\u2019s the miracle.\u201d\n\u2022 New hope for young patients with rare genetic disease (\u201cCBS Evening News,\u201d 10/16/15)\n\u2022 Follow the Calliope Joy Foundation on Twitter, Facebook and Instagram\nAmy recalled: \u201cShe\u2019s sitting on the bed in her tutu and her colorful sweater, and they\u2019re telling me she\u2019s gonna die.\u201d\n\nMany children with the disorder are dead by the age of 6.\nAnd so we said, \u2018Well, we\u2019ll start selling cupcakes.\u2019\u201d\n\nThe Calliope Joy Foundation was formed in 2013.\n\u201cAnd I turned around and said, \u2018Liviana, what\u2019s wrong?\u2019 And she said, \u2018Mommy, my legs don\u2019t work.\u2019\u201d\n\nLiviana was diagnosed in the fall of 2010.\nTeichner asked Brad and Amy Price, \u201cYou keep using the word \u2018miracle.\u2019 In what way is all of this a miracle?\u201d\n\n\u201cOur son\u2019s still with us, and Cecilia as well,\u201d they replied.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is made very clear that the treatment is not available in the U.S., and likely won\u2019t be for some time.\nWhile this deserves a Satisfactory rating, there are two ways in which the reporter might have dealt with the availability issue differently. First, it might have been worth saying the treatment may\u00a0never be available in the U.S., since the research is at too early a stage to guarantee success. Second, it would have been informative to find out from the drug company what they think will happen next.\u00a0GlaxoSmithKline are reported to have said they will seek approval in 2017\u2013is that based on this current study or are they planning to do more research?", "answer": 1}, {"article": "\u2022 Surgery should be followed by intraperitoneal, or localized, chemotherapy delivered to the abdomen.\nThe goal is to have no cancer visible to the naked eye of the surgeon after the surgery.\nChemotherapy before surgery might provide a false assurance that there's no more residual cancer, whereas microscopic tumour may remain after the surgery, leading to cancer recurrence and possibly, death.\n\"We should offer all women the possibility of a cure.\"\nIt is the combined effect of surgery and chemotherapy that works best.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the release that the treatment options being urged as the standard of treatment are already well established.", "answer": 1}, {"article": "Funding for the study was provided by the Wake Forest Translational Science Institute and Center for Integrative Medicine and the Claude Pepper Older Americans Independence Center of Wake Forest Baptist.\nAt the beginning of this pilot study, the research team found that more than half of the participants had insufficient concentrations of vitamin D in the blood (less than 20 ng/ml), while less than a quarter had concentrations in the optimal range (30 ng/ml or more).\nThe study included the participants' history of falls and their fear of falling, blood tests at the beginning and at end of the trial to measure 25-hydroxyvitamin D (biomarker for vitamin D in blood), and a monthly diary recording falls during the trial period.\nThe study is published in the early online edition (8/16/2015) of the Journal of the American Geriatrics Society.\nWINSTON-SALEM, N.C. - Aug. 17, 2015 - Every year falls affect approximately one in three older adults living at home, with approximately one in 10 falls resulting in serious injury.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll rate this Not Applicable. Although no mention was made of the availability of the vitamin supplements, it is fair to assume most readers know that they are readily available in nearly any supermarket or drug store. However, the high dose vitamin D used in this study is typically available by prescription only.", "answer": 2}, {"article": "Visit redrazz.org for more information, and follow us on our social media channels:\nWhile additional research, particularly in humans, is warranted, preliminary evidence from these studies suggests that the actions of essential nutrients, fiber, and polyphenolic phytochemicals found in red raspberries may play a role in supporting key metabolic functions, including anti-inflammatory, anti-oxidative and metabolic stabilizing activity.\n* Noratto, G. Garcia-Mazcorro, J. Chew, B. and Mertens-Talcott, S. Dietary Supplementation with Raspberry Whole Fruit Modifies the Relative Abundance of Fecal Microbial Communities in Obese Diabetic (db/db) Mice.\nIn a secondary objective of the blood sugar control study, researchers found that subjects in the PreDM group who reported the highest level of hunger at baseline experienced greater satiety after the control meal compared to raspberry containing meals (p<0.05).\nIn an eight-week pilot study, researchers from the Institute for Food Safety and Health from the Illinois Institute of Technology examined the impact of consumption of red raspberry pur\u00e9e or fructo-oligosaccharide on the gut microbiota and the subsequent bioavailability of red raspberry polyphenols in healthy volunteers.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Availability generally isn\u2019t an issue\u2014raspberries are a common fruit known to most who shop at grocery stores. However, prices (and therefore access) can fluctuate widely depending on where you live. ", "answer": 2}, {"article": "LONDON (Reuters) - Scientists in Britain have developed a type of HIV test using a USB stick that can give a fast and highly accurate reading of how much virus is in a patient\u2019s blood.\n\u201cMonitoring viral load is crucial to the success of HIV treatment.\nThis is sent to the USB stick, which shows the result on a computer or electronic device.\nSome 36 million people worldwide are infected with the human deficiency virus (HIV) that causes AIDS, and the majority of them live in sub-Saharan Africa.\nAny HIV in the sample triggers an acidity change, which the chip transforms into an electrical signal.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re\u00a0told\u00a0the\u00a0technology\u00a0is\u00a0in\u00a0the\u00a0\u201cearly\u00a0stages\u201d and is thus not yet available.", "answer": 1}, {"article": "A new, detailed mammography exam catches more cancers while causing fewer false alarms, according to the company that sells it. The downside, some physicians say, is that it costs more and delivers twice as much radiation as traditional mammograms.\n\nTomosynthesis, or three-dimensional mammography, has been available in the U.S. since February from Hologic Inc., Bedford, Mass. In just a few months, radiologists say they are finding cancers they would have missed with the standard exam.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the article stated the device had been available in the U.S. since February, it was unclear if this was only for people in clinical trials, or if hospitals and cancer centers across the country were currently using it. Nonetheless, we\u2019ll give the story the benefit of the doubt on this one.", "answer": 1}, {"article": "Contact: Paul R. Sanberg at psanberg@health.usf.edu, Shinn-Zong Lin at shinnzong@yahoo.com.tw, or Associate Editor Samantha Portis at celltransplantation@gmail.com\n(June 1, 2016) - A two-year, multi-center clinical study with 167 patients with class III-IV refractory angina randomized to low and high dose CD34+ cells or placebo has revealed that patients who received either a high or low dose of CD34 -- a member of a family of proteins that have an impact on vascular-associated tissue -- cells had a significant reduction in angina frequency over patients who received placebo.\n\"There are an increasing number of patients with advanced coronary artery disease that are not amenable to surgical or percutaneous revascularization,\" said study co-author Dr. Timothy D. Henry of the Cedars-Sinai Heart Institute.\n\"The results of our study are even more provocative given that the outcomes represent the effect of a single treatment,\" wrote the researchers.\nThe researchers concluded that for \"no option\" patients with class III/IV angina refractory that was unresponsive to conventional medical therapy and who were not candidates for revascularization, injection of CD34+ cells resulted in persistent improvement in angina at two years post-treatment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that this paper stemmed from a phase II clinical trial. It didn\u2019t tell readers how long ago the trial took place, or what the treatment\u2019s prospects are (even in general terms) for potential clinical use. In 2012, Baxter issued a news release announcing plans to launch a phase III trial for CD34+ treatment to \u201d\u00a0increase exercise capacity in patients with chronic myocardial ischemia.\u201d That trial appears to be related to this research, although that\u2019s not entirely clear. Is it related? And, if so, has that trial moved forward?", "answer": 0}, {"article": "Doctors use brain imaging, evaluation of behavior, psychiatric tests, and other means to diagnose the disease.\n''This is a simple test that has high accuracy and can be run from a single drop of blood,\" says Robert Nagele, PhD, a professor of medicine at the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine.\nAn estimated 5.4 million Americans have Alzheimer's disease, the most common form of dementia, according to the Alzheimer's Association.\nIt works by determining the amount of amyloid plaque, associated with the disease, in people's brains.\nWe all know we need an accurate, relatively noninvasive way to diagnose Alzheimer's.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\nDeep in the story, it explains that \u201cif all goes well\u201d the developer is hopeful the test could be available within a year. That is followed by an Alzheimer\u2019s Association spokesman saying this is \u201cpreliminary.\u201d\u00a0 So the developer\u2019s optimism is tempered somewhat.\n", "answer": 1}, {"article": "For every one point increase in processed foods consumption, they lost 1.67 points in IQ.\n\"This can have a series of deleterious effects, including decreased cognitive ability, poor behavior and social skills,\" she said.\n\"Fast and junk food seem like an easy and affordable option for busy parents, but defaulting to high-fat, high-sugar, high-calorie foods is putting their children's health and future at risk,\" Heller said.\nWhen a child's diet consists primarily of high-calorie foods that are low in the nutrients they need (such as healthy fats, vitamins and minerals), their brains don't get the compounds necessary to develop and function properly, Heller said.\nCommenting on the study, Samantha Heller, a dietitian, nutritionist and exercise physiologist in Fairfield, Conn., said that \"most of us do not realize that the foods we eat have direct consequences on brain growth, function and performance.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of healthy foods is not generally in question, although it may\u00a0be\u00a0difficult to find fresh produce\u00a0in\u00a0urban areas\u00a0that aren\u2019t served by grocery stores.", "answer": 1}, {"article": "\u201cThat\u2019s what\u2019s good about this program.\nThe text messages were most effective at reducing distress at the 2- and 4-month marks, according to the data presented by chief author Kuang-Yi Wen, an assistant professor in the Cancer Prevention and Control program at Fox Chase.\nAt the fourth month mark, \u201cthe gap was huge\u201d between the texting and control groups, she told Reuters Health in a telephone interview.\nThe feasibility study was designed to see if texting could relieve some of the anxiety that comes with the fatigue, hair loss and other body changes that can accompany anticancer drugs.\nEveryone has different information-seeking behavior\u201d and the system can respond to that, Dr. Wen said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned this was a feasibility study, signalling the system isn\u2019t available. Still, it could have explored whether any text messaging systems are being used for chemo patients.", "answer": 1}, {"article": "When planning a day at the beach, should you add Polypodium leucotomos to your picnic basket? The company that sells the natural fern extract says a daily dose can help protect against sunburn, sun-related aging and even genetic mutations that cause skin cancer. Dermatologists say preliminary evidence suggests the extract does protect against the sun -- but don't throw away your sunscreen yet.\n\nEvery year, 36% of U.S. adults get at least one sunburn, according to the federal Centers for Disease Control and Prevention....", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that this supplement is available over the counter.", "answer": 1}, {"article": "As the study's authors point out, \"The mechanism(s) by which circumcision reduced acquisition of an STI [sexually transmitted infection] is thought to be related to the microenvironment of the thin, lightly keratinized mucosal lining of the inner foreskin.\"\nCircumcision, of course, removes this protective environment.\nFirst, a bit of background.\nCircumcision was reported in 68.8% of the cases and 71.5% of the controls.\nDon't smoke.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of circumcisions is not in question.", "answer": 2}, {"article": "The Company's website can be accessed at http://www.\nThe investigators found that Enclomiphene citrate restored blood testosterone levels to normal after 16 weeks while maintaining sperm concentrations, whereas Androgel restored blood testosterone levels but caused marked reductions in sperm concentrations by suppressing the function of the testes.\nWhile testosterone replacement therapy can boost men's energy levels, sex drive, and mood, the treatment can fool the body into thinking that it is producing enough testosterone, so that it in turn starts making less of its own.\nIn the randomized studies, 44 men started on 12.5 mg of oral enclomiphene citrate daily, with 25 men being up-titrated to 25 mg; 42 men received a topical 1.62 percent AndroGel; and 41 men received a placebo.\nThe findings, which are published in BJU International, could change the way men are treated for low testosterone.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release did not explicitly describe the availability of\u00a0Enclomiphene citrate.\nThe study indicated that clomiphene, closely related to the study drug, is used \u201coff label\u201d for hypogonadal men. It has not been approved by the FDA for use in men.", "answer": 0}, {"article": "\"Although it is not clear if bisphosphonates are the cause, these unusual femur fractures have been predominantly reported in patients taking bisphosphonates,\" the FDA says.\nAgain, Merck disputes the connection.\nThat's obviously a lot more benefit than risk.\nThese unusual fractures can occur suddenly without any trauma, such as a fall.\nThat's called the relative risk, and it seems alarming.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story describes the drugs as commonly available.", "answer": 1}, {"article": "CHICAGO -- The diabetes drug Actos was able to slow the progression of plaque buildup in artery walls, while an older diabetes drug failed to stop the progression in patients with diabetes and coronary-artery disease, according to a study released Monday.\n\nUntil now, no diabetes-therapy regimen has been shown to reduce the progression of coronary atherosclerosis within the arterial walls among patients with Type 2 diabetes, a disease characterized by high blood-glucose levels that result from the body's inability to use insulin.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not describe the availability of Actos.", "answer": 0}, {"article": "\u201cI had one guy that came crawling into my practice and handed me his MRI, and I put him on the table.\nThe new beds, Fuh said, are much different than similar beds made 20 years ago where patients would lie on their stomachs, put a strap around their pelvis and \u201chold onto handle bars for dear life.\u201d\n\n\u201cThe table now, you just lay on your back, and the machine does all of the work.\nI would say a quarter of my patients fall asleep.\u201d\n\nThe decompression therapy is used to treat herniated discs, ruptured discs, sciatica, bulging discs, degenerative discs, posterior facet syndrome and spinal stenosis/arthritis.\nThe space agency noticed astronauts, who did not have gravity compressing their spines in space, reporting the disappearance of neck and back pain.\nSome of them returned to Earth 1 inch to 2 inches taller.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story does explain that this treatment is available and claims that the treatment is common on the West Coast but not in the Midwest, this is not sufficient information on availability. The story doesn\u2019t give the reader any information on where to look for the treatment other than the owner of one facility. ", "answer": 0}, {"article": "Saturated fats can remain a part of a healthy diet, in limited amounts \u2013 but there are two easy ways to help:\n\u2022 Saturated fats should make up 10 percent of total caloric intake daily.\nFollow her on Twitter @drfernstrom.\nAll that is known is the participants had a normal cholesterol levels and normal blood pressure.\nA new study suggests the answer may be no.\nWhether statins have additional properties to reduce risk, in addition to lowering serum cholesterol remain under study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The different oils are widely available; this is N/A.", "answer": 2}, {"article": "But are they benefiting from acupuncture itself, or just getting a placebo effect?\nThe results came out with no difference between the groups.\u201d\n\nThe MD Anderson research and other recent acupuncture studies have fueled speculation that the prick of a needle, whether from real acupuncture or a sham version, can influence the way the body processes and transmits pain signals.\n\u201cThere is a body of literature that argues that the whole approach to studying acupuncture doesn\u2019t lend itself to the Western reductionist scientific method.\u201d\n\nBut the study\u2019s lead author, Dr. Maria E. Suarez-Almazor, notes that the sham treatment was developed with the help of trained acupuncturists.\nBut the real lesson, acupuncture supporters say, is how difficult it can be to apply Western research standards to an ancient healing art.\nThere is little dispute that people feel better after receiving the treatment, in which thin needles are inserted deeply into the skin at specific points on the body.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "      \n\n\n \n\n \nThe article does not discuss the availability of acupuncture in the United States. This is an important question. There appear to be significant obstacles\u00ad\u2014relating to geography, licensing, and reimbursement\u2014 to the widespread availability and utilization of acupuncture.\n\u00a0\n ", "answer": 0}, {"article": "Smokers who count on nicotine patches or gum to help them quit may want to reconsider: A new study finds that these and other nicotine replacement products aren't effective at preventing former smokers from relapsing in real-world conditions.\nThose who had used nicotine patches, gum, inhalers or nasal sprays were just as likely to relapse as those who had quit without them, researchers from Harvard University and the University of Massachusetts found.\nIn some cases, studies have found that people who use products like nicotine patches and gums are more likely to relapse than their counterparts who go cold turkey.\nThe findings run counter to the results of several randomized clinical trials conducted before the Food and Drug Administration gave the thumbs-up to these nicotine replacement products in the 1990s.\nBut the latest results are in line with other studies that have found little \u2014 if any \u2014 benefit from the products when used by smokers in real life.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story basically used sales information to indicate availability. We did appreciate that this story mentioned a wide variety of nicotine products, including nasal sprays.", "answer": 1}, {"article": "Researchers recommend large-scale clinical trials to confirm that nighttime fasting results in favorable changes to biomarkers of glycemic control and breast cancer risk.\nIt may have a big impact on public health without requiring complicated counting of calories or nutrients.\u201d\n\nWomen who fasted for longer periods of time overnight had significantly better control over blood glucose concentrations.\n\u201cNew evidence suggests that when and how often people eat can also play a role in cancer risk.\u201d\n\nWomen in the study reported eating five times per day with a mean nighttime fasting of 12 hours.\nThe data shows that each three hour increase in nighttime fasting was associated with a 4 percent lower postprandial glucose level, regardless of how much women ate.\nNewswise \u2014 A decrease in the amount of time spent eating and an increase in overnight fasting reduces glucose levels and may reduce the risk of breast cancer among women, report University of California, San Diego School of Medicine researchers in the journal Cancer Epidemiology, Biomarkers & Prevention.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Again, we\u2019ll rule this criterion Not Applicable. \u00a0Fasting is something that anyone could do, although some people should consult with a doctor before limiting their calorie intake or increasing the amount of time between meals.", "answer": 2}, {"article": "\u201cThis is hugely significant.\nOur study also demonstrates that statins could be a valuable addition to breast cancer treatment, and that this warrants investigation in clinical trials.\u201d\n\nThe research has not yet been tested in humans.\nCholesterol production by the tumour will not be the only reason why ER-positive breast cancers recur, but campaigners are excited by the possibilities for a treatment if further research corroborates these findings.\n\u201cThis study breaks new ground in uncovering how some breast cancers continue to survive without oestrogen and suggests that women could benefit from adding statins to standard anti-hormone treatments.\nTesting the patient\u2019s tumour for 25-HC or the enzymes that make it may allow us to predict which patients are likely to develop resistance hormone therapy, and tailor their treatment accordingly.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says statins are currently used for lowering cholesterol. However, it should have described the clinical trials and government approval processes required for statins to become a treatment for breast cancer.\nIt\u2019s important to add that the headline says\u00a0statins\u00a0\u201ccould be\u201d added to breast cancer treatment. This sort of statement may mislead some patients who feel desperate to try anything and therefore may seek out and take statins not currently prescribed for them.", "answer": 1}, {"article": "Leptin, they reasoned, tells the brain how much fat is on the body.\n\"Obesity is the one disease I can think of where your body fights the cure,\" he said.\nThey also usually stop losing weight and often gain back what they have already lost.\nThey also measured thyroid hormone concentrations in the blood and found that leptin reversed the declines in those levels that occurred with weight loss.\nIf people lose weight, they have less leptin.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Doesn\u2019t mention that there is no FDA approval for the use of \nleptin in maintenance of weight loss.", "answer": 0}, {"article": "The FDA advisory pointed to a single study showing a six-fold increased risk of a condition called persistent pulmonary hypertension in newborns whose mothers were taking antidepressants.\n\"The risk increase of taking antidepressants late in pregnancy, if present, is much more modest than previous studies have found,\" says Krista Huybrechts, Ph.D., an epidemiologist at Brigham and Women's Hospital.\nBOSTON -- In 2006, the FDA warned the public that the use of common antidepressants, like Prozac and Paxil, late in pregnancy could put a baby at risk for respiratory failure.\nDr. Economy warns patients about the potential risks like withdrawal in the newborn and a small risk of heart defects, but says for many women, the worst time to stop their medications is at the end of pregnancy when postpartum depression becomes a concern.\nBut now a new, large-scale study finds that the risk is negligible -- much lower than previously believed, reports CBS Boston's Dr. Mallika Marshall.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told\u00a0this study applies to \u201ccommon\u201d antidepressants, and a few widely known prescription name brands are mentioned. The availability (through diagnosis and a medical professional\u2019s prescription) isn\u2019t overtly established, but it\u2019s implied.", "answer": 1}, {"article": "To learn more about NAMS, visit http://www.\nAlthough there is ongoing debate regarding the safety and effectiveness of vaginal laser surgery, a new study suggests that it may be effective, especially after multiple treatments.\nHowever, more robust randomized, sham-controlled data are needed, with larger numbers of women, to evaluate long-term safety, benefits, and risks,\" says Dr. JoAnn Pinkerton, NAMS executive director.\nIn the case of microablative fractional CO2 laser surgery, a series of microscopic laser beams using fractionated energy penetrate the skin to remove old and damaged skin cells, intended to rebuild the vaginal pathway.\nFounded in 1989, The North American Menopause Society (NAMS) is North America's leading nonprofit organization dedicated to promoting the health and quality of life of all women during midlife and beyond through an understanding of menopause and healthy aging.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s mentioned that vaginal laser surgery represents \u201cone of the newer and more hotly contested approaches\u201d to menopause symptoms.\nSo we\u2019ll give this a satisfactory mark, but it would have helped readers to give them a ballpark sense of how widely the surgery is being used in North America.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070805/13folate.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned the folate fortification of the North American food supply; it also noted that folic acid is found in multivitamins.\u00a0 The story is mainly about recent analysis about possible consequences of folate supplementation of the food supply.\n\u00a0", "answer": 1}, {"article": "CDC recommends treatment of suspected cases of flu among pregnant women with antiviral drugs as soon as possible, without waiting for test results to confirm influenza.\n\"All pregnant women should receive annual influenza vaccination to prevent influenza and associated complications for themselves and their infants,\" the study authors wrote.\n\"Overall, considering the accumulating evidence of fetal benefit and safety, influenza vaccination of pregnant and postpartum women should be a public health priority in accordance with national recommendations,\" the commentary authors wrote.\nBased in Arlington, Va., IDSA is a professional society representing nearly 10,000 physicians and scientists who specialize in infectious diseases.\n\u2022 Annual vaccination against flu is recommended for everyone 6 months of age and older, including pregnant women, who are at high risk of serious flu illness and complications.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Readers can infer that oseltamivir is available, since it was used in hospitals to treat patients.", "answer": 1}, {"article": "Overweight people on low-carbohydrate and Mediterranean diets lost more weight and got greater cardiovascular benefits than people on a conventional low-fat diet, according to a study that endorses alternative diets published in a major medical journal.\n\nThe study, which tracked 322 Israelis for two years, surprisingly found that a low-carb diet, often associated in the U.S. with high levels of meat consumption -- was better than a low-fat diet in boosting blood levels of \"good\" cholesterol, or high-density lipoproteins...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The three popular diet plans discussed in this article\u00a0are\u00a0widely available and have been used by thousand of people in the U.S. and elsewhere.\u00a0 This article does due diligence in pointing out that the dieters in the\u00a0study received support in the workplace to help them stick to their diets.\u00a0 In addition, the study dieters had the advantages of\u00a0purchasing meals in their work cafeteria\u00a0 with color-coded menu information corresponding to their diet requirements.\u00a0\u00a0\u00a0", "answer": 1}, {"article": "Dupixent is for the hard-core cases that aren\u2019t helped by anything else.\n\u201cScratching leads to swelling, cracking, weeping clear fluid, and finally, coarsening and thickening of the skin.\u201d\n\nThere are many treatments out there now, from simple skin lotions to steroid creams and immune suppressant drugs like tacrolimus.\nIt\u2019ll cost $37,000 a year but the drug\u2019s makers, Regeneron Pharmaceuticals and Sanofi, have stressed that\u2019s the wholesale price and make a point of saying there will be programs to help people pay for it.\n\u201cThe most common side effects include injection site reactions; cold sores in the mouth or on the lips; and eye and eyelid inflammation, including redness, swelling and itching,\u201d the FDA notes.\n\u201cOf the adults with uncontrolled moderate to severe atopic dermatitis in the United States, it is estimated that 300,000 are most in need of new treatment options,\u201d Regeneron said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is now FDA approved for sale. It also says the drug \u201cis a twice-a-month injection under the skin. Patients can do it at home.\u201d However, it didn\u2019t broach the topic of how likely insurance companies are to cover this drug. Patient demand is likely to be high, but insurers may push back due to the high cost.", "answer": 1}, {"article": "Investigators in the Netherlands report the results of a three-year follow-up of a randomized controlled trial that compared three noninvasive treatments that included imiquimod and fluorouracil cream.\nThe prognosis is excellent, but it can cause significant disfigurement by invading surrounding tissues.\nThe three study groups had a similar distribution of baseline characteristics, with the exception of tumor size.\nFluorouracil has the advantage of being less expensive than imiquimod.\nFull text of this article is available to credentialed journalists upon request.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release implies that each of these are available treatments and the goal is to compare existing treatments.", "answer": 1}, {"article": "Active older people resemble much younger people physiologically, according to a new study of the effects of exercise on aging.\n\u201cWe wanted to understand what happens to the functioning of our bodies as we get older if we take the best-case scenario,\u201d said Stephen Harridge, senior author of the study and director of the Centre of Human and Aerospace Physiological Sciences at King\u2019s College London.\nOlder people tend to be quite sedentary nowadays, and being sedentary affects health, making it difficult to separate the effects of not moving from those of getting older.\nOf course, this study is based on a single snapshot of an unusual group of older adults, Dr. Harridge said.\n\u201cIf you gave this dataset to a clinician and asked him to predict the age\u201d of one of the cyclists based on his or her test results, Dr. Harridge said, \u201cit would be impossible.\u201d On paper, they all look young.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As noted above, finding time and places to ride a bicycle is not always as easy at it sounds. But we\u2019ll rate this not applicable since we\u2019ve already dinged the story for this issue above under \u201ccosts.\u201d", "answer": 2}, {"article": "Results in these two papers \u2014 and basically all the others we\u2019ll look at here \u2014 therefore report their results in \u201chazard ratios.\u201d A hazard rate of 0.90, for example, means a 10 percent reduction in the risk of death.\nBut a closer look at the data suggests that this is probably just a statistical artifact: This intense running group contains only 36 people and two deaths, versus hundreds of people in the more casual running groups.\nConsider, for example, the many posts on The New York Times\u2019 Well blog on the topic (walking versus running, the \u201cright dose of exercise,\u201d \u201cwalk hard, walk easy\u201d), all of which focus on the relative benefits of walking versus jogging versus running.\nHowever, in the developed Western world, where exercise tends to be an extracurricular activity, there is apparently tremendous interest in just how fast you should move in order to improve your health.\nBut since the people in the studies are of different ages, researchers can\u2019t just look to see whether they have, say, a 2 percentage point lower risk of death in a given year, since that lower risk would mean a lot more for someone who is 30 than for someone who is 90.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Most people are aware that walking, jogging and running are exercise options. So while no specific comment was made about availability, we\u2019ll rule it Not Applicable. The story could have touched on availability in the sense that injuries, mobility issues, and health problems might prevent some people from participating in such activities.", "answer": 2}, {"article": "The pill is his blood pressure medication.\nIt occurs when something blocks or reduces the flow of blood to brain cells.\nThe evidence is clearest for a type of dementia called vascular dementia.\n\"With every pulse of your heart, you are pushing blood into these very small blood vessels in the brain,\" he says.\nHe also keeps his blood pressure down by exercising and paying attention to his weight and diet.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear in the story that blood pressure medications and lifestyle changes are readily available.", "answer": 1}, {"article": "So what is it about tai chi that works?\nSince it is a low-impact, gentle, non-threatening, accessible activity, it may be a perfect exercise for debilitated patients with fibromyalgia who otherwise cannot or choose not to do other forms of exercise,\" Yeh said.\nMost patients, according to background information in the article, remain in pain years after the diagnosis, are aerobically unfit, have poor muscle strength and flexibility, and need medications to control symptoms.\nThe syndrome can also cause psychological issues, including anxiety, depression, and memory and concentration problems, sometimes called the \"fibromyalgia fog.\"\n\"Also, since tai chi has a meditative component, it may also help to address the stress and anxiety that may be associated with the condition.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers are left to make their own assumptions about the availability of tai chi classes in their communities. More problematic is that the story does not provide any detail about the style or rigor of the tai chi classes (aside from the fact that the classes last an hour), making it difficult for a patient, or health care advisor, to make an informed decision as to how to proceed.", "answer": 0}, {"article": "\u201cBut,\u201d she added, \u201cit should be noted that yoga controlled the blood sugar levels which otherwise rose in the control group.\u201d\n\nIn addition to that, the study found, signs of so-called oxidative stress declined in the yoga group.\nSome are vigorous work-outs involving complicated poses that would not be appropriate for older adults with chronic health conditions.\nThe yoga used in this study was a gentle form, Hegde said, and parts of the practice were adapted for people who had additional health problems; certain poses were avoided in people who had heart disease, for example.\nIn the U.S., hospitals and local community centers are increasingly offering such classes.\nLong-term oxidative stress is believed to contribute to a host of chronic diseases.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that gentle yoga classes might be found in hospitals and local community settings.", "answer": 1}, {"article": "(Weathers noted more than 100 other drug-resistant patients also have been successfully treated with DLA tablets.)\nIn addition, while the combination therapy is designed to be less prone to the drug resistance that has rendered previous antimalarial agents ineffective, increasingly the malaria parasite is showing signs of resistance to ACT, particularly in Southeast Asia.\nWhile the processes for manufacturing ACT is costlier and requires a higher degree of expertise, producing DLA tablets can be accomplished with simpler equipment and a modest amount of training.\nThere are more than 40 WPI project centers throughout the Americas, Africa, Asia-Pacific, and Europe.\nAccording to the World Health Organization (WHO), more than 212 million people contracted malaria in 2015 and some 429,000 died, with young children and pregnant women being particularly vulnerable.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "These tablets are only available as part of experimental compassionate use. We think the release makes it clear they aren\u2019t widely available.\u00a0  ", "answer": 1}, {"article": "The study found that, among the women treated with the hormones, there was an increased risk of heart attacks, strokes, blood clots and, most frightening of all to many women, a slightly higher risk of breast cancer among those randomized to take the leading H.R.T.\nThere are also lots of products now available and different ways to use them that enhance the safety of hormone replacement.\nEver since the large government study called the Women\u2019s Health Initiative found a number of risks associated with menopause hormones, millions of women who are in or near menopause have been weathering hot flashes and other symptoms on their own.\nFor women without a history of cancer, blood clots or heart disease, most professional medical societies concerned with women\u2019s health now recommend treatment for menopausal symptoms for up to five years using therapy that combines estrogen and progesterone and even longer for those who take estrogen alone.\nDr. Manson is distressed about the large number of women \u2014 about a third of those now on hormone replacement \u2014 who are relying on \u201ccustom-compounded\u201d products that have not been reviewed for safety and effectiveness by the Food and Drug Administration.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All of the therapies in the story are widely available, and the story establishes this with this sentence:\u00a0\u201cThere are also lots of products now available and different ways to use them that enhance the safety of hormone replacement.\u201d", "answer": 1}, {"article": "Meditation consisted of sitting with eyes closed for about 20 minutes twice a day.\nTUESDAY, Nov. 13, 2012 (HealthDay News) -- For black Americans suffering from heart disease, meditation might help prevent heart attacks, strokes and early death, a small new study suggests.\n\"One of the reasons we did the study is because insurance and Medicare calls for citing evidence for what's to be reimbursed,\" Schneider said.\n\"You've got to have a teacher right there in front of you teaching according to experience,\" he said.\nFor the study, Schneider's team randomly assigned 201 black Americans with heart disease either to a Transcendental Meditation stress-reducing program or health education class about lifestyle modification in diet and exercise.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indirectly addresses availability as it notes that live training in meditation from an instructor is necessary (a home video apparently won\u2019t cut it), and insurance won\u2019t cover the costs. It could provided some sense as to how easy it is to find qualified instructors in different areas (i.e. urban vs rural settings).", "answer": 1}, {"article": "Mumford, who's now 30, says he's never felt better.\nAlso, patients can get the treatment in about three weeks -- as opposed to six to eight for bone marrow from an adult donor, said Laughlin, founder and medical director of the Cleveland Cord Blood Center.\nBut the registry's more than 12 million donors meet the needs of only about 60 percent of Caucasians in the United States and only 5 to 15 percent of minorities, who are underrepresented.\nCord blood stem cell transplants have the same risks as adult bone marrow transplants: the new blood rejecting the host, called graft-versus-host disease.\nIf collected and stored for private use, the procedure can cost as much as $2,000 or more, plus annual storage fees.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This topic was unclear. The story implies that the chain of events from cord blood donation, national registration, and transplantation is currently available. We would like to have seen a clearer, more direct discussion on its current availability, and the statistics were vague. \"Cord blood transplants among unrelated donors have risen from 1 percent in 2001 to 24 percent last year.\" 24 percent of what? Of all stem cell transplants? How many of those recipients were children?\nThe important distinction between use of this procedure in children and in adults should have been discussed.", "answer": 0}, {"article": "Bushra Imtiaz, Heidi Taipale, Antti Tanskanen, Miia Tiihonen, Miia Kivipelto, Anna-Mari Heikkinen, Jari Tiihonen, Hilkka Soininen, Sirpa Hartikainen, Anna-Maija Tolppanen.\nThe study also showed that the postmenopausal removal of ovaries, uterus or both was not significantly linked to the risk of Alzheimer's disease, irrespective of the indication of surgery or hormone therapy use.\nThe protective effect of hormonal therapy may depend on the health status of neurons at baseline and may be lost if therapy starts years after menopause,\" Dr Imtiaz concludes.\nHormonal therapy may protect cognition if started at the onset of menopause\n\nIn the present study, long-term use of hormonal replacement therapy was associated with a better performance in certain cognitive domains - global cognition and episodic memory - and a lower risk of Alzheimer's disease.\nThe study explored the association between postmenopausal hormone replacement therapy, Alzheimer's disease, dementia and cognition in two nation-wide case-control studies and two longitudinal cohort studies.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release presumes that people know that hormone replacement therapies are available. In this particular case, there has been so much negative news around hormone replacement therapies because of their linkage to cancer risks that it would have been worth noting that the therapies are available by prescription.", "answer": 0}, {"article": "But she refused to discuss a timetable.\nThis summer, a critical review of existing research in BMJ, The British Medical Journal, \u201ccast doubt over the size of the effect of these medications\u201d for the general population, said Dr. Roger Harrison, an author of the paper, \u201cbut still suggested that they might benefit some people as a treatment.\u201d\n\nDr. Harrison said he believed that people should generally increase their intake of omega-3 acids, best done by eating more fish.\nThe fact that it\u2019s not licensed for this has definitely kept doctors away.\u201d\n\nFor example, on Solvay Pharmaceutical\u2019s Web site for Omacor, www.solvay-omacor.com, the first question a user sees is, \u201cAre you a U.S. citizen?\u201d\n\nIf the answer is yes, the user is sent to a page where heart attacks are not mentioned.\n\u201cIn other countries, uptake may be harder because doctors think of it as just a dietary intervention.\u201d\n\nIn the largest study of fish oil \u2014 conducted more than a decade ago \u2014 Italian researchers from the Gissi Group (Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Infarto), gave 11,000 patients one gram of prescription fish oil a day after heart attacks.\n\u201cIf you ask me do I take omega-3 supplements every day, then, embarrassingly, the answer is yes,\u201d said Dr. Harrison, a professor at Bolton Primary Care Trust of the University of Manchester in England.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article explicitly states that prescribed fish oil is not approved by the FDA for use in heart patients as a treatment. This is not an accurate statement. The FDA announced approval of a qualified health claim of reduced risk of coronary heart disease for omega-3 fatty acids in 2004. And while not FDA approved for use for all coronary disease, there is currently an omega-3 fatty acid product on the market that has been approved for the treatment of very high triglycerides. Fish oil is widely available over the counter, which is the most important piece of information for readers. This story focuses too much on the availability of one prescription fish oil brand.", "answer": 0}, {"article": "\"This smartphone reader has the potential to improve access and speed up healthcare delivery,\" said Li.\nThey have filed a patent and hope to move forward with clinical trials that could lead to commercialization.\nIf they send results off to a lab in a distant city, the doctors sometimes must wait for days -- by which time the infection may have become widespread.\nBuying the components themselves, the research team was able to build the device for about $50, but the manufacturing cost would probably be lower than that, he said.\n\"If we find out about infections, we can treat them more quickly, which makes a difference especially in low-resource, remote areas.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that the researchers \u201chope to move forward with clinical trials that could lead to commercialization.\u201d", "answer": 1}, {"article": "Even so, he says, \"our results provide additional support for the potential benefit of daily aspirin for [reducing] cancer mortality.\"\nHe found an association, not cause and effect.\nThe new analysis is published in the Journal of the National Cancer Institute.\nHe describes that reduction as modest.\nMany other strategies will also reduce the risk of cancer, he says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of aspirin is not in question.", "answer": 2}, {"article": "NEW ORLEANS (Reuters) - Abbott Laboratories Inc\u2019s experimental Absorb heart stent, designed to dissolve and thereby restore the blood vessel\u2019s natural flexibility, has proven safe and effective a year after being implanted in patients, researchers said.\n\u201cThe baby will grow and the biodegradable material will disappear,\u201d he said.\nDuring the same period, no blood clots were reported among patients who were far enough along in testing to be evaluated in the 101-patient study.\nHe said Absorb and stents like it will likely be the next generation of stents and ultimately improve outcomes for patients.\nIt hopes to seek U.S. approval for the product in 2015, several years before any competitor.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that the device is available in Europe but not in the US.", "answer": 1}, {"article": "Publicity in recent years about emotional, cognitive, and memory problems in aging football and hockey players who suffered multiple concussions during their careers has raised the anxiety level around the topic. A lawsuit by thousands of NFL players who claim the league did not keep them well enough informed about the long-term risks of concussion - dementia is one of them - is based in Philadelphia and has raised even higher the profile of what doctors call mild traumatic brain injury.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story refers to the growing use of cognitive rest.", "answer": 1}, {"article": "Heart defects and other health problems are also common, according to the March of Dimes.\nSUNDAY, March 6, 2011 (HealthDay News) -- A simple blood test may one day offer a safe way to detect Down syndrome during pregnancy, researchers say.\nIn each case, the test quickly pinpointed the chromosomal variation, identifying 14 Down syndrome cases and 26 normal fetuses, the study authors said.\nBecause these tests, while 80 percent accurate, carry a 1 percent to 2 percent risk of miscarriage, only about one in 10 pregnant women opts for them, he said.\nNoting that most of his Down syndrome patients say they lead fulfilling lives, Skotko said, \"The overwhelming majority of family members say they can't imagine their life without their family member with Down syndrome.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "More reserved than its Reuters competitor, this story emphasizes the test \u201cmay one day\u201d be available\u2026 \u201cif larger clinical trials confirm the results.\u201d\n\u201cSmall study\u201d and \u201cexperimental\u201d stressed in second sentence.", "answer": 1}, {"article": "\"Observing this, we asked ourselves if it was possible to pharmacologically induce immune quiescence with medication that was better assured of reaching the point of infection,\" said Ho.\nThe tool, a vaginal implant, decreases the number of cells that the HIV virus can target in a woman's genital tract.\nUnlike conventional methods of HIV prevention, such as condoms or anti-HIV drugs, the implant takes advantage of some people's natural immunity to the virus.\nHIV infects the body by corrupting T cells that are mobilized by the immune system when the virus enters a person's body.\n\"What we don't know yet is if this can be a stand-alone option for preventing HIV transmission or if it might be best used in conjunction with other prevention strategies.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not made clear enough that this vaginal implant is experimental, in development, and has never been tested on humans and that it could be years \u2014 if ever \u2014 before the device is available.", "answer": 0}, {"article": "Wine rounds out the list of of 10 \"brain healthy\" food groups that help protect against Alzheimer's: green leafy vegetables, other vegetables, nuts, berries, beans, whole grains, fish, poultry, olive oil and wine.\nNow here are the five food groups it says you should avoid to reduce your risk of developing dementia...\n\nYou already know they're not so good for your waistline, and it turns out pastries and other sweets could have a negative effect on brain health as well.\nThe study, published in the journal Alzheimer's & Dementia, looked at more than 900 people between the ages of 58 and 98 who filled out food questionnaires and underwent repeated neurological testing.\nBut the MIND diet helped slow the rate of cognitive decline and protect against Alzheimer's regardless of other risk factors.\nDiet appears to be just one of \"many factors that play into who gets the disease,\" said nutritional epidemiologist Martha Clare Morris, PhD, the lead author of the MIND diet study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Certainly all of the components of the MIND diet are available in most supermarkets.\u00a0 While there might be a problem in areas where supermarkets are scarce, overall the diet\u2019s foods are available. This would have been easy to mention in the story. Since the story did not touch on availability, however, we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "Guallar and his colleagues wanted to look specifically at the link between selenium and cholesterol.\n\u201cIn a population like the U.S. where selenium levels are adequate, there\u2019s no reason to take extra selenium in supplements.\u201d\n\nThe question of the link between selenium and health outcomes, Guallar said, \u201cis a very interesting story that\u2019s still developing.\u201d\nA healthy cholesterol level is less than 200 mg/dL, according to the American Heart Association, while 200 to 239 mg/dL is considered \u201cborderline high.\u201d\n\nIn the groups taking 100 and 200 micrograms of selenium daily, total cholesterol dropped an average of 8.5 mg/dL and 9.7 mg/dL, respectively, compared to the group taking a placebo pill.\n\u201cIn a sense it\u2019s a necessary micronutrient and we need it, but we might be (in) a situation where we have enough \u2014 we might even have too much.\u201d\n\nSelenium is found in meat, bread, and some nuts.\nStill, the finding is \u201creassuring\u201d because previous research had linked high selenium with higher cholesterol levels, said study author Dr. Eliseo Guallar, from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story discusses food sources of selenium and notes that the mineral is sold\u00a0as a supplement, so availability is not an issue.The story could have mentioned that selenium is pretty uniformly a component of multivitamin formulations. Individuals adding a selenium-specific supplement to a multivitamin could easily exceed the levels used in this study.", "answer": 1}, {"article": "When it comes to health, I\u2019m skeptical of willpower. Sure, I talk to my students about personal responsibility, but when it comes to the health of populations, I look for big fixes more than for small acts of will.\n\nThat\u2019s why my ears perked up when I heard that two old physician friends had decided to start taking, as a preventive measure, some of the medications often included in what the field has dubbed the \u201cpolypill.\u201d My friends are both top doctors in their 60s, with good diet and lifestyle, and this is now part of their...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This was a confusing point for us\u2013the author mentions having two friends who appear to be self-medicating using several of the mentioned drugs, with the aim of preventing heart disease and diabetes. Then we\u2019re told that a similar\u00a0regimen could feasibly be rolled into a one-size-fits-all\u00a0\u201cpolypill\u201d for the general public, and the story speculates what that pill \u201cmight\u201d contain. \nThe story then adds, as an aside, that there is a less comprehensive \u201cpolypill\u201d available via online ordering, and provides a link to the site. \nIt\u2019s not clear if or when a more comprehensive polypill for the masses might become available.", "answer": 0}, {"article": "Van Hemelrijck and colleagues studied more than 30,000 men in Sweden with prostate cancer who got hormone therapy between 1997 and 2006, for about three years.\n\"For the vast majority of men, the benefits of hormone therapy are absolutely clear: it can halt the disease or stop it for years,\" she said.\n\"There is no definitive evidence, though the risk of heart problems is definitely something doctors should consider when prescribing hormone treatment,\" Thun said.\n\"What we can do with these results is to raise a flag with hormone treatments,\" said Mieke Van Hemelrijck, a cancer epidemiologist at King's College in London and the study's lead researcher.\nExperts said the findings could make doctors think twice before prescribing the standard hormone treatment to men with prostate cancer, particularly if they are at risk of heart disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n \nThe story points out that hormone therapy is commonly given to men with prostate cancer.\n However, the lead sentences mislead readers by describing hormone therapy as a single treatment, rather than a collection of different treatments. The distinction is particularly important because this study and others indicate that different hormonal therapy techniques may be associated with different risks of heart disease. ", "answer": 1}, {"article": "The game, \u201cWizard\u201d, is designed to help so-called episodic memory \u2014 the type of memory needed to remember where you left your keys several hours ago, or to remember a few hours later where you parked your car in a multi-storey car park.\n\u201cWe need a way of treating the cognitive symptoms of schizophrenia, such as problems with episodic memory, but slow progress is being made toward developing a drug treatment,\u201d said Barbara Sahakian from the department of psychiatry at Cambridge University.\nThis study, published in the journal Philosophical Transactions of the Royal Society B, found that 22 patients who played the memory game made significantly fewer errors and needed significantly fewer attempts to remember the location of different patterns specific tests.\nImportantly, the patients also said they enjoyed the game and were motivated to play it across the eight hours of cognitive training.\nSchizophrenia is a long-term mental health condition that causes a range of psychological symptoms, ranging from changes in behavior through to hallucinations and delusions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t tell readers whether the game, called \u201cWizard,\u201d is currently available for iPad users. This is particularly problematic, because searching for an iPad game called Wizard returns a number of options. Are any of those options the correct game? What is the current stage of availability?", "answer": 0}, {"article": "The falls were lower in those given smaller doses rather than higher monthly doses of vitamin D.\n\nThe clinical trial, the first to examine vitamin D's impact on respiratory infections in nursing home residents, looked at 107 patients with an average age of 84 over a 12 month period.\nHe cautioned that the study is not definitive proof that vitamin D can prevent ARI but it suggests that it can and at little risk to the patient.\nBut vitamin D can reinforce it and prevent illnesses like pneumonia, influenza and bronchitis.\nThey also had over double the incidence of falls, the study said.\n\"This is a potentially life-saving discovery,\" Ginde said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no mention of availability, but it\u2019s generally understood that vitamin D is widely available.", "answer": 2}, {"article": "Researchers said they had identified a family of retroviruses in patients with chronic fatigue syndrome, opening up a potentially promising new avenue of treatment for a debilitating disease that afflicts as many as four million Americans and 17 million people world-wide.\n\nThe finding will likely spur patients with the condition to seek treatment with drugs used to fight HIV, the virus that causes AIDS. Although HIV and the newly identified virus group are different, they are both retroviruses.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>1clip_themedata.thmx\"/>1clip_colorschememapping.xml\"/>\n\n\n\n\nThe story mentions that chronic fatigue syndrome has \u201cno effective treatment.\" It also states that \"some doctors are already prescribing drugs approved for HIV\u00a0for fatigue patients.\" We\u2019ll give the story a satisfactory score on this criterion, although we have mixed feelings about the message it left with readers. \n", "answer": 1}, {"article": "\u201cNow that you can just write a prescription, I use them in my practice a lot more.\u201d\n\nSince the Food and Drug Administration approved the first topical Nsaid in 2007, sales in the United States have soared \u2014 to more than $264 million in 2009, according to IMS Health, a health care research company.\nStill, in one of the only head-to-head trials between topical and oral Nsaids, subjects taking the pills had a much higher rate of indigestion, diarrhea, abdominal pain, abnormal liver tests and anemia than those using the creams.\nThe main advantage of a skin cream is that it bypasses the stomach and much of the bloodstream, theoretically minimizing serious side effects.\nThe risks in the most vulnerable population \u2014 people with other illnesses, like liver disease, or those on blood thinners \u2014 are not known, because these patients are generally excluded from studies.\n\u201cThe turning point for topical Nsaids was the fright over heart problems with Vioxx,\u201d Dr. Moore said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n\nThe story reports that only three topical NSAIDs (nonsteroidal anti-inflammatory drugs) are approved for sale with a prescription in the United States, while several brands are sold over the counter in Europe. ", "answer": 1}, {"article": "Abagyan says it's still possible, though unlikely, the effect could be due to a still unidentified confounding factor.\nThe FAERS database contains more than 8 million patient records.\nThe research team focused on patients in the database who received ketamine, narrowing their study population down to approximately 41,000.\nThey applied a mathematical algorithm to look for statistically significant differences in reported depression symptoms for each patient.\nFor financial and ethical reasons, ketamine has never been tested for its safety and effectiveness in treating depression in a large-scale clinical trial, but it reportedly works much more rapidly than standard antidepressants.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not address availability or how many physicians currently prescribe ketamine for depression.", "answer": 0}, {"article": "Researchers randomly assigned 241 women with urinary incontinence to daily medicine and a placebo injection, or a Botox injection and a daily placebo pill.\n\u201cThese are both effective treatments,\u201d said the lead author, Dr. Anthony G. Visco, an associate professor of obstetrics and gynecology at Duke.\nThe medicine has to be taken daily, while Botox is given in a single injection that is effective for about 6 to 12 months.\nThe most common treatment for urinary incontinence is a daily dose of an anticholinergic medicine that alters the action of certain nerves.\nNow a placebo-controlled study has found that the treatments are equally useful in reducing the frequency of episodes of incontinence, but vary in side effects and long-term effectiveness.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article mentions that anticholinergic medicine is the \u201cmost common treatment\u201d for urinary incontinence. It is also well-known that botox injections are readily available.", "answer": 1}, {"article": "The Food and Drug Administration cleared silver diamine fluoride for use as a tooth desensitizer for adults 21 and older.\nIt\u2019s been used for decades in Japan, but it\u2019s been available in the United States, under the brand name Advantage Arrest, for just about a year.\nBut studies show it can halt the progression of cavities and prevent them, and dentists are increasingly using it off-label for those purposes.\nNow there\u2019s an alternative: an antimicrobial liquid that can be brushed on cavities to stop tooth decay \u2014 painlessly.\nNobody looks forward to having a cavity drilled and filled by a dentist.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the use of SDF is not widespread in the U.S., but that it is becoming increasingly available.", "answer": 1}, {"article": "But the lower doses used in this study (1.5 or 0.75 mcg) \"may help to improve the overall safety profile, particularly for geriatric patients,\" he said.\nThe treatment group also experienced a \"significant increase\" in the length of time they could sleep before awakening to urinate.\nThere's more on nocturia at the National Association for Continence.\nThese findings will also be presented at the American Urological Association meeting.\nIn the United States there's no approved drug to treat the problem, the study authors said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that it\u2019s not FDA approved yet.", "answer": 1}, {"article": "Liao feared that cutting open Holmes\u2019 chest and sternum for an open bypass surgery would disrupt his rehabilitation from the cardiac arrest and delay his plans to return to athletics.\nStudies have disagreed on whether the outcomes of these surgeries are better when using the robotic system versus other minimally invasive techniques.\nA controversial robotic surgery is gaining popularity among Minnesota cardiac surgeons for repairing defective heart valves and bypassing clogged coronary arteries.\nThe robotic systems come with million-dollar price tags and are used for a limited number of surgeries \u2014 mostly the removal of cancerous prostates in men or uteruses in women.\nThe only other option is open-heart surgery, which carries a higher risk of infections and longer recoveries.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article does a good job of specifying how many daVinci surgery robots are available in Minnesota\u2013and which facilities have them. ", "answer": 1}, {"article": "Taking statins the day of a coronary artery bypass operation may significantly improve survival, a study in the Annals of Thoracic Surgery found.\n\u201cWe already knew that people on statins before surgery had a decreased risk of death,\u201d said a co-author, Dr. Yi Deng, an assistant professor of anesthesiology at Baylor College of Medicine.\nAfter controlling for many preoperative health and behavioral characteristics, they found that compared with other patients, those who took statins on the day of surgery had a 48 percent reduced risk of dying in the next 30 days.\nThe 1,788 who continued statins up to the day of surgery had a risk of death within 30 days of 1.7 percent, compared with 2.9 percent for 452 who stopped one to three days before surgery, and 3.8 percent for 781 who did not take statins or stopped more than 72 hours before their operations.\nResearchers looked at 3,021 heart surgery patients, most of whom were taking cholesterol-lowering statins.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There is no mention of whether statins are widely available, available by prescription only, etc. We might presume that everyone knows how popular statins are and how widely prescribed, but we always think it\u2019s a good idea to make it clear how someone would gain access to a particular therapy.\nA simple line saying something to the effect of \u201cthese medicines have been around for many years, are widely used and available in inexpensive generic formulations\u201d would have addressed this.", "answer": 0}, {"article": "The Johns Hopkins researchers also calculated the effects of surgery on health costs for the patients.\nThe researchers argue that the findings, drawn from data on four years of claims made in seven states, support coverage of bariatric surgery by insurers because of the savings and improvements in patients' health.\nThe most common drugs before treatment were metformin, a generic taken by about half of patients, followed by the medicines Avandia and Actos, taken by more than one-third of patients.\nBy year three, the data were only available for 288 patients, about 13 percent of those who got the surgery.\nAfter a $616 increase in expenses during the first year following surgery, the costs declined by $2,179 in the second year and $4,497 in year three.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story says the researchers argue that the results support coverage of the surgery by insurers. That at least implied that not every plan covers the surgery now for this type of patient \u2013 which is at least indirectly a comment on availability.\u00a0 It could have been more explicit. ", "answer": 1}, {"article": "Doctors and patients\u2019 advocates urged women considering the procedure to go for counseling and take their time before making a decision, noting that other risk-reducing options were available, like tamoxifen therapy for estrogen receptor-positive breast cancer and the use of more sensitive magnetic resonance imaging screening for earlier detection.\nThough the researchers had limited information about the patients, Dr. Tuttle suggested that younger women might be choosing the procedure because their cancers tended to be very aggressive, and they had more years ahead of them in which a second cancer might develop.\nThough all women with breast cancer are at risk of developing a second cancer in the uninvolved breast, the risk is slightly greater with lobular histology, Dr. Tuttle said, and white women may be more likely to carry genetic mutations associated with an increased risk of developing cancer in the contralateral breast.\n\u201cFor the vast majority of our patients, this does not impact the chances of dying of breast cancer, and that\u2019s the key thing here,\u201d said Dr. Julie R. Gralow, the chairwoman of the communications committee of the American Society of Clinical Oncology and an associate professor of medical oncology at the University of Washington and the Fred Hutchinson Cancer Research Center in Seattle.\n\u201cWhat we\u2019re actually seeing is more and more women at the two extremes: either having minimal surgery, a lumpectomy, or having a bilateral mastectomy,\u201d Dr. Tuttle said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes surgical treatments available for women who are diagnosed with breast cancer. The story also notes via Dr. Gralow\u2019s comments\u00a0 that women should be appropriatley informed about the absolute survival benefits of their treatment choices. ", "answer": 1}, {"article": "\u201cThis is a patient population that\u2019s at risk for thrombotic [clotting] issues.\u201d\n\nZafgen said its six-month study involving 107 patients suffering from Prader-Willi syndrome met its two primary goals, known as end points: showing significant weight loss by many patients and a decrease of hyperphagia-related behavior, meaning excessive eating.\nIt can dominate the lives of patients and their families, leading to excessive overeating, choking, and stomach rupture, along with slowed metabolism and psychiatric disorders.\nThere are currently no treatments for Prader-Willi syndrome, the most common genetic cause of life-threatening obesity.\n\u201cWe\u2019ve seen individuals who have lost significant amounts of weight in the six-month period.\n\u201cAs of today, we have no evidence to suggest that Beloranib by itself can cause blood clots,\u201d Hughes said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is made clear that the beloranib drug is still under experimentation and pending FDA approval.", "answer": 1}, {"article": "John Anderson, president of medicine and science for the American Diabetes Association, says \u201cIt\u2019s very promising and opens up new avenues of research, but we are a long way from replacing insulin, or a cure, or even knowing how this [hormone] will work in human tissue.\u201d\n\nThose concerns aren\u2019t lost on Melton, who also recognizes that more research is needed to confirm that betatrophin may benefit patients.\nIt\u2019s also possible that diabetics could lower their dependence on insulin and might even be able to wean themselves off of the injection altogether if their beta cell production is robust enough to provide the insulin they need.\nEventually, the overwhelmed system leaves these sugars, in the form of glucose, to build up in the blood, which can lead to obesity, damage the heart, and cause other metabolic problems.\nIn type 2 diabetes, the body gradually loses its ability to make enough insulin to keep up with the sugar coming in from the diet.\nHis pursuit of a better understanding of this population, and the forces that cause them to falter in diabetes, led his team to the discovery of betatrophin.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that any possible treatment resulting from this research is still a long way away.", "answer": 1}, {"article": "More than half of those women who had been categorized as mastectomy-only patients were also able to go the lumpectomy route and experience a good outcome.\nThe women were classified into three groups as the study began: \"marginal\", meaning that the women were eligible for a lumpectomy to conserve the breast, but that it would be disfiguring or require several operations; \"mastectomy-only\", meaning a lumpectomy was not considered possible; and \"inoperable\", meaning that doctors believed that even a mastectomy would not completely remove the cancer.\nAfter the four months of estrogen-lowering therapy, the research team found that 82 percent of those women in the marginal group were, in fact, able to undergo successful breast-conservation surgery.\nThe most common form of breast cancer, ER+ accounts for about three-quarters of all breast cancer cases in the United States, the authors noted.\nThe investigation was funded by the American College of Surgeons Oncology Group and led by Dr. Julie A. Margenthaler, an assistant professor of surgery and a breast surgeon at the Siteman Cancer Center at Washington University in St. Louis.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story should have done a better job of explaining how the drugs discussed in this story, known as aromatase inhibitors,\u00a0are\u00a0currently used in\u00a0cancer treatment and why this study may represent an advance over current approaches.\u00a0All of the drugs\u00a0discussed are currently approved\u00a0by the FDA for breast cancer, but they are typically administered to women\u00a0only after\u00a0surgery or as\u00a0an adjunct to other drugs\u00a0in order to prevent a cancer recurrence. The new study is testing these treatments prior to surgery to see if this improves outcomes. The\u00a0story isn\u2019t explicit about most of this and\u00a0assumes that readers are already\u00a0aware of this background.\u00a0Many probably are, but others are not.\u00a0\u00a0\u00a0", "answer": 0}, {"article": "\u201cOur study shows that there may be some relationship between dietary factors and things like egg quality so one idea may be recommending supplementation with omega 3s to improve fertility.\u201d\n\nExactly how the healthy omega 3 fatty acids are helping the ovary to produce better quality eggs isn\u2019t clear yet.\nThese could then mature into a healthy egg that is fertilized and can lead to a live birth.\nHigher quality eggs improves the chances that the egg will be fertilized and develop into a live pup.\nWhen the ovaries were examined even further, Skaznik-Wikiel also found that the quality of the eggs were better among the animals with higher levels of omega 3s.\nWhat she found: The mice with the higher levels of omega 3 fatty acids seemed to have more precursors to egg cells than control mice with lower levels of the fat, meaning they had a larger reserve of eggs-to-be.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both omega 3-rich foods and omega 3 supplements are widely available.", "answer": 1}, {"article": "TORONTO, May 22, 2018 - A non-surgical procedure, called percutaneous coronary intervention (PCI), along with prescribed medication, is better than medication alone as initial treatment for people who have the most common form of heart disease, suggests an analysis of an international clinical trial co-led by St. Michael's Hospital.\nCoronary artery disease is the most common type of heart disease in North America and Europe, and is a serious health problem worldwide.\n\"With these measurements we were able to identify patients who would benefit from PCI in addition to medication.\"\nThrough the Keenan Research Centre and the Li Ka Shing International Healthcare Education Centre, which make up the Li Ka Shing Knowledge Institute, research and education at St. Michael's Hospital are recognized and make an impact around the world.\nThe medication used in the FAME 2 trial consisted of a combination of aspirin, cholesterol-lowering and blood pressure-lowering drugs as required by current treatment guidelines.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s apparent that PCI is widely available and that there is debate about when to use it.", "answer": 1}, {"article": "His \"tactile imaging system\" capitalizes on the fact that cancerous lumps tend to feel harder and less movable than harmless abnormalities such as fluid-filled cysts or fibrous nodules. The fist-sized, $1,000 machine \u2014 with an elastomer probe, a light, and a camera \u2014 acts like ultrasensitive fingertips. It measures the size, elasticity, and mobility of a breast lump, then a computer program converts the data into a score from 1 to 5, with scores under 2 likely to be benign.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes it clear that the device is being developed and that human trials are needed to test its accuracy.", "answer": 1}, {"article": "Related Material: The invited commentary, \"Systemic Effects of Radiotherapy in Ductal Carcinoma In Situ,\" by Mira Goldberg, M.D., and Timothy J. Whelan, B.M., B.Ch., of McMaster University, Ontario, Canada, also is available on the For The Media website.\nEvery article is free online from the day of publication.\nThe article contains conflict of interest disclosures.\nResearchers were not intervening for purposes of the study and cannot control all the natural differences that could explain the study findings.\nLinks will be live at the embargo time http://jamanetwork.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that radiation and surgery are widely available treatments.", "answer": 2}, {"article": "\u201cI could see all these things from combat I was afraid to look at before, and I had a totally new perspective.\nThe current protocol calls for patients to take MDMA two or three times, each a month apart, interspersed with psychotherapy.\n\u201cThe MDMA seems to act as a catalyst that allows the healing to happen.\u201d\n\nWhat do patients say about it?\nThe drug floods the brain with hormones and neurotransmitters that evoke feelings of trust and well-being, users report.\nHe tried help at a Veterans Affairs hospital, but couldn\u2019t let his guard down enough to benefit from standard psychotherapy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s made clear that MDMA \u201cis about to enter larger Phase III trials,\u201d the FDA has granted pharmaceutical grade MDMA breakthrough therapy status, and that illegal sources exist but are potentially dangerous.\nIt\u2019s also mentioned that there have already been several other small-scale studies of the drug, and that if MDMA is eventually approved by the FDA it will only be administered by a licensed therapist.\nWe did have one quibble\u2013the story predicts that, if larger studies go well, the drug could be approved for this use \u201cby 2021.\u201d In reality, there\u2019s really no way of knowing what year a drug will get approved.", "answer": 1}, {"article": "WEDNESDAY, Sept. 21, 2016 (HealthDay News) -- New guidelines issued by three leading cancer organizations suggest that more breast cancer patients should consider radiation therapy after a mastectomy.\n\"The guideline is timely,\" said Dr. Janna Andrews, an attending physician in radiation medicine at Norwell Health Cancer Institute, in Lake Success, N.Y. \"The field of post-mastectomy radiation is changing.\n\"In the past, if a woman had a small tumor, less than 5 centimeters, and not more than three or four positive lymph nodes, many doctors would say she does not need [post-mastectomy radiation therapy],\" she said.\n\"There is a great deal of controversy about whether women with one, two or three lymph nodes [with cancer] have sufficient risk to warrant radiation,\" he said.\nFor instance, he explained, ''a woman 65 who has microscopic involvement in a single lymph node and an estrogen-receptor positive cancer would be very different from a 38-year-old who has three lymph nodes involved and so-called triple-negative breast cancer.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t address availability. However, since it is referring to an existing form of therapy that is widely used, we\u2019ll rate this as not applicable.", "answer": 2}, {"article": "Overall, the biggest differences in brain activity were seen at 9 months \u2013 which is much earlier than when a child typically shows behavioral problems associated with autism.\nHe said that, judging by the differences in brain activity, he and his colleagues could detect which babies were in the high-risk group.\nHe hopes to expand the number of babies in his study to 200.\nThe differences in brain activity were smaller as the babies got older.\n\"This study needs to be replicated by their lab and independent scientists,\" she says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made it clear that this was an experimental diagnostic tool and not ready for the pediatrician\u2019s office.", "answer": 1}, {"article": "Colic is usually defined as excessive and inconsolable crying for at least three hours a day for more than three days a week over more than three weeks.\nThis implies the improvement may \"have more to do with the therapeutic effect of touch than the actual therapy itself,\" Dr. Edzard Ernst, of the department of complementary medicine at Peninsula Medical School, Universities of Exeter and Plymouth, in the United Kingdom, and colleagues wrote in the report.\n\"This is pertinent given that simethicone is considered the best available and most commonly prescribed treatment for colic, although it previously has been shown to be no more effective than the placebo,\" according to the authors.\n\"It's reasonable for parents to consider those kinds of interventions for which there is some suggestion of benefit but no known risks,\" said Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at Steven and Alexandra Cohen Children's Medical Center of New York.\nA study of probiotics, which are reputed to help digestion, found that 95 percent of infants given L. reuteria probiotics seemed to reduce their average crying time compared to 7 percent of babies given simethicone, which is marketed to relieve gas under the brand names Mylicon and PediaCare Infants' Gas Relief.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All of the alternative therapies discussed are widely available, but we think the story could have made this more explicit. For example, if you are a mom in rural Montana, are you expected to know how widespread is the availability (and where) of fennel extract, probiotics, etc.?\u00a0 Even the line about \u201csimethicone is considered the best available\u201d doesn\u2019t tell you what that means. She may have no idea whether you can find these things in the drug store, in the grocery store, in a health food store or all of the above.", "answer": 0}, {"article": "Dr. Eric A. Klein, chairman of the Glickman Urological and Kidney Institute at the Cleveland Clinic, said that he would like to see the findings of the new study independently confirmed, but that other studies also have suggested that the risk of cancer is low in men whose P.S.A.\nThey still have a very low individual risk of dying from prostate cancer, judging from the new data.\nBut once cancer is detected, many men, frightened by the diagnosis, opt for aggressive surgical and radiation treatments that do far more damage than their cancers would have, leaving many impotent and incontinent.\nThough use of the test is widespread, studies show that the screening saves few, if any, lives.\nThe results also will reassure men who decide to continue with regular screenings that the benefits most likely outweigh the risks.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0While not being explicit, the story strongly implied (correctly) that the PSA test is readily available.", "answer": 1}, {"article": "Reiki, a therapy in which hands are placed lightly on the body or just above it, is increasingly being used to reduce cancer-related fatigue, anxiety, nausea and pain. Several studies suggest a benefit to patients, but scientists say more large, rigorous studies are needed.\n\nCancer patients\u2014due to the disease and to side effects of chemotherapy\u2014often suffer from severe mental and physical fatigue, doctors say. Anxiety, nausea and pain are also common. In recent years, many cancer centers have been offering Reiki, a form of...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The premise of the story is that this is a treatment that is \u201cincreasingly being used.\u201d The story says, \u201cReiki, a therapy in which hands are placed lightly on the body or just above it, is increasingly being used to reduce cancer-related fatigue, anxiety, nausea and pain.\u201d The story never goes on to prove that this is a method that is increasingly being used. All we are given are a few examples of treatment centers that do offer Reiki and then this: \u201cOther centers don\u2019t offer Reiki, citing insufficient evidence. \u201cThere isn\u2019t a good evidence base for its utility in cancer care as of yet,\u201d says Lorenzo Cohen, a professor in the departments of general oncology and behavioral science at M.D. Anderson Cancer Center in Houston.\u201d\nReaders across the country may be left wondering just how widespread this practice is.", "answer": 0}, {"article": "Higher grade tumors correlate with higher restricted water volume in the cancer cells\u2019 large nuclei.\nIt provides a better target for biopsies, especially for smaller tumors,\u201d said Rebecca Rakow-Penner, MD, PhD, a research resident in the Department of Radiology and the study\u2019s first author.\nIt corrects for magnetic field distortions and focuses upon water diffusion within tumor cells.\nBut diffusion MRI suffers from magnetic field artifacts that can distort the actual location of tumors by as much as 1.2 centimeters or roughly half an inch \u2013 a significant distance when surgeons are attempting, for example, to assess whether a tumor extends beyond the prostate and into adjacent nerve bundles.\nBut many tumors do not significantly differ from surrounding healthy tissues with contrast enhanced MRI and so evade easy detection.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear from the release when or whether this technology might become available, if it\u2019s not available already.", "answer": 0}, {"article": "Assistant professor Mads Fiil Hjorth \n\nDepartment of Nutrition, Exercise and Sports, University of Copenhagen \n\nEmail: madsfiil@nexs.ku.dk \n\nTel.\n\"Recognizing fasting plasma glucose as a key biomarker enables a new interpretation of the data from many previous studies, which could potentially lead to a breakthrough in personalized nutrition,\" said Arne Astrup, M.D., Head of Department of Nutrition, Exercise and Sports at University of Copenhagen.\nApproximately one hundred different institutes, departments, laboratories, centres, museums, etc., form the nucleus of the University.\nThe Department of Nutrition, Exercise and Sports conducts research, education, innovation, and dissemination of information in nutrition, human physiology and sports at the highest international level, and incorporates the humanities as well as health and social sciences.\nFor people with type 2 diabetes, the analysis found that a diet rich in healthy fats from plant sources would be effective for achieving weight loss.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The two biomarkers are said to be a simple alternative to other means of customizing dietary plans for persons with pre-diabetes or type 2 diabetes.\nHow do you know what kind of diet you\u2019re supposed to eat based on your biomarker profile? Presumably you\u2019re prescribed a diet and told what to eat. But if you\u2019re a consumer, how do you know what that diet is? In other words, how do you benefit from this? Is someone selling personalized nutrition recommendations based on these biomarkers? ", "answer": 0}, {"article": "The combination allowed many women with metastatic hormone-receptor-positive, HER2-negative cancer to delay the start of chemotherapy, which is the traditional treatment option in these patients once hormone drugs have stopped working.\nSome 67 per cent of the 347 women in the palbociclib plus fulvestrant group showed clinical benefit - either a reduction in tumour size or control of disease for at least six months - compared with 40 per cent of the 174 women in the placebo plus fulvestrant group.\nIt provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease.\nThe study also aimed to assess whether cancers with particular genetic traits responded less well or better to the combination than others.\nPalbociclib is a first-in-class drug - with a different mechanism of action to other approved drugs - which simultaneously blocks two proteins called CDK4 and CDK6 in cancer cells.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t say whether fulvestrant and palbociclib are available or FDA approved.", "answer": 0}, {"article": "These findings suggest the pills may help protect against death in patients with pneumonia.\n\u201cGiven the potential low number needed to treat to prevent a death suggested by this study, we believe that a strong case exists for randomized trials of statins in people with serious infection to determine if a simple and practical intervention at the point of diagnosis of pneumonia has a beneficial effect.\u201d\n\nDouglas\u2019s team, whose research was published in the British Medical Journal, used data from computerized medical records of doctors\u2019 practices in Britain to identify statin users.\nPatients with a record of pneumonia were followed for six months to see if they died, and the researchers found that 13 percent (109 out of 847) of statin users died compared with 20 percent (578 out of 2,927) of non-statin users.\n\u201cStatins are safe, cheap, and an easy intervention in terms of delivery,\u201d said Ian Douglas, a lecturer in epidemiology at the LSHTM who led the research.\nDouglas noted that since this study looked at patients who were already taking statins when they developed pneumonia, a full randomized clinical trial was needed to find out whether starting a statin at the time of diagnosis has a similar effect.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Statin drugs are commercially available in\u00a0brand name and generic formulations as indicated.\nWe do think it\u2019s a bit odd \u2013 and unnecessary \u2013 to mention the manufacturer and the brand name.\u00a0 Early in our journalism training, we were discouraged from doing so unless absolutely necessary in the story \u2013 which is not the case herein.", "answer": 1}, {"article": "PARIS (Reuters) - Sanofi-Aventis\u2019 cabazitaxel candidate prostate cancer drug combined with prednisone reduced the risk of death by 28 percent compared with another treatment, the outcome of a final-stage trial showed.\nFiling for approval in the EU has been completed.\nThis compared with 1.9 percent using mitoxantrone.\nThe primary endpoint of the so-called Tropic trial was overall survival.\nThe FDA\u2019s review should happen in the third quarter, Sanofi said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story indicated that the drug reported on was not yet approved for use in the EU; it also mentioned that drug is currently scheduled for an expedited review by the US FDA.\u00a0 ", "answer": 1}, {"article": "Doctors numbed the lower half of O'Brien's body.\nThe new surgery simply moves them to the side in order to fit the knee with titanium and plastic caps \u2014 creating a knee joint free of pain and arthritis.\n\"With this kind of surgery we don't cut into the muscle at all,\" Dr. Bergersaid.\nThe day of the surgery, Berger has his patients conquer what amounts to a knee-bending obstacle course before they're able to leave \u2014 walking up and down a hallway and up and down a flight of stairs.\n\"Therefore the physical therapy is easy to do and it's quick and it's not very painful for them at all.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story did not include discussion about availability of this treatment or whether it was an FDA approved medical device. According to the company website, in 2004 there were more than 500 orthopedic surgeons trained in the use of this device. So it\u2019s availability is limited. There was no mention that this particular type of knee replacement was not an option for all patients who were candidates for standard total knee replacement. Factors that may rule out some patients include variation in knee structure, prior surgery on the same knee, obesity, a recent history of deep vein thrombosis (DVT), and other unstable medical conditions. ", "answer": 0}, {"article": "\"If you have your choice, you want to get poked with a needle or you want to try this?\nAnd the same vaccine continues to be recommended and used in European Union markets, AstraZeneca says.\nThe vaccine's effectiveness was just 3 percent, so low that \"no protective benefit could be measured\" for children ages 2 to 17, the CDC said in a statement.\n\"To create the jet, you have to instantaneously create 100 times more pressure than you've got in the tire of a car,\" he says.\n\"We continue to pursue a broad-based investigation to identify potential causes of lower effectiveness\" in recent years, the company said in a statement, adding that one of the four flu virus strains it used in the vaccine during the past two flu seasons may have been the problem.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Overall, this story adequately addresses availability. It\u00a0explains that flu patches aren\u2019t yet available on the market; it may be some time until readers can walk down to the corner pharmacy and buy their own flu patch over the counter. The jet injection and nasal spray are described as already widely available.", "answer": 1}, {"article": "\"I wasn't interested in going as far as getting an amniocentesis because of the risk associated with that,\" she explains, \"and so when I heard about this test, that was part of the reason that I was most interested in it.\"\nIt's only been on the market since October 2011 and is not regulated by the Food and Drug Administration \u2014 the FDA does not regulate this type of genetic testing service.\nUntil the new testing technology came along, the only less invasive option was for an expectant mother to get an ultrasound, plus have her blood tested for specific proteins.\n\"Places are reporting doing fewer than half the number of procedures that were being done previously.\"\nSome worry that the companies' websites and marketing materials don't make the limitations clear enough.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned the tests were new to the market (available since 2011), and that many doctors were still not familiar with them. The story made it clear that these tests were not regulated by the FDA.", "answer": 1}, {"article": "The resource you are looking for might have been removed, had its name changed, or is temporarily unavailable.", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u201ds clear that \u201cThe Baseball Diet\u201d materials are for sale now. A link to the product web site is included.", "answer": 1}, {"article": "What are the limitations of IVM?\nThey also note that the technology hasn\u2019t been widely used and that there are no studies looking at the outcomes of birth defects or developmental delays.\nAlthough there are different protocols for IVF, and there aren\u2019t any randomized controlled trials that have compared IVF and IVM side by side, studies that look at standard IVF cycles show a significantly higher pregnancy rate than IVM, Shastri said.\nFor starters, since there is less time involved with IVM, women who are undergoing chemotherapy, radiation or plan to have surgery may be good candidates.\nAlthough ICSI is safe and effective, the bigger concern is if a patient going through IVM doesn\u2019t use ICSI, Shastri said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article really could have used some information about how widely available assisted reproductive medical expertise is in the U.S. and the fact that academic medical center, and major public hospitals and health systems, also offer the treatments along with free standing fertility clinics.", "answer": 0}, {"article": "One of the top research universities in the world, MSU focuses its vast resources on creating solutions to some of the world\u2019s most pressing challenges, while providing life-changing opportunities to a diverse and inclusive academic community through more than 200 programs of study in 17 degree-granting colleges.\n\u201cThis decrease of cells could slow down, or maybe even stop, the inflammatory process, potentially helping patients maintain their cognitive function longer,\u201d Rizzo said.\n\u201cThe patients who didn\u2019t smoke marijuana had a very high level of inflammatory cells compared to those who did use,\u201d Kaminski said.\n\u201cWhat we learn from this could also have implications to other brain-related diseases like Alzheimer\u2019s and Parkinson\u2019s since the same inflammatory cells have been found to be involved.\u201d\n\nKnowing more about this interaction could ultimately lead to new therapeutic agents that could help HIV patients specifically maintain their mental function.\nWith antiretroviral therapy \u2013 a standard form of treatment that includes a cocktail of drugs to ward off the virus \u2013 these cells have a better chance of staying intact.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Given that marijuana is still illegal in most states and considered illegal by the federal government, it would be worth mentioning that patients hoping to receive a marijuana treatment would have to live in a state where it is legal for medicinal purposes.", "answer": 0}, {"article": "Larsson and her colleagues combed through research databases spanning the last 45 years to find studies that tracked how much magnesium people took and how many of them had a stroke over time.\n\"It's again the diet per se, not any one individual component of the diet.\"\nThose are things that have low sodium, high potassium and high magnesium,\u201d said Larry Goldstein, director of the stroke center at the Duke University Medical Center in Durham, North Carolina.\nBut Larsson told Reuters Health in an email that she could not say whether other aspects of what the people ate partially or entirely explained the finding.\nOther experts said the results were consistent with dietary recommendations.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of this kind of diet is not in question.", "answer": 2}, {"article": "But, she adds, epidemiological studies consistently show positive health effects from fish consumption on mortality, cardiovascular risk factors and, now, dementia.\nThe average level of DHA among all the participants was 3.6 percent of all fatty acids, and the top 25 percent of the population had values above 4.2 percent.\nThe finding that DHA alone reduces risk, the authors write, is consistent with earlier data showing high levels of DHA in healthy brain tissue and low levels in the brains of people with Alzheimer\u2019s disease.\n\u201cIt\u2019s an observational study that presents an identified risk factor, and the next step is a randomized placebo-controlled study in people who do not yet have dementia.\u201d Dr. Schaefer is chief of the Lipid Metabolism Laboratory at Tufts University.\nThe study was financed in part by Martek, a concern that manufactures DHA, and one author received a grant from Pfizer, France.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story mentioned that omega-3 fatty acid docosaheaenoic acid (DHA) was found in fatty fish, as well as supplements in the form of fish oil or DHA.\u00a0 It was good to point out that neither DHA or fish oild supplements have FDA approval for prevention of dementia.\nThe story curiously mentioned that it was also found in some meats.\u00a0However, the only tissues in which DHA is found in significant quantities are the brain, retina, and testes \u2013 which are not frequently consumed by people.\u00a0 Thus the story ought not to have included 'some meats' as a source of DHA. ", "answer": 1}, {"article": "Also, can we distinguish autism from other forms of developmental delay?\"\nIt is estimated that the condition affects one in 110 children in the United States, according to the U.S. Centers for Disease Control and Prevention.\n\"Although this technique holds promise for identifying infants at risk for autism, it still needs to be determined whether the atypical patterns of brain activation are specific to autism,\" said Geraldine Dawson, chief science officer for Autism Speaks.\nAnother expert, Dr. Robert F. Lopez-Alberola, chief of pediatric neurology at the University of Miami Miller School of Medicine, said that \"it's nice to have an objective measure, but it doesn't really do much.\"\n\"What we can measure are signals in the brain, in a specific language area, that are depressed in autistic children and normal in typical children,\" she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that using MRIs to diagnose autism is an uNPRoven approach. The author of the study says, \u201cThis is not the diagnostic that you can package and send to all community health centers in the United States. This is an announcement that this can be done,\u201d she said. The story could have pointed out that the validity of the testing would be dependent on the expertise of the radiologist, as reading functinal MRI is different from traditional MRI.", "answer": 1}, {"article": "DURHAM, N.C. - Most high-risk lung cancer patients might not need annual low-dose computed tomography (LDCT) screenings if they are cleared of disease in their initial test, according to a study led by a Duke Cancer Institute researcher.\nIn the first year after a negative screen and before the scheduled first annual screen, 17 patients (0.09 percent of all initial negative LDCT participants) were diagnosed with lung cancer.\nThe researchers found that even former heavy smokers appear to have a reduced incidence of lung cancer if their initial LDCT screening is negative, suggesting that less frequent screening might be warranted.\nAn additional 75 patients (0.4 percent of the initial negative group) were diagnosed with lung cancer between the first and second annual screening.\n\"Our analysis suggests that annual screens may not be warranted for patients who have had an initial negative scan, and future risk prediction and cost-effectiveness models could incorporate these data to improve screening guidelines,\" Patz said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t specify where low-dose CT is used and if most readers can access it. We do know that the screen has been approved for use in the United States and is being adopted by some health centers.", "answer": 0}, {"article": "\"Cardiovascular disease is the number one cause of death in the U.S., and while statins are very effective, a good proportion of people are not meeting their goals, and in this setting the shot could be a valuable addition,\" he said.\nAn LDL of less than 100 mg/dL of blood is considered optimal.\nThe study included 54 men and two women aged 18 to 45 who did not have elevated cholesterol levels.\nNow, researchers are testing the new shot in people who have high cholesterol.\nThere were also decreases seen in levels of total cholesterol and apo-B (tiny fat particles in the blood that also increase the risk for heart disease).\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that this potential treatment is in an early phase of development and not yet available to the public.", "answer": 1}, {"article": "Sixty percent of the people who considered pets to be a part of their social networks placed them in the central, most important circle \u2014 the same place many people put close family and social workers.\nMany of the study participants are unemployed because of their illness, she notes.\nHaving a pet that was well taken care of was a source of pride for them.\nSo they're doing a lot of the work of managing their conditions.\nThey give affection without needing to understand the disorder.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re going to act under the assumption that readers are familiar with the idea of pet ownership.", "answer": 2}, {"article": "\"Cluster headache is a rare, debilitating and difficult to treat disorder with few effective acute therapies,\" Dr. Stephen Silberstein, director of the headache center at Jefferson University in Philadelphia, said in a statement.\nThe company, which says gammaCore is already available in the European Union, expects to start selling it later this year in the U.S.\n\nVagus nerve stimulation is used to treat a range if disorders, including epilepsy, depression and overeating.\n\"The FDA release of gammaCore is an important advance in the treatment of the pain associated with cluster headache,\u201d Silberstein said in the statement provided by the company.\nThe device is a vagus nerve stimulator and it\u2019s not entirely clear how it works.\nThere aren\u2019t many specific treatments but they include the migraine drug sumatriptan, delivered via auto-injector, and inhaled oxygen.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes that the product is available in the EU and that the company will begin selling it in the U.S. later in 2017.", "answer": 1}, {"article": "Recipients were at most seven years older or younger than the donors.\nItalian researchers retrospectively studied 647 kidney transplants, grouping the donors according to whether they were in their 50s, 60s, 70s or 80s.\nIn an average follow-up of five years, they found that the rate of unusable donor kidneys and the long-term outcomes of recipients varied little among the first three age groups \u2014 around 18 percent of the organs had to be discarded, and the five-year survival was about 88 percent\nA new study has found a kidney transplanted from a deceased 79-year-old can be as effective as one from a person 30 years younger.\nGenerally, guidelines classify donors older than 50 as \u201cextended criteria donors,\u201d but shortages have led to using these donors more frequently.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Given that this study ran in a U.S. publication, we wanted to know what the guiding rules are on age of donors, in case they differ from what is standard in Italy. If older donors can donate in the U.S. already, then this study isn\u2019t very newsworthy, for example.", "answer": 0}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nThe test approximates the average blood glucose levels over the previous 2 or 3 months, based on the amount of glucose that has accumulated on the surface of red blood cells.\nAccording to the authors, comparatively few studies have examined whether the HbA1c test could help identify the risk for gestational diabetes, and these studies have been limited to women already at high risk for the condition.\nThe authors noted that further studies are needed to confirm whether measuring HbA1c levels in early pregnancy could determine a woman\u2019s later risk for gestational diabetes.\n\u201cOur results suggest that the HbA1C test potentially could help identify women at risk for gestational diabetes early in pregnancy, when lifestyle changes may be more effective in reducing their risk,\u201d said the study\u2019s senior author, Cuilin Zhang, Ph.D., of the Epidemiology Branch at NIH\u2019s Eunice Kennedy Shriver National Institute of Child Health and Human Development.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that this test is far from ready for use in clinical screening. It states:\nThe test is not currently recommended to diagnose gestational diabetes at any point in pregnancy.", "answer": 1}, {"article": "Nezhat advises women to look for a surgeon experienced in doing minimally invasive surgery.\n\u201cThe robot will not really decrease human errors but it will make the surgery easier,\u201d Dr. Tommaso Falcone of the Cleveland Clinic, in Ohio, who was also not involved in the study, told Reuters Health in an e-mail.\n\u201cWith minimally invasive surgery by an experienced surgeon\u2019s hands, the incisions are smaller, pain and suffering is less, visualization is better, and recovery is faster than with open surgery,\u201d Dr. Ceana Nezhat of the Emory University School of Medicine in Atlanta who was not involved in the review, told Reuters Health.\nOn the other hand, the newness of the technology could have deterred surgeons from using it for difficult cases, potentially biasing the results in a positive way for the robotic technique.\n\u201cHowever, if the surgeon is skilled enough to do the hysterectomy without the robot by laparoscopy then the outcomes will be similar.\u201d\n\nNezhat further noted that while robotic assistance can be a good \u201cenabler\u201d for a minimally invasive approach, surgeons should have at least the basic knowledge of regular laparoscopy too, as there may be times when the robotic equipment doesn\u2019t work.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t include \u2013 and it wouldn\u2019t have taken much to do so \u2013 any estimate of the number of robotic surgery facilities in the US.\u00a0 And it didn\u2019t give any estimate of how often the open, laparoscopic or robotic procedures are done.", "answer": 0}, {"article": "The all-Achillion regimen could hit the U.S. market by 2020 in a conservative scenario, Deutsche Bank\u2019s Alethia Young estimated.\nThe new-generation hepatitis C regimens use a two- to three-drug combination \u2013 a nucleotide analog inhibitor or \u201cnuke\u201d and a NS5A inhibitor in Gilead\u2019s case \u2013 to achieves a cure in about eight to 12 weeks, making them faster and more effective than older treatment options.\nThe question then becomes whether ACH-3422 plus ACH-3102 - a weaker nuke and a stronger NS5A inhibitor - could be a good enough doublet as Harvoni, William Blair\u2019s Katherine Xu said.\nThe main goal is to achieve a cure, or sustained virological response, 12 weeks after the completion of therapy.\nLaunched in October, its sales touched $2.11 billion in the quarter ended Dec. 31.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story calls the new drug \u201cexperimental,\u201d suggesting it\u2019s not yet available. But the story doesn\u2019t really address what will be the major obstacle to availability should the drug make it to approval: the cost and who will pay for it. What will be the limitations put on coverage by insurance companies looking at a huge potential total cost?", "answer": 0}, {"article": "All participants took calcium and vitamin D as well.\nAccording to an editorial accompanying the study, this complication occurs in about 5 percent of cancer patients who are taking a high-dose bisphosphonate (Zometa or Aredia) to control or prevent spread of malignancy to the bone.\n\"I think that it's really an important important proof-of-concept that you can inject locally and get a response,\" said Dr. Rena D'Souza, chair of biomedical sciences at Texas A&M Health Science Center Baylor College of Dentistry in Dallas.\n\"These were patients with severe periodontal disease but who were otherwise systemically healthy,\" said study senior author Dr. Laurie K. McCauley, chair of the department of periodontic and oral medicine at the University of Michigan in Ann Arbor.\n\"There was a significant improvement in clinical measures of gum and bone,\" McCauley stated.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It could\u2019ve been more explicit about the drug\u2019s current availability via prescription.\u00a0We also don\u2019t applaud the comment that Forteo is \u201cnot yet\u201d approved for this indication. It could\u2019ve been worded in a less presumptive manner.", "answer": 1}, {"article": "The test, developed by researchers at the Institute of Cancer Research (ICR) in London and the Royal Marsden NHS foundation trust, picks out men suitable for treatment with olaparib, part of a revolutionary class of drugs called \u201cPARP-inhibitors\u201d, which stops damaged cells from repairing themselves.\nThe ICR chief executive, Prof Paul Workman, said the test could \u201cusher in a new era of precision medicine for prostate cancer\u201d.\nThey also used the test to analyse DNA in the blood after treatment had started, so people who were not responding could be identified and switched to alternative therapy in as little as four to eight weeks.\nWe think it could be used to make clinical decisions about whether a PARP-inhibitor is working within as little as four to eight weeks of starting therapy.\nThe liquid biopsy, less invasive than a tissue biopsy, also detects early signs of resistance to olaparib and monitors the cancer\u2019s evolution over time, according to the paper, published in Cancer Discovery on Monday.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not help readers understand whether this blood test is available now\u2013or if not, when it might become available for wider, non-research use.\n\u00a0", "answer": 0}, {"article": "TUCSON, Ariz., Nov. 18, 2015 /PRNewswire/ -- In a clinical trial conducted for HSRx Group, an Arizona-based biopharmaceutical company, the OTC acne treatment product HSRx 2121 significantly outperformed a market-leading product in reducing acne count, redness and severity.\nAfter 24 hours treatment, the percentage of subjects with reduced acne count was 64% greater for those using HSRx 2121 than for subjects using the competing product.\nAt seven days, the percentage of subjects exhibiting reduced severity was six times greater for those using HSRx 2121, compared to those using the competing product.\nAll HSRx OTC drug products utilize natural ingredients in their formulations.\nAt 24 hours, the percentage reduction in total acne count with HSRx 2121 was 20 times greater than it was for subjects using the competing product.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t state if the product is available now or when it might become available.", "answer": 0}, {"article": "When the researchers used the longer Tao brush, they were able to detect endometrial cancer in all but 7% of the women who had the disease, and close to half of the ovarian cancers. Combined with the fact that these tests were performed with a mere swipe of the uterine wall, these measures of \u201csensitivity\u201d \u2014 the ability to detect cancers that are actually there \u2014 represent a major improvement over the screening tests currently available.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t discuss if women can get this test \u2014 a vital piece of information for those with a high risk of endometrial or ovarian cancers. While individual parts of the PapSeek test are FDA-approved, e.g. Pap smears and Tao brushes, the PapSeek genetic analysis does not yet appear to be approved (though approval criteria for medical devices are not as strict as they are for medications).\nAlso, there\u2019s been a reduction in frequency of Pap testing in recent years. It\u2019d be good to have a discussion of how implementing a new screening test in this environment muddies a message that\u2019s already been disseminating about how frequently women should be getting pelvic exams and Pap smears (i.e., less often, with some stopping altogether after a certain age). How would a test like this have to work upstream to be reincorporated into gynecological screening?", "answer": 0}, {"article": "\"These are exciting results.\nThough too early to call it a cure, the procedure has enabled the young people, who have Type I diabetes, to live insulin-free so far, some for as long as three years.\n\"It's the first time in the history of Type 1 diabetes where people have gone with no treatment whatsoever ... no medications at all, with normal blood sugars,\" said study co-author Dr. Richard Burt of Northwestern University's medical school in Chicago.\n\"It's the threshold of a very promising time for the field,\" said Dr. Jay Skyler of the Diabetes Research Institute at the University of Miami.\nDr. Lainie Ross, a medical ethicist at the University of Chicago, said the researchers should have studied adults first before exposing young teens to the potential harms of stem cell transplant, which include infertility and late-onset cancers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The\u00a0story tells readers that the new treatment is still experimental and this treatment appears to have been used for the first time in a recent research study.\u00a0 One physician is quoted saying the idea \"is not ready for prime time\" so viewers should know they can not turn to their local doctor to have this treatment.\u00a0 ", "answer": 1}, {"article": "\"The paradigm for the last 20 years for patients like this been: 'Mr.\nThe findings underscore the danger of rushing to adopt a procedure before careful studies have been conducted to fully determine its benefits, Boden and others said.\nSome cardiologists who specialize in the procedures, however, argued that the study did not focus on the sickest patients who are most likely to benefit, and that the main purpose of angioplasty in many is to alleviate chest pain, not to prevent heart attacks.\nThe study is the first large, well-designed comparison of angioplasty to non-surgical care for patients who are not having a heart attack or in imminent danger of having one.\nThe study of more than 2,000 patients found that those who underwent the expensive procedure, known as angioplasty, in non-emergency situations were no less likely to suffer a heart attack or die than those who took only aspirin and other medicines to lower blood pressure and cholesterol and prevent clots, along with adopting lifestyle changes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states the new study challenges routine use of a procedure \u2013 angioplasty \u2013 that has become standard care, thereby letting readers know that this procedure is\u00a0currently used and\u00a0widely available.\u00a0 ", "answer": 1}, {"article": "\u201cAlthough it\u2019s very exciting, it is very early days,\u201d added Sha.\n\"We do have a study with what we think is a commercially viable product that will start early next year,\" McCracken said.\nAnd, McCracken says, the company is working to figure out just what it is in the plasma that might affect aging and disease.\nThe work made headlines and launched a company, Alkahest, that\u2019s working to develop young human plasma into treatments for aging-related diseases.\n\u201cThere is a theory that there is an inflammatory process that is driving the disease and the plasma is helping that,\u201d she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the small \u201cproof of concept trial\u201d is just the beginning, and that the company \u201cplans to move forward with formal clinical trials in 40 volunteers next year.\u201d That presumably would be just a phase one trial to show safety so readers should know that any working product would be years away, at the least (and if ever).", "answer": 1}, {"article": "Until now, there has been little research into its activity.\nProfessor Brian Walker, Head of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"These findings suggest that corticosterone could provide a safer alternative to traditional cortisol replacement therapy for conditions such as Addison's disease and congenital adrenal hyperplasia.\"\nThe researchers say that, with further research, these findings may one-day lead to improved therapies for other conditions that respond to steroid treatment, including asthma and rheumatoid arthritis.\nDr Mark Nixon, of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"The discovery of this selective corticosterone pump in fat cells could lead to a completely new approach in our search for safer steroid medications.\"\nThe new treatment - expected to have fewer side effects than existing therapies - could help people with disorders of the adrenal gland whose bodies are unable to produce a class of steroids called corticosteroids.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The research article is clear that corticosterone is available only for research purposes at this time, but the release is not specific about that, instead employing phrases such as \u201cAn improved therapy\u2026is a step closer\u201d) that suggest unavailability but also encourage the reader to conclude that the treatment is just around the corner.", "answer": 0}, {"article": "Yet, the researchers' risk assessment questionnaire was equally poor.\nIn addition to timing, further research will be needed to determine which blood test for iron deficiency without anemia is accurate, cost-efficient and practical for routine doctor's office use.\nIn the first study, when the researchers analyzed the NHANES study data, 9 percent of females who were 12 to 21 years old had iron deficiency without anemia.\nTaken together, the studies suggest that risk factors and assessments should not be used to determine which young women should receive testing for iron deficiency.\nThe researchers then looked at potential iron deficiency risk factors in this group, including the age when they started menstruating, as well as their race and ethnicity, poverty status, food insecurity, tobacco or nicotine use, dietary information, body mass index (BMI) and physical activity.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that low-cost hemoglobin tests are affordable and given to most young women, but that more sensitive tests that screen for iron deficiency are more costly and thus \u201cdifficult to obtain in the doctor\u2019s office.\u201d", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nBut the five people who got inactive stimulation on the first visit, and active tDCS at the brain target on the second visit, consumed an average of 700 fewer calories and lost an average of 0.8 pounds on the second visit.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nNext, the researchers will compare a group getting only active tDCS with a separate group getting only sham stimulation.\nMore study is needed to confirm the safety and effectiveness of tDCS for weight loss.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "A brief comment that this is not expected to be available anytime soon would have been helpful to readers. However, the release does say that \u201cMore study is needed to confirm the safety and effectiveness of tDCS for weight loss.\u201d While it\u2019s a close call, we think most readers can gather from this that the technique isn\u2019t likely to be available soon.", "answer": 1}, {"article": "Nivolumab unleashes an immune system attack on cancer by blocking activation of a protein called PD-1 on T cells, white blood cells that find and attack cells, viruses or bacteria that have specific targets.\n\"We can get good results without choosing to treat patients based on PD-L1 status,\" said Sharma, who also is scientific director of MD Anderson's immunotherapy platform and an investigator with the Parker Institute for Cancer Immunotherapy at MD Anderson.\n\"The response rate is better than we've seen for other potential second-line treatments and nivolumab is really well-tolerated, which is important because bladder cancer patients are a fragile group after frontline treatment with platinum chemotherapy,\" said Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology at MD Anderson.\nAt a median follow up of 213 days, 33.3 percent remained on treatment, and 45.6 percent of patients survived for at least one year, which Sharma noted \"is better than anything we've seen in the past.\"\nBoth nivolumab, known as Opdivo, and ipilimumab, known as Yervoy, were developed and marketed by Bristol-Myers Squibb, which funded the clinical trial.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The main reason that this is not satisfactory is that it is pretty confusing for non-expert readers. Nivolumab has not been approved by the FDA for use in treating metastatic bladder cancer. However, the release tells readers that nivolumab has been approved by the FDA for use in treating a variety of other cancers \u2014 and goes on to discuss survival rates for patients who take the drug (alone or in combination with ipilimumab). What does the FDA approval for treating other cancers have to do with the likelihood of nivolumab\u2019s future availability for treating bladder cancer? That\u2019s not clear, because the release doesn\u2019t tell us.", "answer": 0}, {"article": "Others have such high cholesterol that taking statins alone is not enough.\n\"It seems that the group that takes them, compared to the group that doesn't, has half the rate of cardiovascular events and mortality as those that don't,\" Dr. Seth S. Martin of the Johns Hopkins School of Medicine told CBS News.\nIn an editorial published along with the study, experts note that although the results are promising, more long-term research is needed to make definitive conclusions about the drug.\nOne in six American adults lives with high cholesterol, and millions have trouble getting it under control, according to the Centers for Disease Control and Prevention.\nThe results, published in the Annals of Internal Medicine, also show that the drugs have a significant effect on reducing heart attacks and overall mortality.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There is no discussion of when and where these new drugs may be available to the average person, or at what price. A statement that these drugs are not currently FDA approved, and a description of what\u2019s needed to attain that approval, would be appropriate.", "answer": 0}, {"article": "WEDNESDAY, May 4, 2011 (HealthDay News) -- Among men under 65 with early stage prostate cancer, those who have the prostate gland removed are less likely to die than those who adopt a \"watchful waiting\" approach, according to a new long-term study out of Europe.\nThe earlier study also found that undergoing a radical prostatectomy lowered the risk of the cancer spreading, as well as the death rate from prostate cancer or any other cause.\nThe benefit was primarily seen among men younger than 65 and the authors estimated that seven men under the age of 65 and 8 over the age of 65 would need to be treated to save one life.\nBut much remains to be known about how best to treat different types of prostate cancer.\nAlso, the men in this study were diagnosed only after they had symptoms, unlike the majority of men in the United States, Greenberg said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "An important caveat about how the prostate cancer in the study differed from the way in which prostate cancer is most commonly detected today in the US was explained.", "answer": 1}, {"article": "COPENHAGEN (Reuters) - Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemotherapy.\nAn editorial in the New England Journal of Medicine, where the Merck monotherapy results were published, said Keytruda could become \u201ca new standard of care\u201d.\nU.S. regulators are expected to decide whether to approve Keytruda for first-line non-small cell lung cancer, the most common type, by Dec. 24.\nIn the event, researchers reported that Merck\u2019s combination cut the risk of disease progression or death by 47 percent compared to chemotherapy alone after 10.6 months, while 55 percent of patients saw their tumors shrink versus 29 percent.\nThe failure of Opdivo to work for \u201call comers\u201d in lung cancer was first announced in August, without any details.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says:\n\u201cU.S. regulators are expected to decide whether to approve Keytruda for first-line non-small cell lung cancer, the most common type, by Dec. 24.\u201d\nBut it doesn\u2019t explain how that\u2019s different from it\u2019s already approved use for advanced non-small cell lung cancer.", "answer": 0}, {"article": "Unlike traditional stents that remain in place after implantation, Absorb is designed to disappear fully within three years of the procedure.\n\u201cNo metal may also reduce the potential of future blockages that occur with permanent metallic stents.\u201d\n\nData released in October concluded Absorb was comparable to Abbott\u2019s own Xience drug-coated metal stent in safety and effectiveness but showed a higher risk of heart attacks and blood clots.\n(Reuters) - U.S. health regulators said on Tuesday they approved a stent by Abbott Laboratories that is the first designed to be absorbed into the bloodstream after it is implanted.\n\u201cThere are no longer going to be permanent metal implants in the artery.\u201d\n\nAbsorb releases the drug everolimus to combat the growth of scar tissue that can form within a stent and cause the artery to narrow again, the U.S. Food and Drug Administration, which approved the stent, said.\n\u201cNo metal means the treated artery can pulse and flex naturally as demands on the heart change with everyday activities,\u201d said Gregg Stone of Columbia University Medical Center, who led clinical trials for Absorb.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that Abbott Labs plans to make the stent available to some 100 hospitals in the near future, in order to train surgeons in its use, before \u201cramping up sales.\u201d This was information that we wished had been in the Associated Press story on the topic, which we also reviewed.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070311/19clot.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story reported on a new method for detecting clots that can cause cardioembolic strokes and a new method for treating massive deep vein thrombosis in the leg.\u00a0 The story could have emphasized that neither of these is routinely used.\u00a0 Although the story did say that they are new, readers could easily be confused about this application of MRI because they may be familiar with the use of MRI for other diagnostic procedures.\nThe story also included no information about the availability of the Angiojet, the medical device discussed.\u00a0 While the story made it sound like this was something new, this device has had FDA approval since 1999.\u00a0 http://www.fda.gov/cdrh/pdf/P980037b.pdf", "answer": 0}, {"article": "DBS has been used to treat tremors associated with Parkinson\u2019s disease, but Machado said the new approach, if successful, will achieve something novel.\n\u201cThe big difference is that when we are treating the motor symptoms of Parkinson\u2019s disease, we\u2019re trying to make the symptom, like a tremor, go away,\u201d he said.\nSomeone has a stroke in the United States every 40 seconds, and it has become the leading cause of serious long-term disability among Americans.\nThe hospital recently received the green light from federal authorities to start the first ever human trial of DBS for stroke, and plans to announce Tuesday that it will perform the procedure as soon as an initial patient is identified.\nClose to 800,000 Americans have a stroke each year and estimates suggest about half of those people will be disabled from it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story is pretty clear that actual clinical application of DBS for stroke patients is a long way off, given that the first patient on which this will be tried hasn\u2019t been identified yet.\u00a0 So we\u2019ll rate this a marginally Satisfactory, with the caveat that stories like this which raise patient hopes prematurely can do real harm to people and their families. We would have liked it better if the story had spelled out how many steps it will take before this becomes an actual treatment (if ever).", "answer": 1}, {"article": "An experimental Johnson & Johnson drug substantially reduced the severity of the inflammatory skin disorder psoriasis, according to a new study.\n\nJ&J is developing ustekinumab as part of a new category of drugs that targets proteins known as interleukins. In addition to psoriasis, J&J is studying the compound's potential to treat Crohn's disease, a gastrointestinal ailment.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that the drug ustekinumab is an experimental drug still being studied. ", "answer": 1}, {"article": "The positive results surprised even Stagl.\nThe women who took the 10-week stress-management class shortly after surgery reported feeling better and having fewer depressive symptoms such as anxiety than those who took a one-day, breast-cancer education session.\n\u201cWhile I certainly wouldn\u2019t say that anyone could take a 10-week course and be set for life, I think anyone could take a 10-week course and be much better at coping with stress.\u201d\n\nNext, the study team, led by Michael Antoni of the University of Miami, hopes to show that an easier-to-manage five-week group class works as well as the 10-week one.\n\u201cThis is really a teachable moment.\u201d\n\nThe skills taught in the course are useful at many stressful moments, Porter said, not just when cancer is diagnosed.\nIf a woman\u2019s stress level remains high indefinitely after diagnosis, she may have a worse outcome than if she can bring it back down, Stagl said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Many breast cancer treatment providers can offer patients information about programs to help patients deal with stress, anxiety, and other depressive symptoms associated with a cancer diagnosis. However, the story does not make clear how widely available such programs are, and how much existing programs resemble the study intervention.", "answer": 0}, {"article": "With better drugs and radiation techniques available, the proportion of women with Stage 4 breast cancer who had surgery dropped from 67.8 percent in 1988 to 25.1 percent in 2011, according to a study published Wednesday in the journal JAMA Surgery.\nOver the past few decades, as breast cancer has increasingly been treated as a systemic disease, the number of surgeries performed on the most serious cases has plummeted.\n\"Aggressive local therapy may benefit select women, such as those with an already established potential for durable remission,\" they wrote in their paper.\nBut with better therapies to control the cancer systemically and improved imaging that finds ever-smaller deposits of cancer in other parts of the body, it may be time to see whether surgery also can help increase the length of survival times, they said.\nOr it could be continuously \"seeding\" the spread of cancer to other parts of the body.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of risk-reducing\u00a0 breast surgery is not in question, since it is not a new intervention.", "answer": 2}, {"article": "But the procedure had never been done in people.\n\u201cIt really opens up a lot to the imagination.\u201d\n\nMost drugs are blocked from entering the brain by the \u201cblood-brain barrier,\u201d which protects against infection, but also makes it tricky to treat brain tumors, diseases like Alzheimer\u2019s, and mental illness.\n\u201cIf we feel like we have a safe method of getting drugs in there,\u201d he said, \u201cit will open up a whole new slew of clinical trials.\u201d\n\nMainprize said the patient, a \u201cremarkable woman,\u201d was chosen to go first, because of the status and large size of her tumor, because it was an area of the brain that the ultrasound machinery could easily reach, and because of her willingness to help the research.\nBecause the trial was designed solely to determine the safety of focused ultrasound to the brain, the patient was not given a therapeutic dose of doxorubicin and the procedure is not expected to help in her recovery, Mainprize said.\nThe microscopic bubbles \u2014 roughly the size of red blood cells \u2014 had previously been injected into a vein, along with a chemotherapy drug called liposomal doxorubicin and a tracing molecule.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes this is a very new, very experimental technology, and several other patients are lined up for testing. Even after that testing, further testing will be necessary to establish appropriate doses etc, so we think it\u2019s pretty clear that this won\u2019t be available any time soon.", "answer": 1}, {"article": "Investigators conducted a randomized controlled trial in the pediatric Emergency Department at The Mount Sinai Hospital comparing lung ultrasound to chest X-ray in 191 children from birth to 21 years of age.\nThe Mount Sinai Hospital is ranked as one of the nation's top 10 hospitals in Geriatrics, Cardiology/Heart Surgery, and Gastroenterology, and is in the top 25 in five other specialties in the 2014-2015 \"Best Hospitals\" issue of U.S. News & World Report.\nThe research team was led by James Tsung, MD, MPH, Associate Professor in the Department of Emergency Medicine and Department of Pediatrics at the Icahn School of Medicine at Mount Sinai, and former clinical fellow Brittany Pardue Jones, MD, who's currently Assistant Professor in the Department of Pediatrics at Vanderbilt University School of Medicine.\nFurthermore, the reduction in chest X-rays in the investigational arm resulted in an overall cost savings of $9,200, and length of stay in the Emergency Department was decreased by 26 minutes.\n\"In the era of precision medicine, lung ultrasound may also be an ideal imaging option in children who are at higher risk for radiation-induced cancers or have received multiple radiographic or CT imaging studies,\" says Dr. Tsung.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does make a point that ultrasound technology is widely available in health care facilities around the world.\u00a0 We would have liked for the release to include the fact that in perhaps three-quarters of the world, there is a lack of facilities that can provide even diagnostic X-rays. This fact, attributed to the WHO in the journal article, is absent in the news release. High resolution ultrasound machines would be even further out of reach in these countries.", "answer": 1}, {"article": "Every healthy newborn in the United States should receive a new vaccine designed to protect against an intestinal germ called rotavirus, a federal advisory panel decided yesterday as it set aside theoretical concerns about the vaccine's safety.\nThe vaccine won approval from the Food and Drug Administration on Feb. 3, and some doctors have received supplies of it.\nVirtually every child in the world contracts the virus repeatedly by age 5, gradually building immunity.\nRotaTeq \"generally appears to have a better safety profile than the earlier vaccine,\" said Umesh D. Parashar, a medical epidemiologist at the CDC.\nThe problem occurs naturally, albeit rarely; it showed up at a sharply elevated rate in babies who received RotaShield.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "For more information visit http://www.\nProfessor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"Nivolumab is one of a new wave of immunotherapies that are beginning to have an impact across cancer treatment.\nMore than double the number of patients taking nivolumab were alive after one year as those treated with chemotherapy, reported the major international trial, published today (Sunday) in the New England Journal of Medicine.\nSome of the data was presented at 16:25 CEST today (Sunday) at the European Society for Medical Oncology 2016 Congress in Copenhagen.\nUK trial lead Professor Kevin Harrington, Professor of Biological Cancer Therapies at The Institute of Cancer Research, London, and Consultant at The Royal Marsden NHS Foundation Trust, said:\n\n\"Nivolumab could be a real game-changer for patients with advanced head and neck cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that nivolumab is not yet approved for use in head and neck cancer patients in Europe (including the U.K.).", "answer": 1}, {"article": "Eli Lilly announced promising data on its efforts to have its Cymbalta depression treatment also used as pain medicine, saying a study showed the drug \"significantly\" reduced chronic lower-back pain.\n\nLilly has been looking at the potential of Cymbalta for relieving the discomfort of fibromyalgia and osteoarthritis pain as well as back pain. The company's results of late have been boosted by the antidepressant, whose second-quarter sales jumped 26% to $654.4 million.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "If you piece together everything that this story said about Cymbalta, you could probably figure out that it\u2019s approved for depression and not yet approved for fibromyalgia or back pain. Of course, physicians may prescribe previously approved medications for non-approved indications. Such stories may increase use of the medicine even before the FDA has considered it for this indication \u2013 which is just fine with the company, you can be sure. \u00a0 ", "answer": 1}, {"article": "The researchers are continuing to evaluate that.\nThe study is well done and important, said Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society.\nThe two drugs are Tykerb (lapatinib) and Herceptin (trastuzumab).\nIn another study, published online Jan. 17 in The Lancet Oncology, researchers from Germany reported that Tykerb is less beneficial than Herceptin as a single-drug therapy.\nThe dual-drug approach greatly boosted the chances of eliminating microscopic signs of early cancer by the time a woman was due to have surgery, said researcher Dr. Jose Baselga, chief of hematology/oncology at Massachusetts General Hospital Cancer Center and a professor of medicine at Harvard Medical School.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers have to connect the dots to figure out the availability of these drugs.\u00a0 We\u2019re told that Tykerb was approved in 2007 and we\u2019re told its retail price \u2013 so you can infer that it\u2019s available. There was no overt description of the availability of Herceptin.\nWe\u2019ll call this satisfactory by a weak nod.", "answer": 1}, {"article": "WEDNESDAY, May 11, 2011 (HealthDay News) -- It may be possible to assess a man's fertility by checking his \"anogenital distance,\" the gap between his scrotum and anus, a new study suggests.\nOne expert who's done her own research in this area applauded the study.\nThey measured the scrotum-anus distance as well as the penis length of 117 infertile and 56 fertile men visiting an andrology clinic.\nThe American Academy of Family Physicians has more about male infertility.\nFurther research is needed to compare techniques for measuring anogenital distance and assess their accuracy, he and his colleagues said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of such a measurement approach is not in question.", "answer": 2}, {"article": "This establishes a baseline time.\nFor now, he says, it probably should be used in conjunction with other tests.\nIf the time is slower, even by a small amount, he or she probably has a concussion, according to neurologists.\nAn easy, two-minute vision test administered on the sidelines after a young athlete has hit his or her head can help to reliably determine whether the athlete has sustained a concussion, according to a new study of student athletes, some as young as 5.\nThat situation prompted researchers at New York University\u2019s Langone Concussion Center to begin wondering recently whether there might be other, easier diagnostic tools to check young players for concussions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not explicitly state that one can purchase this test, but the implication is that it is available. We\u2019ll give the benefit of the doubt, but we\u2019d prefer it if the story linked to the sole supplier of the product offering yearly packages from its website. It\u2019s also available on the iTunes App Store.", "answer": 1}, {"article": "\"When you make IGF less active, it reduces risk factors linked to diabetes and cardiovascular disease,\" says Miguel Toribio-Mateas, Chairman of the British Association for Applied Nutrition and Nutritional Therapy.\n\"The diet is turning on the body's ability to renew itself,\" says Longo.\nTheir idea follows on from the long running trend of caloric restriction, mostly known through diets such as the 5-2 diet and intermittent fasting.\nThe team have since calculated that following the diet every three months could provide enough of an impact as effects are thought to last up to six months.\n\"Five days is safe: going on for longer is difficult to do outside of a clinic,\" says Longo.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that fasting participants were given a specific type of meal that isn\u2019t available to the general public.", "answer": 1}, {"article": "\"The interesting thing about the Safety Planning Intervention is that it is a relatively brief intervention and can be used in a lot of different [health care] settings,\" says Brian Ahmedani, director of behavioral health research at the Henry Ford Health System in Detroit, who wasn't involved in the new study.\nIn other words, the intervention had nearly halved the risk of suicide in the six months after discharge.\nThe hospital wasn't part of the new study but was also using a safety planning intervention as part of its efforts to prevent suicides.\nHe says she also agreed to use a crisis help line if things escalated.\n\"That's what is so powerful about a safety plan,\" says Ahmedani.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told that the SPI approach is becoming increasingly more available in hospitals across the country.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - There may be a seed of truth amidst the many health claims for pomegranate juice, researchers from Israel said Thursday, at least for kidney patients on dialysis.\nEven if the findings hold up, he said, it is still unclear what accounts for them.\nThey also made fewer trips to the hospital.\nAntioxidants are found in different levels in fruits and vegetables, such as blueberries or broccoli.\n\u201cThis study does not demonstrate anything special about pomegranate juice,\u201d she told Reuters Health in an e-mail.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. The availability of pomegranate juice is not in question.", "answer": 2}, {"article": "Flavonoids have been found to relax blood vessels and thereby improve blood flow, inhibit platelets from sticking together in the blood, and have a beneficial antioxidant effect. What still is not known is whether regularly eating dark chocolate, especially with its high sugar and fat content, eventually will lead to an unhealthy weight gain that would erase the beneficial effects of the flavonoids found in the cocoa.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Though it would seem reasonable to think that the Hershey\u2019s cocoa mixes used in this study are available on grocery store shelves, it\u2019s impossible to know. (It\u2019s not readily clear from Hershey\u2019s web site either.) Nonethless, we'll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "SAN DIEGO, July 14, 2015 /PRNewswire/ -- GenomeDx Biosciences today announced that a study featured on the cover of Urology demonstrates that Decipher\u00ae Prostate Cancer Classifier significantly influenced treatment recommendations following prostate surgery, reducing disagreement between urologists and radiation oncologists, and has the potential to enhance personalization of patient care.\nDecipher is covered by Medicare and multiple private insurance plans in the US.\nDecipher was developed in partnership with the Mayo Clinic.\nUsing clinical information alone, observation rather than adjuvant radiation therapy was recommended in 42% of decisions made by urologists and 23% of decisions by radiation oncologists (P < .0001).\nDecipher results indicating genomic high risk resulted in intensification of treatment, whereas genomic low risk resulted in less aggressive recommendations.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told Decipher is commercially available and that Medicare can pay for the test.", "answer": 1}, {"article": "Representative Rosa DeLauro, Democrat of Connecticut, said that the new guidelines would have no effect on federal policy and that \u201cRepublicans are using these new recommendations as a distraction.\u201d\n\n\u201cMaking such arguments, especially at this critical point in the debate, merely clouds the very simple issue that our health reform bill would increase access to care for millions of women across the country,\u201d she said.\nIt is by no means clear that doctors or patients will follow the new guidelines.\nOnly some people who are exposed to it develop cancer; in most, the immune system fights off the virus.\ninfection or having an organ transplant or other condition that would lead to a suppressed immune system.\nIf cancer does develop, it can take 10 to 20 years after exposure to the virus.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of Pap testing is assumed.\u00a0 ", "answer": 2}, {"article": "\"This is outside the box. I've never used it this far out,\" Metz said. \"My radar is up if I see [such an injury] again. As we get more follow-up from David, it will be important to publish this case so people will be aware.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article mentioned hyperbaric chambers are located in about 1,400 hospitals across the US. Given that Medicare also reimburses for hyperbaric therapy, access is probably relatively easy.", "answer": 1}, {"article": "The manufacturer of the sleep aid Snooz'n says its 2.5-ounce \"shots\" contain five milligrams of melatonin; Unwind, a \"relaxation blend,\" has three milligrams per 12-ounce can.\nHowever, a study published in January in the Journal of the American Geriatrics Society found that a pre-bedtime cocktail of magnesium, zinc and a five-milligram dose of melatonin significantly improved sleep among a group of 43 elderly Italian insomniacs.\nIt's typically released by the pineal gland around 10 p.m.; secretion stops around 4 or 5 a.m., helping to trigger the body to wake up, Scharf says.\nNow, the field includes a slew of new drinks promising a better night's sleep using such ingredients as melatonin, valerian root and - think turkey - tryptophan.\nIn a statement, Drank inventor Peter Bianchi says \"the safety of Drank's consumers remains a top priority\" and the company is working to modify the product's packaging and marketing \"to reflect its classification as a dietary supplement.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story provided some good information on the regulatory differences between beverages and dietary supplements and how manufacturers who don\u2019t follow the rules can run afoul of the FDA.\u00a0As to the more basic question \u2014 where do I buy this stuff?\u00a0\u2014 the story says the drinks are available\u00a0in grocery and convenience stores and pharmacies.", "answer": 1}, {"article": "(Reuters Health) - Brain surgery for children whose epilepsy is resistant to drug therapy can produce a 10-fold increase in the odds of being seizure-free after one year and can do it without affecting IQ, according to a new Indian study of 116 patients in The New England Journal of Medicine.\nRather than pay $35,000 to $50,000 on surgery that might cure the problem and prevent further damage to the child, insurance companies prefer to demand that more drugs be tried, even if the odds of them working in drug-resistant cases is small, he said.\nNot only \u201cdoes it reassure us that several surgical procedures are effective,\u201d she said, it demonstrates that surgery \u201cshould be done as early as possible\u201d once it becomes clear that a child is not responding to two anti-seizure medications.\nAbout 50 million people worldwide suffer with epilepsy and drugs can\u2019t control the seizures in approximately 30 percent of the cases.\nThe researchers said that was to be expected and, without surgery, patients probably would have experienced similar problems as a result of their continuing seizures.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Beyond noting that costs are a frequent barrier in India to getting the surgery, the article does not say anything about general availability of the operations, or define categories of candidates.", "answer": 0}, {"article": "It may actually help you live longer, according to new research from the Harvard T.H.\nOptimistic people are likely to have better diets, they\u2019re exercising more, and they\u2019re getting better sleep.\u201d\n\nHowever, even after the researchers accounted for these factors, the results still suggest that optimism itself is linked to a longer life.\nHowever, they note, \u201cthere is no clear basis for believing that the effects of optimism on health differ by sex or race.\u201d\n\nFinally, the researchers emphasize that while some people may think they\u2019re just not optimistic, it is something that is modifiable.\n\u201cOptimism is linked with lower inflammation and healthier biomarker levels and lipid levels, so there could be an independent effect on optimism.\u201d\n\nShe said her team plans to focus more on the potential impact of optimism on biological functioning in future research.\nThe study, published in the American Journal of Epidemiology, found that women who were optimistic had a significantly lower risk of dying from several major diseases, including cancer, heart disease, stroke, and respiratory disease, compared to other women whose outlook on life was less positive.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Optimism\u00a0may not be FDA-approved, but we\u2019ll optimistically assume all readers know that it\u2019s widely available. There could have been more included on how optimism can be a learned skill, for those who would like to become more optimistic.", "answer": 2}, {"article": "TRENTON, N.J. (AP) - GlaxoSmithKline PLC on Wednesday applied for approval in the U.S. and Europe to sell an existing breast-cancer drug as a first-line treatment.\nBut chemotherapy medicines, which often are given intravenously, attack healthy cells as well as cancerous ones, causing nasty side effects such as vomiting and hair loss that limit how much of those medicines can be given.\nThe British pharmaceutical company's Tykerb was approved here two years ago as part of a treatment for most women with advanced breast cancer that wasn't stopped after chemotherapy and other drugs.\nIn addition, \"at a certain point in time, the cells don't respond anymore to the hormonal therapy,\" said Dr. Debasish Roychowdhury, head of oncology medicines development at GlaxoSmithKline.\nNormally women with advanced, hormone-sensitive breast cancer get a hormonal drug \u2013 one that blocks estrogen from attaching to cell receptors and making cancer cells multiply \u2013 along with chemotherapy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The angle of the story is the drug company applying for approval in the US and Europe for its drug Tykerb as a first-line treatment for advanced breast cancer that is hormone sensitive..", "answer": 1}, {"article": "Abraham is a consultant for the company.\nThe research team tested the safety and effectiveness of a transvenous phrenic nerve stimulator made by Respicardia Inc. Much like a pacemaker, it sends a regular signal telling the diaphragm to breathe during sleep.\n\"Not only did we see this reduction in events per hour, the patients also rated themselves better on the Epworth Sleepiness Scale (meaning they were less sleepy during the day) and on a global assessment of their overall quality of life,\" Abraham said.\nUnlike the more common obstructive sleep apnea, in which the airway partially collapses and causes pauses in breathing, central sleep apnea (CSA) occurs when the brain fails to control breathing during sleep.\n\"This tells us the effects of neurostimulation are clinically relevant and this could be a promising therapy for those with central sleep apnea.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The implant was made available to patient volunteers through a clinical trial, and that\u2019s an implication to savvy readers that the device isn\u2019t available to the general public. But there\u2019s no clear indication of whether the device is on the market or not. The news release should have stated that it is not generally available and it is unknown if major payers will cover it if it ever comes into wider use.", "answer": 0}, {"article": "The rate for 413 volunteers given placebo treatment was 7.7 percent.\nA second infection study, also reported in the journal, found that a chlorhexidine-alcohol combination produced 41 percent fewer surgical-site infections as the commonly used mixture of povidone and iodine, which gives a yellow-orange tinge to the skin.\nIn a commentary, Dr. Richard Wenzel of the Virginia Commonwealth University in Richmond said the chlorhexidine-alcohol mixture should replace the older disinfectant when scrubbing people for surgery, and the nasal disinfection technique should primarily be used for people undergoing cardiac surgery, receiving an implant, or whose immune system is likely to be affected.\nThe 504 patients treated with the antibiotic nose gel mupirocin, also known as Bactroban, and washed with chlorhexidine, a common ingredient in mouthwash, developed an S. aureus infection 3.4 percent of the time.\nThe new study, published in the New England Journal of Medicine, used a rapid test to identify which patients, most of whom were scheduled to undergo surgery, had the bacteria in at least one nostril.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability is not discussed. The story should have noted that the resources used in the Bode study are currently available in US hospitals, just not routinely applied. We think this should have been noted in the story. ", "answer": 0}, {"article": "Toni Weiser is a veteran of skin-cancer removals. The 75-year-old retired teacher in Santa Fe, N.M., says she\u2019s had at least eight basal and squamous cell cancers scraped, frozen and surgically excised from her arms, face and shoulders.\n\nWhen a basal-cell cancer reappeared on Mrs. Weiser\u2019s nose last year, her dermatologist suggested a new, painless, nonsurgical treatment and she eagerly agreed. After 16 treatments with a small radiation device held millimeters from her nose, the tumor was gone. \u201cI felt nothing\u2014just some mild...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story discusses Medicare and private insurance coverage for the procedure, and that description gives readers some insight as to availability. \u201cAs of now, Medicare covers eBx in 21 Western and Midwestern states. It covers the treatment on a case-by-case basis in Texas and the South and doesn\u2019t cover it in Florida or New England, where it is more difficult to find. Private insurance coverage also varies.\u201d", "answer": 1}, {"article": "Revenues from pharmaceutical and device corporations and health insurance providers are available at http://www.\nPrevious separate studies have shown that a Mediterranean diet reduces certain risk factors for cardiovascular disease, as does a vegetarian diet; however, this was the first study to compare effects of the two distinct eating patterns\n\nCurrent study authors said they wanted to evaluate whether switching to a lacto-ovo-vegetarian diet would also be heart-healthy in people who were used to eating both meat and fish.\nThe study included 107 healthy but overweight participants, ages 18-75, who were randomly assigned to follow for three months either a low-calorie vegetarian diet, which included dairy and eggs, or a low-calorie Mediterranean diet for three months.\nStill, \"the take-home message of our study is that a low-calorie lacto-ovo-vegetarian diet can help patients reduce cardiovascular risk about the same as a low-calorie Mediterranean diet,\" Sofi said.\n\"To best evaluate this issue, we decided to compare a lacto-ovo-vegetarian diet with a Mediterranean diet in the same group of people,\" said Francesco Sofi, M.D., Ph.D, lead study author and professor of clinical nutrition at the University of Florence and Careggi University Hospital in Italy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release didn\u2019t specifically address availability.\u00a0 We do acknowledge that while different fruits and vegetables are limited in different parts of the world, it is feasible to adopt a Mediterranean style or vegetarian style diet almost anywhere by substituting some vegetables and protein sources for others.", "answer": 2}, {"article": "event of the year.\u201d\n\n\u201cIf everything checks out,\u201d Jami Rubin of Goldman Sachs said in an interview, \u201cthat will confirm in our minds that Eliquis has potential to take a majority share of the $10 billion anticoagulation market.\u201d\n\nMore than 2.6 million people have atrial fibrillation in the United States, according to the Centers for Disease Control and Prevention.\nThe first new drug, Pradaxa, from the German drug maker Boehringer Ingelheim, was introduced in the United States last fall.\nThe drug acts on an enzyme that leads to blood clots.\nThere is great appeal and demand for new drugs that do not vary so much and deliver the same stroke-preventing benefits.\nAs many as 12 million people will have it by 2020 because of an aging population with longer life expectancy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story opened by indicating that Eliquis (apixabane) was experimental and closed by indicating the expectation of submission to the FDA for approval.", "answer": 1}, {"article": "\u201cHe said, \u2018Doc, give me what I got last time.\nIts potential effects on depression were discovered in animal experiments in the late 1980s and early 1990s showing that glutamate, a brain chemical messenger, might play a role in depression, and that drugs including ketamine that target the glutamate pathway might work as antidepressants.\nExactly how ketamine works is unclear, but one idea is that by elevating glutamate levels, ketamine helps nerve cells re-establish connections that were disabled by depression, said ketamine expert Dr. Carlos Zarate, chief of experimental therapies at the National Institute of Mental Health.\n\u201cIt truly has revolutionized the field,\u201d changing scientists\u2019 views on how depression affects the brain and showing that rapid relief is possible, said Yale University psychiatrist Dr. Gerard Sanacora, who has done research for or consulted with companies seeking to develop ketamine-based drugs.\n(AP Photo/Teresa Crawford)\n\nCHICAGO (AP) \u2014 It was launched decades ago as an anesthetic for animals and people, became a potent battlefield pain reliever in Vietnam and morphed into the trippy club drug Special K.\n\nNow the chameleon drug ketamine is finding new life as an unapproved treatment for depression and suicidal behavior.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that ketamine is widely available for treating depression \u2014 at \u201cabout 150 US. ketamine clinics,\u201d although it has not been approved by the FDA for that purpose.", "answer": 1}, {"article": "Treatment typically involves the use of inhaled steroids and bronchodilators to open airways and make breathing easier.\nThe study showed that acupuncture may improve stomach function, making it easier for people with COPD to eat a healthy diet and maintain a normal weight.\nCOPD is the umbrella term for chronic lung diseases, including chronic bronchitis and emphysema.\nIt is often marked by a chronic cough and shortness of breath.\nThose who received acupuncture along with their daily medication for three months were able to walk longer without becoming breathless, compared to those who got the sham acupuncture treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story does mention that patients \u201cmust choose a licensed and experienced acupuncturist,\u201d it does not detail how many of those professionals practice in the US.", "answer": 0}, {"article": "2014;157(4):799-806.\nBased on published data, the efficacy and safety endpoints in these trials compared favorably to other formulations of cyclosporine A with the advantage of early onset.\nJerry St. Peter, Vice President and Head of Sun Ophthalmics, added: \"A key strategic imperative for our ophthalmic business is to participate in the rapidly growing, underserved, and dynamic Dry Eye market, which is expected to reach $5 billion by 2020.\n[7] Based on this successful confirmatory Phase 3 trial, Seciera\u2122 has the potential to strengthen our emerging ophthalmics pipeline, which includes the recent launch of BromSite\u2122 and late stage development programs for Xelpros\u2122 and DexaSite\u2122.\"\n[1]\n\nAccording to Dilip Shanghvi, Managing Director, Sun Pharma, \"We are happy to see the early onset of action and strong efficacy results for Seciera\u2122.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This was another close call. We\u2019ll rate this category satisfactory since the release reports on a phase 3 trial, which means the product is not yet available to the public, and a Sun Pharma executive is quoted as saying, \u201cWe look forward to discussing these results with US FDA and agree on next steps for the program.\u201d\u00a0 FDA approval is prerequisite on a product\u2019s availability to the public.", "answer": 1}, {"article": "MONDAY, Nov. 5, 2012 (HealthDay News) -- An experimental drug may help patients who can't tolerate statins lower their cholesterol, a new Australian study suggests.\nMore trials need to be done of this unique treatment, she added.\n\"In this phase 2 study, the results are certainly impressive and warrant further investigation,\" Ong said.\nThey received injections of a placebo or different doses of AMG145, which is a human monoclonal antibody.\nThe American Academy of Family Physicians has more about cholesterol-lowering drugs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that the drug is experimental.", "answer": 1}, {"article": "\u201cThe high degree of certainty in one report and the extreme caution in the other,\u201d said Rebecca Goldberg, a senior scientist with Environmental Defense, an advocacy group, \u201cwill make people more confused than ever.\u201d\n\nTo the surprise of Institute of Medicine officials, NOAA sponsored the hastily called press conference at which the Harvard report was released, even though that study conflicted with the one prepared by the institute.\nThe two studies, which conflict in important aspects, seem unlikely to provide much clarity.\nto eat tuna,\u201d Ms. Houlihan said.\nBoth reports have come under criticism from environmental groups and from the Consumers Union.\n\u201cWe\u2019re just trying to make consumers feel good,\u201d said William T. Hogarth, assistant administrator for fisheries of the National Marine Fisheries Service, part of NOAA.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There isn't any doubt about the availability of fish.", "answer": 1}, {"article": "Hoberman is chief of the general academic pediatrics division at Children's Hospital of Pittsburgh of UPMC.\nThe children ranged in age from 9 months to 23 months, and were randomly selected to receive either a standard 10-day course of antibiotics or a shortened five-day course of antibiotics followed by five days of placebos.\n\"Though we should be rightly concerned about the emergence of resistance overall for this condition, the benefits of the 10-day regimen greatly outweigh the risks,\" he added.\nWhat's more, the children in the five-day group didn't have a lower risk of antibiotic resistance or of side effects such as diarrhea or diaper rash.\nAbout three-quarters of children have ear infections in their first year of life.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story just generally refers to the drugs used as \u201cantibiotics\u201d making it unclear what specific drug was studied. Without that information, availability is impossible to even infer.", "answer": 0}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\nOAK BROOK, Ill. - An MRI breast imaging technique that requires no contrast agent, combined with sophisticated data analysis, could reduce the number of unnecessary breast biopsies, according to a new study appearing online in the journal Radiology.\n\"Diffusion kurtosis imaging has been introduced in DWI to provide important information on tissue structures at a microscopic level,\" said study lead author Sebastian Bickelhaupt, M.D., from the German Cancer Research Center in Heidelberg, Germany.\nShould the results hold in larger trials, the model has potential advantages in the clinic beyond its ability to reduce unnecessary biopsies in women with BI-RADS 4 lesions.\n\"Since malignant lesions disrupt the tissue structures at this level, diffusion kurtosis might serve as a relevant marker of changes.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This report is based on a retrospective study early in the process of testing the new imaging procedure. It is too early to comment on availability. Also, it appears this study was conducted in Europe so it\u2019s unclear if the algorithm would become available to use in US clinics.", "answer": 2}, {"article": "That's when they learned cocoa compounds named epicatechin monomers enhanced beta cells' ability to secrete insulin.\nBut here's the thing: BYU researchers have discovered certain compounds found in cocoa can actually help your body release more insulin and respond to increased blood glucose better.\n\"These results will help us get closer to using these compounds more effectively in foods or supplements to maintain normal blood glucose control and potentially even delay or prevent the onset of type-2 diabetes,\" said study co-author Andrew Neilson, assistant professor of food science at Virginia Tech.\n\"You probably have to eat a lot of cocoa, and you probably don't want it to have a lot of sugar in it,\" said study author Jeffery Tessem, assistant professor of nutrition, dietetics and food science at BYU.\n\"The epicatechin monomers are making the mitochondria in the beta cells stronger, which produces more ATP (a cell's energy source), which then results in more insulin being released.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Readers of the entire release are told that this work is an early step toward developing compounds for testing. However, the headline, lead paragraphs and images (featuring Hershey\u2019s bars) all conspire to imply that the researchers looked at chocolate found on candy shelves.\nCocoa is widely available, the compound being investigated in this study is not, and the\u00a0researchers\u00a0don\u2019t give any idea about how hard it is to extract it.", "answer": 0}, {"article": "Arterburn and Simon's coauthors are GHRI Senior Investigator Denise M. Boudreau, PhD, Research Project Management Director Emily O. Westbrook , Programmer Analyst Mary Kay Theis, and Andy Bogart; Tamar Sofer, PhD, a biostatistician at the UW School of Public Health and post-doctoral research fellow at Harvard University; and Sebastien Haneuse, PhD, an associate professor of biostatistics at the Harvard T.H.\nBupropion is often used to help patients stop smoking.\n\"All other antidepressants are linked to varying degrees of weight gain.\"\nChan School of Public Health, who used to work at GHRI.\nGovernment and private research grants provide its main funding.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that all of the antidepressants are available and approved.", "answer": 1}, {"article": "But you can't make any conclusions about definite health benefits\" based on the study findings, said lead author Suzanna M. Zick, a naturopathic physician and research associate professor at University of Michigan Medical Center, Ann Arbor.\nThe researchers found that the level of inflammation in the subjects who took the ginger pills fell by an average of 28 percent, while staying about the same in those who took the placebo.\nIt's already clear that people with inflammatory conditions such as inflammatory bowel disease are at higher risk of colon cancer, he noted.\nIf more funding becomes available, the researchers hope to launch a larger study, Zick said.\nThe amount of ginger in the pills is equivalent to 20 grams of raw ginger root, the authors said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says ginger is found in supplements and in many foods. The availability of ginger supplements is implied elsewhere in the story.", "answer": 1}, {"article": "The latest health and science updates, breakthroughs, research, and the best in investigative and informative journalism.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned the availability of the products discussed.", "answer": 1}, {"article": "(CNN) A new blood test may be as accurate as a test requiring a painful spinal tap for differentiating Parkinson's disease from similar disorders, according to a study published Wednesday in Neurology, the medical journal of the American Academy of Neurology.\nAccording to Dr. Paul Wright, chairman of neurology at North Shore University Hospital in Manhasset, New York, and Long Island Jewish Medical Center in New Hyde Park, New York, the importance of this study is that it brings to light that there are new biomarker tests that can delineate between these neurological diseases.\nThough atypical parkinsonism conditions look very similar to Parkinson's at first, they \"have a different underlying molecular cause,\" according to Bronstein, and so it is important to recognize them early in order to treat them properly.\nWhen validating a new biomarker for disease, \"one should always analyze at least two different (groups of patients and controls) to make sure that the results are reproducible,\" said Hansson, who added that participants should also include both early- and late-stage patients established at different clinics.\nYet patients with atypical disorders \"usually have a much worse prognosis, with faster disease progression, (with) more disabling symptoms\" than Parkinson's patients, so early identification is crucial.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Via the lead researcher\u2019s discussion of what the test may do in the future, the article implies that the blood test is not yet available.\nIdeally that hint should have been more explicit and perhaps accompanied by some details on what\u2019s left before this test becomes available.", "answer": 1}, {"article": "and some .\nThe technique has been shown to work better than a placebo, but the proportion of patients who show complete relief ranges widely, from as few as 10 percent to as many as 57 percent, according to various studies.\nThe treatment, which has been approved by the Food and Drug Administration, is covered by Medicare in five states, but few private insurers pay for it routinely.\nThe costs of ECT \u2014 typically about $3,300 for four weeks of thrice-weekly treatments, according to AHRQ data \u2014 are covered by most private insurers as well as by Medicare and Medicaid.\nMagnetic stimulation is aimed at patients with such \u201ctreatment-resistant depression.\u201d\n\nSupporters say rTMS is worth the cost \u2014 between $6,000 and $12,000 for the four-to-six-week treatment \u2014 because it enables people such as Curtis to resume productive lives.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that an rTMS device has been approved by the FDA and that availability of treatment is growing. It also explains that treatment usually is not covered by insurance, so patients are on the hook for the $6,000 to $12,000 cost of treatment.\nStill, availability is very limited in most parts of the country", "answer": 1}, {"article": "WASHINGTON -- A new study shows patients taking the anticlotting drug Plavix along with a type of drug used to block stomach acid have an increased risk of a subsequent hospitalization for heart trouble.\n\nThe study, which is being published in this week's Journal of the American Medical Association, adds to other recent studies that suggest proton pump inhibitors like Aciphex, Nexium, Prevacid and Protonix reduce the effectiveness of Plavix, which is marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis SA.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that these drugs have been and continue to be readily available to patients.\u00a0", "answer": 1}, {"article": "CHICAGO (Reuters) - The common diabetes drug metformin may hold promise as a way to keep smokers from developing lung cancer, U.S. researchers said on Wednesday.\nThey treated the mice with metformin either orally or with an injection.\nMetformin has been shown to switch on an enzyme that blocks mTOR \u2014 a protein that helps tobacco-induced lung tumors grow.\nThe findings were so strong the team now wants to test it in smokers to see if it can keep then from developing tumors.\nOther studies have shown that metformin can cut diabetics\u2019 risk of pancreatic and breast cancers, and the latest finding now suggests it may defend the body against smoking-induced lung tumors.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says metformin \"is already widely used in people.\" ", "answer": 1}, {"article": "Epilepsy is a neurological disorder that disrupts electrical communication between neurons in the brain.\n(CNN) Cannabidiol, which is found in marijuana plants, reduced the number of convulsive seizures in children with a severe and often fatal epilepsy disorder, according to research published Wednesday in the New England Journal of Medicine .\n\"No one study decides an issue; the sample size is still relatively small (because this is a rare syndrome and so hard to study large numbers of cases) and the duration of treatment so far has been relatively short,\" Hall, who was not involved in the research, wrote in an email.\n\"After 3,800 years of cannabis use for epilepsy ... we finally have solid evidence,\" said Dr. Orrin Devinsky, lead author of the study and director of NYU Langone's Comprehensive Epilepsy Center.\nShe added that the new study is \"critically important\" for the epilepsy community, which believes a CBD-based medical product would be a first-in-class therapeutic option.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There is a significant section on availability of marijuana and marijuana-derived drugs. A reader can fairly easily infer that this intervention is not yet available.\nBut, as we noted in our news release review, \u201cThe FDA does, however, consider cannabidiol an investigational product for treating children with epilepsy and has \u201cexpanded access provisions\u201d that allow its use.\u201d\nThis would have been useful information to include in the story.", "answer": 1}, {"article": "Images on paint can display on the left, a cancer free mouse; image on right illustrates how the tumor paint shows cancerous cells even after the cancerous organ has been removed.\n\nWhen treating cancer with surgery, there's nothing as important as making sure that every last bit of the disease has been removed. That's not always possible, since tumors have nasty habits of embedding themselves within healthy tissue and of breaking away and spreading malignancies to other parts of the body. But Researchers at Seattle's Fred Hutchinson Cancer Research Center have come up with an innovative way of giving surgeons the upper hand against these wily tumors. They have created a molecular \"paint\" that coats cancer cells so doctors can see the wayward cells that they may otherwise miss.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned that testing of the \"paint\" described in the research would be expected to begin next year.\u00a0 Presumably these would be tests to determine effectiveness; before that there would need to be tests conducted to determine whether it is safe for use in humans.\nIt is not clear that the equipment (Xenogen IVIS-100 system) needed to visualize the \"paint\" in patients is available.\nIn general, the leap that is required from animal research to possible human application is not well explained. \u00a0", "answer": 0}, {"article": "\u201cWe expected to see some response, but I don\u2019t think we expected to see a 45% significant response,\u201d says Forde.\n\u201cTo give you some idea of how significant that is, with chemotherapy we normally see the same degree of response around 20% of the time.\u201d\n\nForde says that the strong response seen in people at the beginning of the disease could suggest that immunotherapies might be useful in re-training the immune system to fight cancer for long periods of time \u2014 possibly even a lifetime.\n\u201cThere is definitely a high unmet need,\u201d says Patrick Forde, assistant professor of oncology and associate member of the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, of the lack of effective treatments for lung cancer.\nThe medications target a protein called PD-1, its related PD-L1, or CTLA-4, which protect the body\u2019s cells from being killed by immune cells; because tumors are normal cells growing out of control, they take advantage of this molecular security blanket to avoid getting detected by immune cells.\n\u201cAnd while our study is only with 21 patients, the early indications from this study are very positive.\u201d\n\nTaken together, the results could fundamentally change the way lung cancer is treated, significantly improving people\u2019s ability to both hold off lung cancer for longer periods of time, as well as live longer with the disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says Keytruda is \u201calready approved for treating about 25% to 30% of people with advanced (non-small cell lung cancer) who have a certain genetic profile that makes their cancer vulnerable to the drug.\u201d\nMore generally it says that \u201ca series of checkpoint inhibitor drugs was first approved in 2011 initially for treating melanoma.\u201d\nThe story could have clarified whether additional FDA approvals are needed to expand uses of these drugs.", "answer": 1}, {"article": "Anderson estimates Jardiance could boost Lilly\u2019s earnings per share by 8 percent on average across 2016 to 2020.\nThe benefits were especially impressive because they added to protection that patients received from taking cholesterol fighters and other life-saving heart drugs, Zinman said.\nThe vast majority of those patients could be candidates for Jardiance, which costs over $4,000 per year, Morningstar analyst Damien Conover said.\nIn the study, patients taking Jardiance had a 38 percent reduction in cardiovascular death, including from heart attacks and strokes.\nZinman noted that Jardiance, like other SGLT2 drugs, causes weight loss and reduced blood pressure, besides lowering both blood sugar levels and body fat, and also reduces swelling, which all help the cardiovascular system.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that Jardiance was approved for use in the United States last fall, so it\u2019s clear that the drug is available.", "answer": 1}, {"article": "Most bills do allow parents to opt out, because the question remains: Where to make this decision - at the statehouse ... or your house.\nNot yet,\" Alexander says.\nKen Alexander understands.\n\"Even if you think you aren't at risk, you are,\" adds Audrey.\nBut some worry that may sends a mixed signal by protecting girls against a sexually transmitted disease while at the same time telling them they shouldn't have sex.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the FDA only recently approved the vaccine.", "answer": 1}, {"article": "Thus, we foresee an exciting, long term relationship that will benefit cancer patients and cancer research.\u201d\n\nIn December 2007, Hitachi was the first company in the U.S. to clear FDA Premarket Notification Special 510(k) for the \u201cPROBEAT\u201d system with its spot scanning irradiation technology.\nThe next-generation system \u201cPROBEAT\u201d, which comes with IMPT (Intensity Modulated Proton Therapy) and cone-beam CT, will have improved spot scanning capability in all 3 gantry-type treatment rooms, along with a fixed irradiation room dedicated to cancer research.\nThis collaboration, which includes a 10-year maintenance service, marks the first multi-room PBT application in the nation\u2019s capital.\nToshiaki Higashihara, President & COO of Hitachi, Ltd. stated that, \u201cWe are greatly honored that Johns Hopkins selected Hitachi as their proton partner.\nUnlike conventional scattering technology, spot scanning technology delivers narrow beams to the tumor and the complex tumor shape can be irradiated through repetitive beam delivery with quick position change.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Several PBT systems are under construction in Washington, DC, proper and within the region. The release did not establish when the newly announced facility is expected to be ready or when those other facilities will be ready. The availability of proton therapy outside the DC area is not discussed.", "answer": 0}, {"article": "\"The issue of exercise-induced bronchospasm is real -- but if you use your releaver medication, blue puffer, before you exercise, and then take the time to cool down afterwards, you should be okay,\" he says.\nMany report having poor control of their symptoms.\nEven the smallest amount of activity is beneficial.\"\nThat's a message Bacon hopes resonates.\nOnly 100 said they engaged in the optimal 30 minutes a day.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of exercise is not in question.", "answer": 2}, {"article": "Anticipating wide interest in the psilocybin research from scientists, clinicians and the public, the journal solicited 11 commentaries to be co-published with the study results written by luminaries in psychiatry, palliative care and drug regulation, including two past presidents of the American Psychiatric Association, a past president of the European College of Neuropsychopharmacology, the former deputy director of the U.S. Office of National Drug Control Policy, and the former head of the U.K.\n\"The most interesting and remarkable finding is that a single dose of psilocybin, which lasts four to six hours, produced enduring decreases in depression and anxiety symptoms, and this may represent a fascinating new model for treating some psychiatric conditions,\" says Roland Griffiths, Ph.D., professor of behavioral biology in the Departments of Psychiatry and Behavioral Sciences and of Neuroscience at the Johns Hopkins University School of Medicine.\n\"Before beginning the study, it wasn't clear to me that this treatment would be helpful, since cancer patients may experience profound hopelessness in response to their diagnosis, which is often followed by multiple surgeries and prolonged chemotherapy,\" says Griffiths.\nIn a small double-blind study, Johns Hopkins researchers report that a substantial majority of people suffering cancer-related anxiety or depression found considerable relief for up to six months from a single large dose of psilocybin -- the active compound in hallucinogenic \"magic mushrooms.\"\nThe study was funded by grants from the Heffter Research Institute, the RiverStyx Foundation, William Linton, the Betsy Gordon Foundation, the McCormick family, the Fetzer Institute, George Goldsmith, Ekaterina Malievskaia and the National Institute on Drug Abuse (R01DA03889).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is not clear from the release whether psilocybin treatment is currently available, or what the short- or long-term prospects are for psilocybin treatment availability.\nPsylocybin is categorized as a Schedule 1 drug by the Drug Enforcement Administration and its availability is tightly controlled. There is a precautionary note in the release,\u201d\u2026they do not recommend use of the compound outside of such a research or patient care setting.\u201d \u00a0But given the availability of \u201cmagic mushrooms\u201d and the availability of DIY instructions on identifying and growing same, we think that some additional comments would have been worthwhile.", "answer": 0}, {"article": "Bathing-suit season is here and with it, anxiety over cellulite. A new laser device that burrows under the skin is getting praise from some doctors who say it gives more dramatic and longer-lasting results than previous treatments, but others caution that more research is needed.\n\nCellulite is a dimpled, uneven appearance of skin caused by fat underneath. It affects some 85% of women and about 5% of men. Until recently, the main treatments to battle cellulite have been external treatments such as creams and radio-frequency and...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that the laser approach \u201chit the US market in February.\u201d", "answer": 1}, {"article": "Frustrated by the high relapse rate of traditional addiction treatments, scientists are working on a strategy that recruits the body's own defenses to help addicts kick drug habits.\n\nThe new approach uses injected vaccines to block some addictive substances from reaching the brain. If a vaccinated addict on the path to recovery slips and indulges in a drug, such as tobacco or cocaine, no pleasure will result.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article helpfully states that \u201cIt could be years, if ever, before any vaccines to treat addiction reach the market.\u201d The article does a good job of describing how far along the various experimental vaccines mentioned in the article are in their development.", "answer": 1}, {"article": "Others need regular exposure to milk in order to maintain protection against allergic reactions.\nIt's still in the early stages, but Dr. Robert Wood of Johns Hopkins, who has been on the forefront of food allergy research, estimates the treatment could be brought to the public within six to eight years.\nResearchers are separately looking at a drug called omalizumab (Xolair), approved by the U.S. Food and Drug Administration for the treatment of severe asthma, to see if it could help people with food allergies, too.\nSome children are allergic to many foods, and it's impossible to know based on preventive testing whether someone will have a mild or severe reaction.\n\"With milk that\u2019s not too hard,\" Wood says, because one could \"eat pizza a couple of times a week.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As noted, the story made it clear that this is preliminary research and that the approach \u201cmay one day\u201d be available.\nThen the story quoted the researcher estimating that \u201cthe treatment could be brought to the public within six to eight years.\u201d\nThis is not entirely accurate, as oral immunotherapy for food allergies (including milk allergy) is currently being administered clinically by a handful of physicians. The concept behind the treatment (basically, exposing patients to food proteins) is not FDA regulated, and so there is theoretically no barrier to physicians offering this type of therapy to their patients. Citing the potential for adverse reactions and other concerns, however, most experts say that it is much too soon to use oral immunotherapy outside of a research setting. And so the story\u2019s bottom line message about availability is correct for the vast majority of patients. Still, the estimate of availability \u201cwithin 6 to 8 years\u201d may cause confusion to parents who have heard, via allergy blogs or other media sources, that it is already available.", "answer": 0}, {"article": "\u2022 This is the first time tandospirone has be shown to reverse the deficit in brain neurogenesis induced by heavy alcohol consumption\n\u2022 The researchers also showed in mice that the drug was effective in stopping anxiety-like behaviours associated with alcohol withdrawal, and this was accompanied by a significant decrease in binge-like alcohol intake\n\n\"This is a novel discovery that tandospirone can reverse the deficit in neurogenesis caused by alcohol,\" said study leader neuroscientist Professor Selena Bartlett from QUT's Institute of Health and Biomedical Innovation.\n\"This drug is relatively new and available only in China and Japan.\n\"This is not just another drug that shows promise in helping to reduce binge drinking,\" she said.\nIt is commonly used there and shown to be highly effective in treating general anxiety and well tolerated with limited adverse effects.\"\n\"We know that with heavy drinking you are inhibiting your ability to grow new neurons, brain cells.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release clarifies that \u201cThis drug is relatively new and available only in China and Japan.\u201d", "answer": 1}, {"article": "For more information, visit http://www.\nPatients using this therapeutic are asked to identify an emotion displayed in a series of faces, and for each face, they are asked to identify the number of faces earlier in the series in which they encountered the same emotion.\nThis aims to balance brain activity in these regions to work in concert with each other.\nDr. Iacoviello added, \"We will be advancing these encouraging results to the next level, by incorporating this therapeutic into a highly engaging mobile platform and launching it through the CNI platform.\nThe initial results demonstrate that the efficacy of this digital therapeutic is comparable to drug therapy, with a highly favorable safety profile.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Because the release is about a new therapy, we assume it is not available outside of a clinical study yet.", "answer": 2}, {"article": "(Reuters) - Shares of Evofem Biosciences Inc jumped as much as 38 percent on Monday after its birth control gel showed effectiveness in a late-stage study, bringing the first hormone-free contraceptive close to approval.\nThe rate stands at about 91 percent for oral pills and intrauterine devices, according to brokerage Roth Capital Partners.\nCondoms, the most common non-hormonal method of contraception, have an efficacy rate of 82 percent.\nAn estimated 16.5 million women in the United States do not use any method of contraception, according to the company, on fear of side effects, leaving them highly susceptible to unwanted pregnancies and sexually transmitted diseases.\nThe company plans to resubmit the marketing application for Amphora in the second quarter next year and if approved, plans to launch the product in January 2020.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that this a product under development, not yet approved or marketed.", "answer": 1}, {"article": "Current treatments target the immune cells involved in the disease and none are specific for FLS.\n\"Here, we investigated whether this venom component, called iberiotoxin, would be able to specifically block the FLS potassium channel and reduce the severity of the rheumatoid arthritis in rat models of the disease.\"\n\"We think that this venom component, iberiotoxin, can become the basis for developing a new treatment for rheumatoid arthritis in the future.\"\n\"Although these results are promising, much more research needs to be conducted before we can use scorpion venom components to treat rheumatoid arthritis,\" Beeton said.\nOther contributors of this work include Michael W. Pennington, Brayden H. Chamberlain, Redwan Huq, Elizabeth J. Gehrmann, Teresina Laragione and P\u00e9rcio S. Gulko.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release makes it clear that scorpion venom isn\u2019t available yet as a treatment with this researcher\u2019s quote: \u201cWe think that this venom component, iberiotoxin, can become the basis for developing a new treatment for rheumatoid arthritis in the future.\u201d But since the drug is available through Peptide International it is possible that some people may try to get it from the company and try it.", "answer": 1}, {"article": "For more information about the AACR, visit http://www.\nIn addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers.\nIn an interview, Sakoda said, \"Metformin use was not associated with lung cancer risk when we looked at all patients with diabetes.\nSome laboratory studies and a number of observational studies suggest that metformin may prevent cancer, but the data from human studies, however, are conflicting, explained Sakoda.\nAmong nonsmokers who had diabetes, those who took the diabetes drug metformin had a decrease in lung cancer risk, according to a study in Cancer Prevention Research, a journal of the American Association for Cancer Research, by Lori Sakoda, PhD, MPH, research scientist at the Kaiser Permanente Division of Research in Oakland, California.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not directly address the availability of metformin. However, it\u2019s apparent that the drug is available, since thousands of people in the study have been taking it for years.", "answer": 1}, {"article": "They\u2019re also studying the cost difference.\n\u201cWe are actually not surprised that there isn\u2019t a big difference between the two because both therapies are effective at relaxing the overactive bladder muscles.\u201d\n\nWomen can choose between a surgical procedure, which is more expensive at first, versus regular Botox injections, which are less costly and less invasive but which could add up over time, Amundsen said.\nThe Botox injections freed 20 percent of the women in the study of incontinence, compared to 4 percent who had a nerve stimulator implant, Amundesen and colleagues reported in the Journal of the American Medical Association.\n\u201cPregnancy, childbirth, menopause, and the structure of the female urinary tract account for this difference.\u201d\n\nThe researchers at nine medical centers did a head to head comparison of a single Botox injection to the implanted medical device, assigning 381 women to randomly get one or the other treatment.\nOn average, both treatments cut the number of \u201caccidents\u201d \u2013 Botox by almost four times a day and the nerve stimulator by about three times a day.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both of these treatments are widely available. But,\u00a0a description of the procedures themselves would have been helpful (they are both quite invasive and require seeing providers with special training). While \u2018regular\u2019 Botox cosmetic treatments can be easily given by various medical professionals, without specialized training, in the office, this may not be the case for Botox injections into the bladder.", "answer": 1}, {"article": "\"The idea is when you get the treatment and it is successful and the pain gets better then you can start cutting down the on the medication, and see how low you can go\" said Dr. Richard Cruciani.\nIt's called TDCS, Transcranial Direct Current Stimulation.\nHe says his pain drops significantly after therapy and then slowly returns over time.\n\"I take about 35 pills a day,\" he said.\n\"That's the hope,\" says Lapook.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The segment states that transdermal direct current stimulation (TDCS) is still in clinical trials. ", "answer": 1}, {"article": "While the value of CT scans for screening remains the focus of debate, no one questions the value of the tests for allowing doctors to quickly diagnose a wide variety of health problems, including head injuries, heart problems, cancer, appendicitis, fractures and gallstones.\nThese are X-rays from a CT scan.\nThose are X-rays that the folks at Hiroshima and Nagasaki got.\n\"Now if you go into an emergency room you can be scanned in a few minutes.\n\"It's apples and oranges.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly CT scans are available.", "answer": 1}, {"article": "Though the findings are correlational, walnuts are uniquely high in omega-3 and omega-6 fatty acids, which may be of particular value in Type 2 diabetes prevention.\n\u201cThis is the first on walnuts and diabetes.\nPrevious studies have suggested an inverse relationship between tree nut consumption and diabetes.\nBeginning in 1999 they collected data on walnut consumption, and followed the women for the next 10 years.\nEating walnuts may reduce the risk for Type 2 diabetes in women, a large new study concludes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of walnuts is not in question.", "answer": 2}, {"article": "Reduction in high blood pressure has added health benefits because it can potentially reduce the likelihood of heart attacks, strokes, chronic heart failure and kidney disease.\nThe study also measured changes in risk scores of developing heart disease and stroke in the next 10 years, diastolic blood pressure, dietary changes, smoking cessation, cholesterol levels excluding the good cholesterol (HDL) and pulse pressure, which is the difference between the higher and lower (diastolic) numbers on the blood pressure reading.\nIn part, most of the studies here today show what to do \u2014 not how to achieve it,\u201d said Eric Peterson, a professor at Duke University School of Medicine and an associate editor of the Journal of the American Medical Association, during the conference.\nThe study is very useful in telling and confirming that we should talk to the patients, no matter how we do it,\u201d said Bernard Wong, a cardiologist based in Hong Kong.\nThe randomized, double-blind study included 264 participants with an average age of 58, of whom 58 percent were women.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t address the availability of the web-based program.\u00a0Because high blood pressure\u00a0is so common, we think it would have been useful for the story to address when or if this technology will become widely available.", "answer": 0}, {"article": "A small new study published in suggests that one easy way for older adults to get deeper sleep and stronger memories is to listen to a certain soothing sound called \u201cpink noise\u201d\u2014a mix of high and low frequencies that sounds more balanced and natural than its better-known cousin, \u201cwhite noise.\u201d\n\nIt may sound strange, but previous studies have found that playing so-called pink noise during sleep improves the memory of younger adults.\n\u201cIt\u2019s just noticeable enough that the brain realizes it\u2019s there, but not enough to disturb sleep.\u201d The sounds were timed to match their slow-wave oscillations.\n\u201cThat\u2019s very much tied to what part of the slow wave the stimulus is hitting on.\u201d\n\nThat doesn\u2019t mean there aren\u2019t benefits to other soothing background sounds.\nOn one of those nights, headphone-clad participants were played a series of short bursts of pink noise during deep sleep, spaced out enough to prevent the brain from getting used to and ignoring them.\nBut first, says Zee, larger and longer studies are needed to confirm the findings and show that there are benefits to long-term use, rather than on just one night.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that a pink noise generator timed to slow wave sleep is not yet available. The article does mention (parenthetically) that pink noise apps exist.", "answer": 1}, {"article": "The DAWN trial included trial locations in the United States, Spain, France, Australia and Canada.\n\"Our research and clinical teams are immensely proud of these breakthrough findings, which are so profound they will likely result in a paradigm shift that will not be seen again for many years in the field of stroke therapeutics,\" says Michael Frankel, MD, professor of neurology, Emory University School of Medicine, chief of neurology and director of the Marcus Stroke and Neuroscience Center for the Grady Health System.\n\"These findings could impact countless stroke patients all over the world who often arrive at the hospital after the current six-hour treatment window has closed,\" says co-principal investigator Raul Nogueira, MD, professor of neurology, neurosurgery and radiology at Emory University School of Medicine and director of neuroendovascular service at the Marcus Stroke & Neuroscience Center at Grady Memorial Hospital.\n\"Looking at the physiological state of the brain and evaluating the extent of tissue damage and other clinical factors seems to be a better way to decide if thrombectomy will benefit patients as opposed to adhering to a rigid time window,\" says Nogueira.\nThe international multi-center clinical study, known as the DAWN trial, randomly assigned 206 stroke victims who arrived at the hospital within six to 24 hours to either endovascular clot removal therapy, known as thrombectomy, or to standard medical therapy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "In this case, availability has to do with whether hospitals offer this procedure. Since the procedure is already part of standard practice we\u2019ll rate this Satisfactory, even though it\u2019s not explicitly stated.", "answer": 1}, {"article": "The procedure, called a prostatic urethral lift, does not improve flow as much as surgery, in which a physician cuts away some of the inside of the prostate to allow better flow. But the lift procedure and recovery are much quicker, with no hospital stay and fewer complications. And patients who get the sutures can always come back for surgery later.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We learn that \u201cthe first patients were treated in Australia by the end of 2005. Initial clearance from the U.S. Food and Drug Administration did not come until 2013, but now more than half of the 30,000 patients treated to date are in this country,\u201d according to the manufacturer\u2019s chief executive officer Dave Amerson.\nThe story would have been stronger if it had discussed how many\u00a0urologists can do the procedure.", "answer": 1}, {"article": "\"The bottom-line finding of the Alpha Omega Trial is that [omega]-3 fatty acids did not reduce the primary endpoint major cardiovascular events,\" Kromhout said, noting that the ALA finding needs further confirmation.\nThe amount of supplementation added to the various margarines was deemed to be \"low-dose.\"\nAt the study's start, the patients were instructed to consume (over a period lasting a little over three years) one of four different types of margarines: one supplemented with omega-3 fatty acids; one supplemented with the plant-derived ALA; one supplemented with both omega-3 fatty acids and ALA; and one with no supplements.\nIn fact, neither low doses of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which are found in fish oil, nor of alpha-linolenic acid (ALA), derived from nuts and several vegetable oils, provided any benefit to the vast majority of heart patients, the study showed.\n\"But here, in some cases the patients they looked at are years following their first heart attack when they start taking these supplements,\" he stressed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story was not clear that the margarines used in the study reported on were formulated specifically for use in the study and are not commercially available.\u00a0 Nor did it explain \u2013 as other stories did \u2013 that there are similar products already on the market.", "answer": 0}, {"article": "\u201cDoes everybody need to practice at least 20 minutes a day three times a week?\n\u201cAt a certain point in time you learn what your back needs.\u201d\n\nAs an alternative to yoga, stretching may be a viable option.\n\u201cMore participants in the yoga and stretching groups were very satisfied with their overall care for back pain.\u201d\n\nDr. Sherman said that like many other therapies for low back pain, yoga probably would not work for everyone.\nThis is a much larger study, and the findings are robust.\u201d\n\nAbout four out of five people experience low back pain at some point in their lives, prompting Americans to spend $50 billion a year on medications, physical therapy and related costs.\nThe latest study, published in The Archives of Internal Medicine, involved more than 200 people who were followed for up to 26 weeks.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\n \nThe writer probably assumed that yoga classes and stretching programs are widely available across the United States. So we\u2019ll award a \u201csatisfactory\u201d here.\nBut it is not actually all that clear that similar \u201cviniyoga\u201d classes and intensive stretching programs are available in most communities\u2014or that physicians and patients can easily find them. And it is not clear to what extent they are covered by health insurance plans.\n", "answer": 1}, {"article": "For the study, the researchers followed 57,872 women in B.C.\nThe study, published today in the British Medical Journal Open, found that low-income pregnant women who receive care from a midwife compared to a physician are less likely to go into early labour, to have a baby with a low birth weight, or to have a small-for-gestational age birth, meaning a fetus or infant that is smaller or less developed than normal for the number of weeks in pregnancy.\n\"Our findings show that women who are more vulnerable benefit from the care of a midwife, likely because they receive more time, counselling and education on how to care for themselves,\" said the study's lead author Daphne McRae, a post-doctoral research fellow at the UBC school of population and public health who conducted the study while she was a PhD student at the University of Saskatchewan.\n\"Our research could help develop policies that make the service more accessible to low-income women,\" added senior author Nazeem Muhajarine, a professor in community health and epidemiology at the University of Saskatchewan and McRae's supervisor while she conducted the research.\nMidwives, general practitioners (GPs) and obstetricians (OBs) are all qualified to provide safe prenatal care for women during their pregnancy, labour and birth, but each offer a different style of care that matches different women's preferences and needs.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This was a strong point. The news release noted that midwifery is \u201cnot available in all parts of the country.\u201d\nIt added:\n\u201cWaitlists for midwives can be quite long, so women who are educated and health-conscious typically access midwives early on in their pregnancies,\u201d said [lead author Daphne] McRae. \u201cBut more vulnerable women might not be as aware of the services available to them, so expanding midwifery to make it available for all women is important.\u201d", "answer": 1}, {"article": "\u201cIt may provide more of a one-stop shop.\u201d\nThe developer, Ironwood Pharmaceuticals, said the drug, linaclotide, met all the goals in the first late-stage trial testing it as a treatment for the type of irritable bowel syndrome accompanied by constipation.\n\u201cThe exciting thing about the data on linaclotide is that it improves both of those symptoms,\u201d he said.\nAbout one-third of the cases involve constipation, another third diarrhea and the rest both constipation and diarrhea, according to Dr. William D. Chey, an expert at the University of Michigan.\nAs many as 20 percent of American adults have some symptoms of irritable bowel syndrome, according to the National Institutes of Health.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this is an experimental drug that is not yet approved by the FDA. It notes that the drug will have to succeed in another phase 3 trial before the manufacturer plans to submit an application for approval to the FDA. It doesn\u2019t speculate inappropriately about when the drug is expected to be approved.", "answer": 1}, {"article": "\"I\u2019m hoping this will help the women who need it.\u2019\u2019\n\nOne expert, Andrew Goldstein who runs the Sexual Wellness Center in Annapolis, Md., described a \"huge\u2019\u2019 unmet need for a medical treatment.\nThe findings show women who took the drug had more sex, wanted more sex and experienced less distress related to lack of desire.\nIn the area of sexual dysfunction, it may be the woman\u2019s turn for a break-through.\nIt could take two to three years to come to market in the United States, the company said.\nFor some, the new pill might be the answer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article accurately states that flibanserin is an experimental drug and is not FDA approved or commercially available.", "answer": 1}, {"article": "For example, over 6 years of follow-up, no ovarian cancer cases were seen among BRCA2 mutation carriers who underwent salpingo-oophorectomy, compared with 3 percent of carriers who did not undergo the procedure, the researchers report.\nRoughly half of the women in the study had undergone either mastectomies (surgery to remove their breasts) or salpingo-oophorectomies (surgery to remove the ovaries and fallopian tubes) between 1974 and 2008, in order to proactively lower their risk of cancer.\n\"One of the main messages of our study is that salpingo-oophorectomy should be part of any management plan for any woman who is found to have these genetic mutations,\" said Rebbeck.\nThe 22-center trial, one of the largest of its kind, studied nearly 2,500 women who were found to have inherited mutations in the BRCA1 or BRCA2 genes.\nWomen who carry these mutations have a lifetime risk of breast cancer of anywhere between 56 percent to 84 percent, according to the researchers, whereas the risk for ovarian cancer ranges from 36 percent to 63 percent for BRCA1 mutation carriers and 10 percent to 27 percent for BRCA2 mutation carriers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story does not mention that the type and quality of genetic testing, genetic counseling, surgery and surveillance offered to women in this study may not be available to women in other settings.", "answer": 0}, {"article": "\"Women should be informed that the benefit is smaller than expected, and there should be a balanced discussion on the benefit and the possible harms of screening, such as overdiagnosis, false-negative and -positive tests and psychological distress,\" said the study's lead author, Dr. Mette Kalager, an epidemiologist with the Cancer Registry of Norway in Oslo and a visiting scientist at the Harvard School of Public Health in Boston.\nThey both said that the time frame was insufficient to assess the effect of screening.\nThe difference in the rate of death from breast cancer among women in the screening group versus the control group was 28 percent.\n\"It's clearly muddying the waters,\" he said.\nBut since the advent of routine mammograms in the 1990s, the rate of death from breast cancer has dropped 30 percent, he observed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of mammograms is clear from the story. ", "answer": 1}, {"article": "A variation of a drug commonly given to cancer patients with bone damage appears to be an effective tool for preventing repeat hip fractures in elderly patients, according to a study in the New England Journal of Medicine.\n\nThe study results, which were to be presented yesterday in Hawaii, have potentially big implications because hip fractures are a common and debilitating injury for older people. Most of the 300,000 hip fractures each year in the U.S. are related to osteoporosis in older people, as well as falls, according...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that the company that produces the drug is planning on seeking FDA approval for a new indication.\u00a0 It also reported that the drug is currently available and used for the treatment of Paget\u2019s disease and for treating osteoporosis in wpmen after menopause.\nIt is noteworthy that this story accurately reported on both of these aspects about availability.", "answer": 1}, {"article": "First published on May 11, 2008 at 12:00 am\nThe 106-year-old Children's Institute (formerly called the Rehabilitation Institute) plans to fund the room through the $30 million capital campaign it launched in 2005, after buying out its Shady Avenue site from the University of Pittsburgh Medical Center.\n\"We know that the data for this is just emerging, but we feel it's a very safe intervention, and it's empowering for families and very reasonable,\" he said.\nHis findings are complicated, but basically blood tests show 70 percent of his autistic patients have zinc deficiencies (pointing to problems with processing heavy metals), and the vast majority also have immune system problems of varying kinds.\nBut we wonder -- we speculate -- that it's possible if we have children living in a unique environment that has not [previously] been created scientifically that we can make a difference.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The pollutant-free \"clean room\" experiment, designed to attempt to detoxify the bodies of young patients with autism, is in the conceptual\u00a0and fund-raising stages, which have\u00a0yet to be completed.\u00a0 This article does not indicate that the\u00a0experimental protocol will not likely be implemented in the near future and that it will not be available to autistic children who are not enrolled in the research study. ", "answer": 0}, {"article": "The oral drug targets an enzyme called Syk.\nNow Harvard researcher Michael E. Weinblatt, MD, reports results from a phase II clinical trial in which 457 patients with active rheumatoid arthritis despite methotrexate treatment received R788 or placebo for six months.\n\"Inhibition of the Syk pathway offers a new drug target for rheumatoid arthritis,\" Weinblatt and colleagues conclude.\nWeinblatt reports receiving grants, fees, or honoraria from a number of drug and biomedical companies, including Rigel.\nIt's not clear whether long-term use of R788 will increase cancer risk; longer-term clinical trials will have to evaluate this risk.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says up high that results from \"a pilot study\" showed that the drug\u00a0was promising in reducing the\u00a0symptoms of rheumatoid arthritis. It then says, \"Now Harvard researcher Michael E. Weinblatt, MD, reports results from a phase II clinical trial,\" making it clear that the drug is not currently available.", "answer": 1}, {"article": "New York Eye and Ear Infirmary of Mount Sinai is ranked No.\nPublished today in the Journal of Oncology Practice, the study also determined that a systemized process of referrals resulted in significant improvements in 30-day readmission rates, hospice referral, and receipt of chemotherapy after discharge in patients with advanced cancers.\n\u201cPalliative care involvement helps patients understand their prognosis, establish goals of care, and formulate discharge plans in line with those goals, and this study is the first to confirm the impact of using standardized criteria and automatic palliative care consultation on quality of cancer care.\u201d\n\nCo-authors of the study include Kerin Adelson, MD, Division of Hematology/Oncology at Yale University School of Medicine.\nThis is the first study to demonstrate that among advanced cancer patients admitted to an inpatient oncology service, standardized use of triggers for palliative care consultation is associated with substantial improvement on multiple quality measures.\nThe Mount Sinai Hospital is also ranked as one of the nation\u2019s top 20 hospitals in Geriatrics, Gastroenterology/GI Surgery, Cardiology/Heart Surgery, Diabetes/Endocrinology, Nephrology, Neurology/Neurosurgery, and Ear, Nose & Throat, and is in the top 50 in four other specialties.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although this piece makes it plain that palliative care has positive implications for cancer care, it doesn\u2019t tell readers what is currently happening at hospitals around the country. It assumes readers are already aware of palliative care availability but that may not always be the case.", "answer": 0}, {"article": "Newsday's coverage of the Class of 2019, led by Mariano Rivera and Mike Mussina.\nAt 14, MS-13 was his family.\nHere\u2019s how he got out.\nA former gang member recently recalled when he decided to join the gang.\nA hijab, a turban, a beard: What aren\u2019t you seeing?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Information on breast cancer is available at cancer.gov.\nAbout 1 of every 8 women in the United States will develop breast cancer at some point.\nAll were taking the medication at least three times a week.\nThose taking low-dose aspirin were 16 percent less likely to have developed any type of breast cancer, compared with women who took no NSAID.\nThose who take a daily low-dose aspirin, also called a baby aspirin, usually do so to prevent cardiovascular disease, the leading cause of death for women older than 25.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Low-dose aspirin is already widely available and is used by many women to reduce their risk of cardiovascular disease.", "answer": 2}, {"article": "NEW YORK -- Scientists acknowledged that an HIV vaccine recently tested in Thailand may be less effective than they originally suggested, but said it still provided valuable leads for further research.\n\nWhen first publicly disclosing the outcome of the vaccine trial in September, researchers said the vaccine had lowered the risk of infection by about 31%. That result was modest but statistically significant. Coming after two decades of failed HIV-vaccine trials, the announcement was welcomed by researchers around the world.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0This story makes it known that the vaccine is still in the testing phase and is not yet available.\u00a0 ", "answer": 1}, {"article": "\u201cSafety strategies while driving can include minimizing distractions, stopping at stop signs, respecting speed limits, yielding right-of-way, buckling a seatbelt, signaling all turns and not driving after drinking alcohol,\u201d Redelmeier said.\nExposure to bright light didn\u2019t appear to improve reaction times or sleepiness.\nBut light was associated with better driving.\nShift workers with chronic sleep deprivation also face an increased risk of accidents.\nNone of the people who slept at home crashed, and neither did any of the sleep-deprived people who got bright light therapy before getting behind the wheel, the study found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Light sources are readily available.", "answer": 2}, {"article": "Has he had any use of prescription painkillers since he started the study?\n\"They make you feel great; I'm not going to lie, you take a couple pills, you feel relaxed, you don't feel nervous, you have the weight of the world off your shoulders,\" said one young man named Brian who would not letreveal his identity.\nHere's how it works: When people are addicted, new receptors are created in the brain, which crave opioids.\nThe hope is one day that Suboxone can do for painkiller addiction that drugs like Prozac did for depression: convince the public that addiction is a brain disease, not a character flaw.\n\"When you're taking Suboxone, you're not high, you're not in withdrawal, you're at work, you're dealing with your loved ones, you're having regular interactions...you're going about your life,\" Gourevitch said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The segment states that Suboxone (sublingual buprenorphine) is available from \"any doctor, even a family physician.\" \nIt\u2019s a bit more complicated than that. In order to prescribe Suboxone, a physican without specialized training in addiction needs to be certified by submitting an application to the federal government, completing an 8-hour training course and meeting other criteria.\u00a0 \nThe segment is unclear about availability in a second case. The segment itself implies (correctly) that the drug is currently available. But then the host says the drug is currently in clinical trials. The physician-reporter\u2019s response does not clarify that these trials are for approval of an additional, specific use of the currently available drug. \u00a0", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070408/16healy.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It's clear that hormone therapy is readily available and has been for many years.", "answer": 1}, {"article": "\"It's clear that these medications are beneficial,\" said Wadden, who has been a paid consultant to pharmaceutical companies as well as Weight Watchers. \"Unfortunately, there's a sense that they must not work if you have to take them indefinitely. But I think obesity medications should be used on a long-term basis for chronic weight management, just as I take a [cholesterol-lowering] statin and a blood-pressure medication for the long term.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that there are a wide range of counseling activities that are available. The story also covers medications for weight loss and the fact that they are under-prescribed given the obesity\u00a0epidemic.", "answer": 1}, {"article": "Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.\n\nThe test, developed by closely held Epic Sciences Inc., San Diego, detects a mutation associated with a poor response to two new drugs, Xtandi from Medivation Inc. and Astellas Pharma Inc. of Japan, and Zytiga from Johnson & Johnson.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is made clear that the blood test is not currently available, and the article gives a prospective date for\u00a0when the test will be launched.", "answer": 1}, {"article": "I\u2019d rather have done 10 rounds with Mike Tyson.\u201d\n\nRichard Burt of Northwestern University in Chicago, who carried out the first HSCT for MS in 1995 and is coordinating the international trials, told the BBC: \u201cThere has been resistance to this in the pharma[ceutical] and academic world.\nThe treatment has traditionally been used to treat bone and blood cancers.\u201d\n\nBasil Sharrack, a consultant neurologist at Sheffield teaching hospitals NHS foundation trust, said: \u201cThe new treatment is showing some remarkable results in the small number of patients we have treated so far.\nI got my life and my independence back and the future is bright again in terms of being a mum and doing everything with Isla.\u201d\n\nTwo years after the treatment, she has had no relapses and there was no evidence of active disease on her scans.\n\u201cI couldn\u2019t dress or wash myself; I didn\u2019t even have the strength to carry my daughter.\u201d\n\nShe had needed a wheelchair before her transplant, but after the treatment she walked out of hospital.\nAt one point, I couldn\u2019t even hold a spoon and feed myself.\u201d\n\nWithin a few days of the transplant, he was able to move his toes, and after four months could stand unaided, although he still needs a wheelchair.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The reader must infer that, because the information comes from an ongoing clinical trial, the treatment is not yet available. And the story implies that it may be available outside of a research study: \u201cIt needs to be carried out at an accredited centre or as part of a clinical trial\u201d. Does this mean that if I have 30,000 pounds, I can have this done to me in the UK?", "answer": 0}, {"article": "A growing number of doctors are offering an expensive laser procedure they say zaps away a common fungus that causes ugly, discolored nails. Published data on laser treatment for nail fungus is scant, but early results suggest it is a reasonable option for people who don't want the side effects of oral medications.\n\nOnychomycosis, or fungal infection of nails\u2014most often on the toes\u2014affects about 12% of Americans, according to the American Academy of Dermatology. Some people are genetically prone to it. Others, including swimmers...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The \u201cgrowing number of doctors\u201d offering this procedure, the lack of insurance coverage, the FDA OK for one device and off-label use of others all address general availability issues.", "answer": 1}, {"article": "Chronic rhinosinusitis (CRS) affects a sizable minority -- 14 percent to 16 percent -- of U.S. residents.\n\"Some people with stage 1 and 2 diseases may even get cured.\nThis second finding is probably explained by the fact that people going for second or further surgeries were probably sicker to begin with, Josephson said.\nFollowing the surgery, about 76 percent of patients had \"clinically significant\" improvement in quality of life, as measured by various validated scales.\nThis is a wonderful renewed hope of feeling better.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that endoscopic sinus surgery has been used for a long time and the reader can infer that it\u2019s been in widespread use. ", "answer": 1}, {"article": "Ultrasound waves applied to the whole brain improve cognitive dysfunction in mice with conditions simulating vascular dementia and Alzheimer's disease.\nThe researchers conclude that their study, recently published in the journal Brain Stimulation, provides the first experimental evidence that whole-brain LIPUS therapy markedly improves cognitive dysfunctions without serious side effects by enhancing specific cells related to dementia's pathology.\nBut there are currently no curative treatments available for vascular dementia or Alzheimer's disease, the most common causes of dementia.\nThe team, led by cardiologist Hiroaki Shimokawa, found that applying low-intensity pulsed ultrasound (LIPUS) to the whole brain of the mice improved blood vessel formation and nerve cell regeneration without having obvious side effects.\nOther studies have reported that LIPUS increases the production of proteins involved in nerve cell survival and growth, in addition to a role in promoting nerve regeneration.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that clinical trials are underway, which tells us (not quite clearly) that the LIPUS treatment isn\u2019t yet available to the public.", "answer": 1}, {"article": "Related: De Niro says 'find the truth on vaccines'.\n\u201cWe\u2019re going to combine those two markers to see if we can improve the prediction closer to the 90 percent range, where it could be really clinically useful,\u201d said Shen.\nRelated: See the special bond between a boy with autism and a deaf shelter dog\n\nThe study results are \u201cvery exciting,\u201d said Dr. Adriania Di Martino, a professor of child and adolescent psychiatry at NYU Medical School.\nThe scans showed that 70 percent of high-risk toddlers diagnosed with autism at age 2 had an elevated amount of cerebrospinal fluid around their brains at 6 and 12 months, compared to toddlers who were not diagnosed with autism.\nBut if the fluid is not flowing properly, these byproducts hang around and cause inflammation, which could \u201champer brain development\u201d and lead to autism, said Shen.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "No explicit discussion is provided about the availability of MRIs for this sort of detection procedure (and if any special, different tools or procedures are needed), but the story does make it clear that this idea is still under research, so it\u2019s experimental for now.", "answer": 1}, {"article": "I took her to somebody who supposedly could heal through touch,\u201d she said.\n\u201cShe couldn't do anything to stop it, and I really began to realize that her brain wouldn't let her, even if she wanted to be good, her brain wasn't allowing her to.\u201d\n\nMallory\u2019s oppositional behavior reached a fever pitch when the family moved from their home in Hoboken, N.J. to the suburb of Glen Rock, N.J. in 2014.\n\u201cWe tried some medication therapies that ended up being really a nightmare for us, and making matters worse.\u201d\n\nMedication is often the first line of defense in conventional medicine for kids with ADD and ADHD, with doctors prescribing everything from stimulants to antipsychotics and even antidepressants to help control the symptoms.\n\u201cThe easiest way to get their brain to become coordinated is by making their body coordinated, so a large part of what we're doing is this sensory motor interaction, building their muscle tone, building their strength, building their body spatial awareness.\u201d\n\nThe program also incorporates what Melillo calls \u201cbionutritional\u201d guidelines to make sure children are getting the proper nutrition for optimal learning.\n\u201cAnd if [kids] have poor coordination in their body, they often have poor coordination in their brain -- poor coordination between their networks -- so they can't bring all these networks together to learn in the most optimal way.\u201d\n\nThe program uses a combination of sensory motor (physical) exercises and academic learning to help stimulate and strengthen the parts of the brain responsible for certain disorders.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There are dozens of\u00a0Brain Balance centers in the United States. The story does not directly address availability and could lead readers to think the New Jersey facility was one of a kind. But maybe the news organization felt it covered the issue when it\u00a0generously offered a free link to the centers at the end of the piece.", "answer": 0}, {"article": "I know it's a cure.\n\"Those stem cells are given back to the patient where they can go back to the bone marrow and make the blood cells for the rest of the patient's life,\" Kohn said.\nDr. Kohn said of an experimental treatment for SCID, \"It's gone from a 'one day, maybe' to a real clinical reality.\"\nThe Vaccaros turned to Dr. Donald Kohn at the Broad Stem Cell Research Center at UCLA, where Kohn focuses on the development of new methods to treat genetic diseases of blood cells.\nThat means an actual cure for the disease, said Kohn, who is also director of the Human Gene Medicine Program at UCLA.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes, \u201cDr. Kohn is currently working with the FDA to make his treatment available nationwide. He\u2019s also testing the same method as a cure for sickle cell disease. Clinical trials for that treatment are now underway.\u201d This gives the impression that although the approach is still experimental, its availability nationally is a forgone conclusion.\u00a0In fact, many treatments get to this stage and do not pan out.", "answer": 0}, {"article": "Indiana University researchers have found that magnesium intake may be beneficial in preventing pancreatic cancer.\nThe study also found that the effects of magnesium on pancreatic cancer did not appear to be modified by age, gender, body mass index or non-steroidal anti-inflammatory drug use, but was limited to those taking magnesium supplements either from a multivitamin or individual supplement.\nThe study found that every 100-milligrams-per-day decrease in magnesium intake was associated with a 24 percent increase in the occurrence of pancreatic cancer.\n\"For those at a higher risk of pancreatic cancer, adding a magnesium supplement to their diet may prove beneficial in preventing this disease,\" Dibaba said.\nBut few studies have explored the direct association of magnesium with pancreatic cancer; of those that did, their findings were inconclusive, said Daniel Dibaba, a Ph.D. student at the School of Public Health-Bloomington, who led the IU study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release briefly mentions dietary magnesium can be found in \u201cdark, leafy greens or nuts\u201d but a longer list of dietary sources might have been helpful. It\u2019s generally understood that magnesium supplements are widely available on any grocery or drug store shelf.", "answer": 1}, {"article": "Angle founder and chief executive Andrew Newland said the study had demonstrated the ability to correctly detect cancer, and importantly correctly detect the absence of cancer.\nThe test will enable women with ovarian cancer to be referred to gynaecological surgeons who specialize in the care of women with ovarian cancer, while patients with a benign tumor will not have to travel to specialist centers.\n\u201cThe vision is that a woman who has been diagnosed with having an abnormal pelvic mass will have a simple blood test and from that we will deduce whether or not she has cancer and if she does which drug would be most suitable for her,\u201d he said.\nThe performance of the test would now be validated in another study designed to meet European CE Mark and US FDA regulatory requirements, he said.\nHeadline results from a study of 400 patients in Europe and the United States showed the test to detect cancerous cells in the bloodstream correctly identified cancer in up to 95 percent of cases, the company said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicates that further studies are needed to fulfill European and US regulatory requirements, implying that the test is not yet available. But the comments of the company spokesperson make the likelihood of approval seem like a foregone conclusion.", "answer": 1}, {"article": "Overall, the investigators said, adding sestamibi SPECT/CT helped identify 7 of 9 benign tumors, and conventional imaging with added sestamibi SPECT/CT outperformed conventional imaging alone, as measured by a statistical analysis that measures tradeoffs between sensitivity and specificity.\nThe remaining 40 were classified as a variety of other tumor types, including malignant renal cell carcinomas.\nConventional imaging combined with sestamibi SPECT/CT had a value of 0.85, while conventional imaging alone had a value of 0.60.\nOn this measure, a value of 0.50 indicates that a diagnostic test is no better than chance.\nFollowing surgery, similarly \u2018blinded\u2019 pathologists analyzed the tumors without knowing the radiologists\u2019 imaging results.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes in several places, including in the first sentence, that the technique is \u201cwidely available.\u201d We know that to be true.", "answer": 1}, {"article": "Blitz said debate should be aired publicly, and he is not rattled by opposition to plans for a regional approach.\nMany hospitals and cities have been slow to adopt the heart association recommendations.\nIt's the most common cause of sudden cardiac arrest.\nChances of surviving depends largely on where you live.\nThough it's not unusual to have debate over new therapies, the benefits of induced hypothermia is not a new discovery.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that availability of this treatment varied around the country.", "answer": 1}, {"article": "\u2018\u2018I\u2019ve had chemotherapy.\nOthers besides Oncotype DX also are on the market, and Hudis said he hopes the new study will encourage more, to compete on price and accuracy.\nMary Lou Smith, a breast cancer survivor and advocate who helped design the trial for ECOG, the Eastern Cooperative Oncology Group, which ran it, said she thought women \u2018\u2018would be thrilled\u2019\u2019 to skip chemo.\nIn the study, women who skipped chemo based on the test had less than a 1 percent chance of cancer recurring far away, such as the liver or lungs, within the next five years.\nBut independent monitors recommended the results on the low-risk group be released, because it was clear that adding chemo would not improve their fate.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The Associated Press report talks about costs of the Oncotype DX gene test by California company Genomic Health and adds that other tests are also on the market.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - A small U.S. study suggests daily hormone injections may boost mental agility in older people with and without mild cognitive problems.\nPeople who got growth hormone-releasing hormone (GHRH), as opposed to inactive injections, improved on tests of attention and concentration skills - what psychologists call executive function.\nAt the end, those who got the drug did better on psychological tests of executive function - whether or not they had mild cognitive impairment.\nIt\u2019s possible health problems could show up down the road, and the mental boost may be short-lived.\nThe researchers found no serious side effects in the study, although people who got the hormone more often complained of symptoms like skin reactions and joint pain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We wish the story had included even a line about how GHRH is used in medicine right now and whether there\u2019s any knowledge of off-label use for mild cognitive impairment.", "answer": 0}, {"article": "But another finding from that study sheds an interesting light on one of 5-Hour Energy\u2019s central claims \u2014 that the energy shot, unlike competitors\u2019, produces \u201cNo Crash Later.\u201d\n\nAccording to the study, 24 percent of test participants who received 5-Hour Energy had reactions similar to a \u201cmoderately severe crash that left them extremely tired and in need of rest, another drink or some other action,\u201d lawsuit filings show.\nWhatever the case, the energy drink boom has come full circle in Asia, the region where it started.\nAsked whether consumers mistakenly believe that the shot does not produce a caffeine-related crash, Ms. Lutz said that the use of the special mark and its explanation were clear.\nBut she declined to say why the results of the study, which was apparently conducted five years ago, had not yet appeared.\n\u201cI don\u2019t believe that it is misleading,\u201d said Ms. Lutz, who added that the advertising division of the Council of Better Business Bureaus had approved the \u201cNo Crash Later\u201d claim.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of energy drinks is not in question.", "answer": 2}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\n\u201cAlthough further evaluation of the benefits and risks of HDIT/HCT is needed, these five-year results suggest the promise of this treatment for inducing long-term, sustained remissions of poor-prognosis relapsing-remitting MS,\u201d said Richard Nash, M.D., of Colorado Blood Cancer Institute and Presbyterian-St. Luke\u2019s Hospital.\n\u201cThese encouraging results support the development of a large, randomized trial to directly compare HDIT/HCT to standard of care for this often-debilitating disease.\u201d\n\nMS symptoms vary widely and may include motor and speech difficulties, weakness, fatigue and chronic pain.\n\u201cIf these findings are confirmed in larger studies, HDIT/HCT may become a potential therapeutic option for patients with active relapsing-remitting MS, particularly those who do not respond to existing therapies,\u201d said Daniel Rotrosen, M.D., director of NIAID\u2019s Division of Allergy, Immunology and Transplantation.\nThe trial, called HALT-MS, was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and conducted by the NIAID-funded Immune Tolerance Network (ITN).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no mention of whether this therapy is currently available, where it\u2019s performed, or whether regulatory approval is required. Also, there\u2019s no discussion of whether it is likely to be covered by most insurance plans. It appears that this is still purely a research therapy and would not be\u00a0available outside of research settings. \u00a0However, there are many physician\u00a0practices that do research, usually for industry, which don\u2019t\u00a0have the same safety features as this\u00a0research lab had.", "answer": 0}, {"article": "Most recently, the F.D.A.\nAlthough smoking rates in the United States have declined in recent decades, tens of millions of adults continue to smoke, and the habit causes more than 440,000 deaths a year, according to the Centers for Disease Control and Prevention.\nWhile the market for smoking cessation therapies is estimated to be more than $1 billion annually, many smokers continue to fail in their efforts to quit even while using the available products, with long-term success rates generally peaking at about 20 percent.\nThe most widespread therapies currently available are nicotine-replacement products, like nicotine patches and gum, which are designed to wean the smoker by administering trickles of nicotine to the body, replacing the surges delivered by cigarettes.\n\"It's the period between four-week abstinence and one-year abstinence that's the critical period,\" said Dr. Victor I. Reus, a professor of psychiatry at the University of California, San Francisco, and a lead investigator on the NicVax study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly describes the current stage in the drug approval process: The story discusses that NicVax (Nicotine Conjugate Vaccine) has been fast-tracked for approval by the FDA, however, the story also notes that this vaccine is still in Phase 2 clinical trials (tests of safely and efficacy), and additional large-scale, randomized controlled Phase 3 trials are needed before NixVac can apply for final FDA approval. ", "answer": 1}, {"article": "Saxon and her team reported their observations in the Nov. 22 online edition of Circulation.\nThe finding is based on an analysis of nearly 186,000 patients outfitted with either an implantable cardioverter defibrillator (ICD), a cardiac resynchronization therapy device (CRT), or a defibrillator combined with a CRT device (a CRT-D).\nThe study authors noted that the observation is somewhat surprising, given that some of the patients not enrolled in structured studies have already experienced a cardiac event and are therefore prescribed such devices to prevent a recurrence.\n\"I'm very encouraged that survival after defibrillator implant is as good as it is for as long as it is,\" co-author Dr. Leslie A. Saxon, chief of the division of cardiovascular medicine at the University of Southern California's Keck School of Medicine in Los Angeles, said in a news release from the American Heart Association.\nThe study team also found that patients whose implants were monitored remotely, on a continual basis, by a health facility network were about half as likely to die as patients who only had intermittent in-person assessments.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says, \u201cThe finding is based on an analysis of nearly 186,000 patients outfitted with either an implantable cardioverter defibrillator (ICD), a cardiac resynchronization therapy device (CRT), or a defibrillator combined with a CRT device (a CRT-D).\u201d The size of the study might make one think that these devices are widely available, but because we are talking about three different devices, some nod should have been made to how widespread they are.\u00a0The story does make it clear that the remote monitoring system used is available to patients.\u00a0We give this a barely satisfactory as a result.\n", "answer": 1}, {"article": "WASHINGTON\u2014People with mild Alzheimer\u2019s disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial.\n\nThe outcome may bolster the company\u2019s case that the drug, solanezumab, can slow the decline of memory and function in mild Alzheimer\u2019s patients, despite prior studies with negative results. But the new data aren\u2019t final proof of the drug\u2019s benefit\u2014a separate, continuing study due to end in late 2016 is designed to...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly notes that solanezumab is the subject of a more definitive trial that won\u2019t end until at least 2016, and that aducanumab is still in early-stage clinical trials. That\u2019s sufficient for a Satisfactory rating. However, we wish that the story had explained that it will be years \u2014 at least \u2014 before either drug is on the market. And it\u2019s entirely possible that neither will come to market. On a health issue like this one, when people are often willing to grasp at straws to help a loved one, it\u2019s important to be as clear as possible when it comes to availability.", "answer": 1}, {"article": "Other authors on the paper include: Shanthi Marur (Johns Hopkins Medicine) and Anthony Cmelak (Vanderbilt University).\nPatients with good clinical response then received reduced radiation.\nAfter radiation treatment, patients often experience severe, lifelong swallowing, eating, and nutritional issues.\nStudy results also showed that patients who had a history of smoking less than 10 packs of cigarettes a year had a very high disease control compared with heavy smokers.\n\u201cYounger patients may have to deal with these side effects for decades after cancer treatment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The issue of availability of\u00a0reduced dosages doesn\u2019t apply here.", "answer": 2}, {"article": "Six months after treatment, the YAG group reported significantly greater improvement in self-reported floater-related visual disturbance (54 percent) compared with sham controls (9 percent).\nThree management options exist for floaters: patient education and observation; surgery; and the laser procedure, YAG vitreolysis, of which there are limited published studies on its effectiveness for treating floaters.\nChirag P. Shah, M.D., M.P.H., and Jeffrey S. Heier, M.D., of the Ophthalmic Consultants of Boston, randomly assigned 52 patients (52 eyes) to receive YAG laser vitreolysis (n = 36) in one session or a sham (placebo) laser treatment (control; n = 16).\nEMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JULY 20, 2017\n\nThe commentary, \u201cYAG Laser Vitreolysis\u2014Is It as Clear as It Seems?,\u201d by Jennifer I. Lim, M.D., of the University of Illinois at Chicago; and Editor, JAMA Ophthalmology, also is available at the For The Media website.\n\u201cGreater confidence in these outcomes may result from larger confirmatory studies of longer duration,\u201d the authors write.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although wording of the release makes it clear that laser treatments are an option for eye floaters, the release does not provide information about availability.\nHowever, there is\u00a0enough information in the published study for any\u00a0ophthalmologist who is skilled\u00a0in the use of the YAG laser to be able to use the\u00a0treatment.", "answer": 0}, {"article": "The team recruited 45 healthy participants aged 21-70 years who were either obese or overweight.\nIt is well known that avocados are high in fat, but the majority of an avocado's fat is monounsaturated, which is deemed a \"good\" type of fat.\nFrom both of the moderate-fat diets, participants gained 34% of calories from fat, of which 17% were from monounsaturated fatty acids (MUFAs).\nThe lower-fat diet provided participants with 24% of calories from fat, of which 11% was from MUFAs.\nIt is known that monounsaturated fats can help lower levels of bad cholesterol, reducing the risk of heart attack and stroke.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does note that avocados are available but somewhat expensive at certain times of the year. We\u2019ll call this satisfactory, although the story could have noted that some areas may lack access to more exotic fresh produce such as avocados.\n\u00a0", "answer": 1}, {"article": "MONDAY, July 11, 2011 (HealthDay News) -- Teens who have high levels of folic acid appear to do better in school than those with lower levels, Swedish researchers report.\nFor more information on folic acid, visit the U.S. National Library of Medicine.\nNone of the other factors they examined accounted for their finding, Nilsson's team noted.\n\"We know that, in young children, folate deficiencies are associated with poorer neurocognitive function and neurocognitive development,\" he noted.\nInsufficient folic acid is a cause of certain birth defects of the spine and brain, including spina bifida.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reported on the results of the study without helping readers understand that it was conducted on a population of youngsters without access to a folic acid supplemented food supply.\u00a0 The competing Reuters story made this point clearly.", "answer": 0}, {"article": "More information can be found at http://www.\nThe discovery could greatly expand the window for diagnosing concussions, especially in patients who experience a delayed onset of symptoms.\nThese proteins are found in glial cells, which surround neurons in the brain, and when an injury occurs, the GFAP are released.\nAlmost all concussions in children are diagnosed only by symptoms, which are either observed, like vomiting or loss of balance, or symptoms reported by the child, like blurred vision or headaches.\nWhat makes them unique is that they pass the blood-brain barrier and enter the bloodstream, making them easy to detect with this particular test.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that the test is only part of a clinical trial and not available.", "answer": 1}, {"article": "[11]\n\nEVZIO (naloxone HCl injection) Auto-injector is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.\nAdditionally, there are nearly two times the number of prescription opioid-related deaths as compared to heroin-related deaths.1 On average, 3,300 children five years old and younger are admitted to emergency departments each year due to accidental opioid exposure.\nFor example, taking high doses of opioids, taking an opioid in combination with other drugs (e.g., benzodiazepines) or alcohol, or if there is a history of certain medical conditions (e.g., COPD, severe asthma) places individuals at significantly higher risk for life-threatening OIRD.\n\"People at an overdose scene may be very emotional, so it really helps that EVZIO has audio instructions on how to administer this potentially life-saving medication,\" said Laurie Fugitt, RN, BSN, co-founder of Georgia Overdose Prevention.\n\"By empowering more patients to have access to this potentially life-saving medicine, we believe that EVZIO will help reduce the burden of opioid overdose in the United States.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that the product is FDA approved and quotes numerous public officials discussing its use in their communities, so one can infer that it is on the market. However, since the release suggests that everyone should have the product in their medicine cabinets, it\u2019s really important to know whether and how members of the general public could purchase this product. It\u2019s not made clear that naloxone is something that must be prescribed. So we\u2019re rating this Not Satisfactory on that basis.", "answer": 0}, {"article": "Sandoval is alive today because of an experimental form of immunotherapy called CAR-T.\nOn Friday, Moffitt Cancer Center and MD Anderson reported test results of 101 patients with advanced lymphoma who had failed previous therapy and were treated with CAR-T.\n\n\u201cIt puts a GPS navigation on the front of the cell so that when they\u2019re infused back in they know where to go and kill the lymphoma,\u201d said Dr. Frederick Locke, who helped lead the trial.\nThe FDA will review these results and could make a decision on approval by the end of the year.\nWith CAR-T, a patient\u2019s own immune cells are removed from the body, reprogrammed to find and destroy cancer cells, then put back into the bloodstream.\nNormally, our immune cells are good at killing invaders like bacteria but bad at fighting cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that this treatment is being reviewed by the FDA. It says that a decision \u201ccould\u201d come by the end of the year, which provides wiggle room.", "answer": 1}, {"article": "5 Million Have Heart Failure in U.S.\n\nMore than 5 million Americans have heart failure, which occurs when the heart muscle loses its ability to pump enough blood throughout the body.\nSpecially developed software divides patients into groups depending on the pattern of molecules detected.\nThe new study involved 27 people with heart failure so severe that they were comfortable only at rest, 25 people with less severe heart failure, and 28 healthy people.\nThe findings were presented here at the European Society of Cardiology Congress 2011.\nThe researchers are now testing more than 1,000 patients and trying to identify the odorous molecules unique to heart failure patients, Kechagias says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this device is still in the early phases of testing.", "answer": 1}, {"article": "The early results are \u201cpromising and exciting,\u201d said Dr. Allison Baker, a psychiatrist at Massachusetts General Hospital\u2019s Center for Women\u2019s Mental Health, but \u201cwe need to see replication of this data over a much wider range in terms of numbers.\u201d\n\nThe study is small and has not been peer-reviewed; Sage disclosed the results in a press release.\nInterestingly, none of the patients who took the drug reported psychiatric side effects, such as abnormal dreams, insomnia, and anxiety \u2014 but 5 of the 11 women on the placebo reported such symptoms.\nA few patients in each group experienced dizziness or a sedative effect.\nThe drug has a \u201cvery, very short half-life\u201d in the body, Jonas said, meaning that it can be metabolized quickly.\nIts next steps: expanding the trial to enroll more women and to determine optimum doses.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that this drug is still being tested and that the company has not applied for FDA approval.", "answer": 1}, {"article": "Rosenfeld says it's never wrong to prescribe an antibiotic for a well-diagnosed ear infection.\nOnly children who really had ear infections were included in the trials.\nIn treatment outcomes for pain, there was no difference, he notes.\nHowever, antibiotics do come with significant side effects including diarrhea, rashes, yeast infections and vomiting.\nThe study authors caution about the overuse of these drugs and the risk of antibiotic resistance.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of antibiotics to treat ear infections is not in question.", "answer": 2}, {"article": "\"More than 30 years since the discovery of the antidepressant effects of sleep deprivation, we still do not have an effective grasp on precisely how effective the treatment is and how to achieve the best clinical results,\" said study senior author Philip Gehrman, PhD, an associate professor of Psychiatry and member of the Penn Sleep Center, who also treats patients at the Cpl.\nReviewing more than 2,000 studies, the team pulled data from a final group of 66 studies executed over a 36 year period to determine how response may be affected by the type and timing of sleep deprivation performed (total vs early or late partial sleep deprivation), the clinical sample (having depressive or manic episodes, or a combination of both), medication status, and age and gender of the sample.\nThe findings of this meta-analysis hope to provide relief for the estimated 16.1 million adults who experienced a major depressive episode in 2014.\nSuch drugs typically take weeks or longer to experience results, yet 16.7 percent of 242 million U.S. adults filled one or more prescriptions for psychiatric drugs in 2013.\nPHILADELPHIA - Sleep deprivation -- typically administered in controlled, inpatient settings -- rapidly reduces symptoms of depression in roughly half of depression patients, according the first meta-analysis on the subject in nearly 30 years, from researchers at the Perelman School of Medicine at the University of Pennsylvania.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not say whether sleep-deprivation therapy is available as an alternative for most patients. In fact, sleep deprivation is not used as a treatment \u2014 only in research studies \u2014 and has been for decades.", "answer": 0}, {"article": "She worries about the small chance of benefit in light of the larger chance of finding and treating a cancer that did not need to be treated.\nAfter all, mammography had improved and, in Norway, each mammogram was independently read by two radiologists, which should make it less likely that cancers would be missed.\nThe investigators found that women 50 to 69 who had mammograms and were treated by the special teams had a 10 percent lower breast cancer death rate than similar women who had had neither.\nThe study, published Thursday in The , looked at what happened in before and after 1996, when the country began rolling out mammograms for women ages 50 to 69 along with special breast cancer teams to treat all women with breast cancer.\n\u201cMortality from breast cancer is decreasing, and I have to believe that screening mammography has played a part,\u201d Dr. Lee said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe availability of mammography screening is not at issue. This story does point out that the women who were screened in Norway had access to special treatment teams. And it noted that these treatments are available at \u201cmany major medical centers in the United States.\u201d", "answer": 1}, {"article": "Rothwell and his colleagues published their findings Dec. 7 in the online edition of The Lancet.\nThe current observations follow prior research conducted by the same study team, which reported in October that a long-term regimen of low-dose aspirin appears to shave the risk of dying from colorectal cancer by a third.\nThe potential impact of aspirin on pancreatic, stomach and brain cancer death rates was more problematic to gauge, the authors noted, due to the relative paucity of deaths from those specific diseases.\nAnd while cautioning that more research is necessary to build on this \"proof of principle,\" the authors suggested that people who embark on a long-term, low-dose aspirin regimen in their late 40s and 50s are probably the ones who stand to benefit the most.\nThe protective impact of low-dose aspirin on stomach and colorectal cancer death was not seen until 10 years out, and for prostate cancer, the benefits first appeared 15 years down the road.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of aspirin is not in question. The story would have been better if, like some of the other stories we reviewed, it had pointed out that aspirin is approved for use as an anagesic and, for certain people, to reduce the risk of some cardiovascular events, but it is not currently recommended for cancer prevention.", "answer": 1}, {"article": "Newswise \u2014 CHAPEL HILL, NC \u2013 UNC researchers say the results from the multi-site phase 2 and 3 trials of brexanolone injection are not only promising, but could change the way postpartum depression (PPD) is treated.\nThe first statistically significant reduction in depression severity with brexanolone injection relative to placebo was observed as early as 24 hours after dosing.\nA unique dose group of brexanolone 60 \u00b5g/kg/hr in one of the studies was not included in the integrated efficacy analysis, but was included in integrated analyses of safety.\nHaving a drug approved to treat PPD that works quickly and effectively, yet is also durable, would be a huge step forward for psychiatry in general,\u201d Meltzer-Brody said.\nA New Drug Application is currently under review by the FDA and brexanolone injection has been granted Breakthrough Therapy Designation.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the drug is currently under FDA review, with a decision on its approval expected by the end of the year.", "answer": 1}, {"article": "Does one side of the face droop?\n\u201cThey are destined to be in a nursing home or to be dead and when we re-establish blood flow \u2014 often times right there on the table \u2014 they get better.\u201d\n\nStent retriever therapy is a new procedure experts call the most major advance in stroke treatment in two decades.\nCurrently, stent retriever therapy is offered in just a few hundred hospitals across the country, including more than 100 Comprehensive Stroke Centers accredited by the American Heart Association and The Joint Commission.\nResearchers examined data on patients treated with both tissue plasminogen activator (tPA), the standard in stroke treatment, and stent retrievers and found that restoration of blood flow within 2.5 hours of stroke onset was associated with minimal or no disability in 91 percent of patients.\n\u201cThe earlier that patients with acute ischemic stroke get to a hospital offering the appropriate treatment, the higher the likelihood is of a good outcome,\u201d said the study\u2019s lead author, Dr. Mayank Goyal of the Hotchkiss Brain Institute at the University of Calgary.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this procedure is not going to be widely available in the U.S. It says, \u201cCenters accredited by the American Heart Association.currently, stent retriever therapy is offered in just a few hundred hospitals across the country, including all 96 Comprehensive Stroke Centers.\u201d It also provides a map showing how few centers there are in the West.", "answer": 1}, {"article": "CBS News correspondent Kelly Wallace reports Kate Miller's 15-year-old son Cody killed himself just 17 days after starting the drug.\nHis mom now believes that Singulair cost him his life.\nShe's now writing letters to every patient who takes Singulair, urging them not to over-react.\nThe agency recently began notifying the public earlier about possible safety issues.\nTheir labeling does not contain language about suicide.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The segment makes clear that Singulair is widely used. ", "answer": 1}, {"article": "After several trips to the doctor, the Mullins received the worst possible news.\n\"It's wonderful to go and talk to a parent, whose child has just diagnosed with an advanced neuroblastoma and say the odds of being cured has increased dramatically,\" said Dr. M. Fevzi Ozkaynak with the Maria Fareri Children's Hospital at the Westchester Medical Center in New York.\nThis new treatment is still experimental, but it's a step forward in the strategy of manipulating a person's own immune system to fight cancer.\n\"I've been through it, it was the past, time to move on,\" he said.\nOne tagged with antibody, the cancer can be more easily recognized and attacked by the body's own white blood cells.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story ended by informing viewers that the treatment was experimental.\u00a0 There could have been more emphasis on the early nature of the findings \u2013 i.e. so far \u2013 the results have only been presented at a meeting, meaning that they have not yet undergone peer review.", "answer": 1}, {"article": "Caution was urged by Dr. Richard B. Lipton, vice chairman of neurology at Albert Einstein College of Medicine in New York City, who has done work on the genetics of Alzheimer's disease.\nIt is produced when enzymes act to convert a precursor molecule, angiotensinogen.\nBut there have been a number of observational studies implicating various molecules, including estrogens, in dementia, he said.\n\"Any study like this is hypothesis-generating,\" he said.\nBy blocking bad receptors, you are left with the good ones so that helps neurons become more resilient.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although never explicity stated, the widespread availability of angiotensin inhibiting drugs can be inferred from the story. ", "answer": 1}, {"article": "(Reuters) - A combination of two Bristol-Myers Squibb drugs that help the immune system fight melanoma led to significantly greater tumor shrinkage than treatment with one of the medicines, according to a midstage study presented on Monday.\nThe overall response rate, defined as tumors that shrank by at least 30 percent, was 61 percent for the 72 patients who received the combination versus 11 percent among the 27 who got Yervoy alone.\n\u201cThe response rates and the depth of responses are quite impressive,\u201d Dr. Stephen Hodi, director of the Melanoma Center at Dana-Farber Cancer Institute and co-lead author of the study, said in an interview.\n\u201cLonger follow-up will be helpful to see the durability of these responses and what happens to patients who had complete responses,\u201d said Hodi, who presented data from the Checkpoint-069 study at the American Association for Cancer Research meeting in Philadelphia.\nThe combination of the two drugs also led to far higher levels of side effects, such as colitis and inflammation of lung tissue, at 54 percent versus 24 percent for Yervoy alone.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that both drugs are currently on the market. However, the story doesn\u2019t make clear to readers that both drugs have been approved by the FDA for use in treating advanced melanoma. That said, it\u2019s not a major oversight for most readers.", "answer": 1}, {"article": "Sabourin Lussier, born with spina bifida, faced the possibility of kidney failure when she was just 19 years old. Her bladder, damaged by the devastating birth disorder, leaked uncontrollably and often backed urine up into her kidneys.\n\nA conventional surgery to reconstruct her bladder with intestinal tissue threatened further health complications. So in May 2000, Ms. Lussier and her mother, Gail Johnston, agreed to an experiment under which she and eight other patients with spina bifida would receive partial, laboratory-built...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that this transplantation has only been done in a very small number of people and it is still very experimental. FDA approval has not given because tissue-based products need to be manufactured to standards similar to those for drugs or medical devices. ", "answer": 1}, {"article": "When the researchers spoke sentences to the patient, language areas in her brain spiked in the same way healthy volunteers\u2019 did.\nDr. Nicholas Schiff, a neuroscientist at Weill Cornell Medical College in New York, said that the study provided \u201cknock-down, drag-out\u201d evidence for mental awareness, but that it was not clear \u201cwhether we\u2019ll see this in one out of 100 vegetative patients, or one out of 1,000, or ever again.\u201d\n\nIn a more recent exam, more than 11 months after her injury, the patient exhibited a sign of responsiveness: she tracked with her eyes a small mirror, as it was moved slowly to her right, and could fixate on objects for more than five seconds, said Dr. Steven Laureys, a neurologist at the University of Li\u00e8ge and an author of the study.\nThe imaging techniques used in the new study could help identify which patients are most likely to emerge \u2014 once the tests are studied in larger numbers of unconscious people, said Dr. Joseph Fins, chief of the medical ethics division of New York Presbyterian Hospital-Weill Cornell Medical Center.\nThe journal that published the new paper, Science, promoted the finding in a news release, but added a \u201cspecial note\u201d citing the Schiavo case and warning that the finding \u201cshould not be used to generalize about all other patients in a vegetative state, particularly since each case may involve a different type of injury.\u201d\n\nThe brain researchers, led by Adrian Owen at the Medical Research Council Cognition and Brain Sciences Unit in Cambridge, England, performed scans on the patient\u2019s brain five months after her accident.\nThis means by definition that the young woman has transitioned from an unresponsive, vegetative state to a sometimes responsive condition known as a minimally conscious state, Dr. Laureys said in an interview.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention if the functional MRI imaging is available and in use for clinical practice or if it is simply a research tool. Functional MRI is an established imaging technique but is not widely available at the present time like standard imaging studies including MRIs and CTs. Functional MRI is mainly used for research purposes, but its potential role in clinical care is likely to increase over time.", "answer": 0}, {"article": "The body mass index, or BMI, associated with the lowest risk of death has increased since the 1970s, a study finds, from 23.7, in the \"normal\" weight category, to 27, which is deemed \"overweight.\"\nI know you journalists always want that,\" Nordestgaard says.\n\"This is total speculation,\" Nordestgaard says.\nMore than 100,000 people were involved.\nSo he and his colleagues sliced and diced the data to see what could account for the shift.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 2}, {"article": "\u201cThis isn\u2019t a magic bullet.\nThat kind of approach could be risky.\u201d\n\nNutt said the results showed that psilocybin \u201cis safe and fast acting, so may - if administered carefully - have value for these patients.\u201d\nWe\u2019re just learning how to do this treatment.\u201d\n\nMagic mushrooms grow worldwide and have been used since ancient times, both for recreation and for religious rites.\nBlood pressure, heart rate and the self-reported intensity of the effects of psilocybin were monitored during each session, and the patients were seen by a psychiatrist the next day and one, two, three and five weeks after the second dose.\nThe World Health Organization estimates that some 350 million people worldwide are affected by depression, a common mental disorder characterized by sadness, loss of interest or pleasure, tiredness, feelings of guilt or low self-worth, disturbed sleep and appetite, and poor concentration.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There are some small hints (it was called a \u201cpilot study\u201d), and one of the researchers warns readers\u00a0to avoid \u201cpicking their own magic mushrooms,\u201d but the story offers no other availability information. This sort of treatment under the supervision of a physician would not occur until after FDA approval for this specific indication, which would take many years.", "answer": 0}, {"article": "Routledge added that current evidence shows that not smoking, only consuming alcohol within recommended limits, staying active, monitoring cholesterol levels and eating a balanced diet can all help with the health of the heart and brain.\nThere is currently no cure for dementia, though medication can be used to temporarily treat its symptoms.\nOver time, the researchers believe this led more frequently to cognitive decline in participants in the study.\nDementia is an umbrella term used to describe symptoms related to the loss of brain function.\nThose two conditions make up the vast majority of cases of dementia.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that more work needs to be done before this becomes anything approaching a standard of care.", "answer": 1}, {"article": "The first CT scan was OK.\nIt turned out to be cancer.\nNearly 175,000 Americans will be diagnosed with lung cancer this year.\nHe was operated on successfully.\nBut a new study proves there may be a better way to detect the disease \u2014 early enough to beat it\n\nBarton Lazarus is one of the lucky ones.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention if lung cancer screening is widely available.", "answer": 0}, {"article": "Dr. Evangelia Charmandari, associate professor pediatric and adolescent endocrinology at at the Medical School of the National and Kapodistrian University of Athens and lead author of the study, said: \"These findings suggest that simple vitamin D supplementation may reduce the risk of overweight and obese children developing serious heart and metabolic complications in later life.\u201d\n\nThe findings are set to be presented at the 57th Annual European Society for Pediatric Endocrinology Meeting, and have therefore not yet been reviewed.\nVitamin D is most commonly associated with the development and maintenance of strong bones as the body needs it to absorb calcium.\nChildren who took vitamin D had a significantly lower BMI, the researchers found.\nTaking vitamin D could help overweight and obese children lose weight, scientists believe.\nEarlier this year, researchers in the Netherlands published a study indicating higher levels of belly fat are linked to lower vitamin D levels.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Vitamin D is easy to find and used pervasively, so we\u2019ll mark this N/A.", "answer": 2}, {"article": "It has been 51 years since the first birth-control pill became available in the U.S., bringing dozens of contraceptive options for women in its wake. There are currently two options on the market for men\u2014vasectomy or a condom.\n\nThe research pipeline is full of possibilities, though. Scientists at Columbia University Medical Center have halted sperm production and started it again in mice with no apparent side effects, using a drug that blocks receptors for vitamin A. An injectable synthetic substance, in Phase 3 clinical trials...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We like the left column sidebar that lists 3 \u201cpromising\u201d methods and specifies status and availability.\u00a0 Nice touch.", "answer": 1}, {"article": "MORE: A Cheaper Way to Quit Smoking?\nThe authors conclude, \u201cThis initial study provides evidence for nicotine-induced cognitive improvement in subjects with MCI; however, whether these effects are clinically important will require larger studies.\u201d\n\nThe study found no problematic side effects associated with the nicotine patch and none of the patients had withdrawal symptoms when it was stopped.\nWhile smoking is a public health scourge, the nicotine in cigarettes may have some promise in treating another growing problem, mild cognitive impairment (MCI), which can be a precursor to Alzheimer\u2019s disease or other forms of dementia.\nThe research was funded by the National Institute on Aging, but some of the authors also receive pharmaceutical industry funding and one reported funding from Philip Morris.\nThe randomized controlled trial included 74 people, mainly in their late 70\u2019s, with mild cognitive impairment (MCI).\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re going to rule this one Not Applicable because \u2013 while availability was not explicitly addressed \u2013 this is a product that\u2019s probably well known to most readers.\u00a0 However, both stories we reviewed could have been more specific about the exact types of patches that were studied and in what doses.", "answer": 2}, {"article": "The technique has the potential to be a \u201cgame-changer,\u201d says Tzvi Small, M.D., Director of the Department of Plastic and Reconstructive Surgery at The Valley Hospital, who performed the breast reconstruction procedure on Hasbrouck Heights resident Vanessa Burt, 43.\nAfter a recovery period of approximately two months \u2014 during which the woman\u2019s chest skin heals, blood supply replenishes, and the expanders are gradually inflated to stretch the skin \u2014 the patient returns for an outpatient surgical procedure to replace the tissue expanders with permanent breast implants.\n\u201cIt\u2019s important to listen to each woman\u2019s needs and then to decide together what is the best approach to treatment, so that in the end the cancer will be gone and the woman can move on with her life,\u201d says Dr. Wilson.\nNewswise \u2014 The breast surgery and reconstructive team at The Valley Hospital in Ridgewood, NJ, is taking the lead in providing new and progressive advances in breast cancer surgery.\nAfter consulting with several breast surgeons and reconstructive surgeons, Ms. Burt opted for a nipple-sparing mastectomy performed by breast surgeon Tihesha Wilson, M.D., Assistant Medical Director of Valley\u2019s Breast Center.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told\u00a0The Valley Hospital performed this surgery, and \u2014 by implication of going through the effort of issuing a news release \u2014 we have to assume the hospital plans to perform\u00a0this surgery again for patients who qualify. However, that isn\u2019t made clear.", "answer": 0}, {"article": "Botox and Myobloc carry labels warning of possible adverse reactions near the injection site such as drooping eyelids, and of severe difficulty swallowing in patients with neuromuscular disorders.\nThe way it usually works is, the rats and mice die first.\nSomething else that can be seen in a different light is the hospitalizations and deaths that have been reported following Botox injections.\nOne of the deadliest poisons in nature and a possible bioterrorism agent, this neurotoxin reached the market, in very dilute doses, starting in 1989 as Botox.\nNot surprisingly, these \"preclinical tests\" (that is, those performed before testing on humans) were especially rigorous for botulinum.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that Botox reached the market in 1989. ", "answer": 1}, {"article": "ASTHMA According to conventional wisdom, asthma and other allergic diseases like hay fever are made worse by dirty environments. Recent evidence has suggested, however, that children exposed to dirt and germs early in life may have a lower risk of developing asthma and other allergies. Studies have found that the children of farmers -- who presumably are exposed to a ... (Full article: 838 words)", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is about a trial of a drug called candesartan, which is currently approved for treating hypertension. Researchers studied it for managing a condition that is now called pre-hypertension. But the story didn\u2019t make clear where the drug stood with the FDA for approval for the use described in the article.", "answer": 0}, {"article": "THURSDAY, Dec. 9, 2010 (HealthDay News) -- The bone drug zoledronic acid (Zometa), considered a potentially promising weapon against breast cancer recurrence, has flopped in a new study involving more than 3,360 patients.\nSince the current study was presented at a meeting, its findings should be considered preliminary until published in a peer-reviewed journal.\n\"There is no overall difference in recurrence rates or survival rates [between patients who got the bone drug and those who did not], except in older patients, defined as more than five years after menopause.\"\nOther research has found that healthy women on bone drugs were less prone to develop breast cancer, so experts were hoping the drugs had an anti-tumor effect.\nIn one previous study, the use of the drug was linked with a 32 percent improvement in survival and lowered recurrence in younger women with breast cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article did not make it clear that the FDA has not yet approved zoledronic acid as adjunctive treatment for women with early breast cancer.\n\u00a0", "answer": 0}, {"article": "We know early intervention is extremely important.\nThe technology has been around for awhile -- developed in the late 1920s, it has been used for more than 60 years to detect seizures in epileptics.\n\"In this study, we have taken the first step in showing that there is definitive information in the electrical signals measured by EEG to distinguish normal controls from infants at high risk for developing autism,\" Bosl said.\n\"My hope is we would have a simple way of measuring brain activity in every child and see the patterns emerging that might track autism characteristics,\" Bosl said.\nAnd unlike MRIs, they require no sedation, so testing could be put to widespread use, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a good job setting up the study by explaining that researchers already know that having a sibling with autism can be a risk factor for developing autism and goes on to explain that this method of reading an electroencephalogram (EEG) is experimental.\u00a0The story accurately states that EEGs are not new, but have been used for detecting seizures for many years.", "answer": 1}, {"article": "The benefits were still seen after a year.\nFibromyalgia treatment usually starts with medications such as the nerve pain medication Lyrica (pregabalin), and if that fails or is only partly effective, doctors might add acupuncture to the mix, Rances said.\n\"Both acupuncture and traditional medicine have a place in treating fibromyalgia,\" said Dr. Alexander Rances, an acupuncturist, pain management specialist and attending physician at North Shore University Hospital in Manhasset, N.Y.\n\n\"A combination of Western as well as traditional Chinese medicine probably offers these patients the best possible therapy,\" he said.\nAccording to the study authors, nine out of 10 patients try some form of alternative therapy, such as massage or acupuncture, in addition to their regular pain medication.\n\"Individualized acupuncture is a safe and good therapeutic option for the treatment of patients with fibromyalgia,\" said lead researcher Dr. Jorge Vas, of the pain treatment unit at Dona Mercedes Primary Health Center in Seville, Spain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Acupuncture is now considered a fairly common alternative therapy for a number of conditions and is usually available in most locales. The story hints as much when it says that 9 out of 10 patients with fibromyalgia report using some form of alternative therapy, including acupuncture.", "answer": 1}, {"article": "The process of RNA interference involves putting two strands of RNA together to form so-called \"small interfering RNAs\" (siRNAs) and inserting them into cells.\nObviously, the process will have to be refined and optimized before it's actually used for treatment.\nBut the work that nabbed the prize was done in worms -- a far cry from humans.\nThis team, from the California Institute of Technology (CalTech), devised a super-small nanoparticle system that, when injected into the body, would make its way to the tumor, deposit the siRNAs into the tumor cell and leave them to their assigned task.\nOnce there, these interlopers cut the messenger RNA (mRNA) that is ordinarily used to make specific proteins.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Unlike the Reuters story, this story was very clear with this statement:\u00a0 \"Obviously the process will have to be refined and optimized before it\u2019s actually used for treatment.\" ", "answer": 1}, {"article": "She noted a second study in Nature that used transplant tissue grown in the laboratory from stem cells to treat damaged corneas, saying it also holds promise.\nIn addition, we are testing if this approach can be used in treating other leading causes of blindness, such as macular degeneration and glaucoma,\" said Zhang.\n\"The main excitement for me is the ability to regenerate an organ or a tissue within an organ,\" said Canto-Soler, a retina specialist.\n\"The study's stem cell engineering has led to the regeneration of transparent lens tissue in children, showing that the concept offers a potential therapeutic approach,\" Daniels wrote.\nTraditional surgery can cause opacity in the line of a child's vision and, because the eye is still growing, it is difficult to provide good vision with eye glasses, explained Julie T. Daniels, from University College London Institute of Ophthalmology, in an accompanying commentary in Nature.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story includes several statements by the researchers saying that larger studies are needed as well as a longer follow-up period in patients before the success with this research is confirmed, which should give the average reader and understanding that this approach is not available at this time. A quote from one of the researchers also lets us know they hope to bring this surgery to the public within four to five years.", "answer": 1}, {"article": "This study was supported by intramural funds from the National Cancer Institute.\n\"Immunotherapy marshals the exquisite specificity of the immune system to destroy cancer, and some types may have potentially fewer side effects than traditional chemotherapy,\" said Jay A. Berzofsky, MD, PhD, chief of the Vaccine Branch at the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.\n\"We are using a vaccine approach to generate an immune response to HER2, which is found at high levels on and drives the growth of several types of cancer, including breast, ovarian, lung, colorectal, and gastroesophageal cancers.\nNEW YORK -- Treatment with a HER2-targeted therapeutic cancer vaccine provided clinical benefit to several patients with metastatic HER2-positive cancers who had not previously been treated with a HER2-targeted therapeutic, according to data from a phase I clinical trial presented at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held Sept. 30-Oct. 3.\nThe final product, which is administered intradermally (between the layers of the skin), comprises patient-derived dendritic cells genetically modified with an adenovirus to produce parts of the HER2 protein.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There was no discussion of the availability, although with it being a phase 1 clinical trial, you can assume that it is not available yet. There was no mention about scaling this work since the vaccine was produced using each individual\u2019s immune cells to create the vaccine. It\u2019s unclear if the trial moves forward and enrolls more subjects, how difficult (or costly) it would be to bring this method of treatment to a wider audience.", "answer": 0}, {"article": "Larger people have higher bone density to support their larger frames.\n\"I think this gives us yet another reason to support the recommendations for a healthy diet in the Dietary Guidelines for Americans.\"\nThe study, led by Tonya Orchard, an assistant professor of human nutrition at The Ohio State University, appears in the Journal of Bone and Mineral Research.\n\"This suggests that a high-quality, less-inflammatory diet may be especially important in reducing hip fracture risk in younger women,\" the researchers wrote.\nThe lower bone density to start could be because women with healthier diets are more likely to be of a smaller build, Orchard said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We are giving this a pass here because the release makes mention of \u201ca diet higher in beneficial fats, plants and whole grains,\u201d which includes foods that are widely available.", "answer": 1}, {"article": "But the mind is a powerful thing.\nBut only about 1 percent of the population has an autoimmune response to gluten.\nWhy the results of these studies differ is unclear.\nThe latter is more common, affecting about 1 percent of the population.\nThey found no difference in symptoms among the groups.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly notes the now-widespread availability of gluten-free foods.", "answer": 1}, {"article": "A diet that includes tomatoes could lower the chance of having a stroke.\n\nA new study shows that men who had the highest levels of lycopene\u2014an antioxidant found in tomatoes\u2014had fewer strokes than men who had the lowest level of lycopene in their blood. Overall, the risk of strokes was reduced by 55%.\n\nThe study, based in Finland, will be published...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of tomatoes is not in question.", "answer": 2}, {"article": "Results from two phase III boceprevir trials are published in the New England Journal of Medicine.\nThe Merck drug boceprevir and Vertex Pharmaceutical\u2019s similar drug telaprevir are expected to win FDA approval within months, following phase III trials showing that both drugs boosted cure rates to around 70% when used with standard therapy.\nAdding one of the drugs to the current two-drug regimen of peginterferon and ribavirin will make the treatment of hepatitis C more complex, but it will also cure a lot more people, hepatitis C specialist Donald M. Jensen, MD, of the University of Chicago Medical Center, tells WebMD.\nThe drugs will be used in patients with HCV genotype 1 -- the hardest to treat form of the viral infection.\n\u201cTriple-drug therapy represents a major advance in the treatment of hepatitis C for patients,\u201d he says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story makes it clear that boceprevir and telaprevir are not yet available, but they may be reviewed by the FDA at the end of April.\n ", "answer": 1}, {"article": "Tim Barham, the vice president of HBB, the maker of Lazy Cakes, said, \u201cWe look at the brownie as a supplement.\u201d\n\nNews reports have classified Lazy Cakes as dietary supplements, but last month, Douglas Karas, an F.D.A.\n\u201cThe promoters of these are appealing to people who think it\u2019s better to do things outside of the medical establishment,\u201d he said, adding that \u201cthe desire to help people is an extremely strong motivator, but so is money.\u201d He pointed to a section of the National Institutes of Health\u2019s Web site that lists several drugs, including sedatives like clonazepam and birth control pills, whose efficacy might be altered by melatonin.\nIt also warned that women who are pregnant or trying to conceive should avoid melatonin \u201cbased on possible hormonal effects.\u201d (Drank\u2019s bottle now say it is a dietary supplement.)\nFor me, it\u2019s to get a good night\u2019s sleep.\u201d\n\nYet the products, intended for adults only, are being marketed as a novel way to relax in a stressed-out, wired world.\n\u201cIt\u2019s a colossally bad idea to put melatonin in food,\u201d Dr. Czeisler said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The widening availability of these products is eminently clear from the story.\u00a0 And the fact that melatonin has not approved by the FDA as a food additive is explained.", "answer": 1}, {"article": "Doctors say it has given them a new weapon in the battle against sleep apnea, and many patients who struggled with C.P.A.P.\nThe device contains two pinhole-size valves, one over each nostril.\nBut not everyone finds that Provent alleviates their apnea.\nHe has prescribed Provent to about 300 of his patients.\nA follow-up study tracked people over the course of a year and had similar results.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this device is becoming more widely prescribed but is not necessarily found everywhere.", "answer": 1}, {"article": "Thourani V, Jensen H, Babaliaros V, Kodali S, Rajeswaran J, Ehrlinger J, Blackstone E, Suri R, Don C, Aldea G, Williams M, Makkar R, Svensson L, McCabe J, Dean L, Kapadia S, Cohen D, Pichard A, Szeto W, Herrmann H, Devireddy C, Leshnower B, Ailawadi G, Maniar H, Hahn R, Leon M, Mack M. Outcomes in Nonagenarians Undergoing Transcatheter Aortic Valve Replacement in the PARTNER-I Trial.\nFor the study, the researchers used two different approaches: transfemoral TAVR (TF-TAVR), which is the traditional approach performed via the groin, and transapical TAVR (TA-TAVR), which is performed via the heart muscle.\nAs part of the PARTNER-I trial, Vinod H. Thourani, MD, from Emory University in Atlanta, and colleagues from 12 other institutions in the United States found that transcatheter aortic valve replacement (TAVR) is a safe and effective way to treat aortic stenosis in nonagenarians who qualify for the surgical technique.\nIn the largest series published to date, between April 2007 and February 2012, 531 nonagenarians underwent TAVR: 329 with TF-TAVR and 202 with TA-TAVR.\nWhile the current study did not evaluate other alternative options for TAVR, these techniques may include transaortic, transcaval, transcarotid, or trans-subclavian.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Based on the language in the release, it is not possible to tell whether TF-TAVR and/or TA-TAVR are widely available, if they are available only at specialized medical centers, or if these treatment options are still undergoing review for use outside of clinical trials. It is implied that this is an available procedure, but it could have been stated more clearly.", "answer": 0}, {"article": "Software engineer Ben Wallace underwent subchondroplasty in November to help shore up a damaged hip.\n\"We don't want to send the message to people who have bone-on-bone, with big bone spurs and limited range of motion that they're all of a sudden going to get relief from injecting a little bit of cement into their bone,\" Hepinstall said.\nThe best candidates for the procedure are patients who still have some cartilage protecting their joint, but have somehow \"overloaded\" and injured the bone, causing swelling and pain, Hepinstall said.\n\"But there's a very narrow window of patients who are good ideal candidates for this, who basically have a real overload of their bone causing severe enough pain to warrant a surgical procedure, but also have healthy enough cartilage that doing something about the bone swelling is going to alleviate the majority of their pain,\" he stressed.\nThe procedure involves a smaller incision than joint replacement surgery, so there's less risk of infection, and a quicker recovery time that means fewer of the side effects associated with being bedridden, Vasileff said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Bone cement procedures seem to be widely available for vertebral compression fractures, but it is not clear from this story or an internet search whether access to a bone cement procedure for knee and/or hip pain is still very limited or relatively accessible.", "answer": 0}, {"article": "For more information about Pitt Public Health, visit the school's Web site at http://www.\n\"If a patient who is on an anticoagulant to avoid a stroke has a major bleeding event, doctors are faced with a catch-22: Discontinue the anticoagulant to avoid future bleeding, but again place their patient at increased risk of stroke; or resume the anticoagulant to continue avoiding a stroke, but then have to worry about another bleeding event,\" said lead author Inmaculada Hernandez, Pharm.D., Ph.D., an assistant professor in Pitt's School of Pharmacy, who completed this work as a doctoral student at Pitt's Graduate School of Public Health.\nThe analysis, published today in the journal Stroke, determined that resuming anticoagulation therapy after a person suffers a major bleeding event was associated with a higher likelihood of stroke-free survival than discontinuing anticoagulation.\nThe risk of dying from any cause or having a stroke was 23 to 34 percent higher in patients who discontinued anticoagulation therapy compared to those who resumed it.\n\"It causes a lot of uncertainty for physicians, especially because patients at highest risk of recurrent bleeding also are at highest risk of stroke,\" said co-author Yuting Zhang, Ph.D., associate professor of health policy and management at Pitt Public Health, and Hernandez's doctoral dissertation committee chair.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states that warfarin has been used as a medication since 1954 and dabigatran was approved by the U.S. Food and Drug Administration in 2010. It could have added that both are usually covered in drug plans, although the co-pay for dabigatran may make it less feasible for some patients.", "answer": 1}, {"article": "To study the relationship between berry consumption and heart disease, Cassidy and her collaborators at the Harvard School of Public Health analyzed findings from the Nurses Health Study 2 which includes more than 90,000 nurses in the U.S.\n\"But nonetheless, for the first time I think we have some evidence that the intake of theses anthocyanins may have a protective effect.\"\n\"Even when we adjusted for things like fat intake, fiber intake, medication use, or body size, and for example, exercise, we still got these strong reductions in risk,\" Cassidy says.\nAnd if they're out of season, like now, studies show frozen berries have similar levels of beneficial compounds.\n\"We showed for the first time that a regular intake of substances that are naturally present in red-, blue-colored fruits and vegetables can reduce the risk of a heart attack by about 32 percent in young and middle-aged women [ages mid-40s to 60],\" compared with women who ate berries once a month or less, says study author Aedin Cassidy of the University of East Anglia.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of strawberries and blueberries is not in question. But it does remind readers that if berries are not in season, frozen berries are still available and may have the same effect (if there is an effect).", "answer": 2}, {"article": "For more information about the School of Medicine, see http://www.\nThis finding indicates that patients with higher initial eosinophil counts benefited more from mepolizumab than those with lower eosinophil counts, Sciurba said.\nMepolizumab is already approved by the Food and Drug Administration (FDA) to reduce symptom flare-ups and improve quality of life in eosinophilic asthma.\n\"In addition to providing a new treatment option for patients with treatment-resistant, moderate to severe COPD, the new results also are important because they identify a potential biomarker for the disease and demonstrate that eosinophilic inflammation plays a role in flare-ups in COPD,\" Sciurba said.\n\"These patients already have been given every treatment we have to offer them and are still having flare-ups that significantly interfere with their quality of life and can lead to deterioration in lung function and higher mortality,\" said Sciurba.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release gets a satisfactory in this category since it mentions that the drug maker intends to seek FDA approval for its use in this type of patient, a fact that suggests to readers that it isn\u2019t currently available to patients.", "answer": 1}, {"article": "Pain patches have a number of benefits, Rosenquist and Dombrowski said, not the least of which is convenience.\nThe active ingredients in Salonpas are methyl salicylate and menthol, common components of pain-relieving gels and creams, such as Bengay.\nBefore the FDA action, pain-relieving patches were available in the United States only by prescription, said Dr. John Dombrowski, director of the Washington Pain Center in Washington, D.C. Their active ingredients include such medications as lidocaine, capsaicin and non-steroidal anti-inflammatory drugs, or NSAIDs.\n\"Salonpas is the Western world catching up with Asia,\" said Dr. Rick Rosenquist, a professor of anesthesia and director of pain medicine at the University of Iowa Carver College of Medicine and chairman of the American Society of Anesthesiologists' committee on pain medicine.\n\"If you are an Asian kid, you've had these placed on you since time immemorial,\" he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that pain-relief patches have been used in some form for decades while only recently becoming popular in the US. \u201cThe U.S. Food and Drug Administration approved the country\u2019s first over-the-counter, pain-relieving transdermal patches in 2008. But the patches, marketed under the brand name Salonpas, are nothing new. They\u2019ve been sold in various countries in Asia since the 1930s, according to their manufacturer, the Japanese firm Hisamitsu Pharmaceutical.\u201d", "answer": 1}, {"article": "So why weren't they all cured?\nHowever, half of the 417 children in this latest study who had sleep apnea and were bedwetters stopped wetting the bed after they had their tonsils or adenoids removed.\n\"Bedwetting is multifactorial even within these groups, and eventually we should be able to pinpoint the cause for every single child,\" Lakshmanan said.\n\"If they haven't seen an ear, nose and throat specialist, see one to see if the child who wets the bed has OSA that can be cured by tonsil or adenoid removal,\" said study author Dr. Yegappan Lakshmanan, chief of pediatric urology at Children's Hospital of Michigan, in Detroit.\n\"Children snore because their tonsils and adenoids are enlarged, and they end up getting other behaviors that go along with sleep apnea, including bedwetting,\" she explained.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. The story does not explicitly state how common tonsillectomies are, but the surgery is so routine at this point, we do not feel there is a need for further explanation.", "answer": 2}, {"article": "July 30, 2012 -- If it weren't for routine PSA prostate cancer screening, an extra 17,000 Americans each year would learn that they had the worst form of the disease, a new study suggests.\nThat kind of prostate cancer -- metastatic prostate cancer, in which the cancer spreads to the bone or other parts of the body -- is rapidly fatal, usually within two years or less.\nThe new study seems to make a powerful argument in favor of PSA testing.\nBut he would not yet have symptoms or detectable metastatic disease, so he'd be diagnosed with earlier-stage disease.\nBut it's not that simple, says Barnett Kramer, MD, MPH, associate director for disease prevention at the National Institutes of Health.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that PSA screening is \u201cwidespread.\u201d", "answer": 1}, {"article": "Ms. Visco said, \"How is it ethical to do that, to make this much hype around something that is not a health emergency, and you can't check their data?\"\nIn 1,000 high-risk women like those in the study, for instance, without treatment 40 would be expected to develop invasive breast cancer over the next five years.\nEven better news, the cancer institute said, was that those taking raloxifene \"had 36 percent fewer uterine cancers and 29 percent fewer blood clots.\"\n\"It will take some time for experts to review the data to determine which of the two treatments is preferable.\"\nIn the meantime, Dr. Ford said, at least tamoxifen and raloxifene give women at risk the chance to do something.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that Raloxifene is already marketed as Evista, a drug used to prevent osteoporosis after menopause, but that Eli Lilly has petitioned the FDA to approve it to prevent breast cancer.", "answer": 1}, {"article": "\"Dislocation is a common reason for a total hip replacement to fail, and when it happens, sufferers can experience significant pain and require another surgery to fix the problem,\" explains lead study author Jonathan Vigdorchik, MD, an assistant professor of orthopedic surgery at NYU School of Medicine and associate fellowship director of the Division of Adult Reconstructive Surgery at NYU Langone Orthopedic Hospital.\nIn addition to Vigdorchik and Buckland, study authors in NYU Langone's Department of Orthopedic Surgery include Ameer Elbuluk, BA, and Richard Iorio, MD.\nMore than 310,000 hip replacements are performed in the United States each year, and an estimated 2.5 million Americans are currently living with hip replacements.\n\"We were able to stop these implant dislocations from occurring in the first place, sparing our patients follow-up care and the need for revision surgery.\"\nP0072 A New Risk-Assessment Score and Treatment Algorithm for Patients at High-Risk of Dislocation following Total Hip Arthroplasty Jonathan Vigdorchik MD, Ameer Elbuluk BA, Kaitlin Carroll BS, David Mayman MD, Richard Iorio MD, Aaron Buckland FRACS, Seth Jerabek MD.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that patients who undergo hip replacement at NYU Langone Orthopedic Hospital have access to the risk assessment screening and treatment algorithm prior to surgery. But what about patients who can\u2019t travel to New York? Is anything similar in use at other institutions? The release is silent on this point.", "answer": 0}, {"article": "ZURICH (Reuters) - An experimental cancer drug that Novartis hopes will raise the profile of its oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hard-to-target gene mutation.\nNovartis said earlier this year that this study, called SOLAR-1, of hormone receptor positive, HER2- breast cancer with mutations of the PIK3CA gene showed that YL719 helped patients.\nBut this specific benefit data is being released on Saturday at the European Society for Medical Oncology\u2019s annual conference in Munich.\n\u201cWe don\u2019t see as much diarrhea, we do not have CNS (central nervous system) side effects, we do not have the liver effects,\u201d he said.\nLike other companies, Novartis is seeking to personalize treatment for cancer patients by using biomarkers like those showing PIK3CA gene mutations to help guide treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states that Novartis plans to file for approval for the drug this year.", "answer": 1}, {"article": "The designer of that treatment, Dr. Katherine A.\nIf all goes well, a genetic treatment for hemophilia B \u201ccould be available for widespread use in a couple of years.\u201d\n\nIn a trial in 2006, a patient injected with a corrective gene produced his own Factor IX but only for 10 weeks.\nThe virus used by Dr. Nathwani\u2019s team, known as adeno-associated virus-8, generally stays outside the chromosomes, so it should not present this problem.\nTreating a patient with concentrate costs $300,000 a year, with a possible lifetime cost of $20 million, but the single required injection of the new delivery virus costs just $30,000, Dr. Katherine P. Ponder of the Washington University School of Medicine in St. Louis notes in her commentary in The New England Journal of Medicine, calling the trial \u201ca landmark study.\u201d\n\nThe patients have continued to produce their own Factor IX for up to 22 months, said Dr. Edward G. D. Tuddenham, director of the Hemophilia Center at the Royal Free Hospital in London.\n\u201cWe attribute this to the fact that he had an inflammation, and although we treated it promptly, we should have been quicker off the mark,\u201d Dr. Tuddenham said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that this is an experimental approach, but the story didn\u2019t challenge a researcher\u2019s claim that a genetic treatment for hemophilia B \u201ccould be available for widespread use in a couple of years.\u201d\u00a0 That kind of statement requires some kind of explanation of what the road to widespread use may look like\u2026and how unpredictable such a prediction can be.", "answer": 0}, {"article": "The requested document is forbidden. Please try your operation again .", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that the robotic apparatus needed for the procedure reported on is not available in all facilities though it was becoming more common.", "answer": 1}, {"article": "Co-authors on the paper, all from Boston University, are T.A.\n\"The potential of digital UV technology for phototherapy is enormous,\" said Dr. Robert C. Walker, RayVio's CEO.\nRayVio's 293nm LED showed the most significant potential for vitamin D3 production in the shortest amount of time,\" said Dr. Holick, a Professor of Medicine, Physiology and Biophysics at Boston University School of Medicine, and endocrinologist at Boston Medical Center.\n\"This study will lead to a new generation of technology that can be labeled as photopharmacology in which the use of LEDs with targeted wavelengths can cause specific biologic effects in human skin to help treat and prevent chronic illnesses.\"\nThanks to the work of the research team and the pioneering work of the Boston University Photonics Center on UV LEDs, we may soon see innovative treatment options like simple integration with a wearable device could aid millions of people.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "RayVio already has other UV LEDs out on the market for health and hygiene purposes, but these don\u2019t include the 293nm UV LED \u2014 the prototype tested in this study. The news release makes clear that this technology is still being developed, hinting that a \u201cwearable device\u201d could be available to consumers in the future.\nWe wish the news release had given more information on the types of UV light therapies accessible now for patients, as well as what a treatment session currently looks like.\nSince the news release makes clear that the 293nm UV LED technology isn\u2019t widely available, we rate this one Satisfactory.", "answer": 1}, {"article": "\u201cAnd when stimulation arrived in a good state, the average was about 15 to 20 percent worse than usual.\u201d\n\nDr. Doris Greenblatt, a psychiatrist who participated in the trial at Emory, said she sought the surgery because her epilepsy had long caused memory problems.\nThe new study is the latest chapter in an extraordinary, decades-long collaboration among cognitive scientists, brain surgeons and people with severe epilepsy being evaluated for an operation.\nThis approach \u2014 called direct neural recording, and piggybacking entirely on the clinical placement of the electrodes \u2014 has become the leading edge of research into the biology of human memory.\nThe preoperative \u201cevaluation\u201d is a fishing expedition of sorts, in which doctors sink an array of electrodes through the top of the skull and wait for a seizure to occur, to see whether it\u2019s operable.\nIn a series of experiments, the researchers had patients memorize lists of words and later, after a distraction, asked them to freely recall as many of the words as they could.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s made clear that this study focused on epilepsy patients whose doctors deemed they needed brain-stimulating implants, and that the research may not apply to broader populations.", "answer": 1}, {"article": "And studies suggest that fortifying corn masa with folic acid could prevent an additional 40 to 120 cases of neural tube defects among babies born to Hispanic mothers each year.\nIt all has to do with nixtamalization, the process by which tough corn kernels are softened by soaking in an alkaline solution, usually of slaked lime.\nThe rates are highest among Hispanics: Latina women are roughly 20 percent more likely to have a baby with a neural tube defect compared to non-Latina white women.\nInstead, they were consuming corn masa flour products, because that was the staple grain in that diet,\" says Cynthia Pellegrini, senior vice president of public policy and government affairs at the March of Dimes.\nBut there's one notable exception to this success story \u2014 Hispanic women \u2014 and researchers think the reason may lie in a staple of their diet: tortillas.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that extra folic acid is already widely available in other flours. It notes that there is debate about adding it to corn flour.\u00a0Concerns about the technical difficulty of\u00a0adding folic acid that remains in usable effective form is a central point.", "answer": 1}, {"article": "A new generation of treatments for severe eczema is on the horizon, which doctors say could help millions more patients gain relief from chronic outbreaks of the oozing, itchy and sometimes debilitating rashes that come with the disease.\n\nAt least two new eczema medicines could be approved by the U.S. Food and Drug Administration in 2017, and a half-dozen more drugs are being tested in clinical trials.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states\u00a0that the drug companies involved plan to ask FDA for approval later this year. This is a clear enough signal that the drugs aren\u2019t available yet.\nHowever, by speculating on how these drugs will be used by doctors, some of the statements imply that the drugs will definitely be approved, e.g.: \u201cMany doctors say they expect the drug to benefit patients whose diseases go undertreated because their fears about steroids cause them to use the drugs less frequently than prescribed.\u201d\nMany FDA applications for approval can be derailed by unforeseen safety concerns or other issues, and so the passage above could have been toned down to indicate this still all hinges on events that haven\u2019t happened yet.", "answer": 1}, {"article": "\u201cThis test looks very promising, but it is also very expensive,\u201d\n\nWhile there are risks attached to amniocentesis and CVS screens, these are minimized when the test is performed by a skilled obstetrician, she says.\nFor now the test just looks for Down syndrome, but \u201ctechnology will advance to the point where noninvasive testing will encompass more of the less common genetic anomalies,\u201d she says.\n\u201cIt\u2019s not ready for prime time, but researchers are actively working on methods to increase its efficiency,\u201d he says.\nWhile the new screen only looks for Down syndrome, Sullivan says that some of the other trisomy birth defects can be more easily identified on an ultrasound exam.\nStill, he adds, \u201cit\u2019s an important step forward.\u201d\n\nThe technology is likely prohibitively expensive and time-consuming at this point, he says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story leans on an independent expert to say that the test is \u201cnot ready for prime time\u2026.in a year or two, this test may be available.\u201d", "answer": 1}, {"article": "Doctors said Thursday that the increased risk did not outweigh the benefits of the drugs.\nThe drugs, which include Depakote, Lamictal, Topamax, Keppra, Lyrica and Neurontin, are sometimes prescribed for chronic pain and headaches, as well.\n\u201cWhat\u2019s really important to say is that bipolar disorder is very difficult to treat, the burden is enormous, and these medications help keep people free of mood and anxiety symptoms and allow them to function,\u201d said Andrew A. Nierenberg, medical director of the bipolar clinic and research program at Massachusetts General Hospital.\nThe Food and Drug Administration undertook a combined analysis of 199 clinical trials with 43,892 patients and found 4 suicides and 105 reports of suicidal symptoms among the 27,863 patients who were given the drugs compared to no suicides and 35 reports of suicidal symptoms among the 16,029 patients treated with placebos.\nDrugs for epilepsy, bipolar illness and mood problems double the risks of suicidal thoughts and behavior, and patients taking them should be watched for sudden behavioral changes, drug regulators have said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes some pharmacological treatments available for epilepsy.\u00a0 The story notes these same medications may also be used to treat chronic pain, mood disorders and headaches. The risks of suicidality are not as great in non-epileptics. ", "answer": 1}, {"article": "Dr. Christina Luedke of Children\u2019s Hospital Boston said she carefully screens teenagers and their families before prescribing a pump.\nThe pumps are used for those with Type 1 diabetes, which accounts for about 5 to 10 percent of all diabetes cases and used to be called \u201cjuvenile diabetes.\u201d The more common form is Type 2, which is often linked to obesity and more often affects adults.\nThe federal review of use by young people over a decade found 13 deaths and more than 1,500 injuries connected with the pumps.\n\u201cWithout appropriate glucose monitoring, the pumps can increase the risk of getting sick more quickly compared to injections,\u201d Luedke said.\nIn the FDA study, appearing in the May issue of the journal Pediatrics, the reports of adverse events and deaths in adolescents using the pumps occurred from 1996 to 2005.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story establishes availability in its lead sentence when it clearly states that insulin pumps are used by tens of thousands of teenagers worldwide.\u00a0 ", "answer": 1}, {"article": "Cocaine use is widespread in the Western World.\nThe results of this pilot study, published in the peer-reviewed journal European Neuropsychopharmacology, suggest that this may become an effective medical treatment for patients with cocaine addiction, although a larger trial is needed to confirm the initial findings.\nIn addition, 69% (11/16) patients) in the experimental group showed no relapse to cocaine use, whereas only 19% (3/16) patients) in the control group showed a similar positive result (the results are adjusted for patients who dropped out of the trial).\nAs author, Dr Antonello Bonci (Scientific Director, National Institute on Drug Abuse, and Adjunct Professor, John Hopkins University, Baltimore) said:\n\n\"Despite the fact that more than 20 million people worldwide suffer from cocaine use disorders2, there are no effective neurobiological treatments for patients with this devastating condition\".\nWe have continued to follow patients from the trial, and the improvement seems to be sustained over time, up to 12 months, although we don't have any hard data on that yet.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "While the release does state that this particular form of brain stimulation is being used to treat some other conditions, there is no suggestion that the treatment is readily available in most hospital or out-patient facilities, information which would help readers gauge the practicality of seeking such treatments.", "answer": 0}, {"article": "Children in high-income households tend to perform better on behavioral and cognitive tests -- which could mask some possible harms from their mothers' light drinking during pregnancy.\n\"What we tell women is that we don't know of a safe threshold for drinking alcohol during pregnancy.\nWomen were defined as light drinkers if they had no more than one or two drinks a week.\nThe children were last given a battery of behavioral and cognitive tests when they were 5 years of age.\nMothers were first asked about their alcohol use when the kids were 9 months old.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This does not seem to apply.", "answer": 0}, {"article": "The patients' cognitive performance, life quality and life expectancy is also affected by having the condition.\nIt is known that newborn babies who suffer perinatal asphyxia may develop permanent brain injury resulting in cerebral palsy or other conditions, like epilepsy.\nProfessor Marianne Thoresen said: \"Even if we account for a lesser severity of perinatal asphyxia, our research has shown that therapeutic hypothermia reduces the number of children who develop epilepsy later in childhood.\nEven if a lesser severity of perinatal asphyxia is accounted for, cooling therapy has increased the number of healthy survivors and there are very few children with epilepsy needing drug treatment.\nFor up to eight years, the researchers followed 165 infants who were born in the south west and who received cooling therapy at St Michael's Hospital, Bristol, part of University Hospitals Bristol NHS Foundation Trust.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Someone reading the release could easily think that therapeutic hypothermia is a treatment currently available only from the researchers who worked on this study. That\u2019s not the case. It\u2019s not something available at every hospital, but it is available at many hospitals. A 2014 report from the American Academy of Pediatrics addressed related limitations and challenges regarding the use of hypothermia to treat neonatal encephalopathy. This quote from that report would seem to apply here as well: \u201cInfants selected for cooling must meet the criteria outlined in published clinical trials. The implementation of cooling needs to be performed at centers that have the capability to manage medically complex infants. Because the majority of infants who have neonatal encephalopathy are born at community hospitals, centers that perform cooling should work with their referring hospitals to implement education programs focused on increasing the awareness and identification of infants at risk for encephalopathy, and the initial clinical management of affected infants.\u201d", "answer": 0}, {"article": "The number of prostate cancer diagnoses dropped by more than 12% (1363 cases) in the month after the USPSTF draft guideline was issued and the number continued to drop, resulting in an overall decline of 28% in incident prostate cancer diagnoses in the year after the draft guideline was issued.\nThe decreases were similar across all subgroups of age, comorbidity, race, income, and insurance.\nBy contrast, the number of monthly colon cancer diagnoses remained stable.\nProstate cancer remains the second leading cause of cancer death among men in the U.S., with nearly 30,000 deaths annually.\nDiagnoses of low, intermediate, and high risk prostate cancers all decreased significantly, but new diagnoses of non-localized disease did not change.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is pretty clear from the release that PSA testing and related treatment are widely available.", "answer": 1}, {"article": "The other is that, for tens of thousands of years, parasites and other infections unusual in modern society were a major problem in humans. The body developed a defense mechanism - inflammation - to fight them. Now, there aren't as many of these infectious diseases for our bodies to deal with, but we still have this defense mechanism. It has begun to target other things, such as allergens in the environment. Immunotherapy helps teach the body to better tolerate these harmless parts of our environment.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The report makes clear what\u2019s FDA approved and what\u2019s not; and where to get the latest immunotherapies, and where people cannot get them. Good job on this.", "answer": 1}, {"article": "Adverse reactions associated with UroLift System treatment were comparable to other minimally invasive surgical therapies as well as standard cystoscopy.\n\"We are committed to providing patients with the highest quality, most effective options to address their urology needs,\" said Matthias Hofer, MD , urologist at Northwestern Memorial Hospital.\nThe UroLift System's permanent implants, delivered during a minimally-invasive procedure, act like window curtain tie-backs to hold the lobes of an enlarged prostate open.\nThe most common adverse events reported during the study included pain or burning with urination, blood in the urine, pelvic pain, urgent need to urinate, and the inability to control urine because of an urgent need to urinate.\nFor these patients, the classic alternative is surgery that cuts or ablates prostate tissue to open the blocked urethra.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The FDA \u201ccleared\u201d this surgical implant system in 2013 and it is available at Northwestern University, but there are no details about its general availability in other regions or health systems. We are left wondering.", "answer": 0}, {"article": "A popular new type of prenatal test intended to find genetic flaws in a fetus can in rare cases also reveal previously undiagnosed cancer in the mother.\n\nThe unexpected finding emerged in a study involving eight women who initially had abnormal results from the prenatal blood test, but for whom a subsequent assessment showed their babies were normal. When the mothers\u2019 DNA was reanalyzed, researchers said, the anomalies were linked to cancer in each of the women.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Again, the story could\u00a0have benefited from some cost information about the tests and whether they are covered by most insurance plans. It also would have benefited from a sentence about how women can best arrange for such testing, and how widely available they are at prenatal clinics and private practices. But it does give information about the total number of tests done in the U.S. and about their growing popularity.", "answer": 1}, {"article": "The study had some limitations, the authors acknowledged.\nThere was a concern that statins could be harmful as they might lower the level of coenzyme Q10 in the blood.\nFor example, only about 70 percent of people who were taking drugs to lower cholesterol were actually on statins at the study's start.\nThe data are compelling evidence that statins are not detrimental for people with or at risk of Parkinson's disease, he said.\nThis effect may be even more pronounced among people younger than 60, according to the study published in the March issue of Archives of Neurology.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "One could argue that statins are among the most popular drugs and, therefore, their availability is widely known. But this story should have at least mentioned the specific statin being studied and the fact that they are only available by prescription.", "answer": 0}, {"article": "In late July, Sen. David Vitter, R-Louisiana, wrote a letter to the FDA saying that there are no new safety concerns and that \"the [FDA advisory] committee's concerns appear to have been based on cost-effectiveness.\"\n\"There was a delay in progression of the tumor, but it had no effect on quality of life, or survival,\" Visco says.\nIn 2008, the FDA granted Avastin what's known as accelerated approval as a therapy for metastatic breast cancer.\nAt that price, insurance coverage is crucial, and patients and doctors fear that an FDA reversal will lead to most insurers no longer signing the checks.\nAs a condition of the approval, the company that makes Avastin -- Genentech -- agreed to conduct more extensive research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that Avastin received preliminary approval for treating metastatic\u00a0breast cancer in 2008 and formal FDA approval is currently pending. ", "answer": 1}, {"article": "Women who took part in diet, exercise or combination programs were about 20 percent less likely than women in standard-care groups to gain too much weight while pregnant, the researchers report.\nOther benefits may include a lower risk of cesarean delivery, excessive birth weight, and respiratory\n\nproblems in the newborn, \u201cparticularly for high-risk women receiving combined diet and exercise interventions,\u201d add the researchers, led by Benja Muktabhant of Khon Kaen University in Thailand.\nThere was no clear benefit among the women in the diet and exercise groups when the researchers looked at other complications, such as cesarean delivery, but it did look like there may be some benefit, they write.\nAfter including the new studies, the new review found \u201chigh-quality evidence\u201d to show diet, exercise or both can reduce the risk of excessive weight gain during pregnancy, write the researchers in The Cochrane Library.\n(Reuters Health) - Women who take part in exercise, diet programs or a combination of the two during pregnancy can prevent excessive weight gain, according to a fresh review of past research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It might have been useful to give readers a sense of\u00a0whether diet and/or exercise programs are routinely available to pregnant women (either through their obstetricians or in the community). However, we won\u2019t penalize the story for not addressing this, since it\u2019s also possible to exercise without any supervision.", "answer": 2}, {"article": "This new view of sugar could change the advice that doctors and government health officials give about eating the sweet stuff.\n\u201cThis is causation.\u201d\n\nThe diet he provided the children isn\u2019t considered ideal from a health perspective \u2014 starches are still a considerable source of calories and can contribute to weight gain.\nNow, in a paper published Tuesday, he and his colleagues believe they have come up with the definitive evidence that sugar, as Lustig says, \u201cis toxic.\u201d\n\nIn most lab studies, the doses of sugar that scientists test are quite high; they want to see what the effect is quickly and, depending on the research, they may not have time to wait to study the more gradual effects that might emerge.\nBut I worry that people are going to hang everything on this when we still need to reduce consumption.\u201d\n\nLustig hopes that won\u2019t happen as more data emerges that details how sugar is altering the body in unhealthy ways outside of its caloric contribution.\nThat\u2019s the point.\u201d\n\nMORE: The Trouble With Sugar Free Kids\n\nNot everyone is convinced that the results definitely prove sugar, and not weight loss, is the culprit, however.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the dietary changes they made in the study could be made by anyone. The story says:\n\u201cWe took chicken teriyaki out, and put turkey hot dogs in. We took sweetened yogurt out, and put baked potato chips in. We took pastries out and put bagels in,\u201d says Lustig. \u201cSo there was no change in [the children\u2019s] weight and no change in calories.\u201d", "answer": 1}, {"article": "This press release contains forward-looking statements.\nAs featured in the ASTRO Scientific Session poster titled \"High Dose Adaptive MRI Guided Radiation Therapy Improves Overall Survival of Inoperable Pancreatic Cancer,\" key data points and findings from the presentation include the following:\n\u2022 The study detailed a retrospective review of 42 locally-advanced pancreatic cancer patients treated with MRIdian at four institutions (University of California Los Angeles, University of Wisconsin, VU University Medical Center, Washington University).\nAs a result, MRIdian's on-table adaptive radiation therapy allows doctors to respond to subtle anatomical changes observed on a day-to-day basis and reshape the dose to better match the current contours of the tumor.\nThe early results highlighted above, along with other data obtained using MRIdian will be tested in a multi-center, prospective, single-arm clinical trial for inoperable, locally advanced or borderline resectable pancreatic cancer.\nViewRay, Inc. (Nasdaq: VRAY), maker of the world's first and only clinical MRI-guided radiation therapy system, announced today outcomes data presented during the recent 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release notes that the next step is a prospective clinical trial and that tells savvy readers that this treatment strategy has a long road of testing ahead. Still, we think the release could have done a better job clarifying that this therapy is not yet ready for patients, outside of the clinical trial.\nA study that suggests a doubling of median survival is sure to capture the attention of patients newly diagnosed with pancreatic cancer. These patients and their families are closely aware of the glum statistics for the disease. This is a practical concern that the release should have touched on.", "answer": 1}, {"article": "Though CA125 is valuable to look for recurrence of cancer, it is not recommended for screening because it can surge, for example, during menstruation. However, guidelines from the American College of Obstetricians and Gynecologists and the National Comprehensive Cancer Network (NCCN) recommend a CA125 test plus vaginal ultrasound imaging for a woman with nonspecific symptoms that could signal ovarian cancer, such as bloating and pain. A CT or MRI scan may be added, although these are expensive. A biopsy is usually avoided because it could spread cancer cells.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the two blood tests have been available since 2009.", "answer": 1}, {"article": "\u201cFinding a way to help infants exposed to smoking and nicotine in utero recognizes the unique dangers posed by a highly advertised, addictive product and the lifetime effects on offspring who did not choose to be exposed.\u201d\n\nIn a previous study, the authors had shown that 72 hours after birth, babies of mothers who smoked had better lung function if their mothers were randomized to vitamin C (500 mg/day) during their pregnancies compared to those born to mothers who smoked and were randomized to placebo.\nFEFs measure how fast air can be exhaled from the lung and are an important measure of lung function because they can detect airway obstruction.\nThis study was funded by the National Heart, Lung, and Blood Institute and the Office of Dietary Supplements.\nInfants in this study will continue to be followed to track their lung function and respiratory outcomes.\nThe researchers also discovered an association between the infant FEFs and a genetic variant some of the mothers possessed that appeared to amplify the negative impact of nicotine on the babies before they were born.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address availability but it can be safely presumed that readers know vitamin C supplements are widely available.", "answer": 2}, {"article": "To learn more, visit stjude.org or follow St. Jude at @stjuderesearch\nThe paper's other authors are Qifan Zhu, Liqin Zhu, Zhiping Liu, Rajendra Karki, Ankit Malik, Deepika Sharma, Liyuan Li, R.K. Subbarao Malireddi, Prajwal Gurung, Geoffrey Neale, Scott Olsen, Robert Carter, Daniel McGoldrick, Gang Wu, David Finkelstein, Peter Vogel and Richard Gilbertson, all of St. Jude.\n'Since reduced AIM2 activity in colorectal cancer patients is associated with poor survival, it might be useful to detect the level of AIM2 expression in polyps taken from colonoscopy and use this as one of the biomarkers for prognosis,' Kanneganti said.\nThe team, led by Thirumala-Devi Kanneganti, Ph.D., a member of the St. Jude Department of Immunology, published their findings in a recent issue of the journal Cell.\n'We have only scratched the surface of the role of AIM2 in controlling stem cell proliferation and the maintenance of a healthy gut microbiota,' Kanneganti said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release quotes one story author on this point: \u201c\u2018We have only scratched the surface of the role of AIM2 in controlling stem cell proliferation and the maintenance of a healthy gut microbiota,\u2019 Kanneganti said. \u2018How exactly AIM2 does both of these functions is an exciting research area to pursue.'\u201d Unfortunately, that\u2019s the last paragraph of the release. And the first seven paragraphs talk about research as if it were done in a human model. It\u2019s not until the eighth paragraph that we learn the study was done using mice. In short, this work is far, far removed from any potential clinical intervention for cancer patients. That should be said explicitly somewhere in the text, and the fact that the work was done in an animal model should have been made clear at the very top.", "answer": 0}, {"article": "\u201cYou saw less foreign body response.\n\u201cOur goal is to bring that kind of biological cure across the spectrum of type 1 diabetes.\u201d\n\nThe potential of the approach has attracted interest from both small startups and large biopharmaceutical companies that are looking at stem cell-based therapies for diabetes.\nThe human beta cells survived exquisitely well.\u201d\n\nThe studies show \u201cyou can take stem cells and make a limitless supply of [human beta cells] and put them in a device and cure an entirely different species of animal,\u201d Anderson said.\n\u201cThis is really the first demonstration of the ability of these novel materials in combination with a stem-cell derived beta cell to reverse diabetes in an animal model,\u201d said Julia Greenstein, vice president of discovery research at JDRF, an organization trying to end type 1 diabetes that provided some funding for the studies.\nThe researchers behind two studies published Monday demonstrated they had made progress on both fronts, encapsulating the cells in a protective bubble to shield them from the body\u2019s immune response, and creating beta cells from stem cells, which are potentially limitless.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story at the top makes it clear that the treatment is not available, saying, \u201cScientists on Monday showed they had overcome some of the major hurdles standing in the way of a long-sought\u00a0therapeutic fix for patients with type 1 diabetes, outlining an approach that the body\u2019s immune system could tolerate and providing a possible pathway toward clinical trials in the next few years.\u201d Not the qualifier of \u201cpossible\u201d in that sentence.", "answer": 1}, {"article": "Pill That Hits A Cause Of Cystic Fibrosis Beats Expectations\n\nMore than 20 years after the gene behind cystic fibrosis was identified, a pill that could fix the problem in some people is getting closer to reality.\nBut a key takeaway is that the medicine gets at a root cause of cystic fibrosis in some people rather than just relieving their symptoms.\nNow there are some promising results from a study in 161 people with a specific genetic mutation that affects about four percent of cystic fibrosis patients.\nNow, to be perfectly clear, all we know about the latest data is from press releases.\nUltimately, the drug might be used by around 3,000 patients worldwide, if approved, and Schoenebaum expects it would be command a very high price, perhaps $250,000 a year.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that the drug is experimental, and that it hasn\u2019t even been put before the FDA for review yet.", "answer": 1}, {"article": "Researchers agreed that until there\u2019s clearer evidence for benefit, men with healthy hearts shouldn\u2019t seek out statin prescriptions for the purpose of lowering their prostate cancer risks.\nWhen they accounted for whether or not men were overweight and their other health problems and medications, it turned out that those with fatal cancers were 63 percent less likely to have ever taken a statin, according to findings published in Cancer.\nTo prove that statins protect against aggressive cancer would require a large study in which cancer-free men, or those with early-stage disease, are randomly assigned to take statins or not and then tracked for years to see how many of them die from cancer.\n\u201cIf a person\u2019s on the fence about taking a statin medication for their heart, this is another potential benefit they may have by taking one of these,\u201d he told Reuters Health.\nThat type of study, especially involving healthy, disease-free men, would be very expensive and time consuming, said Dr. Nelly Tan, from the University of California, Los Angeles, who has studied statins and prostate cancer risk.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that about one-quarter of adults age 45 and older in the U.S. take statins to lower cholesterol and protect against heart attacks.", "answer": 1}, {"article": "The people who do this are specially trained.\nThe procedure must start within six hours of the onset of a stroke, which means that emergency teams and hospitals will have to move fast, Powers said.\n\"If you actually deploy or open one in the middle of a clot, it smooshes out and the clot gets caught in the chicken wire, and then you pull the whole thing out back through the artery,\" Powers said.\nThat last point is especially important, because the stent retrieval device will not fit into the smaller blood vessels that branch out further into the brain, Powers said.\nThe major risk of using the device is that it could tear an artery and cause bleeding in the brain, particularly since it will be used on people who have already received very potent blood thinners, Kandzari said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that these procedures can only be performed by highly-trained interventionists at specialized stroke treatment centers. The story emphasizes the importance of getting patients to these centers quickly. That\u2019s sufficient for a Satisfactory rating, but it would have been nice to know how many of these stroke centers there are throughout the country. And do most residents in the US live close enough to get to one within the magic short window?\u00a0\u00a0", "answer": 1}, {"article": "\u201cMore often than not, it\u2019s not clear-cut which way to go,\u201d explained Barry Rosenstein, professor of radiation oncology at Mt.\nThis kind of work is important not just for prostate cancer, but all cancers.\nWhile there has been greater success in treating cancer, survivors may live many years with side effects after treatment.\nThe number of men studied was eventually winnowed down to 260 patients with erectile dysfunction and 205 controls.\nPatients were assessed every three to six months for signs of sexual dysfunction for up to five years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article clearly indicates that this work is experimental and would require extensive validation before it could be considered for clinical practice.", "answer": 1}, {"article": "April 28, 2010 -- Federal researchers say a new treatment can reverse vision loss in many patients with diabetic macular edema, a leading cause of blindness in people with diabetes.\n\nIn a news conference yesterday, researchers announced findings from a government study comparing treatments for swelling of the retina caused by leaking blood vessels in the eye.\n\nNearly 50% of patients given eye injections of the drug Lucentis along with laser treatments showed improvement in vision after a year of treatment, compared to just over a fourth of patients treated with laser alone.\n\nFor several decades, laser has been the standard treatment for diabetic macular edema, or DME, in which fluid builds up near the center of the retina.\n\n\u201cFor the first time in 25 years we have definitive proof that a new treatment can lead to better results for the eye health of people with diabetes,\u201d said Neil M. Bressler, MD, who oversaw the study as chairman of the Diabetic Retinopathy Clinical Research Network.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that Lucentis was approved 4 years ago for another cause. ", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061008/16healthwatch.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story reported on a common dietary component and its association with bone mineral density.", "answer": 1}, {"article": "Until more research is in, what should a woman with a personal history of breast cancer do?\n\"There are some tumors that don't show up on mammography as well as they do on MRI,\" he explained.\nCurrently, the American Cancer Society recommends annual breast MRI plus mammography for women at very high risk for breast cancer, such as those with a known genetic mutation known as BRCA or those with a very strong family history.\nStudying the effectiveness of MRI screening on all three groups of women, Dr. Wendy DeMartini, an assistant professor of radiology at the University of Washington Medical School, said MRI imaging found proportionally more cancers in women who had been treated for breast cancer than in the women considered at very high risk.\nWhile the society recommends neither for nor against MRI imaging for those with a personal history of breast cancer, he said it regularly reviews study findings to determine if the guidelines need updating.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story does not address the availability of appropriate equipment and skilled operators and radiologists. The story should have pointed out that MRI imaging available to women in general may not match the quality of the work done in this research study.", "answer": 0}, {"article": "By far, the lowest incidence of colorectal cancers was seen in pesco-vegetarians, people who eat fish at least once a month but eschew all other types of meat. Compared to omnivores, pesco-vegetarians were 43% less likely to be diagnosed with these cancers during the course of the study.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. Vegetarian foods are widely available.", "answer": 2}, {"article": "\u201c[PRP] works, and the results have been amazing,\u2019\u2019 says John Ferrell, the sports medicine physician who treated me.\nWe will be able to treat ailments noninvasively, and at an earlier stage.\u2019\u2019\n\nThe procedure involves collecting several ounces of blood from a patient\u2019s arm, spinning the blood in a centrifuge to concentrate the platelets and injecting the concentrated platelets into the injury site to stimulate healing.\nIt showed tissue healing in five of seven of the patients who received PRP, as well as improvements in their pain and function.\nThose who seek this treatment must look for a clinician with considerable PRP experience \u2014 someone who does the procedure several times a day, not once or twice a month \u2014 and who has a good success rate, Ferrell says.\nThe researchers call the results \u201cclinically relevant,\u2019\u2019 despite the study\u2019s small size, and say the next step should be a larger, controlled clinical trial.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that platelets are removed from a patient\u2019s blood using a centrifuge, equipment readily available in most practices.\u00a0 It makes the point of advising readers to seek out practitioners who do the procedure frequently.\u00a0 The story suggests that the PRP procedure is becoming more available.", "answer": 1}, {"article": "Although the study looked at patients taking warfarin (Coumadin), newer drugs -- including rivaroxaban (Xarelto) and apixaban (Eliquis) -- should reduce the risk of dementia even more, Bunch said.\nIt causes the heart to beat abnormally or quiver.\nIn high-risk patients, a delay increased the risk 136 percent, the researchers reported.\nThis causes blood to pool, and then it can clot.\nThe longer the delay in giving blood thinners, the more the risk for dementia, the researchers said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Warfarin is a common drug, as are a number of other blood thinners.", "answer": 1}, {"article": "The fact that this uncertainty is occurring so long after the 1998 approval of Herceptin \u2014 the paragon of \u201cpersonalized medicine\u201d \u2014 suggests that it will not be so easy to tailor other drugs to patients based on gene or protein tests.\nYet the women with those tumors also experienced a reduction in cancer recurrence from Herceptin, in some cases as great as that in the Her2-positive women.\nBut scientists have now gone back and retested those preserved tumor samples and found that as many as 20 percent of them were actually Her2-negative.\nBut two studies discussed at the oncology meeting found that patients who were considered Her2-negative even using both tests benefited from Herceptin.\nFor a woman to have entered those trials, her tumor had to be classified as Her2-positive by a local clinical laboratory.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story correctly points out that Herceptin treatment has been approved and available for about ten years, and discusses testing for the presence of the HER2 receptor.\u00a0 ", "answer": 1}, {"article": "There\u2019s good evidence this happened to many \u2014 but not all \u2014 opioid painkiller users: A 2014 study in JAMA Psychiatry found 75 percent of heroin users in treatment started with painkillers, and a 2015 analysis by the CDC found people who are addicted to painkillers are 40 times more likely to be addicted to heroin.\n\u201cThere are people who do not do well with tapering.\u201d\n\nBut the study suggests that getting some patients off opioids could improve their pain outcomes.\nFor one, the reviewed studies generally looked at the results of tapering, when patients are slowly weaned off opioid painkillers \u2014 a process that, Stanford psychiatrist Anna Lembke told me, can take months or even years.\nThe fundamental problem is many of these patients don\u2019t get addiction treatment once they lose access to painkillers or before they progress to heroin or fentanyl.\nAnd the studies only evaluated voluntary reductions in opioid doses; it\u2019s entirely possible that involuntary reductions in opioid doses would lead to sharply different outcomes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story delivers: It states that tapering is available, yet that it\u2019s to be attempted with caution. Non-opioid pain-relief treatments, which are also noted by the story, are also said to be available, though out of reach for many.", "answer": 1}, {"article": "Two new just-released studies offer fresh insights into the best way to lose weight and keep it off. Jennifer Corbett Dooren has details on The News Hub. Photo: Bloomberg\n\nA diet based on healthy carbohydrates\u2014rather than a low-fat or low-carbohydrate diet\u2014offers the best chance of keeping weight off without bringing unwanted side effects, a study published Tuesday in the Journal of the American Medical Association suggests.\n\nStudy participants following a low-glycemic-index diet, which is similar to a Mediterranean diet and focuses on fish, fruit, vegetables, nuts and whole grains, also saw improved cholesterol levels and other important markers that lower the risks of developing heart disease...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of these different diets is not in question.", "answer": 2}, {"article": "Together, stomach and oesophageal cancer account for around 1.4 million new cancer diagnoses each year worldwide [2].\nThe results showed that the test was 85% accurate overall, with a sensitivity of 80% and a specificity of 81%.\nThe team is also working on breath tests for other types of cancer, such as colorectal and pancreatic, which could be used as first-line tests in general practice surgeries.\nThis means that not only was the breath test good at picking up those who had cancer (sensitivity), it was also good at correctly identifying who did not have cancer (specificity).\nThis study suggests that we may be able detect these differences and use a breath test to indicate which patients are likely to have cancer of the oesophagus and stomach, and which do not.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that the breath test is not available. The release did not make any predictions about when such a test might make its way through the full course of experimental trials.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070107/15downs.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does state that the availability of the new\u00a0ultrasound may be limited to academic or large city hospitals.", "answer": 1}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\nThe study, published this month in the Journal of Drugs and Dermatology, found patients who were originally prescribed spironolactone changed to a different drug within one year at almost the same rate as those who were prescribed antibiotics.\nWithin a year, 14.4 percent of spironolactone patients and 13.4 percent of antibiotic patients had switched to alternative treatments, suggesting each treatment was working at almost the same rate, despite the fact that tetracycline-class antibiotics are prescribed five times as frequently.\nThe prescription change is a proxy for ineffectiveness, since switching is often the result of treatment failure due to lack of efficacy, side effects, cost, or other factors.\nSpironolactone, marketed under the name aldactone, is currently approved to treat high blood pressure, heart failure, and conditions that cause people to retain fluid.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release explains that both methods are currently available and in use. It states that while some dermatologists already prescribe\u00a0spironolactone for acne, the FDA has not approved it for that use. Without FDA approval, most insurers will not cover the cost of treatment.", "answer": 1}, {"article": "\u2022 4.9 million babies are born with a serious birth defect worldwide every year\n\u2022 3.3 million children under five die from serious birth defects annually\n\u2022 Congenital heart disease is the most common form of birth defect, affecting 1 in 100 babies\n\u2022 42 babies are born with a heart defect in Australia every week\n\u2022 30 babies will undergo heart surgery in Australia every week\n\u2022 Heart defects account for 30% of deaths in children under five\n\n[1] Baker H, DeAngelis B, Holland B, Gittens-Williams L, Barrett T Jr. Vitamin Profile of 563 Gravidas during Trimesters of Pregnancy.\nNAD synthesis is essential for energy production, DNA repair and cell communication.\nClick here to read the latest statement from the Victor Chang Institute.\nAfter the dietary change, both the miscarriages and birth defects were completely prevented, with all the offspring born perfectly healthy.\n\u201cWe believe that this breakthrough will be one of our country\u2019s greatest medical discoveries.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release noted that niacin is available as a dietary supplement. ", "answer": 1}, {"article": "Drug list (formulary): To see a list of covered drugs for the plan you\u2019re considering, use the drop-down menus below.\n\nIf your employer is offering coverage, contact HR for the pharmacy plan name.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Story about FDA approval for women with early-stage invasive disease.", "answer": 1}, {"article": "If it can, and the drug agency approves Avodart for cancer prevention, doctors and patients may have to decide between a generic drug used off-label or a more expensive brand-name drug that does much the same thing.\nThe study was designed to look for a reduction in the overall prostate cancer rate.\nThe concern was that the drug might be preventing cancers that never spread.\nThe researchers had a way to learn if they were correct.\nA pathologist could carefully examine every one of those 500 prostates and compare the kinds of cancers found at surgery to those initially diagnosed at biopsy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story accurately mentions the availability of this drug as a prescription medication.", "answer": 1}, {"article": "\"Our findings show that ocrelizumab rapidly suppresses inflammatory activity,\" noted the study authors, led by Dr. Ludwig Kappos from the University Hospital, Basel, Switzerland, in a journal news release.\nWhat's more, to date the treatment appears to be safe.\nAfter 24 weeks, some of the doses were adjusted.\nThe number of active lesions had dropped 89 percent more among the 600-mg group compared with those getting a placebo.\nWhat's more, relapse rates were much lower among those taking the new drug, in contrast to those taking a placebo.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that the approach \u201cis only in the early stages of exploration.\u201d", "answer": 1}, {"article": "The other 10 received a fake treatment.\nThis condition often occurs after a stroke on the right side of the brain and is typically treated with a combination of physical therapy and brain retraining or mental tasks using a pen and paper or computer.\nResearcher Giacomo Koch, MD, PhD, of the Santa Lucia Foundation in Rome, Italy, and colleagues point out that the changes could be the combined effects of the mental tasks and the TMS.\nThey can\u2019t see or recognize anything on one side of their body.\nThe tests also measured activities of daily living affected by neglect, such as dialing numbers on a phone, reading a menu, and sorting coins.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The study is described as \u201cpreliminary\u201d and the treatment is called \u201cnot ready for prime time.\u201d We think readers get the idea that this treatment is not available for stroke rehabilitation outside of a research setting.", "answer": 1}, {"article": "The marketing materials suggested it already had.\n\u201cThe images sort of sell themselves.\u201d\n\nMuch of the criticism focused on the data the task force had used to make its decision, which consisted largely of the results from prospective, randomized clinical trials conducted in the United States.\nSo the outcomes may be better, too.\u201d The studies the task force had chosen to examine showed that screening beginning at age 40 had little impact on mortality while at the same time generating a significant number of false positives.\nAn ad for GE\u2019s 2-D digital system that ran during the Summer Olympics called it a \u201cmajor new breakthrough in the fight against breast cancer.\u201d Digital technology, the thinking went, would show nuances that film never could, because it could render, literally, many more shades of gray.\nSo perhaps it\u2019s not surprising that the company\u2019s PowerPoint presentation to the FDA included the unsubtle phrase \u201chuge breakthrough,\u201d or that the first American patient to undergo 3-D mammography \u2013 Laura Lang, a polished 55-year-old Boston marketing executive and breast cancer survivor \u2013 did so in front of a CBS camera crew last February.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Early in the piece, the story mentions the limited availability of 3-D mammography, which received FDA approval in February 2011.\u00a0 The technology is currently available in \u201c\u2026at least nine states, three of which have multiple sites.\u201d\u00a0 The technology is clearly available for the paper\u2019s readers because the piece focuses on Massachusetts General Hospital, which was both a development and\u00a0a test site for the equipment.", "answer": 1}, {"article": "A new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may help patients whose condition is not well controlled by existing medicines, according to the results of a small clinical trial released Tuesday.\n\nIn the 12-week study, the number of asthma attacks or other outbreaks of symptoms decreased by 87 percent in those getting the drug, dupilumab, compared with those getting a placebo.\n\nOther measures of lung function and disease control also improved, according to the study results, which were published online Tuesday in The New England Journal of Medicine and presented at the annual meeting of the American Thoracic Society in Philadelphia.\n\nDupilumab blocks the action of interleukin-4 and interleukin-13, two inflammatory chemicals made by the body that are believed to contribute to asthma. Sanofi and Regeneron say there are also preliminary signs dupilumab works against the skin condition atopic dermatitis, suggesting it can be blocking a biological pathway that contributes to multiple allergic conditions.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "In the fifth paragraph, the story says, \u201cStill, much larger studies, taking at least two or three years, are likely to be needed before the drug could reach the market.\u201d", "answer": 1}, {"article": "WEDNESDAY, Nov. 30, 2011 (HealthDay News) -- Eating baked or broiled fish as little as once a week may boost brain health and lower the risk for mild cognitive impairment and Alzheimer's disease, new brain scan research suggests.\n\"They had larger brain cells in areas of the brain responsible for memory and learning.\n\"We're talking about just a half serving a day,\" he said.\nFor now, the connection must be viewed as an association, rather than a cause-and-effect.\nFor more on brain health, visit the Society for Neuroscience.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of fish is not in question.\n ", "answer": 2}, {"article": "Pancreatic cancer is currently very difficult to detect while it is still resectable.\nThere is currently no cure and few treatment options for advanced pancreatic cancer, which is the late stage when pancreatic cancer is usually diagnosed\", explains Carl Borrebaeck, professor at the department of Immunotechnology at Lund University.\nIn the future, the screening method could be used to screen people who are at a higher risk of developing pancreatic cancer, such as those with a hereditary risk, newly onset diabetes patients and patients with chronic inflammation of the pancreas.\n\"Our test can detect pancreatic cancer with 96% accuracy at stage I and II, while there is still the possibility of successful surgical intervention.\nSince the immune system is the first to respond to threats like complex diseases, such as cancer, autoimmune diseases and infections, the microarray was designed to mirror this early response.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "At the very end of the news release we read:\n\u201cIn the future, the screening method could be used to screen people who are at high risk of developing pancreatic cancer, such as those with a hereditary risk, newly onset diabetes patients, and patients with chronic inflammation of the pancreas. The next step has already been initiated, which is a large US prospective study for high risk individuals.\u201d\nThis is an important inclusion but it would have helped to put this higher up in the news release because it provides an opportunity to emphasize that the blood test is unproven as a screening tool.\nMore importantly, it\u2019s currently not commercially available and the news release should have made this clear.", "answer": 0}, {"article": "But there\u2019s a problem with a low-FODMAP diet.\nInstead, it\u2019s fermentable oligosaccharides, disaccharides, monosaccharides and polyols, or FODMAPS.\nGluten is not a carbohydrate; it\u2019s a mix of proteins found in wheat and its close relatives (including spelt, kamut and farro), as well as in barley and rye.\nThey may assume that they have gluten sensitivity, but some researchers believe that it\u2019s not the gluten they\u2019re sensitive to.\nIt\u2019s what gives bread its elasticity, but it also sets off the immune system of people with celiac disease, damaging the small intestine and sometimes producing painful and unpleasant symptoms.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article provides a good listing of foods to choose from that are both high and low in FODMAPS. All are widely available.", "answer": 1}, {"article": "The U.S. drugmaker on Monday said patients taking the approved 2 milligram dosage of Keytruda and those taking an experimental 10 milligram dose had longer overall survival compared with those taking docetaxel, a standard treatment for non small cell lung cancer (NSCLC), the most common form of lung cancer.\nThe approval was contingent on the company providing more detailed data in the future on Keytruda\u2019s safety and effectiveness.\nKeytruda thereby met its main goal of the study.\nThose whose tumors expressed PD-L1, but not at high levels, did not show such a statistically significant benefit in progression-free survival.\nSafety of Keytruda was consistent with what had been seen in previous trials among lung cancer patients, Merck said in a release that included only summary \u201ctopline\u201d information from the results.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that Keytruda has been approved for use in treating lung cancer.", "answer": 1}, {"article": "Avastin is undercutting sales of Lucentis, which totaled $1.1 billion in the United States last year.\nBut he said there were other factors as well, like a belief that Lucentis might have been the better drug.\n\u201cObviously you can\u2019t underplay $9 million,\u201d said Dr. Ferris of the eye institute, which is part of the part of the National Institutes of Health.\nAlthough it is a cancer drug, Avastin is often used off-label for eye diseases because it is far cheaper than Lucentis, costing only $20 to $100 a dose, compared with $2,000 for Lucentis.\nAfter the first year, only 3 to 4 percent of the eyes treated with Lucentis suffered a visual loss of two or more lines compared to 13 percent that got only laser therapy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story was crystal clear that the drug reported on, Lucentis, is available as it is FDA approved for another condition; the story also mentioned that it is not yet FDA approved for treatment of diabetic macular edema.", "answer": 1}, {"article": "He cautioned that persistent use of ibuprofen can lead to gastritis, or inflammation of the stomach lining, but said that, in comparison, \"there is very little to lose when measuring its side effects against the effects of Parkinson's,\" which can include loss of balance, stiffness, hallucinations and dementia.\nNo other pain reliever was found to lower the risk for Parkinson's.\nIn a six-year span, 293 were diagnosed with the disease.\nThe National Parkinson's Foundation has more on Parkinson's disease.\nTagliati called the study \"eye-opening.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that ibuprofen is a common anti-inflammatory drug. ", "answer": 1}, {"article": "Breaking the diet with so much as a few cookies can cause seizures to flare up.\n\u201cThis is the first time that we\u2019ve really got Class 1 evidence that this diet works for treatment of epilepsy,\u201d said Dr. J. Helen Cross, professor of pediatric neurology at University College London and Great Ormond Street Hospital.\nThough its exact mechanism is uncertain, the diet appears to work by throwing the body into ketosis, forcing it to burn fat rather than sugar for energy.\nAs the first randomized trial of the diet, the new study lends legitimacy to a treatment that has been used since the 1920s but has until recently been dismissed by many doctors as a marginal alternative therapy.\nFor the British trial, the researchers enrolled 145 children ages 2 to 16 who had never tried the diet, who were having at least seven seizures a week and who had failed to respond to at least two anticonvulsant drugs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that this dietary approach to managing epilepsy is a standard treatment at hospitals and epilepsy centers in the United States and abroad.\u00a0 So we get somewhat of a sense of its availability.\u00a0 But the story doesn\u2019t make clear just how many hospitals and epilepsy centers use this approach, or how many have the necessary cross-discipline resources to manage the approach.\u00a0 ", "answer": 1}, {"article": "LONDON (Reuters) - British scientists conducting early-stage research have found that a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia(MLL) \u2014 the most common form of leukemia in babies.\nIn a study published in the journal Nature, scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151, mimics a chemical tag which is key to preventing the process of activating the leukemia genes.\nUsing I-BET151 to treat leukaemias in mice and human cancer cells in a lab, the researchers found that the chemical could halt the disease, paving the way for more research to be done in first-stage, or so-called Phase I, human trials.\n\u201cAlthough this research is only in the lab at the moment, we hope it will move quickly toward clinical trials in patients.\u201d\n\nLeukemia is the most commonly diagnosed cancer in children and accounts for a around a third of all cancers diagnosed in children.\nKouzarides\u2019s team found that in the disease, the MLL-fusion proteins are targeted to leukemia-causing genes by proteins from the BET family, which recognize certain chemical \u201ctags\u201d on chromatin, the scaffold on which DNA is arranged.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story had several reminders for readers of the early stage of this research.\u00a0 The reminder that \u201cit will probably be many years before the drug could potentially reach the market\u201d is almost premature in itself given that this is something that hasn\u2019t even been tested outside the lab yet \u2013 with not one human experiment having been conducted.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - When symptom-free people have heart scans to look for clogged arteries, they can end up with overtreatment and side effects, researchers said Monday.\nBy contrast, it\u2019s well known that the scans expose patients to a high dose of X-rays, which can increase their likelihood of developing cancer.\nAlthough the study can\u2019t prove that getting a scan caused the extra medication use, the gap could not be explained by differences in risk factors for heart disease, such as cholesterol levels or smoking.\n\u201cPhysicians cannot easily ignore diagnoses made with screening tests because it is impossible for them to determine whether their patients have real disease or pseudodisease,\u201d Lauer notes.\n\u201cOverdiagnosis is threatening to become an increasingly important public health problem because of the enthusiasm for and proliferation of unproven screening tests,\u201d Lauer writes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was clear that the scans are not currently recommended by guidelines but that \u201cthere have been several reports of doctors doing CCTA heart scans in healthy patients, although the practice is currently discouraged by the American Heart Association.\u201d", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/15/national/a141001S34.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "The new analysis was published online Monday in Archives of Internal Medicine.\nThe results \"provide the most robust evidence to date that acupuncture is a reasonable referral option,\" wrote the authors, who include researchers with Memorial Sloan-Kettering Cancer Center in New York and several universities in England and Germany.\nWhile the difference in results for real versus fake acupuncture was small, it suggests acupuncture could have more than a psychological effect, said lead author Andrew Vickers, a cancer researcher at Memorial Sloan-Kettering.\n\"Perhaps a more productive strategy at this point would be to provide whatever benefits we can for our patients, while we continue to explore more carefully all mechanisms of healing,\" he wrote.\nThe military has used it to help treat pain from war wounds, and California recently passed legislation that would include acupuncture among treatments recommended for coverage under provisions of the nation's new health care law.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that acupuncture is becoming more mainstream and might be covered in some states under the new health care law. However,\u00a0a dearth of licensed acupuncturists might restrict availability in some areas, especially rural locations. The story could have mentioned this. But we\u2019ll give it the benefit of the doubt for its general discussion of availability.", "answer": 1}, {"article": "\"The study is encouraging enough that we should certainly go ahead and do a [larger] clinical trial because we showed that it is safe and does have significant effects on Alzheimer's biomarkers,\" said Dr. R. Scott Turner, professor of neurology at Georgetown University Medical Center and lead investigator of the study, which was published on Friday in the journal Neurology.\nThere is probably little benefit in taking currently available resveratrol supplements, even if they claim to contain levels similar to the ones used in this study.\nEven if concentrated forms of resveratrol pills like the kind used in this study were available, it's too soon to recommend going out and getting some just yet.\nNow, the first study in people with Alzheimer's suggests that the compound, when taken in concentrated doses, may actually have benefit in slowing progression of this disease.\nThe researchers looked at several biomarkers of Alzheimer's, and found that people who took up to four pills a day for a year had higher levels of amyloid-beta proteins in their spinal fluid than those who took a placebo (control) pill.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The study addresses this specifically: \u201cEven if concentrated forms of resveratrol pills like the kind used in this study were available, it\u2019s too soon to recommend going out and getting some just yet.\u201d", "answer": 1}, {"article": "Researchers then narrowed their analysis to see how the urine test scores matched the men\u2019s Gleason score, which helps doctors gauge how aggressive a cancer may be.\nThose scores were then compared to the biopsy results.\nThe two tests together appeared to generate both sensitive and specific results.\nBased on the levels of PCA3 and TMPRSS2:ERG detected, the men were given numerical scores that were classified as being high, medium, or low.\n\u201cThe men in the highest group have a risk of cancer on biopsy of about 70% and those in the lowest group have a risk of cancer of about 20%,\u201d says Tomlins.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that the test was in development.", "answer": 1}, {"article": "The page you are looking for has moved. Please go to the main EurekAlert! homepage to locate the section you are interested in and reset your bookmarks.\n\nFor further assistance, please contact webmaster@eurekalert.org.", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Most readers will know that ibuprofen is a widely available, over-the-counter drug.\nHowever, it\u2019s not made clear how available (or accurate) the saliva test for Abeta42 is.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/01/17/national/a130050S19.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This\nrating does not apply, as the story focuses on watchful waiting and active surveillance in lieu of preventative surgery for\nhernias. Hernia operations are a common procedure and available in most hospitals; the new treatment (no intervention, save\nfor monitoring general health or symptoms typical of a hernia) is also now an evidence-based option for treatment.", "answer": 2}, {"article": "For the process they used recombinant human collagen, a substance synthesized in the laboratory to mimic human tissue and supplied by the San Francisco biotech firm FibroGen Inc.\n\u201cWith further research, this approach could help restore sight to millions of people who are waiting for a donated human cornea for transplantation.\u201d\n\nThe cornea is a tiny piece of transparent, film-like tissue that covers the surface of our eyes.\nThe researchers found that, eventually, the cells and nerves from nine of the 10 patients regrew completely and packed themselves into the implant, resulting in a kind of \u201cregenerated\u201d cornea that looked and functioned like normal, healthy eye tissue.\n\u201cThis study ... is the first to show that an artificially fabricated cornea can integrate with the human eye and stimulate regeneration,\u201d said May Griffith of the Ottawa Hospital Research Institute, who led the study.\nIn the United States, an estimated 42,000 corneal grafts a year are performed using tissue from posthumous donors, but there are sometimes problems with rejection and experts say failure rates are significant.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There is no discussion of the availability. Unlike the WebMD\u00a0story, this story did not make it clear how preliminary this research is. Instead, it used phrases such as, \"their findings offered hope for the millions of people who go blind each year because of a worldwide shortage of corneas for donation\" and \"this approach could help restore sight to millions of people who are waiting for donated human corneas for transplantation.\"", "answer": 0}, {"article": "Lorren Sandt, chairwoman of the National Viral Hepatitis Roundtable, an advocacy group, called the trial results impressive.\nThe standard therapy of interferon and ribavirin was given for either 24 weeks or 48 weeks, depending on how the patients were faring after four weeks and 12 weeks.\n\u201cThese data support the vision that we have long had for fundamentally changing the treatment for hepatitis C,\u201d Dr. Robert Kauffman, Vertex\u2019s chief medical officer, said in a conference call with securities analysts.\nOf those who got 12 weeks of telaprevir, 75 percent had a sustained viral response, meaning the virus was not detectable in their blood 24 weeks after completing treatment.\nThe virus is transmitted by blood, so most people who have hepatitis C either have injected illegal drugs or received blood transfusions or blood products before the early 1990s.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The second word in the story is \"experimental.\" It talks about the drug being in three different Phase 3 clinical trials and about the company looking forward to applying for approval from the FDA. What it does not do is make it clear how quickly the drug could be brought to market (or slowly) especially given the problems of side effects also noted in the story.", "answer": 1}, {"article": "Massage Therapy May Rub It Out\n\nLow back pain is second only to cold symptoms when it comes to complaints that send people to the doctor.\n\"We found that both types of massage were equally effective in helping people improve their function and diminish their symptoms,\" Cherkin says.\nStudy participants were randomly assigned to one of three treatments.\nAfter each session she walked around the block, standing straighter and walking further each time.\nOnly about one-third of patients receiving the usual care experienced similar relief.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Massage is widely available. The story states, \u201crelaxation massage is more widely available\u201d.", "answer": 1}, {"article": "\"These treatments really have the potential to transform people's lives,\" Vickery said, \"and I have seen it happen firsthand: the sense of relief [families] get when a child becomes desensitized.\"\nOverall, participants experienced fewer side effects during the study than the researchers had anticipated.\n\"Having stomach cramps did not feel very good,\" she said.\nI would say it's been some work to go through this study, just in terms of a time commitment.\"\nShe'd gone into anaphylaxis, a severe allergic reaction.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the treatment is not yet FDA-approved, and is not currently commercially available.", "answer": 1}, {"article": "\"We now feel pretty confident that, in many children with autism, there are alterations either in structure growth or connectivity of the brain, but we really don't understand the implications of that for core features of autism, one of which is problems with communication,\" Amaral said.\nThis allowed the investigators to see which parts of the brain were being activated in typical children versus children with autism.\n\"We were interested in what was going on in the earliest period of life that could account for these differences,\" she continued.\nBut in the autistic children, there was slightly more right hemisphere response than left hemisphere, and there was no change in activity across the age range.\nThe Autism Society of America has more on this disorder.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear several ways that this is early research and would require further development before a detection protocol was available.", "answer": 1}, {"article": "Duchenne muscular dystrophy affects an estimated one in 3,500 males, according to the National Institutes of Health.\nBecause of the involvement of the X chromosome, boys are far more likely to be affected than girls, who have two copies of the X chromosome and, thus, are likely to have a \u201cspare\u201d copy of the healthy gene.\nIt is not clear just how the drug is helping the mice, they reported in the Proceedings of the National Academy of Sciences, but they said it may be worth trying it as a treatment for muscular dystrophy.\n\u201cAlthough PDE5 inhibitors will certainly not cure DMD, the current studies suggest that they could be used in combination with current or future therapies,\u201d the researchers wrote.\nViagra, known generically as sildenafil, is sold by Pfizer Inc for erectile dysfunction and under the brand name Revatio to treat a heart condition called pulmonary hypertension.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story reports that sildenafil is the drug in Viagra, used to treat erectile dysfunction, and also Revatio, which is used to treat pulmonary hypertension. The story would have been better if it referred to the active ingredient in Viagra, rather than Viagra itself, and had pointed out that to treat heart problems, the drug would be given continually (as it is for pulmonary hypertension) and not just occasionally as it is when used to treat erectile dysfunction.", "answer": 1}, {"article": "Toenail fungus causes nails to become thick, yellow and brittle in a way that looks pretty ugly and can be painful.\nIn this case, there is a chance.\u201d\n\nEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\nCompared with oral medication, he says, \u201cthe odds of success are better with the laser; plus, there\u2019s no side effects.\u201d\n\nThe most common oral treatment, Lamisil, works for about two out of three patients, according to Lamisil\u2019s FDA-approved prescribing information, but it has been associated with rare cases of serious liver problems.\nIn one small study about laser treatment for toenail fungus, which appeared last year in the Journal of the American Podiatric Medical Association, \u201c26 eligible toes (ten mild, seven moderate, and nine severe)\u201d were treated with a laser produced by Nomir Medical Technologies, which is still seeking FDA approval.\nLast year, the Food and Drug Administration cleared the first laser, PinPointe, for \u201ctemporary increase of clear nail\u201d in patients with onychomycosis, the medical term for a fungal infection of the nail.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says, \u201cLast year, the Food and Drug Administration cleared the first laser, PinPointe, for \u201ctemporary increase of clear nail\u201d in patients with onychomycosis, the medical term for a fungal infection of the nail. The FDA cleared a second one, GenesisPlus, in April. Practitioners have been using other lasers on toenail fungus since about 2009.\u201d This covers the necessary bases.", "answer": 1}, {"article": "WASHINGTON (Reuters) - A urine test can help doctors better spot prostate cancer than either the current blood test or a rectal exam alone, U.S. researchers reported on Tuesday.\nThe test was approved for use in Europe in 2006 but is not yet approved in the United States.\nThe test had a sensitivity of 49 percent, meaning it correctly identified 49 percent of cancers.\n\u201cIf you had no cancer your PCA3 was at 25 or 20.\nIt is a string of RNA that does not appear to have any function but that is overexpressed, or overactive, in prostate cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story stated that this test is approved for use in Europe but not the US.", "answer": 1}, {"article": "Yet the study suggests the opposite has happened.\nFinally, since the study looked at correlation (not causation), it\u2019s possible that it missed some other factor driving up overdose deaths among concurrent benzodiazepine and opioid users \u2014 perhaps, for whatever reason, these users may be more likely to misuse their drugs.\nBut there\u2019s a catch: Such overdoses seem to be very closely tied to the opioid epidemic, with the majority of benzodiazepine overdose deaths involving both benzodiazepines and opioids.\nSo it\u2019s not really controversial to conclude that simultaneously using opioids and benzodiazepines dramatically increases the risk of drug overdose \u2014 or, conversely, that stopping the concurrent use of these two drugs could reduce the risk of overdose.\n\u201cEven if we didn\u2019t change opioid prescribing at all, the data here suggest that we could cut overdoses dramatically just [by] getting prescribers to not put people on a benzodiazepine at the same time,\u201d Humphreys said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "On balance the story could have done a better job of exploring what it would take to halt these dangerous drug interactions. The headline describes their elimination as a \u201csimple way to help combat the opioid epidemic,\u201d but the story acknowledges otherwise:\nFor some patients, eliminating these co-prescriptions could involve some tough trade-offs. If someone genuinely suffers from pain and anxiety, doctors and patients will need to work out which condition is more important to treat and which one can be treated with alternatives \u2014 to avoid a potentially deadly overdose.\nThe story also could have addressed the difficulty in changing physicians\u2019 prescribing patterns. If indeed, as the story contends, \u201cit\u2019s well established that benzodiazepine and opioids compound each other\u2019s overdose risk,\u201d why have so many dual prescriptions been written?\u00a0 Are there readily available and affordable alternatives to these two classes of drugs? The story doesn\u2019t say.", "answer": 0}, {"article": "Ramsden acknowledged that the Sydney study had been narrowly focused on a specific group of people: middle-aged men with a history of heart disease, who were asked to consume linoleic acid in quantities far exceeding both AHA guidelines and the dietary habits of most Americans.\n\"There is more than one type of polyunsaturated fatty acid,\" explained Dr. Christopher Ramsden, who headed the re-analysis and is a clinical investigator with the laboratory of membrane biophysics and biochemistry at the National Institute on Alcohol Abuse and Alcoholism, part of the U.S. National Institutes of Health.\n\"And so, we were interested in trying to evaluate just one of these compounds, linoleic acid, by looking at this old trial using modern statistical methods, and also by re-including some original data that had gone missing from the first analysis,\" Ramsden explained.\nBut in the ensuing years, researchers have come to understand that not all PUFAs are alike, with key biochemical differences -- and perhaps varying cardiovascular impacts -- observed among multiple types of omega-3s (found in fish oils) and omega-6 linoleic acids.\nThe original \"Sydney Diet Heart Study,\" was initially conducted between 1966 and 1973, at a time when the cholesterol-lowering benefits of all polyunsaturated vegetable acids (PUFAs) were touted with a broad brush.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story mostly used terms like \u201comega-6 fat\u201d and \u201clinoleic acid.\u201d But\u00a0food fats and oils\u00a0\u2014 things like corn oil and soybean oil\u00a0that people actually look for in the grocery store \u2014\u00a0contain\u00a0differing\u00a0combinations of omega-6 linoleic acid,\u00a0omega-3 fats, and other fatty acids. Although the story notes that the study involved safflower oil, it would have been helpful to explain how much linoleic acid is found in other types of oils, and\u00a0whether these oils also include omega-3 fats.", "answer": 0}, {"article": "So mystery and grief hung heavy when he collapsed from a cardiac arrest Jan. 6 inside the Teutonia M??\nThe ambulance service was close by and transported him without delay to AGH only blocks away.\nBut that number is one or two higher than would occur without hypothermic therapy.\nOnce oxygen returns to the brain, further damage can occur.\nThroughout the procedure he remained sedated to prevent shivering.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that this treatment is not available at all hospitals.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Monitoring high-risk pregnancies with ultrasound tests may help prevent some fetal and newborn deaths, a new research review finds.\nAbnormal findings indicate that the fetus may be under stress.\nIn these cases, the fetus may not be getting enough nutrients and oxygen through the placenta.\nSome had flaws in their design, while in other cases the researchers failed to provide details on key elements of the study design.\nIn practice, Doppler ultrasound may also be recommended for women who have diabetes or are having a prolonged pregnancy (beyond 42 weeks).\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story notes that Doppler is an established technique used to monitor high-risk pregnancies.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061008/16organ.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article discusses several consortia or organizations of hospitals that participate in paired matching of organs. Based on the limited number of participating hospitals in selected regions, it seems clear this is not widely available at present. Plus, the article mentions that legislation is needed before a federally funded organ donation organization (UNOS) could get involved, potentially making this much more widely available. ", "answer": 1}, {"article": "\u201cThey often don\u2019t appreciate the downside of screening,\u201d Dr. Brooks said, \u201cand they don\u2019t appreciate the delay in benefit.\u201d In addition, Dr. Brooks said, primary care doctors often \u201coverestimate the likelihood that early detection of prostate cancer will lead to survival benefits.\u201d\n\nAdded to that, Dr. Brooks said, is the length of time it takes to discuss the pros and cons of screening with patients.\nThe men were aged 55 to 74 when the study began.\nThey note that prostate cancer is a common cancer, found in most men\u2019s prostates on autopsy, although often the men had no idea they had it.\nSide effects can include impotence and incontinence.\nOften it is easier to just order the test.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that \u2018routine\u2019 PSA testing is readily available.", "answer": 1}, {"article": "A growing body of evidence suggests that weight-loss surgery is more effective than diet and exercise at getting rid of Type 2 diabetes.\n\nA small but rigorous randomized trial published Wednesday in JAMA Surgery provides the latest evidence showing the superiority of bariatric surgery over lifestyle changes in resolving the chronic condition involving high blood sugar.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers would have benefited from some information about the availability of weight loss surgery in the U.S. Is the newer sleeve gastrectomy procedure available everywhere across the country? What are the criteria for insurance coverage?", "answer": 0}, {"article": "THURSDAY, May 9, 2013 (HealthDay News) -- Scientists report positive results in early testing of a wireless pacemaker that's placed in the heart instead of being connected to it via wires from the upper chest.\nIf the old device is left in place, it is not known what the long-term effects of this will be.\"\n\"This is going to be the future,\" he said.\nIt's also not clear when the pacemaker may be publicly available, and its cost is unknown.\nThe new pacemaker is about the size of a AAA battery and provides jolts to one chamber of the heart, Reddy said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "In the second paragraph the story explains that \u201cit\u2019s not clear when the pacemaker may be publicly available.\u201d", "answer": 1}, {"article": "London, England (CNN) -- Researchers hope a new treatment developed in the United Kingdom will prove vital in controlling future flu pandemics such as H1N1 (swine) flu, bird flu as well as ending the need for annual flu jabs.\nThe vaccine would be an important step in treating seasonal flu, not just pandemics.\nNormally it's the very old or very young that die from flu, but every year there are deaths from influenza A,\" said Gilbert.\nYou could stockpile the vaccine and wouldn't have this wait to make a new pandemic-specific vaccine,\" she said.\n\"I think it's a very interesting and very elegant approach and the data so far looks very, very good,\" he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that the vaccine is in the early stage of development and will not be available for at least several more years. ", "answer": 1}, {"article": "We can't find the page you're looking for. Try one of these options.\n\nAre you sure this is the right web address? Let us know.", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the first sentence that the device is not yet available and that the FDA just approved the device for marketing to breast cancer patients.\nDigniCap wrote on its website: \u201cWe will be finalizing agreements with major cancer centers and community oncology groups across the country so that they will be able to offer DigniCap\u00ae treatments to patients as soon as possible.\u201d", "answer": 1}, {"article": "Aug. 15, 2012 -- If you aspire to fatherhood, it might not hurt to go a little nuts.\nWalnuts, that is.\nThe other men were told to continue their regular diet but not to eat any tree nuts.\nBefore and after the experiment, the men\u2019s semen quality was analyzed by a researcher who did not know which ones had eaten walnuts.\nEating 2.5 ounces of walnuts a day -- a little more than half a cup -- for 12 weeks improved sperm quality in healthy young men, researchers report.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of walnuts is not in question.", "answer": 2}, {"article": "'This is not the end': Using immunotherapy and a genetic glitch to give cancer patients hope\n\nNew shingles vaccine is highly effective \u2014 and in short supply\n\nResearchers use immune-cell 'army' to battle another tough cancer\nFDA Commissioner Scott Gottlieb said the approval was \u201ca reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies.\u201d The medication, tested in three randomized, placebo-controlled trials with more than 500 patients, was effective in reducing seizures, the FDA said.\nFor those who have long argued that cannabis offers medical benefits, the FDA approval represents a milestone, \u201ca recognition that the plant is a rich source of compounds which have potential therapeutic activity,\u201d Justin Gover, chief executive of GW Pharmaceuticals, the London-based company that developed the drug, said in an interview last week.\nThe disorders afflict fewer than 45,000 people in the United States, but experts expect Epidiolex to be prescribed for other types of epilepsy as well.\nNow that Epidiolex is approved by the FDA, cannabidiol is expected to be reclassified by the Drug Enforcement Administration within 90 days.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article does not state exactly when the drug will be on the U.S. market, but generally, FDA approval coincides with market availability.", "answer": 1}, {"article": "Lanctot and Fargo do not recommend that relatives or friends of those with agitated Alzheimer's provide them medical marijuana to ease their suffering.\n\"This is the first clinical trial to show that a cannabinoid can decrease agitation,\" said lead researcher Krista Lanctot, a senior scientist at Sunnybrook Health Sciences Center in Toronto.\n\"We would love to see this study done in a larger group of people, to see if it continues to be effective in a larger group, and how worried we need to be about this sedation side effect,\" Fargo said.\nTUESDAY, July 24, 2018 (HealthDay News) -- The active ingredient in pot that gets you high can calm agitation in people with advanced Alzheimer's disease, a small new study suggests.\nFor example, only one person out of five to 14 treated with antipsychotics actually experiences a decrease in agitation, Lanctot said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s mentioned that a form of synthetic THC (dronabinol; trade name \u2018Marinol\u2019) also is available in the U.S. (The story makes it sound like Nabilone is only available in Canada, but it does appear to be FDA approved in the US for cancer treatment as side effects, known as Cesamet.)\nGiven the fact that this a Canadian study (where medical marijuana has been legal since 2001), and that the legality of medical marijuana in the US varies by state, it might have helped readers to clarify if a synthetic like nabilone is considered legal, experimental, and/or requires a prescription.", "answer": 1}, {"article": "MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.\nThe full paper is accessible via the online edition of The Journal of Urology.\nAll other trademarks and service marks are the property of their respective owners.\nSelectMDx is available in the US and all EU member states.\n2011.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that the test is already in use.", "answer": 1}, {"article": "(Reuters Health) - When a migraine strikes, patients might one day be able to make the experience less painful by using a smartphone-controlled device to deliver mild electric shocks to their arm, a company-funded experiment suggests.\nEven though the study\u2019s participants were not told whether they were assigned active or placebo treatment, one limitation of the experiment is that participants often stopped placebo treatments before the recommended 20-minute course of stimulation was done, the authors note in Neurology.\nIf the device works in larger trials and becomes widely available for migraine patients, it might offer an alternative for people who can\u2019t tolerate migraine drugs or an option patients could try in addition to medication when they don\u2019t get enough pain relief from drugs alone, Schoenen said.\n\u201cWe worked on stimulation at a far away location, which makes the treatment more convenient and more discrete so people can use it even during working hours without anyone noticing,\u201d Yarnitsky added by email.\n\u201cThe percentage of attacks for which TENS is sufficient as sole treatment and allows sustained pain relief remains to be determined,\u201d Schoenen cautioned.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story establishes that TENS was already available for use on the head, but uses a researcher\u2019s words to carefully note that\u00a0it remains to be seen if TENS on the arm is a reliable stand-alone treatment that doesn\u2019t need to be paired with drugs. It also makes it clear that the technology is still being tested.", "answer": 1}, {"article": "The researchers wanted to evaluate whether in a group of women suffering from severe menstrual pain, aged between 18 and 34, self-acupressure would be more effective at achieving a sustained reduction in menstrual pain than usual care alone (e.g.\nA total of 221 participants were randomly assigned to one of two treatment groups, both of which received a study app and short introduction.\nIn contrast to acupuncture, this technique can be used as a form of self-care and is suitable for use at home.\nAcupressure-based features - with instructions on how to administer self-acupressure shortly before and during menstruation - were only made available to the intervention group.\nRather than using needles, this technique involves massage or pressure being applied to specific points on the body.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release links to a website where the app is available in German and where it can be downloaded for free.", "answer": 1}, {"article": "New stretch marks were also softer and smoother in 54 women who used the cream for three months, says Zoe Draelos, MD, a consulting professor of dermatology at Duke University Medical Center in Durham, N.C. \"The stretch marks did not go away,\" she tells WebMD.\nThey're not harmful to your health, but many people are bothered by their appearance.\nOnions contain flavonoids, a type of antioxidant, that have anti-inflammatory properties, Draelos says.\nDraelos has served as a consultant to Merz.\nAnd it has sulfur, which fights bacteria and infection, and a moisturizing cream to help rehydrate the skin, Draelos says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the product is available in drug stores.", "answer": 1}, {"article": "She bases this bold claim on her experience with seriously obese patients and a detailed analysis of the best studies yet done showing weight-loss surgery\u2019s ability to reverse the often devastating effects of being extremely overweight on health and quality of life.\n\u201cThese patients have lost hundreds of pounds over and over again,\u201d Dr. Twells said.\n\u201cI haven\u2019t come across a patient yet who wouldn\u2019t recommend it,\u201d Dr. Twells said in an interview.\nIn reviewing studies that followed patients for five to 25 years after weight-loss surgery, Dr. Twells and colleagues found major long-lasting benefits to the patients\u2019 health and quality of life.\nAnd the reason is not a lack of willpower.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that bariatric surgeries are common and widely available\u2013if not necessarily covered by one\u2019s insurance plan.", "answer": 1}, {"article": "MUSC operates a 700-bed medical center, which includes a nationally recognized children's hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute-designated center), Level I Trauma Center, Institute of Psychiatry, and the state's only transplant center.\nCraving and depression were also reduced in the NAC-treated group.\nThe average age of the veterans was 49 years and many were veterans of the Vietnam War.\n\"This is a tough patient population with SUD to work with.\"\nOf the veterans enrolled in the trial, 83% completed it, a very high rate for this difficult-to-treat population.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We learn it is sold over-the-counter and available everywhere.", "answer": 1}, {"article": "\"By wearing the brace, I could get back to sports and was able to call my physician and say 'why didn't we try this first?'\"\nThe brace used in the study was provided by Ossur, which also provided financial support to the study through a research grant and sponsored the media briefing.\nAll study participants led active lifestyles before they got sidelined by knee OA, and said they hoped to return to their previous level of activities.\nTheir quality of life improved, and their activity level went from one that did not permit recreational sports to one that did.\nWhen surgery failed to repair his damaged knee, Peterson's doctor suggested a knee brace.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There was no discussion of how widespread is the use/availability of knee braces in general or of the studied knee brace specifically. ", "answer": 0}, {"article": "Arena then hopes to file its request for market approval with the Food and Drug Administration by the end of 2009.\nThe experimental drug stimulates the 5-HT2C serotonin receptor, which is located in the hypothalamus, an area of the brain associated with regulation of food intake and metabolism.\nThe drug also proved to be highly selective, meaning it hit the intended targets inside the body and did not cause troubling side effects.\nBut one of the two components of that drug made by Wyeth, fenfluramine, also hit a second target in the heart, which was linked to heart valve problems.\nThose people taking the drug also saw reduced cholesterol levels and waist size, changes that have been linked to lessening cardiovascular risk factors such as blood pressure.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was clear that it was reporting on the results of a recent clinical trial and that a request for FDA approval had not yet been made, from which the reader could conclude that the drug is currently not available.", "answer": 1}, {"article": "Fear of doctors, the prospect of being poked and prodded in strange places, a lack of insurance to cover the costly test -- or a combination of all three -- are to blame for as many as half of the over-50 crowd putting off or avoiding the screening test altogether.\nNot since 1998, when the FDA approved the PSA test for early detection of prostate cancer, had new technology been created in early cancer detection until the stool DNA test.\nCompared to more invasive procedures, the test still might miss some polyps and cancers and may need to be repeated more often.\nThey then created techniques for detecting the DNA change when it expelled from the body in feces.\nWhile colonoscopy is still viewed as the best screening agent, it's not effective if it's not being used, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that one stool DNA test has been commercially available since 2003. Others will be available later in 2008 and in 2009.", "answer": 1}, {"article": "\"Right now it's hard to say whether an older person with normal cognition or mild cognitive impairment is likely to develop dementia,\" said lead author Cyrus A. Raji, MD, PhD, an assistant professor of radiology at Washington University's Mallinckrodt Institute of Radiology.\n\"If water molecules are not moving normally it suggests underlying damage to white tracts that can underlie problems with cognition.\"\nPeople could make decisions on their financial and living arrangements while they are still in full control of their faculties.\nMRI brain scans are widely available and give doctors a glimpse into what's going on inside a person's brain.\n\"Diffusion tensor imaging is a way of measuring the movement of water molecules along white matter tracts,\" Raji said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "MRI scans are described as \u201cwidely available.\u201d", "answer": 1}, {"article": "Merck & Co. and Schering-Plough Corp. said a long-awaited trial showed their cholesterol drug Vytorin failed to slow progression of heart disease better than a cheaper drug, threatening the companies' $5 billion-a-year cholesterol-fighting franchise.\n\nSchering-Plough's shares fell 8% to $25.52 and Merck declined 1.3% to $59.78 at 4 p.m. in New York Stock Exchange composite trading.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The drug detailed in the story was described as heavily marketed direct to consumers and several clinicians\u2019 quotes included in the story questioned the wisdom of prescribing this medication. \u00a0", "answer": 1}, {"article": "\"We wouldn't want to be encouraging people to drink that much [coffee], without people considering the other risks factors,\" Hashibe says.\nIt\u2019s not exactly known why coffee may help prevent these cancers.\nCoffee did not decrease the risk of a third type of oral cancer \u2013 laryngeal cancer.\nBut he is concerned that the side effects of coffee are not addressed in this study.\nToo much coffee may make it harder to conceive and can increase the risk of miscarriage.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable \u2013 the availability of coffee is not in question. ", "answer": 2}, {"article": "The drug was also granted a priority review.\n\u201cNuplazid represents an important treatment for people with Parkinson\u2019s disease who experience these symptoms.\u201d\n\nAn estimated 50,000 Americans are diagnosed with Parkinson\u2019s disease each year, according to the National Institutes of Health, and about one million Americans have the condition.\nIn clinical trials, the most common side effects reported by participants taking Nuplazid were: swelling, usually of the ankles, legs, and feet due to the accumulation of excessive fluid in the tissue (peripheral edema); nausea; and abnormal state of mind (confused state).\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release is reporting FDA\u2019s recent approval of Nuplazid so it\u2019s understood the drug isn\u2019t available now. Ideally, for patients\u2019 sake, the news release would have mentioned the company\u2019s announced roll-out plans.\nAccording to a company news release, the firm intends to launch the drug in June 2016.", "answer": 1}, {"article": "Cooper and his colleagues looked at 29,507 births to women covered by Medicaid in Tennessee between 1985 and 2000.\nThe number of women taking them early in pregnancy is unknown but probably is small, the study suggests.\nThe agency will consider broadening the \"black box\" warning against taking ACE inhibitors late in pregnancy, he said.\nThey came on the market 25 years ago.\nACE inhibitors are the second-most commonly prescribed class of pharmaceuticals in the United States, with 149 million prescriptions dispensed last year.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that ACE inhibitors are a class of drugs available since the early 1980s; they are commonly prescribed.", "answer": 1}, {"article": "And patients may need to continue treatment.\n\"The short-term course, is excellent so far \u2014 beyond our wildest expectations, says Dr. Lawrence Yannuzzi a leading macular generation specialist.\nFor more than 100 years, the Lighthouse has been the leader worldwide in helping people of all ages who are blind or partially sighted overcome the challenges of vision loss.\nThe thought that you could lose your vision is very, very depressing,\" Daniel says.\n\"These symptoms were these wavy lines \u2014 and especially on the periphery of your vision,\" says macular generation patient Daniel Davison.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that Lucentis was recently approved by the FDA. The story should have been more clear that the approval was for neovascular, or \u201cwet\u201d, age-related macular degeneration (AMD) and not the more common \u201cdry\u201d form of AMD.", "answer": 1}, {"article": "\"What we've had available the last 16, 17 years has made a big difference,\" Richert says, \"and what we have coming onboard now, these are going to make even a larger difference.\n\"In reality, these are extremely potent pills that have the potential to cause a variety of serious side effects,\" he says.\n\"You want to be careful to jump into something new and risk the side effects from something you haven't tried before.\"\n\"In spite of the fact that I hate injections, I probably would not leap at the first pill that comes to market,\" he says.\n\"People will be more prone to take them early, more prone to stay on the drugs,\" Richert says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was clear that the drugs in question are not yet on the market and that \"federal regulators may go slowly with the two new drugs.\"", "answer": 1}, {"article": "Injections of botulinum toxin, best known as a wrinkle treatment, are now being used increasingly to prevent chronic migraine sufferers. Scientific data are mixed, but two large recent studies show Botox can reduce the number of headache days in chronic sufferers.\n\nMigraine headache is a debilitating neurological condition that manifests itself as an intense throbbing pain on one or both sides of the head, according to the Migraine Research Foundation, a New York nonprofit. Some 14 million people experience migraine attacks...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Botox injections are so widely available in the U.S. that this doesn\u2019t merit much discussion. The article accurately identified the regulatory status of Botox injections for chronic migraines.\n\n \n", "answer": 1}, {"article": "\u201cThere are areas in the brain that become poorly perfused as you age, and that\u2019s believed to be associated with dementia and poor cognition.\u201d\n\nResearchers from the Translational Science Center looked at how dietary nitrates affected 14 adults aged 70 and older over a four-day period.\nAnd nitrites help open blood vessels in the body, increasing blood flow and oxygen to places lacking in oxygen.\nOn the second day, after another 10-hour fast, the participants returned to the lab and ate their assigned breakfasts.\nBeet roots contain high concentrations of nitrates, which are converted into nitrites by bacteria in the mouth .\n\u201cThere have been several very high-profile studies showing that drinking beet juice can lower blood pressure, but we wanted to show that drinking beet juice also increases perfusion, or blood flow, to the brain,\u201d Daniel Kim-Shapiro, PhD, director of the Translational Science Center at Wake Forest University, says in a news release.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that nitrites are found in high concentrations in beets, celery, cabbage and other leafy green vegetables like spinach.", "answer": 1}, {"article": "A minimally invasive procedure designed to shrink prostate tissue with a series of nine-second blasts of steam offers men a new treatment for urinary symptoms commonly associated with enlarged prostates.\n\nThe procedure, called Rez\u016bm (pronounced \u201cresume\u201d) and developed by NxThera Inc. of Maple Grove, Minn., became widely available in the U.S. in the second half of 2016. Thermal energy in the form of steam is applied to the prostate with a needle. As it cools it releases heat energy into the tissue, killing cells and shrinking...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that Rez\u016bm is clinically available.", "answer": 1}, {"article": "The full picture of the knock-on effects of exposing your gut flora to antibiotics is still coming into focus, said Ramanan Laxminarayan, director of the Center for Disease Dynamics, Economics, and Policy and a leading voice on the dangers of mounting antibiotic resistance.\nThe rate of infection increased in every age group over the age of 15, in both men and women, and in all ethnic groups.\nIn reality, the median use among the men was about 6.8 pills per month.\nThe Bill and Melinda Gates Foundation was one of its funders.\nThey were told to take two pills per encounter, and no more than six in a week, ideally within 24 hours and no later than 72 hours after the intercourse.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that doxycycline is widely available and that it is used to treat other diseases, including acne.", "answer": 1}, {"article": "Studies have shown that the intimate association between the gut microbiome and GI tissue has a significant effect on the GBA.\nThe GI tract is also home to the intestinal microbiome, a complex population of roughly 100 trillion microorganisms (more than ten times the number of cells that make up the human body) that interacts with the mucosal lining of the GI tract.\nOverall, these results indicate that changes in intestinal inflammation can alter the trajectory of psychiatric mood disorders and that modulating the intestinal microbiota may be a new avenue of treatment for patients suffering from these diseases.\nThere is also mounting evidence linking imbalances in the microbial species that make up the gut microbiome to a number of health problems including allergies, autoimmune disorders, and psychiatric mood disorders.\nHowever, an emerging field of research is exploring the use of probiotics--often thought of as \"good bacteria\"--as a potential new avenue for treatment of bipolar and other psychiatric mood disorders.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The dosage and composition of the probiotic mixture used in this study are not clarified. Therefore, readers have no idea if just any probiotic will do. This is worrisome since some readers \u2014 particularly those with bipolar illness \u2014 may extrapolate from the news release headline and start self-medicating based on these preliminary findings that don\u2019t prove probiotics help bipolar illness.", "answer": 0}, {"article": "In 2008 Sciencewatch (Thomson Reuters http://sciencewatch.com/ana/st/hpv/08julHPVWheler/) ranked her global citation contributions over the past decade, 7th in human papillomavirus contributions and in the top 1% in the field of clinical medicine.\nThey found that the vaccine protected the women against HPV infections during the follow-up period and that the women were protected from many types of HPV across a broad age range.\nInfection with HPV can take place at any time throughout adulthood and women in this age group may have already been exposed to HPV.\nOne of the premier cancer centers nationwide, the UNM CCC has more than 125 board-certified oncology physicians, forming New Mexico\u2019s largest cancer care team.\nIn the US, only about 40 percent of girls and 21 percent of boys receive the three-dose vaccination series.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Most readers are probably aware of HPV vaccinations and that the vaccine is widely available. However, the vaccine isn\u2019t affordable to all.", "answer": 2}, {"article": "If it does, Orlistat (xenical) -- currently sold only by prescription -- could be available over-the-counter (OTC) later this year.\nNor is Orlistat a quick fix for unwanted pounds.\nThey range from flatulence and increased bowel movements to diarrhea and anal leakage.\n\"It's very exciting,\" Klein says.\nWhen fat that's eaten isn't absorbed, it must be eliminated.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Article \nincludes the fact that the switch in status from prescription only to OTC is under FDA consideration.", "answer": 1}, {"article": "While the study was relatively small, we believe the data suggest that DBS surgery targeting the fornix can be performed safely in this patient population.\nWhereas in Parkinson's disease and essential tremor, the target for the electrodes are nodes within the motor circuits, the Alzheimer's study targeted the fornix, which is part of the memory pathway.\nAdverse effects such as headache and infection occurred in 11.9% (5 of 42) of the patients in this study, consistent with rates reported in other DBS trials.\nThe ADvance Trial, using a device from Functional Neuromodulation, Inc., is aimed at evaluating the safety, efficacy and tolerability of DBS in this patient population.\n\"The first phase of this study was designed to evaluate the 90-day postoperative safety of this particular surgical method.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that the device is only approved for use in patients with Parkinson\u2019s disease and essential tremor. It\u2019s available to those patients, and only for research in other conditions.", "answer": 1}, {"article": "Participants also developed nausea, headaches and could not tolerate head movements during the attacks.\n\"It's possible that the vertigo occurs when this unstable mechanism is disrupted by factors either within the person's body or in their environment,\" Kim said in a journal news release.\n\"These conditions can be difficult to diagnose and quite debilitating for people, so it's exciting to be able to discover this new diagnosis of a condition that may respond to treatment,\" said Dr. Ji-Soo Kim, a researcher at Seoul National University in South Korea.\nThe researchers noticed that uncontrolled eye movements, called nystagmus, lasted longer in people with this new form of vertigo.\nVertigo -- episodes of dizziness that can last for minutes or days -- may be triggered by a number of health issues, ranging from an inner ear disorder to tumors.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The mechanism for diagnosis of this supposed new form of vertigo is explained by both the news story and the original paper.\u00a0 It requires some sort of audio-visual equipment to record eye movements, and there was discussion of a non-named medication providing relief. There is not enough information to fully inform the reader about the availability of getting screened for this type of vertigo, nor how to treat it.", "answer": 0}, {"article": "The EAGeR trial focused on women with a history of one or two prior pregnancy losses.\nHowever, he adds, \"We were happy to be able to conduct research considering women having the most difficulty getting and staying pregnant, and to provide messages about common lifestyle factors they may be able to address.\"\nFurther study is necessary to clarify possible mechanisms through which walking and vigorous activity might affect time-to-pregnancy.\"\nFor the 1,214 women in the study, the association of walking with the ability to become pregnant, known as fecundability, varied significantly by body mass index, the authors report.\nFurther, he says, \"We were happy to be able to add scientific evidence to general recommendations about physical activity.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "As noted above, the release mentions walking as both easily accessible and a potentially modifiable factor for those trying to get pregnant.", "answer": 1}, {"article": "Neck pain was assessed by the Northwick Park Questionnaire (NPQ) at 3, 6, and 12 months.\nChronic neck pain is a leading cause of disability.\nThe study is published in Annals of Internal Medicine.\nOver time, both interventions resulted in a greater increase in self-efficacy than did usual care, and these improvements were associated with better NPQ outcomes.\nBoth interventions had a high rate of acceptability, and greater adherence was associated with better pain outcomes.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the release that both of these therapies are widely available.", "answer": 1}, {"article": "Greenwood says he'd like to see many more patients try diabetes prevention programs.\nHe began with 2,000 steps logged during his morning walk but has now increased his steps significantly.\nThe weight began to fall off, and he started to move more.\nLast year he received an email from his doctor at Kaiser Permanente with some test results.\nThis means his blood sugar level was elevated, but not yet high enough to be diagnosed with the condition.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear the Omada program is available and in use around the country and even links to the company website.", "answer": 1}, {"article": "The FDA said Kybella demonstrated safety and efficacy in two clinical trials involving more than 1,000 adults.\nA reduction in chin fat was \"observed more frequently\" in patients receiving the treatment than in those who got a placebo.\nPatients can receive as many as 50 injections of the drug in a single treatment, the agency said, with up to six treatments administered no less than a month apart.\nThe most common side effects included swelling, bruising, pain, numbness, redness and areas of hardness in the vicinity of the injection.\nThe drug, Kybella, is a form of synthetically derived deoxycholic acid, which the body produces naturally to help absorb fats.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the drug will probably not be available before June.", "answer": 1}, {"article": "Is that a good thing?\n\"Oxygen is different, because it has a direct biological effect on brain tissue,\" said Paul G. Harch, a physician in New Orleans who over the past three decades has used hyperbaric oxygen to treat hundreds of people with chronic brain injury as well as stroke.\nA growing group of scientists and physicians say that hyperbaric treatment, which exposes patients to pure oxygen at higher-than-normal air pressure, may work.\nFor the past 50 years, hyperbaric therapy has been approved by the Food and Drug Administration as a treatment for non-healing wounds, carbon monoxide poisoning, burns and decompression sickness.\nOverall, there is relatively little research on hyperbaric treatment for brain injury, in part because pressurized oxygen can't be patented, which limits its potential profitability.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability of hyperbaric chambers, or rooms, is not discussed.\nAccording to the Undersea & Hyperbaric Medicine Society, there are over 200 accredited facilities in the United States.\nOne thing we wanted to note: The statement from a researcher that there\u2019s no way to patent (and thus, make money from) hyperbaric oxygen therapy as an explanation for why the evidence base is so fragmentary seemed to ring false in the setting of these private clinics that can create frequent return visits for long periods of time.", "answer": 0}, {"article": "Elizabeth Williams, from the School of Biomedical Sciences at Queensland University of Technology, tells Newsweek the two studies \u201cdescribe tantalizing complementary and consistent results in Phase 1 trials in melanoma patients using vaccines.\"\nBut working out the unique mutations of each person\u2019s cancer, a time-consuming and complicated process, must first be identified before a vaccine can be developed for them.\nThey used a similar approach to Wu and her team to identify the mutations, then tested the vaccine on 13 people who were being treated for melanoma.\nCancer vaccines that are personalized to the patient\u2014designed to help the immune system identify tumors as foreign bodies and destroy them\u2014have been considered as a potential treatment for a number of years.\nThe next step will be to test these personalized vaccines in larger clinical trials to see if they are better than existing treatments, if they improve survival, and what their long-term side effects could be.\u201d\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although not explicitly stated, most readers will understand that the vaccines are not currently available and have to undergo a lot more testing before they are available \u2014 if ever.", "answer": 1}, {"article": "[1]\n\nWriting in a linked Comment, Dr Nahid Bhadelia from Boston University School of Medicine and Boston Medical Center, Boston, USA says, \"[This study] validates the accuracy of the ReEBOV RDT in patients who are well into their illness...suggesting it could be used to triage this subset of patients if RT-PCR is not available, particularly in those with a high index of clinical suspicion for a differential diagnosis...the data presented provide crucial information about the point of-care function of this rapid diagnostic test, such as ease of use, quality of samples taken at the bedside, and the concordance with venous samples...the results raise caution regarding the performance of the widely used altona RT-PCR assay, which the authors suggest might have underperformed because of laboratory specific technical and performance factors.\"\nThe study is the first to show that a point-of-care EVD test (ReEBOV Antigen Rapid Test; Corgenix) is faster than and as sensitive as a conventional laboratory-based molecular method used for clinical testing during the recent outbreak in Sierra Leone.\n106 suspected Ebola patients admitted to two treatment centres in Sierra Leone (run by the Ministry of Health and Sanitation of Sierra Leone and supported by the non-governmental organisation Partners In Health) during February 2015 were tested by both RDT (performed on a fingerstick blood sample at the point-of-care) and by standard RT-PCR (performed on plasma in the laboratory).\nAlthough the RDT requires refrigeration, this is already available in many health centres in endemic areas, particularly those that store vaccines and other medical products.\"\nA new test can accurately predict within minutes if an individual has Ebola Virus Disease (EVD), according to new research published in The Lancet.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re\u00a0told the following, via a quote from a researcher: \u201cAlthough the RDT requires refrigeration, this is already available in many health centres in endemic areas, particularly those that store vaccines and other medical products.\u201d Although we\u2019d like to know more about the regulatory approval status of the test, we\u2019ll award a Satisfactory here.", "answer": 1}, {"article": "Visit the Mayo Clinic News Network.\nWhile twice-daily injections of low-molecular-weight heparin has been the traditional treatment of choice for cancer patients who suffer a venous clot, Dr. McBane notes that there are numerous limitations to this therapy.\n\"As a class, these drugs have a number of advantages, including oral delivery, lack of interactions with foods or other medications, and the lack of a need for monitoring drug levels.\"\nThe drug was associated with fewer major bleeding events and fewer recurrent blood clots, compared to low-molecular- weight heparin.\n\"Nearly 1 in 5 patients with cancer will develop a clot in the veins, referred to as either a deep vein thrombosis or pulmonary embolism,\" says Dr. McBane.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that apixaban, a member of a new class of \u201cblood thinners called \u2018direct oral anticoagulants\u2019 have become available.\u201d Both oral and injectable anti-coagulant medications are now widely available at hospitals and clinics where they are administered to patients.", "answer": 1}, {"article": "How an Activity Tracker Caught an Unexpected Pregnancy Fitness trackers, by nature of being worn around the clock, have the potential to capture unexpected insights about how your body works \u2014 and simplify laborious acts like manually figuring out your fertile days.\nBy monitoring these multiple biomarkers while a woman is asleep, Ava\u2019s wearable and app can notify her during the five days she\u2019s most fertile, ending in ovulation, according to von Bidder, who says Ava has conducted studies on about 60 people.\nAs a low-risk medical device registered with the Food and Drug Administration, it doesn\u2019t need in-depth review by the agency to be sold, according to the company.\nThe women also logged their periods on Clue\u2019s app, and took daily urine tests to track when there was a surge in the key hormones that signaled they were entering ovulation.\nOne reason to potentially shy away from trusting Fitbit\u2019s heart-rate sensors: In a class-action lawsuit, some unhappy consumers have accused them of being inaccurate.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Fitbits are widely available, though the story seems to take it for granted that readers will know this. Similarly, the story refers to the relevant app, called \u201cClue,\u201d as a \u201cwomen\u2019s health data startup.\u201d It\u2019s not clear from that description whether the relevant app is already available. (It is.) The story does note the availability of other, related technologies.", "answer": 0}, {"article": "The practical value of the tests depends critically on details like their sensitivity, meaning the proportion of tumors that are detected, and their specificity, meaning how many of the positive results are in fact false alarms.\nDr.\n\u201cExact Sciences has gotten close to that.\nProponents of each test note possible weaknesses of the other.\nThe trial will be completed in 2012 and the test, if approved, should be available shortly thereafter.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "U.S.News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual \"America's Best Hospitals\" survey.\n\"Heart disease and strokes are a leading cause of death in the United States.\nPatients came for treatment from every state and 180 countries.\n\"This level of control can only be performed for small numbers and provides the essential empirical data that cannot be obtained from large observational studies.\nAt the beginning and end of each diet period, participants spent three days undergoing metabolic testing in a clinical research setting.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Whole grain foods are readily available at grocery stores and markets, so availability is not an issue here.", "answer": 2}, {"article": "Epclusa carries a warning for patients and health care providers that serious slowing of the heart rate (symptomatic bradycardia) and cases requiring pacemaker intervention have been reported when amiodarone is used with sofosbuvir in combination with another HCV direct-acting antiviral.\nEpclusa also carries a warning not to use with certain drugs that may reduce the amount of Epclusa in the blood which could lead to reduced efficacy of Epclusa.\nThe most common side effects of Epclusa include headache and fatigue.\nKnowing the genotype helps inform treatment recommendations and the duration of treatment.\nEpclusa is a fixed-dose combination tablet containing sofosbuvir, a drug approved in 2013, and velpatasvir, a new drug, and is the first to treat all six major forms of HCV.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is announcing the approval of the drug which usually means it will be available in the near future.", "answer": 1}, {"article": "Dr. Susan Huang, a professor of infectious disease at the University of California, Irvine, wrote an editorial accompanying the study.\nAfter 18 months of using the program, infection rates among hospital patients in general wards dropped by one-third, while catheter use had dropped about 1 percent.\n\"This program can reduce urinary infections in hospitals if a team is assembled to ensure adoption of best practices and to rapidly correct reasons for failing to comply with these processes,\" she added.\n\"Patients and families should request that a catheter not be put in, and if there is one there, the patient should ask every day whether it is still needed,\" Saint suggested.\n\"A lot of patients and families don't realize that there are problems with a urinary catheter, so they may request them because they think it will allow patients to stay in bed,\" Saint said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told the procedure is in use at 600 hospitals, though it would have helped to note they\u2019re spread across 32 states, plus Washington D.C. and Puerto Rico. It could have been made clearer that any hospital can use this safety bundle now that the methods are published widely.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061210/18vitamin.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story included a statement that \"a mere 10 to 15 minutes outdoors at midday gives the average fair-skinned person 10,000 international units\" which\u00a0is hyperbole because\u00a0season and latitude greatly\u00a0affect the amount of vitamin D synthesis that occurs. Even though the story included a statement about latitude a little later, the first statement is misleading for the reader.\nThe story included mention of food sources for \"relatively modest amounts\" of vitamin D, though that does little to help the reader know how much of the foods would need to be consumed.\u00a0 Although the last sentence of the article listed one mini-meal plan, which, along with supplements would supply the suggested level of Vitamin D, this was an incomplete method of telling readers how to achieve adequate vitamin D intake.\u00a0 The story also failed to mention the effect of sunscreen on vitamin D production by the body.", "answer": 0}, {"article": "That aching back is hard to fix, but here are a few things to try\n\nThese real-life cyborgs hack their bodies with chips, magnets and other tech\nSo it makes sense that Jay jumped at the chance to experience long-term pain relief with the help of a spinal-cord stimulator.\nAccording to the National Center for Health Statistics, an estimated 25.3 million Americans, or 11.2 percent of U.S. adults, experience chronic pain.\nBut she shares a similarity with those characters: Her all-too-human body has been upgraded with a machine.\nShe also describes her path to spinal stimulation, how the device works with the body to short-circuit pain, and the many roadblocks to relief that patients face.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that these devices are available and in some cases covered by insurance. Though it may have been helpful to note that these devices are usually performed by specialists and particularly in rural areas, access to them may be harder to get.", "answer": 1}, {"article": "The device was developed over 15 years by a team that included Alain F. Carpentier, the French surgeon-scientist who, along with Albert Starr, received the 2007 Albert Lasker Award for Clinical Medical Research.\nWhen all expenses are considered, including hospital and surgical expenses, it says it will cost just over $315,000, about the same as a transplant.\nIt is operated by a microcontroller and powered by electromagnetic induction through the skin or through a plug implanted behind the patient\u2019s ear.\nThe device, made of both synthetic and animal tissue, is driven by two miniature electric motors.\nImplanted in the patient\u2019s chest after the diseased heart is removed, it uses information gleaned from sensors to mimic the activity of the natural organ.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that human testing is far off:\u00a0 \"The company hopes to start human testing in France by the end of next year.\"", "answer": 1}, {"article": "\"This study highlights the collaborative spirit of academic medicine, and how our rheumatology and bariatric surgery researchers worked together to not only help our patients directly, but inform the medical community at large,\" says study co-author Jose U. Scher, MD, assistant professor of rheumatology and co-director of the NYU Langone's Psoriatic Arthritis Center.\nPatients who saw the most improvements had more severe disease at the time of surgery and were of an older age at diagnosis.\nPatients were on average monitored for more than six years, with an average excess weight loss of 46.2 percent body weight.\nFurther analysis showed those who lost the most excess weight a year after surgery showed the biggest improvements in their disease activity.\nIt is estimated that as many as 20 percent of individuals with moderate to severe psoriasis develop psoriatic arthritis in their lifetime.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Bariatric surgery is widely available and most people with internet access (or any access to medical care) can figure that out fairly quickly in their area.", "answer": 1}, {"article": "MONDAY, Jan. 21 (HealthDay News) -- A skin patch for the treatment of migraines, and the intense waves of nausea that often accompany these debilitating headaches, has been approved by the U.S. Food and Drug Administration.\nThe most frequent side effects were pain at the site of application along with tingling, itching, warmth and discomfort.\nThe patch is attached to the upper arm or thigh, and when the patient pushes a button the drug is delivered through the skin.\nA nasal spray is available, as is an injection, but many patients aren't comfortable with these options, Khan and Waltman noted.\nOne study found that 18 percent of patients using the patch were headache-free after two hours, compared with 9 percent of those using an inactive placebo.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story estimates, from a company source, that this produce will be available toward the end of 2013.", "answer": 1}, {"article": "Before Starting A Statin, Talk It Over With Your Doctor\n\nA study published Monday is pushing back against the notion that up to 40 percent of Americans should be taking statin drugs to reduce the risk of heart disease.\nThe most common side effect of these drugs is muscle pain, which usually goes away if patients stop taking the medicines.\nAnd it is only useful as a screening test for people who haven't had heart disease.\nYet that kind of dialog is increasingly the expectation.\nOn the other hand, the benefits aren't that great, either.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that statins are widely prescribed.", "answer": 1}, {"article": "Patients played the role of cab drivers who picked up passengers and delivered them to one of six requested shops in the city.\nCurrently, deep brain stimulation is used to control the tremors associated with Parkinson's, symptoms of obsessive-compulsive disorder and some other psychiatric conditions, including depression.\n\"Our preliminary results provide evidence supporting a possible mechanism for enhancing memory, particularly as people age or suffer from early dementia.\nAt the same time, we studied a small sample of patients, so our results should be interpreted with caution,\" Fried added.\nAlthough the results are still preliminary, the method may potentially hold promise for boosting memory in patients with early Alzheimer's disease, the researchers said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that this research is in its early stages, though devices are available that provide similar deep brain stimulation to patients with other disorders.", "answer": 1}, {"article": "People with Type 2 diabetes get an earful of grim lectures about their health prospects and endure much hardship to manage their condition well. But new research offers those who do so a rare reward. A glass of wine every day not only won't hurt, says a new study: It can actually improve cardiac health, help manage cholesterol and foster better sleep.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is obvious that red and white wine are readily available to most readers.", "answer": 1}, {"article": "First published on September 5, 2007 at 12:00 am\nThe maker of the robotic systems, Intuitive Surgical Inc. of Sunnyvale, Calif., is an enthusiastic backer of the University of Chicago's initiative.\nThe robots have proven popular for urologic, gynecologic and some general surgery, Pappas said, but few coronary surgeons use them for valve repairs and fewer still do bypass procedures.\nMany who trained to use robots to do coronary bypass run out of patience after three or four procedures, Jeevanandam said, which is why he decided to hire Dr. Sudhir Srivastava, who performed hundreds of robotic bypasses while working at a center in Odessa, Texas.\nWhile surgical robots have been available for most of this decade, few are used to do cardiac bypass surgery, even though that was their focus when the machines were introduced.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article does not clearly\u00a0state how widely robotic treatments are available, either for bypass surgery or other operations. The article reports 504 units are in use in the U.S., but it\u2019s not clear how they are distributed or what they are used for, even in the Chicago area. Nonetheless, we\u2019ll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "In traditional transplants, hair follicles are taken from an area that runs an inch or two above the ears and temples to the back of the head.\n\u201cHe had resorted to cropping his hair short to obscure the problem.\u201d\n\nWith the patients under local anesthesia, Dr. Umar used a device that creates microscopic wounds around hair follicles in the back of the leg; the follicles were then removed and transplanted to the hairline.\nIf you take that hair and use it in the hairline, it can end up looking harsh and pluggy, because the hair is too thick.\u201d\n\nDr. Umar was inspired to develop the procedure in part from personal experience.\n\u201cThe hairline was fully grown and soft-looking by nine months\u201d in the 35-year-old, he wrote, \u201cat which time the patient started combing his hair backward and sporting a ponytail, exposing his hairline comfortably.\u201d\n\nSince then, Dr. Umar has done eight more of the procedures, including one in a woman.\nThe procedure has the potential to restore the hairlines of millions of men with male pattern baldness, the most common cause of hair loss and often an enormous source of stress.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "From the claims made at the top of the story, one would think that there is only one place in the world to undergo this technique: a clinic in Redondo Beach, California. That does not appear to be the case. In a brief online search, we were able to identify multiple dermatologists who suggest transplanting of hair from legs, chest and pubic region.", "answer": 0}, {"article": "TUESDAY, Dec. 29, 2009 (HealthDay News) -- Many older adults consume ginkgo biloba, hoping to keep their minds sharp, but a new study finds that the herbal product doesn't stave off cognitive decline.\nAlso, the age of the subjects is quite advanced, at an average of 79 years at the beginning of the trial.\nHowever, ginkgo was safe and no serious side effects were noted, DeKosky added.\nThese results remained the same regardless of sex, age, race or education, the researchers noted.\nThis age group is not typical of the age of both healthy people and those with mild cognitive impairment who use ginkgo for improving mental performance.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that ginkgo biloba is used widely. ", "answer": 1}, {"article": "For more information, visit http://www.\n\"If you could imagine saving the cost from the number of patients whose readmission you were able to prevent, that result could provide significant savings to the health system,\" Dr. Gunter said.\n\"We have demonstrated that a population of complex and high-risk patients, many of whom are older adults and novice smartphone users, can complete this protocol with high fidelity and satisfaction,\" the researchers concluded.\n\"This approach allows us to intervene at an earlier time rather than waiting for patients to come back in after the problem has already developed past the point of being able to manage it on an outpatient basis.\"\nPatients gave universally positive feedback about the app's ease of use and the ability to have wounds monitored\n\nCHICAGO (Jan. 19, 2018): A new smartphone app called WoundCare is successfully enabling patients to remotely send images of their surgical wounds for monitoring by nurses.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no discussion of how many hospitals are using this app.\nThe release did discuss some of the practical aspects of implementation but nothing about whether such an app is available or if insurance will pay for any of the costs involved.", "answer": 0}, {"article": "Animal models had skin injuries infected with Pseudomonas aeruginosa, Staphylococcus aureus or Acinetobacter baumannii, three different types of bacteria that commonly infect wounds and develop biofilms that are treatment resistant.\nIt could be applied immediately to wounds help keep bacteria from mobilizing and start promoting healing until the soldier could be transported to a facility for more intensive medical care.\u201d\n\nThe team already has interest from several industry partners, and is hoping to begin testing the new technology in patients before the end of the year to determine optimal treatment duration and more about the healing effects of electrical fields on skin cells on a molecular level.\nThe immune system cannot penetrate the biofilm, and antibiotics can\u2019t get in either \u2013 causing constant inflammation and low-level infection that can further dampen the healing process.\nThe team\u2019s next move is to focus on the bioelectric bandage as a treatment for chronic wounds in a patient population; however, the technology could also be used to treat acute injuries.\nWorking with a mechanical and aerospace engineering team led by Shaurya Prakash, PhD and Vish Subramaniam, PhD, the scientists have optimized the bandage\u2019s design and the amount of electrical current delivered.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that this research of an \u201cadvanced\u201d WED is experimental and the technology has not yet been tested in humans. There\u2019s a strong implication that the bandages won\u2019t be available anytime soon.", "answer": 1}, {"article": "But there are still hurdles to clear.\nIt\u2019s by no means a cure for migraines, but it should be enough to merit Food and Drug Administration approvals if the companies can replicate those results in larger trials, according to Eric Schmidt, a securities analyst at Cowen and Co.\n\nEach treatment is now in late-stage development, targeting the roughly 38 percent of migraine sufferers who, like Novak, have at least four headache days per month.\n\u201cI felt like my life was being stolen from me.\u201d\n\nCollectively, Americans miss about 113 million workdays each year because of migraine.\n\u201cThat\u2019s a perfect combination of things that make people feel able to dismiss it.\u201d\n\nNovak, a professor of photography at New York University\u2019s Tisch School of the Arts, spent years trying to hide her migraines because of the stigma attached to the condition.\nAnd thus four drug makers \u2014 Amgen, Eli Lilly, Teva Pharmaceuticals, and Alder Biopharmaceuticals \u2014 have fashioned antibodies that can bind to CGRP molecules and block their activity.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Yes, and the news is not good: The drugs are moving through the clinical trial process\u00a0and have not yet received FDA approval. The story speculates that \u201cthe first therapy could hit the market in 2018,\u201d a prediction that presumes no glitches will slow the process.", "answer": 1}, {"article": "For more information, visit the Quaker Oats Center of Excellence at www.QuakerOats.com.\nFor more information, please visit www.QuakerOats.com, www.Facebook.com/Quaker or follow us on Twitter @Quaker.\nThe statistically significant results of the randomized, controlled crossover study (n=47) showed that a 250-calorie instant oatmeal serving (with an additional 113 calories of skim milk) enhanced satiety and feelings of fullness, reduced the desire to eat and may even lead to a lower caloric intake at lunch, compared to a 250-calorie serving of cold, oat-based cereal, also served with an additional 113 calories of skim milk.\nAfter an analysis of the types of fiber in each cereal, the researchers suspected that the higher molecular viscosity of the beta-glucan in the instant oatmeal contributed to its satiating effect over the oat-based, cold cereal.\n\"When we took it a step further and evaluated the intake four hours post-breakfast, we found that after consuming instant oatmeal, the participants chose to eat significantly less at lunch compared to those who ate the oat-based, cold cereal.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release, by naming the brand of oatmeal studied, makes it clear that it is available. Few people will not have heard of Quaker instant oatmeal.", "answer": 1}, {"article": "On the surface, this seems to contradict a U.S. trend toward holding off on surgery and monitoring men who have low-risk cancers with what's called \"active surveillance.\"\nAnd it applied to men with tumors considered low-risk, meaning they have a relatively low Gleason score, a marker of tumor aggressiveness.\nFirst, only about 1 in 20 men in the Swedish study had a prostate cancer diagnosis based on a high PSA level.\n\"Active surveillance means observing the patient in a proactive way, with regularly scheduled biopsies,\" he adds.\nUnfortunately, there haven't been any large studies in which prostatectomy and radiation therapy have been compared in patients with early-stage prostate cancer who have been randomly assigned to one or the other.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story discussed the treatments in the study, radical prostatectomy and watchful waiting, and explained how watchful waiting differed from the active surveillance approach used in this country.", "answer": 1}, {"article": "MONDAY, Oct. 1, 2012 (HealthDay News) -- A new anti-clotting drug called apixaban was better than warfarin at preventing stroke in patients with the heart rhythm disorder atrial fibrillation, a new study found.\nThis increases the risk for blood clots that can cause stroke.\nThis may simplify how physicians make decisions and also improve patient care.\"\nCurrent practice guidelines permit the use of either anti-clotting therapy with aspirin or warfarin.\nAspirin is less effective than warfarin, but carries a lower risk of bleeding for patients with atrial fibrillation and one risk factor for stroke.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the drug has not yet been approved by the FDA.", "answer": 1}, {"article": "For further information about the company go to creativemedicaltechnology.com.\n\"Based on establishment of safety of the CaverStem\u2122 procedure in a formal university-based clinical trial, and independent confirmation of efficacy in an European clinical trial1, we have launched commercialization for the CaverStem\u2122 procedure,\" said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings.\n2013 Jun 9;11:139. https://www.ncbi.nlm.nih.gov/pubmed/23758954\n\nOTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.\nAccording to the National Institutes of Health, approximately 30 million men in the United States suffer from Erectile Dysfunction2, of which 9 million do not respond to pharmacological treatments such as Viagra, Levitra and Cialis.\nThe trial, sponsored by Creative Medical Technology Holdings, was conducted at the University of California Los Angeles Harbor Hospital/LA Biomed under Institutional Review Board (IRB) approval.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release appears to be overly optimistic in stating when this therapy may be available to patients. Moreover, other than the study site that performed this small trial, there is no mention of where this procedure may be had.\nThe news release did say that they expect \u201cthat the procedure will be available to patients that meet the eligibility criteria within the next 60 days.\u201d Yet this statement raises some red flags. First of all, it does not say what the eligibility criteria are, which may give ineligible patients false hope. Secondly, the 60-day time frame is incredibly quick. Even after promising safety studies, most medications and procedures undergo a third study that looks solely at efficacy (the primary outcome of this study was listed as safety and tolerability).\u00a0 ", "answer": 0}, {"article": "Using sophisticated computer software, researchers were able to coordinate the actions of a commercially available continuous glucose monitoring device and insulin pump to allow automatic insulin delivery in response to real-time glucose readings.\nThe system proved better than a conventional insulin pump for maintaining optimal blood sugar levels during the night in a study from the U.K.'s University of Cambridge.\nFeb. 4, 2010 - It has been called the Holy Grail of treatment for insulin-dependent diabetes, and it may be close to reality.\nAaron J. Kowalski, PhD, of the Juvenile Diabetes Research Foundation, which was involved in funding the research, says the study represents an important step forward in the search for a clinically feasible artificial pancreas to improve outcomes and quality of life among insulin-dependent diabetes patients.\nNow new technology is making this possible, and new research shows that an experimental system can improve nighttime blood sugar control.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story did a better job than the competing Reuters piece in explaining that the system tested in this study actually consisted of a commercially available glucose monitor and insulin pump\u2013not a \"new device\"\u00a0per se.\u00a0However, it still left the reader with the impression that system was automatically managing patients\u2019 glucose without any outside human intervention, which was not the case. We also wish the story had resisted the temptation to\u00a0predict that a new \"artificial pancreas\" system might be\u00a0be available clinicially in 3 to 5 years. The FDA approval process is notoriously uNPRedictable, and this technology has a lot of hurdles to clear before it will be available for patients.", "answer": 0}, {"article": "For men with advanced prostate cancer, the news for decades has been mostly bleak. Until recently, only two treatments had been shown to prolong survival.\n\nResearchers reported Monday that the drug abiraterone, being developed by Johnson & Johnson, extended survival by an average of 3.9 months among men with cancer that has spread beyond the prostate and for whom other treatments have failed. Among men, prostate cancer is the second-leading cancer killer, behind only lung cancer.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story points out that the drug is experimental and is not available. However, it says the manufacturer intends to file for approval later this year, \u201craising prospects that the drug could be on the market next year.\u201d While that statement is only a tentative prediction of what could happen, it still gives readers the impression that approval is likely, even though the full data from this trial has yet to be inspected by anyone other than the investigators. Nonetheless, we\u2019ll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "Please visit http://www.\nSince then, more than half of the U.S. schools and colleges of dentistry have adopted CAMBRA in one form or another as part of their standard curriculum.\nThe authors published their initial validation of CAMBRA for ages 6 through adult in 2006, followed by several additional years of data published in 2011, 2012, 2015 and 2016.\nA dentist who uses CAMBRA obtains the patient's dental and medical history and conducts a clinical exam to assess caries early enough to reverse or halt progression and to determine caries risk factors.\nWhile not as significant as the CAMBRA group in this study, the risk level of these patients dropped more dramatically over time than for those in the 2012 UCSF CAMBRA study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This CAMBRA method is available at about half of US schools and colleges of dentistry according to the release. However, the prescription fluoride toothpaste is available from most pharmacies.", "answer": 1}, {"article": "The key to making the therapy work?\nThe only treatment is a bone-marrow transplant \u2014 if a compatible donor can be found \u2014 or a transplant with cord blood, if it was saved at birth.\nFor the first time, doctors have used gene therapy to stave off a fatal degenerative brain disease, an achievement that some experts had thought impossible.\nThe patients were children who had inherited a mutated gene causing a rare disorder, adrenoleukodystrophy, or ALD.\nThe disease strikes about one in 20,000 boys; symptoms first occur at an average age of 7.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t make clear that this treatment is, at the very least, years away from clinical use. The story notes only that Bluebird Bio is \u201cin hopes of marketing gene therapy for ALD.\u201d This line, found more than halfway through a 1,300 word story, isn\u2019t sufficient. This is an area where the Associated Press story fared better, noting that the FDA \u201crequires gene therapy participants to be monitored for 15 years, so these patients will continue to be studied.\u201d The AP story also notes that Bluebird Bio \u201cplans to seek approval of the therapy in the U.S. and Europe.\u201d The AP was stronger on this criterion.", "answer": 0}, {"article": "\"Of concern is that complication rates are still higher than desirable for this procedure, and there was suboptimal use of stroke-preventing anticoagulation [anti-clotting] therapy after the procedure,\" added Fonarow, who was not involved with the study.\nCatheter ablation is covered by most insurance, including Medicare, the researchers said.\nThese patients had no atrial arrhythmias -- irregular heart beats -- for three to 12 months after the procedure.\nPatients should not be going into this thinking they will have a 99 percent cure rate with no risk,\" he added.\nBurning or freezing specific areas of the heart can alleviate the common irregular heart beat called atrial fibrillation in 74 percent of patients.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Catheter ablation is available in most medical centers offering broad cardiac services, but the story didn\u2019t explain that.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a180226S32.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Coffee, tea, or decaf-no matter what your choice, drinking any of these beverages may reduce your risk of diabetes, according to a new analysis of 18 studies including hundreds of thousands of people.\nFor every additional cup of coffee a person consumed each day, the study\u2019s authors found, a person\u2019s risk of diabetes was reduced by 7 percent.\nIn the six studies that looked at decaf coffee, the researchers found, people who consumed more than three or four cups a day were at 36 percent lower risk of diabetes.\nClinical trials are needed to investigate whether these beverages do indeed help prevent diabetes, the researchers say.\nAnd in seven studies that examined tea drinking and diabetes risk, people who drank more than three or four cups daily were at 18 percent lower diabetes risk.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availabilty of coffee and tea is not in question. ", "answer": 2}, {"article": "MONDAY, June 6, 2011 (HealthDay News) -- There's too little evidence to say definitively whether treating early, localized prostate cancer with radiation is a better option than \"watchful waiting,\" new research finds.\nThere was also \"moderate strength evidence\" that a higher external beam radiation was more effective than a lower dose.\nThey should also consider age and overall health status, including whether or not the patient has other conditions more likely to cause death than the prostate cancer.\n\"Some of the distinctions being made are not really supported by the evidence.\"\nIn the meantime, what are men diagnosed with early prostate cancer to do?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The story didn\u2019t explicitly address the availability of radiation facilities, but that wasn\u2019t necessary.", "answer": 2}, {"article": "But the supplement has largely failed to show benefits in human athletes.\nAlcoholic beer happens to be drenched in polyphenols, too \u2014 \u201ceven more than nonalcoholic beer,\u201d Dr. Scherr said \u2014 but has the signal disadvantage of being alcoholic.\n\u201cIncidence of upper respiratory tract infections was 3.25-fold lower\u201d in the nonalcoholic beer drinkers, the scientists reported, in the journal Medicine & Science in Sports & Exercise.\n\u201cFurthermore, it is not possible to drink one to one and a half liters of alcoholic beer per day, especially not during strenuous training.\u201d We all knew that, right?\nAn analysis of 10 human studies of the supplement presented at the American College of Sports Medicine annual meeting in June concluded that quercetin supplementation \u201cis very unlikely to provide an endurance performance advantage.\u201d\n\nBut the beer experiment did not begin by looking at mice.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nNot applicable.\u00a0 The availability of nonalcoholic beer is not in question.\nHowever, it is not clear from the original abstract whether the type of beer matters, as the brand and/or the characteristics (such as calories) were not provided. This is not mentioned in the story. (note: the brand was provided in a press release)", "answer": 2}, {"article": "They returned at weeks 26, 39 and 52 for safety assessments, which included an evaluation of adverse events, clinical laboratory tests and physical examinations.\nThe AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.\n\"Making sure an oral treatment is safe and effective for men and for the children and partners at risk for inadvertent testosterone transference is the top priority, and what we've found so far has shown we're on the right track.\"\nFounded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 21,000 members throughout the world.\nAbout the American Urological Association: The 111th Annual Meeting of the American Urological Association takes place May 6 \u2013 10 at the San Diego Convention Center in San Diego, CA.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states \u201cThere is currently no oral form of testosterone therapy approved for use in the United States by the Federal Drug Agency\u201d and then talks about this new product under development. Readers can assume the product is not yet available.", "answer": 1}, {"article": "The last update, in 2005, put more emphasis on chest pushes by alternating 30 presses with two quick breaths; those \"unable or unwilling\" to do the breaths could do presses alone.\nHands-only will be added to CPR training.\nOnly about 6 percent of those who are stricken outside a hospital survive, although rates vary by location.\nNow the heart association has given equal standing to hands-only CPR.\n\"It's a second lease on life,\" he added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Hands-only CPR is implictly available anywhere. ", "answer": 1}, {"article": "For more information, visit http://www.\nIn a new study published in the American Journal of Medicine, Charles H. Hennekens, M.D., senior author and first Sir Richard Doll Professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University, indicates that black and white women ages 75 to 84 years who had an annual mammogram had lower 10-year breast cancer mortality than corresponding women who had biennial or no/irregular mammograms.\nAlthough a number of randomized trials demonstrate the clear benefits of mammography screening in women up to age 74 on reducing mortality, data are sparse in women over the age of 74, especially minorities.\nThe researchers selected 69 as the lower age limit because Medicare coverage of the general population begins at age 65, and the exposure of interest was regular mammography screening in the four years immediately preceding breast cancer diagnosis.\nToday, the University, with an annual economic impact of $6.3 billion, serves more than 30,000 undergraduate and graduate students at sites throughout its six-county service region in southeast Florida.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that mammograms are widely available. However, most current guidelines cap recommended annual or biannual mammograms at age 74. These recommendations have a direct effect on Medicare and private insurance coverage.", "answer": 1}, {"article": "The study, \"Survival Outcomes in Men Undergoing Radical Prostatectomy after Primary Radiation Treatment for Adenocarcinoma of the Prostate,\" recently was published by Clinical Genitourinary Cancer, a peer-reviewed journal on the detection, diagnosis, prevention and treatment of genitourinary cancers.\nIf the cancer is localized, a highly skilled surgeon can remove the gland and surrounding tissue using a robotic minimally invasive technique or through an open surgery.\n\"However, this study shows that it is a viable treatment option.\nThis can bring a renewed hope and peace of mind to men living with prostate cancer.\"\n\"Because radical prostatectomy is a complex surgery, there can be a reluctance to undergo the procedure,\" Pokala said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Data analyzed in the release relates to surgeries performed between 1988 and 2010 at many different institutions so we assume it is widely available.", "answer": 2}, {"article": "That view is shared by Deborah Giaschi, a professor of ophthalmology and visual sciences at the University of British Columbia in Vancouver who has conducted MRI studies of the brains of people with dyslexia. \"There's really no scientific basis\" for ChromaGen lenses, she says. In her opinion, the claim that the lenses slow down visual processing doesn't make sense. Even if the lenses had that effect, she doesn't see how that would help anyone read.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The column explained that the lenses are marketed on a company website, which also gives a list of providers.", "answer": 1}, {"article": "But his thoughts were out of control.\nAnd almost from the time it reached the market it has also been used as a mind-bending party drug.\nIt typically appears in childhood and often doesn't respond to traditional psychiatric drugs.\nAnd his mood could go from ebullient to dark in a matter of minutes.\n\"My wife took a summer off to be with me because she was scared of what was going to happen to me,\" he says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story highlights a patient using a ketamine nasal spray without making it clear that this form of the drug has not been approved by the FDA.", "answer": 0}, {"article": "With knee-replacement surgery on the rise, more patients with two bad knees are opting for a controversial procedure that replaces both at the same time.\n\nSimultaneous bilateral knee replacement, as the surgery is known, is a subject of debate among orthopedic surgeons, with conflicting evidence about the risks and benefits. Proponents say it eliminates the need for a second hospital stay and grueling rehabilitation period, reduces time spent under anesthesia and costs less.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It was made clear that both bilateral and staged knee replacement surgeries are fairly common and widely available. Similarly, it was made clear that some surgeons refuse to perform bilateral surgeries, or will only perform them for patients that meet fairly stringent criteria.", "answer": 1}, {"article": "At the top of the list?\n\"The good news is that we now understand which foods we need to target to prevent Americans from dying prematurely from cardiometabolic diseases,\" says lead study author Renata Micha, a public health nutritionist and epidemiologist at the Friedman School at Tufts University.\nThis means that a single 200-calorie sugary drink may be OK for a person who typically consumes a 2,000 calorie-per-day diet.\nHe says the bigger point is this: \"Whether poor diet is causing 1,000 cardiovascular and diabetes deaths per day, or 500, it remains among the leading causes of preventable suffering.\"\n\"This is a remarkable burden, nearly 1,000 deaths each day\" linked to dietary habits, says senior study author Dariush Mozaffarian, dean of the Friedman School at Tufts.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability of the foods discussed in the story is not an issue, which is why we\u2019ll rate this Not Applicable. However, the fact that so many \u201cbad for you\u201d foods are so much more readily available today than they used to be is something the story could have touched on. In addition, such foods are often cheaper\u00a0than more healthy alternatives in many communities.", "answer": 2}, {"article": "BioSure UK has begun selling a $45 take-home HIV test that lets customers prick their fingers, smear the blood on a testing stick, and get their HIV results within 15 minutes.\nWhen asked if any test similar to BioSure\u2019s new take-home test was in development, Tara Goodin, a press officer for the Food and Drug Administration, said: \u201cThe FDA cannot confirm the existence of or comment on any current/pending product applications.\u201d\n\nThe FDA has approved two take-home HIV tests, but neither has all the strengths of the BioSure test.\nIt adjusted the raw data to mirror the demographics of the U.K. as a whole and estimated that in 2012, 22 percent of all residents with HIV were undiagnosed.\nAnd because the incidence of other sexually transmitted infections declined for these men, after the diagnosis, the scientists had reason to believe the self-reports of condom usage were accurate.\nIn the United States, the Affordable Care Act designates HIV testing as a preventive service, meaning that all insurers must cover it without charging a co-pay.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly reports that this HIV test is now available in the UK, but not in the US. However, the murky quote from an FDA spokesperson leaves readers in the dark about whether the company selling this test in Britain has, or is planning to, apply for approval in the US.", "answer": 1}, {"article": "Bangalore said this is critically important because \"compliance is big issue with our patients.\"\nThe idea that ACE inhibitors are more effective than ARBs was based on comparing studies on ACE inhibitors going as far back as the 1980s and into the 1990s with newer studies on ARBs in the 2000s.\nMost significantly, research showed a significant effect in reducing the risk of death with ACE inhibitors but not with ARBS.\n\"The patients in the '80s and '90s were a higher-risk group than those in the 2000s,\" Bangalore explained.\nBut some doctors and researchers were puzzled by the fact that in head-to-head comparisons between the two classes of drugs they appeared to equally safe and effective.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does point out that ACE inhibitor drugs have been available for decades and that ARBs have been available since the year 2000.", "answer": 1}, {"article": "TUESDAY, March 27, 2012 (HealthDay News) -- When taken as a supplement, unroasted -- or green -- coffee-bean extract can help people shed pounds, according to a small preliminary study.\nGreen coffee-bean extracts are sold online at prices ranging from about $10 to $20 for 60 capsules.\n\"Those studies demonstrated that patients experienced somewhat mild weight loss.\nThe study was conducted in India and funded by Applied Food Sciences, the American manufacturer of two green-coffee-extract products.\nA follow-up study involving 60 patients is now in the planning stages.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that green coffee bean extract is sold online.", "answer": 1}, {"article": "\u201cIt is not clear that it is the specific early introduction of an allergenic food that renders immunological protection, rather than the accompanying increased diversity in the diet that occurs as a by-product,\u201d writes Dr. Matthew Greenhawt, an allergy and immunology specialist at Children\u2019s Hospital Colorado, in the accompanying editorial.\nExactly why is a question researchers are still exploring.\nMore research is necessary to figure out the ideal amounts of these allergens, the optimum times of introduction and the reasons behind the link.\nThe authors of the just-published study reviewed all of the available evidence on the topic and included 146 studies in their final analysis.\nEggs, too, showed this association when they were introduced between ages 4 and 6 months.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The food items are widely available.", "answer": 2}, {"article": "An experimental treatment for prostate cancer tumors using high-intensity focused ultrasound (HIFU) shows promise as an effective treatment with fewer side effects than existing therapies.\nThe procedure was carried out under general anesthesia and most of the patients had hospital stays of less than 24 hours after the treatment.\nNone of the patients reported urinary incontinence a year after treatment, and only 1 in 10 suffered from poor erections.\nThe new study, designed as a proof-of-concept study, involved just 41 men.\nOverall, about 95% of the men were cancer-free after a full year following the trial.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was about a British study.\u00a0 There was no mention of the availability of HIFU in the US.", "answer": 0}, {"article": "March 15, 2012 -- A new prescription gel may quickly treat a common precancerous skin condition called actinic keratosis, a new study shows.\nThe new gel, Picato (ingenol mebutate), is applied once daily for two or three days, depending on the area being treated.\nBecause the new gel is only used for a few days, any irritation is usually short-lived.\nBy contrast, only 4% and 5%, respectively, of the people who received the placebo had complete clearance.\nOther available topical treatments must be used for several weeks, and often irritate the skin.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story repeatedly refers to the drug as a \u201cnew gel\u201d but never explains if it is available.\u00a0 It was recently approved by the FDA.", "answer": 0}, {"article": "Observational studies, which include all people with a condition, can never conclusively prove cause and effect, Keating acknowledged, because \"the thing we can't account for is whether people who are on a treatment are different from those who aren't.\"\nThe study she led looked at its effects on about 37,000 men treated for prostate cancer at Veterans Affairs hospitals.\nBut lots of men get the therapy where it has not been shown to have a benefit.\"\nOne example is so-called PSA-recurrent cancer.\n\"We are beginning to realize that there can be significant problems in terms of cardiovascular risk.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story accurately indicates that androgen deprivation therapy is commonly used in men with prostate cancer.", "answer": 1}, {"article": "LONDON -- AstraZeneca PLC said Monday its experimental heart pill Brilinta was more effective at preventing heart attacks and strokes in a large clinical trial than the blockbuster pill Plavix, boosting commercial prospects for the U.K. drug maker's still unmarketed treatment.\n\nPlavix, which is marketed by Sanofi-Aventis SA and Bristol-Myers Squibb Co., was the second-biggest-selling drug in the world last year, with global revenue of $8.6 billion, according to IMS Health. Any competitor to it could have a shot at big sales.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that Brilinta is not yet available. It says the company plans to submit the drug for approval in the fourth quarter of this year. \nWisely, the reporter resists predicting when the drug might be on the market, since this is not guaranteed. ", "answer": 1}, {"article": "New research analyzing more than 22,000 U.S. cases of aortic aneurysm repair is likely to hasten the trend toward more procedures being done with a device called a stent-graft instead of the typical surgery that requires up to eight weeks of recovery.\n\nThe study by doctors at Harvard Medical School and the federal Centers for Medicare and Medicaid Services found the death rate in surgery, 4.8%, was four times that of the 1.2% death rate in placing stent-grafts to seal off the aneurysm. Surgery tended to provide a more permanent...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was about a study comparing two treatments for abdominal aortic aneurysms.\u00a0 Because the story mentioned that it was about aneurysm repair in 2001 and 2004, a reader could infer that both are current procedure.\u00a0", "answer": 1}, {"article": "It was a struggle at first, but by the end of the trial he was able to complete the action three out of five times in a 10-minute period.\nFor starters, the device that records the brain signals will need to be much smaller so it's fully implanted under the paralysed person's skin.\nThe study builds on previous work in which humans have been able to move computer cursors and robotic arms using their own brain signals, and a study in which monkeys with paralysed arms were able to move them again thanks to a similar intervention.\nThere are still many challenges to be overcome to bring this work out of the lab and into the lives of the millions of people who are paralysed.\nThis is the first time a person with paralysis has regained movement in their hands and individual fingers using signals from their brain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that this device is in laboratory testing. The comments from independent sources at the very end of the story help describe the long and uncertain road ahead for researchers.", "answer": 1}, {"article": "(Reuters Health) - Many women with severe menopausal symptoms are not being treated for them even though safe, effective remedies are available, a study from Australia suggests.\nHormone replacement therapy (HRT), which generally combines estrogen plus progestin, is very effective.\nThe women who did use hormones were mostly taking pills containing estrogen, rather than preparations that are absorbed into the skin and that are potentially safer, the researchers found.\nBut after the initial findings of the Women\u2019s Health Initiative study showed that HRT can increase the risk of breast cancer, stroke and other serious problems, many women stopped using it.\nBut overall, he said, it is a combination of patients not wanting therapy or not having information about it, and also the provider not prescribing it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story establishes that all of the treatments discussed \u2014 hormone pills, estrogen creams, and non-hormonal treatments \u2014 are available.", "answer": 1}, {"article": "The Wyss Institute for Biologically Inspired Engineering at Harvard University uses Nature's design principles to develop bioinspired materials and devices that will transform medicine and create a more sustainable world.\nThe potential of this assay to detect pathogen materials was demonstrated in both animal studies and a prospective human clinical study, whose results also suggest that it also could serve as a companion diagnostic to monitor the success of antibiotic and dialysis-like sepsis therapies.\nThe standard of care for detecting such blood-borne infections is blood culture, but this takes days to complete, only identifies pathogens in less than 30% of patients with fulminant infections, and it is not able to detect toxic fragments of dead pathogens that also drive the exaggerated inflammatory reactions leading to sepsis.\n\"The animal models clearly told us that the assay can sensitively trace spikes of PAMPs released during antibiotic therapy, or residual infectious PAMP materials, even when no living bacteria circulate anymore in blood but they remain hidden inside internal organs.\n\"This assay could become a real game changer in this clinical area, and it also should lead to more judicious use of antibiotics, helping to decrease the worrisome rise we are seeing in antibiotic-resistant organisms.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release gets a pass here but just barely. Unless you\u2019re reading carefully you might think the test is already ready for prime-time. Instead, a researcher notes that \u201cWe are currently working to ready it for for high-throughput use in clinical and point of care situations and to accelerate it even further.\u201d", "answer": 1}, {"article": "He wanted to be able to go to the beach.\u201d\n\nA nephrologist at the University of North Carolina School of Medicine, Dr. Hladik understood better than most how kidney dialysis could consume a patient\u2019s days.\nHe died at home in November, a year and a half after saying no to dialysis.\nHis doctors managed his heart disease and hypertension with drugs.\n\u201cDialysis may have prolonged his life, but I suspect only by a couple of months,\u201d Dr. Hladik said.\n\u201cHe wanted to be at home with his dog.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story presents it as a given that dialysis, renal clinics and so on are common in the health system.", "answer": 1}, {"article": "We're sorry, but we seem to have lost this page.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is something that the story really should have done high up. Why has it become standard practice to do a CT\u00a0scan and not an MRI? One of the authors says that 40% of his time is spent giving MRIs and 40% doing CT scans. Is that typical? Nonethless, we\u2019ll give it the benefit of the doubt. ", "answer": 1}, {"article": "\u201cThe important point was the intensity of the activity,\u201d Erin Richman, a postdoctoral fellow at UCSF, said in a statement.\nMore than 2.2 million men in the U.S. are living with prostate cancer.\nProstate cancer is the second leading cause of cancer death in men.\nThe patients\u2019 average age at diagnosis was 65.\nDuring the follow-up, there were 8,092 cases of prostate cancer \u2014 significantly fewer in the group who took acetaminophen daily for five years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 There\u2019s no question about the availability of the two \u201cinterventions\u201d \u2013 walking and acetaminophen.", "answer": 2}, {"article": "Natural remedies have an obvious appeal, but how do you know which ones to choose and whether the claims are backed by science?\nThe study was carried out by pediatricians at the Pennsylvania State University medical school and supported by a grant from the National Honey Board, an industry-backed agency of the Department of Agriculture.\nThe Science: For decades, parents looking for an over-the-counter medicine to cure a child\u2019s sickness and coughing have turned to syrupy medicines containing dextromethorphan, a popular cough suppressant found in products like Children\u2019s Dimetapp DM and Robitussin DM.\nIn a similar study published in the journal Pediatrics in 2004, researchers recruited 100 children with upper respiratory tract infections who had been coughing for an average of over three days.\nThe Risks: According to the National Institute of Allergy and Infectious Diseases, honey may be useful in relieving coughing, but it should never be given to children under a year of age because in rare cases it can cause infantile botulism.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the standard treatment for colds in kids was the subject of a 2007 ban by the FDA, and that the other standard remedy \u2013 honey \u2013 is a grocery store staple.", "answer": 1}, {"article": "Shi's lab has developed a promising live-attenuated Zika vaccine candidate called ZIKV-LAV that had been shown to be safe, non-virulent, and effective in protecting against infection in mice and non-human primates.\nThen, once such a virus infects a cancer cell and kills it, the immune modulator would be released to alert and activate the patient's systemic immune system against the remaining cancer cells.\nComparing those profiles, the team found that in the treated cells, the virus triggered a strong antiviral response in the cells, which induced inflammation and eventually cell death.\n(image: transmission electron micrograph of Zika virus, NIAID)\n\n\"If we could find a way to specifically target those GSCs that are the source of recurrence, then that might provide an option to prevent recurrence or even a cure,\" says Qin.\nIn a study published this week in mBio\u00ae, an open-access journal of the American Society for Microbiology, the team shows that a live, attenuated version of the Zika virus could form the basis of a new treatment option for this fatal brain cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear this treatment isn\u2019t yet available for use in humans. The release could have put the findings into clearer perspective if it noted that availability for human use is years in the future, if ever.", "answer": 2}, {"article": "For more information, visit http://www.\n\"Breast cancer survival is strongly tied to the sensitivity of tumor detection; accurate methods for detecting smaller, earlier tumors remains a priority,\" says Prof. Yehuda Zeiri, a member of Ben-Gurion University's Department of Biomedical Engineering.\n\"Our new approach utilizing urine and exhaled breath samples, analyzed with inexpensive, commercially available processes, is non-invasive, accessible and may be easily implemented in a variety of settings.\"\nAbout American Associates, Ben-Gurion University of the Negev\n\nAmerican Associates, Ben-Gurion University of the Negev (AABGU) plays a vital role in sustaining David Ben-Gurion's vision: creating a world-class institution of education and research in the Israeli desert, nurturing the Negev community and sharing the University's expertise locally and around the globe.\nThe study reports breast cancer is the most commonly diagnosed malignancy among females and the leading cause of death around the world.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release quotes the lead author claiming: \u201cWe\u2019ve now shown that inexpensive, commercial electronic noses are sufficient for classifying cancer patients at early stages.\u201d This implies that such \u201cnoses\u201d are already commercially available for breast cancer detection but we\u2019re not told where they are available and how frequently they\u2019re used.", "answer": 0}, {"article": "Ten percent of study participants who had not had a hysterectomy showed precancerous changes in the lining of the uterus, and all of those resolved with weight loss.\n\"The study results demonstrate that there is a huge alteration, but I don't even know what to say about that, except it is really new and intriguing area to look at in the link between obesity and cancer.\n\"So I could never say that effect is definitive, but it is suggestive, given that we know already the incredibly strong link between endometrial cancer and obesity.\"\nWhile the study speaks to the transformative effect bariatric surgery can have, Modesitt urged people to avoid gaining weight in the first place and for those seeking to lose weight to exercise and eat more healthily before turning to surgery.\nThe study looked at the effects of bariatric surgery in a relatively short timeframe, one to three years after surgery.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the release that the participants underwent a standard bariatric surgery and that these procedures are available. The release could have specified the criteria used to determine who is eligible for such procedures and whether insurance will cover it.", "answer": 1}, {"article": "\"The reason we talk about it so much is in the 1960s and 70s, researchers discovered people living there had lower blood pressure problems, cholesterol problems so they started to analyze the diet,\" Dr. Senay told The Early Show co-anchor Julie Chen.\nFor more further information, you can see the studies here and here.\nAs far as alcohol goes, they consume red wine in moderation.\nThey are the first studies to examine the association between the Mediterranean Diet and neurological diseases \u2013 specifically Alzheimer's.\n\"Those who most closely adhered to the Mediterranean diet had a 68 percent reduction in the risk of Alzheimer's disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that foods that comprise the Mediterranean diet are available to many people. ", "answer": 1}, {"article": "She cited a 2010 review estimating that 11 million to 12 million women a year will suffer from a UTI, accounting for 1.6 billion antibiotic prescriptions a year.\nVisit the U.S. Centers for Disease Control and Prevention for more on UTIs.\nDr. Hunter Wessells, who wasn't involved in the study, called the additional fluid intake \"substantial,\" leading to a corresponding increase in urine output.\nWomen are more prone to UTIs than men, partly due to their anatomy.\nThe women were followed for a year, with clinic visits at the beginning of the study as well as 6 and 12 months later.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "For most people in the U.S, water is easily available.", "answer": 2}, {"article": "\u2022 Online Press registration process: The online registration deadline has expired, we still accept advance registrations though, but the process is slightly different.\nThe findings from this PROOF study were confirmed in a meta-analysis preformed by the same group and reported at this same EuroPRevent congress.3 This analysis, drawing on data involving almost 120,000 subjects, found that \"low-dose\" moderate-to-vigorous physical activity - of, say, 75 minutes per week or 15 minutes per day - significantly reduced mortality in the elderly.\nIndeed, most physical activity guidelines are the same for the middle-aged adults as for the elderly, even though it is estimated that over 60% of the elderly are unable to achieve this same level of exercise.\n\u2022 Credential: either your ID press card or letter of assignment with proof of 3 published articles\n\u2022 Press registration is not available to Industry or its Public Relations representatives, event management, marketing or communications representatives\n\u2022 The decision of the ESC Press Office is final regarding all press registration requests.\nIn commenting on the results, Dr Hupin said several conclusions might be drawn but notably that the level of physical activity in the elderly was negatively associated with mortality rate in a \"dose-dependent\" way and that even a low level of exercise below current recommendations had some protective effect.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It isn\u2019t a big deal that the news release didn\u2019t discuss the availability of exercise methods, since the elderly can pursue any physical activity for at least 15 minutes a day, five days a week. But we\u2019d note that access to some of the activities mentioned (cycling, swimming, gymnastics) might be limited, and the release could have noted that as well.", "answer": 2}, {"article": "How can this bile acid affect the heart in such a dramatic way?\"\n\"It offers hope to those who are living with heart failure,\" adds Luis Agellon, co-principal investigator and a professor at McGill University's School of Dietetics and Human Nutrition.\n\"We don't yet have a full understanding--nobody does--of how the bile acid actually does what it does in heart cells,\" explains Michalak.\n(Edmonton, AB) Groundbreaking research from the University of Alberta and McGill University has opened the door towards the future prevention of cardiac fibrosis--a condition leading to heart failure for which there is currently no treatment.\n\"This is something that nobody has ever seen before,\" says Marek Michalak, co-principal investigator and a distinguished professor in the Department of Biochemistry at the University of Alberta's Faculty of Medicine & Dentistry.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is silent on the availability of\u00a0TUDCA, the bile salt used in the study. As noted above, it is available commercially as a supplement. However, due to the pre-clinical nature of the research it is premature and ill-advised to rely on TUDCA for cardiac fibrosis prevention.", "answer": 0}, {"article": "Feb. 1, 2012 -- A new drug appears to be effective for shrinking uterine fibroids and controlling the heavy menstrual bleeding they often cause, according to new research from Europe.\nIn one study, the drug ulipristal acetate proved to be much more effective than a placebo for shrinking the non-malignant uterine tumors.\nIn another, ulipristal acetate was found to be as effective as monthly injections of the drug Lupron for reducing heavy bleeding in women with uterine fibroids.\nUlipristal acetate is the active chemical in the emergency contraceptive sold in the U.S. as Ella, but the daily doses taken by the fibroid patients in the studies were much smaller than those in the contraceptive.\nIf trials now under way in the U.S. prove positive, New Jersey-based Watson Pharmaceuticals Inc. and Swiss-based PregLem hope to market ulipristal acetate as a fibroid treatment under the trade name Esmya, says Watson spokesman Charlie Mayr.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is a variation of a drug already on the market but that it is not yet approved for use.", "answer": 1}, {"article": "The U.S. Food and Drug Administration said Tuesday it has approved Cotellic, a drug produced by Swiss biotech company Roche, for use in combination with the vemurafenib medication as a treatment for advanced melanoma.\n\nThe drugs are intended to target the illness after it has spread to other parts of the body or can\u2019t be removed by surgery.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Because this is an announcement from the FDA about approval, the drug will now be marketed for treatment, and the story clearly indicates that the drug combination is distributed by Genentech.\nWe\u2019ll rule this Satisfactory, but we\u2019d caution that\u00a0FDA approval does not necessarily equal availability. The key factor here is the cost and who will pay for it, or not. The story doesn\u2019t address this.", "answer": 1}, {"article": "CHICAGO (Reuters) - A computerized brain training program cut the risk of dementia among healthy people by 48 percent, U.S. researchers said on Sunday in reporting an analysis of the results of a 10-year study.\nEdwards did a secondary analysis of the 10-year data, looking at the time it took individuals to develop dementia.\nResults of that study, published in 2014, found modest benefits in the reasoning and speed-of-processing groups, but not memory.\nThe program got harder with each correct answer.\nThe institute is part of the National Institutes of Health, which funded the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "According to the article, there already exist companies such as Posit Science who offer these so-called brain games.", "answer": 1}, {"article": "\"They have a lot of promise and are potentially very important,\" said Katherine Hamilton, a headache specialist at Penn Medicine. The drugs, which are injected under the skin, offer hope for patients who have not responded to other treatments, but Hamilton said that what is \"potentially even more clinically relevant is they have a lower side-effect profile\" than other medications commonly used for migraine. She added, though, that it remains to be seen how patients who take them for long periods will fare. As new drugs, their long-term impact is not yet known.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reported that all three drugs have been approved for sale by the FDA and a fourth \u2014 which isn\u2019t named \u2014 is in development.", "answer": 1}, {"article": "Guadecitabine works to reverse a so-called epigenetic change in cancer cells known as methylation, which may alter genetic activity in cells in a way that can block the action of tumor-suppressing genes, pushing cells to become cancerous and resistant to therapy.\n\"We did see that giving a higher dose of the drug seemed to produce a better methylation response among patients,\" says Valerie Lee, M.D., a fellow at the Johns Hopkins Kimmel Cancer Center.\nAmong the side effects of the combined treatment, 16 patients experienced neutropenia, a low count of the infection-fighting white blood cells called neutrophils; five patients with neutropenia had fevers; three patients became anemic; and two patients developed thrombocytopenia, a lowered count of blood-clotting platelets.\nThe current study was based on previous studies in the laboratory of Nita Ahuja, M.D., director of the Sarcoma and Peritoneal Surface Malignancy Program and professor of surgery at the Johns Hopkins University School of Medicine, which showed that guadecitabine limited the growth of colorectal cancer cell lines when combined with irinotecan, says Azad.\nResults of the study are expected to be presented April 17 at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans (abstract CT017).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that this was a preliminary trial and that a phase II trial is ongoing. That\u2019s good. In addition, the release states: \u201cGuadecitabine is an experimental drug that has not been approved for use by the U.S. Food and Drug Administration.\u201d That\u2019s great. We wish all releases were this straight-forward about drug/treatment availability.", "answer": 1}, {"article": "Dr. Ellen Marmur, the chief of the division of dermatologic and cosmetic surgery at Mount Sinai Medical Center in Manhattan, did say Algenist could fairly claim that alguronic acid offers protection against ultraviolet damage to cells, and that she might use the product as \u201ca nice sun protection on top of S.P.F.\nThe patent-pending alguronic acid in Algenist is a \u201csingle, purified, highly bioactive compound,\u201d said Tony Day, the vice president for research and development at Solazyme, and therefore delivers \u201cmuch higher activity to the skin\u201d than products using only a microalgae extract.\nBut Dr. McDaniel, who does research into using plant-derived products to lengthen the life of cells, says he thinks the comparative data must be viewed with caution because the studies that yielded it are \u201cchallenging to do accurately, hard to interpret and not necessarily predictive of final products.\u201d\n\nSoon, consumers will judge whether Algenist products are a breakthrough.\n\u201cWe want to give it a lot of visibility all at the same time.\u201d But Mr. Burke knows that marketing has its limits.\nAfter reviewing press materials and Solazyme\u2019s 84-page patent application, Dr. David McDaniel, a dermatologist and the director of the Institute of Anti-Aging Research in Virginia Beach, Va., said he was impressed by the in-vitro testing of alguronic acid.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story starts out by making it clear that \u201cAlgenist moisturizers, serum and eye balm are already available at Sephora.com and will go on sale in the company\u2019s stores this week.\u201d", "answer": 1}, {"article": "(Reuters Health) \u2013 Patients who need to be rehospitalized within a month after major surgery have a lower risk of death over the next two months if they return to the hospital where they had the surgery rather than going to a different facility, according to a new study.\nPatients readmitted at the original hospital also tended to be readmitted one to two days earlier than those who ended up at different hospitals.\nMore than nine million patients underwent one of 12 such surgeries during the study period, and between six and 22 percent, depending on the surgery, were readmitted to the hospital within a month.\nIf these patients have complications weeks later, they end up going to a local hospital, not the one where they had surgery.\nThose who returned to the original hospital were 26 percent less likely to die within three months of surgery than those admitted to a different hospital, as reported in The Lancet.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As noted above, seeking to ensure that patients who have undergone major surgery would be readmitted to the hospital where the initial surgery was performed would appear to be logistically difficult, at best. The story did not address that concern.", "answer": 0}, {"article": "General.\nCritics have gone so far as to send letters to newspapers that covered her work apologizing to patients \u201con behalf of Dr. Faustman\u201d for \u201chaving their expectations cruelly raised.\u201d She has also struggled for funding, receiving much of her research support from the private Iacocca Family Foundation, rather than in federal grants.\nIt alters the immune system so as to increase levels of T regulatory cells; T regs keep other immune cells in check, including those that attack the pancreas\u2019s insulin-making cells \u2014 the root cause of type 1 diabetes.\nAlthough many studies of BCG are underway around the world in diabetes and other autoimmune diseases, including multiple sclerosis, there has been little interest among U.S. researchers outside Faustman\u2019s lab.\n(The standard of care is a continuous glucose monitor, in which a probe is inserted into the abdomen, plus an insulin pump.)\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not explicitly address the issue of when, if ever, patients might have access to the BCG vaccine as a treatment for Type 1 diabetes. However, it does state that the treatment is being tested in a Phase 2 clinical trial involving 150 patients with Type 1 diabetes. The story also notes that one barrier to further development of BCG as a diabetes treatment is that it would appear to have little commercial value, meaning that drug manufacturers aren\u2019t interested in it.", "answer": 1}, {"article": "\"Are they normal variations?\nIf proved effective, it could become the norm for identifying heart conditions that put one in 10,000 people at risk when doing top-level physical activities, researchers say.\n\"The saddest day for me had to be the day of (baseball) try-outs,\" Jordan says.\n\"One of our goals is to advance the field \u2026 in areas either untouched or unappreciated as being important,\" Towbin says.\n\"The hope would be that with data, we could get the entire system interested in participating \u2026 get funding to run a clinical trial, locally and maybe nationally.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "From the way the tests are described in the story, they appear to be routinely available. However, there is no discussion of whether the capacity exists to test and properly interpret test results for the millions of teens who would need to undergo screening if it were demonstrated to be beneficial.", "answer": 1}, {"article": "the bigger issue though is, is the increased costs associated with protons worth it to society?\nIt's the most expensive device in medicine today.\nHuge magnets direct the beam of radiation the length of a football field into treatment rooms.\nBut proton beam therapy is at the heart of the debate over rising health-care costs.\nThat's because proton beam radiation is highly targeted - delivering its dose only to the tumor and sparing the surrounding tissue, which is important for certain rare cancers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story describes the limited availability of proton beam therapy.", "answer": 1}, {"article": "\"Vitamin D supplementation trial in infancy: body composition effects at 3years of age in a prospective follow-up study from Montr\u00e9al\", by T. J. Hazell, S. Gallo, C. A. Vanstone, S. Agellon, C. Rodd, and H. A. Weiler, Pediatric Obesity doi:10.1111/ijpo.12105\nThe additional benefit in terms of body composition came as a surprise for the research team.\nThis amount is in line with current Canadian health guidelines.\nBut the body scans used to assess bone density also allowed the team to measure the children's muscle and fat mass.\nThe researchers found that higher doses did not provide any additional benefit -- at least not in terms of bone development.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that vitamin D supplementation is already widely recommended for infants.", "answer": 1}, {"article": "About UABKnown for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham is the state of Alabama\u2019s largest employer and an internationally renowned research university and academic medical center; its professional schools and specialty patient-care programs are consistently ranked among the nation\u2019s top 50.\nIn all four studies, eye dryness was significantly reduced, with two of the studies showing improvements at week two.\nThere are more than 30-plus new dry eye basic, translational and clinical studies being funded by the NEI/National Institutes of Health to further explore these lipids and proteins, with more than 50 papers being published monthly.\n\u201cDry eye is a common complaint to eye care professionals, with millions of U.S. adults experiencing the symptoms of this often chronic disease,\u201d Nichols said.\nSigns and symptoms were assessed at baseline and at weeks two, six and 12.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Though the news release does not say anything about availability, it does note that the FDA has approved the product.\u00a0 The drug was approved July\u00a012, 2016.", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nThe group, led by NIH\u2019s National Institute of Allergy and Infectious Diseases (NIAID), tested 60 cerebral spinal fluid samples, including 12 from people with Parkinson\u2019s disease, 17 from people with dementia with Lewy bodies, and 31 controls, including 16 of whom had Alzheimer\u2019s disease.\nThe group conducted the tests using Real-Time Quaking-Induced Conversion (RT-QuIC), an assay developed and refined over the past decade at NIAID\u2019s Rocky Mountain Laboratories.\nThe NIAID group continues to adapt the RT-QuIC assay to detect additional types of neurological diseases with greater accuracy using the least invasive patient sample possible \u2014 whether that is blood, skin, nasal brushings, or other samples.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The tentative wording of the lead \u2014 that the test could \u201coffer the possibility of improving early diagnosis\u201d \u2014 raises the question of what needs to happen for this test to become widely available. The release doesn\u2019t answer that question.\nNor does the study discuss improved diagnosis since that\u2019s not the intent of the test\u2019s development \u2014 it\u2019s research to determine who to include in trials and follow their disease progression.", "answer": 0}, {"article": "The average age of children in the study was 7.\nThe findings suggest that non-verbal tests related to smell might serve as useful early indicators of ASD, the researchers say.\nThe researchers now plan to test whether the sniff-response pattern they've observed is specific to autism or whether it might show up also in people with other neurodevelopmental conditions.\nEarlier evidence had indicated that people with autism have impairments in \"internal action models,\" the brain templates we rely on to seamlessly coordinate our senses and actions.\n\"We can identify autism and its severity with meaningful accuracy within less than 10 minutes using a test that is completely non-verbal and entails no task to follow,\" Sobel says.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release not only makes clear that a sniff test is \u201cin no way ready\u201d for clinical use, but lays out several questions for relevant future research that needs to be done before such a clinical tool can be developed.", "answer": 1}, {"article": "AstraZeneca PLC's cholesterol drug Crestor sharply lowered risk of heart attacks among apparently healthy patients in a major study that challenges longstanding heart-disease prevention strategies. The findings could substantially broaden the market for statins, the world's best-selling class of medicines.\n\nHeart experts said the findings, presented Sunday at the annual scientific meeting of the American Heart Association in New Orleans, could reshape cholesterol-treatment guidelines used for more than a decade to fight cardiovascular...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "From the story, it was clear that Crestor, the medication reported on, was currently available. \u00a0In addition, the story indicated that it did not have FDA approval for use in the way it was employed in the study.", "answer": 1}, {"article": "Three trials had used zinc acetate lozenges and found that colds were shortened on average by 40%.\nNevertheless, he also considers that \"the current evidence of efficacy for zinc lozenges is so strong that common cold patients should be encouraged to try them for treating their colds, but the patients should ascertain that the lozenges do not contain citric acid or its salt citrate.\"\nPreviously zinc lozenges containing citric acid were shown to be ineffective in treating colds because citric acid binds zinc ions very tightly and no free zinc is released.\nZinc lozenges appear to influence the common cold through the release of free zinc ions into the oro-pharyngeal region.\nIf that outlier trial was excluded, the difference between the three zinc acetate and the three zinc gluconate trials shrinked to just 2%, i.e., a 40% vs. 38% reduction in common cold duration.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t talk about the availability of zinc lozenges, but given that a search on Amazon turns up hundreds of sources, and most grocery and drug stores stock zinc, that\u2019s not a significant omission.", "answer": 2}, {"article": "Please visit http://www.\n\"This study underscores the ongoing need for more effective prevention measures and policies to increase exercise, improve diet quality and reduce tobacco use in our population,\" said senior author June M. Chan, ScD, from the departments of Urology, and Epidemiology and Biostatistics at UCSF.\nWhile there were fewer cases and less detailed data collected in the physicians' study, the score was similar in both populations, indicating the potential benefit of healthy lifestyle habits in warding off lethal prostate cancer, said the authors.\n\"We estimated that 47 percent of lethal prostate cancer cases would be prevented in the United States if men over 60 had five or more of these healthy habits,\" said Kenfield, assistant professor in the Department of Urology at UCSF Medical Center, and formerly of the Department of Medicine at Harvard Medical School in Boston, where the study was initiated.\nWe calculated the population-attributable risk for American men over 60 and estimated that 34 percent of lethal prostate cancer would be reduced if all men exercised to the point of sweating for at least three hours a week,\" Kenfield said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The study was limited to a relatively high level income group and the interventions may not be attainable for all men, in all socioeconomic groups. Does partaking of vigorous physical exercise on a regular basis require access to a gym or just a high degree of motivation? Are tomatoes and fish attainable year round for all socioeconomic groups? The study addresses this to some extent when it says, \u201cIt takes co-operation and effort from multiple areas, like insurance companies, employers, policy makers and city planners, to figure out how to creatively support and encourage more exercise into most busy adults\u2019 working day.\u201d We\u2019ll award a Satisfactory here.", "answer": 1}, {"article": "Visual analog pain scores at 6 weeks after the injections improved by a mean 3.8 points or 61.47 percent in patients who had the PRP injections compared to the autologous blood group, a mean 2.5 points or 41.6 percent improvement.\n\u201cWhole blood treatment is a god alternative in remote areas or in health systems that do not support financially the use of PRP,\u201d he told Reuters Health in an email.\nThe findings were published in The American Journal of Sports Medicine.\n\u201cThere is now a solution for patients suffering from unrelenting \u2018tennis elbow,\u2019\u201d said Christos Thanasas from Henry Dunant Hospital, Athens, who led the study.\nBoth groups experienced more improvement at 3 and 6 months after the injections, with no significant in pain scores between the treatments.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Gaziano and colleagues created a computer simulation to see if giving statins to more people would be worth the risk of side-effects and the extra cost.\nThere\u2019s an online tool that people or their doctors can use to calculate their risk of heart disease, which is based on age, sex, blood pressure and cholesterol levels.\nIt would be, they report in the Journal of the American Medical Association.\nOne of the recommendations was that statins should be prescribed to anyone with a 7.5 percent risk or higher of developing heart disease over the next 10 years.\nStatins, which include Lipitor, Mevacor, Crestor and Zocor, are extremely popular.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made it clear that statins are widely available. They are also paid for by insurance plans.", "answer": 1}, {"article": "MUSC operates a 750-bed medical center, which includes a nationally recognized Children's Hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute designated center) Level I Trauma Center, and Institute of Psychiatry.\nIn their next steps, the researchers are undertaking the VITAL 2.0 study to determine if the VIPS device can use complex machine learning algorithms to teach itself how to discriminate between minor and severe stroke without the help of neurologists.\nThe researchers hope that the device will save valuable time -- especially important in stroke where time is brain -- when it is deployed with emergency medical personnel in the field.\nHe predicts that the device has the potential to be used widely by emergency personnel but also to appear in other public spaces.\nYet the consultants did not have access to the VIPS radio wave data during their review of the images, thereby eliminating the potential of the consultants to choose data that might artificially inflate the device's accuracy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We learn that this is very preliminary research and that the researchers will do another study to \u201cdetermine if the VIPS device can use complex machine learning algorithms to teach itself how to discriminate between minor and severe stroke without the help of neurologists.\u201d", "answer": 1}, {"article": "Though they may suffer from physical and emotional pain as a result of VVA, women may not feel comfortable discussing these symptoms with a healthcare professional, may not recognize the symptoms as treatable, may not fully understand the treatment options available, or if they did receive treatment, found the current prescription treatment options inconvenient, messy, or uncomfortable to use.\nPrevious publications have shown TX004HR to be safe and effective at alleviating symptoms of VVA.\nUH is the second largest employer in northern Ohio with 26,000 employees.\nUH Cleveland Medical Center is perennially among the highest performers in national ranking surveys, including \"America's Best Hospitals\" from U.S. News & World Report.\nVVA affects 50 to 70 percent of post-menopausal women, and is characterized by pain with sexual activity, dryness, and discomfort.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release says nothing about when these softgels might be available.", "answer": 0}, {"article": "\"This is one more reason to consume fruits and vegetables - at least 5 a day - and it's good to include tomatoes in that mix,\" Willett said.\nElevated blood pressure is major risk factor for stroke.\nIf that vessel is in the brain, the blockage can cause a stroke.\nWhen these deposits build up, a blockage forms.\nHowever, daily intake of tomatoes may give better protection.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of tomatoes is not in question.", "answer": 2}, {"article": "Self-rated overall health [6] emerged as the single most powerful predictor of death in men, and previous cancer diagnosis the strongest predictor in women (see figure 1 of the Article).\nThe performance of the score was validated in 35810 participants enrolled at two Scottish centres which were not used to develop the score, and was found to have around 80% accuracy in men and women (table 2).\nWe hope that our score might eventually enable doctors to quickly and easily identify their highest risk patients, although more research will be needed to determine whether it can be used in this way in a clinical setting.\nThe score, which uses measures that can be obtained by simple questionnaires without any need for physical examination, such as self-rated health and usual walking speed, could be used by individuals to improve awareness of their health status, and by doctors to identify high-risk individuals for further treatment, say the authors.\nFor example, the research shows that self-reported information, such as usual walking pace and illness and injuries in the past 2 years, is generally a stronger predictor of death and survival than biological measurements, such as pulse rate and blood pressure.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Notes at the end of the news release speak to the availability of the interactive \u201cUbble\u201d website once the research article is published. We could not access the calculator, perhaps due to high traffic levels accompanying the rollout.", "answer": 1}, {"article": "The fact that recognizing and acknowledging a familiar person is such...\nA lateral X-Ray of the head of a 38-year-old man shows two Deep Brain Stimulation (DBS) leads with four electrodes attached to each implanted in the subcortical area of the brain called the thalamus.\nYou must then summon the speech centers in your frontal lobes, which recruit your breath and muscles and at last allow you to utter the words Hi, Mom.\nFrom there it is relayed to your memory center, where it is identified by comparison with every other face you've ever seen.\nA glimpse of Mom must first register on your occipital lobes as a pattern of light and shadow.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicates that the highlighted treatment, deep-brain stimulation (DBS) , is a technology used to treat the tremors of Parkinson\u2019s disease, and provides a list of other conditions for which it\u2019s use is being investigated.\u00a0 \nIt would have been best to\u00a0be absolutely clear\u00a0that its use for patients with minimally conscious state is investigational.\u00a0 In the publication describing this case study, the authors state \"\u2026the generalizability of the results is unknown, and expectations raised by this report should be tempered.\" (Nature (2007)448:600-604.\nThe article mentions many conditions for which there does not appear to be FDA approval for the use of this technology.\u00a0 ", "answer": 0}, {"article": "MONDAY, March 23, 2015 (HealthDay News) -- Vitamin D supplements may slow or prevent low-grade prostate cancer from progressing, a small new study suggests.\nDoctors often recommend a \"watch and wait\" period for men with low-grade, or less aggressive, prostate tumors.\n\"In greater than 60 percent of those taking it, vitamin D actually made the cancer better,\" said Hollis.\nWhen the prostate gland was examined after their surgery, researchers found that many who received vitamin D had improvements in their prostate tumors, while the tumors in the placebo group remained the same or got worse.\nVitamin D, known as the \"sunshine vitamin,\" is produced by the body when it's exposed to sun.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Vitamin D is ubiquitous in stores, food and sun exposure, and that fact was made clear.", "answer": 1}, {"article": "WEDNESDAY, Sept. 8, 2010 (HealthDay News) -- Statins, lauded for their ability to lower cholesterol and prevent heart attacks and strokes, may also reduce the risk of developing rheumatoid arthritis, Israeli researchers report.\nThis work received no outside or corporate finding, the researchers noted.\nUnfortunately, our previous study indicated that, despite their benefits, many patients on statins discontinue their treatment,\" Chodick said.\nA previous study on the same group indicated that persistent use of statins was associated with substantially lower all-cause mortality, which could not be explained only by the prevention of cardiovascular disease, he said.\nFor more information on statins, visit the U.S. National Library of Medicine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story notes that statins are already used to prevent heart attacks and stroke.", "answer": 1}, {"article": "Participants filled in a questionnaire about what they usually eat over the year and researchers calculated a diet quality score, where good diets included a healthy diet with lots of fruit and vegetables, whereas poorer-quality diets had more saturated fat, refined carbohydrates and alcohol.\nA total of 133 participants were randomly assigned to take a combination of nutraceuticals (compounds derived from foods such as vitamins or minerals that treat or prevent a disease or disorder) including the anti-inflammatory amino acid n-acetylcysteine (NAC), or NAC alone, or a placebo (a dummy pill) for 16 weeks.\nNow a group of Australian, German and American scientists have shown those who have a high quality diet, a less inflammatory diet, and/or a low BMI (Body Mass Index) may respond better to an add-on nutraceutical treatment provided as part of a clinical trial.\nWhile current medications are useful, they are better at targeting mania symptoms (the 'up' phase), leaving a lack of effective treatment for people experiencing depressive episodes.\n\"If we can confirm these results, then it's good news for people with Bipolar Disorder, as there is a great need for better treatments for the depressive phase of Bipolar Disorder\" said lead researcher Melanie Ashton of Deakin University in Australia.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release suggests \u201cnutraceuticals,\u201d including the\u00a0anti-inflammatory amino acid n-acetylcysteine (NAC) are potentially helpful. NAC is widely available in both prescription and over-the-counter formulations.", "answer": 1}, {"article": "Bredesen said that to simplify the program, they are connecting patients with health coaches.\nThe MEND protocol, outlined in a 2014 study in the journal Aging, calls for interventions to treat conditions that could be associated with Alzheimer's such as inflammation, stress and diabetes.\nThe study noted that some of the patients who had to quit working as a result of their memory decline, were able to return to work after adopting MEND and participants who were struggling at their jobs reported an improvement in job performance.\nA cure for Alzheimer's disease (AD), a condition marked by progressive, debilitating cognitive decline that affects more than 5.4 million Americans, is the holy grail in disease research.\nBut Bredesen believes that the only way to treat Alzheimer's is to treat all of the underlying problems, which may require intervention with supplements.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story quotes Bredesen saying \u201chis team has a couple of larger trials planned to confirm or refute the results in the current study and to address key questions about how long results can be maintained and how late in the course of cognitive decline reversal is possible.\u201d\nBut the story could have served readers better if it had pressed Bredesen for specifics about when these trials might occur. The complexity of the protocol, the expense and time involved and questions about insurance coverage all make availability\u00a0a very key question.", "answer": 0}, {"article": "The signature was found in the cerebrospinal fluid (CSF) of 90% of people with a diagnosis of Alzheimer's disease and 72% of people with mild cognitive impairment (MCI) -- a disorder that often progresses to Alzheimer's.\nLow levels of the amyloid protein amyloid-beta 1-42, along with high levels of total tau and elevated phospho tau 181 (P-tau 181), identified Alzheimer's disease in three independent study groups, Hugo Vanderstichele, PhD, of the Belgian biotech company Innogenetics, tells WebMD.\nAug. 9, 2010 -- Researchers have identified a protein \"signature\" in the spinal fluid of patients with Alzheimer's disease, which could represent an important advance in its diagnosis.\n\"Using this approach, which was totally independent of diagnosis, we were able to identify patients with Alzheimer's disease,\" Vanderstichele says.\nIn one study, this protein signature was also seen in spinal fluid samples from all patients with mild cognitive impairment who progressed to Alzheimer's disease within five years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story points out that most clinicians are not able to provide this sort of test and that at least one expert says that specialized testing centers would need to be developed.", "answer": 1}, {"article": "To find out more about the activities of EULAR, visit: http://www.\n\"The optimal management of RA involves achieving the lowest possible disease activity - ideally remission, and then maintaining this level of control,\" said lead author, Dr. James Galloway, Department of Rheumatology, King's College Hospital NHS Foundation Trust, UK.\nThe OPTTIRA study is a 12-month multicentre, randomised controlled trial designed to evaluate if reducing TNFi doses (of either etanercept or adalimumab) caused a loss of response in RA patients who were also receiving a synthetic DMARD.\nFor further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress \n\nPress Office in Room 5B of Fiera Roma during EULAR 2015 or on: \n\nEmail: eularpressoffice@cohnwolfe.com \n\nOnsite tel: +44 (0) 7738 890 799 / +44 (0) 20 7331 5442 \n\nTwitter: @EULAR_Press \n\nYoutube: Eular Pressoffice\n\nThe European League Against Rheumatism (EULAR) is an umbrella organisation which represents scientific societies, health professional associations and organisations for people with rheumatic diseases throughout Europe.\nRome, Italy, 13 June 2015: The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that, in rheumatoid arthritis (RA) patients, a good clinical response to maintenance treatment with a tumour necrosis factor inhibitor (TNFi) was maintained even when the dose was reduced by one-third.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although availability is not explicitly addressed, the release does note that\u00a0biologic drugs are used as an add-on treatment option to methotrexate, which suggests that they are approved and available. This is true in the U.S., and also seems to be true in the UK, where the study originated.", "answer": 1}, {"article": "The findings suggest that ibuprofen-acetaminophen is a reasonable alternative to opioid management of acute extremity pain due to sprain, strain, or fracture, but further research to assess longer-term effect, adverse events and dosing is warranted.\nThe combination of ibuprofen and acetaminophen may represent an effective non-opioid alternative.\nDespite the epidemic, opioid analgesics remain a first-line treatment for moderate to severe acute pain in the emergency department.\nAbout 1 in 5 patients required additional medication to control their pain.\nFor more details and to read the full study, please visit the For The Media website.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not address this explicitly, but it is fairly clear from the context that all of these painkillers are already clinically available.", "answer": 1}, {"article": "A video in which Professor Probert explains how the machine works can be found here\nOur aim is to create a test that avoids this procedure at initial diagnosis by detecting cancer in a non-invasive way by smelling the disease in men's urine.\nThe positioning of the prostate gland which is very close to the bladder gives the urine profile a different algorithm if the man has cancer.\"\n\"The Odoreader has a 30 metre column that enables the compounds in the urine to travel through at different rates thus breaking the sample into a readable format.\nMr Raj Prasad, Consultant Urologist at Southmead Hospital, North Bristol NHS Trust, said: \"If this test succeeds at full medical trial it will revolutionise diagnostics.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that this screening tool is still in development and that the developers are seeking funders to expand the testing.", "answer": 1}, {"article": "What's more, he added, there are already several good ways to catch colon cancer -- or, even better, precancerous growths called polyps, which can then be removed before a tumor develops.\nIn the end, the researchers were able to correctly identify the cancer patients 76 percent of the time.\nIt's still unclear which breath chemicals should be measured, or what statistical method is best for weeding out cases of colon cancer.\nThey then used a statistical model to see if certain VOC patterns separated the colon cancer patients from the healthy participants.\nNow, a small pilot study suggests such a test could be developed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that this test won\u2019t be available any time soon.", "answer": 1}, {"article": "Anal cancer that has spread to lymph nodes is linked to a worse prognosis and lower chance of survival.\nThe project's findings however have uncovered a phenomenon suggesting rates of lymph node spread are being overestimated, potentially leading to overtreatment of patients with chemo radiotherapy.\nThe study worked with data on more than 10,000 patients, examining whether current methods of checking if anal cancer has spread to lymph nodes are giving experts an accurate picture of survival rates.\n\"These findings will help us to better understand how anal cancer patients should be treated, ultimately improving survival rates and quality of life.\nShe said: \"My first thought on diagnosis was that I wanted to survive, I gave little thought to long term or late effects of treatment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that the study is likely to have an impact on treatment plans of future patients, but we never learn what that impact might precisely be, and what next steps might be taken by the oncology treatment community to use the findings and correct misleading statistics on diagnosis and treatment.", "answer": 0}, {"article": "Khalsa's article highlights the principles and practices of this 12-minute meditation, with corresponding SPECT scans showing how it successfully activates the posterior cingulate gyrus, an important region of the brain that helps regulate memory and emotional function.\n\"We've been studying the impact of meditation on memory for more than 20 years, and are as encouraged as we've ever been on its powerful role in maximizing brain health,\" said Khalsa, president and medical director of the Alzheimer's Research and Prevention Foundation and a clinical associate professor of integrative medicine at the University of New Mexico School of Medicine.\nAbout the Alzheimer's Research and Prevention Foundation\n\nThe Alzheimer's Research and Prevention Foundation is a non-profit organization dedicated to reducing the incidence of Alzheimer's disease by conducting clinical research and providing educational outreach about the lifestyle changes that can help prevent Alzheimer's disease.\nTUCSON, Ariz., July 15, 2015 /PRNewswire/ -- Meditation and spiritual fitness are key components in reducing the risk of Alzheimer's disease according to a new article, \"Stress, Meditation, and Alzheimer's Prevention: Where the Evidence Stands\", published in an early online version of the Journal of Alzheimer's Disease 48(1).\nThe full text of \"Stress, Meditation, and Alzheimer's Prevention: Where the Evidence Stands\" can be accessed at http://content.iospress.com/articles/journal-of-alzheimers-disease/jad142766.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release establishes that the Kirtan Kriya meditation technique is currently in use. Instructions can be found on the Alzheimer\u2019s Research and Prevention Foundation\u2019s website.", "answer": 1}, {"article": "Dec. 20, 2010 -- Scientists using brain scanning technologies say they have been able to predict with 90% accuracy which children with dyslexia will be able to improve reading skills over a period of a few years.\n\nResearchers say their findings reveal activity in specific brain regions during reading that could eventually lead to new treatments for people with dyslexia.\n\n\u201cAt this time, we cannot say which treatment type will each child benefit from,\u201d study researcher Fumiko Hoeft, MD, PhD, an imaging expert at Stanford University, tells WebMD in an email. \u201cBut with more research, and if researchers combine it with intervention studies, then we should be able to identify brain patterns that are predictive of responding to one type of intervention or another.\u201d\n\nShe says in a news release that the study \u201cgives us hope that we can identify which children might get better over time\u201d and that the findings represent \u201ca huge step forward.\u201d\n\nThe discovery of brain regions involved in the learning disorder \u201cmay provide a mechanism for enduring improvement that promotes relatively successful reading development,\u201d according to the study, published in the Dec. 20 issue of the Proceedings of the National Academy of Sciences.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nFunctional MRI and Diffusion Tensor MRI are research tools not routinely available in community hospitals and not routinely used in clinical practice.\u00a0 The story does not provide any information on their availability.\u00a0 It also doesn\u2019t tell us anything about the two approaches and why/how they are different.\u00a0 It just name-drops fMIR\u00a0and DTI as if readers are supposed to know what that means.\n", "answer": 0}, {"article": "Researchers from Nemours and UCF found that nanoparticles can be used to deliver curcumin to tumor sites.\nThis research demonstrates a novel method of treating this tumor without the toxicity of aggressive therapy that can also have late effects on the patient's health,\" said Tamarah J. Westmoreland, MD, PhD, a pediatric surgeon at Nemours Children's Health System and senior author of the study.\nThe study, conducted in partnership by researchers at Nemours Children's Hospital and the University of Central Florida, demonstrates a potentially novel treatment for neuroblastoma, the most common cancer in infants.\n\"This shows that nanoparticles can be an effective delivery vehicle for cancer drugs,\" said Professor Sudipta Seal, who directs of UCF's NanoScience Technology Center and Advanced Materials Processing Analysis Center, and is a collaborator on the study.\nAttaching curcumin, a component of the common spice turmeric, to nanoparticles can be used to target and destroy treatment-resistant neuroblastoma tumor cells, according to a new study published in Nanoscale.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The beginning of the news release makes it sound like this technology is available at your local hospital. Later in the report, however, the news release makes it clear that this study was conducted in cell lines in a laboratory. Researchers hope to expand this research to animal models and direct the curcumin nanoparticles to tumor sites, the news release adds.\nWe feel this is enough for a Satisfactory rating.", "answer": 1}, {"article": "MONDAY, July 9, 2012 (HealthDay News) -- A daily drink combining several nutrients appears to help people with early Alzheimer's disease improve their memory, a new study suggests.\nIt is probable that any introduction would take place first in Europe.\"\nBut more research is needed before the drink could be made available to the public.\n\"I don't think it has any effect on the fundamental diseases process, but we'll see,\" he said.\nThat makes it difficult to make a clear-cut statement about the value of the product, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The fact that there were no plans yet to market the product was explained.", "answer": 1}, {"article": "Nucleix Ltd. develops, manufactures and markets innovative, non-invasive, molecular cancer diagnostic tests.\nThe results will be presented in a poster presentation titled Lung EpiCheck \u2122 - Results of the Training and Test Sets of a Methylation-Based Blood Test for Early Detection of Lung Cancer at the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, to take place on September 22-26, 2018 in Toronto, Canada.\nThe reason for the high mortality rate is that currently most cases are detected when the patient becomes symptomatic, which is usually at late stages of the disease.\nIt is estimated that there are about 1.8 million new cases of lung cancer annually worldwide and about 1.55 million die from the disease each year.\nIn particular, in the non-small-cell lung carcinoma group (n=162), the most prevalent type of lung cancer affecting about 85% of lung cancer patients, Lung EpiCheck was able to identify correctly approximately 70% of patients.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll give this a marginal satisfactory for giving readers a hint that the test is not yet available when it says the company is \u201clooking forward to begin extensive clinical trials in the US,\u00a0Europe\u00a0and\u00a0China\u00a0next year, in order to get the test to the market as soon as possible at an affordable price.\u201d That tells us that the test is likely years away from being commercialized \u2014 if ever.", "answer": 1}, {"article": "Noonan says the small trial helped her and her colleagues learn more about which patients may benefit from MILs therapy.\n\"What we learned in this small trial is that large numbers of activated MILs can selectively target and kill myeloma cells,\" says Johns Hopkins immunologist Ivan Borrello, M.D., who led the clinical trial.\nResults of the trial involving a particular type of tumor-targeting T cell, known as marrow-infiltrating lymphocytes (MILs), are described in the May 20 issue of Science Translational Medicine.\nFor the clinical trial, the Johns Hopkins team enrolled 25 patients with newly diagnosed or relapsed multiple myeloma, although three of the patients relapsed before they could receive the MILs therapy.\nBut in our clinical trial, we were able to harvest and grow MILs from all 22 patients,\" says Kimberly Noonan, Ph.D., a research associate at the Johns Hopkins University School of Medicine.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release points out that \u201cseveral U.S. cancer centers have conducted similar experimental treatments\u201d but adds that Johns Hopkins is the only one using the MIL cells. It also points to several other ongoing clinical trials at Hopkins that build on the findings of this small study. Using the terms \u201cpilot\u201d and \u201cexperimental,\u201d the release signals that availability is very limited.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - A large waistline more than doubles the risk that people in their 40s will develop precancerous cells in the colon, according to Korean researchers.\nIn younger people, it is unclear that the benefits of screening offset the risks.\nA camera at the tip shows the inside of the gut, so that unusual cell clumps can be found and removed.\nDuring widely used colonoscopy, for instance, bleeding or perforation of the colon may happen in rare cases.\nOne in 40 of those younger than 50 years had late-stage polyps, but no one actually had colon cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly colon cancer screening is available.", "answer": 1}, {"article": "Drugs such as aspirin and ibuprofen treat inflammation, the body's immune response to infections or pathogens.\nThe immune system acts like a thermostat, turned down low most of the time but cranked up when we have an infection, according to Khandaker.\nTheir potential side effects also must be investigated, Khandaker said, adding that \"we and other research groups from both sides of the Atlantic are currently planning and conducting such randomized control trials.\"\nLooking to the future\n\n\"Evidence at this point suggests that cytokine antagonists -- which are much more specific in their anti-inflammatory effects than drugs like aspirin -- show modest antidepressant effects in individuals with depression and increased inflammation,\" said Raison, who did not participate in in Khandaker's research.\nIn some people, the thermostat is always set slightly higher, behaving as if they have a persistent low-level infection.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that more research needs to be done before the new anti-inflammatories could be prescribed as a direct therapy for depression, and\u00a0one of the researchers notes that it\u2019s too early to prescribe them for depression.\u00a0We\u00a0also liked that the story mentioned other diseases that are treated by anti-inflammatories.", "answer": 1}, {"article": "TUESDAY, May 4, 2010 (HealthDay News) -- Noninvasive stool DNA testing can detect two types of colorectal precancers and could play a larger role in colon cancer prevention, say two new studies.\n\"This study shows that cancer and precancer in IBD can be detected noninvasively,\" senior investigator Dr. David Ahlquist said in a Mayo news release.\nThe first study found that stool DNA testing detected five out of five cases of colon cancer and four out of five cases of a precancerous lesion called dysplasia in 10 patients with inflammatory bowel disease (IBD).\nIt's important for people with IBD because they are at much higher risk for colorectal cancer than the general population.\nSerrated colorectal polyps, which are believed to be the forerunner in about 30 percent of colon cancer cases, can be difficult to detect using most types of colorectal cancer screening.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "At one point the story says the test is \"under development.\"\u00a0 In another place it says the methods \"were developed.\"\u00a0 No where is it clear if this is a method that is currently available. ", "answer": 0}, {"article": "TUESDAY, Nov. 15, 2011 (HealthDay News) -- An apple a day won't necessarily keep the doctor away, but three kiwis just might help, at least according to a small study that showed that the brown, fuzzy fruit may lower blood pressure levels.\nA blood pressure reading that is less than 120/80 is considered ideal.\nIn addition, the study looked at the whole fruit, not individual nutrients.\n\"Don't count on this to be the complete answer to high blood pressure,\" he said.\n\"Kiwi is not the wonder fruit, but certainly adding kiwi to your diet can help decrease mildly high blood pressure levels.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story noted that kiwis \u201care not easy to find\u201d", "answer": 1}, {"article": "And the experimental combined system itself was not fully automated.\nThe new study in The Lancet, proponents say, represents a proof-of-concept milestone in the quest to develop such a system.\nIndeed, even if device makers are able to develop fully automated prototypes of combination systems, they are likely to face regulatory hurdles, analysts said, and would have to factor in product liability concerns.\nAlthough the Lancet study was small \u2014 only 17 children completed the entire protocol \u2014 it is significant because it demonstrated that a computer algorithm could safely interpret glucose data and calculate appropriate insulin doses for a pump, he said.\n\u201cThe significance is in showing that the existing devices, which are available commercially, can be combined to create the first version of an artificial pancreas,\u201d said Dr. Roman Hovorka, the lead author of the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The Times did a good job of describing the system used in this study and how close it is to being commercially available.\u00a0\u00a0It called the system \"experimental\"\u00a0and said that it was \"not\u00a0fully automated.\" It said that a fully\u00a0automated glucose monitor/insulin\u00a0delivery system was still \"hypothetical\" and would face regulatory hurdles before it could be marketed to the public.", "answer": 1}, {"article": "The regimen included exercising four to five times a week, generally in 30-minute sessions, plus warmup and cool-down:\n\u2022 One of the weekly sessions included a high-intensity 30-minute workout, such as aerobic interval sessions in which heart rate tops 95 percent of peak rate for 4 minutes, with 3 minutes of recovery, repeated four times (a so-called \"4 x 4\").\nIn the study, exercise sessions were individually prescribed based on exercise tests and heart rate monitoring.\n\u2022 One day's session lasted an hour and was of moderate intensity.\nIn its most severe form, blood can back up into the lungs.\nTo start the study, researchers recruited 53 participants, ages 45 to 64.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The intervention in question here is aerobic exercise. Widely available.", "answer": 2}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\nThe standard Medicare per-injection costs of the three anti-VEGF drugs evaluated in the study are about $1960 for aflibercept (Eylea), $1200 for ranibizumab (Lucentis) and $70 for bevacizumab (Avastin).\nThe most common diabetic eye disease and a leading cause of blindness is diabetic retinopathy, which is caused by elevated blood sugar levels damaging the blood vessels of the retina and affects approximately 7.7 million Americans.\nNewswise \u2014 BOSTON \u2013 (February 19, 2015) \u2013 In the first clinical trial directly comparing three drugs most commonly used to treat diabetic macular edema, researchers found all were effective in improving vision and preventing vision loss.\nWith the rate of diabetes increasing dramatically worldwide, many individuals will be at risk for vision loss from diabetic eye complications and DME is a major global health concern,\u201d says Jennifer K. Sun, M.D., M.P.H., a member of the study research team and writing committee, and an Investigator in the Section on Vascular Biology, an ophthalmologist in Beetham Eye Institute at Joslin and an Assistant Professor at Harvard Medical School.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Two of these drugs are available specifically for macular edema and the third, although used off label, is also available in proper form and dosage. The story makes this clear. Since\u00a0availability also relates to cost and who will pay for it \u2014 especially this era of high deductible health plans \u2014 some comment about the increased availability of the lower-cost option would not have been inappropriate.", "answer": 1}, {"article": "The study's primary endpoint was OS.\nThe technique uses an intricate network of magnets to aim a narrow proton beam at a tumor and \"paint\" the radiation dose onto it layer by layer.\nAt five years, the median OS was 26.5 months, and the corresponding five-year OS was 29 percent.\nThey deposit the bulk of their cancer-fighting energy right at the tumor, thereby reducing the dose to cardiopulmonary structures, which impacts the toxicity, functional status, quality of life and even survival for patients, explained Chang.\n\"Obviously, the technology has improved dramatically over the last decade and has made a significant impact on diagnosis and staging.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "How widespread the treatment options are is not clear. The release does clearly state that this was done at a single site. However, it would have been relatively easy to state that there are only a small number of facilities that can deliver proton beam therapy.", "answer": 0}, {"article": "\u201cWe don\u2019t see cost as being a limiting factor here.\u201d\n\nUVC lamps could also have potential implications in clinical settings, as well \u2014 in the operating room during surgeries, for example.\n\u201cThe lamp we\u2019re using at the moment costs less than $1,000, and you can imagine that if it were put into general circulation, the price would drop dramatically,\u201d he says.\nThe light inactivated the viruses with about the same efficiency as conventional germicidal UV light, while a control group of bacteria not exposed to light remained active.\n\u201cNo matter how well you sterilize a room beforehand, the medical staff can still bring in dangerous bacteria like MRSA,\u201d says Brenner.\nThe researchers suspected that it can penetrate and destroy microscopic bacteria and viruses, but can\u2019t travel through the protective outer layers of human skin or eyes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is a just passing satisfactory\u2013it\u2019s implied that the product is not available yet, because the story mentioned the lead author \u201cis working with a company to develop a commercially available version of the lamp.\u201d", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061015/23addict.b.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that rimonabant has been approved for use in Europe.\u00a0 When mentioning that the manufacturer hopes for approval by the end of the year, it did not emphasize that the drug is not approved in the U.S., is not available in the U.S. and that it is not possible to predict the timing of FDA approval or whether the FDA will, indeed, approve it.\u00a0 ", "answer": 0}, {"article": "\"The results of our analysis are especially important for patients, given that many ARBs are now also generic, which reduces their costs,\" he added.\nPrevious studies have suggested that older ACE inhibitors are more effective than ARBs.\nAlthough ACE inhibitors were developed 10 years earlier, both types of drugs showed similar effects in the analysis, challenging previous findings that suggest ACE inhibitors have greater benefits.\nBoth ARBs and ACE inhibitors interfere with the function of a hormone called angiotensin II, which regulates blood pressure, but they do this in different ways, the study authors said.\nAngiotensin II restricts blood flow through vessels, raising blood pressure.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that both ACE inhibitors and ARBs have been around for years, the latter since the year 2000 and the former for at least a decade earlier, so readers can easily understand this story is about currently available drugs", "answer": 1}, {"article": "But a 2012 Cochrane review of randomized clinical trials found there's no evidence that removing wisdom teeth will prevent or reduce crowding of other teeth down the line.\n\"The risk for complications increases as people get older, and the duration of disability after the operation gets longer as people get older,\" says oral surgeon Dr. Thomas Dodson.\n(The same thing happened with tonsils, which doctors no longer remove just to get rid of the chance of infection later on.)\nBut there's a serious debate between dentists and oral surgeons: should they preemptively remove someone's wisdom teeth if the patient doesn't have any symptoms?\n\"Many people don\u2019t have adequate space in their jaw for the teeth to come into full position, but that alone isn\u2019t justification of having them all removed,\" says Dr. Scott Tomar of University of North Carolina's School of Dentistry.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t acknowledge the gap in dental care access and how that might affect the numbers of people having wisdom teeth removed. Uninsured people are far less likely to pay out-of-pocket for elective surgery.\u00a0These issues could have been addressed with one additional sentence", "answer": 0}, {"article": "To conduct the study, the researchers asked 164 healthy participants with an average age of 30 to wear a wrist actigraph \u2014 a device that monitors sleep \u2014 for one week to establish their baseline sleep habits.\nThe actigraphy measured sleep in a much more accurate way than information researchers get from self-reports, he says.\nThe found the chronic poor sleepers became sick more often: those who slept for five hours or less each night were 4.5 times more likely to catch the cold than people who slept seven hours or more.\nLater, they sequestered the participants in a hotel and, using nasal drops, dosed each of them with a rhinovirus\u2014 aka the common cold bug.\nParticipants who slept for six hours each night did only slightly better -- they were 4.2 times more likely to develop a cold than the seven-hour-a-night folks.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Of course, not everyone can find six or more hours in a day to sleep. But the study did not address this.", "answer": 0}, {"article": "That was not statistically significant.\nThe detailed results also showed no increase in hospitalization for heart failure, which had been a particular concern with DPP-4 inhibitors, the class to which Januvia belongs.\nJanuvia, an oral medication known chemically as sitagliptin that helps lower blood sugar levels, had sales of about $4 billion in 2014, plus another $1.8 billion for the related combination product Janumet\n\nOn the study\u2019s main focus, after about three years 11.4 percent of Januvia patients had experienced cardiovascular death, non-fatal heart attack, non-fatal stroke or hospitalization for unstable angina versus 11.6 percent in the placebo group.\n\u201cNumerically this is hardly a major risk, just something we need to keep an eye on,\u201d Holman said.\nThere were 228 such hospitalizations for Januvia and 229 in the placebo group, according to data also published in the New England Journal of Medicine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug has been available but has been hampered in terms of sales because of safety concerns. The drug\u00a0is widely available, widely used, expensive, and of unproven value in terms of important outcomes.", "answer": 1}, {"article": "The researchers found that overall 30-day mortality decreased from 1.6 percent (84 of 5,275 patients) to 0.7 percent (26 of 3,878 patients) after FSI implementation.\nOn the basis of this review, clinicians from surgery, anesthesia, critical care, and palliative care were notified of the patient\u2019s frailty and associated surgical risks; if indicated, perioperative plans were modified based on team input.\nIt also suggests the potential to improve postoperative survival among the frail through systematic administrative screening, review, and optimization of perioperative plans.\nImprovement was greatest among frail patients (12.2 percent to 3.8 percent), although mortality rates also decreased among the robust patients (1.2 percent to 0.3 percent).\nAs the U.S. population ages, the number of operations performed on elderly patients will likely increase.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is not clear if the screening index and action plans for surgery among frail patients are readily available for other institutions to use.", "answer": 0}, {"article": "The medical approach to treating tonsil infections has evolved over recent decades.\nThe study results showed \"there may be new evidence that supports expanding the criteria and opening up the procedure to more individuals,\" said Dr. Alyssa Hackett, an otolaryngologist with the New York Eye and Ear Infirmary of Mount Sinai in New York City.\n\"Though a tonsillectomy is low-risk, it is not risk-free, and those risks need to be weighed against the benefits for each individual child,\" Chinnadurai said.\n\"The decision about whether those children should have tonsillectomy for that temporary benefit is really tied to what those children need or what they're suffering with,\" Chinnadurai said.\n\"But for the tonsils and adenoids, there are great quality-of-life benefits that are evident for the surgery, but no child has ever died because they haven't gone through the surgery.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that \u201cTonsillectomy is the third most common surgery performed on U.S. children.\u201d\u00a0 We know tonsillectomies are readily available through the health care system, if needed.", "answer": 1}, {"article": "In a twist in the debate about the safety of menopause hormones, new research suggests the real problem may not be the hormone itself, but the fact that it's typically swallowed as a pill.\n\nThis week, the medical journal Circulation offers some of the strongest evidence yet that the risks of hormones are dramatically reduced when the drugs are absorbed through the skin in patches and gels rather than taken as pills. The study by French researchers showed that one of the most serious risks associated with hormone use -- blood...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the patches are popular in Europe but not used as widely in the U.S.", "answer": 1}, {"article": "The actual number of deaths averted was fairly modest - 354 died in the spiral CT group over the eight-year study period compared with 442 deaths among those who got chest X-rays.\nWhile the spiral CTs emit less radiation than standard CT scans used to diagnose disease, researchers also will analyze whether the radiation exposures from three scans changes a smoker's lifetime risk of other radiation-related cancers.\nStill, \"a validated approach that can reduce lung cancer mortality by even 20 percent has the potential to spare very significant numbers of people from the ravages of this disease,\" he said.\nSome previous studies have suggested that the earlier detection helps, while other research concluded it may do more harm than good by spotting too many benign growths.\nThe scans aren't risk-free: They frequently mistake scar tissue from an old infection or some other benign lump for cancer, leading to unnecessary biopsies or surgery that in turn can cause a collapsed lung, infection or other problems.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nWhile this story does call the CT scans used in this trial \u201cspecial\u201d and different from conventional CT scans, it does not make clear that the trial applied rigorous standards to the equipment, operators and radiologists that may not be followed by other providers who offer CT scans to smokers.", "answer": 0}, {"article": "Connolly does not advocate abandoning the nicotine replacement medication.\nRelapse rates of the quitters were similar during the study period, whether they used the products alone or with counseling, or they did not use them.\nIt gives a more ''real world'' picture, he tells WebMD.\n\"In the short term, what it is designed for is treatment of withdrawal,\" he says.\nThe findings are at odds with clinical trials, Connolly says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We like that this story was very specific on what types of nicotine products were studied. \u201cThe participants told whether they had used a patch, gum, inhaler, or spray. They told how long they used the product continuously.\u201d", "answer": 1}, {"article": "FRIDAY, Nov. 4, 2016 (HealthDay News) -- Obese patients who swallowed balloon capsules that helped them eat less lost an average of 15 pounds, roughly two times more weight than patients who just dieted and exercised, researchers report.\nThe findings were to be presented Friday at the annual meeting of the American Society for Metabolic and Bariatric Surgery and the Obesity Society in New Orleans.\nThe balloon treatment will be available starting in January, but the cost hasn't been announced, Pryor said.\nThe role for such technology-based approaches to weight control should be a small one, he said.\nAn advantage of the balloons is that patients have no downtime and can go back to work the same day, the researchers said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that the Obalon balloon was approved by the FDA in September and will be available in January 2017.", "answer": 1}, {"article": "Such an analysis is months away.\n\u201cThe challenge now shifts from proving the efficacy of the method to developing the proper quality standards, infrastructure and guidelines to bring this needed benefit to those at high risk for the disease \u2014 now,\u201d Ms. Fenton said.\nBut health officials involved in the study refused to endorse widespread screening of current or former smokers, saying more analysis of the study\u2019s results is needed to further identify who benefited most.\nPatients wishing to get a CT lung screen will most likely have to pay the roughly $300 charge themselves, since few insurers pay for such scans unless an illness is suspected.\nAnd they pointed out that the study offers no reassurance about the safety of smoking or the advisability of CT scans for younger smokers or nonsmokers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nWhile it may seem obvious that CT scanning is widely available, this trial used a specific and rigorous protocol for selecting the type of low-dose CT scanners used, how they were maintained and operated, as well as certifying the training and practices of the radiologists who interpreted the scans. The sort of CT machines, operators and radiologists generally available to smokers may not meet the demanding standards of this trial and thus may not be able to match the results.", "answer": 0}, {"article": "The U.S. Food and Drug Administration today approved Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis.\n\"Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and today\u2019s approval provides patients with another treatment option for their psoriasis,\" said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nSiliq is also approved with a Medication Guide to inform patients of the risk of suicidal ideation and behavior, and that because Siliq is a medication that affects the immune system, patients may have a greater risk of getting an infection, or an allergic or autoimmune condition.\nSiliq is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or injected) or phototherapy (ultraviolet light treatment) and have failed to respond, or have stopped responding to other systemic therapies.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Since Siliq is a new psoriasis drug that just received FDA approval, it is clear that it is now coming onto the market. The news release states the drug will only be available through a restricted program called the Siliq Risk Evaluation and Mitigation Strategy. The release then lists the requirements of the program, which include patient counseling, signing of a patient-prescriber agreement form and pharmacy certification.\nWe feel this is good enough for a Satisfactory rating here.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - New findings add to confusion over whether taking aspirin, ibuprofen or related painkillers reduces the risk of developing melanoma.\nThe findings are interesting, but should not lead people to conclude that popping a few painkillers will reduce their risk of skin cancer, cautioned Dr. Maryam Asgari of Kaiser Permanente Northern California and the University of California San Francisco, who co-authored the 2008 study.\nAnimal experiments have suggested that the class of painkillers known as nonsteroidal anti-inflammatory drugs (NSAIDs) could play a role in preventing melanoma, but a large 2008 study failed to find any evidence to support this possibility.\nSpecifically, more than 40 percent of people who were cancer-free said they\u2019d been taking NSAIDs at least once per week for more than 5 years, versus only 28 percent of those who developed melanoma.\nNow, a smaller study that asked people with melanoma and those without the disease to recall their use of NSAIDs has found that taking these drugs - particularly aspirin - at least once a week for more than 5 years may have offered some protection against the deadly disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 There isn\u2019t any question about the availability of aspirin, ibuprofen or related painkillers.", "answer": 2}, {"article": "New blood tests will speed up diagnosis for the most common GI disorder\n\nLOS ANGELES (May 14, 2015) - Millions of people afflicted by irritable bowel syndrome can now be diagnosed quickly and accurately with two simple blood tests developed by a Cedars-Sinai gastroenterologist.\nAn estimated 10 percent of the world's population suffers from the condition.\nFatigue and the stress of trying to plan one's life around visits to the bathroom can be debilitating.\nThe disorder, nearly impossible to diagnose until now, is characterized by a cluster of confounding symptoms that include chronic bloating, abdominal pain, gas, and bouts of relentless diarrhea, constipation, or both.\nIBS is the most common gastroenterological disorder in the United States, affecting nearly 40 million people.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release clearly states that the tests are already on the market.", "answer": 1}, {"article": "\"VNS has a quality of cardiac surgery to it, a certain cachet,\" and it lacks the stigma of shock treatments, said Karasu, adding that six of his patients adamantly refused ECT and opted instead for VNS.\nLast July, a top FDA official, citing the lack of alternatives for severely depressed patients, overruled unanimous opposition by 20 members of his staff and approved the device as a depression treatment for adults who had failed four other treatments.\nThe company's Web site says that \"preliminary imaging studies suggest that VNS Therapy affects many areas of the brain implicated in mood regulation.\"\nFor years experts have known that depression -- unlike, say, type 1 diabetes -- can get better without treatment.\nAlthough he takes antidepressants, Donovan said, he is sure drugs are not responsible, because they hadn't helped him previously.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains how many Americans have had the device implanted (more than 550 since FDA approval), how many are waiting insurance company approval (7,000), and how many Washington, DC-area physicians have been trained in the use of the device (more than 3,700). ", "answer": 1}, {"article": "But there's good news about the experimental treatment that he pioneered.\nUnder the trial protocol, some patients received Temodar for the first five days of the month, and some received it for the first 21 days.\n\"But two years later, I'm in good shape, living a normal life and still returning cancer-free scans every month, thanks to this trial.\nLate Houston surgeon's work may fight cancer that killed him Surgeon's trial study on cancer is hailed\n\nBrain tumor took his life, but his pioneering therapy now may give others hope\n\nThe death of Houston neurosurgeon Samuel Hassenbusch from the brain cancer he treated has been one of 2008's sadder stories.\nBecause chemotherapy kills patients' white blood cells, it is usually considered incompatible with vaccines or, as they're also known, immunotherapy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained that the treatment described was available only as part of a clinical trial.\nWhile this was accurately reported, the story should have mentioned whether or not patient recruitment for the trial was ongoing and if so, it could have included a link to \u00a0http://clinicaltrials.gov/.", "answer": 1}, {"article": "Two studies reported nearly 80% of Freespira-treated patients were panic attack free at 12 months post-treatment.\nFreespira is both easy to use and effective.\nTreatment is authorized and completed under the supervision of a licensed healthcare provider.\nOnce a licensed healthcare provider authorizes the treatment and after a single training session, the patient uses Freespira at home, performing two 17-minute breathing sessions a day over a four-week period, after which the treatment is complete.\nTheir first product, Freespira, is an FDA-cleared treatment for individuals suffering from panic disorder, panic attacks and other symptoms of panic.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The device has apparently been commercially available for many years but this is not specifically addressed in the release.", "answer": 0}, {"article": "[3]\n\nWriting in a linked Comment, Professor Avan Aihie Sayer from the University of Southampton, Southampton, UK, and Professor Thomas Kirkwood from Newcastle University, Newcastle upon Tyne, UK discuss whether grip strength could be a new biomarker of ageing, writing that, \"This is not a new idea, but findings from PURE add support.\nThe study, published in The Lancet, also found that grip strength is a stronger predictor of death than systolic blood pressure, and the authors suggest that it could be used as a quick, low-cost screening tool by doctors or other healthcare professionals to identify high-risk patients among people who develop major illnesses such as heart failure and stroke.\nA low grip strength was linked with higher death rates in people who develop cardiovascular (eg, heart attack or stroke) and non-cardiovascular diseases (eg, cancer), suggesting that muscle strength can predict the risk of death in people who develop a major illness.\nLoss of grip strength is unlikely to lie on a single final common pathway for the adverse effects of ageing, but it might be a particularly good marker of underlying ageing processes, perhaps because of the rarity of muscle-specific diseases contributing to change in muscle function.\"\nThe findings show that every 5kg decline in grip strength [2] was associated with a 16% increased risk of death from any cause; a 17% greater risk of cardiovascular death; a 17% higher risk of non-cardiovascular mortality; and more modest increases in the risk of having a heart attack (7%) or a stroke (9%).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release implies that the type of dynamometer used to assess grip strength in this study is widely available, but a clearer statement about availability, especially in low-income countries, would have made the release better.", "answer": 1}, {"article": "For more information, visit http://www.\nThis new radionuclide drug shows strong binding to the protein PSMA and is readily and safely taken up by malignant PSMA-positive tumors.\nResults of the human study showed that imaging was effective for the evaluation of metastatic prostate cancer, and subsequent therapy resulted in a drop in prostate-specific antigen levels from 38.0 to 4.6 nanograms per milliliter.\nDiagnostic imaging was followed by a therapy-grade radionuclide, lutetium-177, which delivers a more powerful dose of radiation that penetrates and destroys the cells and tissues of tumors when combined with PSMA-617.\nApproximately one out of seven men will be diagnosed with prostate cancer in their lifetime, according to 2015 statistics from the American Cancer Society.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This release does eventually make it clear that only one patient has been tested, that this is very preliminary work and that the drug is not available.", "answer": 1}, {"article": "Moreover, the test's rapid turnaround and relatively low cost, especially compared to next-generation DNA sequencing, provide a potential opportunity for universal monitoring of more patients than is currently done,\" explained lead investigator Hanlee P. Ji, MD, Associate Professor in the Department of Medicine at Stanford University and Senior Associate Director of the Stanford Genome Technology Center.\nThe report describes the use of the test to analyze samples from six patients.\nIn one patient, the assay was able to show the presence of three different mutations.\nIt has been truly motivating to work with a technology that will help transform the way that we monitor and treat individuals with cancer.\n\"This test is simple enough to set up and analyze without extensive training, and therefore, it can be implemented by anyone, making it highly accessible to any laboratory.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the release that the test is not widely available and is only just now being developed.", "answer": 1}, {"article": ", and receive monthly highlights by signing up at http://www.\n\"Inflammation plays a critical role in acute and chronic tendon injuries and healing,\" said Chang H. Lee, Ph.D., a researcher involved in the work and an assistant professor at the Regenerative Engineering Laboratory (Columbia University Irving Medical Center, New York).\nIt is the world's most cited biology journal according to the Institute for Scientific Information and has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century.\n\"Our findings represent an important foundation for the development of a new treatment that would regulate overwhelmed inflammation for tendon ruptures and tears, tendonitis, tendinopathy, and other tendon injuries and diseases.\"\nOur mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t provide any indication when a therapy might be available \u2014 if ever. This very preliminary basic research has\u00a0a long research path ahead.", "answer": 0}, {"article": "ABOUT CLEARPOP\n\nClearPop for Rapid Earache Relief represents a simple, safe, pediatrician recommended, clinically effective and fun way to treat earaches.\nThe earache episode was totally resolved for 80%.\nAfter 20 minutes, 88.5% reported their ear pain dramatically reduced or vanished.\nCLINICAL TESTS\n\nChildren diagnosed with Acute Otitis Media, or ear infection, consumed the xylitol and Vitamin C-based product in pediatric offices.\nThe beleaguered parent now drags hollering kid to the doctor's office, only to find the pediatrician reluctant to prescribe antibiotics.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release\u00a0states clearly where the product is available.", "answer": 1}, {"article": "Doctors currently diagnose colds and flus through a patchwork of testing, observation and process of elimination.\nThe test is expected to be used mainly in hospitals and emergency rooms, but doctors can send the swab to a local lab.\nThe new test, called the xTAG respiratory panel, approved earlier this year by the U.S. Food and Drug Administration, is the most comprehensive FDA-approved virus-panel to date.\nBut many of the current tests available are not very sensitive, and most test for only one or two viruses at a time.\nIn the lab, genetic material from the swab is magnified millions of times and then bound to fluorescent markers, which are then read by a machine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story provides good information about availability.\u00a0 The Xtag test is mainly used in hospitals and emergency rooms but can also be done in the primary care setting.\u00a0 Other important information on variability of the length of time needed to process the test, from hours to 1-2 days, was also provided. ", "answer": 1}, {"article": "Around 180 million people globally have chronic HCV infection,1 including approximately 15 million people in the EU.2 The prevalence of HCV infection in children varies from 0.05%-0.36% in the United States and Europe and up to 1.8%-5.8% in some developing countries.3 While direct-acting antivirals have been used to treat and cure adult patients with HCV,4-7 until now children have been mainly treated for 24 to 48 weeks with pegylated interferon plus ribavirin (RBV), an older treatment which causes severe side effects.8\n\n\"Direct-acting antivirals have transformed the treatment of adults with chronic HCV, however, studies of these new therapies in children are required,\" said Dr Karen Murray, University of Washington School of Medicine and Seattle Children's, Seattle, United States, and lead author of the study.\nThis year, the congress is expected to attract approximately 10,000 delegates from all corners of the globe.\nThis annual congress is the biggest event in the EASL calendar, attracting scientific and medical experts from around the world to learn about the latest in liver research.\nThis ongoing, open-label study enrolled 90 children aged between six and 11 years with chronic HCV, mostly genotype 1 (n=86).\nLedipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release doesn\u2019t explain what hurdles, such as FDA approval, are required to make this therapy available to children.", "answer": 0}, {"article": "Results show that there were significant and clinically meaningful improvements in general quality of life and sleep-related quality of life measures after the initiation of PAP therapy for sleep apnea.\nThe study involved 2,027 patients with sleep apnea who began PAP therapy between Jan. 1, 2010, and Dec. 31, 2014.\nFor a copy of the study, \"Impact of Sleep-Disordered Breathing Treatment on Quality of Life Measures in a Large Clinic-Based Cohort,\" or to arrange an interview with a study author or an AASM spokesperson, please contact the AASM at 630-737-9700 or media@aasm.org.\nImplementation of a quality assurance program to track these quality measures can help improve patient outcomes, reduce the public health burden of sleep apnea, and provide a measurable standard for evaluating and managing sleep apnea.\nThe study was funded by a scholar award from the Cleveland Clinic Neurological Institute-Center of Research Outcomes and Evaluation and by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release made no mention of the availability of CPAP machines, even though they are easy to find. As mentioned above, however, their cost can often be prohibitive. It would have been helpful if the news release discussed low-cost options, especially since they mentioned that the intervention seemed to have less effect for lower socio-economic subgroups.", "answer": 0}, {"article": "Turner says the findings don\u2019t suggest that red wine is a cure for Alzheimer\u2019s.\nThe amounts of resveratrol in the purified doses that the participants took were extremely high and beyond those found on the market currently \u2014 around what would be contained in about 1,000 bottles of red wine.\nIn what the authors describe as the largest and longest study of resveratrol in people with mild to moderate Alzheimer\u2019s disease, there\u2019s encouraging news that the component, which is found in red wine, grapes and dark chocolate, may keep the disease from progressing.\nI think resveratrol is an engaging target that\u2019s very interesting and could be pharmacologically manipulated to develop a treatment.\u201d\n\nMORE: Red Wine Not That Healthy After All, Study Shows\n\nThe resveratrol group showed no change in the levels of a protein that builds up in the brains of Alzheimer\u2019s patients.\nIn a study published in , he described how they randomly assigned half of a group of 119 men and women to take up to 1,000 mg of resveratrol daily, and the other half to a placebo, for a year.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does make clear that this study does not mean people should begin drinking red wine or taking resveratrol supplements to combat Alzheimer\u2019s disease, and notes that more studies are needed to determine benefit or to create drugs for clinical use.", "answer": 1}, {"article": "A response was considered a 30% reduction in the Yale-Brown Obsessive Compulsive Scale (YBOCS) score, which is used to measure the severity of OCD symptoms.\nThe procedure is noninvasive and doesn't require anesthesia, and the pulses are delivered via an electromagnetic device or coil that is placed or worn on the head.\nOverall, 38% of the people with the real device responded to the treatment compared with 11% of those with the sham device.\nThe FDA first approved TMS devices for major depression in 2008, and in 2013 they were approved to treat pain associated with some types of migraine headaches.\nThe approval was based on a clinical trial of 100 people with obsessive-compulsive disorder, where roughly half received treatment with TMS and the other half had a sham treatment that didn't deliver the electromagnetic pulses.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers will understand that the TMS device is now commercially available for OCD, although the article does not offer any information about facilities that offer the treatment.", "answer": 1}, {"article": "Patient groups may also put some pressure on the Food and Drug Administration to approve the drug quickly.\nIt would also represent a success, after decades of setbacks, for the technology eteplirsen uses, called antisense, which is a way of turning off specific genes.\nBut Ms. McNary said Sarepta had refused to provide the drug to Max\u2019s 13-year-old brother, Austin, who could not be in the trial because he already could not walk.\nAlso, eteplirsen would be appropriate for only about 13 percent to 15 percent of Duchenne patients, those with the particular genetic mutation the drug is meant to counteract.\n\u201cIf you wait and require this company to do another two-year study, a lot of these boys are going to be in a wheelchair,\u201d Christopher Garabedian, the Sarepta chief executive, said in an interview.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is investigational and not available at the present.\u00a0 It also provided some additional insight, \u201cBut Ms. McNary said Sarepta had refused to provide the drug to Max\u2019s 13-year-old brother, Austin, who could not be in the trial because he already could not walk.\u201d\u00a0 \u201cMr. Garabedian said Sarepta did not have the money or the manufacturing capacity to make the drug available outside of clinical trials. \u201cThat would be the quickest path to insolvency,\u201d he said.\u201c", "answer": 1}, {"article": "A limitation of the study is that the evidence on acetaminophen was mainly for acute low back pain, but as the University of Leeds's Philip Conaghan explained, \"There is very little long-term data [on chronic back pain], and if a drug doesn't work in the acute problem, it seems unlikely to work in the chronic phase \u2014 though back pain may be even more complex than osteoarthritis pain.\"\nFor example, patients with kidney, gastric, cardiovascular, or bleeding problems may need to avoid NSAIDS like ibuprofen, so doctors might suggest Tylenol in these cases.\nNow, Moore was referring here to acute pain that strikes after a specific event, like a surgery, a cut, or a burn, but his message was simple: Ibuprofen seems to work best, followed by acetaminophen, and then aspirin.\nI used to take acetaminophen (usually referred to by its brand name, Tylenol) for the occasional headache or sore muscle, mostly because that's what we used in my house growing up.\nI asked him to describe the overall success rates for the most common three: acetaminophen (like Tylenol), ibuprofen (like Advil), and aspirin.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s obvious from the story that all of the medications profiled have been widely available without a prescription for many decades. Aspirin, a modified version of salicyclic acid, was created by a Bayer chemist in 1897; acetaminophen followed in 1956; and ibuprofen in 1962.", "answer": 1}, {"article": "FDA approves first drug aimed at women with inherited breast cancer\n\nU.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.\n\nThe Food and Drug Administration on Friday approved AstraZeneca PLC\u2019s Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says the FDA just approved the drug for patients with inherited BRCA gene mutations who have undergone chemotherapy, and that it\u2019s been on the market since 2014 for ovarian cancer. Presumably, that means it\u2019s widely available.\nBut, it then mentions that a \u201ccompanion\u201d blood test was also just approved to look for these genes. It\u2019s not clear if this test specifically will be required before women receive the new drug, and if that test will be available right away.", "answer": 0}, {"article": "Other New York counties took similar actions after New York City\u2019s measure was enacted.\n\u201cHere we find on a population level when we restrict them, it benefits society by reducing heart attacks and strokes.\u201d\n\nThe findings suggest the FDA\u2019s action will lead to health benefits across the country, he added.\nBrandt and colleagues write that in 2015, the U.S. Food and Drug Administration (FDA) removed manufactured trans fats from its list of safe food additives.\nIn 2006, there were 753 hospital admissions for heart attack or stroke per 100,000 people in counties that never enacted restrictions compared to 726 per 100,000 people in counties that put restrictions in place.\nBy 2018, those fats will be nearly eliminated from American diets, they add.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes where trans fats are now restricted (New York City) and explains that restrictions will become nationwide in 2018.\nBy 2018, those fats will be nearly eliminated from American diets, they add.", "answer": 1}, {"article": "With this new approach, SD-101 is the match that starts the fire.\"\nThe results of the study suggest that the combination of pembrolizumab and SD-101 could provide an alternative treatment for people with melanoma whose tumors have not responded or would be unlikely to respond to other therapies.\n\"We are really starting to understand the science of how immunotherapies work in patients,\" said Ribas, who is also the director of the Parker Institute for Cancer Immunotherapy Center at UCLA.\n\"We have found that the reason patients with metastatic melanoma do not initially respond to immunotherapy with an anti-PD-1 is that their immune system was not ready,\" said Dr. Antoni Ribas, the study's lead author, a professor of medicine at the David Geffen School of Medicine at UCLA and director of the UCLA Jonsson Comprehensive Cancer Center Tumor Immunology Program.\nThe research showed that using the immunotherapy drug pembrolizumab and the experimental agent SD-101, a sequence of nucleic acids that mimics a bacterial infection, altered the microenvironment around the tumor in a way that enabled the immune system to more effectively attack the cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release makes clear that this is an experimental therapy that is not yet available. The release could have been improved by noting that Keytruda was approved by the FDA for use in metastatic melanoma in 2015.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - A less common form of obesity surgery may spur more weight loss than its far more popular cousin, gastric bypass \u2014 but at the price of greater long-term risks, researchers reported Tuesday.\nIn a 2008 study, it accounted for just 1 percent of weight-loss, or bariatric, surgeries done in the U.S., and 5 percent in Europe.\nThe technique is often reserved for \u201csuperobese\u201d patients with a body mass index (BMI) of 50 or higher \u2014 though some surgeons perform it with less severely obese patients too, explained Dr. Torgeir T. Sovik of Oslo University in Norway, the lead researcher on the new study.\nThe surgeon removes part of the stomach, and the remaining \u201csleeve\u201d-like stomach is attached to the final section of the small intestine; that puts even greater limits on the body\u2019s absorption of calories and nutrients.\nIn general, experts say that surgery could be an option for anyone with a BMI of 40 or higher; that translates, roughly, to a man who is at least 100 pounds overweight or a woman who is 80 pounds overweight.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that duodenal switch is \u201cless common\u201d and that \u201cDuodenal switch is not a popular procedure.\u201d In a 2008 study, it accounted for just 1 percent of weight-loss, or bariatric, surgeries done in the U.S., and 5 percent in Europe.\u201d", "answer": 1}, {"article": "The paper, co-written by Hayes and four colleagues from UCL and Oxford University, concluded that: \u201cLithium remains an important treatment for individuals with bipolar disorder.\u201d It accepts that \u201cthere is clear evidence that its use is associated with a number of adverse events.\u201d\n\nHowever, it adds: \u201cThese risks need to be offset with the potentially superior effectiveness and anti-suicidal benefits of the drug compared to other treatment options.\u201d\n\nThe researchers studied a nationally representative sample of 6,671 patients across the UK who were treated for bipolar disorder between 1995 and 2013.\nHowever, none of the drugs caused more severe kidney problems.\nThat means that people end up in hospital more often than they need to and end up achieving less in their lives than they could do if they were on lithium.\nThose on olanzapine added the most weight and experienced high blood pressure as a result.\nBut as with all areas of mental health there is still more research to be done.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the four drugs studied are indeed available.", "answer": 1}, {"article": "You know, they go to rehab and there\u2019s not much more [more] they can recover usually.\u201d\n\nFor the study, Steinberg and his team recruited 18 patients who had suffered their first and only stroke six months to three years prior to the trial.\nSome of the patients bound to wheelchairs were even able to walk again.\nIn other words, they are the precursors to muscle, fat, bone, and tendon tissue.\nAbout 800,000 people in the United States suffer from a stroke each year.\nAnd in a clinical trial testing the technique, researchers found injections can safely improve patients' motor function.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes that the investigators are planning a larger trial of the procedure.", "answer": 1}, {"article": "\"While ENDS may have the potential to benefit established adult smokers ... [they] should not be used by youth and adult non-tobacco users because of the harmful effects of nicotine and other risk exposures,\" says Tim McAfee, director the Office on Smoking and Health at the U.S. Centers for Disease Control and Prevention.\n\"The intent of big tobacco is to sell their product,\" concludes Peruga.\n\"Exposure to nicotine can harm adolescent brain development.\"\nThat craving is caused by smoking tobacco but is now being increasingly satisfied by e-cigarettes and the trend to \"vape\" instead of smoke.\n\"For every 10% increase in tax you have 4% reduction in tobacco consumption,\" says Peruga.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All of the products discussed are readily available.", "answer": 1}, {"article": "Migraines are characterised by an intense, throbbing headache, sensitivity to light and noise, nausea, vomiting, low energy, and visual disturbances.\n\u201cThe results of Strive represent a real transition for migraine patients from poorly understood, re-purposed treatments, to a specific migraine-designed therapy.\u201d\n\nSimon Evans, chief executive of the charity Migraine Action, said: \u201cMigraine is too often trivialised as just a headache when, in reality, it can be a debilitating, chronic condition that can destroy lives.\nLead investigator Prof Peter Goadsby, from King\u2019s College hospital, London, said: \u201cStrive \u2026 represents an incredibly important step forward for migraine understanding and migraine treatment.\u201d\n\nThe findings, reported in the New England Journal of Medicine, clearly showed that blocking the CGRP pathway could reduce the impact of migraine, he said.\n\u201cAn option that can prevent migraine and that is well tolerated is therefore sorely needed, and we hope that this marks the start of real change in how this condition is treated and perceived.\u201d \n\n\n\n\u201cBroadly speaking I think this is a very interesting study and I think it is a good step forward for the field and I think it is a good day for migraine sufferers,\u201d said professor Zameel Cader, Director of the Oxford Headache Centre who was not involved in the research, pointing out that the results were on a par with currently available therapies for migraine.\nThe research revealed that by months four to six, at least a 50% reduction in mean migraine days per month was achieved for just over 43% of patients injected under the skin with 70-mg of erenumab each month, while half of patients injected with the higher dose of 140-mg had such results.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of\u00a0erenumab was never clear established. Yes, one could deduce that a Phase III trial was just reported, so it probably isn\u2019t on the market yet. But the story never said that. In addition, there can still be a troubled road between completion of a Phase III trial and approval. For a story that trumpeted \u201cincredibly important step forward\u2026.start of a real change (in treatment)\u2026first drug in 20 years proven to prevent migraine attacks\u201d and other superlatives, the story could have helped readers see through one trial\u2019s optimism to explain what pitfalls might lie ahead.", "answer": 0}, {"article": "Co-authors are Erinn M. Hade, Ph.D.; Tracie C. Collins, M.D., M.P.H., M.H.C.D.S.\nThe study was also limited by the relatively small number of strokes that occurred during the follow-up period (just 3.4 percent of the women experienced a stroke during the study period and 1.6 percent reported having had a stroke prior to the study) and by the Women's Health Initiative's exclusion of women who had already had severe strokes at the time of recruitment.\nBecause the study was observational, it couldn't establish a cause-and-effect relationship between breastfeeding and lower stroke risk, meaning that it is possible some other characteristic that distinguishes between women who breastfeed and those who don't is the factor changing the stroke risk.\nHowever, because the Women's Health Initiative is large, researchers were able to adjust for many characteristics, and the effects of breastfeeding remained strong, Jacobson said.\nCurrently, the American Academy of Pediatrics and the World Health Organization recommend exclusive breastfeeding for six months, with continuation of breast feeding for one year or longer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release requests that pregnant women make breastfeeding part of their \u201cbirthing plan\u201d and to breastfeed for at least six months to receive the most benefits. It\u2019s assumed readers know that breastfeeding is an available option unless there are medical or lifestyle barriers.", "answer": 1}, {"article": "About nine years ago, scientists discovered that the tumors of about half of patients with melanoma have a mutation in a gene called BRAF.\nIt's not known at this time if the drug can improve overall survival, and a sizable proportion of participants developed resistance to the drug, the researchers say.\nThe findings join other recent reports of potential treatments for melanoma in what appears to be an exciting time for the field.\nThe drug, PLX4032, just completed a phase 1 clinical trial in which 81 percent of participants with a particular gene mutation had a partial response, meaning at least some shrinkage of the tumor.\nIt's always signaling to the nucleus [of the tumor cells] that it's time to divide,\" Chapman explained.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story specifies that the new drug is \"experimental\" and in phase 1 clinical research. Readers can conclude from this that the drug is not widely available.\u00a0", "answer": 1}, {"article": "In another 12%, tumors stopped growing for at least six months.\n\"This is the first study looking at women who have failed so many other treatments,\" Krop tells WebMD.\n\"But we think these results are as good as we've ever seen is such a refractory [sick] population,\" he says.\nDec. 15, 2009 (San Antonio) -- A new targeted cancer drug has been shown to shrink tumors in women with metastatic breast cancer after an average of seven other drugs, including Herceptin, failed.\nIt's a Trojan horse approach, where Herceptin homes in on cancer cells and delivers the cancer-killing agent directly to its target.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "By not mentioning that this was a Phase II trial \u2014 an early stage, uncontrolled, non-randomized study \u2014 and that the compound is still investigational, the\u00a0article is unclear about T-DM1\u2019s development status and prospects for becoming available in the future.\u00a0In addition, some of the results are preliminary, or \"immature\" according to\u00a0Genentech press release, with final results to be presented at a future meeting. The fact that these are early data is also not mentioned.\nThe article does mention that other studies of T-DM1 are ongoing and are comparing T-DM1 to other treatments. However, the key explanation is missing that the other ongoing trial is Phase III, and comparisons of T-DM1 to other treatments is the key to its FDA approval for use in patients.", "answer": 0}, {"article": "D'Onofrio is also a co-author of several studies based on patient data from Sweden that found similarly lower risk for substance abuse and transport accidents in people with ADHD who used medication.\nThe majority of the ADHD medicines used in the study were stimulants such as Adderall, an amphetamine, and Ritalin, or methylphenidate.\nAs one of the largest analyses on the risks and benefits of ADHD medication, the study drew on anonymous health care data from 146 million people with employer-based health insurance in the United States from 2005 to 2014.\nThe larger number of people in the two more recent studies -- as well as the use of U.S. patients in the new analyses -- strengthens this earlier evidence.\nThe results, based upon nearly 3 million people with ADHD in the United States, are reported in the American Journal of Psychiatry.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release did not discuss the availability of ADHD medications. However, these are commonly prescribed medications that are widely available in the US and Europe.", "answer": 2}, {"article": "The latest trial success follows Roche\u2019s announcement last week about a separate study in which Tecentriq mixed with chemotherapies carboplatin and Abraxane boosted progression-free survival, compared with chemotherapy alone, in first-line treatment of patients with advanced squamous non-small cell lung cancer.\nShe also said the survival benefit was observed across key subgroups, including those with varying levels of a protein called PD-L1 that can help tumors avoid detection.\nThe Basel-based company, which had previously announced Tecentriq, Avastin and chemotherapy had reduced the risk of disease progression or death, said on Monday it hopes for a quick approval from authorities for the cocktail.\nThis could help Roche make the case that its cocktail is suitable for broad patients groups, not just those with specific biomarkers.\n\u201cWe are pleased the IMpower150 study demonstrated a clinically meaningful survival benefit for people receiving their initial treatment for this type of advanced lung cancer,\u201d said Sandra Horning, Roche\u2019s chief medical officer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "For better or worse, the story makes clear that Roche intends to submit the new data to regulators right away.", "answer": 1}, {"article": "Sarah Ellis will never forget her darkest days battling depression and the series of prescriptions the Sioux Falls, South Dakota mother of three endured.\n\"It gave us an answer \u2014 that this was her physiology and her genetics and not something in her head.\u201d\n\nThe Avera Institute for Human Genetics (AIHG) in Sioux Falls, South Dakota is among several institutions exploring the role of pharmacogenomics \u2014 the science of how our inheritance and genetic makeup influences the way we metabolize medications.\nDNA Tests May Be a Guide\n\n'One piece of the puzzle'\n\nAIHG\u2019s pharmacogenomics research has led to the development of Genefolio, a genetic test that uses an individual\u2019s unique DNA to predict how that individual will respond to medications.\nWhile the results are striking, this technology is not a guarantee of complete resolution of depressive symptoms or medication side effects.\nShe was also prescribed selective serotonin reuptake inhibitors (SSRIs) \u2014 a class of drugs including Prozac which are used to treat anxiety and depression \u2014 but they \"made me feel like I was losing my mind,\" Ellis told NBC News.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It says Avera is \u201coffering\u201d the test and that there are others used in hospitals. It\u2019s pretty clear that they are available, at least to some people. This is sufficient for a Satisfactory rating, though the story would have been stronger if it had explained this more thoroughly.", "answer": 1}, {"article": "For more information about NIH and its programs, visit http://www.\nThe study shows that for adults aged 75 years and older with high blood pressure, a systolic blood pressure goal of less than 120 mm Hg reduced rates of cardiovascular events, such as heart attack and heart failure, as well as stroke, by 33 percent.\nTo address this issue, the SPRINT study tapped more than 2,600 volunteers aged 75 and older, assigning half to a target blood pressure of less than 140 mm Hg and half to target of less than 120 mm Hg.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nThe new analysis singles out adults aged 75 and older and confirms that those with high blood pressure also benefit from the lower pressure target similar to the larger group studied in the earlier research: non-diabetic adults aged 50 and older.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Without naming the drugs used in the study, the release leaves us to assume the ready availability of any of the medications. It would have been easy for the news release to indicate that the study did not use any investigational agents \u2014 just widely available blood pressure medicines. Unfortunately, the release doesn\u2019t explain that, thus netting an unsatisfactory rating.", "answer": 0}, {"article": "For older people who fracture a hip, the prognosis is grim: a third or more die within a year and only about 1 in 5 return to their pre-injury level of function.\n\nA new approach to care could mean it doesn\u2019t have to be that way.\n\nMore hospitals are putting hip fracture patients on a fast track from the emergency room to the operating room,...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear how widely available this fast-track surgery option is in general, but this is\u00a0something you\u2019d want to know if you were a patient/caregiver trying to find some place that offers this.", "answer": 0}, {"article": "Error code 404. Something went\n\nwrong and we can't seem to find\n\nthe page you're looking for.\n\n Report a broken link.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says \u201ca small but growing number of hospitals offer microsurgical attempts at relief from lymphedema.\u201d It also mentions that it\u2019s sometimes covered by insurance.", "answer": 1}, {"article": "\u201cWe have to be mindful of the placebo effect, and we have to take [the findings] with a grain of salt,\u201d Matthew Sullivan, an associate professor of microbiology at The Ohio State University, said in the release.\nOne of the study\u2019s limitations is its small size, and researchers cautioned that families should not try to replicate the treatment at home.\nThe study, which was published in the journal Microbiome, included 18 children with autism and moderate to severe gastrointestinal problems.\n\u201cTransplants are working for people with other gastrointestinal problems,\u201d lead study author Ann Gregory, a microbiology graduate student at The Ohio state University, said in a news release.\nResearchers also asked the children\u2019s doctors to perform pre- and post-diagnostic evaluations, which suggested lasting benefits.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story could have been more explicit about how this treatment is nowhere ready for widespread use, but it did indicate the study was small, and it included the warning that \u201cresearchers cautioned that families should not try to replicate the treatment at home.\u201d", "answer": 1}, {"article": "(Reuters) - Asterias Biotherapeutics Inc said initial data from a small study showed that its lead stem cell therapy could improve mobility in patients paralyzed by a spinal cord injury.\nData showed that the severity of the spinal injury was reduced in the first patient and two other patients were able to resume their rehabilitation programs soon after being injected with the stem cells.\nIn an early-stage study conducted by Geron, the therapy showed potential in repairing spinal injury in four of the five patients tested, without any adverse events.\nAsterias is looking to show recovery of mobility in four out of every 10 patients treated with OPC-1, compared with two out of 10 achieving the same level of improvement without any treatment, Chief Executive Pedro Lichtinger told Reuters in early August.\n\u201cIt is important to know that we do not expect patients to get up and play basketball,\u201d he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The Reuters story makes it fairly clear that this therapy is in its early phases. The article describes how Asterias acquired the therapy from another research company in 2013 and how this announcement has been the first about the research in more than two years.", "answer": 1}, {"article": "Cancer cells remain elusive and tough to locate, but a new crop of nuclear-imaging tests promises to lead to more accurate prognosis and treatment.\n\nThe tests use imaging agents that combine radioactive isotopes with targeted molecules that can spot cancer at the cellular level. The ability to accurately locate the cancers helps physicians make better and earlier diagnoses\u2014and may eventually make possible targeted nuclear-medicine therapies that identify and kill cancer cells, but not the surrounding healthy cells.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article provides no information\u00a0about the availability of the new tests, either temporally or geographically.", "answer": 0}, {"article": "SUNDAY, Aug. 28, 2011 (HealthDay News) -- An experimental drug, apixaban (Eliquis), appears better than the old standby warfarin in preventing strokes in people with the abnormal heart rhythm called atrial fibrillation, a new study finds.\nThe issue of cost remains a factor, however.\nThe new trial comes on the heels of another study on apixaban that was stopped early due to safety concerns.\nAlso, unlike warfarin, apixaban has few interactions with other drugs or foods, he added.\n\"This represents a very important therapeutic advance in the care of patients with atrial fibrillation.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was clear that apixabane, the medication reported on, was experimental.", "answer": 1}, {"article": "A rare form of blindness inched closer to a cure, after two groups published preliminary studies on replacing the bad gene that causes the condition. The results are likely to boost the prospects of gene therapy, a technique that shows promise but has yet to prove it can be used to cure many diseases.\n\nAbout 2,000 people in the U.S. have Leber's congenital amaurosis No. 2, caused when a child inherits a certain flawed gene from both parents. Patients with the bad gene can't make a protein that is supposed to nourish the eye's...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This article clearly\u00a0indicates\u00a0that the two studies studies are preliminary and\u00a0that this treatment is in the experimental stages.\u00a0 It is implicit that the treatment is not clinically available but\u00a0available only to patients participating in clinical trials.\u00a0 ", "answer": 1}, {"article": "The IVC required cross-clamping in 24 cases.\n\"This is a complex condition and the complication rate with open surgery is 12% to 47%, depending on the thrombus level, with a mortality rate of 5% to 10%,\" explained lead investigator Ronney Abaza, MD, Robotic Surgery Director at OhioHealth Dublin Methodist Hospital.\nRobotic nephrectomy for inferior vena cava tumor thrombus has favorable outcomes and reproducibility when performed by surgeons with adequate robotic experience, according to first multi-institutional report, published in the journal of urology\n\nNew York, NY, Feb. 7, 2016 - Renal cell carcinoma can sometimes spread to the inferior vena cava (IVC), the body's largest vein, posing a threat to the heart and brain.\n\"Using robotic nephrectomy, our complication rate and lack of mortalities compare reasonably with open series with no grade III to V complications, according to the Clavien system, in any patient, including no deaths.\"\nRenal vein surgery can often be managed with minimally invasive laparoscopic techniques, but this is not typically advisable for an IVC thrombus (a fibrous clot), which is surgically far more complex with potentially fatal complications that can occur in the course of removing the thrombus and reconstructing the IVC.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that robot assisted minimally invasive surgery is available in many institutions and has become the mainstay for prostatic surgery. The news release does point out that the surgeons who participated in the story were experienced with the technique. While implied in some parts of the release and downplayed in others, this is not a surgical procedure that should be undertaken lightly.", "answer": 1}, {"article": "\"But my question here is, 'Is there a real benefit?'\"\nThe current effort, focused on patients already diagnosed with autism, used MRIs to locate areas of the brain where the left and right hemispheres do not communicate properly.\nTHURSDAY, Oct. 14, 2010 (HealthDay News) -- With the aim of catching autism in children at an earlier age than currently possible, scientists are exploring the potential of using MRI scans as a screening tool.\nThe study was limited to high-functioning males and so did not allow researchers to generalize the findings to females, younger children, or \"lower functioning\" individuals with autism, the researchers wrote.\n\"I would say that if this is geared to, or opens up, any specific avenue to targeted therapy that can help left and right brain communication among certain children for whom that's the pathway to autism, then it should certainly be explored,\" Bono said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "MRI is FDA approved and has been around for a good while and is available to most of the US population.\u00a0Still, there is no explicit mention in the story of MRI\u2019s availability in general, nor any specific mention some mention of how much difficulty patients might have seeking an MRI for this use. ", "answer": 0}, {"article": "Vivus also has a plan to minimize the chances that pregnant women will take it.\n\"We have two-thirds of all Americans who are overweight or obese, and the costs are nearing $150 billion a year,\" says Christine Ferguson, a health policy professor at George Washington University.\nPart of what's going on is that the FDA has gotten a lot more cautious about approving new drugs in general after some serious drug-safety problems, such as heart problems linked to the painkiller Vioxx.\n\"There's been a long history with obesity drugs that we've had to take off the market.\nAnd the fact that there isn't ... medical treatments for obesity, including pharmaceuticals, really is a challenge, considering how big the problem is in this country.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The whole story was about the FDA review of the drug and its meeting next week.\nAs noted above, the New York Times reported, \u201cThrough a regulatory loophole of sorts, many obesity doctors prescribe two separate drugs that, when taken together, are essentially the same medicine.\u201d This was an interesting perspective that the NPR post didn\u2019t include.", "answer": 1}, {"article": "The researchers adjusted for risk factors such as hormone therapy, age, race, education, body mass index, sleep quality, depression, hypertension, prior cardiovascular disease, diabetes, smoking, and alcohol consumption.\nIn 10 years or less of follow-up with annual assessments of cognitive function, 388 of these women received a diagnosis of probable dementia or some form of global cognitive impairment.\n\"What is unique about this study is that we had an unprecedented opportunity to examine the relationships between caffeine intake and dementia incidence in a large and well-defined, prospectively-studied cohort of women.\"\nAmong a group of older women, self-reported caffeine consumption of more than 261 mg per day was associated with a 36 percent reduction in the risk of incident dementia over 10 years of follow-up.\nThose who consumed above the median amount of caffeine for this group (with an average intake of 261 mg per day) were diagnosed at a lower rate than those who fell below the median (with an average intake of 64 mg per day).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release quotes the principal investigator saying, essentially, that caffeine is an easy thing to add to the diet and is widely available.\u00a0True enough.", "answer": 1}, {"article": "(CNN) Jet lag might be the worst part of long-distance travel, especially when it leaves you feeling tired, cranky and off-kilter for days.\nParticipants were able to sleep through the flashes of light without waking.\nThere's still more testing to be done before the technique is available to the public.\nThis time around, researchers tried to further optimize the process.\nJet lag occurs when sleeping and waking patterns are not synchronized to circadian rhythms.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that the light therapy wasn\u2019t ready for prime time yet.", "answer": 1}, {"article": "Fried, a dermatologist and clinical psychologist, points out that psoriasis itself can be associated with mental health problems.\nBy blocking the receptor from being activated, it keeps the body from receiving signals that can fuel inflammatory responses and psoriasis progression.\nIt can raise patients\u2019 risk of infections and shouldn\u2019t be used by people with certain chronic conditions, such as Crohn\u2019s disease or active tuberculosis infections.\n\u201cEffective treatment has consistently shown reduction in the incidence and severity of depression and reduced likelihood of suicide,\u201d says Fried.\nThe drug\u2019s recommended dosage schedule is an injection once a week for the first three weeks, followed by an injection every other week.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story deals with the availability issue by saying it \u201cexpects to begin sales and marketing in the second half of 2017.\u201d", "answer": 1}, {"article": "\"Results lend support to current national initiatives from the National Academies, White House, and bipartisan legislation requesting that the U.S. Food and Drug Administration create a new regulatory classification for hearing devices meeting appropriate specifications to be available over the counter,\" the authors write.\nPresently, hearing aids can only be purchased in the United States through a licensed professional, with an average cost of $4,700 for two hearing aids (uncovered by Medicare).\nThe researchers found that the change in accuracy in speech understanding from unaided to aided varied by device.\nAccording to nationally representative estimates, less than 20 percent of adults with hearing loss report hearing aid use.\nA comparison between less-expensive, over-the-counter hearing assistance devices and a conventional hearing aid found that some of these devices were associated with improvements in hearing similar to the hearing aid, according to a study published by JAMA.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Availability of both hearing aids (\u201cthrough a licensed professional\u201d) and PSAPs (\u201cover-the-counter\u201d) is clearly established.", "answer": 1}, {"article": "On the other hand, that analysis also found aspirin increased the rate of bleeding from 0.7 to 1 per 1,000 people per year, making the authors conclude the drug was of \u201cuncertain net value.\u201d\n\nHeart disease is the leading killer worldwide and accounts for more than a third of deaths in the U.S., according to the American Heart Association.\n\u201cThere is not universal agreement on what is high risk,\u201d he told Reuters Health.\nEvery year, heart attacks alone kill some 400,000 Americans.\nAbout 100,000 men and women age 45 and up took part in the studies.\n\u201cWe can\u2019t tell from the existing study if that is going to hold up or not,\u201d he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of aspirin is not in question.", "answer": 2}, {"article": "\"When the benefits of phospholipids on PMS and PMDD came to light through Lipogen's research, we immediately explored its potential,\" says David Rutenberg, CEO for Lipogen.\nAt the end of the 2-month study, out of 220 women under the age of 40 who consumed the product regularly, 23 women (10.45%) reported that they noticed relief of premenstrual syndromes.\n\"Based on these strong results, we improved the formulation and applied for a patent in the US market,\" explains Rutenberg.\n\"We also have begun an ongoing, double-blind, randomized, placebo-controlled clinical trial with daacro GmbH, Trier, Germany, to learn more how Lipogen's formulation can help alleviate PMS and PMDD symptoms.\nAccording to the Medical University of South Carolina, current available treatments include SSRIs and other drug treatments that treat side effects and can cost from US$60.00 - US$535.00 per month.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t mention when or in which formulation the supplement might be available in the U.S. market, even though the release is introducing the supplement to a U.S. audience.", "answer": 0}, {"article": "And it needs to be strong enough and elastic enough that it actually affects the recoil of the skin.\u201d\n\nThat, he said, \u201cis the challenge I put to them.\u201d\n\nDr. Robert Langer, a biomedical engineer who is a professor at M.I.T.\nThe skin still has to be able to breathe through this stuff.\n\u201cWe wanted something that is elegant, and the ultimate test is right there on your face,\u201d she said.\nIf you can achieve that you\u2019ve done something impressive.\u201d\n\u201cA lot of what happens when we age and skin starts wrinkling and sagging is loss of elastic recoil,\u201d he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story establishes\u00a0these as preliminary studies, adding that they haven\u2019t obtained enough data yet to submit the product for FDA approval.", "answer": 1}, {"article": "Hialeah bucket list: All the things you need to do in Hialeah before you die\n\nYou can spend your whole life working on this list.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story\u00a0indirectly states\u00a0that lung cancer screening is not widely available (e.g.\u00a0\"would widespread screening reduce cancer deaths?\").\u00a0\u00a0 ", "answer": 1}, {"article": "An \"investigational new drug\" application was required by the U.S. Food and Drug Administration to test the pure synthetic (pharmaceutical-grade) resveratrol in the study.\nA working hypothesis is that the treatments may reduce inflammation (or brain swelling) found with Alzheimer's.\n\"I definitely want the medical community to find a cure,\" she says.\nResveratrol and similar compounds are being tested in many age-related disorders including cancer, diabetes and neurodegenerative disorders.\nA similar decrease in brain volume was found with some anti-amyloid immunotherapy trials,\" Turner adds.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states resveratrol is not available commercially in the 1-gram oral form.", "answer": 1}, {"article": "\u201cI've responded great.\nI think the prognosis is going to be good now.\u201d\n\nThe most frequent mutation across all cancers occurs in a gene called p53, which contributes to cells becoming oncogenic when they produce a mutant form of the p53 protein (p53 gene mutations are present in about 50% of malignancies).\n\u201cEven the marks where it was climbing up my neck are all gone.\u201dFurther study needed\n\nWhat Diamond is hoping for now is funding for a full clinical trial so that he can test the combination in advanced triple-negative breast cancer patients who test positive for p53.\nBut we\u2019ve got to get these patients in.\u201d\n\nFollowing the success in Young, the formula has recently been given to two other triple negative breast cancer patients at City of Hope.\nIn a subsequent laboratory study, the COH researchers showed that these patients\u2019 immune cells could be reactivated by treatment with a PD1 inhibitor that is a biosimilar to the clinical drug called pembrolizumab.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "While part of the drug combination (pembrolizumab) mentioned in the release is available, the experimental p53 vaccine appears to only be available through a City of Hope researcher. There was mention of a desire to create clinical trials open to \u201cto women from all over the country\u201d but that\u2019s far from certain.\nIt\u2019s clear from the release that City of Hope is trying to recruit new patients and generate pharmaceutical sponsors. Many patients with this type of breast\u00a0 cancer may get the impression from the release that they, too, can receive this \u201cremarkable\u201d treatment if they make their way to the hospital. But how practical is their open invitation?\u00a0Experimental therapies like the vaccine are not covered by health insurance.", "answer": 0}, {"article": "You've probably heard about it \u2014 maybe you even remember seeing it once \u2014 but you're not really sure what it is or even where to find it.\n\nThe female condom (FC2), or internal condom, is a non-hormonal barrier method of birth control. But instead of going on a penis, it goes in a vagina, which is why it's also sometimes referred to as an internal condom. For more information, BuzzFeed Health spoke with two experts who could demystify this lesser-known contraceptive:\n\n* Dr. Harry Fisch, clinical professor of urology and reproductive medicine at Weill Cornell Medical College, and chief corporate officer of Veru Healthcare, which distributes FC2\n\n* Dr. Lauren Streicher, associate clinical professor of obstetrics and gynecology at Northwestern University\u2019s Feinberg School of Medicine", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a good job of handling the nuances of availability.", "answer": 1}, {"article": "Those drugs could not be used, however, until they received emergency use authorizations from the F.D.A.\nThe government is paying an average of only $450 a course for those other drugs \u2014 only one-fifth of what it is paying for peramivir.\nWhile some clinical trials showed the drug had an effect in resolving flu symptoms, others did not show statistically significant differences between peramivir and either a placebo or Tamiflu.\nRight now, Dr. Lurie said, peramivir is the only drug that can be used intravenously so the government had to pay a high price.\nThe federal government said late Thursday that it had also ordered 10,000 treatment courses each of intravenous versions of Tamiflu and Relenza, with options to buy 30,000 more courses of each.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story makes very clear that peramivir is experimental and is being offered only because some patients cannot take or aren\u2019t helped by approved antiviral drugs.", "answer": 1}, {"article": "The requested URL was not found on this server. That\u2019s all we know.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story makes it clear that statins are widely available. ", "answer": 1}, {"article": "TUESDAY, Aug. 2, 2011 (HealthDay News) -- There's still no cure for the common cold, but there may be a way to shorten its misery: A new study suggests that higher doses of zinc lozenges in certain formulations may cut the length of colds by more than 40 percent.\n\"Much of the variation in the published study findings can be explained by the daily dose of zinc administered in the zinc lozenges,\" said Hemila, who funded the research himself.\nDespite the popularity of zinc supplements, controversy over their effectiveness has continued since a much-publicized 1984 study first suggested a cold-limiting effect.\n\"When focusing on those studies which have used large daily doses of zinc, there is strong evidence that zinc lozenges shorten the duration of colds.\"\nThe study is published in The Open Respiratory Medicine Journal.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned the \u201cpopularity of zinc supplements\u201d but never established how popular, widespread are their use and never explained\u00a0\u00a0 if the lozenges on market shelves are at the same dosages as discussed in the story.\nWe can\u2019t give it a satisfactory score; we\u2019ll rule it N/A.", "answer": 2}, {"article": "O'Neil said it's important to help people, not blame them.\nWhile the Weight Management Center has a high success rate at helping patients lose weight to fight diabetes, many people with the condition don't live near a specialized program and need help that's readily available.\nA study coordinated by the MUSC Health Weight Management Center shows the scales tipping in Weight Watchers' favor instead of standard care when it comes to helping people with Type 2 diabetes.\nThe MUSC Health Weight Management Center takes a scientific approach to weight loss, focusing on changes in activity levels, behavior, thinking, diet and support systems.\nLeft uncontrolled, the condition can damage blood vessels and nerves, putting people at risk of having a heart attack or stroke.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that because Weight Watchers \u201chas centers all over the country, including sites in small towns with limited or no medical facilities, its program could help meet this need if combined with diabetes-specific counseling.\u201d We\u2019ll give this a marginal satisfactory because while there are, indeed, many Weight Watchers centers, the program will be too costly for many.", "answer": 1}, {"article": "These drugs work by increasing bone thickness, thereby reducing the risk of fractures, the researchers said.\nThe findings in this study show that bisphosphonates are associated with a reduced risk of developing colorectal cancer, but they cannot confirm a causal effect -- that is, the study doesn't prove that the use of bisphosphonates is responsible for the lower risk of colorectal cancer.\nTUESDAY, Feb. 15, 2011 (HealthDay News) -- People who take drugs called bisphosphonates to prevent bone loss may also reduce their risk of developing colorectal cancer by almost 60 percent compared to those not on the drugs, a new study suggests.\n\"The magnitude of the reduced risk is less important because this is an association study; however, it is very significant after controlling for a dozen other known risk factors,\" Rennert said.\n\"We also found a similar effect last year with risk of breast cancer, which has already been replicated by three other groups,\" Rennert added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both stories make it clear that these are drugs currently on the market. This story provided even more detail, saying, \u201cBisphosphonates include such common drugs as Fosamax (alendronate), Boniva (ibandronate), Actonel (risedronate) and Reclast (zoledronic acid). These drugs work by increasing bone thickness, thereby reducing the risk of fractures, the researchers said.\u201d", "answer": 1}, {"article": "What is the effect of Topical Curcumin Gel for treating burns and scalds?\nThe author of the study believes that the effectiveness of curcumin gel on the skin - or topical curcumin - is related to its potent anti-inflammatory activity.\nThe process goes through a sequence of acute and chronic inflammatory events, during which there is redness, swelling, pain and then healing, often with scarring in the case of burns and scalds of the skin.\n\"Curcumin gel appears to work much better when used on the skin because the gel preparation allows curcumin to penetrate the skin, inhibit phosphorylase kinase and reduce inflammation,\" explains Dr Heng.\nBased on studies that she has done both in the laboratory and in patients over 25 years, the key to curcumin's effectiveness on burns and scalds is that it is a natural inhibitor of an enzyme called phosphorylase kinase.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release discusses the uses of curcumin for gastronomical and cosmetic purposes \u2014 many of which go back centuries. It adds that medicinal aspects of curcumin have been studied intensely for various human ailments in recent years.\nIt\u2019s also clear from the news release that patients have the option of taking curcumin tablets orally for \u201cother conditions.\u201d A quick Google search shows that curcumin tablets are available for purchase at health food stores.\nFor these reasons, we give the news release a Satisfactory rating.", "answer": 1}, {"article": "Feb. 2, 2011 -- The human papillomavirus (HPV) vaccine can help stave off genital warts in boys and men, according to a new study in the Feb. 3 issue of the New England Journal of Medicine.\nThe vaccine is recommended for optional use in boys and men.\nThe vaccine is used in girls and boys and young adults ages 9 to 26 for prevention of genital warts caused by HPV types 6 and 11.\nHPV, a sexually transmitted disease, can be transmitted through vaginal, anal, and oral sex and has been linked to genital warts as well as cervical, vaginal, vulvar, oral, penile, and anal cancers.\nOf 4,065 boys and men aged 16 to 26 from 18 countries, vaccination with an HPV vaccine that targets four types of HPV infection -- HPV-6, HPV-11, HPV-16, and HPV-18 -- protects against infection with these types of HPV and potentially the development of related external genital warts or lesions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that Gardasil is avaialble and has been approved for use in girls and young women as well as in their male counterparts.", "answer": 1}, {"article": "A flu drug \u2014 shown to reduce the duration of symptoms \u2014 could upend treatment in U.S.\n\nNext winter, there may be a new drug for people who contract influenza \u2014 one that appears to be able to shut down infection quickly and, unlike anything else on the market, can be taken as a single dose.\n\nThe Food and Drug Administration on Tuesday said that it would give the drug, baloxavir marboxil, a priority review, and approval has the potential to upend the way influenza is treated.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that the FDA is expected to decide by the end of the year whether to approve this new flu medication.", "answer": 1}, {"article": "\"These findings suggest that this therapeutic approach is feasible and has the potential to provide a treatment strategy for cardiac regeneration after [heart attack],\" write University of Hong Kong researchers Chung-Wah Siu and Hung-Fat Tse.\nAll that's needed is a little help from one's own heart stem cells.\nHe invented the \"cardiosphere\" culture technique used to create the stem cells and founded the company developing the treatment.\nIf so, this could change the nature of medicine.\nIt's the first completed, controlled clinical trial showing that scarred heart tissue can be repaired.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the treatment is still in the experimental stage.\n\u00a0", "answer": 1}]